{"e1198332637cce59d7ccbc64356e3989b4f67810": [["What does this study add?\u2022 Only 14.5% HCWs exposed to COVID-19 cases were stratified \"high risk\" contacts, and the most common reason for high-risk contacts was non-formal workplace interactions such as having meals together.What does this study add?\u2022 The overall test positivity rate among the high-risk contacts was 7.1%, while it was higher in symptomatic high-risk contacts as compared to those who were asymptomatic (10.2% vs. 6.3%).How might this impact on clinical practice?\u2022 Contact tracing and risk stratification can be used to minimize unnecessary quarantine of COVID-19 exposed health care workers and prevent the depletion of healthcare workers amidst the pandemic to continue the healthcare services optimally.How might this impact on clinical practice?.", [["COVID-19", "CHEMICAL", 573, 581], ["this study", "TEST", 10, 20], ["COVID", "TEST", 54, 59], ["this study", "TEST", 235, 245], ["The overall test positivity rate", "TEST", 252, 284], ["clinical practice", "TREATMENT", 463, 480], ["Contact tracing", "TEST", 483, 498], ["COVID", "TREATMENT", 573, 578], ["clinical practice", "TREATMENT", 749, 766]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)IntroductionIn India, the coronavirus disease pandemic is on the rise ever since the first case was detected on January 30, 2020 (1).", [["CC", "CHEMICAL", 0, 2], ["coronavirus disease pandemic", "DISEASE", 225, 253], ["coronavirus", "ORGANISM", 225, 236], ["coronavirus", "SPECIES", 225, 236], ["the coronavirus disease pandemic", "PROBLEM", 221, 253], ["med", "ANATOMY", 102, 105], ["coronavirus disease", "OBSERVATION", 225, 244]]], ["As of July 16, 2020, the numbers of COVID-19 cases crossed one million mark with more than 25,000 deaths (2) .", [["deaths", "DISEASE", 98, 104], ["COVID", "TEST", 36, 41]]], ["With the progression of pandemic, the risk of exposure of health care workers (HCWs) to COVID-19 patients was increasing.", [["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["pandemic", "PROBLEM", 24, 32], ["COVID", "TEST", 88, 93], ["progression", "OBSERVATION_MODIFIER", 9, 20]]], ["Transmission of COVID-19 infection to HCWs in health care settings weaken the health care delivery systems at such crucial times.", [["COVID-19", "CHEMICAL", 16, 24], ["infection", "DISEASE", 25, 34], ["COVID-19", "ORGANISM", 16, 24], ["COVID", "TEST", 16, 21], ["infection", "PROBLEM", 25, 34], ["the health care delivery systems", "TREATMENT", 74, 106], ["infection", "OBSERVATION", 25, 34]]], ["It is further underscored by the high numbers of deaths of HCWs due to across the globe (4).IntroductionCase investigation, contact tracing, and quarantine remain an essential public health tool for controlling infectious disease outbreaks (5) .", [["deaths", "DISEASE", 49, 55], ["infectious disease outbreaks", "DISEASE", 211, 239], ["IntroductionCase investigation", "TEST", 92, 122], ["contact tracing", "TEST", 124, 139], ["controlling infectious disease outbreaks", "PROBLEM", 199, 239], ["high", "OBSERVATION_MODIFIER", 33, 37], ["numbers", "OBSERVATION_MODIFIER", 38, 45], ["globe", "ANATOMY", 82, 87]]], ["Irrational or unnecessary quarantine may lead to a shortage of workforce adversely impacting health care services.", [["unnecessary quarantine", "TREATMENT", 14, 36]]], ["Whereas, not quarantining those at high risk of infection following COVID-19 case exposure may potentially lead to transmission of infection to other HCWs and patients.", [["infection", "DISEASE", 48, 57], ["infection", "DISEASE", 131, 140], ["patients", "ORGANISM", 159, 167], ["patients", "SPECIES", 159, 167], ["infection", "PROBLEM", 48, 57], ["COVID", "TREATMENT", 68, 73], ["infection", "PROBLEM", 131, 140], ["infection", "OBSERVATION", 48, 57], ["infection", "OBSERVATION", 131, 140]]], ["The World Health Organization (WHO) and the U. S. Centers for Disease Control and Prevention (CDC) issued interim recommendations for protection and quarantine of HCWs from time to time (6, 7) .", [["Disease Control", "TREATMENT", 62, 77]]], ["Consequently, the Government of India also changed its quarantine policies (8, 9) .IntroductionThough success stories of prompt contact tracing and quarantine to control COVID-19 are available from countries like South Korea, Singapore, and Hong Kong, there was a dearth of evidence that could guide targeted quarantine in India (10) (11) (12) .", [["COVID-19", "CHEMICAL", 170, 178], ["COVID-19", "DNA", 170, 178], ["prompt contact tracing", "TEST", 121, 143], ["quarantine", "TREATMENT", 148, 158]]], ["Therefore, we developed an algorithm, which was based on risk stratification, to rationalize quarantine among HCWs.", [["an algorithm", "TEST", 24, 36]]], ["We report, in this paper, our experience of quarantining the HCWs based on contact tracing and risk stratification in a tertiary care centre in India.MethodsStudy setting: This study was conducted at a tertiary health care institution, namely the All India Institute of Medical Sciences (AIIMS), New Delhi, India.", [["contact tracing", "TEST", 75, 90], ["This study", "TEST", 172, 182]]], ["In the institution, the hospital premises and the patient care areas were divided into COVID-19 designated areas and non-COVID-19 areas for infection control measures.", [["infection", "DISEASE", 140, 149], ["patient", "ORGANISM", 50, 57], ["patient", "SPECIES", 50, 57], ["the patient care areas", "TREATMENT", 46, 68], ["COVID", "TEST", 87, 92], ["non-COVID", "TEST", 117, 126], ["infection control measures", "TREATMENT", 140, 166], ["infection", "OBSERVATION", 140, 149]]], ["A vast majority of HCWs were employees of the institution who were covered under the Government of India's leave rules.", [["HCWs", "ORGANISM", 19, 23]]], ["These employees, we understand, were paid only for the period for which they provided services.MethodsThe COVID areas included an out-patient screening facility, an in-patient facility for management of cases, and a critical care facility for COVID patients.", [["COVID", "DISEASE", 243, 248], ["patient", "ORGANISM", 134, 141], ["patient", "ORGANISM", 168, 175], ["patients", "ORGANISM", 249, 257], ["patient", "SPECIES", 134, 141], ["patient", "SPECIES", 168, 175], ["patients", "SPECIES", 249, 257], ["management", "TREATMENT", 189, 199], ["COVID patients", "TREATMENT", 243, 257]]], ["The institution had a designated virology laboratory for testing of COVID-19, which was approved by the Indian Council of Medical Research.Methods.", [["COVID", "TEST", 68, 73]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)MethodsThe copyright holder for this preprint this version posted August 4, 2020.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["Study participants: We included all HCWs and other employees of the institution who exposed with another person, (including patients, their attendants, and hospital staff) who had tested positive for COVID-19 at the institution.Central Contact Tracing Team (CCTT)The CCTT was a multidisciplinary team, which consisted of experts from community medicine, infectious disease, hospital administration, internal medicine, and nursing.", [["infectious disease", "DISEASE", 354, 372], ["patients", "ORGANISM", 124, 132], ["participants", "SPECIES", 6, 18], ["person", "SPECIES", 105, 111], ["patients", "SPECIES", 124, 132], ["COVID", "TEST", 200, 205], ["internal medicine", "TREATMENT", 399, 416], ["infectious", "OBSERVATION", 354, 364]]], ["The team reviewed the existing literature on COVID-19 risk assessment, and prepared risk stratification criteria by synthesizing and adapting the guidelines of the WHO, Centres for Disease Control (CDC), and other evidence available in the scientific literature (7,13,14).Protocol for Reporting of cases and Contact TracingWhenever a COVID-19 positive case was reported from any area of the institution, the concerned doctor-in charge or nodal officer at the respective department contacted the CCTT.", [["COVID", "TEST", 45, 50], ["risk assessment", "TEST", 54, 69], ["Disease Control (CDC)", "PROBLEM", 181, 202], ["a COVID", "TEST", 332, 339]]], ["A central helpline telephone number for CCTT was also created.", [["CCTT", "TEST", 40, 44], ["central", "OBSERVATION_MODIFIER", 2, 9]]], ["The CCTT carried out epidemiological investigation for all COVID-19 positive cases.", [["The CCTT", "TEST", 0, 8], ["epidemiological investigation", "TEST", 21, 50], ["all COVID", "TEST", 55, 64]]], ["The period for the investigation started from 48 hours before the onset of the symptoms among symptomatic cases or 48 hours before the collection of nasopharyngeal swab among asymptomatic cases.", [["nasopharyngeal swab", "ANATOMY", 149, 168], ["nasopharyngeal swab", "ORGANISM_SUBSTANCE", 149, 168], ["the investigation", "TEST", 15, 32], ["the symptoms", "PROBLEM", 75, 87], ["symptomatic cases", "PROBLEM", 94, 111], ["nasopharyngeal swab", "TEST", 149, 168], ["nasopharyngeal", "ANATOMY", 149, 163]]], ["It ended at the date when COVID-19 test results became available.", [["COVID", "TEST", 26, 31]]], ["Information from all the listed contacts was gathered either through face-to-face or telephonic interview.Procedure for testing and follow up of contactsThe high-risk contacts were advised quarantine for 14 days and tested at the institution on the fifth day after exposure.", [["Procedure", "TREATMENT", 106, 115], ["testing", "TEST", 120, 127]]], ["All HCWs categorized as low risk but who became symptomatic during 14 days .", [["symptomatic", "PROBLEM", 48, 59], ["low risk", "OBSERVATION_MODIFIER", 24, 32]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted August 4, 2020. . https://doi.org/10.1101/2020.07.31.20166264 doi: medRxiv preprint of follow up also underwent COVID-19 testing.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["COVID", "TEST", 369, 374], ["testing", "TEST", 378, 385], ["med", "ANATOMY", 102, 105]]], ["The low-risk asymptomatic contacts continued to work, with adherence to standard precautions.", [["The low-risk asymptomatic contacts", "PROBLEM", 0, 34], ["standard precautions", "TREATMENT", 72, 92], ["low", "OBSERVATION_MODIFIER", 4, 7]]], ["All contacts were followed for 14 days after the last day of exposure to the COVID19 case.COVID-19 confirmed caseA person who tested positive for COVID-19 by qualitative real-time reverse transcriptase-polymerase chain reaction (qRT-PCR) test, conducted at the virology laboratory of the institution, or at any other laboratory approved by the Indian Council of Medical Research (ICMR).Risk StratificationHigh-risk contacts: Contact with a confirmed case with any of the following:Risk Stratification1.", [["COVID-19", "DNA", 90, 98], ["COVID-19", "DNA", 146, 154], ["reverse transcriptase", "PROTEIN", 180, 201], ["person", "SPECIES", 115, 121], ["the COVID19 case", "TREATMENT", 73, 89], ["COVID", "TEST", 90, 95], ["COVID", "TEST", 146, 151], ["polymerase chain reaction", "PROBLEM", 202, 227]]], ["Performed a respiratory Aerosol Generating Procedure (AGP) without ANY one of the following -N95 face mask, eye/face protection, gloves.Risk Stratification2.", [["eye", "ANATOMY", 108, 111], ["eye", "ORGANISM_SUBDIVISION", 108, 111], ["a respiratory Aerosol", "TREATMENT", 10, 31], ["Procedure (AGP)", "TREATMENT", 43, 58], ["N95 face mask", "TREATMENT", 93, 106], ["eye/face protection", "TREATMENT", 108, 127], ["gloves", "TREATMENT", 129, 135], ["eye", "ANATOMY", 108, 111], ["face", "ANATOMY", 112, 116]]], ["If the patient's body fluids, or respiratory tract secretions, or saliva came in contact with non-intact skin or mucous membrane.Risk Stratification3.", [["body fluids", "ANATOMY", 17, 28], ["respiratory tract secretions", "ANATOMY", 33, 61], ["skin", "ANATOMY", 105, 109], ["mucous membrane", "ANATOMY", 113, 128], ["patient", "ORGANISM", 7, 14], ["body", "ORGANISM_SUBDIVISION", 17, 21], ["fluids", "ORGANISM_SUBSTANCE", 22, 28], ["respiratory tract", "ORGANISM_SUBDIVISION", 33, 50], ["secretions", "ORGANISM_SUBSTANCE", 51, 61], ["saliva", "ORGANISM_SUBSTANCE", 66, 72], ["skin", "ORGAN", 105, 109], ["mucous membrane", "MULTI-TISSUE_STRUCTURE", 113, 128], ["patient", "SPECIES", 7, 14], ["the patient's body fluids", "TEST", 3, 28], ["respiratory tract secretions", "PROBLEM", 33, 61], ["saliva", "PROBLEM", 66, 72], ["mucous membrane", "PROBLEM", 113, 128], ["respiratory tract", "ANATOMY", 33, 50], ["skin", "ANATOMY", 105, 109], ["mucous membrane", "ANATOMY", 113, 128]]], ["Present within 1 meter of the confirmed case without a mask (both case and contact) for more than 15 minutes.Household contacts of a known positive caseLow-risk contacts: All contacts other than \"high risk\" contacts were classified as low-risk contacts.Household contacts of a known positive caseSymptomatic contact: Any contact having symptoms suggestive of COVID-19, such as fever, cough, or breathing difficulty at the time of risk assessment.Household contacts of a known positive caseAsymptomatic contact: Any contact without COVID-19 symptoms such as fever, cough, or breathing difficulty when risk was assessed, irrespective of the development of symptoms later during 14 days follow-up period.Household contacts of a known positive caseStatistical Analysis: Data were entered and managed in MS Excel 2016, and statistical analysis was carried out using STATA 12.0 (Stata Corp LLC 4905, Texas, USA).", [["fever", "DISEASE", 377, 382], ["cough", "DISEASE", 384, 389], ["breathing difficulty", "DISEASE", 394, 414], ["fever", "DISEASE", 557, 562], ["cough", "DISEASE", 564, 569], ["breathing difficulty", "DISEASE", 574, 594], ["a mask", "TREATMENT", 53, 59], ["symptoms", "PROBLEM", 336, 344], ["COVID", "TEST", 359, 364], ["fever", "PROBLEM", 377, 382], ["cough", "PROBLEM", 384, 389], ["breathing difficulty", "PROBLEM", 394, 414], ["risk assessment", "TEST", 430, 445], ["COVID-19 symptoms", "PROBLEM", 531, 548], ["fever", "PROBLEM", 557, 562], ["cough", "PROBLEM", 564, 569], ["breathing difficulty", "PROBLEM", 574, 594], ["symptoms", "PROBLEM", 654, 662], ["statistical analysis", "TEST", 818, 838], ["STATA", "TEST", 861, 866]]], ["Results were presented as frequencies or proportions and 95% confidence interval (CI).Ethical Considerations:The Institute Ethics Committee approved the study.", [["CI", "TEST", 82, 84], ["the study", "TEST", 149, 158]]], ["Informed verbal consent was taken on the phone from the participants.", [["participants", "SPECIES", 56, 68]]], ["The information collected was kept confidential and unique identifiers were removed before analysis.Ethical Considerations:.", [["analysis", "TEST", 91, 99]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted August 4, 2020.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["The CCTT tracked 3,853 hospital employees who exposed to these 321 COVID-19 cases, both patients as well as other HCWs, during the period from April 11 to June 8, 2020 (Figure 1) .", [["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96]]], ["The mean number of contacts for an index case was 13.5.", [["an index case", "TEST", 32, 45], ["mean", "OBSERVATION_MODIFIER", 4, 8]]], ["The maximum number of contacts associated with a single case was 87, out of which 21 (24%) were high risk.(which was not certified by peer review)The two most common reasons for high-risk exposure (~40% each) were informal workplace interactions (not related to patient care), and during routine work being without mask and not maintaining physical distance.", [["patient", "ORGANISM", 262, 269], ["patient", "SPECIES", 262, 269], ["high-risk exposure", "PROBLEM", 178, 196], ["mask", "TREATMENT", 315, 319], ["maximum", "OBSERVATION_MODIFIER", 4, 11], ["number", "OBSERVATION_MODIFIER", 12, 18]]], ["Other reasons included patient care without appropriate PPE, cleaning, or housekeeping activities without adequate PPE (Table 1) .", [["patient", "ORGANISM", 23, 30], ["patient", "SPECIES", 23, 30], ["appropriate PPE", "TREATMENT", 44, 59], ["cleaning", "TREATMENT", 61, 69]]], ["In some cases, there were multiple reasons for high-risk exposure.", [["high-risk exposure", "PROBLEM", 47, 65]]], ["In the patient care settings, the high-risk exposure was largely due to non-use of appropriate PPE, e.g., performing aerosol-generating procedures without eye/face protection, not performing hand hygiene after the examination or inconsistent use of N 95 mask.(which was not certified by peer review)Of the total 3,853 contacts, 118 (3.1%) tested positive for COVID-19 by RT-PCR.", [["eye", "ANATOMY", 155, 158], ["hand", "ANATOMY", 191, 195], ["patient", "ORGANISM", 7, 14], ["eye", "ORGAN", 155, 158], ["hand", "ORGANISM_SUBDIVISION", 191, 195], ["COVID-19", "DNA", 359, 367], ["patient", "SPECIES", 7, 14], ["appropriate PPE", "TREATMENT", 83, 98], ["aerosol-generating procedures", "TREATMENT", 117, 146], ["eye/face protection", "TREATMENT", 155, 174], ["the examination", "TEST", 210, 225], ["N 95 mask", "TREATMENT", 249, 258], ["COVID", "TEST", 359, 364], ["RT", "TEST", 371, 373], ["PCR", "TEST", 374, 377], ["face", "ANATOMY", 159, 163]]], ["Among the 560 high-risk contacts, 40 (7.1%; 95% CI 5.2-9.6) became COVID-19 positive during the quarantine period.", [["CI", "TEST", 48, 50], ["COVID", "TEST", 67, 72]]], ["The positivity rate among the symptomatic high-risk contacts was higher (10.2 %; 95% CI 5.5 -16.7) compared to those who were asymptomatic (6.3%, 95% CI 3.9 -8.5).", [["The positivity rate", "TEST", 0, 19], ["the symptomatic high-risk contacts", "PROBLEM", 26, 60], ["CI", "TEST", 85, 87], ["CI", "TEST", 150, 152]]], ["Similarly, the positivity rate among the low-risk symptomatic contacts was higher (5.3%, 95% CI 3.0 -8.7) compared to lowrisk asymptomatic contact (2.1% (95% CI 1.6 -2.6) ( Table 2 ).DiscussionWe followed up a total of 3,853 contacts, i.e., the HCWs who were exposed to COVID-19 cases.DiscussionMost of the contacts (85.5%) had \"low risk\" exposure as per the risk stratification criteria.", [["the positivity rate", "TEST", 11, 30], ["the low-risk symptomatic contacts", "PROBLEM", 37, 70], ["CI", "TEST", 93, 95], ["CI", "TEST", 158, 160], ["COVID", "TEST", 270, 275]]], ["During the 14 days of the quarantine period, 118 contacts (3.1%, 95% CI 2.5 -3.7) became COVID-19 positive.DiscussionThe test positivity rate is a proxy indicator for secondary attack rate (SAR) of COVID-19.", [["COVID-19", "GENE_OR_GENE_PRODUCT", 89, 97], ["CI", "TEST", 69, 71], ["COVID", "TEST", 89, 94], ["The test positivity rate", "TEST", 117, 141], ["secondary attack rate", "PROBLEM", 167, 188], ["COVID", "TEST", 198, 203]]], ["It is higher in our study than the SAR (1.56%, 95% CI = 0.73 -2.93) reported by nationwide contact tracing data from Taiwan (14).", [["the SAR", "TEST", 31, 38], ["CI", "TEST", 51, 53], ["higher", "OBSERVATION_MODIFIER", 6, 12]]], ["This indicates the relatively rapid progression of COVID-19 pandemic in our institution.Discussion.", [["COVID", "TEST", 51, 56], ["relatively", "OBSERVATION_MODIFIER", 19, 29], ["rapid", "OBSERVATION_MODIFIER", 30, 35], ["progression", "OBSERVATION_MODIFIER", 36, 47]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted August 4, 2020. . https://doi.org/10.1101/2020.07.31.20166264 doi: medRxiv preprint(which was not certified by peer review)We observed a clear trend in the positivity rate with the highest rate among high-risk symptomatic contacts and lowest among low-risk asymptomatic contacts.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["the positivity rate", "TEST", 409, 428], ["med", "ANATOMY", 102, 105], ["clear", "OBSERVATION_MODIFIER", 394, 399], ["trend", "OBSERVATION_MODIFIER", 400, 405]]], ["Still, the test positivity rate among lowrisk asymptomatic contacts was 2.1%.", [["the test positivity rate", "TEST", 7, 31]]], ["If this were to be true, then the utility of the tool would further improve in situations where paid leave is allowed for the quarantine period.(which was not certified by peer review)We did not physically verify the COVID-19 test status of individual HCWs.", [["the COVID", "TEST", 213, 222]]], ["Instead, we had assumed that anyone testing positive would be notified to the CCTT.", [["anyone testing", "TEST", 29, 43]]], ["HCWs for which no positive report was communicated to CCTT were deemed to be COVID-19 negative.", [["CCTT", "CANCER", 54, 58], ["COVID-19", "DNA", 77, 85], ["COVID", "TEST", 77, 82]]], ["Therefore, the observed positivity rate would be an underestimate.", [["the observed positivity rate", "PROBLEM", 11, 39]]], ["The underestimation, if any, is likely to be small enough so as not to challenge the validity of findings seriously.(which was not certified by peer review)While calculating the positivity rate, we had assumed that all contacts were susceptible at the time of exposure.", [["the positivity rate", "TEST", 174, 193], ["underestimation", "OBSERVATION_MODIFIER", 4, 19]]], ["However, some of them might already have had protective antibodies.", [["protective antibodies", "PROTEIN", 45, 66], ["protective antibodies", "PROBLEM", 45, 66]]], ["It would be particularly true because a substantial proportion of COVID infection is reported to be asymptomatic.(which was not certified by peer review)Such a situation would result in an underestimation of the positivity rate.", [["infection", "DISEASE", 72, 81], ["COVID", "CANCER", 66, 71], ["COVID infection", "PROBLEM", 66, 81], ["the positivity rate", "TEST", 208, 227], ["substantial", "OBSERVATION_MODIFIER", 40, 51], ["infection", "OBSERVATION", 72, 81]]], ["We had assumed that none of the contacts were in the incubation period of COVID infection at the time of their exposure.", [["COVID", "CHEMICAL", 74, 79], ["infection", "DISEASE", 80, 89], ["COVID infection", "PROBLEM", 74, 89], ["infection", "OBSERVATION", 80, 89]]], ["Under such a scenario, the observed the positivity rate would be an overestimate of the true situation.", [["the positivity rate", "TEST", 36, 55]]], ["However, we feel that the number of HCWs that could have been in the incubation period of COVID infection is likely to be small and not vitiate the findings of this study.(which was not certified by peer review)Through the risk stratification tool, we aimed to identify those exposed HCWs that required quarantine to protect patients and other HCWs from potential infection.", [["infection", "DISEASE", 96, 105], ["infection", "DISEASE", 364, 373], ["HCWs", "ORGANISM", 36, 40], ["patients", "ORGANISM", 325, 333], ["patients", "SPECIES", 325, 333], ["COVID infection", "PROBLEM", 90, 105], ["this study", "TEST", 160, 170], ["quarantine", "TREATMENT", 303, 313], ["potential infection", "PROBLEM", 354, 373], ["infection", "OBSERVATION", 96, 105], ["likely to be", "UNCERTAINTY", 109, 121], ["small", "OBSERVATION_MODIFIER", 122, 127], ["infection", "OBSERVATION", 364, 373]]], ["Simultaneously, we also aimed to avoid unnecessary quarantine of those HCWs that were likely to be uninfected, and thereby prevent workforce depletion.", [["those HCWs", "TREATMENT", 65, 75], ["workforce depletion", "PROBLEM", 131, 150]]], ["Incorrectly labelling an HCW as low risk and thereby allowing her/him to continue to work rather than being quarantined, entailed serious consequences to co-workers and patients.", [["patients", "ORGANISM", 169, 177], ["patients", "SPECIES", 169, 177]]], ["It was preferable to err on the side of caution at the cost of loss of workforce.", [["loss of workforce", "TREATMENT", 63, 80]]], ["The test positivity rate among low risk symptomatic (5.3%) was closer to the high-risk group (7.1%) compared to low risk asymptomatic (2.1%).", [["The test positivity rate", "TEST", 0, 24], ["low risk symptomatic", "PROBLEM", 31, 51], ["low risk asymptomatic", "PROBLEM", 112, 133]]], ["If we convert the test positivity rate among low-risk asymptomatic contacts in numbers, it will be a substantial number.", [["the test positivity rate", "TEST", 14, 38]]], ["These asymptomatic contacts may further transmit the infection to others, which is evident from the literature (15) .", [["infection", "DISEASE", 53, 62], ["the infection", "PROBLEM", 49, 62], ["infection", "OBSERVATION", 53, 62]]], ["The asymptomatic .", [["asymptomatic", "OBSERVATION_MODIFIER", 4, 16]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted August 4, 2020. . https://doi.org/10.1101/2020.07.31.20166264 doi: medRxiv preprint transmission of COVID-19 remains a major challenge for the protection of HCWs and the curb of pandemic progression.", [["CC", "CHEMICAL", 0, 2], ["COVID-19", "CHEMICAL", 357, 365], ["pandemic", "DISEASE", 435, 443], ["COVID-19", "CHEMICAL", 357, 365], ["The copyright holder", "TREATMENT", 198, 218], ["COVID", "TEST", 357, 362], ["a major challenge", "TREATMENT", 374, 391], ["HCWs", "TREATMENT", 414, 418], ["pandemic progression", "PROBLEM", 435, 455], ["med", "ANATOMY", 102, 105]]], ["Thus, all low-risk asymptomatic contacts were advised to observe adherence to precautions such as physical distancing, hand hygiene and PPE as appropriate, so that in case of an error in stratification, they do not pose the risk of transmission to others and avoid further resurgence of COVID-19 cases.(which was not certified by peer review)We found that informal interactions such as having snacks/meals together was one of the most common reasons for high-risk exposure among the contacts.", [["hand", "ANATOMY", 119, 123], ["hand", "ORGANISM_SUBDIVISION", 119, 123], ["precautions", "TREATMENT", 78, 89], ["PPE", "TREATMENT", 136, 139], ["COVID", "TEST", 287, 292]]], ["Other measures to avoid overcrowding may include restricting the number of persons inside the dining room at any given point of time.", [["persons", "ORGANISM", 75, 82], ["persons", "SPECIES", 75, 82]]], ["We also recommend that during training program of the HCW for infection control practices, the risk due to dining together may be emphasized.(which was not certified by peer review)Our risk stratification strategy prevented the depletion of human resources for continuing healthcare services.", [["infection", "DISEASE", 62, 71], ["human", "ORGANISM", 241, 246], ["human", "SPECIES", 241, 246], ["human", "SPECIES", 241, 246], ["infection control practices", "TREATMENT", 62, 89], ["continuing healthcare services", "TREATMENT", 261, 291]]], ["In our study, 560 contacts were high risk.", [["our study", "TEST", 3, 12]]], ["Of the low-risk contacts (3293), 78 tested positive and thus quarantined.", [["low-risk", "OBSERVATION_MODIFIER", 7, 15]]], ["Therefore, this strategy prevented 3215 HCWs from quarantine following exposure and saved 45,010 person-days till June 8, 2020.", [["person", "SPECIES", 97, 103]]], ["In contrast, all contacts irrespective of the risk status were quarantined in most healthcare institutions, particularly in the facilities with constraint resources for testing.", [["testing", "TEST", 169, 176]]], ["It led to severe depletion of the workforce, and subsequently, shut down of many healthcare institutions in worse affected cities, Mumbai and Delhi (17) (18) (19) (20) .Strengths:We employed multiple strategies, including personal interview and review of records, to prepare the list of contacts of exposed HCW.", [["Delhi (17) (18)", "CHEMICAL", 142, 157], ["severe depletion", "PROBLEM", 10, 26], ["severe", "OBSERVATION_MODIFIER", 10, 16], ["depletion", "OBSERVATION", 17, 26]]], ["The testing for COVID infection was done at an accredited laboratory.", [["infection", "DISEASE", 22, 31], ["The testing", "TEST", 0, 11], ["COVID infection", "PROBLEM", 16, 31], ["infection", "OBSERVATION", 22, 31]]], ["All quarantined participants were contacted, and history obtained at the end of 14 days of follow up.Limitations:The risk stratification was based on the history provided by the participant.", [["participants", "ORGANISM", 16, 28], ["participants", "SPECIES", 16, 28], ["participant", "SPECIES", 178, 189]]], ["Deliberate misinformation was also a possibility, particularly where participants feared that if quarantined, they could lose wages for that period.", [["participants", "SPECIES", 69, 81]]], ["Sanitation staff and hospital attendants that were provided by an external agency were more likely to fall into this category.ConclusionsThe risk stratification tool developed by us served its intended purpose of correctly categorizing the risk category of exposure, as well as minimizing unnecessary quarantine of COVID-19 exposed .", [["COVID-19", "CHEMICAL", 315, 323], ["COVID-19", "CHEMICAL", 315, 323], ["COVID", "TREATMENT", 315, 320]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted August 4, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted August 4, 2020. . https://doi.org/10.1101/2020.07.31.20166264 doi: medRxiv preprint .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["The copyright holder", "TREATMENT", 448, 468], ["medRxiv preprint", "TREATMENT", 574, 590], ["med", "ANATOMY", 102, 105], ["med", "ANATOMY", 311, 314]]], ["CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted August 4, 2020. . https://doi.org/10.1101/2020.07.31.20166264 doi: medRxiv preprint", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 239, 259], ["medRxiv", "TREATMENT", 365, 372], ["med", "ANATOMY", 102, 105]]]], "PMC7127156": [["A crucial barrier to breachA first step during infection is the attachment of microorganisms to various host proteins, which could include basement membrane (BM) proteins.", [["basement membrane", "ANATOMY", 139, 156], ["BM", "ANATOMY", 158, 160], ["infection", "DISEASE", 47, 56], ["basement membrane", "CELLULAR_COMPONENT", 139, 156], ["BM", "CELLULAR_COMPONENT", 158, 160], ["host proteins", "PROTEIN", 104, 117], ["basement membrane (BM) proteins", "PROTEIN", 139, 170], ["A crucial barrier to breachA", "TREATMENT", 0, 28], ["infection", "PROBLEM", 47, 56], ["microorganisms", "PROBLEM", 78, 92], ["various host proteins", "PROBLEM", 96, 117], ["infection", "OBSERVATION", 47, 56]]], ["Generally, adhesion of bacteria and fungi occurs through binding of adhesive molecules, called adhesins, to host proteins.", [["adhesive molecules", "PROTEIN", 68, 86], ["adhesins", "PROTEIN", 95, 103], ["host proteins", "PROTEIN", 108, 121], ["bacteria", "PROBLEM", 23, 31], ["fungi", "PROBLEM", 36, 41], ["bacteria", "OBSERVATION", 23, 31], ["fungi", "OBSERVATION", 36, 41]]], ["Most adhesins are extensively described and some of the motifs participating in these processes have been identified.", [["adhesins", "PROTEIN", 5, 13]]], ["In comparison, knowledge about adhesion of viruses to BM components is scarce.", [["BM components", "ANATOMY", 54, 67], ["BM", "CELL", 54, 56], ["viruses", "PROBLEM", 43, 50], ["viruses", "OBSERVATION", 43, 50]]], ["On adhesion, microorganisms have evolved cunning techniques to overcome the BM barrier, which otherwise hampers their invasive process.", [["BM barrier", "ANATOMY", 76, 86], ["BM barrier", "TISSUE", 76, 86], ["microorganisms", "PROBLEM", 13, 27], ["the BM barrier", "TREATMENT", 72, 86], ["invasive", "OBSERVATION", 118, 126]]], ["Breakdown of the BM, via activation of microbial and/or host proteases, to cross the BM has been shown for many bacteria, fungi and, recently, some viruses.", [["BM", "ANATOMY", 17, 19], ["BM", "ANATOMY", 85, 87], ["BM", "CELL", 17, 19], ["BM", "CELL", 85, 87], ["microbial and/or host proteases", "PROTEIN", 39, 70], ["Breakdown of the BM", "PROBLEM", 0, 19], ["host proteases", "PROBLEM", 56, 70], ["many bacteria", "PROBLEM", 107, 120], ["fungi", "PROBLEM", 122, 127], ["some viruses", "PROBLEM", 143, 155], ["BM", "ANATOMY", 17, 19], ["BM", "ANATOMY", 85, 87], ["bacteria", "OBSERVATION", 112, 120], ["fungi", "OBSERVATION", 122, 127], ["viruses", "OBSERVATION", 148, 155]]], ["Pathogens might also gain access to the connective tissue by hijacking host cells, particularly local immune cells, to cross the BM.", [["connective tissue", "ANATOMY", 40, 57], ["cells", "ANATOMY", 76, 81], ["immune cells", "ANATOMY", 102, 114], ["BM", "ANATOMY", 129, 131], ["connective tissue", "TISSUE", 40, 57], ["host cells", "CELL", 71, 81], ["immune cells", "CELL", 102, 114], ["BM", "TISSUE", 129, 131], ["host cells", "CELL_TYPE", 71, 81], ["local immune cells", "CELL_TYPE", 96, 114], ["hijacking host cells", "PROBLEM", 61, 81], ["local immune cells", "PROBLEM", 96, 114], ["connective tissue", "ANATOMY", 40, 57], ["host cells", "OBSERVATION", 71, 81], ["immune cells", "OBSERVATION", 102, 114], ["BM", "ANATOMY", 129, 131]]], ["This review provides an overview of recent insights into different pathogen\u2013BM interactions during host invasion, discusses these findings and projects how they could contribute to the design of novel strategies to interfere with microbial invasions and pathology.The BM: a specialized extracellular matrix possessing unique propertiesThe BM provides a subtle interface between epithelial or endothelial cells and mesenchymal cells present in connective tissue.", [["BM", "ANATOMY", 76, 78], ["BM", "ANATOMY", 268, 270], ["extracellular matrix", "ANATOMY", 286, 306], ["BM", "ANATOMY", 339, 341], ["epithelial", "ANATOMY", 378, 388], ["endothelial cells", "ANATOMY", 392, 409], ["mesenchymal cells", "ANATOMY", 414, 431], ["connective tissue", "ANATOMY", 443, 460], ["pathogen\u2013BM", "CELL", 67, 78], ["BM", "CELL", 268, 270], ["extracellular matrix", "CELLULAR_COMPONENT", 286, 306], ["BM", "CELL", 339, 341], ["epithelial", "CELL", 378, 388], ["endothelial cells", "CELL", 392, 409], ["mesenchymal cells", "CELL", 414, 431], ["connective tissue", "TISSUE", 443, 460], ["BM", "CELL_TYPE", 268, 270], ["BM", "CELL_TYPE", 339, 341], ["epithelial or endothelial cells", "CELL_TYPE", 378, 409], ["mesenchymal cells", "CELL_TYPE", 414, 431], ["novel strategies", "TREATMENT", 195, 211], ["microbial invasions", "PROBLEM", 230, 249], ["pathology", "TEST", 254, 263], ["a specialized extracellular matrix", "TREATMENT", 272, 306], ["epithelial or endothelial cells", "PROBLEM", 378, 409], ["mesenchymal cells", "PROBLEM", 414, 431], ["BM", "OBSERVATION", 268, 270], ["BM", "OBSERVATION", 339, 341], ["subtle", "OBSERVATION_MODIFIER", 353, 359], ["interface", "OBSERVATION", 360, 369], ["epithelial", "ANATOMY_MODIFIER", 378, 388], ["endothelial cells", "OBSERVATION", 392, 409], ["mesenchymal cells", "OBSERVATION", 414, 431], ["connective tissue", "OBSERVATION", 443, 460]]], ["Besides providing tissue structure, the BM plays an important role in structural integrity, cell behavior and signaling [1].", [["tissue structure", "ANATOMY", 18, 34], ["BM", "ANATOMY", 40, 42], ["cell", "ANATOMY", 92, 96], ["tissue", "TISSUE", 18, 24], ["BM", "CELL", 40, 42], ["cell", "CELL", 92, 96], ["BM", "OBSERVATION", 40, 42]]], ["In proximity to epithelial cells, BM components such as collagen XVII and laminin 5, 6 and 10 are linked to extracellular parts of different molecules, mainly belonging to the integrin family (e.g. \u03b16\u03b24, \u03b15\u03b21 and \u03b19\u03b21) and fibronectin network, present on basolateral cell surfaces.", [["epithelial cells", "ANATOMY", 16, 32], ["BM components", "ANATOMY", 34, 47], ["extracellular parts", "ANATOMY", 108, 127], ["basolateral cell surfaces", "ANATOMY", 255, 280], ["epithelial cells", "CELL", 16, 32], ["BM", "CELL", 34, 36], ["collagen XVII", "GENE_OR_GENE_PRODUCT", 56, 69], ["laminin 5", "GENE_OR_GENE_PRODUCT", 74, 83], ["6", "GENE_OR_GENE_PRODUCT", 85, 86], ["10", "GENE_OR_GENE_PRODUCT", 91, 93], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 108, 121], ["integrin", "GENE_OR_GENE_PRODUCT", 176, 184], ["\u03b16\u03b24", "GENE_OR_GENE_PRODUCT", 198, 202], ["\u03b15\u03b21", "GENE_OR_GENE_PRODUCT", 204, 208], ["\u03b19\u03b21", "GENE_OR_GENE_PRODUCT", 213, 217], ["fibronectin", "GENE_OR_GENE_PRODUCT", 223, 234], ["basolateral cell surfaces", "CELLULAR_COMPONENT", 255, 280], ["epithelial cells", "CELL_TYPE", 16, 32], ["collagen XVII", "PROTEIN", 56, 69], ["laminin 5, 6 and 10", "PROTEIN", 74, 93], ["integrin family", "PROTEIN", 176, 191], ["\u03b16\u03b24", "PROTEIN", 198, 202], ["\u03b15\u03b21", "PROTEIN", 204, 208], ["\u03b19\u03b21", "PROTEIN", 213, 217], ["fibronectin network", "PROTEIN", 223, 242], ["epithelial cells", "PROBLEM", 16, 32], ["BM components", "PROBLEM", 34, 47], ["collagen XVII and laminin", "TREATMENT", 56, 81], ["fibronectin network", "PROBLEM", 223, 242], ["epithelial cells", "OBSERVATION", 16, 32], ["BM components", "OBSERVATION", 34, 47], ["collagen", "OBSERVATION_MODIFIER", 56, 64], ["fibronectin network", "OBSERVATION", 223, 242], ["basolateral", "ANATOMY_MODIFIER", 255, 266], ["cell surfaces", "OBSERVATION", 267, 280]]], ["At the cellular\u2013matrix interface, located underneath the cell-neighboring elements collagen IV, VII and XVIII, laminin 1, entactin/nidogen, BM-40/osteonectin, fibulins and proteoglycans such as bamacan, agrin, perlecan are abundant.", [["cell", "ANATOMY", 57, 61], ["cell", "CELL", 57, 61], ["collagen IV", "GENE_OR_GENE_PRODUCT", 83, 94], ["VII", "GENE_OR_GENE_PRODUCT", 96, 99], ["XVIII", "GENE_OR_GENE_PRODUCT", 104, 109], ["laminin 1", "GENE_OR_GENE_PRODUCT", 111, 120], ["entactin", "GENE_OR_GENE_PRODUCT", 122, 130], ["nidogen", "GENE_OR_GENE_PRODUCT", 131, 138], ["BM-40", "GENE_OR_GENE_PRODUCT", 140, 145], ["osteonectin", "GENE_OR_GENE_PRODUCT", 146, 157], ["fibulins", "GENE_OR_GENE_PRODUCT", 159, 167], ["proteoglycans", "GENE_OR_GENE_PRODUCT", 172, 185], ["bamacan", "GENE_OR_GENE_PRODUCT", 194, 201], ["agrin", "GENE_OR_GENE_PRODUCT", 203, 208], ["perlecan", "GENE_OR_GENE_PRODUCT", 210, 218], ["collagen IV", "PROTEIN", 83, 94], ["VII", "DNA", 96, 99], ["XVIII", "DNA", 104, 109], ["laminin 1", "PROTEIN", 111, 120], ["entactin", "PROTEIN", 122, 130], ["nidogen", "DNA", 131, 138], ["BM-40", "DNA", 140, 145], ["osteonectin", "PROTEIN", 146, 157], ["fibulins", "DNA", 159, 167], ["bamacan", "DNA", 194, 201], ["agrin", "PROTEIN", 203, 208], ["perlecan", "DNA", 210, 218], ["collagen IV", "TREATMENT", 83, 94], ["XVIII, laminin", "TREATMENT", 104, 118], ["entactin/nidogen", "TREATMENT", 122, 138], ["BM", "TEST", 140, 142], ["osteonectin", "TREATMENT", 146, 157], ["fibulins and proteoglycans", "TREATMENT", 159, 185], ["bamacan", "TREATMENT", 194, 201], ["cell", "ANATOMY", 57, 61], ["BM", "ANATOMY", 140, 142]]], ["Towards the lamina propria, collagen I, III, V and VI appear next to proteoglycans.", [["lamina propria", "ANATOMY", 12, 26], ["lamina propria", "TISSUE", 12, 26], ["collagen I", "GENE_OR_GENE_PRODUCT", 28, 38], ["III", "GENE_OR_GENE_PRODUCT", 40, 43], ["V", "GENE_OR_GENE_PRODUCT", 45, 46], ["VI", "GENE_OR_GENE_PRODUCT", 51, 53], ["proteoglycans", "GENE_OR_GENE_PRODUCT", 69, 82], ["collagen I, III, V and VI", "PROTEIN", 28, 53], ["lamina propria", "ANATOMY", 12, 26]]], ["Overall, the BM represents a firm network of the main components, collagen and laminin, bridged by various other components (Figure 1).", [["BM", "ANATOMY", 13, 15], ["BM", "CELL", 13, 15], ["collagen", "GENE_OR_GENE_PRODUCT", 66, 74], ["laminin", "GENE_OR_GENE_PRODUCT", 79, 86], ["collagen", "PROTEIN", 66, 74], ["laminin", "PROTEIN", 79, 86], ["collagen and laminin", "TREATMENT", 66, 86], ["BM", "OBSERVATION", 13, 15], ["firm", "OBSERVATION", 29, 33], ["main", "OBSERVATION_MODIFIER", 49, 53]]], ["Importantly, the average pore size in the collagen\u2013laminin network is approximately 50 nm, which allows only very small particles to diffuse across this thin but firm barrier 2, 3.", [["pore", "ANATOMY", 25, 29], ["collagen\u2013laminin network", "MULTI-TISSUE_STRUCTURE", 42, 66], ["collagen\u2013laminin network", "PROTEIN", 42, 66], ["very small particles", "PROBLEM", 109, 129], ["average", "OBSERVATION_MODIFIER", 17, 24], ["pore", "OBSERVATION_MODIFIER", 25, 29], ["size", "OBSERVATION_MODIFIER", 30, 34], ["approximately", "OBSERVATION_MODIFIER", 70, 83], ["50 nm", "OBSERVATION_MODIFIER", 84, 89], ["very", "OBSERVATION_MODIFIER", 109, 113], ["small", "OBSERVATION_MODIFIER", 114, 119], ["particles", "OBSERVATION", 120, 129], ["diffuse", "OBSERVATION_MODIFIER", 133, 140], ["firm", "OBSERVATION", 162, 166]]], ["This implies that microorganisms have devised ways to cross the BM.Collagen, the superhelix ::: Adhesion of pathogens to BM componentsThree collagen polypeptide chains, called \u03b1 chains, are rich in proline and glycine and together constitute a long, stiff, rope-like superhelix known as the typical collagen molecule 1, 2, 3, 20.", [["BM", "ANATOMY", 64, 66], ["BM components", "ANATOMY", 121, 134], ["proline", "CHEMICAL", 198, 205], ["glycine", "CHEMICAL", 210, 217], ["proline", "CHEMICAL", 198, 205], ["glycine", "CHEMICAL", 210, 217], ["BM", "TISSUE", 64, 66], ["Collagen", "GENE_OR_GENE_PRODUCT", 67, 75], ["BM", "CELL", 121, 123], ["collagen", "GENE_OR_GENE_PRODUCT", 140, 148], ["\u03b1 chains", "GENE_OR_GENE_PRODUCT", 176, 184], ["proline", "AMINO_ACID", 198, 205], ["glycine", "AMINO_ACID", 210, 217], ["collagen molecule 1", "GENE_OR_GENE_PRODUCT", 299, 318], ["Collagen", "PROTEIN", 67, 75], ["collagen polypeptide chains", "PROTEIN", 140, 167], ["\u03b1 chains", "PROTEIN", 176, 184], ["superhelix", "PROTEIN", 267, 277], ["collagen molecule 1, 2, 3, 20", "PROTEIN", 299, 328], ["microorganisms", "PROBLEM", 18, 32], ["Adhesion of pathogens to BM components", "PROBLEM", 96, 134], ["Three collagen polypeptide chains", "TREATMENT", 134, 167], ["a long, stiff, rope-like superhelix", "PROBLEM", 242, 277], ["pathogens", "OBSERVATION", 108, 117], ["BM components", "OBSERVATION_MODIFIER", 121, 134], ["polypeptide chains", "OBSERVATION", 149, 167]]], ["Numerous bacteria are able to interact with collagens via their proper adhesins 20, 21, 22.", [["collagens", "GENE_OR_GENE_PRODUCT", 44, 53], ["collagens", "PROTEIN", 44, 53], ["adhesins 20, 21, 22", "PROTEIN", 71, 90], ["Numerous bacteria", "PROBLEM", 0, 17], ["bacteria", "OBSERVATION", 9, 17]]], ["For many bacterial species, the ability to interact with collagen in the BM is a prerequisite for invasiveness.", [["BM", "ANATOMY", 73, 75], ["collagen", "GENE_OR_GENE_PRODUCT", 57, 65], ["BM", "CELL", 73, 75], ["collagen", "PROTEIN", 57, 65], ["many bacterial species", "PROBLEM", 4, 26], ["collagen in the BM", "TREATMENT", 57, 75], ["bacterial species", "OBSERVATION", 9, 26], ["BM", "OBSERVATION", 73, 75]]], ["For example, PilA from Streptococcus agalactiae, causing meningitis in newborns, binds collagen I, which promotes interaction with integrins and subsequent penetration of the blood\u2013brain barrier (BBB) [23].Collagen, the superhelix ::: Adhesion of pathogens to BM componentsSome fungal pathogens also interact with collagens during host invasion using distinct fungal receptors.", [["blood\u2013brain barrier", "ANATOMY", 175, 194], ["BM components", "ANATOMY", 260, 273], ["PilA", "CHEMICAL", 13, 17], ["Streptococcus agalactiae", "DISEASE", 23, 47], ["meningitis", "DISEASE", 57, 67], ["PilA", "GENE_OR_GENE_PRODUCT", 13, 17], ["Streptococcus agalactiae", "ORGANISM", 23, 47], ["newborns", "ORGANISM", 71, 79], ["collagen I", "GENE_OR_GENE_PRODUCT", 87, 97], ["integrins", "GENE_OR_GENE_PRODUCT", 131, 140], ["blood\u2013brain barrier", "TISSUE", 175, 194], ["BBB", "MULTI-TISSUE_STRUCTURE", 196, 199], ["Collagen", "GENE_OR_GENE_PRODUCT", 206, 214], ["BM", "CELL", 260, 262], ["collagens", "GENE_OR_GENE_PRODUCT", 314, 323], ["PilA", "PROTEIN", 13, 17], ["collagen I", "PROTEIN", 87, 97], ["integrins", "PROTEIN", 131, 140], ["Collagen", "PROTEIN", 206, 214], ["collagens", "PROTEIN", 314, 323], ["fungal receptors", "PROTEIN", 360, 376], ["Streptococcus agalactiae", "SPECIES", 23, 47], ["Streptococcus agalactiae", "SPECIES", 23, 47], ["PilA", "PROBLEM", 13, 17], ["Streptococcus agalactiae", "PROBLEM", 23, 47], ["meningitis", "PROBLEM", 57, 67], ["integrins", "TREATMENT", 131, 140], ["the blood\u2013brain barrier", "TREATMENT", 171, 194], ["Adhesion of pathogens to BM components", "PROBLEM", 235, 273], ["Some fungal pathogens", "PROBLEM", 273, 294], ["distinct fungal receptors", "PROBLEM", 351, 376], ["PilA", "ANATOMY", 13, 17], ["Streptococcus agalactiae", "OBSERVATION", 23, 47], ["meningitis", "OBSERVATION", 57, 67], ["pathogens", "OBSERVATION", 247, 256], ["BM components", "OBSERVATION_MODIFIER", 260, 273], ["fungal pathogens", "OBSERVATION", 278, 294], ["fungal receptors", "OBSERVATION", 360, 376]]], ["Aspergillus fumigatus contains a sialic acid-specific lectin that interacts with collagen types I and IV [24].", [["Aspergillus fumigatus", "ORGANISM", 0, 21], ["sialic acid-specific lectin", "GENE_OR_GENE_PRODUCT", 33, 60], ["collagen types I", "GENE_OR_GENE_PRODUCT", 81, 97], ["sialic acid-specific lectin", "PROTEIN", 33, 60], ["collagen", "PROTEIN", 81, 89], ["Aspergillus fumigatus", "SPECIES", 0, 21], ["Aspergillus fumigatus", "SPECIES", 0, 21], ["Aspergillus fumigatus", "PROBLEM", 0, 21], ["a sialic acid-specific lectin", "PROBLEM", 31, 60], ["fumigatus", "OBSERVATION", 12, 21], ["sialic", "ANATOMY_MODIFIER", 33, 39], ["acid-specific lectin", "OBSERVATION", 40, 60], ["collagen types", "OBSERVATION_MODIFIER", 81, 95]]], ["Similarly, the Als3p glycoprotein, a major player in C. albicans pathogenesis, is responsible for binding collagen IV [25].", [["Als3p glycoprotein", "GENE_OR_GENE_PRODUCT", 15, 33], ["C. albicans", "ORGANISM", 53, 64], ["collagen IV", "GENE_OR_GENE_PRODUCT", 106, 117], ["Als3p glycoprotein", "PROTEIN", 15, 33], ["collagen IV", "PROTEIN", 106, 117], ["C. albicans", "SPECIES", 53, 64], ["C. albicans", "SPECIES", 53, 64], ["binding collagen IV", "TREATMENT", 98, 117]]], ["Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and glycoprotein gp43 of Paracoccidioides brasiliensis bind type I collagen.", [["Glyceraldehyde-3-phosphate", "CHEMICAL", 0, 26], ["Glyceraldehyde-3-phosphate", "CHEMICAL", 0, 26], ["Glyceraldehyde-3-phosphate dehydrogenase", "GENE_OR_GENE_PRODUCT", 0, 40], ["GAPDH", "GENE_OR_GENE_PRODUCT", 42, 47], ["gp43", "GENE_OR_GENE_PRODUCT", 66, 70], ["Paracoccidioides brasiliensis", "ORGANISM", 74, 103], ["type I collagen", "GENE_OR_GENE_PRODUCT", 109, 124], ["Glyceraldehyde-3-phosphate dehydrogenase", "PROTEIN", 0, 40], ["GAPDH", "PROTEIN", 42, 47], ["glycoprotein gp43", "PROTEIN", 53, 70], ["type I collagen", "PROTEIN", 109, 124], ["Paracoccidioides brasiliensis", "SPECIES", 74, 103], ["Paracoccidioides brasiliensis", "SPECIES", 74, 103], ["Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)", "TREATMENT", 0, 48], ["glycoprotein gp43", "TREATMENT", 53, 70], ["Paracoccidioides brasiliensis bind type I collagen", "TREATMENT", 74, 124], ["Paracoccidioides brasiliensis", "OBSERVATION", 74, 103]]], ["Gp43 also binds type IV collagens and laminin, probably via a sialic acid recognition system, similar to A. fumigatus[24].", [["sialic acid", "CHEMICAL", 62, 73], ["sialic acid", "CHEMICAL", 62, 73], ["Gp43", "GENE_OR_GENE_PRODUCT", 0, 4], ["type IV collagens", "GENE_OR_GENE_PRODUCT", 16, 33], ["laminin", "GENE_OR_GENE_PRODUCT", 38, 45], ["sialic acid", "SIMPLE_CHEMICAL", 62, 73], ["A. fumigatus", "ORGANISM", 105, 117], ["Gp43", "PROTEIN", 0, 4], ["type IV collagens", "PROTEIN", 16, 33], ["laminin", "PROTEIN", 38, 45], ["A. fumigatus", "SPECIES", 105, 117], ["A. fumigatus", "SPECIES", 105, 117], ["type IV collagens and laminin", "TREATMENT", 16, 45], ["a sialic acid recognition system", "TREATMENT", 60, 92], ["type IV collagens", "OBSERVATION_MODIFIER", 16, 33], ["fumigatus", "OBSERVATION", 108, 117]]], ["However, for most fungi, adhesins and adhesive mechanisms are still largely unknown 13, 14.Collagen, the superhelix ::: Adhesion of pathogens to BM componentsSo far, viral binding to collagen has not been described.The multidomain glycoprotein laminin ::: Adhesion of pathogens to BM componentsThree laminin chains (\u03b1,\u03b2,\u03b3) form an asymmetric cross-like subunit via disulfide bonds.", [["BM components", "ANATOMY", 145, 158], ["BM components", "ANATOMY", 281, 294], ["disulfide", "CHEMICAL", 365, 374], ["Collagen", "GENE_OR_GENE_PRODUCT", 91, 99], ["BM", "CELL", 145, 147], ["collagen", "GENE_OR_GENE_PRODUCT", 183, 191], ["laminin", "GENE_OR_GENE_PRODUCT", 244, 251], ["BM", "CELL", 281, 283], ["laminin", "GENE_OR_GENE_PRODUCT", 300, 307], ["\u03b1", "GENE_OR_GENE_PRODUCT", 316, 317], ["\u03b2", "GENE_OR_GENE_PRODUCT", 318, 319], ["\u03b3", "GENE_OR_GENE_PRODUCT", 320, 321], ["disulfide bonds", "SIMPLE_CHEMICAL", 365, 380], ["Collagen", "PROTEIN", 91, 99], ["collagen", "PROTEIN", 183, 191], ["multidomain glycoprotein laminin", "PROTEIN", 219, 251], ["laminin chains", "PROTEIN", 300, 314], ["\u03b1", "PROTEIN", 316, 317], ["\u03b2", "PROTEIN", 318, 319], ["\u03b3", "PROTEIN", 320, 321], ["asymmetric cross-like subunit", "PROTEIN", 331, 360], ["adhesive mechanisms", "TEST", 38, 57], ["Adhesion of pathogens to BM components", "PROBLEM", 120, 158], ["viral binding", "PROBLEM", 166, 179], ["Adhesion of pathogens to BM components", "PROBLEM", 256, 294], ["Three laminin chains", "TEST", 294, 314], ["an asymmetric cross", "PROBLEM", 328, 347], ["pathogens", "OBSERVATION", 132, 141], ["BM components", "OBSERVATION_MODIFIER", 145, 158], ["viral binding", "OBSERVATION", 166, 179], ["glycoprotein laminin", "OBSERVATION", 231, 251], ["pathogens", "OBSERVATION", 268, 277], ["BM components", "OBSERVATION_MODIFIER", 281, 294], ["asymmetric", "OBSERVATION", 331, 341], ["disulfide bonds", "OBSERVATION", 365, 380]]], ["This non-collagenous protein contains multiple binding domains for interactions with ECM components (domains III, IV, V and VI) and with cellular receptors (G domain) 1, 2, 3.", [["ECM components", "ANATOMY", 85, 99], ["cellular", "ANATOMY", 137, 145], ["ECM components", "CELLULAR_COMPONENT", 85, 99], ["domains III, IV, V", "GENE_OR_GENE_PRODUCT", 101, 119], ["cellular", "CELL", 137, 145], ["G domain) 1", "GENE_OR_GENE_PRODUCT", 157, 168], ["non-collagenous protein", "PROTEIN", 5, 28], ["multiple binding domains", "PROTEIN", 38, 62], ["ECM components", "PROTEIN", 85, 99], ["domains III, IV, V and VI", "PROTEIN", 101, 126], ["cellular receptors", "PROTEIN", 137, 155], ["G domain) 1, 2, 3", "PROTEIN", 157, 174], ["This non-collagenous protein", "PROBLEM", 0, 28], ["multiple binding domains", "PROBLEM", 38, 62], ["ECM components", "TEST", 85, 99], ["multiple", "OBSERVATION_MODIFIER", 38, 46], ["binding domains", "OBSERVATION", 47, 62]]], ["As described for collagen, many different bacteria and fungi are able to interact with laminins via adhesive proteins 6, 26, 27, 28, 29.", [["collagen", "GENE_OR_GENE_PRODUCT", 17, 25], ["laminins", "GENE_OR_GENE_PRODUCT", 87, 95], ["collagen", "PROTEIN", 17, 25], ["laminins", "PROTEIN", 87, 95], ["adhesive proteins 6, 26, 27, 28, 29", "PROTEIN", 100, 135], ["collagen", "PROBLEM", 17, 25], ["many different bacteria", "PROBLEM", 27, 50], ["fungi", "PROBLEM", 55, 60], ["laminins via adhesive proteins", "TEST", 87, 117], ["bacteria", "OBSERVATION", 42, 50]]], ["Most adhesins recognize multiple molecules.", [["adhesins", "PROTEIN", 5, 13], ["multiple", "OBSERVATION_MODIFIER", 24, 32], ["molecules", "OBSERVATION", 33, 42]]], ["However, there are adhesins that bind laminin but not collagen.", [["laminin", "GENE_OR_GENE_PRODUCT", 38, 45], ["collagen", "GENE_OR_GENE_PRODUCT", 54, 62], ["adhesins", "PROTEIN", 19, 27], ["laminin", "PROTEIN", 38, 45], ["collagen", "PROTEIN", 54, 62]]], ["Lsa24 and Lsa27 of Leptospira interrogans[26], Lmb of Streptococcus agalactiae[27] and others act as specific laminin-binding adhesins.", [["Lsa24", "GENE_OR_GENE_PRODUCT", 0, 5], ["Lsa27", "GENE_OR_GENE_PRODUCT", 10, 15], ["Leptospira interrogans", "ORGANISM", 19, 41], ["Lmb", "GENE_OR_GENE_PRODUCT", 47, 50], ["Streptococcus agalactiae", "ORGANISM", 54, 78], ["laminin-binding adhesins", "GENE_OR_GENE_PRODUCT", 110, 134], ["Lsa24", "PROTEIN", 0, 5], ["laminin-binding adhesins", "PROTEIN", 110, 134], ["Leptospira interrogans", "SPECIES", 19, 41], ["Streptococcus agalactiae", "SPECIES", 54, 78], ["Leptospira interrogans", "SPECIES", 19, 41], ["Streptococcus agalactiae", "SPECIES", 54, 78], ["Lsa24", "TEST", 0, 5], ["Leptospira interrogans", "TEST", 19, 41], ["Streptococcus agalactiae", "PROBLEM", 54, 78]]], ["Recently, ErpX of Borellia burgdorferi was found to have a unique mode of laminin binding through a hydrophobic segment at the center of the bacterial protein.", [["ErpX", "CHEMICAL", 10, 14], ["ErpX", "GENE_OR_GENE_PRODUCT", 10, 14], ["Borellia burgdorferi", "ORGANISM", 18, 38], ["laminin", "GENE_OR_GENE_PRODUCT", 74, 81], ["ErpX", "PROTEIN", 10, 14], ["laminin", "PROTEIN", 74, 81], ["hydrophobic segment", "PROTEIN", 100, 119], ["bacterial protein", "PROTEIN", 141, 158], ["Borellia burgdorferi", "SPECIES", 18, 38], ["Borellia burgdorferi", "SPECIES", 18, 38], ["laminin binding", "PROBLEM", 74, 89], ["laminin", "OBSERVATION", 74, 81], ["bacterial protein", "OBSERVATION", 141, 158]]], ["This protein motif has not been identified yet in other bacterial laminin adhesins [29].The multidomain glycoprotein laminin ::: Adhesion of pathogens to BM componentsFor human papillomaviruses (HPV), recent work has proposed laminin 5 as a possible basal ECM receptor.", [["BM components", "ANATOMY", 154, 167], ["basal ECM", "ANATOMY", 250, 259], ["human papillomaviruses", "DISEASE", 171, 193], ["laminin", "GENE_OR_GENE_PRODUCT", 66, 73], ["laminin", "GENE_OR_GENE_PRODUCT", 117, 124], ["BM", "CELL", 154, 156], ["human", "ORGANISM", 171, 176], ["papillomaviruses", "ORGANISM", 177, 193], ["HPV", "ORGANISM", 195, 198], ["laminin 5", "GENE_OR_GENE_PRODUCT", 226, 235], ["basal ECM", "CELLULAR_COMPONENT", 250, 259], ["bacterial laminin adhesins", "PROTEIN", 56, 82], ["multidomain glycoprotein laminin", "PROTEIN", 92, 124], ["laminin 5", "PROTEIN", 226, 235], ["basal ECM receptor", "PROTEIN", 250, 268], ["human", "SPECIES", 171, 176], ["human papillomaviruses", "SPECIES", 171, 193], ["HPV", "SPECIES", 195, 198], ["This protein motif", "PROBLEM", 0, 18], ["Adhesion of pathogens to BM components", "PROBLEM", 129, 167], ["human papillomaviruses", "PROBLEM", 171, 193], ["proposed laminin", "TREATMENT", 217, 233], ["basal ECM receptor", "TREATMENT", 250, 268], ["glycoprotein laminin", "OBSERVATION", 104, 124], ["pathogens", "OBSERVATION", 141, 150], ["BM components", "OBSERVATION_MODIFIER", 154, 167]]], ["This interaction localizes virus particles to the basal surface of epithelial cells where they can reach their entry receptor, integrin \u03b16\u03b24, the physiological binding partner of laminin 5 [30].", [["basal surface", "ANATOMY", 50, 63], ["epithelial cells", "ANATOMY", 67, 83], ["basal surface", "CELLULAR_COMPONENT", 50, 63], ["epithelial cells", "CELL", 67, 83], ["integrin \u03b16\u03b24", "GENE_OR_GENE_PRODUCT", 127, 140], ["laminin", "GENE_OR_GENE_PRODUCT", 179, 186], ["epithelial cells", "CELL_TYPE", 67, 83], ["entry receptor", "PROTEIN", 111, 125], ["integrin \u03b16\u03b24", "PROTEIN", 127, 140], ["laminin 5", "PROTEIN", 179, 188], ["basal", "ANATOMY_MODIFIER", 50, 55], ["epithelial cells", "OBSERVATION", 67, 83]]], ["However, another recent publication demonstrated that different HPV types show different binding characteristics (Figure 2) [31].", [["HPV", "ORGANISM", 64, 67], ["different HPV types", "PROBLEM", 54, 73]]], ["The nonstructural protein NSP4 of rotavirus plays a key role in the development of severe gastroenteritis by binding ECM proteins laminin \u03b23 and fibronectin.", [["gastroenteritis", "DISEASE", 90, 105], ["NSP4", "GENE_OR_GENE_PRODUCT", 26, 30], ["rotavirus", "ORGANISM", 34, 43], ["ECM", "CELLULAR_COMPONENT", 117, 120], ["laminin \u03b23", "GENE_OR_GENE_PRODUCT", 130, 140], ["fibronectin", "GENE_OR_GENE_PRODUCT", 145, 156], ["nonstructural protein", "PROTEIN", 4, 25], ["NSP4", "PROTEIN", 26, 30], ["ECM proteins", "PROTEIN", 117, 129], ["laminin \u03b23", "PROTEIN", 130, 140], ["fibronectin", "PROTEIN", 145, 156], ["rotavirus", "SPECIES", 34, 43], ["The nonstructural protein NSP4", "TEST", 0, 30], ["rotavirus", "PROBLEM", 34, 43], ["severe gastroenteritis", "PROBLEM", 83, 105], ["binding ECM proteins laminin \u03b23", "TREATMENT", 109, 140], ["fibronectin", "TREATMENT", 145, 156], ["nonstructural protein NSP4", "OBSERVATION", 4, 30], ["severe", "OBSERVATION_MODIFIER", 83, 89], ["gastroenteritis", "OBSERVATION", 90, 105]]], ["Moreover, rotavirus induces phosphatidylinositol 3-kinase (PI3K) activation in intestinal cells, causing upregulation of integrin expression, prolonged attachment of infected cells to collagen and increased virus production 32, 33.The heterogeneous molecule: proteoglycan ::: Adhesion of pathogens to BM componentsTo be typed as a proteoglycan, at least one of the sugar side chains of a molecule has to be a glycosaminoglycan (GAG).", [["intestinal cells", "ANATOMY", 79, 95], ["cells", "ANATOMY", 175, 180], ["BM components", "ANATOMY", 301, 314], ["glycosaminoglycan", "CHEMICAL", 409, 426], ["phosphatidylinositol", "CHEMICAL", 28, 48], ["sugar", "CHEMICAL", 365, 370], ["rotavirus", "ORGANISM", 10, 19], ["phosphatidylinositol 3-kinase", "GENE_OR_GENE_PRODUCT", 28, 57], ["PI3K", "GENE_OR_GENE_PRODUCT", 59, 63], ["intestinal cells", "CELL", 79, 95], ["integrin", "GENE_OR_GENE_PRODUCT", 121, 129], ["cells", "CELL", 175, 180], ["collagen", "GENE_OR_GENE_PRODUCT", 184, 192], ["proteoglycan", "SIMPLE_CHEMICAL", 259, 271], ["BM", "CELL", 301, 303], ["glycosaminoglycan", "SIMPLE_CHEMICAL", 409, 426], ["GAG", "SIMPLE_CHEMICAL", 428, 431], ["phosphatidylinositol 3-kinase", "PROTEIN", 28, 57], ["PI3K", "PROTEIN", 59, 63], ["intestinal cells", "CELL_TYPE", 79, 95], ["integrin", "PROTEIN", 121, 129], ["infected cells", "CELL_TYPE", 166, 180], ["collagen", "PROTEIN", 184, 192], ["rotavirus", "SPECIES", 10, 19], ["rotavirus induces phosphatidylinositol", "TREATMENT", 10, 48], ["activation in intestinal cells", "PROBLEM", 65, 95], ["integrin expression", "PROBLEM", 121, 140], ["infected cells", "PROBLEM", 166, 180], ["increased virus production", "PROBLEM", 197, 223], ["Adhesion of pathogens to BM components", "PROBLEM", 276, 314], ["a molecule", "PROBLEM", 386, 396], ["intestinal cells", "ANATOMY", 79, 95], ["integrin expression", "OBSERVATION", 121, 140], ["infected cells", "OBSERVATION", 166, 180], ["increased", "OBSERVATION_MODIFIER", 197, 206], ["virus", "OBSERVATION", 207, 212], ["heterogeneous", "OBSERVATION_MODIFIER", 235, 248], ["molecule", "OBSERVATION", 249, 257], ["pathogens", "OBSERVATION", 288, 297], ["BM components", "OBSERVATION_MODIFIER", 301, 314]]], ["All GAGs are covalently bound via a tetrasaccharide link to a serine amino acid in the core protein, the central polypeptide chain of proteoglycans 1, 2, 3.", [["amino acid", "CHEMICAL", 69, 79], ["tetrasaccharide", "CHEMICAL", 36, 51], ["serine amino acid", "CHEMICAL", 62, 79], ["GAGs", "GENE_OR_GENE_PRODUCT", 4, 8], ["serine", "AMINO_ACID", 62, 68], ["amino acid", "AMINO_ACID", 69, 79], ["proteoglycans 1", "GENE_OR_GENE_PRODUCT", 134, 149], ["3", "GENE_OR_GENE_PRODUCT", 154, 155], ["core protein", "PROTEIN", 87, 99], ["central polypeptide chain", "PROTEIN", 105, 130], ["proteoglycans 1, 2, 3", "PROTEIN", 134, 155], ["a serine amino acid", "TREATMENT", 60, 79], ["the central polypeptide chain of proteoglycans", "TREATMENT", 101, 147], ["central", "ANATOMY_MODIFIER", 105, 112]]], ["The ability to interact with proteoglycans, often heparan sulfate proteoglycans, is widespread in viruses and bacteria 34, 35.", [["heparan sulfate", "CHEMICAL", 50, 65], ["sulfate", "CHEMICAL", 58, 65], ["heparan sulfate proteoglycans", "GENE_OR_GENE_PRODUCT", 50, 79], ["proteoglycans", "TREATMENT", 29, 42], ["often heparan sulfate proteoglycans", "TREATMENT", 44, 79], ["bacteria", "TEST", 110, 118]]], ["A clear distinction has to be made in this context between cell-surface proteoglycans, ECM-associated proteoglycans in general and specific proteoglycans residing inside the BM.", [["cell", "ANATOMY", 59, 63], ["surface", "ANATOMY", 64, 71], ["ECM", "ANATOMY", 87, 90], ["BM", "ANATOMY", 174, 176], ["cell", "CELL", 59, 63], ["surface proteoglycans", "CELLULAR_COMPONENT", 64, 85], ["ECM", "CELLULAR_COMPONENT", 87, 90], ["proteoglycans", "GENE_OR_GENE_PRODUCT", 140, 153], ["BM", "TISSUE", 174, 176], ["cell-surface proteoglycans", "PROTEIN", 59, 85], ["ECM-associated proteoglycans", "PROTEIN", 87, 115], ["clear", "OBSERVATION", 2, 7], ["BM", "ANATOMY", 174, 176]]], ["Despite the numerous reports on pathogens interacting with ECM-associated proteoglycans in general 34, 35, no specific pathogen BM agrin or pathogen BM perlecan interactions have been described so far.The heterogeneous molecule: proteoglycan ::: Adhesion of pathogens to BM componentsCurrently, only one specific BM proteoglycan\u2013pathogen interaction is known.", [["ECM", "ANATOMY", 59, 62], ["BM", "ANATOMY", 128, 130], ["BM", "ANATOMY", 149, 151], ["BM components", "ANATOMY", 271, 284], ["BM", "ANATOMY", 313, 315], ["ECM", "CELLULAR_COMPONENT", 59, 62], ["agrin", "GENE_OR_GENE_PRODUCT", 131, 136], ["pathogen BM perlecan", "GENE_OR_GENE_PRODUCT", 140, 160], ["proteoglycan", "SIMPLE_CHEMICAL", 229, 241], ["BM", "CELL", 271, 273], ["BM", "CELL", 313, 315], ["ECM", "PROTEIN", 59, 62], ["BM agrin", "PROTEIN", 128, 136], ["specific pathogen BM agrin", "PROBLEM", 110, 136], ["Adhesion of pathogens to BM components", "PROBLEM", 246, 284], ["heterogeneous", "OBSERVATION_MODIFIER", 205, 218], ["molecule", "OBSERVATION", 219, 227], ["pathogens", "OBSERVATION", 258, 267], ["BM components", "OBSERVATION_MODIFIER", 271, 284]]], ["The proteoglycan bamacan is a cellular ligand of vaccinia virus neurovirulence factor N1L.", [["cellular", "ANATOMY", 30, 38], ["bamacan", "CHEMICAL", 17, 24], ["proteoglycan", "GENE_OR_GENE_PRODUCT", 4, 16], ["cellular", "CELL", 30, 38], ["vaccinia virus", "ORGANISM", 49, 63], ["N1L", "GENE_OR_GENE_PRODUCT", 86, 89], ["vaccinia virus neurovirulence factor", "PROTEIN", 49, 85], ["N1L", "PROTEIN", 86, 89], ["vaccinia virus", "SPECIES", 49, 63], ["vaccinia virus", "SPECIES", 49, 63], ["The proteoglycan bamacan", "TREATMENT", 0, 24], ["vaccinia virus neurovirulence factor", "TREATMENT", 49, 85]]], ["This interaction promotes viral growth and might contribute to virulence of the virus [36].Entactin/nidogen, BM-40/osteonectin and fibulins: versatile ECM proteins ::: Adhesion of pathogens to BM componentsMembers of the nidogen family are composed of a series of sulfated monomeric glycoproteins.", [["ECM", "ANATOMY", 151, 154], ["BM components", "ANATOMY", 193, 206], ["Entactin", "GENE_OR_GENE_PRODUCT", 91, 99], ["nidogen", "GENE_OR_GENE_PRODUCT", 100, 107], ["BM-40", "GENE_OR_GENE_PRODUCT", 109, 114], ["osteonectin", "GENE_OR_GENE_PRODUCT", 115, 126], ["fibulins", "GENE_OR_GENE_PRODUCT", 131, 139], ["ECM", "CELLULAR_COMPONENT", 151, 154], ["nidogen", "GENE_OR_GENE_PRODUCT", 221, 228], ["Entactin", "PROTEIN", 91, 99], ["nidogen", "PROTEIN", 100, 107], ["BM-40", "PROTEIN", 109, 114], ["osteonectin", "PROTEIN", 115, 126], ["fibulins", "PROTEIN", 131, 139], ["ECM proteins", "PROTEIN", 151, 163], ["nidogen family", "PROTEIN", 221, 235], ["sulfated monomeric glycoproteins", "PROTEIN", 264, 296], ["the virus", "PROBLEM", 76, 85], ["Entactin/nidogen", "TREATMENT", 91, 107], ["BM", "TEST", 109, 111], ["Adhesion of pathogens", "PROBLEM", 168, 189], ["sulfated monomeric glycoproteins", "TREATMENT", 264, 296], ["viral growth", "OBSERVATION", 26, 38], ["BM", "ANATOMY", 109, 111], ["pathogens", "OBSERVATION", 180, 189]]], ["Three globules, G1, G2 and G3, and one rod-like part, possessing different domains, make up the typical triglobular shape of nidogen 1, 2, 3.", [["globules", "ANATOMY", 6, 14], ["nidogen", "CHEMICAL", 125, 132], ["nidogen 1", "GENE_OR_GENE_PRODUCT", 125, 134], ["nidogen 1, 2, 3", "PROTEIN", 125, 140], ["globules", "OBSERVATION_MODIFIER", 6, 14], ["triglobular shape", "OBSERVATION", 104, 121]]], ["BM-40 is a glycoprotein of the ECM that binds calcium, collagen and hydroxyapatite and regulates the cell\u2013matrix interaction 1, 2, 3.", [["ECM", "ANATOMY", 31, 34], ["calcium", "CHEMICAL", 46, 53], ["calcium", "CHEMICAL", 46, 53], ["hydroxyapatite", "CHEMICAL", 68, 82], ["BM-40", "GENE_OR_GENE_PRODUCT", 0, 5], ["ECM", "CELLULAR_COMPONENT", 31, 34], ["calcium", "SIMPLE_CHEMICAL", 46, 53], ["collagen", "GENE_OR_GENE_PRODUCT", 55, 63], ["hydroxyapatite", "SIMPLE_CHEMICAL", 68, 82], ["glycoprotein", "PROTEIN", 11, 23], ["ECM", "PROTEIN", 31, 34], ["collagen", "PROTEIN", 55, 63], ["cell\u2013matrix interaction 1, 2, 3", "PROTEIN", 101, 132], ["a glycoprotein of the ECM", "TREATMENT", 9, 34], ["calcium, collagen and hydroxyapatite", "TREATMENT", 46, 82]]], ["All fibulins contain epidermal growth factor-like repeats and a unique fibulin-type module at the C terminus that define this family [37].", [["fibulins", "GENE_OR_GENE_PRODUCT", 4, 12], ["epidermal growth factor", "GENE_OR_GENE_PRODUCT", 21, 44], ["fibulin", "GENE_OR_GENE_PRODUCT", 71, 78], ["fibulins", "PROTEIN", 4, 12], ["epidermal growth factor", "PROTEIN", 21, 44], ["fibulin", "PROTEIN", 71, 78], ["C terminus", "PROTEIN", 98, 108], ["epidermal growth factor", "PROBLEM", 21, 44], ["epidermal", "OBSERVATION_MODIFIER", 21, 30], ["growth", "OBSERVATION_MODIFIER", 31, 37]]], ["To date, only one bacterium that uses nidogen as a potential ligand for ECM binding has been reported.", [["ECM", "ANATOMY", 72, 75], ["nidogen", "CHEMICAL", 38, 45], ["nidogen", "CHEMICAL", 38, 45], ["nidogen", "GENE_OR_GENE_PRODUCT", 38, 45], ["ECM", "CELLULAR_COMPONENT", 72, 75], ["nidogen", "PROTEIN", 38, 45], ["ECM", "PROTEIN", 72, 75], ["nidogen", "TREATMENT", 38, 45], ["ECM binding", "PROBLEM", 72, 83]]], ["SgrA of Enterococcus faecium has been identified as a bacterial receptor for nidogen and fibronectin [38].", [["SgrA of Enterococcus faecium", "CHEMICAL", 0, 28], ["SgrA", "GENE_OR_GENE_PRODUCT", 0, 4], ["Enterococcus faecium", "ORGANISM", 8, 28], ["nidogen", "GENE_OR_GENE_PRODUCT", 77, 84], ["fibronectin", "GENE_OR_GENE_PRODUCT", 89, 100], ["SgrA", "PROTEIN", 0, 4], ["bacterial receptor", "PROTEIN", 54, 72], ["nidogen", "PROTEIN", 77, 84], ["fibronectin", "PROTEIN", 89, 100], ["Enterococcus faecium", "SPECIES", 8, 28], ["Enterococcus faecium", "SPECIES", 8, 28], ["Enterococcus faecium", "PROBLEM", 8, 28], ["a bacterial receptor for nidogen", "TREATMENT", 52, 84], ["fibronectin", "TEST", 89, 100], ["Enterococcus faecium", "OBSERVATION", 8, 28]]], ["The opportunistic bacterium Finegoldia magna depends on BM-40 interaction for colonization and survival [39].", [["BM-40", "ANATOMY", 56, 61], ["Finegoldia magna", "ORGANISM", 28, 44], ["BM-40", "CELL", 56, 61], ["Finegoldia magna", "SPECIES", 28, 44], ["Finegoldia magna", "SPECIES", 28, 44], ["The opportunistic bacterium", "PROBLEM", 0, 27], ["colonization", "PROBLEM", 78, 90], ["opportunistic", "OBSERVATION_MODIFIER", 4, 17], ["bacterium", "OBSERVATION_MODIFIER", 18, 27], ["Finegoldia magna", "OBSERVATION", 28, 44]]], ["Serum opacity factor is a streptococcal receptor for fibulin-1 [37].Entactin/nidogen, BM-40/osteonectin and fibulins: versatile ECM proteins ::: Adhesion of pathogens to BM componentsNo other bacteria, fungi or viruses are known to bind nidogen/entactin, BM-40 or fibulins during host invasion.Pathogen-driven breakdown of the BMDisruption of the BM in disease states often involves proteolytic enzymes [40] and an overview of the general characteristics of the different protease types is given elsewhere [41].", [["ECM", "ANATOMY", 128, 131], ["BM components", "ANATOMY", 170, 183], ["BM", "ANATOMY", 347, 349], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["fibulin-1", "GENE_OR_GENE_PRODUCT", 53, 62], ["Entactin", "GENE_OR_GENE_PRODUCT", 68, 76], ["nidogen", "GENE_OR_GENE_PRODUCT", 77, 84], ["BM-40", "GENE_OR_GENE_PRODUCT", 86, 91], ["osteonectin", "GENE_OR_GENE_PRODUCT", 92, 103], ["fibulins", "GENE_OR_GENE_PRODUCT", 108, 116], ["ECM", "CELLULAR_COMPONENT", 128, 131], ["BM", "CELL", 170, 172], ["nidogen", "GENE_OR_GENE_PRODUCT", 237, 244], ["entactin", "GENE_OR_GENE_PRODUCT", 245, 253], ["BM-40", "GENE_OR_GENE_PRODUCT", 255, 260], ["fibulins", "GENE_OR_GENE_PRODUCT", 264, 272], ["BM", "TISSUE", 347, 349], ["Serum opacity factor", "PROTEIN", 0, 20], ["streptococcal receptor", "PROTEIN", 26, 48], ["Entactin", "PROTEIN", 68, 76], ["nidogen", "PROTEIN", 77, 84], ["BM-40", "PROTEIN", 86, 91], ["osteonectin", "PROTEIN", 92, 103], ["fibulins", "PROTEIN", 108, 116], ["ECM proteins", "PROTEIN", 128, 140], ["nidogen", "PROTEIN", 237, 244], ["entactin", "PROTEIN", 245, 253], ["BM-40", "PROTEIN", 255, 260], ["fibulins", "PROTEIN", 264, 272], ["proteolytic enzymes", "PROTEIN", 383, 402], ["Serum opacity factor", "PROBLEM", 0, 20], ["a streptococcal receptor", "TEST", 24, 48], ["fibulin", "TEST", 53, 60], ["Entactin/nidogen", "TREATMENT", 68, 84], ["BM", "TEST", 86, 88], ["Adhesion of pathogens to BM components", "PROBLEM", 145, 183], ["other bacteria", "PROBLEM", 186, 200], ["fungi", "PROBLEM", 202, 207], ["viruses", "PROBLEM", 211, 218], ["entactin", "TEST", 245, 253], ["BM", "TEST", 255, 257], ["fibulins", "PROBLEM", 264, 272], ["Pathogen", "PROBLEM", 294, 302], ["the BM in disease states", "PROBLEM", 343, 367], ["proteolytic enzymes", "TEST", 383, 402], ["the different protease types", "TREATMENT", 458, 486], ["opacity", "OBSERVATION", 6, 13], ["BM", "ANATOMY", 86, 88], ["pathogens", "OBSERVATION", 157, 166], ["BM components", "OBSERVATION_MODIFIER", 170, 183], ["bacteria", "OBSERVATION", 192, 200], ["fungi", "OBSERVATION", 202, 207], ["viruses", "OBSERVATION", 211, 218], ["BM", "ANATOMY", 255, 257], ["invasion", "OBSERVATION", 285, 293], ["BM", "ANATOMY", 347, 349], ["disease", "OBSERVATION", 353, 360]]], ["Many pathogens possess the ability to produce or modulate ECM-degrading enzymes.", [["ECM", "ANATOMY", 58, 61], ["ECM", "CELLULAR_COMPONENT", 58, 61], ["ECM-degrading enzymes", "PROTEIN", 58, 79], ["Many pathogens", "PROBLEM", 0, 14]]], ["Regulation of ECM-degrading enzymes aids pathogens in invading deeper tissues, thereby enhancing dissemination throughout the host.", [["ECM", "ANATOMY", 14, 17], ["tissues", "ANATOMY", 70, 77], ["ECM-degrading enzymes", "GENE_OR_GENE_PRODUCT", 14, 35], ["deeper tissues", "TISSUE", 63, 77], ["ECM-degrading enzymes", "PROTEIN", 14, 35], ["invading", "OBSERVATION_MODIFIER", 54, 62], ["deeper tissues", "OBSERVATION_MODIFIER", 63, 77], ["enhancing", "OBSERVATION_MODIFIER", 87, 96], ["dissemination", "OBSERVATION", 97, 110]]], ["Besides this direct effect of pathogens on BM-degrading enzymes, pathogens might also indirectly affect such enzymes.", [["BM", "ANATOMY", 43, 45], ["BM", "CELL", 43, 45], ["BM-degrading enzymes", "PROTEIN", 43, 63], ["enzymes", "PROTEIN", 109, 116], ["pathogens on BM", "PROBLEM", 30, 45], ["pathogens", "PROBLEM", 65, 74], ["such enzymes", "TEST", 104, 116]]], ["Indeed, during inflammation of infected tissues, local immune cells produce an array of these proteolytic enzymes.", [["tissues", "ANATOMY", 40, 47], ["immune cells", "ANATOMY", 55, 67], ["inflammation", "DISEASE", 15, 27], ["tissues", "TISSUE", 40, 47], ["immune cells", "CELL", 55, 67], ["immune cells", "CELL_TYPE", 55, 67], ["proteolytic enzymes", "PROTEIN", 94, 113], ["infected tissues", "PROBLEM", 31, 47], ["local immune cells", "TREATMENT", 49, 67], ["these proteolytic enzymes", "TEST", 88, 113], ["inflammation", "OBSERVATION_MODIFIER", 15, 27], ["infected tissues", "OBSERVATION", 31, 47], ["immune cells", "OBSERVATION", 55, 67]]], ["This indirect activation of proteases is beyond the scope of this review.Pathogen-driven breakdown of the BMSeveral bacteria encode or modulate BM-degrading proteases, either directly or by engaging host-derived systems.Pathogen-driven breakdown of the BMVarious bacterial pathogens including Bacteroides fragilis and Clostridium perfringens[42] encode or modulate matrix metalloproteinases (MMPs).", [["BM", "ANATOMY", 144, 146], ["BM", "CELL", 144, 146], ["BMVarious bacterial pathogens", "ORGANISM", 253, 282], ["Bacteroides fragilis", "ORGANISM", 293, 313], ["Clostridium perfringens", "ORGANISM", 318, 341], ["matrix metalloproteinases", "GENE_OR_GENE_PRODUCT", 365, 390], ["MMPs", "GENE_OR_GENE_PRODUCT", 392, 396], ["proteases", "PROTEIN", 28, 37], ["BM-degrading proteases", "PROTEIN", 144, 166], ["matrix metalloproteinases", "PROTEIN", 365, 390], ["MMPs", "PROTEIN", 392, 396], ["Bacteroides fragilis", "SPECIES", 293, 313], ["Clostridium perfringens", "SPECIES", 318, 341], ["Bacteroides fragilis", "SPECIES", 293, 313], ["Clostridium perfringens", "SPECIES", 318, 341], ["proteases", "TREATMENT", 28, 37], ["Pathogen", "PROBLEM", 73, 81], ["the BMSeveral bacteria", "PROBLEM", 102, 124], ["modulate BM", "PROBLEM", 135, 146], ["Pathogen", "PROBLEM", 220, 228], ["the BMVarious bacterial pathogens", "PROBLEM", 249, 282], ["Bacteroides fragilis", "PROBLEM", 293, 313], ["Clostridium perfringens", "PROBLEM", 318, 341], ["modulate matrix metalloproteinases", "TREATMENT", 356, 390], ["Clostridium perfringens", "OBSERVATION_MODIFIER", 318, 341]]], ["Other bacteria degrade the BM barrier by encoding or modulating serine proteases.", [["BM barrier", "ANATOMY", 27, 37], ["serine", "CHEMICAL", 64, 70], ["BM barrier", "TISSUE", 27, 37], ["serine proteases", "PROTEIN", 64, 80], ["Other bacteria", "PROBLEM", 0, 14], ["the BM barrier", "TREATMENT", 23, 37], ["modulating serine proteases", "PROBLEM", 53, 80], ["bacteria", "OBSERVATION", 6, 14]]], ["Indeed, many bacterial pathogens, such as Enterobacteriaceae, Fusobacteriaceae, Helicobacteriaceae, Legionellaceae, Mycobacteriaceae, Neisseriaceae, Pasteurellaceae, Peptostreptococcaceae, Porphyromonadaceae, Pseudomonadaceae, Spirochaetaceae, Staphylococcaceae and Streptococcaceae, modulate the plasminogen (Plg)\u2013plasmin system [43] and the structural and functional aspects of this system are described elsewhere [44].", [["Porphyromonadaceae", "CHEMICAL", 189, 207], ["Enterobacteriaceae", "GENE_OR_GENE_PRODUCT", 42, 60], ["Fusobacteriaceae", "GENE_OR_GENE_PRODUCT", 62, 78], ["Helicobacteriaceae", "GENE_OR_GENE_PRODUCT", 80, 98], ["Legionellaceae", "GENE_OR_GENE_PRODUCT", 100, 114], ["Mycobacteriaceae", "GENE_OR_GENE_PRODUCT", 116, 132], ["Neisseriaceae", "GENE_OR_GENE_PRODUCT", 134, 147], ["Pasteurellaceae", "GENE_OR_GENE_PRODUCT", 149, 164], ["Peptostreptococcaceae", "GENE_OR_GENE_PRODUCT", 166, 187], ["Porphyromonadaceae", "GENE_OR_GENE_PRODUCT", 189, 207], ["Pseudomonadaceae", "GENE_OR_GENE_PRODUCT", 209, 225], ["Spirochaetaceae", "GENE_OR_GENE_PRODUCT", 227, 242], ["Staphylococcaceae", "GENE_OR_GENE_PRODUCT", 244, 261], ["Streptococcaceae", "GENE_OR_GENE_PRODUCT", 266, 282], ["plasminogen (Plg)\u2013plasmin", "GENE_OR_GENE_PRODUCT", 297, 322], ["plasminogen (Plg)\u2013plasmin", "PROTEIN", 297, 322], ["many bacterial pathogens", "PROBLEM", 8, 32], ["Enterobacteriaceae", "PROBLEM", 42, 60], ["Fusobacteriaceae", "PROBLEM", 62, 78], ["Helicobacteriaceae", "TEST", 80, 98], ["Legionellaceae", "TREATMENT", 100, 114], ["Mycobacteriaceae", "TREATMENT", 116, 132], ["Neisseriaceae", "TREATMENT", 134, 147], ["Pasteurellaceae", "PROBLEM", 149, 164], ["Peptostreptococcaceae", "TREATMENT", 166, 187], ["Porphyromonadaceae", "TREATMENT", 189, 207], ["Pseudomonadaceae", "TREATMENT", 209, 225], ["Spirochaetaceae", "TREATMENT", 227, 242], ["Staphylococcaceae", "TREATMENT", 244, 261], ["Streptococcaceae", "TREATMENT", 266, 282], ["the plasminogen (Plg)\u2013plasmin system", "TREATMENT", 293, 329], ["many", "OBSERVATION_MODIFIER", 8, 12], ["bacterial pathogens", "OBSERVATION", 13, 32], ["Enterobacteriaceae", "OBSERVATION", 42, 60]]], ["In brief, through the activity of the two main physiological plasminogen activators, urokinase-type plasminogen activator (uPA) and tissue-type plasminogen activator (tPA), plasminogen is converted to plasmin, which degrades laminin and fibronectin and activates precursors of MMPs.", [["plasminogen", "GENE_OR_GENE_PRODUCT", 61, 72], ["urokinase-type plasminogen activator", "GENE_OR_GENE_PRODUCT", 85, 121], ["uPA", "GENE_OR_GENE_PRODUCT", 123, 126], ["tissue-type plasminogen activator", "GENE_OR_GENE_PRODUCT", 132, 165], ["tPA", "GENE_OR_GENE_PRODUCT", 167, 170], ["plasminogen", "GENE_OR_GENE_PRODUCT", 173, 184], ["plasmin", "GENE_OR_GENE_PRODUCT", 201, 208], ["laminin", "GENE_OR_GENE_PRODUCT", 225, 232], ["fibronectin", "GENE_OR_GENE_PRODUCT", 237, 248], ["MMPs", "GENE_OR_GENE_PRODUCT", 277, 281], ["plasminogen activators", "PROTEIN", 61, 83], ["urokinase-type plasminogen activator", "PROTEIN", 85, 121], ["uPA", "PROTEIN", 123, 126], ["tissue-type plasminogen activator", "PROTEIN", 132, 165], ["tPA", "PROTEIN", 167, 170], ["plasminogen", "PROTEIN", 173, 184], ["plasmin", "PROTEIN", 201, 208], ["laminin", "PROTEIN", 225, 232], ["fibronectin", "PROTEIN", 237, 248], ["MMPs", "PROTEIN", 277, 281], ["physiological plasminogen activators", "TREATMENT", 47, 83], ["urokinase-type plasminogen activator (uPA", "TREATMENT", 85, 126], ["tissue-type plasminogen activator (tPA)", "TREATMENT", 132, 171], ["plasminogen", "TREATMENT", 173, 184], ["plasmin", "TREATMENT", 201, 208], ["laminin and fibronectin", "TREATMENT", 225, 248], ["MMPs", "PROBLEM", 277, 281]]], ["Several bacterial pathogens express plasminogen receptors, thereby recruiting plasminogen to the bacterial surface, which leads to enhanced plasminogen activation.", [["surface", "ANATOMY", 107, 114], ["plasminogen receptors", "GENE_OR_GENE_PRODUCT", 36, 57], ["plasminogen", "GENE_OR_GENE_PRODUCT", 78, 89], ["plasminogen", "GENE_OR_GENE_PRODUCT", 140, 151], ["plasminogen receptors", "PROTEIN", 36, 57], ["plasminogen", "PROTEIN", 78, 89], ["plasminogen", "PROTEIN", 140, 151], ["Several bacterial pathogens", "PROBLEM", 0, 27], ["plasminogen receptors", "TEST", 36, 57], ["recruiting plasminogen to the bacterial surface", "PROBLEM", 67, 114], ["enhanced plasminogen activation", "PROBLEM", 131, 162], ["bacterial", "OBSERVATION_MODIFIER", 8, 17], ["pathogens", "OBSERVATION", 18, 27], ["plasminogen receptors", "OBSERVATION", 36, 57], ["plasminogen", "OBSERVATION_MODIFIER", 78, 89], ["bacterial surface", "OBSERVATION_MODIFIER", 97, 114], ["enhanced", "OBSERVATION_MODIFIER", 131, 139], ["plasminogen activation", "OBSERVATION", 140, 162]]], ["In addition, some bacteria bind and/or induce uPA or tPA 43, 45 and/or express bacterial plasminogen activators.", [["uPA", "GENE_OR_GENE_PRODUCT", 46, 49], ["tPA", "GENE_OR_GENE_PRODUCT", 53, 56], ["bacterial plasminogen activators", "GENE_OR_GENE_PRODUCT", 79, 111], ["uPA", "PROTEIN", 46, 49], ["tPA 43, 45", "PROTEIN", 53, 63], ["bacterial plasminogen activators", "PROTEIN", 79, 111], ["some bacteria bind", "PROBLEM", 13, 31], ["uPA", "TEST", 46, 49], ["tPA", "TEST", 53, 56], ["bacterial plasminogen activators", "PROBLEM", 79, 111], ["bacteria bind", "OBSERVATION", 18, 31]]], ["Moreover, some bacteria inactivate plasmin inhibitors [46].Pathogen-driven breakdown of the BMSome bacterial species modulate multiple proteases to cross the BM.", [["BM", "ANATOMY", 158, 160], ["plasmin", "GENE_OR_GENE_PRODUCT", 35, 42], ["BM", "TISSUE", 158, 160], ["plasmin", "PROTEIN", 35, 42], ["proteases", "PROTEIN", 135, 144], ["some bacteria inactivate plasmin inhibitors", "PROBLEM", 10, 53], ["Pathogen", "PROBLEM", 59, 67], ["the BMSome bacterial species", "PROBLEM", 88, 116], ["multiple proteases", "PROBLEM", 126, 144], ["multiple", "OBSERVATION_MODIFIER", 126, 134], ["BM", "OBSERVATION", 158, 160]]], ["In addition to modulating the Plg system, Streptococcus pyogenes also expresses a cysteine protease [47].", [["cysteine", "CHEMICAL", 82, 90], ["Plg", "GENE_OR_GENE_PRODUCT", 30, 33], ["Streptococcus pyogenes", "ORGANISM", 42, 64], ["Plg", "PROTEIN", 30, 33], ["cysteine protease", "PROTEIN", 82, 99], ["Streptococcus pyogenes", "SPECIES", 42, 64], ["Streptococcus pyogenes", "SPECIES", 42, 64], ["modulating the Plg system", "TREATMENT", 15, 40], ["Streptococcus pyogenes", "PROBLEM", 42, 64], ["a cysteine protease", "TREATMENT", 80, 99], ["Streptococcus pyogenes", "OBSERVATION", 42, 64]]], ["Fusobacterium nucleatum can invade the BM in a strain-dependent manner by binding plasminogen [48] and pro-MMP9 and stimulating MMP9 and MMP13 secretion [49].", [["BM", "ANATOMY", 39, 41], ["Fusobacterium nucleatum", "GENE_OR_GENE_PRODUCT", 0, 23], ["BM", "CELL", 39, 41], ["plasminogen [48]", "GENE_OR_GENE_PRODUCT", 82, 98], ["pro-MMP9", "GENE_OR_GENE_PRODUCT", 103, 111], ["MMP9", "GENE_OR_GENE_PRODUCT", 128, 132], ["MMP13", "GENE_OR_GENE_PRODUCT", 137, 142], ["pro-MMP9", "PROTEIN", 103, 111], ["MMP9", "PROTEIN", 128, 132], ["MMP13", "PROTEIN", 137, 142], ["Fusobacterium nucleatum", "SPECIES", 0, 23], ["Fusobacterium nucleatum", "SPECIES", 0, 23], ["Fusobacterium nucleatum", "PROBLEM", 0, 23], ["binding plasminogen", "TEST", 74, 93], ["pro-MMP9", "TEST", 103, 111], ["stimulating MMP9", "TEST", 116, 132], ["MMP13 secretion", "TEST", 137, 152], ["BM", "OBSERVATION", 39, 41]]], ["Helicobacter pylori induces expression of the cysteine protease cathepsin X in gastric epithelial cells and macrophages.", [["gastric epithelial cells", "ANATOMY", 79, 103], ["macrophages", "ANATOMY", 108, 119], ["cysteine", "CHEMICAL", 46, 54], ["Helicobacter pylori", "ORGANISM", 0, 19], ["cathepsin X", "GENE_OR_GENE_PRODUCT", 64, 75], ["gastric epithelial cells", "CELL", 79, 103], ["macrophages", "CELL", 108, 119], ["cysteine protease cathepsin X", "PROTEIN", 46, 75], ["gastric epithelial cells", "CELL_TYPE", 79, 103], ["macrophages", "CELL_TYPE", 108, 119], ["Helicobacter pylori", "SPECIES", 0, 19], ["Helicobacter pylori", "SPECIES", 0, 19], ["Helicobacter pylori", "PROBLEM", 0, 19], ["the cysteine protease cathepsin", "TREATMENT", 42, 73], ["pylori", "OBSERVATION", 13, 19], ["gastric", "ANATOMY", 79, 86], ["epithelial cells", "OBSERVATION", 87, 103], ["macrophages", "OBSERVATION", 108, 119]]], ["In epithelial cells, H. pylori induces morphological and motility changes, partly via MMP9 [50] and probably also via other proteases.", [["epithelial cells", "ANATOMY", 3, 19], ["epithelial cells", "CELL", 3, 19], ["H. pylori", "ORGANISM", 21, 30], ["MMP9", "GENE_OR_GENE_PRODUCT", 86, 90], ["epithelial cells", "CELL_TYPE", 3, 19], ["MMP9", "PROTEIN", 86, 90], ["proteases", "PROTEIN", 124, 133], ["H. pylori", "SPECIES", 21, 30], ["H. pylori", "SPECIES", 21, 30], ["epithelial cells", "PROBLEM", 3, 19], ["H. pylori", "PROBLEM", 21, 30], ["motility changes", "PROBLEM", 57, 73], ["MMP9", "TEST", 86, 90], ["epithelial cells", "OBSERVATION", 3, 19], ["H. pylori", "OBSERVATION", 21, 30]]], ["The mechanisms by which H. pylori induces expression of proteases in epithelial cells and macrophages is unknown.", [["epithelial cells", "ANATOMY", 69, 85], ["macrophages", "ANATOMY", 90, 101], ["H. pylori", "ORGANISM", 24, 33], ["epithelial cells", "CELL", 69, 85], ["macrophages", "CELL", 90, 101], ["proteases", "PROTEIN", 56, 65], ["epithelial cells", "CELL_TYPE", 69, 85], ["macrophages", "CELL_TYPE", 90, 101], ["H. pylori", "SPECIES", 24, 33], ["H. pylori", "SPECIES", 24, 33], ["H. pylori", "PROBLEM", 24, 33], ["proteases in epithelial cells", "PROBLEM", 56, 85], ["macrophages", "PROBLEM", 90, 101], ["epithelial cells", "OBSERVATION", 69, 85], ["macrophages", "OBSERVATION", 90, 101]]], ["It has been suggested that proteolytic activities play a role in gastric tumorigenesis [50].", [["gastric", "ANATOMY", 65, 72], ["gastric tumorigenesis", "DISEASE", 65, 86], ["gastric", "ORGAN", 65, 72], ["proteolytic activities", "TREATMENT", 27, 49], ["gastric", "ANATOMY", 65, 72]]], ["H. pylori also increases expression of the uPA system in gastric epithelial cells [51].", [["gastric epithelial cells", "ANATOMY", 57, 81], ["H. pylori", "ORGANISM", 0, 9], ["uPA", "GENE_OR_GENE_PRODUCT", 43, 46], ["gastric epithelial cells", "CELL", 57, 81], ["uPA", "PROTEIN", 43, 46], ["gastric epithelial cells", "CELL_TYPE", 57, 81], ["H. pylori", "SPECIES", 0, 9], ["H. pylori", "SPECIES", 0, 9], ["H. pylori", "PROBLEM", 0, 9], ["the uPA system", "TEST", 39, 53], ["pylori", "OBSERVATION", 3, 9], ["gastric", "ANATOMY", 57, 64], ["epithelial cells", "OBSERVATION", 65, 81]]], ["Mycobacterium tuberculosis18, 52 and Neisseria meningitidis45, 53 modulate both MMPs (MMP8 and MMP9, respectively) and the plasminogen\u2013plasmin system.", [["Mycobacterium tuberculosis18", "ORGANISM", 0, 28], ["Neisseria meningitidis45", "ORGANISM", 37, 61], ["MMPs", "GENE_OR_GENE_PRODUCT", 80, 84], ["MMP8", "GENE_OR_GENE_PRODUCT", 86, 90], ["MMP9", "GENE_OR_GENE_PRODUCT", 95, 99], ["plasminogen\u2013plasmin", "GENE_OR_GENE_PRODUCT", 123, 142], ["MMPs", "PROTEIN", 80, 84], ["MMP8", "PROTEIN", 86, 90], ["MMP9", "PROTEIN", 95, 99], ["plasminogen\u2013plasmin", "PROTEIN", 123, 142], ["Mycobacterium tuberculosis18", "SPECIES", 0, 28], ["Neisseria meningitidis45", "SPECIES", 37, 61], ["Mycobacterium tuberculosis18", "SPECIES", 0, 28], ["Neisseria meningitidis45", "SPECIES", 37, 61], ["Mycobacterium tuberculosis18", "TEST", 0, 28], ["Neisseria meningitidis45", "TEST", 37, 61], ["MMPs", "TEST", 80, 84], ["MMP8", "TEST", 86, 90], ["MMP9", "TEST", 95, 99], ["the plasminogen\u2013plasmin system", "TEST", 119, 149]]], ["Both morphotypes of Peptostreptococcus micros possess plasminogen receptors.", [["Peptostreptococcus micros", "GENE_OR_GENE_PRODUCT", 20, 45], ["plasminogen receptors", "GENE_OR_GENE_PRODUCT", 54, 75], ["plasminogen receptors", "PROTEIN", 54, 75], ["Peptostreptococcus micros", "TREATMENT", 20, 45], ["plasminogen receptors", "TREATMENT", 54, 75]]], ["For P. micros, both bacterial (streptokinase) and human plasminogen activators (uPA) can activate plasminogen to plasmin.", [["streptokinase", "GENE_OR_GENE_PRODUCT", 31, 44], ["human plasminogen activators", "GENE_OR_GENE_PRODUCT", 50, 78], ["uPA", "GENE_OR_GENE_PRODUCT", 80, 83], ["plasminogen", "GENE_OR_GENE_PRODUCT", 98, 109], ["plasmin", "GENE_OR_GENE_PRODUCT", 113, 120], ["human plasminogen activators", "PROTEIN", 50, 78], ["uPA", "PROTEIN", 80, 83], ["plasminogen", "PROTEIN", 98, 109], ["plasmin", "PROTEIN", 113, 120], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 50, 55], ["P. micros", "PROBLEM", 4, 13], ["both bacterial (streptokinase)", "TREATMENT", 15, 45], ["human plasminogen activators (uPA)", "TREATMENT", 50, 84], ["plasmin", "TEST", 113, 120]]], ["Rough morphotypes also possess chymotrypsin-like and gelatinase serine proteases [54].", [["serine", "CHEMICAL", 64, 70], ["chymotrypsin", "GENE_OR_GENE_PRODUCT", 31, 43], ["chymotrypsin", "PROTEIN", 31, 43], ["gelatinase serine proteases", "PROTEIN", 53, 80], ["Rough morphotypes", "PROBLEM", 0, 17], ["chymotrypsin", "TEST", 31, 43], ["gelatinase serine proteases", "TREATMENT", 53, 80]]], ["Porphyromonas gingivalis upregulates MMPs, modulates the plasminogen\u2013plasmin system and expresses cysteine protease gingipains.", [["cysteine", "CHEMICAL", 98, 106], ["Porphyromonas gingivalis", "GENE_OR_GENE_PRODUCT", 0, 24], ["MMPs", "GENE_OR_GENE_PRODUCT", 37, 41], ["plasminogen\u2013plasmin", "GENE_OR_GENE_PRODUCT", 57, 76], ["MMPs", "PROTEIN", 37, 41], ["plasminogen\u2013plasmin", "PROTEIN", 57, 76], ["cysteine protease gingipains", "PROTEIN", 98, 126], ["Porphyromonas gingivalis", "SPECIES", 0, 24], ["Porphyromonas gingivalis", "SPECIES", 0, 24], ["Porphyromonas gingivalis upregulates MMPs", "PROBLEM", 0, 41], ["the plasminogen\u2013plasmin system", "TREATMENT", 53, 83], ["cysteine protease gingipains", "PROBLEM", 98, 126], ["cysteine protease gingipains", "OBSERVATION", 98, 126]]], ["Gingipains contribute to BM penetration, either directly or by modulating MMP2 and MMP9 [55].", [["BM", "ANATOMY", 25, 27], ["Gingipains", "SIMPLE_CHEMICAL", 0, 10], ["BM", "TISSUE", 25, 27], ["MMP2", "GENE_OR_GENE_PRODUCT", 74, 78], ["MMP9", "GENE_OR_GENE_PRODUCT", 83, 87], ["MMP2", "PROTEIN", 74, 78], ["MMP9", "PROTEIN", 83, 87], ["Gingipains", "PROBLEM", 0, 10], ["BM penetration", "PROBLEM", 25, 39], ["BM penetration", "OBSERVATION", 25, 39]]], ["Pseudomonas aeruginosa expresses an MMP and modulates the plasminogen\u2013plasmin system [56].", [["Pseudomonas aeruginosa", "ORGANISM", 0, 22], ["MMP", "GENE_OR_GENE_PRODUCT", 36, 39], ["plasminogen\u2013plasmin", "GENE_OR_GENE_PRODUCT", 58, 77], ["MMP", "PROTEIN", 36, 39], ["plasminogen\u2013plasmin", "PROTEIN", 58, 77], ["Pseudomonas aeruginosa", "SPECIES", 0, 22], ["Pseudomonas aeruginosa", "SPECIES", 0, 22], ["Pseudomonas aeruginosa", "PROBLEM", 0, 22], ["an MMP", "PROBLEM", 33, 39], ["the plasminogen\u2013plasmin system", "TEST", 54, 84]]], ["Treponema pallidum expresses an MMP-like and serine protease [57], induces MMPs and modulates the plasminogen\u2013plasmin system [43].", [["serine", "CHEMICAL", 45, 51], ["Treponema pallidum", "ORGANISM", 0, 18], ["MMP", "GENE_OR_GENE_PRODUCT", 32, 35], ["serine", "AMINO_ACID", 45, 51], ["MMPs", "GENE_OR_GENE_PRODUCT", 75, 79], ["plasminogen\u2013plasmin", "GENE_OR_GENE_PRODUCT", 98, 117], ["MMP", "PROTEIN", 32, 35], ["MMPs", "PROTEIN", 75, 79], ["plasminogen\u2013plasmin", "PROTEIN", 98, 117], ["Treponema pallidum", "SPECIES", 0, 18], ["Treponema pallidum", "SPECIES", 0, 18], ["Treponema pallidum", "TEST", 0, 18], ["an MMP", "TEST", 29, 35], ["serine protease", "TEST", 45, 60], ["MMPs", "TEST", 75, 79], ["the plasminogen\u2013plasmin system", "TEST", 94, 124]]], ["Vibrio spp. express both MMPs and serine proteases [58].Pathogen-driven breakdown of the BMProtease activity has also been implicated in tissue penetration by pathogenic fungi.", [["tissue", "ANATOMY", 137, 143], ["serine", "CHEMICAL", 34, 40], ["Vibrio spp.", "ORGANISM", 0, 11], ["MMPs", "GENE_OR_GENE_PRODUCT", 25, 29], ["BMProtease", "GENE_OR_GENE_PRODUCT", 89, 99], ["tissue", "TISSUE", 137, 143], ["MMPs", "PROTEIN", 25, 29], ["serine proteases", "PROTEIN", 34, 50], ["BMProtease", "PROTEIN", 89, 99], ["Vibrio spp.", "SPECIES", 0, 11], ["Vibrio spp.", "SPECIES", 0, 11], ["Vibrio spp.", "PROBLEM", 0, 11], ["serine proteases", "TEST", 34, 50], ["Pathogen", "PROBLEM", 56, 64], ["the BMProtease activity", "PROBLEM", 85, 108], ["pathogenic fungi", "PROBLEM", 159, 175], ["spp.", "OBSERVATION", 7, 11], ["tissue penetration", "OBSERVATION_MODIFIER", 137, 155], ["pathogenic fungi", "OBSERVATION", 159, 175]]], ["Different fungi have been associated with multiple BM-degrading proteases.", [["BM", "ANATOMY", 51, 53], ["multiple BM-degrading proteases", "PROTEIN", 42, 73], ["Different fungi", "PROBLEM", 0, 15], ["fungi", "OBSERVATION", 10, 15], ["multiple", "OBSERVATION_MODIFIER", 42, 50], ["BM", "OBSERVATION", 51, 53]]], ["However, knowledge on substrate specificities and their contribution to virulence and pathogenesis is rather poor.", [["virulence", "PROBLEM", 72, 81], ["pathogenesis", "PROBLEM", 86, 98]]], ["During Aspergillus spp. infection, a serine protease, MMP and aspartic protease have been identified [59].", [["Aspergillus spp", "DISEASE", 7, 22], ["infection", "DISEASE", 24, 33], ["serine", "CHEMICAL", 37, 43], ["Aspergillus spp", "ORGANISM", 7, 22], ["MMP", "GENE_OR_GENE_PRODUCT", 54, 57], ["serine protease", "PROTEIN", 37, 52], ["MMP", "PROTEIN", 54, 57], ["aspartic protease", "PROTEIN", 62, 79], ["Aspergillus spp", "PROBLEM", 7, 22], ["infection", "PROBLEM", 24, 33], ["a serine protease", "TREATMENT", 35, 52], ["MMP", "PROBLEM", 54, 57], ["aspartic protease", "TREATMENT", 62, 79], ["Aspergillus spp", "OBSERVATION", 7, 22]]], ["Candida spp. activate host MMP9, decrease tissue inhibitor of metalloproteinase 2 (TIMP2) secretion [18], and secrete aspartic proteases and unidentified MMP and serine protease activity [60].", [["serine", "CHEMICAL", 162, 168], ["Candida spp", "ORGANISM", 0, 11], ["MMP9", "GENE_OR_GENE_PRODUCT", 27, 31], ["tissue inhibitor of metalloproteinase 2", "GENE_OR_GENE_PRODUCT", 42, 81], ["TIMP2", "GENE_OR_GENE_PRODUCT", 83, 88], ["MMP", "GENE_OR_GENE_PRODUCT", 154, 157], ["MMP9", "PROTEIN", 27, 31], ["tissue inhibitor of metalloproteinase 2", "PROTEIN", 42, 81], ["TIMP2", "PROTEIN", 83, 88], ["aspartic proteases", "PROTEIN", 118, 136], ["MMP", "PROTEIN", 154, 157], ["Candida spp", "PROBLEM", 0, 11], ["decrease tissue inhibitor of metalloproteinase", "TREATMENT", 33, 79], ["TIMP2) secretion", "TEST", 83, 99], ["secrete aspartic proteases", "TREATMENT", 110, 136], ["unidentified MMP", "PROBLEM", 141, 157], ["serine protease activity", "TREATMENT", 162, 186]]], ["Cryptococcus neoformans expresses a serine protease [61].", [["Cryptococcus neoformans", "DISEASE", 0, 23], ["serine", "CHEMICAL", 36, 42], ["Cryptococcus neoformans", "ORGANISM", 0, 23], ["serine protease", "PROTEIN", 36, 51], ["Cryptococcus neoformans", "SPECIES", 0, 23], ["Cryptococcus neoformans", "SPECIES", 0, 23], ["Cryptococcus neoformans", "PROBLEM", 0, 23], ["a serine protease", "TREATMENT", 34, 51]]], ["A total of 53 cDNAs encoding proteases were shown in Paracoccidioides brasiliensis including one unidentified gelatinase (collagenolytic protease) and an extracellular serine-thiol protease [62].", [["extracellular", "ANATOMY", 154, 167], ["thiol", "CHEMICAL", 175, 180], ["serine", "CHEMICAL", 168, 174], ["thiol", "CHEMICAL", 175, 180], ["Paracoccidioides brasiliensis", "ORGANISM", 53, 82], ["gelatinase", "GENE_OR_GENE_PRODUCT", 110, 120], ["collagenolytic protease", "GENE_OR_GENE_PRODUCT", 122, 145], ["cDNAs", "DNA", 14, 19], ["proteases", "PROTEIN", 29, 38], ["gelatinase", "PROTEIN", 110, 120], ["collagenolytic protease", "PROTEIN", 122, 145], ["extracellular serine-thiol protease", "PROTEIN", 154, 189], ["Paracoccidioides brasiliensis", "SPECIES", 53, 82], ["Paracoccidioides brasiliensis", "SPECIES", 53, 82], ["A total of 53 cDNAs encoding proteases", "TREATMENT", 0, 38], ["Paracoccidioides brasiliensis", "PROBLEM", 53, 82], ["gelatinase (collagenolytic protease", "TREATMENT", 110, 145], ["an extracellular serine-thiol protease", "TREATMENT", 151, 189], ["Paracoccidioides brasiliensis", "OBSERVATION", 53, 82]]], ["P. brasiliensis also induces MMP9 [63].", [["P. brasiliensis", "ORGANISM", 0, 15], ["MMP9", "GENE_OR_GENE_PRODUCT", 29, 33], ["MMP9", "PROTEIN", 29, 33], ["P. brasiliensis", "SPECIES", 0, 15], ["P. brasiliensis", "SPECIES", 0, 15], ["brasiliensis", "OBSERVATION", 3, 15]]], ["Nectriaceae, Saccharomycetaceae and Trichocomaceae also induce host MMPs [64].Pathogen-driven breakdown of the BMIt has also been reported that viruses modulate host-derived proteolytic activity to alter barrier properties of BMs, thereby enhancing viral dissemination (Figure 2).", [["barrier", "ANATOMY", 204, 211], ["BMs", "ANATOMY", 226, 229], ["Nectriaceae", "GENE_OR_GENE_PRODUCT", 0, 11], ["Saccharomycetaceae", "GENE_OR_GENE_PRODUCT", 13, 31], ["Trichocomaceae", "GENE_OR_GENE_PRODUCT", 36, 50], ["MMPs", "GENE_OR_GENE_PRODUCT", 68, 72], ["BMIt", "GENE_OR_GENE_PRODUCT", 111, 115], ["BMs", "MULTI-TISSUE_STRUCTURE", 226, 229], ["MMPs", "PROTEIN", 68, 72], ["BMIt", "PROTEIN", 111, 115], ["Nectriaceae", "TREATMENT", 0, 11], ["Saccharomycetaceae", "TREATMENT", 13, 31], ["Trichocomaceae", "TREATMENT", 36, 50], ["host MMPs", "TEST", 63, 72], ["Pathogen", "PROBLEM", 78, 86], ["viruses modulate host", "PROBLEM", 144, 165], ["thereby enhancing viral dissemination", "PROBLEM", 231, 268], ["BMs", "ANATOMY", 226, 229], ["enhancing", "OBSERVATION_MODIFIER", 239, 248], ["viral dissemination", "OBSERVATION", 249, 268]]], ["Most viral-induced alterations of BMs involve MMPs.", [["BMs", "ANATOMY", 34, 37], ["BMs", "MULTI-TISSUE_STRUCTURE", 34, 37], ["MMPs", "GENE_OR_GENE_PRODUCT", 46, 50], ["MMPs", "PROTEIN", 46, 50], ["BMs involve MMPs", "PROBLEM", 34, 50], ["BMs", "OBSERVATION", 34, 37]]], ["The latent membrane protein-1 (LMP1) of Epstein\u2013Barr virus (EBV) induces MMP9 and uPA [65].", [["latent membrane protein-1", "GENE_OR_GENE_PRODUCT", 4, 29], ["LMP1", "GENE_OR_GENE_PRODUCT", 31, 35], ["Epstein\u2013Barr virus", "ORGANISM", 40, 58], ["EBV", "ORGANISM", 60, 63], ["MMP9", "GENE_OR_GENE_PRODUCT", 73, 77], ["uPA", "GENE_OR_GENE_PRODUCT", 82, 85], ["latent membrane protein-1", "PROTEIN", 4, 29], ["LMP1", "PROTEIN", 31, 35], ["MMP9", "PROTEIN", 73, 77], ["uPA", "PROTEIN", 82, 85], ["Epstein\u2013Barr virus", "SPECIES", 40, 58], ["EBV", "SPECIES", 60, 63], ["The latent membrane protein", "TEST", 0, 27], ["LMP1", "TEST", 31, 35], ["Epstein\u2013Barr virus", "PROBLEM", 40, 58], ["MMP9", "TEST", 73, 77], ["uPA", "TEST", 82, 85]]], ["Hepatitis B virus x protein (HBx) drives MMP14 expression [66].", [["Hepatitis B", "DISEASE", 0, 11], ["Hepatitis B virus", "ORGANISM", 0, 17], ["HBx", "GENE_OR_GENE_PRODUCT", 29, 32], ["MMP14", "GENE_OR_GENE_PRODUCT", 41, 46], ["Hepatitis B virus x protein", "PROTEIN", 0, 27], ["HBx", "PROTEIN", 29, 32], ["MMP14", "PROTEIN", 41, 46], ["Hepatitis B virus", "SPECIES", 0, 17], ["Hepatitis B virus", "SPECIES", 0, 17], ["Hepatitis B virus x protein", "TEST", 0, 27], ["HBx)", "TEST", 29, 33], ["MMP14 expression", "TEST", 41, 57]]], ["It has been reported that HPV induces MMP2, MMP9 and MMP14 [67].", [["HPV", "ORGANISM", 26, 29], ["MMP2", "GENE_OR_GENE_PRODUCT", 38, 42], ["MMP9", "GENE_OR_GENE_PRODUCT", 44, 48], ["MMP14", "GENE_OR_GENE_PRODUCT", 53, 58], ["MMP2", "PROTEIN", 38, 42], ["MMP9", "PROTEIN", 44, 48], ["MMP14", "PROTEIN", 53, 58], ["HPV", "SPECIES", 26, 29], ["MMP2", "TEST", 38, 42], ["MMP9", "TEST", 44, 48], ["MMP14", "TEST", 53, 58]]], ["The glycoprotein K1 of Kaposi's sarcoma-associated herpesvirus (KSHV) modulates the production of MMP1, MMP2 and MMP9 [68].", [["Kaposi's sarcoma", "DISEASE", 23, 39], ["glycoprotein K1", "GENE_OR_GENE_PRODUCT", 4, 19], ["Kaposi's sarcoma-associated herpesvirus", "ORGANISM", 23, 62], ["KSHV", "ORGANISM", 64, 68], ["MMP1", "GENE_OR_GENE_PRODUCT", 98, 102], ["MMP2", "GENE_OR_GENE_PRODUCT", 104, 108], ["MMP9", "GENE_OR_GENE_PRODUCT", 113, 117], ["glycoprotein K1", "PROTEIN", 4, 19], ["MMP1", "PROTEIN", 98, 102], ["MMP2", "PROTEIN", 104, 108], ["MMP9", "PROTEIN", 113, 117], ["Kaposi's sarcoma-associated herpesvirus", "SPECIES", 23, 62], ["Kaposi's sarcoma-associated herpesvirus", "SPECIES", 23, 62], ["KSHV", "SPECIES", 64, 68], ["The glycoprotein K1", "TEST", 0, 19], ["Kaposi's sarcoma", "PROBLEM", 23, 39], ["associated herpesvirus", "PROBLEM", 40, 62], ["MMP1", "TEST", 98, 102], ["MMP2", "TEST", 104, 108], ["MMP9", "TEST", 113, 117], ["glycoprotein K1", "OBSERVATION_MODIFIER", 4, 19], ["Kaposi", "OBSERVATION", 23, 29], ["sarcoma", "OBSERVATION", 32, 39]]], ["Apart from the involvement of viral-induced proteolytic activities in EBV-, hepatitis B virus-, HPV- and KSHV-induced metastasis, it is unclear at present whether this induction plays a role in viral pathogenesis.", [["hepatitis B", "DISEASE", 76, 87], ["metastasis", "DISEASE", 118, 128], ["EBV", "ORGANISM", 70, 73], ["hepatitis B virus", "ORGANISM", 76, 93], ["HPV", "ORGANISM", 96, 99], ["KSHV", "ORGANISM", 105, 109], ["hepatitis B virus", "SPECIES", 76, 93], ["hepatitis B virus", "SPECIES", 76, 93], ["KSHV", "SPECIES", 105, 109], ["viral-induced proteolytic activities", "PROBLEM", 30, 66], ["EBV", "TEST", 70, 73], ["hepatitis B virus", "PROBLEM", 76, 93], ["HPV", "PROBLEM", 96, 99], ["KSHV", "PROBLEM", 105, 109], ["induced metastasis", "PROBLEM", 110, 128], ["viral pathogenesis", "PROBLEM", 194, 212], ["viral", "OBSERVATION", 30, 35], ["metastasis", "OBSERVATION", 118, 128]]], ["A similar mechanism is observed in human T-cell leukemia/lymphoma virus type I (HTLV-1)-associated adult T-cell leukemia/lymphoma, in which MMP9 expression is increased in HTLV-1-infected malignant cells 69, 70.", [["adult T-cell leukemia", "ANATOMY", 99, 120], ["lymphoma", "ANATOMY", 121, 129], ["malignant cells", "ANATOMY", 188, 203], ["T-cell leukemia/lymphoma", "DISEASE", 41, 65], ["adult T-cell leukemia/lymphoma", "DISEASE", 99, 129], ["HTLV-1-infected malignant", "DISEASE", 172, 197], ["human T-cell leukemia/lymphoma virus type I", "ORGANISM", 35, 78], ["HTLV-1", "ORGANISM", 80, 86], ["adult T-cell leukemia", "CANCER", 99, 120], ["lymphoma", "CANCER", 121, 129], ["MMP9", "GENE_OR_GENE_PRODUCT", 140, 144], ["HTLV-1", "ORGANISM", 172, 178], ["malignant cells", "CELL", 188, 203], ["MMP9", "PROTEIN", 140, 144], ["human", "SPECIES", 35, 40], ["HTLV-1", "SPECIES", 80, 86], ["HTLV-1", "SPECIES", 172, 178], ["human T-cell leukemia/lymphoma virus type I", "SPECIES", 35, 78], ["HTLV-1", "SPECIES", 80, 86], ["HTLV-1", "SPECIES", 172, 178], ["human T-cell leukemia", "PROBLEM", 35, 56], ["lymphoma virus type I", "PROBLEM", 57, 78], ["HTLV", "TEST", 80, 84], ["adult T-cell leukemia", "PROBLEM", 99, 120], ["lymphoma", "PROBLEM", 121, 129], ["MMP9 expression", "TEST", 140, 155], ["HTLV", "TEST", 172, 176], ["infected malignant cells", "PROBLEM", 179, 203], ["cell leukemia", "OBSERVATION", 43, 56], ["lymphoma", "OBSERVATION", 57, 65], ["-cell leukemia", "OBSERVATION", 106, 120], ["lymphoma", "OBSERVATION", 121, 129], ["increased", "OBSERVATION_MODIFIER", 159, 168], ["infected", "OBSERVATION_MODIFIER", 179, 187], ["malignant cells", "OBSERVATION", 188, 203]]], ["HTLV-I encephalitis is associated with MMP2 and MMP9 [70].", [["HTLV-I encephalitis", "DISEASE", 0, 19], ["HTLV-I", "ORGANISM", 0, 6], ["encephalitis", "ORGANISM", 7, 19], ["MMP2", "GENE_OR_GENE_PRODUCT", 39, 43], ["MMP9", "GENE_OR_GENE_PRODUCT", 48, 52], ["MMP2", "PROTEIN", 39, 43], ["MMP9", "PROTEIN", 48, 52], ["HTLV-I encephalitis", "SPECIES", 0, 19], ["HTLV-I encephalitis", "PROBLEM", 0, 19], ["MMP2", "PROBLEM", 39, 43], ["MMP9", "TEST", 48, 52], ["encephalitis", "OBSERVATION", 7, 19]]], ["Other viral infections have also been implicated in neurological conditions because of their involvement in BBB impairment by damaging the vascular BM.", [["neurological", "ANATOMY", 52, 64], ["BBB", "ANATOMY", 108, 111], ["vascular BM", "ANATOMY", 139, 150], ["viral infections", "DISEASE", 6, 22], ["BBB", "MULTI-TISSUE_STRUCTURE", 108, 111], ["vascular BM", "MULTI-TISSUE_STRUCTURE", 139, 150], ["Other viral infections", "PROBLEM", 0, 22], ["BBB impairment", "PROBLEM", 108, 122], ["the vascular BM", "PROBLEM", 135, 150], ["viral", "OBSERVATION_MODIFIER", 6, 11], ["infections", "OBSERVATION", 12, 22], ["vascular", "ANATOMY", 139, 147], ["BM", "OBSERVATION", 148, 150]]], ["Human cytomegalovirus (HCMV) infection of human microvascular endothelial cells (HMEC) induces collagenase type IV secretion, which may lead to BM degradation and subsequent release of infected endothelial cells into the circulation and access into the CNS [71].", [["microvascular endothelial cells", "ANATOMY", 48, 79], ["HMEC", "ANATOMY", 81, 85], ["BM", "ANATOMY", 144, 146], ["endothelial cells", "ANATOMY", 194, 211], ["CNS", "ANATOMY", 253, 256], ["Human cytomegalovirus (HCMV) infection", "DISEASE", 0, 38], ["Human cytomegalovirus", "ORGANISM", 0, 21], ["HCMV", "ORGANISM", 23, 27], ["human", "ORGANISM", 42, 47], ["microvascular endothelial cells", "CELL", 48, 79], ["HMEC", "CELL", 81, 85], ["collagenase type IV", "GENE_OR_GENE_PRODUCT", 95, 114], ["BM", "CELL", 144, 146], ["endothelial cells", "CELL", 194, 211], ["human microvascular endothelial cells", "CELL_TYPE", 42, 79], ["HMEC", "CELL_LINE", 81, 85], ["collagenase type IV", "PROTEIN", 95, 114], ["infected endothelial cells", "CELL_TYPE", 185, 211], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 42, 47], ["Human cytomegalovirus", "SPECIES", 0, 21], ["HCMV", "SPECIES", 23, 27], ["human", "SPECIES", 42, 47], ["Human cytomegalovirus (HCMV) infection", "PROBLEM", 0, 38], ["human microvascular endothelial cells (HMEC)", "TREATMENT", 42, 86], ["collagenase type IV secretion", "PROBLEM", 95, 124], ["BM degradation", "PROBLEM", 144, 158], ["infected endothelial cells", "TREATMENT", 185, 211], ["cytomegalovirus", "OBSERVATION", 6, 21], ["microvascular endothelial cells", "OBSERVATION", 48, 79], ["infected endothelial cells", "OBSERVATION", 185, 211], ["circulation", "ANATOMY", 221, 232], ["CNS", "ANATOMY", 253, 256]]], ["Viral hijacking of immune cells might also modulate vascular permeability.", [["immune cells", "ANATOMY", 19, 31], ["vascular", "ANATOMY", 52, 60], ["immune cells", "CELL", 19, 31], ["vascular", "MULTI-TISSUE_STRUCTURE", 52, 60], ["immune cells", "CELL_TYPE", 19, 31], ["Viral hijacking of immune cells", "PROBLEM", 0, 31], ["immune cells", "OBSERVATION", 19, 31], ["vascular", "ANATOMY", 52, 60], ["permeability", "OBSERVATION_MODIFIER", 61, 73]]], ["Bunyaviridae (Andes virus, ANDV), Dengue virus, HIV and West Nile virus (WNV) enhance dendritic cell (DC) maturation, MMP9 expression and plasma vascular leakage [72].", [["dendritic cell", "ANATOMY", 86, 100], ["DC", "ANATOMY", 102, 104], ["plasma vascular", "ANATOMY", 138, 153], ["Bunyaviridae", "DISEASE", 0, 12], ["Dengue virus", "DISEASE", 34, 46], ["Bunyaviridae", "ORGANISM", 0, 12], ["Andes virus", "ORGANISM", 14, 25], ["ANDV", "ORGANISM", 27, 31], ["Dengue virus", "ORGANISM", 34, 46], ["HIV", "ORGANISM", 48, 51], ["West Nile virus", "ORGANISM", 56, 71], ["WNV", "ORGANISM", 73, 76], ["dendritic cell", "CELL", 86, 100], ["DC", "CELL", 102, 104], ["MMP9", "GENE_OR_GENE_PRODUCT", 118, 122], ["plasma", "ORGANISM_SUBSTANCE", 138, 144], ["vascular", "MULTI-TISSUE_STRUCTURE", 145, 153], ["DC", "CELL_TYPE", 102, 104], ["MMP9", "PROTEIN", 118, 122], ["Andes virus", "SPECIES", 14, 25], ["Dengue virus", "SPECIES", 34, 46], ["HIV", "SPECIES", 48, 51], ["West Nile virus", "SPECIES", 56, 71], ["Andes virus", "SPECIES", 14, 25], ["ANDV", "SPECIES", 27, 31], ["Dengue virus", "SPECIES", 34, 46], ["HIV", "SPECIES", 48, 51], ["West Nile virus", "SPECIES", 56, 71], ["WNV", "SPECIES", 73, 76], ["Bunyaviridae (Andes virus", "PROBLEM", 0, 25], ["ANDV", "TEST", 27, 31], ["Dengue virus", "PROBLEM", 34, 46], ["HIV", "PROBLEM", 48, 51], ["West Nile virus", "PROBLEM", 56, 71], ["dendritic cell (DC) maturation", "TREATMENT", 86, 116], ["MMP9 expression", "PROBLEM", 118, 133], ["plasma vascular leakage", "PROBLEM", 138, 161], ["dendritic cell", "OBSERVATION", 86, 100], ["vascular", "ANATOMY", 145, 153], ["leakage", "OBSERVATION", 154, 161]]], ["MMP9 is also upregulated in both the periphery and brain on WNV infection and is partly localized to brain blood vessels.", [["periphery", "ANATOMY", 37, 46], ["brain", "ANATOMY", 51, 56], ["brain blood vessels", "ANATOMY", 101, 120], ["WNV infection", "DISEASE", 60, 73], ["MMP9", "GENE_OR_GENE_PRODUCT", 0, 4], ["periphery", "TISSUE", 37, 46], ["brain", "ORGAN", 51, 56], ["WNV", "ORGANISM", 60, 63], ["brain blood vessels", "MULTI-TISSUE_STRUCTURE", 101, 120], ["MMP9", "PROTEIN", 0, 4], ["WNV", "SPECIES", 60, 63], ["MMP9", "TEST", 0, 4], ["WNV infection", "PROBLEM", 60, 73], ["upregulated", "OBSERVATION_MODIFIER", 13, 24], ["both", "ANATOMY_MODIFIER", 28, 32], ["periphery", "ANATOMY_MODIFIER", 37, 46], ["brain", "ANATOMY", 51, 56], ["WNV", "OBSERVATION_MODIFIER", 60, 63], ["infection", "OBSERVATION", 64, 73], ["brain", "ANATOMY_MODIFIER", 101, 106], ["blood vessels", "ANATOMY", 107, 120]]], ["WNV may enter the brain directly through the BBB or may be carried within infected leukocytes (described in the next section).", [["brain", "ANATOMY", 18, 23], ["BBB", "ANATOMY", 45, 48], ["leukocytes", "ANATOMY", 83, 93], ["WNV", "ORGANISM", 0, 3], ["brain", "ORGAN", 18, 23], ["BBB", "GENE_OR_GENE_PRODUCT", 45, 48], ["leukocytes", "CELL", 83, 93], ["infected leukocytes", "CELL_TYPE", 74, 93], ["WNV", "SPECIES", 0, 3], ["WNV", "PROBLEM", 0, 3], ["infected leukocytes", "PROBLEM", 74, 93], ["brain", "ANATOMY", 18, 23], ["infected leukocytes", "OBSERVATION", 74, 93]]], ["WNV also upregulates MMP1 and MMP3 [73].", [["WNV", "ORGANISM", 0, 3], ["MMP1", "GENE_OR_GENE_PRODUCT", 21, 25], ["MMP3", "GENE_OR_GENE_PRODUCT", 30, 34], ["MMP1", "PROTEIN", 21, 25], ["MMP3", "PROTEIN", 30, 34], ["WNV", "SPECIES", 0, 3], ["MMP1", "TEST", 21, 25], ["MMP3", "TEST", 30, 34]]], ["Coronaviruses can also induce MMPs in susceptible cells and have been associated with multiple sclerosis-like disease in rodents.", [["cells", "ANATOMY", 50, 55], ["multiple sclerosis-like disease", "DISEASE", 86, 117], ["MMPs", "GENE_OR_GENE_PRODUCT", 30, 34], ["cells", "CELL", 50, 55], ["MMPs", "PROTEIN", 30, 34], ["susceptible cells", "CELL_TYPE", 38, 55], ["Coronaviruses", "PROBLEM", 0, 13], ["MMPs in susceptible cells", "PROBLEM", 30, 55], ["multiple sclerosis-like disease in rodents", "PROBLEM", 86, 128], ["susceptible cells", "OBSERVATION", 38, 55], ["associated with", "UNCERTAINTY", 70, 85], ["multiple", "OBSERVATION_MODIFIER", 86, 94], ["sclerosis", "OBSERVATION", 95, 104], ["disease", "OBSERVATION", 110, 117]]], ["However, the role of MMPs in coronavirus CNS infection is unknown [74].", [["CNS", "ANATOMY", 41, 44], ["coronavirus CNS infection", "DISEASE", 29, 54], ["MMPs", "GENE_OR_GENE_PRODUCT", 21, 25], ["coronavirus CNS", "ORGANISM", 29, 44], ["MMPs", "PROTEIN", 21, 25], ["coronavirus", "SPECIES", 29, 40], ["MMPs in coronavirus CNS infection", "PROBLEM", 21, 54]]], ["Finally, it has been postulated that bovine herpesvirus 5 (BHV-5) entry the CNS is facilitated by leukocytes and MMP9.", [["CNS", "ANATOMY", 76, 79], ["leukocytes", "ANATOMY", 98, 108], ["bovine herpesvirus 5", "ORGANISM", 37, 57], ["BHV-5", "ORGANISM", 59, 64], ["CNS", "ANATOMICAL_SYSTEM", 76, 79], ["leukocytes", "CELL", 98, 108], ["MMP9", "GENE_OR_GENE_PRODUCT", 113, 117], ["leukocytes", "CELL_TYPE", 98, 108], ["MMP9", "PROTEIN", 113, 117], ["bovine", "SPECIES", 37, 43], ["bovine herpesvirus 5 (BHV-5", "SPECIES", 37, 64], ["bovine herpesvirus", "TEST", 37, 55], ["BHV", "TEST", 59, 62], ["leukocytes", "TEST", 98, 108], ["MMP9", "TEST", 113, 117], ["CNS", "ANATOMY", 76, 79]]], ["However, induction of MMP9 expression by BHV-5 has not been directly demonstrated so far [75].Pathogen-driven breakdown of the BMReports describing the involvement of serine protease activity in viral-induced BM distortion are scarce.", [["BM", "ANATOMY", 209, 211], ["BHV-5", "CHEMICAL", 41, 46], ["serine", "CHEMICAL", 167, 173], ["MMP9", "GENE_OR_GENE_PRODUCT", 22, 26], ["BHV-5", "ORGANISM", 41, 46], ["serine protease", "GENE_OR_GENE_PRODUCT", 167, 182], ["BM", "CELL", 209, 211], ["MMP9", "PROTEIN", 22, 26], ["BHV", "PROTEIN", 41, 44], ["serine protease", "PROTEIN", 167, 182], ["MMP9 expression", "TEST", 22, 37], ["BHV", "TEST", 41, 44], ["Pathogen", "PROBLEM", 94, 102], ["serine protease activity", "TREATMENT", 167, 191], ["viral-induced BM distortion", "PROBLEM", 195, 222], ["BM distortion", "OBSERVATION", 209, 222]]], ["As described above, EBV also induces uPA [65].", [["EBV", "ORGANISM", 20, 23], ["uPA", "GENE_OR_GENE_PRODUCT", 37, 40], ["uPA", "PROTEIN", 37, 40], ["EBV", "PROBLEM", 20, 23]]], ["An unidentified trypsin-like serine protease is involved in BM crossing by the porcine pseudorabies virus (PRV) in porcine nasal respiratory explants [76].Pathogen-driven breakdown of the BMIn summary, several bacteria, fungi and viruses enhance invasion through the BM barrier by (mis)using proteolytic systems by encoding and/or modulating host-derived proteases.Hitchhiking across the BMDuring physiological processes, such as development and immune surveillance, and during the pathology of many diseases, such as metastatic cancer, cells frequently traverse the BM barrier.", [["BM", "ANATOMY", 60, 62], ["nasal respiratory explants", "ANATOMY", 123, 149], ["BM barrier", "ANATOMY", 267, 277], ["metastatic cancer", "ANATOMY", 518, 535], ["cells", "ANATOMY", 537, 542], ["BM", "ANATOMY", 567, 569], ["cancer", "DISEASE", 529, 535], ["serine", "CHEMICAL", 29, 35], ["trypsin", "GENE_OR_GENE_PRODUCT", 16, 23], ["serine", "AMINO_ACID", 29, 35], ["BM", "TISSUE", 60, 62], ["porcine", "ORGANISM", 79, 86], ["pseudorabies virus", "ORGANISM", 87, 105], ["PRV", "ORGANISM", 107, 110], ["porcine", "ORGANISM", 115, 122], ["BM barrier", "TISSUE", 267, 277], ["metastatic cancer", "CANCER", 518, 535], ["cells", "CELL", 537, 542], ["BM barrier", "TISSUE", 567, 577], ["trypsin", "PROTEIN", 16, 23], ["serine protease", "PROTEIN", 29, 44], ["host-derived proteases", "PROTEIN", 342, 364], ["porcine pseudorabies virus", "SPECIES", 79, 105], ["porcine", "SPECIES", 115, 122], ["porcine pseudorabies virus", "SPECIES", 79, 105], ["PRV", "SPECIES", 107, 110], ["porcine", "SPECIES", 115, 122], ["An unidentified trypsin-like serine protease", "PROBLEM", 0, 44], ["the porcine pseudorabies virus", "TREATMENT", 75, 105], ["porcine nasal respiratory explants", "TREATMENT", 115, 149], ["Pathogen", "PROBLEM", 155, 163], ["several bacteria", "PROBLEM", 202, 218], ["fungi", "PROBLEM", 220, 225], ["viruses enhance invasion", "PROBLEM", 230, 254], ["the BM barrier", "TREATMENT", 263, 277], ["proteolytic systems", "TREATMENT", 292, 311], ["Hitchhiking across the BMDuring physiological processes", "PROBLEM", 365, 420], ["immune surveillance", "TEST", 446, 465], ["many diseases", "PROBLEM", 495, 508], ["metastatic cancer", "PROBLEM", 518, 535], ["the BM barrier", "TREATMENT", 563, 577], ["trypsin", "OBSERVATION", 16, 23], ["nasal", "ANATOMY", 123, 128], ["respiratory explants", "OBSERVATION", 129, 149], ["bacteria", "OBSERVATION", 210, 218], ["BM", "ANATOMY", 267, 269], ["many", "OBSERVATION_MODIFIER", 495, 499], ["diseases", "OBSERVATION", 500, 508], ["metastatic", "OBSERVATION_MODIFIER", 518, 528], ["cancer", "OBSERVATION", 529, 535]]], ["Transmigration across the BM is a three-stage process (Figure 1).", [["BM", "ANATOMY", 26, 28], ["BM", "CELL", 26, 28], ["Transmigration across the BM", "PROBLEM", 0, 28], ["BM", "ANATOMY", 26, 28], ["three-stage", "OBSERVATION_MODIFIER", 34, 45]]], ["First, invadopodia-like protrusions perforate the BM.", [["invadopodia-like protrusions", "ANATOMY", 7, 35], ["BM", "ANATOMY", 50, 52], ["invadopodia", "CELLULAR_COMPONENT", 7, 18], ["BM", "TISSUE", 50, 52], ["protrusions perforate the BM", "PROBLEM", 24, 52], ["protrusions", "OBSERVATION_MODIFIER", 24, 35], ["perforate", "OBSERVATION", 36, 45], ["BM", "OBSERVATION", 50, 52]]], ["Then these protrusions elongate in the degraded zone and infiltrate the underlying compartment.", [["compartment", "ANATOMY", 83, 94], ["these protrusions elongate", "PROBLEM", 5, 31], ["infiltrate the underlying compartment", "PROBLEM", 57, 94], ["protrusions", "OBSERVATION_MODIFIER", 11, 22], ["elongate", "OBSERVATION_MODIFIER", 23, 31], ["degraded", "OBSERVATION_MODIFIER", 39, 47], ["zone", "OBSERVATION_MODIFIER", 48, 52], ["infiltrate", "OBSERVATION", 57, 67], ["compartment", "ANATOMY_MODIFIER", 83, 94]]], ["It is believed that the rod-like shape of invadopodia allows for focal delivery of proteases to restrictive areas of the BM [77].", [["invadopodia", "ANATOMY", 42, 53], ["BM", "ANATOMY", 121, 123], ["invadopodia", "CELLULAR_COMPONENT", 42, 53], ["proteases", "PROTEIN", 83, 92], ["focal delivery of proteases", "TREATMENT", 65, 92], ["rod-like", "OBSERVATION_MODIFIER", 24, 32], ["shape", "OBSERVATION_MODIFIER", 33, 38], ["invadopodia", "OBSERVATION", 42, 53], ["focal", "OBSERVATION_MODIFIER", 65, 70], ["BM", "ANATOMY", 121, 123]]], ["Although the primary function of immune cells is to sample pathogens to initiate an immune response, over time, several pathogens have developed mechanisms to use these cells as Trojan horses to cross the BM barrier and disseminate throughout the host.", [["immune cells", "ANATOMY", 33, 45], ["cells", "ANATOMY", 169, 174], ["BM barrier", "ANATOMY", 205, 215], ["immune cells", "CELL", 33, 45], ["cells", "CELL", 169, 174], ["Trojan horses", "ORGANISM", 178, 191], ["BM barrier", "MULTI-TISSUE_STRUCTURE", 205, 215], ["immune cells", "CELL_TYPE", 33, 45], ["Trojan horses", "SPECIES", 178, 191], ["immune cells", "PROBLEM", 33, 45], ["sample pathogens", "PROBLEM", 52, 68], ["several pathogens", "PROBLEM", 112, 129], ["these cells", "TREATMENT", 163, 174], ["immune cells", "OBSERVATION", 33, 45]]], ["Mechanisms of intracellular survival involving inhibition of immune cell activation via alteration of their phenotype and function contribute to cell migration according to direct and indirect evidence [78].Hitchhiking across the BMSeveral bacteria survive in polymorphonuclear neutrophil granulocytes (PMN) or neutrophils: Anaplasma phagocytophilum, Bordetella pertussis, Brucella abortus, Chlamydia psittaci, Chlamydia trachomatis, Escherichia coli, Francisella tularensis, Mycobacterium leprae, Neisseria gonorrhoeae, Salmonella enterica serovar Typhi, Salmonella enterica serovar Typhimurium, S. aureus, S. pyogenes and Yersinia enterolytica.", [["intracellular", "ANATOMY", 14, 27], ["immune cell", "ANATOMY", 61, 72], ["cell", "ANATOMY", 145, 149], ["polymorphonuclear neutrophil granulocytes", "ANATOMY", 260, 301], ["PMN", "ANATOMY", 303, 306], ["neutrophils", "ANATOMY", 311, 322], ["Anaplasma phagocytophilum", "DISEASE", 324, 349], ["Bordetella pertussis", "DISEASE", 351, 371], ["Brucella abortus", "DISEASE", 373, 389], ["Chlamydia psittaci", "DISEASE", 391, 409], ["Chlamydia trachomatis", "DISEASE", 411, 432], ["Mycobacterium leprae", "DISEASE", 476, 496], ["Neisseria gonorrhoeae", "DISEASE", 498, 519], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 14, 27], ["immune cell", "CELL", 61, 72], ["cell", "CELL", 145, 149], ["polymorphonuclear neutrophil granulocytes", "CELL", 260, 301], ["PMN", "CELL", 303, 306], ["neutrophils", "CELL", 311, 322], ["Anaplasma phagocytophilum", "ORGANISM", 324, 349], ["Bordetella pertussis", "ORGANISM", 351, 371], ["Brucella abortus", "ORGANISM", 373, 389], ["Chlamydia psittaci", "ORGANISM", 391, 409], ["Chlamydia trachomatis", "ORGANISM", 411, 432], ["Escherichia coli", "ORGANISM", 434, 450], ["Francisella tularensis", "ORGANISM", 452, 474], ["Mycobacterium leprae", "ORGANISM", 476, 496], ["Neisseria gonorrhoeae", "ORGANISM", 498, 519], ["Salmonella enterica serovar Typhi", "ORGANISM", 521, 554], ["Salmonella enterica serovar Typhimurium", "ORGANISM", 556, 595], ["S. aureus", "ORGANISM", 597, 606], ["S. pyogenes", "ORGANISM", 608, 619], ["Yersinia enterolytica", "ORGANISM", 624, 645], ["polymorphonuclear neutrophil granulocytes", "CELL_TYPE", 260, 301], ["PMN", "CELL_TYPE", 303, 306], ["neutrophils", "CELL_TYPE", 311, 322], ["Anaplasma phagocytophilum", "SPECIES", 324, 349], ["Bordetella pertussis", "SPECIES", 351, 371], ["Brucella abortus", "SPECIES", 373, 389], ["Chlamydia psittaci", "SPECIES", 391, 409], ["Chlamydia trachomatis", "SPECIES", 411, 432], ["Escherichia coli", "SPECIES", 434, 450], ["Francisella tularensis", "SPECIES", 452, 474], ["Mycobacterium leprae", "SPECIES", 476, 496], ["Neisseria gonorrhoeae", "SPECIES", 498, 519], ["Salmonella enterica", "SPECIES", 521, 540], ["serovar Typhi", "SPECIES", 541, 554], ["Salmonella", "SPECIES", 556, 566], ["enterica serovar Typhimurium", "SPECIES", 567, 595], ["S. aureus", "SPECIES", 597, 606], ["S. pyogenes", "SPECIES", 608, 619], ["Yersinia enterolytica", "SPECIES", 624, 645], ["Anaplasma phagocytophilum", "SPECIES", 324, 349], ["Bordetella pertussis", "SPECIES", 351, 371], ["Brucella abortus", "SPECIES", 373, 389], ["Chlamydia psittaci", "SPECIES", 391, 409], ["Chlamydia trachomatis", "SPECIES", 411, 432], ["Escherichia coli", "SPECIES", 434, 450], ["Francisella tularensis", "SPECIES", 452, 474], ["Mycobacterium leprae", "SPECIES", 476, 496], ["Neisseria gonorrhoeae", "SPECIES", 498, 519], ["Salmonella enterica serovar Typhi", "SPECIES", 521, 554], ["Salmonella enterica serovar Typhimurium", "SPECIES", 556, 595], ["S. aureus", "SPECIES", 597, 606], ["S. pyogenes", "SPECIES", 608, 619], ["Yersinia enterolytica", "SPECIES", 624, 645], ["intracellular survival", "PROBLEM", 14, 36], ["immune cell activation", "PROBLEM", 61, 83], ["cell migration", "PROBLEM", 145, 159], ["Hitchhiking across the BMSeveral bacteria", "PROBLEM", 207, 248], ["polymorphonuclear neutrophil granulocytes", "TEST", 260, 301], ["PMN", "TEST", 303, 306], ["neutrophils", "TEST", 311, 322], ["Anaplasma phagocytophilum", "PROBLEM", 324, 349], ["Bordetella pertussis", "PROBLEM", 351, 371], ["Brucella abortus", "PROBLEM", 373, 389], ["Chlamydia psittaci", "PROBLEM", 391, 409], ["Chlamydia trachomatis", "PROBLEM", 411, 432], ["Escherichia coli", "PROBLEM", 434, 450], ["Francisella tularensis", "PROBLEM", 452, 474], ["Mycobacterium leprae", "PROBLEM", 476, 496], ["Neisseria gonorrhoeae", "PROBLEM", 498, 519], ["Salmonella enterica serovar Typhi", "PROBLEM", 521, 554], ["Salmonella enterica serovar Typhimurium", "PROBLEM", 556, 595], ["S. aureus", "PROBLEM", 597, 606], ["S. pyogenes", "PROBLEM", 608, 619], ["Yersinia enterolytica", "PROBLEM", 624, 645], ["intracellular survival", "OBSERVATION", 14, 36], ["immune cell activation", "OBSERVATION", 61, 83], ["cell migration", "OBSERVATION", 145, 159], ["polymorphonuclear neutrophil granulocytes", "OBSERVATION", 260, 301], ["neutrophils", "ANATOMY", 311, 322], ["Anaplasma phagocytophilum", "OBSERVATION", 324, 349], ["Chlamydia psittaci", "OBSERVATION", 391, 409], ["Escherichia coli", "OBSERVATION", 434, 450], ["Francisella tularensis", "OBSERVATION", 452, 474], ["Mycobacterium leprae", "OBSERVATION", 476, 496], ["serovar Typhimurium", "OBSERVATION", 576, 595], ["aureus", "OBSERVATION", 600, 606], ["pyogenes", "OBSERVATION_MODIFIER", 611, 619], ["Yersinia enterolytica", "OBSERVATION", 624, 645]]], ["This may provide a mechanism by which bacteria infect distant sites, although this needs further experimental confirmation.", [["sites", "ANATOMY", 62, 67], ["bacteria infect distant sites", "PROBLEM", 38, 67], ["further experimental confirmation", "TEST", 89, 122]]], ["Burkholderia pseudomallei, Chlamydia pneumoniae, Haemophilus somnus and Legionella pneumophila not only survive but also multiply in PMN.", [["PMN", "ANATOMY", 133, 136], ["Burkholderia pseudomallei", "DISEASE", 0, 25], ["Chlamydia pneumoniae", "DISEASE", 27, 47], ["Haemophilus somnus", "DISEASE", 49, 67], ["Burkholderia pseudomallei", "ORGANISM", 0, 25], ["Chlamydia pneumoniae", "ORGANISM", 27, 47], ["Haemophilus somnus", "ORGANISM", 49, 67], ["Legionella pneumophila", "ORGANISM", 72, 94], ["PMN", "CELL", 133, 136], ["PMN", "CELL_TYPE", 133, 136], ["Burkholderia pseudomallei", "SPECIES", 0, 25], ["Chlamydia pneumoniae", "SPECIES", 27, 47], ["Haemophilus somnus", "SPECIES", 49, 67], ["Legionella pneumophila", "SPECIES", 72, 94], ["Burkholderia pseudomallei", "SPECIES", 0, 25], ["Chlamydia pneumoniae", "SPECIES", 27, 47], ["Haemophilus somnus", "SPECIES", 49, 67], ["Legionella pneumophila", "SPECIES", 72, 94], ["Burkholderia pseudomallei", "PROBLEM", 0, 25], ["Chlamydia pneumoniae", "PROBLEM", 27, 47], ["Haemophilus somnus", "PROBLEM", 49, 67], ["Legionella pneumophila", "PROBLEM", 72, 94], ["Chlamydia pneumoniae", "OBSERVATION", 27, 47], ["Haemophilus somnus", "OBSERVATION", 49, 67], ["Legionella pneumophila", "OBSERVATION", 72, 94]]], ["Afterwards, pathogens may enter through the uptake of infected apoptotic PMN, survive and multiply in macrophages, which subsequently may transport bacteria throughout the body 79, 80.Hitchhiking across the BMThe Trojan horse hypothesis is also valid for DCs.", [["PMN", "ANATOMY", 73, 76], ["macrophages", "ANATOMY", 102, 113], ["body", "ANATOMY", 172, 176], ["DCs", "ANATOMY", 255, 258], ["PMN", "CELL", 73, 76], ["macrophages", "CELL", 102, 113], ["DCs", "CELL", 255, 258], ["infected apoptotic PMN", "CELL_TYPE", 54, 76], ["macrophages", "CELL_TYPE", 102, 113], ["DCs", "CELL_TYPE", 255, 258], ["pathogens", "PROBLEM", 12, 21], ["infected apoptotic PMN", "PROBLEM", 54, 76], ["transport bacteria throughout the body", "PROBLEM", 138, 176], ["DCs", "PROBLEM", 255, 258], ["infected", "OBSERVATION_MODIFIER", 54, 62], ["apoptotic PMN", "OBSERVATION", 63, 76]]], ["Coxiella burnetii survives in DCs during infection [81].", [["DCs", "ANATOMY", 30, 33], ["infection", "DISEASE", 41, 50], ["Coxiella burnetii", "ORGANISM", 0, 17], ["DCs", "CELL", 30, 33], ["DCs", "CELL_TYPE", 30, 33], ["Coxiella burnetii", "SPECIES", 0, 17], ["Coxiella burnetii", "SPECIES", 0, 17], ["Coxiella burnetii", "PROBLEM", 0, 17], ["infection", "PROBLEM", 41, 50], ["burnetii", "OBSERVATION_MODIFIER", 9, 17]]], ["DCs also transport intracellular Listeria monocytogenes, M. tuberculosis and S. Typhimurium from mucosal areas towards the draining lymph nodes [82].Hitchhiking across the BMMononuclear phagocytes (monocytes and macrophages) can also be misused by intracellular bacteria to disseminate throughout the host.", [["DCs", "ANATOMY", 0, 3], ["intracellular", "ANATOMY", 19, 32], ["mucosal areas", "ANATOMY", 97, 110], ["lymph nodes", "ANATOMY", 132, 143], ["BMMononuclear phagocytes", "ANATOMY", 172, 196], ["monocytes", "ANATOMY", 198, 207], ["macrophages", "ANATOMY", 212, 223], ["intracellular", "ANATOMY", 248, 261], ["tuberculosis", "DISEASE", 60, 72], ["DCs", "CELL", 0, 3], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 19, 32], ["Listeria monocytogenes", "ORGANISM", 33, 55], ["M. tuberculosis", "ORGANISM", 57, 72], ["S. Typhimurium", "ORGANISM", 77, 91], ["mucosal", "PATHOLOGICAL_FORMATION", 97, 104], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 132, 143], ["BMMononuclear phagocytes", "CELL", 172, 196], ["monocytes", "CELL", 198, 207], ["macrophages", "CELL", 212, 223], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 248, 261], ["DCs", "CELL_TYPE", 0, 3], ["BMMononuclear phagocytes", "CELL_TYPE", 172, 196], ["monocytes", "CELL_TYPE", 198, 207], ["macrophages", "CELL_TYPE", 212, 223], ["Listeria monocytogenes", "SPECIES", 33, 55], ["M. tuberculosis", "SPECIES", 57, 72], ["S. Typhimurium", "SPECIES", 77, 91], ["Listeria monocytogenes", "SPECIES", 33, 55], ["M. tuberculosis", "SPECIES", 57, 72], ["S. Typhimurium", "SPECIES", 77, 91], ["transport intracellular Listeria monocytogenes", "TEST", 9, 55], ["M. tuberculosis", "PROBLEM", 57, 72], ["S. Typhimurium", "PROBLEM", 77, 91], ["Hitchhiking", "PROBLEM", 149, 160], ["intracellular bacteria", "PROBLEM", 248, 270], ["Listeria monocytogenes", "OBSERVATION", 33, 55], ["mucosal", "ANATOMY", 97, 104], ["draining", "OBSERVATION_MODIFIER", 123, 131], ["lymph nodes", "OBSERVATION", 132, 143], ["BMMononuclear phagocytes", "ANATOMY", 172, 196], ["bacteria", "OBSERVATION", 262, 270]]], ["This has been reported or suggested for uropathogenic E. coli[83], L. pneumophila, Salmonella enterica[84], S. Typhimurium [78] and Yersinia pestis[85].", [["Yersinia pestis", "DISEASE", 132, 147], ["uropathogenic", "ORGANISM", 40, 53], ["E. coli", "ORGANISM", 54, 61], ["[83]", "ORGANISM", 61, 65], ["L. pneumophila", "ORGANISM", 67, 81], ["Salmonella enterica", "ORGANISM", 83, 102], ["[84]", "ORGANISM", 102, 106], ["S. Typhimurium", "ORGANISM", 108, 122], ["Yersinia pestis", "ORGANISM", 132, 147], ["E. coli", "SPECIES", 54, 61], ["L. pneumophila", "SPECIES", 67, 81], ["Salmonella enterica", "SPECIES", 83, 102], ["S. Typhimurium", "SPECIES", 108, 122], ["Yersinia pestis", "SPECIES", 132, 147], ["E. coli", "SPECIES", 54, 61], ["L. pneumophila", "SPECIES", 67, 81], ["Salmonella enterica", "SPECIES", 83, 102], ["S. Typhimurium", "SPECIES", 108, 122], ["Yersinia pestis", "SPECIES", 132, 147], ["uropathogenic E. coli", "PROBLEM", 40, 61], ["L. pneumophila", "PROBLEM", 67, 81], ["Salmonella enterica", "PROBLEM", 83, 102], ["S. Typhimurium", "TEST", 108, 122], ["Yersinia pestis", "PROBLEM", 132, 147], ["pneumophila", "OBSERVATION_MODIFIER", 70, 81]]], ["Furthermore, H. influenzae has been found within mononuclear cells both above and below the BM [86].", [["mononuclear cells", "ANATOMY", 49, 66], ["BM", "ANATOMY", 92, 94], ["H. influenzae", "ORGANISM", 13, 26], ["mononuclear cells", "CELL", 49, 66], ["mononuclear cells", "CELL_TYPE", 49, 66], ["H. influenzae", "SPECIES", 13, 26], ["H. influenzae", "SPECIES", 13, 26], ["H. influenzae", "PROBLEM", 13, 26], ["mononuclear cells", "TEST", 49, 66], ["mononuclear cells", "OBSERVATION", 49, 66], ["BM", "ANATOMY", 92, 94]]], ["Although Bacillus anthracis is not an intracellular pathogen, it can use alveolar macrophages to cross airway mucosal barriers [87].", [["intracellular", "ANATOMY", 38, 51], ["alveolar macrophages", "ANATOMY", 73, 93], ["airway mucosal", "ANATOMY", 103, 117], ["Bacillus anthracis", "ORGANISM", 9, 27], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 38, 51], ["alveolar macrophages", "CELL", 73, 93], ["airway mucosal", "MULTI-TISSUE_STRUCTURE", 103, 117], ["alveolar macrophages", "CELL_TYPE", 73, 93], ["Bacillus anthracis", "SPECIES", 9, 27], ["Bacillus anthracis", "SPECIES", 9, 27], ["Bacillus anthracis", "PROBLEM", 9, 27], ["an intracellular pathogen", "PROBLEM", 35, 60], ["alveolar macrophages", "TREATMENT", 73, 93], ["not an", "UNCERTAINTY", 31, 37], ["intracellular pathogen", "OBSERVATION", 38, 60]]], ["Mononuclear phagocyte-facilitated entry into CNS across the BBB has been described for Brucella spp., Ehrlichia chaffeensis, L. monocytogenes, M. tuberculosis and Streptococcus suis type II in swine [78].", [["Mononuclear phagocyte", "ANATOMY", 0, 21], ["CNS", "ANATOMY", 45, 48], ["BBB", "ANATOMY", 60, 63], ["Ehrlichia chaffeensis", "DISEASE", 102, 123], ["M. tuberculosis", "DISEASE", 143, 158], ["Mononuclear phagocyte", "CELL", 0, 21], ["CNS", "ANATOMICAL_SYSTEM", 45, 48], ["BBB", "MULTI-TISSUE_STRUCTURE", 60, 63], ["Brucella spp.", "ORGANISM", 87, 100], ["Ehrlichia chaffeensis", "ORGANISM", 102, 123], ["L. monocytogenes", "ORGANISM", 125, 141], ["M. tuberculosis", "ORGANISM", 143, 158], ["Streptococcus suis type II", "ORGANISM", 163, 189], ["swine", "ORGANISM", 193, 198], ["Mononuclear phagocyte", "CELL_TYPE", 0, 21], ["Brucella spp.", "SPECIES", 87, 100], ["Ehrlichia chaffeensis", "SPECIES", 102, 123], ["L. monocytogenes", "SPECIES", 125, 141], ["M. tuberculosis", "SPECIES", 143, 158], ["Streptococcus suis", "SPECIES", 163, 181], ["swine", "SPECIES", 193, 198], ["Brucella spp.", "SPECIES", 87, 100], ["Ehrlichia chaffeensis", "SPECIES", 102, 123], ["L. monocytogenes", "SPECIES", 125, 141], ["M. tuberculosis", "SPECIES", 143, 158], ["Streptococcus suis type II", "SPECIES", 163, 189], ["swine", "SPECIES", 193, 198], ["Mononuclear phagocyte", "TEST", 0, 21], ["Brucella spp.", "PROBLEM", 87, 100], ["Ehrlichia chaffeensis", "PROBLEM", 102, 123], ["L. monocytogenes", "PROBLEM", 125, 141], ["M. tuberculosis", "PROBLEM", 143, 158], ["Streptococcus suis type II", "PROBLEM", 163, 189], ["BBB", "ANATOMY", 60, 63], ["tuberculosis", "OBSERVATION", 146, 158]]], ["L. monocytogenes invades both directly and when carried within infected leukocytes [82].Hitchhiking across the BMSeveral pathogens, such as Mycobacterium avium[88] and Shigella flexneri[89], predominantly exploit M cells to cross the epithelial barrier into the subepithelial lamina propria and subsequently invade macrophages.", [["leukocytes", "ANATOMY", 72, 82], ["M cells", "ANATOMY", 213, 220], ["epithelial barrier", "ANATOMY", 234, 252], ["subepithelial lamina propria", "ANATOMY", 262, 290], ["macrophages", "ANATOMY", 315, 326], ["L.", "CHEMICAL", 0, 2], ["monocytogenes", "ORGANISM", 3, 16], ["leukocytes", "CELL", 72, 82], ["Mycobacterium avium[88", "ORGANISM", 140, 162], ["Shigella flexneri", "ORGANISM", 168, 185], ["M cells", "CELL", 213, 220], ["epithelial barrier", "TISSUE", 234, 252], ["subepithelial lamina propria", "TISSUE", 262, 290], ["macrophages", "CELL", 315, 326], ["infected leukocytes", "CELL_TYPE", 63, 82], ["M cells", "CELL_TYPE", 213, 220], ["macrophages", "CELL_TYPE", 315, 326], ["L.", "SPECIES", 0, 2], ["monocytogenes", "SPECIES", 3, 16], ["Mycobacterium avium", "SPECIES", 140, 159], ["Shigella flexneri", "SPECIES", 168, 185], ["L.", "SPECIES", 0, 2], ["monocytogenes", "SPECIES", 3, 16], ["Mycobacterium avium", "SPECIES", 140, 159], ["Shigella flexneri", "SPECIES", 168, 185], ["Hitchhiking across the BMSeveral pathogens", "PROBLEM", 88, 130], ["Mycobacterium avium", "TEST", 140, 159], ["Shigella flexneri", "PROBLEM", 168, 185], ["epithelial", "ANATOMY_MODIFIER", 234, 244], ["subepithelial", "ANATOMY_MODIFIER", 262, 275], ["lamina propria", "ANATOMY", 276, 290], ["invade macrophages", "OBSERVATION", 308, 326]]], ["As described earlier, H. pylori is associated with metastatic processes and the spread of malignant cells throughout the body [50].Hitchhiking across the BMSome fungi also exploit immune cells to cross host barriers.", [["malignant cells", "ANATOMY", 90, 105], ["body", "ANATOMY", 121, 125], ["immune cells", "ANATOMY", 180, 192], ["H. pylori", "ORGANISM", 22, 31], ["malignant cells", "CELL", 90, 105], ["immune cells", "CELL", 180, 192], ["malignant cells", "CELL_TYPE", 90, 105], ["immune cells", "CELL_TYPE", 180, 192], ["H. pylori", "SPECIES", 22, 31], ["H. pylori", "SPECIES", 22, 31], ["H. pylori", "PROBLEM", 22, 31], ["metastatic processes", "PROBLEM", 51, 71], ["malignant cells", "PROBLEM", 90, 105], ["Hitchhiking across the BMSome fungi", "PROBLEM", 131, 166], ["immune cells", "PROBLEM", 180, 192], ["pylori", "OBSERVATION", 25, 31], ["associated with", "UNCERTAINTY", 35, 50], ["metastatic", "OBSERVATION", 51, 61], ["spread", "OBSERVATION_MODIFIER", 80, 86], ["malignant cells", "OBSERVATION", 90, 105], ["body", "ANATOMY", 121, 125], ["immune cells", "OBSERVATION", 180, 192]]], ["Histoplasma capsulatun causes systemic mycosis, mainly in immunosuppressed patients, and can survive and multiply in PMN [80].", [["PMN", "ANATOMY", 117, 120], ["Histoplasma capsulatun", "DISEASE", 0, 22], ["mycosis", "DISEASE", 39, 46], ["Histoplasma capsulatun", "ORGANISM", 0, 22], ["patients", "ORGANISM", 75, 83], ["PMN", "CELL", 117, 120], ["Histoplasma capsulatun", "SPECIES", 0, 22], ["patients", "SPECIES", 75, 83], ["Histoplasma capsulatun", "SPECIES", 0, 22], ["Histoplasma capsulatun", "PROBLEM", 0, 22], ["systemic mycosis", "PROBLEM", 30, 46], ["systemic", "OBSERVATION_MODIFIER", 30, 38], ["mycosis", "OBSERVATION", 39, 46], ["immunosuppressed", "OBSERVATION_MODIFIER", 58, 74]]], ["It has been demonstrated that the facultative intracellular pathogen C. neoformans crosses the BBB via mononuclear phagocytes (monocytes and macrophages), together with other mechanisms involving free yeasts [90].Hitchhiking across the BMSeveral viruses hijack immune cells to transverse the BM (Figure 2).", [["intracellular", "ANATOMY", 46, 59], ["BBB", "ANATOMY", 95, 98], ["mononuclear phagocytes", "ANATOMY", 103, 125], ["monocytes", "ANATOMY", 127, 136], ["macrophages", "ANATOMY", 141, 152], ["immune cells", "ANATOMY", 261, 273], ["BM", "ANATOMY", 292, 294], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 46, 59], ["pathogen", "ORGANISM", 60, 68], ["C. neoformans", "ORGANISM", 69, 82], ["BBB", "CELL", 95, 98], ["mononuclear phagocytes", "CELL", 103, 125], ["monocytes", "CELL", 127, 136], ["macrophages", "CELL", 141, 152], ["immune cells", "CELL", 261, 273], ["BM", "TISSUE", 292, 294], ["mononuclear phagocytes", "CELL_TYPE", 103, 125], ["monocytes", "CELL_TYPE", 127, 136], ["macrophages", "CELL_TYPE", 141, 152], ["immune cells", "CELL_TYPE", 261, 273], ["C. neoformans", "SPECIES", 69, 82], ["C. neoformans", "SPECIES", 69, 82], ["the facultative intracellular pathogen", "PROBLEM", 30, 68], ["mononuclear phagocytes", "TEST", 103, 125], ["macrophages", "TEST", 141, 152], ["free yeasts", "PROBLEM", 196, 207], ["Hitchhiking", "PROBLEM", 213, 224], ["facultative", "OBSERVATION_MODIFIER", 34, 45], ["intracellular", "OBSERVATION_MODIFIER", 46, 59], ["pathogen", "OBSERVATION_MODIFIER", 60, 68], ["mononuclear phagocytes", "OBSERVATION", 103, 125], ["BM", "ANATOMY", 292, 294]]], ["DCs and Langerhans cells (LCs), an epidermal DC subtype, are located at mucosal or epidermal sites of entry for many viruses, such as herpesviruses, immunodeficiency viruses and HPV, and are thus of key importance in infections with these viruses.", [["DCs", "ANATOMY", 0, 3], ["Langerhans cells", "ANATOMY", 8, 24], ["LCs", "ANATOMY", 26, 29], ["epidermal DC", "ANATOMY", 35, 47], ["mucosal", "ANATOMY", 72, 79], ["epidermal sites", "ANATOMY", 83, 98], ["herpesviruses, immunodeficiency viruses", "DISEASE", 134, 173], ["infections", "DISEASE", 217, 227], ["DCs", "CELL", 0, 3], ["Langerhans cells", "CELL", 8, 24], ["LCs", "CELL", 26, 29], ["epidermal DC", "CELL", 35, 47], ["mucosal", "TISSUE", 72, 79], ["epidermal sites", "CELLULAR_COMPONENT", 83, 98], ["immunodeficiency viruses", "ORGANISM", 149, 173], ["HPV", "ORGANISM", 178, 181], ["DCs", "CELL_TYPE", 0, 3], ["Langerhans cells", "CELL_TYPE", 8, 24], ["LCs", "CELL_TYPE", 26, 29], ["epidermal DC subtype", "CELL_TYPE", 35, 55], ["HPV", "SPECIES", 178, 181], ["LCs", "TEST", 26, 29], ["an epidermal DC subtype", "PROBLEM", 32, 55], ["many viruses", "PROBLEM", 112, 124], ["herpesviruses", "PROBLEM", 134, 147], ["immunodeficiency viruses", "PROBLEM", 149, 173], ["HPV", "PROBLEM", 178, 181], ["these viruses", "PROBLEM", 233, 246], ["Langerhans cells", "OBSERVATION", 8, 24], ["epidermal DC subtype", "OBSERVATION", 35, 55], ["viruses", "OBSERVATION", 117, 124], ["infections", "OBSERVATION", 217, 227]]], ["Initial infection of epidermal cells with herpes simplex virus type 1 (HSV-1) results in infection of resident LCs.", [["epidermal cells", "ANATOMY", 21, 36], ["LCs", "ANATOMY", 111, 114], ["infection", "DISEASE", 8, 17], ["herpes simplex virus", "DISEASE", 42, 62], ["infection", "DISEASE", 89, 98], ["epidermal cells", "CELL", 21, 36], ["herpes simplex virus type 1", "ORGANISM", 42, 69], ["HSV-1", "ORGANISM", 71, 76], ["LCs", "CELL", 111, 114], ["epidermal cells", "CELL_TYPE", 21, 36], ["resident LCs", "CELL_TYPE", 102, 114], ["herpes simplex virus type 1", "SPECIES", 42, 69], ["HSV-1", "SPECIES", 71, 76], ["herpes simplex virus type 1", "SPECIES", 42, 69], ["HSV-1", "SPECIES", 71, 76], ["Initial infection of epidermal cells", "PROBLEM", 0, 36], ["herpes simplex virus type", "PROBLEM", 42, 67], ["HSV", "TEST", 71, 74], ["infection", "OBSERVATION", 8, 17], ["epidermal cells", "OBSERVATION", 21, 36], ["infection", "OBSERVATION", 89, 98]]], ["After infection, a decrease in epidermal LC density and a corresponding increase in the number of langerin-positive cells in the underlying dermis has been noted, arguing for HSV-induced LC migration from the epidermal layer [91].", [["epidermal LC", "ANATOMY", 31, 43], ["langerin-positive cells", "ANATOMY", 98, 121], ["dermis", "ANATOMY", 140, 146], ["LC", "ANATOMY", 187, 189], ["epidermal layer", "ANATOMY", 209, 224], ["infection", "DISEASE", 6, 15], ["epidermal LC", "TISSUE", 31, 43], ["langerin", "GENE_OR_GENE_PRODUCT", 98, 106], ["dermis", "TISSUE", 140, 146], ["HSV", "ORGANISM", 175, 178], ["LC", "CELL", 187, 189], ["langerin", "PROTEIN", 98, 106], ["positive cells", "CELL_TYPE", 107, 121], ["HSV", "SPECIES", 175, 178], ["infection", "PROBLEM", 6, 15], ["a decrease in epidermal LC density", "PROBLEM", 17, 51], ["a corresponding increase", "PROBLEM", 56, 80], ["langerin-positive cells", "PROBLEM", 98, 121], ["the underlying dermis", "PROBLEM", 125, 146], ["HSV", "PROBLEM", 175, 178], ["the epidermal layer", "TEST", 205, 224], ["infection", "OBSERVATION", 6, 15], ["decrease", "OBSERVATION_MODIFIER", 19, 27], ["epidermal", "OBSERVATION_MODIFIER", 31, 40], ["LC density", "OBSERVATION", 41, 51], ["corresponding", "OBSERVATION_MODIFIER", 58, 71], ["increase", "OBSERVATION_MODIFIER", 72, 80], ["number", "OBSERVATION_MODIFIER", 88, 94], ["positive cells", "OBSERVATION", 107, 121], ["dermis", "ANATOMY", 140, 146], ["LC", "OBSERVATION_MODIFIER", 187, 189], ["migration", "OBSERVATION_MODIFIER", 190, 199], ["epidermal", "OBSERVATION_MODIFIER", 209, 218], ["layer", "OBSERVATION_MODIFIER", 219, 224]]], ["During primary infection with varicella zoster virus (VZV), another herpesvirus, DCs of the respiratory mucosa can transport VZV to human tonsillar CD4+ T lymphocytes, followed by T lymphocyte-mediated dissemination in the host [92].", [["DCs", "ANATOMY", 81, 84], ["respiratory mucosa", "ANATOMY", 92, 110], ["tonsillar CD4+ T lymphocytes", "ANATOMY", 138, 166], ["T lymphocyte", "ANATOMY", 180, 192], ["primary infection", "DISEASE", 7, 24], ["varicella zoster", "DISEASE", 30, 46], ["VZV", "DISEASE", 54, 57], ["varicella zoster virus", "ORGANISM", 30, 52], ["VZV", "ORGANISM", 54, 57], ["herpesvirus", "ORGANISM", 68, 79], ["DCs", "CELL", 81, 84], ["respiratory mucosa", "ORGAN", 92, 110], ["VZV", "ORGANISM", 125, 128], ["human", "ORGANISM", 132, 137], ["tonsillar", "CELL", 138, 147], ["CD4", "GENE_OR_GENE_PRODUCT", 148, 151], ["T lymphocyte", "CELL", 180, 192], ["DCs", "CELL_TYPE", 81, 84], ["human tonsillar CD4+ T lymphocytes", "CELL_TYPE", 132, 166], ["T lymphocyte", "CELL_TYPE", 180, 192], ["varicella zoster virus", "SPECIES", 30, 52], ["human", "SPECIES", 132, 137], ["varicella zoster virus", "SPECIES", 30, 52], ["VZV", "SPECIES", 54, 57], ["VZV", "SPECIES", 125, 128], ["human", "SPECIES", 132, 137], ["primary infection", "PROBLEM", 7, 24], ["varicella zoster virus", "PROBLEM", 30, 52], ["VZV", "PROBLEM", 54, 57], ["another herpesvirus", "PROBLEM", 60, 79], ["the respiratory mucosa", "PROBLEM", 88, 110], ["T lymphocytes", "PROBLEM", 153, 166], ["T lymphocyte", "TEST", 180, 192], ["infection", "OBSERVATION", 15, 24], ["varicella zoster virus", "OBSERVATION", 30, 52], ["respiratory mucosa", "ANATOMY", 92, 110], ["tonsillar", "ANATOMY", 138, 147]]], ["HIV might use LCs for trans-epithelial transport of HIV to susceptible CD4+ T cells [93].", [["LCs", "ANATOMY", 14, 17], ["epithelial", "ANATOMY", 28, 38], ["CD4+ T cells", "ANATOMY", 71, 83], ["HIV", "ORGANISM", 0, 3], ["LCs", "CELL", 14, 17], ["epithelial", "TISSUE", 28, 38], ["HIV", "ORGANISM", 52, 55], ["CD4", "GENE_OR_GENE_PRODUCT", 71, 74], ["LCs", "CELL_TYPE", 14, 17], ["CD4", "PROTEIN", 71, 74], ["T cells", "CELL_TYPE", 76, 83], ["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 52, 55], ["HIV", "PROBLEM", 0, 3], ["HIV", "PROBLEM", 52, 55]]], ["Measles virus (MV) is another virus that uses DCs to gain access to its main target cells in lymphoid tissues [94].", [["DCs", "ANATOMY", 46, 49], ["cells", "ANATOMY", 84, 89], ["lymphoid tissues", "ANATOMY", 93, 109], ["Measles virus", "DISEASE", 0, 13], ["Measles virus", "ORGANISM", 0, 13], ["DCs", "CELL", 46, 49], ["cells", "CELL", 84, 89], ["lymphoid tissues", "TISSUE", 93, 109], ["DCs", "CELL_TYPE", 46, 49], ["target cells", "CELL_TYPE", 77, 89], ["Measles virus", "SPECIES", 0, 13], ["Measles virus", "SPECIES", 0, 13], ["MV", "SPECIES", 15, 17], ["Measles virus", "PROBLEM", 0, 13], ["another virus", "PROBLEM", 22, 35], ["main", "OBSERVATION_MODIFIER", 72, 76], ["target cells", "OBSERVATION", 77, 89], ["lymphoid tissues", "OBSERVATION", 93, 109]]], ["As described earlier, ANDV, Dengue virus, HIV and WNV hijack DCs [72].Hitchhiking across the BMHIV may use not only use LCs but also mononuclear phagocytes (monocytes/macrophages) for BM passage, which could contribute to their ability to invade the brain.", [["DCs", "ANATOMY", 61, 64], ["LCs", "ANATOMY", 120, 123], ["mononuclear phagocytes", "ANATOMY", 133, 155], ["monocytes", "ANATOMY", 157, 166], ["macrophages", "ANATOMY", 167, 178], ["BM", "ANATOMY", 184, 186], ["brain", "ANATOMY", 250, 255], ["Dengue", "DISEASE", 28, 34], ["Dengue virus", "ORGANISM", 28, 40], ["HIV", "ORGANISM", 42, 45], ["WNV", "ORGANISM", 50, 53], ["DCs", "CELL", 61, 64], ["LCs", "CELL", 120, 123], ["mononuclear phagocytes", "CELL", 133, 155], ["monocytes", "CELL", 157, 166], ["macrophages", "CELL", 167, 178], ["BM", "CELL", 184, 186], ["brain", "ORGAN", 250, 255], ["DCs", "CELL_TYPE", 61, 64], ["LCs", "CELL_TYPE", 120, 123], ["mononuclear phagocytes", "CELL_TYPE", 133, 155], ["monocytes", "CELL_TYPE", 157, 166], ["macrophages", "CELL_TYPE", 167, 178], ["HIV", "SPECIES", 42, 45], ["ANDV", "SPECIES", 22, 26], ["Dengue virus", "SPECIES", 28, 40], ["HIV", "SPECIES", 42, 45], ["WNV", "SPECIES", 50, 53], ["BMHIV", "SPECIES", 93, 98], ["Dengue virus", "PROBLEM", 28, 40], ["HIV", "PROBLEM", 42, 45], ["LCs", "TEST", 120, 123], ["mononuclear phagocytes", "TEST", 133, 155], ["monocytes/macrophages", "TEST", 157, 178], ["BM passage", "PROBLEM", 184, 194], ["brain", "ANATOMY", 250, 255]]], ["Early in the course of infection, HIV-1 can enter the CNS.", [["CNS", "ANATOMY", 54, 57], ["infection", "DISEASE", 23, 32], ["HIV-1", "ORGANISM", 34, 39], ["CNS", "ANATOMICAL_SYSTEM", 54, 57], ["HIV-1", "SPECIES", 34, 39], ["HIV-1", "SPECIES", 34, 39], ["infection", "PROBLEM", 23, 32], ["HIV", "PROBLEM", 34, 37], ["infection", "OBSERVATION", 23, 32], ["CNS", "ANATOMY", 54, 57]]], ["HIV encephalitis is characterized by HIV-laden monocytes and macrophage infiltration into CNS parenchyma.", [["monocytes", "ANATOMY", 47, 56], ["macrophage", "ANATOMY", 61, 71], ["CNS parenchyma", "ANATOMY", 90, 104], ["HIV encephalitis", "DISEASE", 0, 16], ["HIV encephalitis", "ORGANISM", 0, 16], ["HIV", "ORGANISM", 37, 40], ["monocytes", "CELL", 47, 56], ["macrophage", "CELL", 61, 71], ["CNS parenchyma", "MULTI-TISSUE_STRUCTURE", 90, 104], ["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 37, 40], ["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 37, 40], ["HIV encephalitis", "PROBLEM", 0, 16], ["HIV", "PROBLEM", 37, 40], ["laden monocytes", "PROBLEM", 41, 56], ["macrophage infiltration into CNS parenchyma", "PROBLEM", 61, 104], ["encephalitis", "OBSERVATION", 4, 16], ["HIV", "OBSERVATION_MODIFIER", 37, 40], ["laden monocytes", "OBSERVATION", 41, 56], ["macrophage infiltration", "OBSERVATION", 61, 84], ["CNS", "ANATOMY", 90, 93], ["parenchyma", "ANATOMY_MODIFIER", 94, 104]]], ["Local inflammation and HIV products such as gp120, Nef and Tat, which upregulate MMP2 and/or MMP9, lead to breaches in the BBB late in HIV CNS disease.", [["BBB", "ANATOMY", 123, 126], ["CNS", "ANATOMY", 139, 142], ["inflammation", "DISEASE", 6, 18], ["HIV CNS disease", "DISEASE", 135, 150], ["gp120", "GENE_OR_GENE_PRODUCT", 44, 49], ["Nef", "GENE_OR_GENE_PRODUCT", 51, 54], ["Tat", "GENE_OR_GENE_PRODUCT", 59, 62], ["MMP2", "GENE_OR_GENE_PRODUCT", 81, 85], ["MMP9", "GENE_OR_GENE_PRODUCT", 93, 97], ["BBB", "MULTI-TISSUE_STRUCTURE", 123, 126], ["CNS", "ANATOMICAL_SYSTEM", 139, 142], ["HIV products", "PROTEIN", 23, 35], ["gp120", "PROTEIN", 44, 49], ["Nef", "PROTEIN", 51, 54], ["Tat", "PROTEIN", 59, 62], ["MMP2", "PROTEIN", 81, 85], ["MMP9", "PROTEIN", 93, 97], ["HIV", "SPECIES", 135, 138], ["HIV", "SPECIES", 23, 26], ["HIV", "SPECIES", 135, 138], ["Local inflammation", "PROBLEM", 0, 18], ["HIV products", "TREATMENT", 23, 35], ["gp120", "TREATMENT", 44, 49], ["Nef and Tat", "TREATMENT", 51, 62], ["MMP2", "TEST", 81, 85], ["MMP9", "PROBLEM", 93, 97], ["HIV CNS disease", "PROBLEM", 135, 150], ["inflammation", "OBSERVATION", 6, 18], ["HIV", "OBSERVATION", 23, 26], ["BBB", "ANATOMY", 123, 126], ["HIV CNS disease", "OBSERVATION", 135, 150]]], ["This enables free virions to enter the brain 95, 96.", [["brain", "ANATOMY", 39, 44], ["brain", "ORGAN", 39, 44], ["brain", "ANATOMY", 39, 44]]], ["In addition, CMV-infected monocytes can enter the CNS in a Trojan horse model [78].", [["monocytes", "ANATOMY", 26, 35], ["CNS", "ANATOMY", 50, 53], ["CMV", "ORGANISM", 13, 16], ["monocytes", "CELL", 26, 35], ["CNS", "ANATOMICAL_SYSTEM", 50, 53], ["horse", "ORGANISM_SUBDIVISION", 66, 71], ["CMV-infected monocytes", "CELL_TYPE", 13, 35], ["CMV", "SPECIES", 13, 16], ["CMV", "TEST", 13, 16], ["infected monocytes", "PROBLEM", 17, 35], ["CMV", "OBSERVATION", 13, 16], ["infected monocytes", "OBSERVATION", 17, 35], ["CNS", "ANATOMY", 50, 53]]], ["For WNV, LCs support initial viral replication, followed by replication in lymphoid tissues and dissemination to organs and the CNS [97]; WNV may enter the brain through the BBB either directly or carried within infected monocytes or macrophages (as described above) [73].Hitchhiking across the BMRecently, it has been shown that equine herpesvirus 1 (EHV-1) might use monocytes, macrophages and lymphocytes as Trojan horses to transport the virus through the BM in nasal mucosae.", [["LCs", "ANATOMY", 9, 12], ["lymphoid tissues", "ANATOMY", 75, 91], ["organs", "ANATOMY", 113, 119], ["CNS", "ANATOMY", 128, 131], ["brain", "ANATOMY", 156, 161], ["BBB", "ANATOMY", 174, 177], ["monocytes", "ANATOMY", 221, 230], ["macrophages", "ANATOMY", 234, 245], ["monocytes", "ANATOMY", 369, 378], ["macrophages", "ANATOMY", 380, 391], ["lymphocytes", "ANATOMY", 396, 407], ["BM", "ANATOMY", 460, 462], ["nasal mucosae", "ANATOMY", 466, 479], ["WNV", "ORGANISM", 4, 7], ["LCs", "CELL", 9, 12], ["lymphoid tissues", "TISSUE", 75, 91], ["organs", "ORGAN", 113, 119], ["WNV", "ORGANISM", 138, 141], ["brain", "ORGAN", 156, 161], ["BBB", "MULTI-TISSUE_STRUCTURE", 174, 177], ["monocytes", "CELL", 221, 230], ["macrophages", "CELL", 234, 245], ["equine herpesvirus 1", "ORGANISM", 330, 350], ["EHV-1", "ORGANISM", 352, 357], ["monocytes", "CELL", 369, 378], ["macrophages", "CELL", 380, 391], ["lymphocytes", "CELL", 396, 407], ["Trojan horses", "ORGANISM", 411, 424], ["BM", "TISSUE", 460, 462], ["nasal mucosae", "MULTI-TISSUE_STRUCTURE", 466, 479], ["LCs", "CELL_TYPE", 9, 12], ["infected monocytes", "CELL_TYPE", 212, 230], ["macrophages", "CELL_TYPE", 234, 245], ["monocytes", "CELL_TYPE", 369, 378], ["macrophages", "CELL_TYPE", 380, 391], ["lymphocytes", "CELL_TYPE", 396, 407], ["equine herpesvirus 1", "SPECIES", 330, 350], ["EHV-1", "SPECIES", 352, 357], ["WNV", "SPECIES", 4, 7], ["WNV", "SPECIES", 138, 141], ["equine herpesvirus 1", "SPECIES", 330, 350], ["EHV-1", "SPECIES", 352, 357], ["WNV", "PROBLEM", 4, 7], ["initial viral replication", "TREATMENT", 21, 46], ["the CNS", "TEST", 124, 131], ["WNV", "PROBLEM", 138, 141], ["macrophages", "PROBLEM", 234, 245], ["equine herpesvirus", "TEST", 330, 348], ["EHV", "TEST", 352, 355], ["monocytes", "TEST", 369, 378], ["lymphocytes", "PROBLEM", 396, 407], ["viral replication", "OBSERVATION", 29, 46], ["lymphoid tissues", "OBSERVATION", 75, 91], ["brain", "ANATOMY", 156, 161], ["infected monocytes", "OBSERVATION", 212, 230], ["macrophages", "OBSERVATION", 234, 245], ["macrophages", "ANATOMY", 380, 391], ["lymphocytes", "ANATOMY", 396, 407], ["BM", "ANATOMY", 460, 462], ["nasal mucosae", "ANATOMY", 466, 479]]], ["EHV-1-infected monocytes, macrophages and lymphocytes were found in connective tissue below the BM in close proximity to epithelial plaques, suggestive of leukocyte-mediated viral passage through the BM [98].", [["monocytes", "ANATOMY", 15, 24], ["macrophages", "ANATOMY", 26, 37], ["lymphocytes", "ANATOMY", 42, 53], ["connective tissue", "ANATOMY", 68, 85], ["BM", "ANATOMY", 96, 98], ["epithelial plaques", "ANATOMY", 121, 139], ["leukocyte", "ANATOMY", 155, 164], ["BM", "ANATOMY", 200, 202], ["EHV-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["monocytes", "CELL", 15, 24], ["macrophages", "CELL", 26, 37], ["lymphocytes", "CELL", 42, 53], ["connective tissue", "TISSUE", 68, 85], ["BM", "TISSUE", 96, 98], ["epithelial plaques", "TISSUE", 121, 139], ["leukocyte", "CELL", 155, 164], ["EHV-1-infected monocytes", "CELL_LINE", 0, 24], ["macrophages", "CELL_TYPE", 26, 37], ["lymphocytes", "CELL_TYPE", 42, 53], ["EHV-1", "SPECIES", 0, 5], ["EHV", "TEST", 0, 3], ["infected monocytes", "PROBLEM", 6, 24], ["macrophages", "PROBLEM", 26, 37], ["lymphocytes", "PROBLEM", 42, 53], ["connective tissue", "PROBLEM", 68, 85], ["epithelial plaques", "PROBLEM", 121, 139], ["leukocyte-mediated viral passage", "PROBLEM", 155, 187], ["infected monocytes", "ANATOMY", 6, 24], ["macrophages", "ANATOMY", 26, 37], ["lymphocytes", "OBSERVATION", 42, 53], ["connective tissue", "OBSERVATION_MODIFIER", 68, 85], ["BM", "OBSERVATION", 96, 98], ["epithelial", "ANATOMY", 121, 131], ["plaques", "OBSERVATION", 132, 139], ["suggestive of", "UNCERTAINTY", 141, 154], ["leukocyte", "OBSERVATION", 155, 164], ["viral passage", "OBSERVATION", 174, 187], ["BM", "ANATOMY", 200, 202]]], ["The closely related EHV-4 did not efficiently infect these local immune cells, which might be the reason why EHV-4-induced viremia is rare [98].", [["immune cells", "ANATOMY", 65, 77], ["EHV-4", "CHEMICAL", 109, 114], ["viremia", "DISEASE", 123, 130], ["EHV-4", "ORGANISM", 20, 25], ["immune cells", "CELL", 65, 77], ["EHV-4", "ORGANISM", 109, 114], ["EHV-4", "DNA", 20, 25], ["local immune cells", "CELL_TYPE", 59, 77], ["EHV", "TEST", 109, 112], ["induced viremia", "PROBLEM", 115, 130], ["immune cells", "OBSERVATION", 65, 77]]], ["It has been postulated that BHV-5 might use a similar invasive mechanism as EHV-1 and that BHV-5 entry into the CNS is facilitated by leukocytes and MMP9 [75].", [["CNS", "ANATOMY", 112, 115], ["leukocytes", "ANATOMY", 134, 144], ["BHV-5", "ORGANISM", 28, 33], ["EHV-1", "GENE_OR_GENE_PRODUCT", 76, 81], ["BHV-5", "ORGANISM", 91, 96], ["CNS", "ANATOMICAL_SYSTEM", 112, 115], ["leukocytes", "CELL", 134, 144], ["MMP9", "GENE_OR_GENE_PRODUCT", 149, 153], ["BHV", "PROTEIN", 91, 94], ["leukocytes", "CELL_TYPE", 134, 144], ["MMP9", "PROTEIN", 149, 153], ["EHV-1", "SPECIES", 76, 81], ["EHV", "TEST", 76, 79], ["leukocytes", "TEST", 134, 144], ["MMP9", "TEST", 149, 153], ["CNS", "ANATOMY", 112, 115]]], ["Lymphocyte-mediated viral entry into the brain has also been demonstrated for HTLV-1 [70].", [["Lymphocyte", "ANATOMY", 0, 10], ["brain", "ANATOMY", 41, 46], ["Lymphocyte", "CELL", 0, 10], ["brain", "ORGAN", 41, 46], ["HTLV-1", "ORGANISM", 78, 84], ["HTLV-1", "SPECIES", 78, 84], ["Lymphocyte", "TEST", 0, 10], ["HTLV", "TEST", 78, 82], ["viral entry", "OBSERVATION", 20, 31], ["brain", "ANATOMY", 41, 46]]], ["The association with MMP activity was described earlier.Hitchhiking across the BMSome oncogenic viruses such as EBV, hepatitis B virus, HPV, HTLV-1 and KSHV drive tumor invasiveness and metastasis by modulating proteases (Figure 2).", [["tumor", "ANATOMY", 163, 168], ["hepatitis B", "DISEASE", 117, 128], ["tumor", "DISEASE", 163, 168], ["MMP", "GENE_OR_GENE_PRODUCT", 21, 24], ["BMSome", "GENE_OR_GENE_PRODUCT", 79, 85], ["EBV", "ORGANISM", 112, 115], ["hepatitis B virus", "ORGANISM", 117, 134], ["HPV", "ORGANISM", 136, 139], ["HTLV-1", "ORGANISM", 141, 147], ["KSHV", "ORGANISM", 152, 156], ["tumor", "CANCER", 163, 168], ["MMP", "PROTEIN", 21, 24], ["proteases", "PROTEIN", 211, 220], ["hepatitis B virus", "SPECIES", 117, 134], ["HTLV-1", "SPECIES", 141, 147], ["hepatitis B virus", "SPECIES", 117, 134], ["HPV", "SPECIES", 136, 139], ["HTLV-1", "SPECIES", 141, 147], ["KSHV", "SPECIES", 152, 156], ["MMP activity", "PROBLEM", 21, 33], ["Hitchhiking", "PROBLEM", 56, 67], ["the BMSome oncogenic viruses", "PROBLEM", 75, 103], ["EBV", "PROBLEM", 112, 115], ["hepatitis B virus", "PROBLEM", 117, 134], ["HPV", "PROBLEM", 136, 139], ["HTLV", "PROBLEM", 141, 145], ["KSHV drive tumor invasiveness", "PROBLEM", 152, 181], ["metastasis", "PROBLEM", 186, 196], ["modulating proteases", "PROBLEM", 200, 220], ["MMP activity", "OBSERVATION", 21, 33], ["oncogenic viruses", "OBSERVATION", 86, 103], ["metastasis", "OBSERVATION", 186, 196]]], ["However, the role of the spread of viral-infected malignant cells in the pathogenesis of these viruses is unclear at present.Hitchhiking across the BMIn conclusion, different bacteria, fungi and viruses exploit host cells, particularly immune cells, to cross the BM barrier and disseminate throughout the host.Concluding remarks and future perspectivesThe BM represents a formidable barrier of the body against the outside world.", [["malignant cells", "ANATOMY", 50, 65], ["cells", "ANATOMY", 216, 221], ["immune cells", "ANATOMY", 236, 248], ["BM barrier", "ANATOMY", 263, 273], ["BM", "ANATOMY", 356, 358], ["body", "ANATOMY", 398, 402], ["malignant cells", "CELL", 50, 65], ["host cells", "CELL", 211, 221], ["immune cells", "CELL", 236, 248], ["BM barrier", "MULTI-TISSUE_STRUCTURE", 263, 273], ["BM", "CELL", 356, 358], ["body", "ORGANISM_SUBDIVISION", 398, 402], ["viral-infected malignant cells", "CELL_TYPE", 35, 65], ["host cells", "CELL_TYPE", 211, 221], ["immune cells", "CELL_TYPE", 236, 248], ["viral-infected malignant cells", "PROBLEM", 35, 65], ["these viruses", "PROBLEM", 89, 102], ["Hitchhiking across the BMIn conclusion", "PROBLEM", 125, 163], ["different bacteria", "PROBLEM", 165, 183], ["fungi", "PROBLEM", 185, 190], ["viruses", "PROBLEM", 195, 202], ["host cells", "PROBLEM", 211, 221], ["immune cells", "PROBLEM", 236, 248], ["spread", "OBSERVATION_MODIFIER", 25, 31], ["viral", "OBSERVATION_MODIFIER", 35, 40], ["infected", "OBSERVATION_MODIFIER", 41, 49], ["malignant cells", "OBSERVATION", 50, 65], ["viruses", "OBSERVATION", 95, 102], ["different", "OBSERVATION_MODIFIER", 165, 174], ["bacteria", "OBSERVATION", 175, 183], ["immune cells", "OBSERVATION", 236, 248], ["BM", "ANATOMY", 263, 265], ["BM", "OBSERVATION", 356, 358], ["formidable", "OBSERVATION_MODIFIER", 372, 382], ["barrier", "OBSERVATION", 383, 390]]], ["However, it is clear that a wide array of pathogens have developed mechanisms to cross the BM and invade the host.", [["BM", "ANATOMY", 91, 93], ["BM", "CELL", 91, 93], ["a wide array of pathogens", "PROBLEM", 26, 51], ["wide", "OBSERVATION_MODIFIER", 28, 32]]], ["One aspect of BM passage that we have not discussed here is the role of local immunity in breaking down ECM during a microbial infection.", [["BM", "ANATOMY", 14, 16], ["ECM", "ANATOMY", 104, 107], ["microbial infection", "DISEASE", 117, 136], ["BM", "CELL", 14, 16], ["ECM", "CELLULAR_COMPONENT", 104, 107], ["BM passage", "PROBLEM", 14, 24], ["a microbial infection", "PROBLEM", 115, 136], ["BM passage", "OBSERVATION", 14, 24], ["infection", "OBSERVATION", 127, 136]]], ["Indeed, immune cells produce a large amount of proteases on stimulation at sites of inflammation and this might rupture important barriers such as the BM, allowing pathogens access to deeper tissues.", [["immune cells", "ANATOMY", 8, 20], ["BM", "ANATOMY", 151, 153], ["tissues", "ANATOMY", 191, 198], ["inflammation", "DISEASE", 84, 96], ["immune cells", "CELL", 8, 20], ["BM", "CELL", 151, 153], ["tissues", "TISSUE", 191, 198], ["immune cells", "CELL_TYPE", 8, 20], ["proteases", "PROTEIN", 47, 56], ["immune cells", "PROBLEM", 8, 20], ["stimulation", "TREATMENT", 60, 71], ["inflammation", "PROBLEM", 84, 96], ["immune cells", "OBSERVATION", 8, 20], ["large", "OBSERVATION_MODIFIER", 31, 36], ["amount", "OBSERVATION_MODIFIER", 37, 43], ["proteases", "OBSERVATION", 47, 56], ["inflammation", "OBSERVATION", 84, 96]]], ["However, inflammation increases the risk that pathogens will be neutralized by the immune system.Box 1Outstanding questions\u2022For what reason did certain pathogens, which might even belong to the same family, evolve different mechanisms of invasion?", [["immune system", "ANATOMY", 83, 96], ["inflammation", "DISEASE", 9, 21], ["immune system", "ANATOMICAL_SYSTEM", 83, 96], ["inflammation", "PROBLEM", 9, 21], ["pathogens", "PROBLEM", 46, 55], ["invasion", "PROBLEM", 238, 246], ["inflammation", "OBSERVATION", 9, 21], ["invasion", "OBSERVATION", 238, 246]]], ["Did they co-evolve with their host?\u2022Does tissue type play a role in the particular mechanism utilized for pathogen invasion?", [["tissue", "ANATOMY", 41, 47], ["tissue", "TISSUE", 41, 47], ["pathogen invasion", "PROBLEM", 106, 123]]], ["Alternatively, is tissue tropism driven by the invasion skills of a pathogen?", [["tissue", "ANATOMY", 18, 24], ["tissue", "TISSUE", 18, 24], ["tissue tropism", "PROBLEM", 18, 32], ["a pathogen", "PROBLEM", 66, 76], ["tissue tropism", "OBSERVATION", 18, 32]]], ["How different are the BM composition and barrier function in different tissues of different species?\u2022To what extent does inflammation really play a role in aiding pathogen invasion through the BM?", [["BM", "ANATOMY", 22, 24], ["tissues", "ANATOMY", 71, 78], ["BM", "ANATOMY", 193, 195], ["inflammation", "DISEASE", 121, 133], ["BM", "TISSUE", 22, 24], ["barrier", "TISSUE", 41, 48], ["tissues", "TISSUE", 71, 78], ["BM", "CELL", 193, 195], ["the BM composition", "TREATMENT", 18, 36], ["barrier function", "TREATMENT", 41, 57], ["different species", "PROBLEM", 82, 99], ["inflammation", "PROBLEM", 121, 133], ["BM composition", "OBSERVATION_MODIFIER", 22, 36], ["barrier function", "OBSERVATION_MODIFIER", 41, 57], ["different tissues", "OBSERVATION_MODIFIER", 61, 78], ["different species", "OBSERVATION", 82, 99], ["inflammation", "OBSERVATION", 121, 133], ["BM", "ANATOMY", 193, 195]]], ["Does immune evasion provide better and more rapid BM crossing?\u2022What intrinsic capacities do viruses possess for host invasion?\u2022Are the proteases involved in viral invasion produced by the virus or cellular proteases that are upregulated by the virus?", [["BM", "ANATOMY", 50, 52], ["cellular", "ANATOMY", 197, 205], ["BM", "CELL", 50, 52], ["cellular", "CELL", 197, 205], ["proteases", "PROTEIN", 135, 144], ["cellular proteases", "PROTEIN", 197, 215], ["What intrinsic capacities", "PROBLEM", 63, 88], ["host invasion", "PROBLEM", 112, 125], ["the proteases", "PROBLEM", 131, 144], ["viral invasion", "PROBLEM", 157, 171], ["the virus", "PROBLEM", 184, 193], ["cellular proteases", "PROBLEM", 197, 215], ["the virus", "PROBLEM", 240, 249], ["viral invasion", "OBSERVATION", 157, 171]]]], "47d9a4720ad71e2f3fa79c9b54ff23ababcec330": [["BackgroundThe emergence of several virus infections during the last decades like dengue, West Nile (WN), Severe acute respiratory syndrome (SARS), chikungunya (CHIK), Middle East respiratory syndrome coronavirus (MERS-CoV), Ebola (EBO), Zika (ZIK) and Yellow Fever (YF) raised some questions on quickness and reliability of laboratory diagnostic tests for verification of suspected cases.", [["infections", "DISEASE", 41, 51], ["dengue", "DISEASE", 81, 87], ["Severe acute respiratory syndrome (SARS), chikungunya", "DISEASE", 105, 158], ["CHIK", "DISEASE", 160, 164], ["Middle East respiratory syndrome coronavirus", "DISEASE", 167, 211], ["Ebola (EBO), Zika (ZIK) and Yellow Fever", "DISEASE", 224, 264], ["YF", "DISEASE", 266, 268], ["West Nile", "ORGANISM", 89, 98], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 167, 211], ["MERS-CoV", "ORGANISM", 213, 221], ["Ebola", "ORGANISM", 224, 229], ["Ebola", "SPECIES", 224, 229], ["West Nile (WN", "SPECIES", 89, 102], ["Severe acute respiratory syndrome (SARS)", "SPECIES", 105, 145], ["Middle East respiratory syndrome coronavirus", "SPECIES", 167, 211], ["MERS-CoV", "SPECIES", 213, 221], ["Yellow Fever (YF)", "SPECIES", 252, 269], ["several virus infections", "PROBLEM", 27, 51], ["dengue", "PROBLEM", 81, 87], ["Severe acute respiratory syndrome", "PROBLEM", 105, 138], ["SARS)", "PROBLEM", 140, 145], ["chikungunya (CHIK)", "PROBLEM", 147, 165], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 167, 211], ["Ebola (EBO)", "PROBLEM", 224, 235], ["Zika (ZIK)", "PROBLEM", 237, 247], ["Yellow Fever (YF)", "PROBLEM", 252, 269], ["laboratory diagnostic tests", "TEST", 324, 351], ["several", "OBSERVATION_MODIFIER", 27, 34], ["virus", "OBSERVATION_MODIFIER", 35, 40], ["infections", "OBSERVATION", 41, 51], ["Severe", "OBSERVATION_MODIFIER", 105, 111], ["acute", "OBSERVATION_MODIFIER", 112, 117], ["respiratory syndrome", "OBSERVATION", 118, 138], ["Middle", "ANATOMY_MODIFIER", 167, 173], ["respiratory syndrome", "OBSERVATION", 179, 199]]], ["All important questions arising with an emerging infection like source and route of transmission, infectivity of patients, recommendation of safety measures for health care personal and distribution in an animal reservoir or other vectors require the performance of laboratory diagnosis.", [["infection", "DISEASE", 49, 58], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["an emerging infection", "PROBLEM", 37, 58], ["safety measures", "TREATMENT", 141, 156], ["an animal reservoir", "TREATMENT", 202, 221], ["laboratory diagnosis", "TEST", 266, 286], ["infection", "OBSERVATION", 49, 58]]], ["To investigate the patient's infections most often a blood sample is taken not only for the analysis of blood parameters but also for pathogen detection mostly by PCR or for testing the presence of specific antibodies.", [["blood sample", "ANATOMY", 53, 65], ["blood", "ANATOMY", 104, 109], ["infections", "DISEASE", 29, 39], ["patient", "ORGANISM", 19, 26], ["blood", "ORGANISM_SUBSTANCE", 53, 58], ["blood", "ORGANISM_SUBSTANCE", 104, 109], ["specific antibodies", "PROTEIN", 198, 217], ["patient", "SPECIES", 19, 26], ["the patient's infections", "PROBLEM", 15, 39], ["a blood sample", "TEST", 51, 65], ["the analysis", "TEST", 88, 100], ["blood parameters", "TEST", 104, 120], ["pathogen detection", "TEST", 134, 152], ["PCR", "TEST", 163, 166], ["testing", "TEST", 174, 181], ["specific antibodies", "PROBLEM", 198, 217]]], ["However, sampling of blood requires medically trained personal and comprises some risks for the patient as well as for the health care personal.", [["blood", "ANATOMY", 21, 26], ["blood", "ORGANISM_SUBSTANCE", 21, 26], ["patient", "ORGANISM", 96, 103], ["patient", "SPECIES", 96, 103]]], ["In particular the blood sampling of patients with highly infectious haemorrhagic fever like Ebola involve a great risk for the physician and the patient.", [["blood", "ANATOMY", 18, 23], ["infectious haemorrhagic fever", "DISEASE", 57, 86], ["Ebola", "DISEASE", 92, 97], ["blood", "ORGANISM_SUBSTANCE", 18, 23], ["patients", "ORGANISM", 36, 44], ["Ebola", "ORGANISM", 92, 97], ["patient", "ORGANISM", 145, 152], ["patients", "SPECIES", 36, 44], ["patient", "SPECIES", 145, 152], ["the blood sampling", "TEST", 14, 32], ["highly infectious haemorrhagic fever", "PROBLEM", 50, 86], ["Ebola", "PROBLEM", 92, 97], ["highly", "OBSERVATION_MODIFIER", 50, 56], ["infectious", "OBSERVATION_MODIFIER", 57, 67]]], ["Therefore, the sampling by non-invasive methods (e.g. saliva and/ or urine) might be a very valuable alternative for investigating a diseased patient.", [["urine", "ANATOMY", 69, 74], ["saliva", "ORGANISM_SUBSTANCE", 54, 60], ["urine", "ORGANISM_SUBSTANCE", 69, 74], ["patient", "ORGANISM", 142, 149], ["patient", "SPECIES", 142, 149], ["the sampling", "TEST", 11, 23], ["non-invasive methods", "TEST", 27, 47], ["saliva and/ or urine", "TEST", 54, 74], ["diseased", "OBSERVATION", 133, 141]]], ["The use of saliva and urine for the diagnosis for many viral infections has been reported, however, it is often not performed in the broad routine diagnostics.BackgroundAfter a viral infection it usually takes some days until the propagation of the virus causes symptoms and a clinical investigation of a patient is indicated.", [["urine", "ANATOMY", 22, 27], ["viral infections", "DISEASE", 55, 71], ["viral infection", "DISEASE", 177, 192], ["saliva", "ORGANISM_SUBSTANCE", 11, 17], ["urine", "ORGANISM_SUBSTANCE", 22, 27], ["patient", "ORGANISM", 305, 312], ["patient", "SPECIES", 305, 312], ["saliva and urine", "TEST", 11, 27], ["many viral infections", "PROBLEM", 50, 71], ["a viral infection", "PROBLEM", 175, 192], ["the virus", "PROBLEM", 245, 254], ["symptoms", "PROBLEM", 262, 270], ["a clinical investigation", "TEST", 275, 299], ["viral", "OBSERVATION_MODIFIER", 55, 60], ["infections", "OBSERVATION", 61, 71], ["viral", "OBSERVATION_MODIFIER", 177, 182], ["infection", "OBSERVATION", 183, 192]]], ["Blood sampling for analysing blood parameters belongs to a routine procedure in developed countries.", [["Blood", "ANATOMY", 0, 5], ["blood", "ANATOMY", 29, 34], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["blood", "ORGANISM_SUBSTANCE", 29, 34], ["Blood sampling", "TEST", 0, 14], ["analysing blood parameters", "TEST", 19, 45], ["a routine procedure", "TREATMENT", 57, 76]]], ["This is different in developing countries, where extensive analyses of clinical parameters are not performed routinely due to financial and technical constraints.", [["clinical parameters", "TEST", 71, 90], ["different", "OBSERVATION_MODIFIER", 8, 17]]], ["Even though the sampling of swaps from the respiratory tracks is a common procedure for influenza, SARS, MERS-CoV and other respiratory infections, the sampling of blood is the prevalent procedure for all other recently emerged viruses.", [["blood", "ANATOMY", 164, 169], ["influenza", "DISEASE", 88, 97], ["SARS", "DISEASE", 99, 103], ["respiratory infections", "DISEASE", 124, 146], ["MERS-CoV", "ORGANISM", 105, 113], ["blood", "ORGANISM_SUBSTANCE", 164, 169], ["MERS-CoV", "SPECIES", 105, 113], ["the respiratory tracks", "PROBLEM", 39, 61], ["a common procedure", "TREATMENT", 65, 83], ["influenza", "PROBLEM", 88, 97], ["SARS", "PROBLEM", 99, 103], ["MERS", "PROBLEM", 105, 109], ["CoV", "PROBLEM", 110, 113], ["other respiratory infections", "PROBLEM", 118, 146], ["the prevalent procedure", "TREATMENT", 173, 196], ["respiratory tracks", "OBSERVATION", 43, 61], ["respiratory", "ANATOMY", 124, 135], ["infections", "OBSERVATION", 136, 146], ["viruses", "OBSERVATION", 228, 235]]], ["However, with the introduction of the highly sensitive Nucleic Acid Tests (NAT) for diagnostic also additional samples like saliva and/or urine were included in diagnostic sample collections.", [["samples", "ANATOMY", 111, 118], ["saliva", "ANATOMY", 124, 130], ["urine", "ANATOMY", 138, 143], ["sample", "ANATOMY", 172, 178], ["Nucleic Acid", "SIMPLE_CHEMICAL", 55, 67], ["saliva", "ORGANISM_SUBSTANCE", 124, 130], ["urine", "ORGANISM_SUBSTANCE", 138, 143], ["Nucleic Acid Tests", "TEST", 55, 73], ["saliva and/or urine", "TEST", 124, 143], ["diagnostic sample collections", "TEST", 161, 190]]], ["The advantage of using non-invasive samples like saliva for dengue serology was successfully proven 18 years ago by Cuzzubbo et al. who discovered that dengue primary and secondary infections can be distinguished by the level of IgG in saliva [1] .", [["samples", "ANATOMY", 36, 43], ["dengue", "DISEASE", 60, 66], ["dengue", "DISEASE", 152, 158], ["primary and secondary infections", "DISEASE", 159, 191], ["saliva", "ORGANISM_SUBSTANCE", 49, 55], ["IgG", "GENE_OR_GENE_PRODUCT", 229, 232], ["saliva", "ORGANISM_SUBSTANCE", 236, 242], ["IgG", "PROTEIN", 229, 232], ["dengue", "SPECIES", 60, 66], ["dengue", "SPECIES", 152, 158], ["non-invasive samples", "TEST", 23, 43], ["dengue serology", "TEST", 60, 75], ["dengue primary", "PROBLEM", 152, 166], ["secondary infections", "PROBLEM", 171, 191], ["secondary", "OBSERVATION_MODIFIER", 171, 180], ["infections", "OBSERVATION", 181, 191]]], ["The specificity of the diagnosis of acute flavivirus infections like dengue, WN and YF has been improved by applying the NAT because it is not impeded by the widespread cross-reactivity found for most serological assays [2] .", [["flavivirus infections", "DISEASE", 42, 63], ["dengue", "DISEASE", 69, 75], ["YF", "DISEASE", 84, 86], ["WN", "ORGANISM", 77, 79], ["YF", "ORGANISM", 84, 86], ["dengue", "SPECIES", 69, 75], ["WN", "SPECIES", 77, 79], ["YF", "SPECIES", 84, 86], ["acute flavivirus infections", "PROBLEM", 36, 63], ["dengue", "PROBLEM", 69, 75], ["YF", "PROBLEM", 84, 86], ["the widespread cross-reactivity", "PROBLEM", 154, 185], ["most serological assays", "TEST", 196, 219], ["acute", "OBSERVATION_MODIFIER", 36, 41], ["flavivirus", "OBSERVATION", 42, 52], ["improved", "OBSERVATION_MODIFIER", 96, 104]]], ["Since urine, saliva and other non-invasive samples were not part of the routine investigation, the sampling procedures and the samples containment are also very different.", [["urine", "ANATOMY", 6, 11], ["samples", "ANATOMY", 43, 50], ["urine", "ORGANISM_SUBSTANCE", 6, 11], ["saliva", "ORGANISM_SUBSTANCE", 13, 19], ["urine", "TEST", 6, 11], ["other non-invasive samples", "TEST", 24, 50], ["the routine investigation", "TEST", 68, 93], ["the sampling procedures", "TEST", 95, 118], ["the samples containment", "TEST", 123, 146]]], ["These differences complicate the interpretation of diagnostic findings and therefore an optimization for these samplings is required.", [["diagnostic findings", "TEST", 51, 70], ["these samplings", "TEST", 105, 120]]], ["An improvement of the sampling and stabilization of viral RNA in the diagnostic material will help to increase significantly the diagnostic sensitivity.BackgroundTo analyse the usefulness of alternative non-invasive samples for diagnostic of infectious viral diseases like SARS, WN, dengue, MERS-CoV, Ebola, Zika and YF, we reviewed the importance of saliva and urine for the diagnosis of recently emerging viruses in comparison to conventional blood sampling.", [["samples", "ANATOMY", 216, 223], ["urine", "ANATOMY", 362, 367], ["blood", "ANATOMY", 445, 450], ["viral diseases", "DISEASE", 253, 267], ["SARS", "DISEASE", 273, 277], ["WN", "DISEASE", 279, 281], ["dengue", "DISEASE", 283, 289], ["Ebola, Zika and YF", "DISEASE", 301, 319], ["MERS-CoV", "ORGANISM", 291, 299], ["Ebola", "ORGANISM", 301, 306], ["saliva", "ORGANISM_SUBSTANCE", 351, 357], ["urine", "ORGANISM_SUBSTANCE", 362, 367], ["blood", "ORGANISM_SUBSTANCE", 445, 450], ["viral RNA", "RNA", 52, 61], ["WN", "SPECIES", 279, 281], ["dengue", "SPECIES", 283, 289], ["MERS-CoV", "SPECIES", 291, 299], ["YF", "SPECIES", 317, 319], ["the sampling", "TEST", 18, 30], ["viral RNA", "PROBLEM", 52, 61], ["the diagnostic sensitivity", "TEST", 125, 151], ["alternative non-invasive samples", "TEST", 191, 223], ["infectious viral diseases", "PROBLEM", 242, 267], ["SARS", "PROBLEM", 273, 277], ["dengue", "PROBLEM", 283, 289], ["Ebola", "PROBLEM", 301, 306], ["Zika", "PROBLEM", 308, 312], ["saliva and urine", "TEST", 351, 367], ["recently emerging viruses", "PROBLEM", 389, 414], ["conventional blood sampling", "TEST", 432, 459], ["improvement", "OBSERVATION_MODIFIER", 3, 14], ["viral RNA", "OBSERVATION", 52, 61], ["viruses", "OBSERVATION", 407, 414]]], ["Since the extensive evaluation of different samples for human patients is often not performed, also investigations of animal models or vectors are considered.", [["samples", "ANATOMY", 44, 51], ["samples", "CANCER", 44, 51], ["human", "ORGANISM", 56, 61], ["patients", "ORGANISM", 62, 70], ["human", "SPECIES", 56, 61], ["patients", "SPECIES", 62, 70], ["human", "SPECIES", 56, 61], ["the extensive evaluation", "TEST", 6, 30]]], ["Therefore, we performed an electronic literature review on PubMed for alternative sampling for SARS, WN, dengue, MERS-CoV, Ebola, Zika and YF.Method of literature searchA review of the literature for urine and saliva samples for diagnostic of CHIK, dengue, Ebola, WN, Zika, YF, SARS and MERS was performed using the electronic database PubMed.", [["urine", "ANATOMY", 200, 205], ["samples", "ANATOMY", 217, 224], ["SARS", "DISEASE", 95, 99], ["dengue", "DISEASE", 105, 111], ["MERS-CoV, Ebola, Zika and YF", "DISEASE", 113, 141], ["dengue", "DISEASE", 249, 255], ["Ebola, WN, Zika, YF", "DISEASE", 257, 276], ["SARS", "DISEASE", 278, 282], ["MERS-CoV", "ORGANISM", 113, 121], ["Ebola", "ORGANISM", 123, 128], ["urine", "ORGANISM_SUBSTANCE", 200, 205], ["saliva samples", "ORGANISM_SUBSTANCE", 210, 224], ["MERS-CoV", "SPECIES", 113, 121], ["YF", "SPECIES", 139, 141], ["YF", "SPECIES", 274, 276], ["alternative sampling", "TEST", 70, 90], ["SARS", "PROBLEM", 95, 99], ["dengue", "PROBLEM", 105, 111], ["Ebola", "PROBLEM", 123, 128], ["Zika", "PROBLEM", 130, 134], ["urine", "TEST", 200, 205], ["saliva samples", "TEST", 210, 224], ["CHIK", "PROBLEM", 243, 247], ["dengue", "PROBLEM", 249, 255], ["Ebola", "PROBLEM", 257, 262], ["Zika", "PROBLEM", 268, 272], ["YF", "PROBLEM", 274, 276], ["SARS", "PROBLEM", 278, 282]]], ["The period for searches was 1 st January 1980 -26 th August 2016.Method of literature searchAppropriate articles were selected according to their abstracts and further reviewed for reason for diagnostic analysis, sample types used and the methods applied for diagnosis focusing on saliva and urine as test samples.Method of literature searchSearch profile used for this review in PubMed for CHIK as an example:Method of literature search\" Another 42 references were considered for analysing the preparation and storage of diagnostic samples as demonstrated in Table 1 , see Additional file 1 for detailed methodology.Method of literature searchThe literature research revealed 711 papers, of which we considered 128 in this study (Additional file 1: Figure S1 ).", [["saliva", "ANATOMY", 281, 287], ["urine", "ANATOMY", 292, 297], ["samples", "ANATOMY", 306, 313], ["saliva", "ORGANISM_SUBSTANCE", 281, 287], ["urine", "ORGANISM_SUBSTANCE", 292, 297], ["diagnostic analysis", "TEST", 192, 211], ["sample types", "TEST", 213, 225], ["the methods", "TREATMENT", 235, 246], ["saliva and urine as test samples", "TEST", 281, 313], ["diagnostic samples", "TEST", 522, 540], ["this study", "TEST", 719, 729]]], ["Furthermore 43 publication analysing the sample processing and preparation were included.Method of literature searchOur analysis shows that there should be put more emphasis on non-invasive sampling to disclose more easy alternatives for collecting human samples for clinical and routine investigations.", [["samples", "ANATOMY", 255, 262], ["human", "ORGANISM", 249, 254], ["human", "SPECIES", 249, 254], ["human", "SPECIES", 249, 254], ["the sample processing", "TEST", 37, 58], ["literature searchOur analysis", "TEST", 99, 128], ["non-invasive sampling", "TEST", 177, 198], ["collecting human samples", "TEST", 238, 262], ["clinical and routine investigations", "TEST", 267, 302]]], ["The present review provides some indications that non-invasive sampling offers a promising alternative for routine diagnostic as well as a favourable diagnostic approach for surveillance studies with high numbers of samples.", [["samples", "ANATOMY", 216, 223], ["non-invasive sampling", "TEST", 50, 71], ["surveillance studies", "TEST", 174, 194]]], ["The review provides an overview of the usability of non-invasive sample for diagnostics of emerging viruses and tries to give recommendation on how this experience could be helpful for future possible outbreaks of emerging viruses.ChikungunyaAfter an epidemic at La Reunion in 2005, an autochthone outbreak in Italy in 2007 and, spread in Caribbean islands in December 2013, chikungunya (CHIK) emerged in 2014 for the first time in Central America spreading into South America and North America [3] [4] [5] [6] [7] .", [["sample", "ANATOMY", 65, 71], ["ChikungunyaAfter", "CHEMICAL", 231, 247], ["chikungunya", "DISEASE", 375, 386], ["[3] [4] [5] [6] [7]", "SIMPLE_CHEMICAL", 495, 514], ["emerging viruses", "PROBLEM", 214, 230], ["epidemic", "OBSERVATION_MODIFIER", 251, 259]]], ["Typical clinical specimens for CHIKV are blood, serum and plasma, but also urine, saliva and in rare cases CSF (Table 1, Additional file 1: Table S1 ).", [["specimens", "ANATOMY", 17, 26], ["blood", "ANATOMY", 41, 46], ["serum", "ANATOMY", 48, 53], ["plasma", "ANATOMY", 58, 64], ["urine", "ANATOMY", 75, 80], ["specimens", "CANCER", 17, 26], ["CHIKV", "ORGANISM", 31, 36], ["blood", "ORGANISM_SUBSTANCE", 41, 46], ["serum", "ORGANISM_SUBSTANCE", 48, 53], ["plasma", "ORGANISM_SUBSTANCE", 58, 64], ["urine", "ORGANISM_SUBSTANCE", 75, 80], ["saliva", "ORGANISM_SUBSTANCE", 82, 88], ["CHIKV", "SPECIES", 31, 36], ["Typical clinical specimens", "TEST", 0, 26], ["CHIKV", "PROBLEM", 31, 36], ["blood", "TEST", 41, 46], ["serum and plasma", "TEST", 48, 64], ["urine, saliva", "TEST", 75, 88]]], ["A systematic evaluation of the CHIK infection in mice and Cynomolgus macaques revealed the infectivity of different body fluids like saliva, urine and vaginal swaps [8] .", [["body fluids", "ANATOMY", 116, 127], ["saliva", "ANATOMY", 133, 139], ["urine", "ANATOMY", 141, 146], ["vaginal", "ANATOMY", 151, 158], ["infection", "DISEASE", 36, 45], ["CHIK", "GENE_OR_GENE_PRODUCT", 31, 35], ["mice", "ORGANISM", 49, 53], ["Cynomolgus macaques", "ORGANISM", 58, 77], ["body fluids", "ORGANISM_SUBSTANCE", 116, 127], ["saliva", "ORGANISM_SUBSTANCE", 133, 139], ["urine", "ORGANISM_SUBSTANCE", 141, 146], ["vaginal", "ORGANISM_SUBDIVISION", 151, 158], ["mice", "SPECIES", 49, 53], ["Cynomolgus macaques", "SPECIES", 58, 77], ["mice", "SPECIES", 49, 53], ["Cynomolgus macaques", "SPECIES", 58, 77], ["A systematic evaluation", "TEST", 0, 23], ["the CHIK infection", "PROBLEM", 27, 45], ["Cynomolgus macaques", "TREATMENT", 58, 77], ["the infectivity of different body fluids", "PROBLEM", 87, 127], ["saliva, urine", "TEST", 133, 146], ["vaginal swaps", "TEST", 151, 164], ["infectivity", "OBSERVATION_MODIFIER", 91, 102], ["vaginal", "ANATOMY", 151, 158]]], ["This could be confirmed by analysis of saliva samples from 4 out of 13 acute CHIKV patients with haemorrhagic manifestations, which were found to contain viral RNA and infectious virus.", [["saliva samples", "ANATOMY", 39, 53], ["CHIKV", "DISEASE", 77, 82], ["saliva samples", "ORGANISM_SUBSTANCE", 39, 53], ["CHIKV", "ORGANISM", 77, 82], ["patients", "ORGANISM", 83, 91], ["infectious virus", "ORGANISM", 168, 184], ["viral RNA", "RNA", 154, 163], ["patients", "SPECIES", 83, 91], ["CHIKV", "SPECIES", 77, 82], ["saliva samples", "TEST", 39, 53], ["haemorrhagic manifestations", "PROBLEM", 97, 124], ["viral RNA and infectious virus", "PROBLEM", 154, 184], ["acute", "OBSERVATION_MODIFIER", 71, 76], ["CHIKV", "OBSERVATION", 77, 82], ["viral RNA", "OBSERVATION", 154, 163], ["infectious virus", "OBSERVATION", 168, 184]]], ["Another study shows that RNA of chikungunya virus can be detected in the saliva at the first seven days of infection but with a lower efficacy than blood samples [9] .", [["saliva", "ANATOMY", 73, 79], ["blood samples", "ANATOMY", 148, 161], ["chikungunya", "DISEASE", 32, 43], ["infection", "DISEASE", 107, 116], ["chikungunya virus", "ORGANISM", 32, 49], ["saliva", "ORGANISM_SUBSTANCE", 73, 79], ["blood", "ORGANISM_SUBSTANCE", 148, 153], ["chikungunya virus", "SPECIES", 32, 49], ["Another study", "TEST", 0, 13], ["RNA of chikungunya virus", "PROBLEM", 25, 49], ["infection", "PROBLEM", 107, 116], ["blood samples", "TEST", 148, 161], ["chikungunya virus", "OBSERVATION", 32, 49], ["infection", "OBSERVATION", 107, 116]]], ["Also the detection of CHIKV genome by RT-PCR in urine was successful in one returning traveller, which is a valuable confirmation of the positive serology [10] .", [["urine", "ANATOMY", 48, 53], ["CHIKV", "ORGANISM", 22, 27], ["urine", "ORGANISM_SUBSTANCE", 48, 53], ["CHIKV genome", "DNA", 22, 34], ["CHIKV", "SPECIES", 22, 27], ["CHIKV genome", "PROBLEM", 22, 34], ["RT-PCR in urine", "TEST", 38, 53], ["the positive serology", "PROBLEM", 133, 154], ["CHIKV genome", "OBSERVATION", 22, 34]]], ["Based on the experience with other viral infections, the analysis of throat swabs and urine are part of recommendation for CHIK diagnostic [11] .DengueCommon clinical specimens used for dengue infection are blood, plasma and serum, but also in some cases CSF and breast milk (Table 1, Additional file 1: Table S2 ).", [["throat swabs", "ANATOMY", 69, 81], ["urine", "ANATOMY", 86, 91], ["specimens", "ANATOMY", 167, 176], ["blood", "ANATOMY", 207, 212], ["plasma", "ANATOMY", 214, 220], ["serum", "ANATOMY", 225, 230], ["breast milk", "ANATOMY", 263, 274], ["viral infections", "DISEASE", 35, 51], ["dengue infection", "DISEASE", 186, 202], ["throat swabs", "MULTI-TISSUE_STRUCTURE", 69, 81], ["urine", "ORGANISM_SUBSTANCE", 86, 91], ["blood", "ORGANISM_SUBSTANCE", 207, 212], ["plasma", "ORGANISM_SUBSTANCE", 214, 220], ["serum", "ORGANISM_SUBSTANCE", 225, 230], ["CSF", "ORGANISM_SUBSTANCE", 255, 258], ["breast milk", "ORGANISM_SUBSTANCE", 263, 274], ["dengue", "SPECIES", 186, 192], ["other viral infections", "PROBLEM", 29, 51], ["the analysis", "TEST", 53, 65], ["throat swabs and urine", "TEST", 69, 91], ["CHIK diagnostic", "TEST", 123, 138], ["DengueCommon clinical specimens", "TEST", 145, 176], ["dengue infection", "PROBLEM", 186, 202], ["blood, plasma and serum", "TEST", 207, 230], ["some cases CSF", "TEST", 244, 258], ["viral", "OBSERVATION_MODIFIER", 35, 40], ["infections", "OBSERVATION", 41, 51], ["breast", "ANATOMY", 263, 269]]], ["Interestingly, the twenty-two selected publications described very well the progress of using saliva and urine as non-invasive samples.", [["saliva", "ANATOMY", 94, 100], ["urine", "ANATOMY", 105, 110], ["samples", "ANATOMY", 127, 134], ["saliva", "ORGANISM_SUBSTANCE", 94, 100], ["urine", "ORGANISM_SUBSTANCE", 105, 110], ["saliva and urine", "TEST", 94, 110], ["non-invasive samples", "TEST", 114, 134]]], ["Based on the existing IgG ELISA for serology, they found that the IgG levels in saliva could be applied to differentiate between dengue primary and secondary infection [1] .", [["dengue primary and secondary infection", "DISEASE", 129, 167], ["IgG", "GENE_OR_GENE_PRODUCT", 22, 25], ["IgG", "GENE_OR_GENE_PRODUCT", 66, 69], ["saliva", "ORGANISM_SUBSTANCE", 80, 86], ["IgG", "PROTEIN", 22, 25], ["IgG", "PROTEIN", 66, 69], ["dengue", "SPECIES", 129, 135], ["the existing IgG ELISA", "TEST", 9, 31], ["serology", "TEST", 36, 44], ["the IgG levels", "TEST", 62, 76], ["dengue primary", "PROBLEM", 129, 143], ["secondary infection", "PROBLEM", 148, 167], ["secondary", "OBSERVATION_MODIFIER", 148, 157], ["infection", "OBSERVATION", 158, 167]]], ["One year later, Artimos de Oliveira et al., used saliva for detection of specific IgM of recent infections [12] .", [["infections", "DISEASE", 96, 106], ["saliva", "ORGANISM_SUBSTANCE", 49, 55], ["IgM", "PROTEIN", 82, 85], ["recent infections", "PROBLEM", 89, 106], ["infections", "OBSERVATION", 96, 106]]], ["In 2000 Torres et al., found for the first time evidence of DENV RNA in saliva and plasma by RT-PCR [13] .", [["saliva", "ANATOMY", 72, 78], ["plasma", "ANATOMY", 83, 89], ["DENV", "ORGANISM", 60, 64], ["saliva", "ORGANISM_SUBSTANCE", 72, 78], ["plasma", "ORGANISM_SUBSTANCE", 83, 89], ["DENV RNA", "RNA", 60, 68], ["DENV", "SPECIES", 60, 64], ["DENV RNA in saliva", "PROBLEM", 60, 78], ["PCR", "TEST", 96, 99], ["DENV", "OBSERVATION", 60, 64]]], ["The evaluation of saliva samples as alternative approaches for serological diagnosis (IgM, IgG, IgA) was further investigated and complemented by more systematic kinetics analysis of 1 st and 2 nd infections also comprising urine as an additional alternative sample [14, 15] .", [["saliva samples", "ANATOMY", 18, 32], ["urine", "ANATOMY", 224, 229], ["infections", "DISEASE", 197, 207], ["saliva samples", "ORGANISM_SUBSTANCE", 18, 32], ["IgG", "GENE_OR_GENE_PRODUCT", 91, 94], ["IgA", "GENE_OR_GENE_PRODUCT", 96, 99], ["urine", "ORGANISM_SUBSTANCE", 224, 229], ["IgM", "PROTEIN", 86, 89], ["IgG", "PROTEIN", 91, 94], ["IgA", "PROTEIN", 96, 99], ["The evaluation of saliva samples", "TEST", 0, 32], ["serological diagnosis", "TEST", 63, 84], ["IgM", "TEST", 86, 89], ["IgG", "TEST", 91, 94], ["systematic kinetics analysis", "TEST", 151, 179], ["1 st and 2 nd infections", "PROBLEM", 183, 207], ["urine", "TEST", 224, 229]]], ["Since the sensitivity (93.3%), specificity (100%), positive predictive value (100%), and negative predictive value (83.3%) of the detection of IgG in saliva are high, it was considered as promising sample type for dengue diagnostics [16] .", [["dengue", "DISEASE", 214, 220], ["IgG", "GENE_OR_GENE_PRODUCT", 143, 146], ["saliva", "ORGANISM_SUBSTANCE", 150, 156], ["IgG", "PROTEIN", 143, 146], ["dengue", "SPECIES", 214, 220], ["the sensitivity", "TEST", 6, 21], ["specificity", "TEST", 31, 42], ["the detection", "TEST", 126, 139], ["IgG in saliva", "PROBLEM", 143, 156], ["dengue diagnostics", "TEST", 214, 232]]], ["Also in case reports analysing acute infections, the detection of DENV in urine and saliva by RT-PCR as well as the application of filter-paper for saliva sampling prove the usefulness of these non-invasive samples [17] [18] [19] .", [["urine", "ANATOMY", 74, 79], ["infections", "DISEASE", 37, 47], ["DENV", "ORGANISM", 66, 70], ["urine", "ORGANISM_SUBSTANCE", 74, 79], ["saliva", "ORGANISM_SUBSTANCE", 84, 90], ["saliva", "ORGANISM_SUBSTANCE", 148, 154], ["DENV", "SPECIES", 66, 70], ["acute infections", "PROBLEM", 31, 47], ["DENV in urine", "PROBLEM", 66, 79], ["PCR", "TEST", 97, 100], ["the application of filter", "TREATMENT", 112, 137], ["saliva sampling", "TREATMENT", 148, 163], ["these non-invasive samples", "TEST", 188, 214], ["acute", "OBSERVATION_MODIFIER", 31, 36], ["infections", "OBSERVATION", 37, 47]]], ["The utility of saliva in an assay that detects DENV-specific IgA in the early phase of a 2 nd dengue infection shows 100% sensitivity from day-one after fever onset with a good correlation to IgA levels in serum and 97% specificity [20] .", [["serum", "ANATOMY", 206, 211], ["dengue infection", "DISEASE", 94, 110], ["fever", "DISEASE", 153, 158], ["saliva", "ORGANISM_SUBSTANCE", 15, 21], ["DENV", "ORGANISM", 47, 51], ["IgA", "GENE_OR_GENE_PRODUCT", 61, 64], ["IgA", "GENE_OR_GENE_PRODUCT", 192, 195], ["serum", "ORGANISM_SUBSTANCE", 206, 211], ["DENV-specific IgA", "PROTEIN", 47, 64], ["IgA", "PROTEIN", 192, 195], ["DENV", "SPECIES", 47, 51], ["dengue", "SPECIES", 94, 100], ["an assay", "TEST", 25, 33], ["DENV", "PROBLEM", 47, 51], ["a 2 nd dengue infection", "PROBLEM", 87, 110], ["fever onset", "PROBLEM", 153, 164], ["IgA levels", "TEST", 192, 202], ["serum", "TEST", 206, 211]]], ["DEN NS1 antigen was detected in urine in around two third of dengue fever and DEN haemorrhagic fever (HF) using ELISA.", [["urine", "ANATOMY", 32, 37], ["dengue fever", "DISEASE", 61, 73], ["DEN haemorrhagic fever", "DISEASE", 78, 100], ["HF", "DISEASE", 102, 104], ["DEN NS1 antigen", "GENE_OR_GENE_PRODUCT", 0, 15], ["urine", "ORGANISM_SUBSTANCE", 32, 37], ["DEN NS1 antigen", "PROTEIN", 0, 15], ["DEN haemorrhagic fever", "SPECIES", 78, 100], ["DEN NS1 antigen", "TEST", 0, 15], ["dengue fever", "PROBLEM", 61, 73], ["DEN haemorrhagic fever", "PROBLEM", 78, 100], ["HF", "PROBLEM", 102, 104], ["ELISA", "TEST", 112, 117]]], ["Follow up the excretion of NS1 in urine is very important particularly in patients developing DF or DHF as an indication of protein leakage.", [["urine", "ANATOMY", 34, 39], ["DF", "DISEASE", 94, 96], ["DHF", "DISEASE", 100, 103], ["NS1", "GENE_OR_GENE_PRODUCT", 27, 30], ["urine", "ORGANISM_SUBSTANCE", 34, 39], ["patients", "ORGANISM", 74, 82], ["NS1", "PROTEIN", 27, 30], ["patients", "SPECIES", 74, 82], ["the excretion of NS1 in urine", "TEST", 10, 39], ["patients developing DF", "PROBLEM", 74, 96], ["DHF", "PROBLEM", 100, 103], ["protein leakage", "PROBLEM", 124, 139], ["NS1", "OBSERVATION", 27, 30], ["DHF", "OBSERVATION", 100, 103], ["protein leakage", "OBSERVATION", 124, 139]]], ["The study demonstrates that the NS1 strip assay is less sensitive for urine compared to the ELISA and both assays need further adaptation to improve the sensitivity [21] .", [["urine", "ANATOMY", 70, 75], ["NS1", "ORGANISM", 32, 35], ["urine", "ORGANISM_SUBSTANCE", 70, 75], ["NS1", "PROTEIN", 32, 35], ["The study", "TEST", 0, 9], ["the NS1 strip assay", "TEST", 28, 47], ["the ELISA", "TEST", 88, 97], ["the sensitivity", "TEST", 149, 164]]], ["This was confirmed by a later study from Saito et al. showing that urine samples could be used for NS1 antigen ELISA but only in case of serum samples are very limited or in poor resource settings [22] .DengueFrom 2012, more studies were performed using saliva and urine samples besides serum for quantitative RT-PCR and other parameters (NS1, IgM, IgG) for dengue diagnostic during the course of the disease [23] [24] [25] .", [["urine samples", "ANATOMY", 67, 80], ["serum samples", "ANATOMY", 137, 150], ["urine samples", "ANATOMY", 265, 278], ["serum", "ANATOMY", 287, 292], ["dengue", "DISEASE", 358, 364], ["urine samples", "ORGANISM_SUBSTANCE", 67, 80], ["NS1 antigen", "GENE_OR_GENE_PRODUCT", 99, 110], ["serum", "ORGANISM_SUBSTANCE", 137, 142], ["samples", "ORGANISM_SUBSTANCE", 143, 150], ["saliva", "ORGANISM_SUBSTANCE", 254, 260], ["urine samples", "ORGANISM_SUBSTANCE", 265, 278], ["serum", "ORGANISM_SUBSTANCE", 287, 292], ["NS1", "GENE_OR_GENE_PRODUCT", 339, 342], ["IgM", "GENE_OR_GENE_PRODUCT", 344, 347], ["IgG", "GENE_OR_GENE_PRODUCT", 349, 352], ["NS1 antigen", "PROTEIN", 99, 110], ["NS1", "PROTEIN", 339, 342], ["IgM", "PROTEIN", 344, 347], ["IgG", "PROTEIN", 349, 352], ["dengue", "SPECIES", 358, 364], ["a later study", "TEST", 22, 35], ["urine samples", "TEST", 67, 80], ["NS1 antigen ELISA", "TEST", 99, 116], ["serum samples", "TEST", 137, 150], ["saliva and urine samples", "TEST", 254, 278], ["serum", "TEST", 287, 292], ["quantitative RT", "TEST", 297, 312], ["PCR", "TEST", 313, 316], ["other parameters", "TEST", 321, 337], ["NS1", "TEST", 339, 342], ["IgM", "TEST", 344, 347], ["IgG", "TEST", 349, 352]]], ["Further studies underline the benefit of saliva as a diagnostic tool for use in developing tropical countries like India nevertheless further research is encouraged before implementation [26] .", [["saliva", "ORGANISM_SUBSTANCE", 41, 47], ["Further studies", "TEST", 0, 15]]], ["The delayed release of DENV in urine allows the diagnosis of an acute dengue infection by RT-PCR and sequencing on day 8 and 18, while the respective serum samples collected on the same period were negative for DENV [27] .DengueAll these promising results using urine and saliva samples for diagnostics stimulated further investigations on DENV RNA stability in urine and serum as well as establishing novel diagnostic device (stacking flow platform) for single-step detection of a target antibody in salivary fluid [28, 29] .", [["urine", "ANATOMY", 31, 36], ["serum samples", "ANATOMY", 150, 163], ["urine", "ANATOMY", 262, 267], ["saliva samples", "ANATOMY", 272, 286], ["urine", "ANATOMY", 362, 367], ["serum", "ANATOMY", 372, 377], ["salivary fluid", "ANATOMY", 501, 515], ["dengue infection", "DISEASE", 70, 86], ["Dengue", "DISEASE", 222, 228], ["DENV", "ORGANISM", 23, 27], ["urine", "ORGANISM_SUBSTANCE", 31, 36], ["serum samples", "ORGANISM_SUBSTANCE", 150, 163], ["Dengue", "ORGANISM", 222, 228], ["urine", "ORGANISM_SUBSTANCE", 262, 267], ["saliva samples", "ORGANISM_SUBSTANCE", 272, 286], ["DENV", "ORGANISM", 340, 344], ["urine", "ORGANISM_SUBSTANCE", 362, 367], ["serum", "ORGANISM_SUBSTANCE", 372, 377], ["salivary fluid", "ORGANISM_SUBSTANCE", 501, 515], ["target antibody", "PROTEIN", 482, 497], ["Dengue", "SPECIES", 222, 228], ["DENV", "SPECIES", 23, 27], ["dengue", "SPECIES", 70, 76], ["DENV", "SPECIES", 211, 215], ["Dengue", "SPECIES", 222, 228], ["DENV", "SPECIES", 340, 344], ["DENV in urine", "PROBLEM", 23, 36], ["an acute dengue infection", "PROBLEM", 61, 86], ["RT-PCR", "TEST", 90, 96], ["sequencing", "TEST", 101, 111], ["the respective serum samples", "TEST", 135, 163], ["DENV", "PROBLEM", 211, 215], ["Dengue", "PROBLEM", 222, 228], ["urine and saliva samples", "TEST", 262, 286], ["diagnostics stimulated further investigations", "TEST", 291, 336], ["DENV RNA stability in urine and serum", "TEST", 340, 377], ["novel diagnostic device", "TREATMENT", 402, 425], ["single-step detection", "TEST", 455, 476], ["a target antibody in salivary fluid", "TEST", 480, 515], ["DENV", "OBSERVATION", 23, 27], ["acute", "OBSERVATION_MODIFIER", 64, 69], ["dengue", "OBSERVATION_MODIFIER", 70, 76], ["infection", "OBSERVATION", 77, 86]]], ["Both studies investigated different conditions using urine or saliva samples for the diagnostics.", [["urine", "ANATOMY", 53, 58], ["samples", "ANATOMY", 69, 76], ["urine", "ORGANISM_SUBSTANCE", 53, 58], ["saliva samples", "ORGANISM_SUBSTANCE", 62, 76], ["Both studies", "TEST", 0, 12], ["urine or saliva samples", "TEST", 53, 76], ["the diagnostics", "TEST", 81, 96]]], ["One study focused on the storage conditions for these samples while the other improved the sample processing to optimize diagnostics using saliva.", [["samples", "ANATOMY", 54, 61], ["sample", "ANATOMY", 91, 97], ["saliva", "ORGANISM_SUBSTANCE", 139, 145], ["One study", "TEST", 0, 9], ["these samples", "TEST", 48, 61]]], ["Andries et al. performed a representative study by analysing plasma, saliva and urine in 267 patients by applying various molecular and serological analyses.", [["plasma", "ANATOMY", 61, 67], ["saliva", "ANATOMY", 69, 75], ["urine", "ANATOMY", 80, 85], ["plasma", "ORGANISM_SUBSTANCE", 61, 67], ["saliva", "ORGANISM_SUBSTANCE", 69, 75], ["urine", "ORGANISM_SUBSTANCE", 80, 85], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["a representative study", "TEST", 25, 47], ["saliva and urine", "TEST", 69, 85], ["serological analyses", "TEST", 136, 156]]], ["Unfortunately, the performances of these assays were better upon using plasma samples [30] .", [["plasma samples", "ANATOMY", 71, 85], ["plasma samples", "ORGANISM_SUBSTANCE", 71, 85], ["these assays", "TEST", 35, 47], ["plasma samples", "TEST", 71, 85]]], ["Analysing commercial rapid diagnostic tests (RDT) for detection of NS1/IgG/IgA in urine and saliva samples suggested that these RDT kits are of higher specificity and limited sensitivity [31] .", [["urine", "ANATOMY", 82, 87], ["saliva samples", "ANATOMY", 92, 106], ["NS1", "GENE_OR_GENE_PRODUCT", 67, 70], ["IgG", "GENE_OR_GENE_PRODUCT", 71, 74], ["IgA", "GENE_OR_GENE_PRODUCT", 75, 78], ["urine", "ORGANISM_SUBSTANCE", 82, 87], ["saliva samples", "ORGANISM_SUBSTANCE", 92, 106], ["NS1", "PROTEIN", 67, 70], ["IgG", "PROTEIN", 71, 74], ["IgA", "PROTEIN", 75, 78], ["RDT", "TEST", 45, 48], ["NS1/IgG/IgA in urine", "TEST", 67, 87], ["saliva samples", "TEST", 92, 106], ["these RDT kits", "TEST", 122, 136]]], ["Interestingly, in dengue secondary infection, the IgA in urine at 4-7 days of disease onset is higher than those with 1 st infections indicating severe Dengue [32] .", [["urine", "ANATOMY", 57, 62], ["dengue secondary infection", "DISEASE", 18, 44], ["infections", "DISEASE", 123, 133], ["Dengue", "DISEASE", 152, 158], ["IgA", "GENE_OR_GENE_PRODUCT", 50, 53], ["urine", "ORGANISM_SUBSTANCE", 57, 62], ["IgA", "PROTEIN", 50, 53], ["dengue", "SPECIES", 18, 24], ["dengue secondary infection", "PROBLEM", 18, 44], ["the IgA in urine", "TEST", 46, 62], ["disease onset", "PROBLEM", 78, 91], ["1 st infections", "PROBLEM", 118, 133], ["severe Dengue", "PROBLEM", 145, 158], ["dengue", "OBSERVATION_MODIFIER", 18, 24], ["secondary", "OBSERVATION_MODIFIER", 25, 34], ["infection", "OBSERVATION", 35, 44], ["higher", "OBSERVATION_MODIFIER", 95, 101], ["severe", "OBSERVATION_MODIFIER", 145, 151], ["Dengue", "OBSERVATION", 152, 158]]], ["Therefore, DENV IgA in urine is an indicator for the disease severity and must be investigated.Ebola and other viral hemorrhagic fevers (VHFs)Ebola virus and other viral hemorrhagic fevers are mostly detected in blood derived samples such as whole blood, plasma or serum.", [["urine", "ANATOMY", 23, 28], ["blood", "ANATOMY", 212, 217], ["samples", "ANATOMY", 226, 233], ["whole blood", "ANATOMY", 242, 253], ["plasma", "ANATOMY", 255, 261], ["serum", "ANATOMY", 265, 270], ["Ebola", "DISEASE", 95, 100], ["viral hemorrhagic fevers", "DISEASE", 111, 135], ["VHFs", "DISEASE", 137, 141], ["Ebola virus", "DISEASE", 142, 153], ["viral hemorrhagic fevers", "DISEASE", 164, 188], ["DENV", "ORGANISM", 11, 15], ["IgA", "GENE_OR_GENE_PRODUCT", 16, 19], ["urine", "ORGANISM_SUBSTANCE", 23, 28], ["Ebola", "ORGANISM", 95, 100], ["viral hemorrhagic fevers", "ORGANISM", 111, 135], ["Ebola virus", "ORGANISM", 142, 153], ["blood", "ORGANISM_SUBSTANCE", 212, 217], ["samples", "ORGANISM_SUBSTANCE", 226, 233], ["blood", "ORGANISM_SUBSTANCE", 248, 253], ["plasma", "ORGANISM_SUBSTANCE", 255, 261], ["serum", "ORGANISM_SUBSTANCE", 265, 270], ["DENV IgA", "PROTEIN", 11, 19], ["Ebola virus", "SPECIES", 142, 153], ["DENV", "SPECIES", 11, 15], ["Ebola virus", "SPECIES", 142, 153], ["DENV IgA in urine", "TEST", 11, 28], ["the disease severity", "PROBLEM", 49, 69], ["Ebola", "PROBLEM", 95, 100], ["other viral hemorrhagic fevers", "PROBLEM", 105, 135], ["VHFs)", "PROBLEM", 137, 142], ["Ebola virus", "PROBLEM", 142, 153], ["other viral hemorrhagic fevers", "PROBLEM", 158, 188], ["blood derived samples", "TEST", 212, 233], ["whole blood", "TEST", 242, 253], ["plasma or serum", "TEST", 255, 270], ["DENV", "OBSERVATION", 11, 15], ["disease", "OBSERVATION", 53, 60], ["viral", "OBSERVATION_MODIFIER", 111, 116], ["hemorrhagic", "OBSERVATION_MODIFIER", 117, 128], ["fevers", "OBSERVATION", 129, 135], ["viral", "OBSERVATION_MODIFIER", 164, 169], ["hemorrhagic", "OBSERVATION_MODIFIER", 170, 181], ["fevers", "OBSERVATION", 182, 188]]], ["Recent studies reported Ebola detection also in body fluids including saliva, urine, sweat, tears, semen and vaginal discharge as well as feces, ammonitic fluids, placenta and breast milk ( Table Table 1 Guanarito, 1 and 1 for a novel Bunya virus.The first report dated from 1980 for RVF virus detection in saliva based on experimentally infected sheep and showed successful virus isolation from saliva [33] .", [["body fluids", "ANATOMY", 48, 59], ["saliva", "ANATOMY", 70, 76], ["urine", "ANATOMY", 78, 83], ["sweat", "ANATOMY", 85, 90], ["tears", "ANATOMY", 92, 97], ["semen", "ANATOMY", 99, 104], ["vaginal", "ANATOMY", 109, 116], ["feces", "ANATOMY", 138, 143], ["ammonitic fluids", "ANATOMY", 145, 161], ["placenta", "ANATOMY", 163, 171], ["breast milk", "ANATOMY", 176, 187], ["Ebola", "DISEASE", 24, 29], ["Ebola", "ORGANISM", 24, 29], ["body fluids", "ORGANISM_SUBSTANCE", 48, 59], ["saliva", "ORGANISM_SUBSTANCE", 70, 76], ["urine", "ORGANISM_SUBSTANCE", 78, 83], ["sweat", "ORGANISM_SUBDIVISION", 85, 90], ["tears", "ORGANISM_SUBDIVISION", 92, 97], ["semen", "ORGANISM_SUBSTANCE", 99, 104], ["vaginal", "ORGANISM_SUBDIVISION", 109, 116], ["feces", "ORGANISM_SUBDIVISION", 138, 143], ["placenta", "TISSUE", 163, 171], ["breast milk", "ORGANISM_SUBSTANCE", 176, 187], ["Bunya virus", "ORGANISM", 235, 246], ["saliva", "ORGANISM_SUBSTANCE", 307, 313], ["sheep", "ORGANISM", 347, 352], ["saliva", "ORGANISM_SUBSTANCE", 396, 402], ["sheep", "SPECIES", 347, 352], ["Bunya virus", "SPECIES", 235, 246], ["RVF virus", "SPECIES", 284, 293], ["sheep", "SPECIES", 347, 352], ["Recent studies", "TEST", 0, 14], ["Ebola detection", "TEST", 24, 39], ["saliva, urine", "TEST", 70, 83], ["tears", "PROBLEM", 92, 97], ["semen", "TREATMENT", 99, 104], ["vaginal discharge", "TREATMENT", 109, 126], ["ammonitic fluids", "TREATMENT", 145, 161], ["placenta and breast milk", "TREATMENT", 163, 187], ["a novel Bunya virus", "PROBLEM", 227, 246], ["RVF virus detection in saliva", "PROBLEM", 284, 313], ["experimentally infected sheep", "PROBLEM", 323, 352], ["successful virus isolation", "PROBLEM", 364, 390], ["Ebola", "OBSERVATION", 24, 29], ["sweat", "ANATOMY", 85, 90], ["tears", "OBSERVATION", 92, 97], ["vaginal", "ANATOMY", 109, 116], ["placenta", "ANATOMY", 163, 171], ["breast", "ANATOMY", 176, 182]]], ["This was completed by the extensive analysis of infected rodents as main transmission vectors for Hantavirus [34] .", [["Hantavirus", "DISEASE", 98, 108], ["Hantavirus", "PROBLEM", 98, 108], ["infected", "OBSERVATION", 48, 56]]], ["Besides virus excretion, Hanta virus could be demonstrated in several organs (lung, kidney, salivary glands and liver) by virus isolation from saliva, urine and feces for up to one year post inoculation.", [["organs", "ANATOMY", 70, 76], ["lung", "ANATOMY", 78, 82], ["kidney", "ANATOMY", 84, 90], ["salivary glands", "ANATOMY", 92, 107], ["liver", "ANATOMY", 112, 117], ["saliva", "ANATOMY", 143, 149], ["urine", "ANATOMY", 151, 156], ["feces", "ANATOMY", 161, 166], ["Hanta virus", "ORGANISM", 25, 36], ["organs", "ORGAN", 70, 76], ["lung", "ORGAN", 78, 82], ["kidney", "ORGAN", 84, 90], ["salivary glands", "ORGAN", 92, 107], ["liver", "ORGAN", 112, 117], ["saliva", "ORGANISM_SUBSTANCE", 143, 149], ["urine", "ORGANISM_SUBSTANCE", 151, 156], ["feces", "ORGANISM_SUBSTANCE", 161, 166], ["Hanta virus", "SPECIES", 25, 36], ["virus excretion", "PROBLEM", 8, 23], ["Hanta virus", "PROBLEM", 25, 36], ["several organs (lung, kidney, salivary glands and liver", "PROBLEM", 62, 117], ["virus isolation from saliva, urine and feces", "PROBLEM", 122, 166], ["inoculation", "PROBLEM", 191, 202], ["virus excretion", "OBSERVATION", 8, 23], ["Hanta virus", "OBSERVATION", 25, 36], ["lung", "ANATOMY", 78, 82], ["kidney", "ANATOMY", 84, 90], ["salivary glands", "ANATOMY", 92, 107], ["liver", "ANATOMY", 112, 117]]], ["Also the intensive investigation of an imported Lassa case to the UK demonstrated the high viral load in blood taken eleven days post onset of the disease as well as significant virus count in urine on day 36, while throat swabs did not yield any detectable virus [35] .", [["blood", "ANATOMY", 105, 110], ["urine", "ANATOMY", 193, 198], ["throat swabs", "ANATOMY", 216, 228], ["Lassa", "ORGANISM", 48, 53], ["UK", "GENE_OR_GENE_PRODUCT", 66, 68], ["blood", "ORGANISM_SUBSTANCE", 105, 110], ["urine", "ORGANISM_SUBSTANCE", 193, 198], ["the high viral load in blood", "PROBLEM", 82, 110], ["the disease", "PROBLEM", 143, 154], ["significant virus count in urine", "PROBLEM", 166, 198], ["throat swabs", "TEST", 216, 228], ["any detectable virus", "PROBLEM", 243, 263], ["viral load", "OBSERVATION", 91, 101], ["disease", "OBSERVATION", 147, 154], ["significant", "OBSERVATION_MODIFIER", 166, 177], ["virus count", "OBSERVATION", 178, 189]]], ["These findings were confirmed during the intensive analysis of an acute Lassa virus infected patient when the use of urine as additional sample to serum was successfully investigated for viral RNA by PCR [36] .", [["urine", "ANATOMY", 117, 122], ["sample", "ANATOMY", 137, 143], ["serum", "ANATOMY", 147, 152], ["Lassa virus infected", "DISEASE", 72, 92], ["Lassa virus", "ORGANISM", 72, 83], ["patient", "ORGANISM", 93, 100], ["urine", "ORGANISM_SUBSTANCE", 117, 122], ["serum", "ORGANISM_SUBSTANCE", 147, 152], ["viral RNA", "RNA", 187, 196], ["Lassa virus", "SPECIES", 72, 83], ["patient", "SPECIES", 93, 100], ["Lassa virus", "SPECIES", 72, 83], ["the intensive analysis", "TEST", 37, 59], ["an acute Lassa virus", "PROBLEM", 63, 83], ["serum", "TEST", 147, 152], ["viral RNA", "PROBLEM", 187, 196], ["PCR", "TEST", 200, 203], ["acute", "OBSERVATION_MODIFIER", 66, 71], ["Lassa", "OBSERVATION", 72, 77]]], ["Vereta and colleagues used urine and urine sediment epithelium for the identification of acute Hanta virus patients showing hemorrhagic fever with renal syndrome (HFRS) [37, 38] .", [["urine", "ANATOMY", 27, 32], ["urine sediment epithelium", "ANATOMY", 37, 62], ["renal", "ANATOMY", 147, 152], ["acute Hanta virus", "DISEASE", 89, 106], ["hemorrhagic fever", "DISEASE", 124, 141], ["renal syndrome", "DISEASE", 147, 161], ["HFRS", "DISEASE", 163, 167], ["urine", "ORGANISM_SUBSTANCE", 27, 32], ["urine sediment epithelium", "TISSUE", 37, 62], ["Hanta virus", "ORGANISM", 95, 106], ["patients", "ORGANISM", 107, 115], ["renal", "ORGAN", 147, 152], ["Hanta virus", "SPECIES", 95, 106], ["patients", "SPECIES", 107, 115], ["Hanta virus", "SPECIES", 95, 106], ["urine and urine sediment epithelium", "TEST", 27, 62], ["acute Hanta virus", "PROBLEM", 89, 106], ["hemorrhagic fever", "PROBLEM", 124, 141], ["renal syndrome", "PROBLEM", 147, 161], ["acute", "OBSERVATION_MODIFIER", 89, 94], ["hemorrhagic", "OBSERVATION_MODIFIER", 124, 135], ["fever", "OBSERVATION", 136, 141], ["renal", "ANATOMY", 147, 152], ["syndrome", "OBSERVATION", 153, 161]]], ["Urine becomes an important sample for serological studies since antibody excretion in the urine coincided with the period of renal structure damage and stopped when the normal renal function was restored.", [["Urine", "ANATOMY", 0, 5], ["sample", "ANATOMY", 27, 33], ["urine", "ANATOMY", 90, 95], ["renal", "ANATOMY", 125, 130], ["renal", "ANATOMY", 176, 181], ["Urine", "ORGANISM_SUBSTANCE", 0, 5], ["urine", "ORGANISM_SUBSTANCE", 90, 95], ["renal", "ORGAN", 125, 130], ["renal", "ORGAN", 176, 181], ["serological studies", "TEST", 38, 57], ["antibody excretion", "TEST", 64, 82], ["the urine", "TEST", 86, 95], ["renal structure damage", "PROBLEM", 125, 147], ["renal", "ANATOMY", 125, 130], ["structure damage", "OBSERVATION", 131, 147], ["renal", "ANATOMY", 176, 181]]], ["The first successful Hantavirus isolation of a fatal HFRS case used urine and brain tissue and was further confirmed by RT-PCR [39] .", [["urine", "ANATOMY", 68, 73], ["brain tissue", "ANATOMY", 78, 90], ["Hantavirus", "DISEASE", 21, 31], ["HFRS", "DISEASE", 53, 57], ["urine", "ORGANISM_SUBSTANCE", 68, 73], ["brain tissue", "TISSUE", 78, 90], ["RT-PCR", "TEST", 120, 126], ["Hantavirus", "OBSERVATION", 21, 31], ["brain tissue", "ANATOMY", 78, 90]]], ["Henceforward, urine was used for antigen and genome detection as well as for serology in experimentally infected pigs demonstrating that pigs can be the host for the viral transmission of HFRS virus [40] .", [["urine", "ANATOMY", 14, 19], ["HFRS", "DISEASE", 188, 192], ["urine", "ORGANISM_SUBSTANCE", 14, 19], ["pigs", "ORGANISM", 113, 117], ["pigs", "ORGANISM", 137, 141], ["HFRS virus", "ORGANISM", 188, 198], ["pigs", "SPECIES", 113, 117], ["pigs", "SPECIES", 137, 141], ["pigs", "SPECIES", 113, 117], ["pigs", "SPECIES", 137, 141], ["HFRS virus", "SPECIES", 188, 198], ["antigen", "PROBLEM", 33, 40], ["genome detection", "TEST", 45, 61], ["serology", "TEST", 77, 85], ["HFRS virus", "PROBLEM", 188, 198]]], ["Petterson et al. could demonstrate that hantavirus RNA was found in saliva few days after disease onset [41] .", [["hantavirus", "ORGANISM", 40, 50], ["saliva", "ORGANISM_SUBSTANCE", 68, 74], ["hantavirus RNA", "RNA", 40, 54], ["hantavirus", "SPECIES", 40, 50], ["hantavirus RNA", "PROBLEM", 40, 54], ["disease onset", "PROBLEM", 90, 103], ["hantavirus", "OBSERVATION", 40, 50]]], ["The association between the anti-Hantavirus IgA and Hantavirus RNA in saliva was inverse, the same is true for detecting RNA and antigen in endothelial cells within the parotid gland of HFRS patients [42] .", [["endothelial cells", "ANATOMY", 140, 157], ["parotid gland", "ANATOMY", 169, 182], ["HFRS", "DISEASE", 186, 190], ["IgA", "GENE_OR_GENE_PRODUCT", 44, 47], ["Hantavirus", "ORGANISM", 52, 62], ["saliva", "ORGANISM_SUBSTANCE", 70, 76], ["endothelial cells", "CELL", 140, 157], ["parotid gland", "ORGAN", 169, 182], ["patients", "ORGANISM", 191, 199], ["anti-Hantavirus IgA", "PROTEIN", 28, 47], ["Hantavirus RNA", "RNA", 52, 66], ["endothelial cells", "CELL_TYPE", 140, 157], ["patients", "SPECIES", 191, 199], ["anti-Hantavirus", "SPECIES", 28, 43], ["the anti-Hantavirus IgA", "TEST", 24, 47], ["Hantavirus RNA in saliva", "PROBLEM", 52, 76], ["RNA and antigen in endothelial cells", "PROBLEM", 121, 157], ["Hantavirus", "OBSERVATION", 52, 62], ["endothelial cells", "OBSERVATION", 140, 157], ["parotid gland", "ANATOMY", 169, 182]]], ["In a recent study, the anti-Hantavirus antibodies in saliva was detected in a risk group in farms in Yorkshire, UK [43] .", [["anti-Hantavirus antibodies", "GENE_OR_GENE_PRODUCT", 23, 49], ["saliva", "ORGANISM_SUBSTANCE", 53, 59], ["anti-Hantavirus antibodies", "PROTEIN", 23, 49], ["anti-Hantavirus", "SPECIES", 23, 38], ["a recent study", "TEST", 3, 17], ["the anti-Hantavirus antibodies in saliva", "PROBLEM", 19, 59]]], ["Hereby, the non-invasive saliva sampling confirms the usefulness of Hantavirus surveillance studies for analyzing the presence of Hantavirus in previously unknown risk areas.", [["Hantavirus", "DISEASE", 68, 78], ["Hantavirus", "DISEASE", 130, 140], ["saliva", "ORGANISM_SUBSTANCE", 25, 31], ["the non-invasive saliva sampling", "TEST", 8, 40], ["Hantavirus surveillance studies", "TEST", 68, 99], ["Hantavirus", "PROBLEM", 130, 140], ["Hantavirus", "OBSERVATION", 130, 140]]], ["Also a recent investigation of Hanta virus persistence in wild rodents is based on the analysis of viral RNA in saliva, urine and feces show a peak during the first month after seroconversion continuing throughout the 8 month study [44] .Ebola and other viral hemorrhagic fevers (VHFs)Urine and saliva as non-invasive samples were also successfully used for analyzing the pathogenesis of Junin virus in the rodent vector responsible for virus transmission for up to 480 days post infection [45, 46] .", [["saliva", "ANATOMY", 112, 118], ["urine", "ANATOMY", 120, 125], ["feces", "ANATOMY", 130, 135], ["Urine", "ANATOMY", 285, 290], ["samples", "ANATOMY", 318, 325], ["Ebola", "DISEASE", 238, 243], ["viral hemorrhagic fevers", "DISEASE", 254, 278], ["VHFs", "DISEASE", 280, 284], ["Junin virus", "DISEASE", 388, 399], ["infection", "DISEASE", 480, 489], ["Hanta virus", "ORGANISM", 31, 42], ["saliva", "ORGANISM_SUBSTANCE", 112, 118], ["urine", "ORGANISM_SUBSTANCE", 120, 125], ["feces", "ORGANISM_SUBSTANCE", 130, 135], ["Ebola", "ORGANISM", 238, 243], ["Urine", "ORGANISM_SUBSTANCE", 285, 290], ["saliva", "ORGANISM_SUBSTANCE", 295, 301], ["Junin virus", "ORGANISM", 388, 399], ["viral RNA", "RNA", 99, 108], ["Ebola", "SPECIES", 238, 243], ["rodent", "SPECIES", 407, 413], ["Hanta virus", "SPECIES", 31, 42], ["Junin virus", "SPECIES", 388, 399], ["Hanta virus persistence", "PROBLEM", 31, 54], ["the analysis", "TEST", 83, 95], ["viral RNA in saliva", "PROBLEM", 99, 118], ["urine and feces", "TEST", 120, 135], ["seroconversion", "TREATMENT", 177, 191], ["Ebola", "PROBLEM", 238, 243], ["other viral hemorrhagic fevers (VHFs)", "PROBLEM", 248, 285], ["Urine", "TEST", 285, 290], ["non-invasive samples", "TEST", 305, 325], ["Junin virus", "PROBLEM", 388, 399], ["virus transmission", "PROBLEM", 437, 455], ["infection", "PROBLEM", 480, 489], ["viral RNA", "OBSERVATION", 99, 108], ["viral", "OBSERVATION_MODIFIER", 254, 259], ["hemorrhagic", "OBSERVATION_MODIFIER", 260, 271], ["fevers", "OBSERVATION", 272, 278], ["Junin virus", "OBSERVATION", 388, 399]]], ["Surviving animals showed a viral dissemination in brain, spleen, kidney and salivary glands with half of the animals shedding Junin virus and the other half being negative for infectious virus, while seroconverted.", [["brain", "ANATOMY", 50, 55], ["spleen", "ANATOMY", 57, 63], ["kidney", "ANATOMY", 65, 71], ["salivary glands", "ANATOMY", 76, 91], ["infectious virus", "DISEASE", 176, 192], ["animals", "ORGANISM", 10, 17], ["brain", "ORGAN", 50, 55], ["spleen", "ORGAN", 57, 63], ["kidney", "ORGAN", 65, 71], ["salivary glands", "ORGAN", 76, 91], ["Junin virus", "ORGANISM", 126, 137], ["Junin virus", "SPECIES", 126, 137], ["a viral dissemination in brain, spleen, kidney and salivary glands", "PROBLEM", 25, 91], ["the animals shedding Junin virus", "PROBLEM", 105, 137], ["infectious virus", "PROBLEM", 176, 192], ["viral dissemination", "OBSERVATION", 27, 46], ["brain", "ANATOMY", 50, 55], ["spleen", "ANATOMY", 57, 63], ["kidney", "ANATOMY", 65, 71], ["salivary glands", "ANATOMY", 76, 91], ["Junin virus", "OBSERVATION", 126, 137], ["negative for", "UNCERTAINTY", 163, 175], ["infectious", "OBSERVATION", 176, 186]]], ["These findings were successfully used for analyzing the prevalence of Junin virus in the rodent population in endemic areas defining risk areas for the Junin virus infection [47] .Ebola and other viral hemorrhagic fevers (VHFs)Non-invasive samples like urine were used for the analysis of guinea pig and Rhesus macaques infectivity experiments with highly infectious and deadly Marburg virus [48] .", [["samples", "ANATOMY", 240, 247], ["urine", "ANATOMY", 253, 258], ["Junin virus", "DISEASE", 70, 81], ["Junin virus infection", "DISEASE", 152, 173], ["Ebola", "DISEASE", 180, 185], ["viral hemorrhagic fevers", "DISEASE", 196, 220], ["VHFs", "DISEASE", 222, 226], ["Junin virus", "ORGANISM", 70, 81], ["Junin virus", "ORGANISM", 152, 163], ["Ebola", "ORGANISM", 180, 185], ["urine", "ORGANISM_SUBSTANCE", 253, 258], ["guinea pig", "ORGANISM", 289, 299], ["Rhesus macaques", "ORGANISM", 304, 319], ["Marburg virus", "ORGANISM", 378, 391], ["rodent", "SPECIES", 89, 95], ["Junin virus", "SPECIES", 152, 163], ["Ebola", "SPECIES", 180, 185], ["guinea pig", "SPECIES", 289, 299], ["Rhesus macaques", "SPECIES", 304, 319], ["Marburg virus", "SPECIES", 378, 391], ["Junin virus", "SPECIES", 70, 81], ["Junin virus", "SPECIES", 152, 163], ["guinea pig", "SPECIES", 289, 299], ["Rhesus macaques", "SPECIES", 304, 319], ["Marburg virus", "SPECIES", 378, 391], ["Junin virus", "PROBLEM", 70, 81], ["the Junin virus infection", "PROBLEM", 148, 173], ["Ebola", "PROBLEM", 180, 185], ["other viral hemorrhagic fevers", "PROBLEM", 190, 220], ["VHFs", "PROBLEM", 222, 226], ["Non-invasive samples like urine", "PROBLEM", 227, 258], ["the analysis", "TEST", 273, 285], ["guinea pig", "TREATMENT", 289, 299], ["Rhesus macaques infectivity experiments", "TREATMENT", 304, 343], ["Junin virus", "OBSERVATION", 70, 81], ["rodent", "OBSERVATION_MODIFIER", 89, 95], ["population", "OBSERVATION_MODIFIER", 96, 106], ["endemic", "OBSERVATION_MODIFIER", 110, 117], ["Junin virus", "OBSERVATION", 152, 163], ["viral", "OBSERVATION_MODIFIER", 196, 201], ["hemorrhagic", "OBSERVATION_MODIFIER", 202, 213], ["fevers", "OBSERVATION", 214, 220], ["infectious", "OBSERVATION_MODIFIER", 356, 366]]], ["In particular for dangerous biosafety level 4 pathogens the sampling of blood is very risky and laboratory infections are possible, which can be avoided by sampling urine.", [["blood", "ANATOMY", 72, 77], ["urine", "ANATOMY", 165, 170], ["infections", "DISEASE", 107, 117], ["blood", "ORGANISM_SUBSTANCE", 72, 77], ["urine", "ORGANISM_SUBSTANCE", 165, 170], ["dangerous biosafety level", "PROBLEM", 18, 43], ["laboratory infections", "PROBLEM", 96, 117], ["sampling urine", "TEST", 156, 170], ["infections", "OBSERVATION", 107, 117]]], ["In the guinea pig model, the persistent shedding of Marburg virus in saliva, urine and feces showed that as early as by the end of incubation period and throughout the disease, the virus could be found in the feces and saliva virtually in the same concentrations [49] , while in the blood the content of the virus was high and increased by the end of the disease.", [["saliva", "ANATOMY", 69, 75], ["urine", "ANATOMY", 77, 82], ["feces", "ANATOMY", 87, 92], ["feces", "ANATOMY", 209, 214], ["blood", "ANATOMY", 283, 288], ["guinea pig", "ORGANISM", 7, 17], ["Marburg virus", "ORGANISM", 52, 65], ["saliva", "ORGANISM_SUBSTANCE", 69, 75], ["urine", "ORGANISM_SUBSTANCE", 77, 82], ["feces", "ORGANISM_SUBSTANCE", 87, 92], ["feces", "ORGANISM_SUBSTANCE", 209, 214], ["saliva", "ORGANISM_SUBSTANCE", 219, 225], ["blood", "ORGANISM_SUBSTANCE", 283, 288], ["guinea pig", "SPECIES", 7, 17], ["pig", "SPECIES", 14, 17], ["Marburg virus", "SPECIES", 52, 65], ["Marburg virus in saliva, urine and feces", "TEST", 52, 92], ["the disease", "PROBLEM", 164, 175], ["the virus", "PROBLEM", 177, 186], ["the virus", "PROBLEM", 304, 313], ["the disease", "PROBLEM", 351, 362], ["persistent", "OBSERVATION_MODIFIER", 29, 39], ["virus", "OBSERVATION", 308, 313], ["high", "OBSERVATION_MODIFIER", 318, 322], ["increased", "OBSERVATION_MODIFIER", 327, 336], ["disease", "OBSERVATION", 355, 362]]], ["A similar approach was used investigating bat fecal and urine samples for Marburg virus after infection of a tourist visiting a cave in Uganda [50] .", [["fecal", "ANATOMY", 46, 51], ["urine samples", "ANATOMY", 56, 69], ["infection", "DISEASE", 94, 103], ["bat", "ORGANISM", 42, 45], ["fecal", "ORGANISM_SUBSTANCE", 46, 51], ["urine samples", "ORGANISM_SUBSTANCE", 56, 69], ["Marburg virus", "ORGANISM", 74, 87], ["Marburg virus", "SPECIES", 74, 87], ["bat fecal and urine samples", "TEST", 42, 69], ["Marburg virus", "PROBLEM", 74, 87], ["infection", "PROBLEM", 94, 103]]], ["Around 2.5% of liver/spleen tissues of captured bats were positive in RT-PCR for Marburg virus.", [["liver", "ANATOMY", 15, 20], ["spleen tissues", "ANATOMY", 21, 35], ["liver", "ORGAN", 15, 20], ["spleen tissues", "TISSUE", 21, 35], ["bats", "ORGANISM", 48, 52], ["Marburg virus", "ORGANISM", 81, 94], ["Marburg virus", "SPECIES", 81, 94], ["PCR", "TEST", 73, 76], ["Marburg virus", "PROBLEM", 81, 94], ["liver", "ANATOMY", 15, 20], ["spleen", "ANATOMY", 21, 27]]], ["Moreover, the virus was detected in 15 different tissues and plasma of Egyptian fruit bats subcutaneously inoculated with Marburg virus, while limited results were obtained applying mucosal swab samples, urine and fecal samples [51] .Ebola and other viral hemorrhagic fevers (VHFs)Antibodies against Ebola virus could not be found in oral fluids, while 100% agreement between the presence of RNA in serum and oral fluids by RT-PCR was observed [52] .", [["tissues", "ANATOMY", 49, 56], ["plasma", "ANATOMY", 61, 67], ["mucosal swab samples", "ANATOMY", 182, 202], ["urine", "ANATOMY", 204, 209], ["fecal samples", "ANATOMY", 214, 227], ["oral fluids", "ANATOMY", 334, 345], ["serum", "ANATOMY", 399, 404], ["oral fluids", "ANATOMY", 409, 420], ["Ebola", "DISEASE", 234, 239], ["viral hemorrhagic fevers", "DISEASE", 250, 274], ["VHFs", "DISEASE", 276, 280], ["Ebola virus", "DISEASE", 300, 311], ["tissues", "TISSUE", 49, 56], ["plasma", "ORGANISM_SUBSTANCE", 61, 67], ["Marburg virus", "ORGANISM", 122, 135], ["mucosal swab samples", "ORGANISM_SUBSTANCE", 182, 202], ["urine", "ORGANISM_SUBSTANCE", 204, 209], ["fecal samples", "ORGANISM_SUBSTANCE", 214, 227], ["Ebola", "ORGANISM", 234, 239], ["viral hemorrhagic fevers", "ORGANISM", 250, 274], ["Ebola virus", "ORGANISM", 300, 311], ["oral", "ORGANISM_SUBDIVISION", 334, 338], ["serum", "ORGANISM_SUBSTANCE", 399, 404], ["oral", "ORGANISM_SUBDIVISION", 409, 413], ["fluids", "ORGANISM_SUBSTANCE", 414, 420], ["Ebola virus", "SPECIES", 300, 311], ["Marburg virus", "SPECIES", 122, 135], ["Ebola virus", "SPECIES", 300, 311], ["the virus", "PROBLEM", 10, 19], ["Egyptian fruit bats", "PROBLEM", 71, 90], ["Marburg virus", "PROBLEM", 122, 135], ["mucosal swab samples", "TEST", 182, 202], ["urine", "TEST", 204, 209], ["fecal samples", "TEST", 214, 227], ["Ebola", "PROBLEM", 234, 239], ["other viral hemorrhagic fevers", "PROBLEM", 244, 274], ["VHFs)", "PROBLEM", 276, 281], ["Antibodies", "TREATMENT", 281, 291], ["Ebola virus", "PROBLEM", 300, 311], ["oral fluids", "TREATMENT", 334, 345], ["RNA in serum", "TEST", 392, 404], ["oral fluids", "TREATMENT", 409, 420], ["RT-PCR", "TEST", 424, 430], ["virus", "OBSERVATION", 14, 19], ["fruit bats", "OBSERVATION", 80, 90], ["fecal", "ANATOMY", 214, 219], ["viral", "OBSERVATION_MODIFIER", 250, 255], ["hemorrhagic", "OBSERVATION_MODIFIER", 256, 267], ["fevers", "OBSERVATION", 268, 274]]], ["Moreover, in 26 confirmed Ebola cases, 16 samples including saliva, stool, semen, breast milk, tears, nasal blood and a skin swab were positive in Ebola culture and/or RT-PCR [53] .", [["samples", "ANATOMY", 42, 49], ["stool", "ANATOMY", 68, 73], ["semen", "ANATOMY", 75, 80], ["breast milk", "ANATOMY", 82, 93], ["tears", "ANATOMY", 95, 100], ["nasal blood", "ANATOMY", 102, 113], ["skin swab", "ANATOMY", 120, 129], ["Ebola", "DISEASE", 26, 31], ["breast milk", "DISEASE", 82, 93], ["Ebola", "ORGANISM", 26, 31], ["saliva", "ORGANISM_SUBSTANCE", 60, 66], ["stool", "ORGANISM_SUBSTANCE", 68, 73], ["semen", "ORGANISM_SUBSTANCE", 75, 80], ["breast milk", "ORGANISM_SUBSTANCE", 82, 93], ["tears", "TISSUE", 95, 100], ["nasal blood", "ORGANISM_SUBSTANCE", 102, 113], ["skin swab", "ORGANISM_SUBSTANCE", 120, 129], ["Ebola", "ORGANISM", 147, 152], ["milk", "SPECIES", 89, 93], ["Ebola", "SPECIES", 147, 152], ["Ebola cases", "TEST", 26, 37], ["saliva, stool, semen, breast milk", "TEST", 60, 93], ["tears", "TREATMENT", 95, 100], ["nasal blood", "TEST", 102, 113], ["a skin swab", "TEST", 118, 129], ["Ebola culture", "TEST", 147, 160], ["RT-PCR", "TEST", 168, 174], ["breast", "ANATOMY", 82, 88], ["nasal", "ANATOMY", 102, 107], ["skin", "ANATOMY", 120, 124]]], ["In case of EBOV, all samples including body fluids must be handled applying the WHO recommendations, since they are highly infectious.The recent Ebolavirus outbreak in Serra Leone, Liberia und Guinea with 11,325 deaths initiated several intensive investigations of different patient specimens like blood, urine, sweat, saliva, conjunctival swaps, stool and semen for infectious virus [54, 55] .", [["samples", "ANATOMY", 21, 28], ["body fluids", "ANATOMY", 39, 50], ["specimens", "ANATOMY", 283, 292], ["blood", "ANATOMY", 298, 303], ["urine", "ANATOMY", 305, 310], ["sweat", "ANATOMY", 312, 317], ["saliva", "ANATOMY", 319, 325], ["conjunctival", "ANATOMY", 327, 339], ["stool", "ANATOMY", 347, 352], ["semen", "ANATOMY", 357, 362], ["deaths", "DISEASE", 212, 218], ["EBOV", "ORGANISM", 11, 15], ["body", "ORGANISM_SUBDIVISION", 39, 43], ["patient", "ORGANISM", 275, 282], ["blood", "ORGANISM_SUBSTANCE", 298, 303], ["urine", "ORGANISM_SUBSTANCE", 305, 310], ["sweat", "ORGANISM_SUBDIVISION", 312, 317], ["saliva", "ORGANISM_SUBSTANCE", 319, 325], ["conjunctival swaps", "MULTI-TISSUE_STRUCTURE", 327, 345], ["stool", "ORGANISM_SUBSTANCE", 347, 352], ["semen", "ORGANISM_SUBSTANCE", 357, 362], ["patient", "SPECIES", 275, 282], ["EBOV", "SPECIES", 11, 15], ["EBOV", "PROBLEM", 11, 15], ["body fluids", "TREATMENT", 39, 50], ["The recent Ebolavirus outbreak", "PROBLEM", 134, 164], ["different patient specimens", "TEST", 265, 292], ["blood, urine, sweat, saliva, conjunctival swaps", "TEST", 298, 345], ["infectious virus", "PROBLEM", 367, 383], ["EBOV", "OBSERVATION", 11, 15], ["highly", "OBSERVATION_MODIFIER", 116, 122], ["infectious", "OBSERVATION", 123, 133], ["Ebolavirus", "OBSERVATION_MODIFIER", 145, 155], ["Serra Leone", "OBSERVATION", 168, 179], ["sweat", "ANATOMY", 312, 317], ["saliva", "ANATOMY", 319, 325], ["conjunctival", "ANATOMY", 327, 339], ["stool", "ANATOMY", 347, 352]]], ["Moreover, public health measures require clear references, when recovered patients are not infectious anymore and can be released from quarantine.", [["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["infectious", "PROBLEM", 91, 101]]], ["The excretion of EBOV in body fluids from infected or recovered patients create a great risk for person in contact [54, 56] as the Ebola virus RNA was detected in the following body fluids weeks up to several months after infection: saliva, conjunctiva/ tears, stool, vaginal fluid, sweat, urine, amniotic fluid, aqueous humor, cerebrospinal fluid, breast milk, and semen raised many concerns regarding the long term transmissibility of infectious virus causing a recrudesce of an outbreak [56] [57] [58] .", [["body fluids", "ANATOMY", 25, 36], ["body fluids", "ANATOMY", 177, 188], ["saliva", "ANATOMY", 233, 239], ["conjunctiva", "ANATOMY", 241, 252], ["tears", "ANATOMY", 254, 259], ["stool", "ANATOMY", 261, 266], ["vaginal fluid", "ANATOMY", 268, 281], ["sweat", "ANATOMY", 283, 288], ["urine", "ANATOMY", 290, 295], ["amniotic fluid", "ANATOMY", 297, 311], ["aqueous humor", "ANATOMY", 313, 326], ["cerebrospinal fluid", "ANATOMY", 328, 347], ["breast milk", "ANATOMY", 349, 360], ["semen", "ANATOMY", 366, 371], ["Ebola", "DISEASE", 131, 136], ["infection", "DISEASE", 222, 231], ["EBOV", "ORGANISM", 17, 21], ["body fluids", "ORGANISM_SUBSTANCE", 25, 36], ["patients", "ORGANISM", 64, 72], ["Ebola virus", "ORGANISM", 131, 142], ["saliva", "ORGANISM_SUBSTANCE", 233, 239], ["conjunctiva", "MULTI-TISSUE_STRUCTURE", 241, 252], ["tears", "TISSUE", 254, 259], ["stool", "ORGANISM_SUBSTANCE", 261, 266], ["vaginal fluid", "ORGANISM_SUBSTANCE", 268, 281], ["sweat", "ORGANISM_SUBDIVISION", 283, 288], ["urine", "ORGANISM_SUBSTANCE", 290, 295], ["amniotic fluid", "ORGANISM_SUBSTANCE", 297, 311], ["aqueous humor", "ORGANISM_SUBSTANCE", 313, 326], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 328, 347], ["breast milk", "ORGANISM_SUBSTANCE", 349, 360], ["semen", "ORGANISM_SUBSTANCE", 366, 371], ["Ebola virus RNA", "RNA", 131, 146], ["patients", "SPECIES", 64, 72], ["person", "SPECIES", 97, 103], ["Ebola virus", "SPECIES", 131, 142], ["EBOV", "SPECIES", 17, 21], ["Ebola virus", "SPECIES", 131, 142], ["EBOV in body fluids", "TREATMENT", 17, 36], ["the Ebola virus RNA", "PROBLEM", 127, 146], ["infection", "PROBLEM", 222, 231], ["saliva, conjunctiva/ tears, stool, vaginal fluid, sweat, urine, amniotic fluid", "TEST", 233, 311], ["aqueous humor", "TEST", 313, 326], ["cerebrospinal fluid", "TEST", 328, 347], ["breast milk", "TREATMENT", 349, 360], ["infectious virus", "PROBLEM", 437, 453], ["excretion", "OBSERVATION_MODIFIER", 4, 13], ["EBOV", "OBSERVATION", 17, 21], ["infected", "OBSERVATION", 42, 50], ["conjunctiva", "ANATOMY", 241, 252], ["vaginal", "ANATOMY", 268, 275], ["amniotic fluid", "OBSERVATION", 297, 311], ["cerebrospinal", "ANATOMY", 328, 341], ["fluid", "OBSERVATION", 342, 347], ["breast", "ANATOMY", 349, 355], ["long term", "OBSERVATION_MODIFIER", 407, 416], ["infectious", "OBSERVATION", 437, 447]]], ["Comparing whole-blood with urine specimen's analysis from Ebola patients in a novel diagnostic film-array with RT-PCR shows a reasonable match of 90% for whole blood and 85% for urine [59] .", [["whole-blood", "ANATOMY", 10, 21], ["urine specimen", "ANATOMY", 27, 41], ["whole blood", "ANATOMY", 154, 165], ["urine", "ANATOMY", 178, 183], ["Ebola", "DISEASE", 58, 63], ["blood", "ORGANISM_SUBSTANCE", 16, 21], ["urine specimen", "MULTI-TISSUE_STRUCTURE", 27, 41], ["Ebola", "ORGANISM", 58, 63], ["patients", "ORGANISM", 64, 72], ["blood", "ORGANISM_SUBSTANCE", 160, 165], ["urine", "ORGANISM_SUBSTANCE", 178, 183], ["patients", "SPECIES", 64, 72], ["urine specimen's analysis", "TEST", 27, 52], ["a novel diagnostic film", "TEST", 76, 99], ["RT-PCR", "TEST", 111, 117], ["whole blood", "TEST", 154, 165], ["urine", "TEST", 178, 183]]], ["Testing the stability of Ebola virus RNA in human blood and urine under environmental African conditions shows that viral RNA testing from blood samples stored in EDTA buffer is more sensitive [60] .", [["blood", "ANATOMY", 50, 55], ["urine", "ANATOMY", 60, 65], ["blood samples", "ANATOMY", 139, 152], ["EDTA", "CHEMICAL", 163, 167], ["Ebola virus", "ORGANISM", 25, 36], ["human", "ORGANISM", 44, 49], ["blood", "ORGANISM_SUBSTANCE", 50, 55], ["urine", "ORGANISM_SUBSTANCE", 60, 65], ["blood samples", "ORGANISM_SUBSTANCE", 139, 152], ["EDTA", "SIMPLE_CHEMICAL", 163, 167], ["Ebola virus RNA", "RNA", 25, 40], ["Ebola virus", "SPECIES", 25, 36], ["human", "SPECIES", 44, 49], ["Ebola virus", "SPECIES", 25, 36], ["human", "SPECIES", 44, 49], ["Ebola virus RNA", "PROBLEM", 25, 40], ["human blood", "TEST", 44, 55], ["urine under environmental African conditions", "TEST", 60, 104], ["viral RNA testing", "TEST", 116, 133], ["blood samples", "TEST", 139, 152], ["EDTA buffer", "TEST", 163, 174], ["Ebola virus", "OBSERVATION", 25, 36]]], ["Viral RNA in urine seems less stable compared to blood since urine samples were found positive by RT-PCR by day 10-14 compared to blood until at least day-18.", [["urine", "ANATOMY", 13, 18], ["blood", "ANATOMY", 49, 54], ["urine samples", "ANATOMY", 61, 74], ["blood", "ANATOMY", 130, 135], ["Viral", "ORGANISM", 0, 5], ["urine", "ORGANISM_SUBSTANCE", 13, 18], ["blood", "ORGANISM_SUBSTANCE", 49, 54], ["urine samples", "ORGANISM_SUBSTANCE", 61, 74], ["blood", "ORGANISM_SUBSTANCE", 130, 135], ["Viral RNA", "RNA", 0, 9], ["Viral RNA in urine", "TEST", 0, 18], ["urine samples", "TEST", 61, 74], ["PCR", "TEST", 101, 104], ["blood", "TEST", 130, 135], ["RNA", "OBSERVATION", 6, 9], ["less", "OBSERVATION_MODIFIER", 25, 29], ["stable", "OBSERVATION_MODIFIER", 30, 36]]], ["Since the CCHF outbreak in Turkey in 2002, the detection of virus in other body fluids received attention to avoid secondary infections.", [["body fluids", "ANATOMY", 75, 86], ["CCHF", "DISEASE", 10, 14], ["infections", "DISEASE", 125, 135], ["body", "ORGANISM_SUBDIVISION", 75, 79], ["virus in other body fluids", "TREATMENT", 60, 86], ["secondary infections", "PROBLEM", 115, 135], ["CCHF", "OBSERVATION_MODIFIER", 10, 14], ["outbreak", "OBSERVATION_MODIFIER", 15, 23], ["virus", "OBSERVATION", 60, 65], ["secondary", "OBSERVATION_MODIFIER", 115, 124], ["infections", "OBSERVATION", 125, 135]]], ["RNA of CCHF virus was identified in the saliva and the urine of 5/6 and 2/3 patients, respectively [61] .", [["saliva", "ANATOMY", 40, 46], ["urine", "ANATOMY", 55, 60], ["CCHF", "DISEASE", 7, 11], ["CCHF virus", "ORGANISM", 7, 17], ["saliva", "ORGANISM_SUBSTANCE", 40, 46], ["urine", "ORGANISM_SUBSTANCE", 55, 60], ["patients", "ORGANISM", 76, 84], ["RNA", "RNA", 0, 3], ["patients", "SPECIES", 76, 84], ["CCHF virus", "SPECIES", 7, 17], ["CCHF virus", "PROBLEM", 7, 17], ["the saliva and the urine", "TEST", 36, 60], ["CCHF", "OBSERVATION", 7, 11], ["urine", "ANATOMY", 55, 60]]], ["This was confirmed by a later study, which detected CCHF virus in urine samples of patients with prolonged viremia [62] .Ebola and other viral hemorrhagic fevers (VHFs)Furthermore, nasopharyngeal aspirates and/or urine were considered as diagnostic samples evaluating a multiplex hybridization array for detecting various infectious diseases [63] .", [["urine samples", "ANATOMY", 66, 79], ["nasopharyngeal aspirates", "ANATOMY", 181, 205], ["urine", "ANATOMY", 213, 218], ["samples", "ANATOMY", 249, 256], ["CCHF", "DISEASE", 52, 56], ["viremia", "DISEASE", 107, 114], ["Ebola", "DISEASE", 121, 126], ["viral hemorrhagic fevers", "DISEASE", 137, 161], ["VHFs", "DISEASE", 163, 167], ["infectious diseases", "DISEASE", 322, 341], ["urine samples", "ORGANISM_SUBSTANCE", 66, 79], ["patients", "ORGANISM", 83, 91], ["Ebola", "ORGANISM", 121, 126], ["VHFs", "CANCER", 163, 167], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 181, 205], ["urine", "ORGANISM_SUBSTANCE", 213, 218], ["patients", "SPECIES", 83, 91], ["Ebola", "SPECIES", 121, 126], ["CCHF virus", "SPECIES", 52, 62], ["a later study", "TEST", 22, 35], ["CCHF virus", "PROBLEM", 52, 62], ["urine samples", "TEST", 66, 79], ["prolonged viremia", "PROBLEM", 97, 114], ["Ebola", "PROBLEM", 121, 126], ["other viral hemorrhagic fevers", "PROBLEM", 131, 161], ["VHFs", "PROBLEM", 163, 167], ["nasopharyngeal aspirates and/or urine", "PROBLEM", 181, 218], ["diagnostic samples", "TEST", 238, 256], ["a multiplex hybridization array", "TEST", 268, 299], ["various infectious diseases", "PROBLEM", 314, 341], ["viral", "OBSERVATION_MODIFIER", 137, 142], ["hemorrhagic", "OBSERVATION_MODIFIER", 143, 154], ["fevers", "OBSERVATION", 155, 161], ["nasopharyngeal", "ANATOMY", 181, 195], ["infectious", "OBSERVATION", 322, 332]]], ["Interestingly, the Plasmodium falciparum was identified as a cause of death in a case of hemorrhagic fever like illness during the Marburg hemorrhagic fever outbreak in Angola in 2004-2005.", [["Plasmodium falciparum", "DISEASE", 19, 40], ["death", "DISEASE", 70, 75], ["hemorrhagic fever", "DISEASE", 89, 106], ["Marburg hemorrhagic fever", "DISEASE", 131, 156], ["Plasmodium falciparum", "ORGANISM", 19, 40], ["Plasmodium falciparum", "SPECIES", 19, 40], ["Plasmodium falciparum", "SPECIES", 19, 40], ["the Plasmodium falciparum", "PROBLEM", 15, 40], ["death", "PROBLEM", 70, 75], ["hemorrhagic fever", "PROBLEM", 89, 106], ["illness", "PROBLEM", 112, 119], ["the Marburg hemorrhagic fever", "PROBLEM", 127, 156], ["Plasmodium falciparum", "OBSERVATION", 19, 40], ["hemorrhagic", "OBSERVATION_MODIFIER", 89, 100], ["fever", "OBSERVATION", 101, 106], ["hemorrhagic", "OBSERVATION_MODIFIER", 139, 150], ["fever", "OBSERVATION", 151, 156]]], ["Also a novel diagnostic array based on beads technology for detection of multiple bat-borne viruses including Ebola and Nipha viruses used urine from wild bats from Australia and Bangladesh for a surveillance study [64] .Ebola and other viral hemorrhagic fevers (VHFs)Analyzing cases in China of a hemorrhagic fever due to a novel Bunya virus, the RNA was identifed in the blood as well as in urine, throat, and fecal specimens [65] .", [["urine", "ANATOMY", 139, 144], ["blood", "ANATOMY", 373, 378], ["urine", "ANATOMY", 393, 398], ["throat", "ANATOMY", 400, 406], ["fecal specimens", "ANATOMY", 412, 427], ["Ebola", "DISEASE", 110, 115], ["Ebola", "DISEASE", 221, 226], ["viral hemorrhagic fevers", "DISEASE", 237, 261], ["VHFs", "DISEASE", 263, 267], ["hemorrhagic fever", "DISEASE", 298, 315], ["bat-borne viruses", "ORGANISM", 82, 99], ["Ebola", "ORGANISM", 110, 115], ["Nipha viruses", "ORGANISM", 120, 133], ["urine", "ORGANISM_SUBSTANCE", 139, 144], ["Ebola", "ORGANISM", 221, 226], ["Bunya virus", "ORGANISM", 331, 342], ["blood", "ORGANISM_SUBSTANCE", 373, 378], ["urine", "ORGANISM_SUBSTANCE", 393, 398], ["throat", "ORGANISM_SUBDIVISION", 400, 406], ["Ebola", "SPECIES", 110, 115], ["bat-borne viruses", "SPECIES", 82, 99], ["Nipha viruses", "SPECIES", 120, 133], ["Bunya virus", "SPECIES", 331, 342], ["beads technology", "TEST", 39, 55], ["multiple bat-borne viruses", "PROBLEM", 73, 99], ["Ebola", "PROBLEM", 110, 115], ["Nipha viruses", "PROBLEM", 120, 133], ["a surveillance study", "TEST", 194, 214], ["Ebola", "PROBLEM", 221, 226], ["other viral hemorrhagic fevers", "PROBLEM", 231, 261], ["a hemorrhagic fever", "PROBLEM", 296, 315], ["a novel Bunya virus", "PROBLEM", 323, 342], ["the RNA", "PROBLEM", 344, 351], ["the blood", "TEST", 369, 378], ["urine, throat, and fecal specimens", "TEST", 393, 427], ["viral", "OBSERVATION_MODIFIER", 237, 242], ["hemorrhagic", "OBSERVATION_MODIFIER", 243, 254], ["fevers", "OBSERVATION", 255, 261], ["hemorrhagic", "OBSERVATION_MODIFIER", 298, 309], ["fever", "OBSERVATION", 310, 315], ["throat", "ANATOMY", 400, 406], ["fecal", "ANATOMY", 412, 417]]], ["Further studies are necessary to investigate the significance of non-invasive samples for analyzing the virus pathogenesis and the infectivity of different body fluids.West NileClinical specimens used for WNV detection are blood derived samples and CSF (Table 1 and Additional file 1: Table S4 ).", [["samples", "ANATOMY", 78, 85], ["body fluids", "ANATOMY", 156, 167], ["specimens", "ANATOMY", 186, 195], ["blood", "ANATOMY", 223, 228], ["samples", "ANATOMY", 237, 244], ["body", "ORGANISM_SUBDIVISION", 156, 160], ["WNV", "ORGANISM", 205, 208], ["blood", "ORGANISM_SUBSTANCE", 223, 228], ["CSF", "ORGANISM_SUBSTANCE", 249, 252], ["WNV", "SPECIES", 205, 208], ["Further studies", "TEST", 0, 15], ["non-invasive samples", "TEST", 65, 85], ["the virus pathogenesis", "PROBLEM", 100, 122], ["different body fluids", "TREATMENT", 146, 167], ["WNV detection", "TEST", 205, 218], ["blood derived samples", "TEST", 223, 244], ["CSF (Table", "TEST", 249, 259]]], ["Since the safety of blood banks was important, testing of blood samples was the evident choice.", [["blood", "ANATOMY", 20, 25], ["blood samples", "ANATOMY", 58, 71], ["blood", "ORGANISM_SUBSTANCE", 20, 25], ["blood samples", "ORGANISM_SUBSTANCE", 58, 71], ["testing of blood samples", "TEST", 47, 71]]], ["Even though Steele et al. found infectious WN in several organs (brain, heart, spleen, liver, kidney, adrenal intestines, pancreas, lung and ovary) of birds, it took four years until Tesh and others published the investigation of urine samples used for pathogenesis studies in hamsters and birds [66] [67] [68] [69] .", [["organs", "ANATOMY", 57, 63], ["brain", "ANATOMY", 65, 70], ["heart", "ANATOMY", 72, 77], ["spleen", "ANATOMY", 79, 85], ["liver", "ANATOMY", 87, 92], ["kidney", "ANATOMY", 94, 100], ["adrenal intestines", "ANATOMY", 102, 120], ["pancreas", "ANATOMY", 122, 130], ["lung", "ANATOMY", 132, 136], ["ovary", "ANATOMY", 141, 146], ["urine samples", "ANATOMY", 230, 243], ["organs", "ORGAN", 57, 63], ["brain", "ORGAN", 65, 70], ["heart", "ORGAN", 72, 77], ["spleen", "ORGAN", 79, 85], ["liver", "ORGAN", 87, 92], ["kidney", "ORGAN", 94, 100], ["adrenal intestines", "MULTI-TISSUE_STRUCTURE", 102, 120], ["pancreas", "ORGAN", 122, 130], ["lung", "ORGAN", 132, 136], ["ovary", "ORGAN", 141, 146], ["birds", "ORGANISM", 151, 156], ["urine samples", "ORGANISM_SUBSTANCE", 230, 243], ["hamsters", "ORGANISM", 277, 285], ["hamsters", "SPECIES", 277, 285], ["infectious WN in several organs (brain, heart, spleen, liver, kidney, adrenal intestines, pancreas, lung and ovary", "PROBLEM", 32, 146], ["urine samples", "TEST", 230, 243], ["pathogenesis studies", "TEST", 253, 273], ["infectious", "OBSERVATION", 32, 42], ["brain", "ANATOMY", 65, 70], ["heart", "ANATOMY", 72, 77], ["spleen", "ANATOMY", 79, 85], ["liver", "ANATOMY", 87, 92], ["kidney", "ANATOMY", 94, 100], ["adrenal intestines", "ANATOMY", 102, 120], ["pancreas", "ANATOMY", 122, 130], ["lung", "ANATOMY", 132, 136], ["ovary", "ANATOMY", 141, 146]]], ["These findings were later confirmed in different animal models like chipmunks, fox squirrels, hamsters and mice analyzed for WNV pathogenesis research [70] [71] [72] [73] [74] .", [["chipmunks", "ORGANISM", 68, 77], ["fox squirrels", "ORGANISM", 79, 92], ["hamsters", "ORGANISM", 94, 102], ["mice", "ORGANISM", 107, 111], ["WNV", "ORGANISM", 125, 128], ["fox squirrels", "SPECIES", 79, 92], ["hamsters", "SPECIES", 94, 102], ["mice", "SPECIES", 107, 111], ["fox squirrels", "SPECIES", 79, 92], ["hamsters", "SPECIES", 94, 102], ["mice", "SPECIES", 107, 111], ["WNV", "SPECIES", 125, 128]]], ["The first report of WN detection in urine was in an acute severe case with encephalitis found positive eight days after symptoms onset [75] .", [["urine", "ANATOMY", 36, 41], ["encephalitis", "DISEASE", 75, 87], ["WN", "ORGANISM", 20, 22], ["urine", "ORGANISM_SUBSTANCE", 36, 41], ["WN detection in urine", "TEST", 20, 41], ["an acute severe case", "PROBLEM", 49, 69], ["encephalitis", "PROBLEM", 75, 87], ["symptoms onset", "PROBLEM", 120, 134], ["acute", "OBSERVATION_MODIFIER", 52, 57], ["encephalitis", "OBSERVATION", 75, 87]]], ["Further studies detected WNV RNA up to 6.7 years in urine indicating for a persistent renal infection for several years [76] .", [["urine", "ANATOMY", 52, 57], ["renal", "ANATOMY", 86, 91], ["renal infection", "DISEASE", 86, 101], ["WNV", "ORGANISM", 25, 28], ["urine", "ORGANISM_SUBSTANCE", 52, 57], ["renal", "ORGAN", 86, 91], ["WNV RNA", "RNA", 25, 32], ["WNV", "SPECIES", 25, 28], ["Further studies", "TEST", 0, 15], ["WNV RNA", "TEST", 25, 32], ["urine", "TEST", 52, 57], ["a persistent renal infection", "PROBLEM", 73, 101], ["persistent", "OBSERVATION_MODIFIER", 75, 85], ["renal", "ANATOMY", 86, 91], ["infection", "OBSERVATION", 92, 101]]], ["This was confirmed by a number of studies demonstrating the long persistence of WNV particularly in patients with WN fever compared to patients with WN neuro-invasive disease, which had a higher vireamia for a shorter period than those with West Nile fever [77] [78] [79] [80] .", [["WNV", "DISEASE", 80, 83], ["WN fever", "DISEASE", 114, 122], ["neuro-invasive disease", "DISEASE", 152, 174], ["Nile fever", "DISEASE", 246, 256], ["WNV", "ORGANISM", 80, 83], ["patients", "ORGANISM", 100, 108], ["WN fever", "ORGANISM", 114, 122], ["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 100, 108], ["patients", "SPECIES", 135, 143], ["WNV", "SPECIES", 80, 83], ["studies", "TEST", 34, 41], ["WNV", "PROBLEM", 80, 83], ["WN fever", "PROBLEM", 114, 122], ["WN neuro-invasive disease", "PROBLEM", 149, 174], ["WNV", "OBSERVATION", 80, 83], ["invasive disease", "OBSERVATION", 158, 174]]], ["In the meantime, the advantage of using urine instead or additionally to serum is demonstrated by many investigations and could prove its value also for routine diagnostic [81] [82] [83] [84] [85] [86] .", [["urine", "ANATOMY", 40, 45], ["serum", "ANATOMY", 73, 78], ["[81] [82] [83] [84] [85] [86]", "CHEMICAL", 172, 201], ["urine", "ORGANISM_SUBSTANCE", 40, 45], ["serum", "ORGANISM_SUBSTANCE", 73, 78], ["[81] [82] [83] [84] [85] [86]", "SIMPLE_CHEMICAL", 172, 201], ["urine", "TEST", 40, 45]]], ["Also WNV could be successfully isolated from urine samples and further analyzed by sequencing.West NileIn summary, one could state that the use of urine is a suitable alternative diagnostic sample compared to serum and should be listed in fact sheets from national and international organizations (WHO, PAHO, CDC, ECDC).", [["urine samples", "ANATOMY", 45, 58], ["urine", "ANATOMY", 147, 152], ["serum", "ANATOMY", 209, 214], ["WNV", "ORGANISM", 5, 8], ["urine samples", "ORGANISM_SUBSTANCE", 45, 58], ["urine", "ORGANISM_SUBSTANCE", 147, 152], ["serum", "ORGANISM_SUBSTANCE", 209, 214], ["WNV", "SPECIES", 5, 8], ["WNV", "PROBLEM", 5, 8], ["urine samples", "TEST", 45, 58], ["serum", "TEST", 209, 214], ["WNV", "OBSERVATION", 5, 8]]], ["Further studies are needed investigating if urine samples are a useful source for surveillance studies for WNV distribution and for analyzing the severity of the disease in patients with neuro-invasive and/or kidney manifestation.ZikaThe Zika virus was detected in blood, serum, saliva, and urine, as well as in semen, vaginal discharge, sweat, tears, ammonitic fluids, placenta and breast milk (Table 1 and Additional file 1: Table S5 ).", [["urine samples", "ANATOMY", 44, 57], ["kidney", "ANATOMY", 209, 215], ["blood", "ANATOMY", 265, 270], ["serum", "ANATOMY", 272, 277], ["saliva", "ANATOMY", 279, 285], ["urine", "ANATOMY", 291, 296], ["semen", "ANATOMY", 312, 317], ["vaginal", "ANATOMY", 319, 326], ["sweat", "ANATOMY", 338, 343], ["tears", "ANATOMY", 345, 350], ["ammonitic fluids", "ANATOMY", 352, 368], ["placenta", "ANATOMY", 370, 378], ["breast milk", "ANATOMY", 383, 394], ["urine samples", "ORGANISM_SUBSTANCE", 44, 57], ["WNV", "ORGANISM", 107, 110], ["patients", "ORGANISM", 173, 181], ["kidney", "ORGAN", 209, 215], ["Zika virus", "ORGANISM", 238, 248], ["blood", "ORGANISM_SUBSTANCE", 265, 270], ["serum", "ORGANISM_SUBSTANCE", 272, 277], ["saliva", "ORGANISM_SUBSTANCE", 279, 285], ["urine", "ORGANISM_SUBSTANCE", 291, 296], ["semen", "ORGANISM_SUBSTANCE", 312, 317], ["vaginal", "ORGANISM_SUBDIVISION", 319, 326], ["sweat", "ORGANISM_SUBDIVISION", 338, 343], ["tears", "TISSUE", 345, 350], ["placenta", "TISSUE", 370, 378], ["breast milk", "ORGANISM_SUBSTANCE", 383, 394], ["patients", "SPECIES", 173, 181], ["WNV", "SPECIES", 107, 110], ["Zika", "SPECIES", 230, 234], ["Zika virus", "SPECIES", 238, 248], ["Further studies", "TEST", 0, 15], ["urine samples", "TEST", 44, 57], ["surveillance studies", "TEST", 82, 102], ["WNV distribution", "TEST", 107, 123], ["the disease", "PROBLEM", 158, 169], ["neuro-invasive and/or kidney manifestation", "PROBLEM", 187, 229], ["The Zika virus", "PROBLEM", 234, 248], ["blood, serum, saliva, and urine", "TEST", 265, 296], ["vaginal discharge", "PROBLEM", 319, 336], ["tears", "PROBLEM", 345, 350], ["ammonitic fluids", "TREATMENT", 352, 368], ["placenta and breast milk", "TREATMENT", 370, 394], ["disease", "OBSERVATION", 162, 169], ["kidney", "ANATOMY", 209, 215], ["Zika virus", "OBSERVATION", 238, 248], ["vaginal", "ANATOMY", 319, 326], ["tears", "OBSERVATION", 345, 350], ["placenta", "ANATOMY", 370, 378], ["breast", "ANATOMY", 383, 389]]], ["The expansion of Zika to Brazil via New Caledonia 2015 stimulates the development of diagnostic assays for NAT and serology to analyze the increasing number of cases [87] .", [["diagnostic assays", "TEST", 85, 102], ["NAT and serology", "TEST", 107, 123], ["expansion", "OBSERVATION_MODIFIER", 4, 13]]], ["In a surveillance study, ZIKV was identified in 19.2% (total 182 patients) of saliva samples, but not in blood [88] .", [["samples", "ANATOMY", 85, 92], ["blood", "ANATOMY", 105, 110], ["ZIKV", "ORGANISM", 25, 29], ["patients", "ORGANISM", 65, 73], ["saliva samples", "ORGANISM_SUBSTANCE", 78, 92], ["blood", "ORGANISM_SUBSTANCE", 105, 110], ["patients", "SPECIES", 65, 73], ["ZIKV", "SPECIES", 25, 29], ["a surveillance study", "TEST", 3, 23], ["ZIKV", "TEST", 25, 29], ["saliva samples", "TEST", 78, 92], ["blood", "TEST", 105, 110]]], ["The detection of ZIKV in saliva samples increased the molecular detection rate of ZIKV in acute case but ZIKV did not persist for longer time frame in saliva as in urine or semen.", [["saliva samples", "ANATOMY", 25, 39], ["urine", "ANATOMY", 164, 169], ["semen", "ANATOMY", 173, 178], ["ZIKV", "CHEMICAL", 82, 86], ["ZIKV", "GENE_OR_GENE_PRODUCT", 17, 21], ["saliva samples", "ORGANISM_SUBSTANCE", 25, 39], ["saliva", "ORGANISM_SUBSTANCE", 151, 157], ["urine", "ORGANISM_SUBSTANCE", 164, 169], ["semen", "ORGANISM_SUBSTANCE", 173, 178], ["ZIKV", "DNA", 17, 21], ["ZIKV", "SPECIES", 17, 21], ["ZIKV", "SPECIES", 82, 86], ["ZIKV", "SPECIES", 105, 109], ["ZIKV in saliva samples", "PROBLEM", 17, 39], ["ZIKV", "PROBLEM", 82, 86], ["ZIKV", "PROBLEM", 105, 109], ["ZIKV", "OBSERVATION", 17, 21]]], ["Nevertheless, saliva sample was advantageous in children and neonates [89] .", [["saliva sample", "ANATOMY", 14, 27], ["saliva", "ORGANISM_SUBSTANCE", 14, 20], ["children", "ORGANISM", 48, 56], ["children", "SPECIES", 48, 56]]], ["Interestingly, the ZIKV can be detected in urine samples for even longer.", [["urine samples", "ANATOMY", 43, 56], ["ZIKV", "GENE_OR_GENE_PRODUCT", 19, 23], ["urine samples", "ORGANISM_SUBSTANCE", 43, 56], ["ZIKV", "DNA", 19, 23], ["ZIKV", "SPECIES", 19, 23], ["the ZIKV", "PROBLEM", 15, 23], ["urine samples", "TEST", 43, 56], ["ZIKV", "OBSERVATION", 19, 23]]], ["Combination of urine and saliva besides serum is of great significant in ZIKV diagnostics [90] .", [["urine", "ANATOMY", 15, 20], ["serum", "ANATOMY", 40, 45], ["urine", "ORGANISM_SUBSTANCE", 15, 20], ["saliva", "ORGANISM_SUBSTANCE", 25, 31], ["serum", "ORGANISM_SUBSTANCE", 40, 45], ["ZIKV", "SPECIES", 73, 77], ["urine and saliva besides serum", "TEST", 15, 45], ["ZIKV diagnostics", "TEST", 73, 89], ["urine", "OBSERVATION", 15, 20]]], ["This was also true in a rhesus macaque model used for analyzing plasma, saliva, urine and cerebrospinal fluid by RT-PCR for ZIKV detection [91] .ZikaMoreover, RNA of ZIKV was detected in semen by RT-PCR on the 7 th day of the appearance of symptoms but was not identified on the 21 st day, which was confirmed by Reusken et al. [92, 93] .", [["plasma", "ANATOMY", 64, 70], ["saliva", "ANATOMY", 72, 78], ["urine", "ANATOMY", 80, 85], ["cerebrospinal fluid", "ANATOMY", 90, 109], ["semen", "ANATOMY", 187, 192], ["rhesus", "ORGANISM", 24, 30], ["macaque", "ORGANISM", 31, 38], ["plasma", "ORGANISM_SUBSTANCE", 64, 70], ["saliva", "ORGANISM_SUBSTANCE", 72, 78], ["urine", "ORGANISM_SUBSTANCE", 80, 85], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 90, 109], ["ZIKV", "GENE_OR_GENE_PRODUCT", 166, 170], ["semen", "ORGANISM_SUBSTANCE", 187, 192], ["ZIKV", "DNA", 166, 170], ["rhesus macaque", "SPECIES", 24, 38], ["rhesus macaque", "SPECIES", 24, 38], ["ZIKV", "SPECIES", 124, 128], ["ZIKV", "SPECIES", 166, 170], ["a rhesus macaque model", "TREATMENT", 22, 44], ["analyzing plasma, saliva, urine and cerebrospinal fluid", "TEST", 54, 109], ["PCR", "TEST", 116, 119], ["ZIKV detection", "TEST", 124, 138], ["ZIKV", "PROBLEM", 166, 170], ["PCR", "TEST", 199, 202], ["symptoms", "PROBLEM", 240, 248], ["cerebrospinal", "ANATOMY", 90, 103], ["ZIKV", "OBSERVATION", 166, 170]]], ["This finding consequently leads to the possibility of an infection via sexual intercourse as documented by D'Ortenzio et al. with a high viral load in the semen obtained on sample collected after 18 days [94, 95] .", [["semen", "ANATOMY", 155, 160], ["sample", "ANATOMY", 173, 179], ["infection via sexual intercourse", "DISEASE", 57, 89], ["semen", "ORGANISM_SUBSTANCE", 155, 160], ["an infection", "PROBLEM", 54, 66], ["a high viral load", "PROBLEM", 130, 147], ["infection", "OBSERVATION", 57, 66], ["viral load", "OBSERVATION", 137, 147]]], ["In several smaller and bigger studies, the usability of saliva and urine beside blood samples was demonstrated for the Zika virus diagnostics [96] [97] [98] .", [["saliva", "ANATOMY", 56, 62], ["urine", "ANATOMY", 67, 72], ["blood samples", "ANATOMY", 80, 93], ["saliva", "ORGANISM_SUBSTANCE", 56, 62], ["urine", "ORGANISM_SUBSTANCE", 67, 72], ["blood samples", "ORGANISM_SUBSTANCE", 80, 93], ["Zika virus", "ORGANISM", 119, 129], ["Zika virus", "SPECIES", 119, 129], ["saliva and urine", "TEST", 56, 72], ["blood samples", "TEST", 80, 93], ["the Zika virus diagnostics", "TEST", 115, 141], ["several", "OBSERVATION_MODIFIER", 3, 10], ["smaller", "OBSERVATION_MODIFIER", 11, 18], ["bigger", "OBSERVATION_MODIFIER", 23, 29]]], ["The excretion of viral RNA in urine and saliva was observed for up to 29 days after symptom onset and with higher viral load than in blood [99, 100] .", [["urine", "ANATOMY", 30, 35], ["blood", "ANATOMY", 133, 138], ["urine", "ORGANISM_SUBSTANCE", 30, 35], ["saliva", "ORGANISM_SUBSTANCE", 40, 46], ["blood", "ORGANISM_SUBSTANCE", 133, 138], ["viral RNA", "RNA", 17, 26], ["viral RNA in urine and saliva", "PROBLEM", 17, 46], ["symptom onset", "PROBLEM", 84, 97], ["higher viral load", "PROBLEM", 107, 124], ["blood", "TEST", 133, 138], ["excretion", "OBSERVATION_MODIFIER", 4, 13], ["viral RNA", "OBSERVATION", 17, 26]]], ["The high risk for transmission by patient's body fluids also raised concern for appropriate safety measures for health care personal as discussed in several publications [101] [102] [103] .Yellow FeverYellow Fever is generally detected in blood, plasma, serum and CSF as other flaviviruses (Table 1 and Additional file 1: Table S6 ).", [["body", "ANATOMY", 44, 48], ["blood", "ANATOMY", 239, 244], ["plasma", "ANATOMY", 246, 252], ["serum", "ANATOMY", 254, 259], ["patient", "ORGANISM", 34, 41], ["body", "ORGANISM_SUBDIVISION", 44, 48], ["blood", "ORGANISM_SUBSTANCE", 239, 244], ["plasma", "ORGANISM_SUBSTANCE", 246, 252], ["serum", "ORGANISM_SUBSTANCE", 254, 259], ["CSF", "ORGANISM_SUBSTANCE", 264, 267], ["S6", "PROTEIN", 328, 330], ["patient", "SPECIES", 34, 41], ["patient's body fluids", "TREATMENT", 34, 55], ["Yellow FeverYellow Fever", "PROBLEM", 189, 213], ["blood", "TEST", 239, 244], ["plasma, serum and CSF", "TEST", 246, 267], ["other flaviviruses", "TEST", 271, 289]]], ["Although alternative samples demonstrate their usefulness for other flavivirus infections like urine or saliva samples for diagnostics of dengue or West Nile, YF were not investigated until 2011 [104, 105] .", [["samples", "ANATOMY", 21, 28], ["urine", "ANATOMY", 95, 100], ["samples", "ANATOMY", 111, 118], ["flavivirus infections", "DISEASE", 68, 89], ["dengue", "DISEASE", 138, 144], ["YF", "DISEASE", 159, 161], ["samples", "CANCER", 21, 28], ["flavivirus", "ORGANISM", 68, 78], ["urine", "ORGANISM_SUBSTANCE", 95, 100], ["saliva samples", "ORGANISM_SUBSTANCE", 104, 118], ["West Nile", "ORGANISM", 148, 157], ["YF", "ORGANISM", 159, 161], ["flavivirus", "SPECIES", 68, 78], ["dengue", "SPECIES", 138, 144], ["YF", "SPECIES", 159, 161], ["alternative samples", "TEST", 9, 28], ["other flavivirus infections", "PROBLEM", 62, 89], ["saliva samples", "TEST", 104, 118], ["dengue", "PROBLEM", 138, 144]]], ["These are the first reports showing the usefulness of urine samples for diagnostic of adverse events after YF vaccination.", [["urine samples", "ANATOMY", 54, 67], ["urine samples", "ORGANISM_SUBSTANCE", 54, 67], ["YF", "ORGANISM", 107, 109], ["YF", "SPECIES", 107, 109], ["urine samples", "TEST", 54, 67], ["adverse events", "PROBLEM", 86, 100], ["YF vaccination", "TREATMENT", 107, 121]]], ["For vaccinees developing severe side effects after vaccination it could be clearly shown that viral shedding is prolonged up to day 25 post vaccination.", [["vaccinees", "PROBLEM", 4, 13], ["severe side effects", "PROBLEM", 25, 44], ["vaccination", "TREATMENT", 51, 62], ["viral shedding", "PROBLEM", 94, 108], ["severe", "OBSERVATION_MODIFIER", 25, 31], ["side effects", "OBSERVATION_MODIFIER", 32, 44]]], ["The release of YF RNA could be found in urine at day 198 after vaccination.", [["urine", "ANATOMY", 40, 45], ["YF", "ORGANISM", 15, 17], ["urine", "ORGANISM_SUBSTANCE", 40, 45], ["YF RNA", "RNA", 15, 21], ["YF", "SPECIES", 15, 17], ["YF RNA", "PROBLEM", 15, 21], ["vaccination", "TREATMENT", 63, 74]]], ["If the detection of the YF attenuated 17D vaccine virus could be demonstrated in urine easily.", [["urine", "ANATOMY", 81, 86], ["YF", "DISEASE", 24, 26], ["YF", "ORGANISM", 24, 26], ["urine", "ORGANISM_SUBSTANCE", 81, 86], ["YF attenuated 17D vaccine virus", "SPECIES", 24, 55], ["the YF attenuated 17D vaccine virus", "TREATMENT", 20, 55]]], ["However, representative data of alternative samples like urine or saliva from YF infections are missing.", [["samples", "ANATOMY", 44, 51], ["urine", "ANATOMY", 57, 62], ["infections", "DISEASE", 81, 91], ["urine", "ORGANISM_SUBSTANCE", 57, 62], ["saliva", "ORGANISM_SUBSTANCE", 66, 72], ["YF", "ORGANISM", 78, 80], ["YF", "SPECIES", 78, 80], ["alternative samples like urine", "PROBLEM", 32, 62], ["saliva from YF infections", "PROBLEM", 66, 91], ["infections", "OBSERVATION", 81, 91]]], ["In particular for cases with a severe course of disease with numerous hemorrhagic bleedings the use of non-invasive sampling would be a real alternative preventing bodily injury of the patient.Severe acute respiratory syndrome (SARS)When SARS emerged in November 2002, it was obvious to analyze samples from the respiratory tract for diagnostic.", [["samples", "ANATOMY", 295, 302], ["respiratory tract", "ANATOMY", 312, 329], ["hemorrhagic bleedings", "DISEASE", 70, 91], ["acute respiratory syndrome", "DISEASE", 200, 226], ["SARS", "DISEASE", 228, 232], ["SARS", "DISEASE", 238, 242], ["bodily", "ORGANISM_SUBDIVISION", 164, 170], ["patient", "ORGANISM", 185, 192], ["respiratory tract", "ORGANISM_SUBDIVISION", 312, 329], ["patient", "SPECIES", 185, 192], ["disease", "PROBLEM", 48, 55], ["numerous hemorrhagic bleedings", "PROBLEM", 61, 91], ["non-invasive sampling", "TREATMENT", 103, 124], ["bodily injury", "PROBLEM", 164, 177], ["Severe acute respiratory syndrome", "PROBLEM", 193, 226], ["severe", "OBSERVATION_MODIFIER", 31, 37], ["disease", "OBSERVATION", 48, 55], ["numerous", "OBSERVATION_MODIFIER", 61, 69], ["hemorrhagic", "OBSERVATION_MODIFIER", 70, 81], ["bleedings", "OBSERVATION", 82, 91], ["acute", "OBSERVATION_MODIFIER", 200, 205], ["respiratory syndrome", "OBSERVATION", 206, 226], ["respiratory tract", "ANATOMY", 312, 329]]], ["However, even for the first SARS patients other samples beside blood and nasopharyngeal aspirate samples like feces and urine were found positive with 97% and 42% for viral RNA, respectively [106] (Table 1 and Additional file 1: Table S7 ).", [["samples", "ANATOMY", 48, 55], ["blood", "ANATOMY", 63, 68], ["nasopharyngeal aspirate samples", "ANATOMY", 73, 104], ["feces", "ANATOMY", 110, 115], ["urine", "ANATOMY", 120, 125], ["SARS", "DISEASE", 28, 32], ["patients", "ORGANISM", 33, 41], ["blood", "ORGANISM_SUBSTANCE", 63, 68], ["nasopharyngeal aspirate samples", "ORGANISM_SUBSTANCE", 73, 104], ["feces", "ORGANISM_SUBSTANCE", 110, 115], ["urine", "ORGANISM_SUBSTANCE", 120, 125], ["viral RNA", "RNA", 167, 176], ["patients", "SPECIES", 33, 41], ["other samples", "TEST", 42, 55], ["blood and nasopharyngeal aspirate samples", "TEST", 63, 104], ["feces and urine", "TEST", 110, 125], ["viral RNA", "TEST", 167, 176], ["nasopharyngeal", "ANATOMY", 73, 87]]], ["This was confirmed by analysis of throat wash and saliva showing a high virus load up to 6x10 6 and 6x10 8 RNA copies per ml, respectively [107] .", [["throat", "ANATOMY", 34, 40], ["throat", "ORGANISM_SUBDIVISION", 34, 40], ["saliva", "ORGANISM_SUBSTANCE", 50, 56], ["throat wash", "TEST", 34, 45], ["saliva", "TEST", 50, 56], ["a high virus load", "PROBLEM", 65, 82], ["throat", "ANATOMY", 34, 40]]], ["Moreover, the detection of SARS in plasma, sputum, endotracheal aspirates, stool, throat swabs and saliva revealed significant differences between the types of samples [108] as all samples from the lower respiratory tract were tested positive.", [["plasma", "ANATOMY", 35, 41], ["sputum", "ANATOMY", 43, 49], ["endotracheal aspirates", "ANATOMY", 51, 73], ["stool", "ANATOMY", 75, 80], ["throat swabs", "ANATOMY", 82, 94], ["samples", "ANATOMY", 160, 167], ["samples", "ANATOMY", 181, 188], ["lower respiratory tract", "ANATOMY", 198, 221], ["SARS", "DISEASE", 27, 31], ["plasma", "ORGANISM_SUBSTANCE", 35, 41], ["sputum", "ORGANISM_SUBSTANCE", 43, 49], ["endotracheal aspirates", "MULTI-TISSUE_STRUCTURE", 51, 73], ["stool", "ORGANISM_SUBSTANCE", 75, 80], ["throat swabs", "ORGANISM_SUBSTANCE", 82, 94], ["saliva", "ORGANISM_SUBSTANCE", 99, 105], ["lower", "ORGANISM_SUBDIVISION", 198, 203], ["respiratory tract", "ORGANISM_SUBDIVISION", 204, 221], ["SARS in plasma", "TEST", 27, 41], ["sputum", "TEST", 43, 49], ["endotracheal aspirates", "TEST", 51, 73], ["stool, throat swabs and saliva", "TEST", 75, 105], ["all samples", "TEST", 177, 188], ["the lower respiratory tract", "TEST", 194, 221], ["endotracheal", "ANATOMY", 51, 63], ["significant", "OBSERVATION_MODIFIER", 115, 126], ["lower", "ANATOMY_MODIFIER", 198, 203], ["respiratory tract", "ANATOMY", 204, 221]]], ["Cheng et al. found that death was associated with higher virus load in nasopharyngeal specimens obtained on day 10 after the onset of symptoms [109] .", [["nasopharyngeal specimens", "ANATOMY", 71, 95], ["death", "DISEASE", 24, 29], ["nasopharyngeal specimens", "CANCER", 71, 95], ["death", "PROBLEM", 24, 29], ["higher virus load in nasopharyngeal specimens", "PROBLEM", 50, 95], ["symptoms", "PROBLEM", 134, 142], ["nasopharyngeal", "ANATOMY", 71, 85]]], ["Different samples like serum, nasopharyngeal aspirates (NPA), throat swabs, nasal swabs, rectal swab, stool and urine were used for analysis of the viral pathogenesis during the course of the disease [109] [110] [111] [112] .Severe acute respiratory syndrome (SARS)The diarrhea and hepatic dysfunction was associated high viral load in NPA, while in urine is associated with abnormal urinalysis findings.", [["samples", "ANATOMY", 10, 17], ["serum", "ANATOMY", 23, 28], ["nasopharyngeal aspirates", "ANATOMY", 30, 54], ["throat swabs", "ANATOMY", 62, 74], ["nasal swabs", "ANATOMY", 76, 87], ["rectal swab", "ANATOMY", 89, 100], ["stool", "ANATOMY", 102, 107], ["urine", "ANATOMY", 112, 117], ["hepatic", "ANATOMY", 282, 289], ["urine", "ANATOMY", 350, 355], ["acute respiratory syndrome", "DISEASE", 232, 258], ["SARS", "DISEASE", 260, 264], ["diarrhea", "DISEASE", 269, 277], ["hepatic dysfunction", "DISEASE", 282, 301], ["NPA", "CHEMICAL", 336, 339], ["NPA", "CHEMICAL", 336, 339], ["serum", "ORGANISM_SUBSTANCE", 23, 28], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 30, 54], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 76, 87], ["rectal swab", "MULTI-TISSUE_STRUCTURE", 89, 100], ["stool", "ORGANISM_SUBSTANCE", 102, 107], ["urine", "ORGANISM_SUBSTANCE", 112, 117], ["hepatic", "ORGAN", 282, 289], ["NPA", "SIMPLE_CHEMICAL", 336, 339], ["urine", "ORGANISM_SUBSTANCE", 350, 355], ["Different samples", "TEST", 0, 17], ["serum", "TEST", 23, 28], ["nasopharyngeal aspirates", "TEST", 30, 54], ["NPA", "TEST", 56, 59], ["throat swabs", "TEST", 62, 74], ["nasal swabs", "TEST", 76, 87], ["rectal swab, stool and urine", "TEST", 89, 117], ["analysis", "TEST", 132, 140], ["the viral pathogenesis", "PROBLEM", 144, 166], ["Severe acute respiratory syndrome", "PROBLEM", 225, 258], ["SARS", "PROBLEM", 260, 264], ["The diarrhea", "PROBLEM", 265, 277], ["hepatic dysfunction", "PROBLEM", 282, 301], ["high viral load in NPA", "PROBLEM", 317, 339], ["abnormal urinalysis findings", "PROBLEM", 375, 403], ["serum", "OBSERVATION_MODIFIER", 23, 28], ["nasopharyngeal", "ANATOMY", 30, 44], ["aspirates", "OBSERVATION", 45, 54], ["nasal", "ANATOMY", 76, 81], ["rectal", "ANATOMY", 89, 95], ["acute", "OBSERVATION_MODIFIER", 232, 237], ["respiratory syndrome", "OBSERVATION", 238, 258], ["hepatic", "ANATOMY", 282, 289], ["dysfunction", "OBSERVATION", 290, 301], ["high", "OBSERVATION_MODIFIER", 317, 321], ["viral load", "OBSERVATION", 322, 332]]], ["The extensive analysis of 415 SARS patients revealed the presence of SARS in respiratory specimens two weeks after disease onset, and in stool, rectal swab and urine specimens for up to four weeks.", [["respiratory specimens", "ANATOMY", 77, 98], ["stool", "ANATOMY", 137, 142], ["rectal swab", "ANATOMY", 144, 155], ["urine specimens", "ANATOMY", 160, 175], ["SARS", "DISEASE", 30, 34], ["SARS", "DISEASE", 69, 73], ["patients", "ORGANISM", 35, 43], ["stool", "ORGANISM_SUBSTANCE", 137, 142], ["rectal swab", "ORGANISM_SUBSTANCE", 144, 155], ["urine specimens", "ORGANISM_SUBSTANCE", 160, 175], ["patients", "SPECIES", 35, 43], ["The extensive analysis", "TEST", 0, 22], ["SARS in respiratory specimens", "PROBLEM", 69, 98], ["disease onset", "PROBLEM", 115, 128], ["stool", "TEST", 137, 142], ["rectal swab", "TEST", 144, 155], ["urine specimens", "TEST", 160, 175], ["SARS", "OBSERVATION", 69, 73], ["rectal", "ANATOMY", 144, 150]]], ["Throat and nasal swabs is less significant that the NPA specimens, therefore, the high viral load in NPA has a major impact on the airborne transmission, which played a major role during the outbreak in Hong Kong [113] .Severe acute respiratory syndrome (SARS)The evaluations of commercial PCR kits and in-house antigen-ELISAs for the quality of SARS diagnostic are an important task to select the most appropriate test for the selected sample.", [["Throat", "ANATOMY", 0, 6], ["nasal swabs", "ANATOMY", 11, 22], ["NPA specimens", "ANATOMY", 52, 65], ["NPA", "CHEMICAL", 101, 104], ["acute respiratory syndrome", "DISEASE", 227, 253], ["SARS", "DISEASE", 255, 259], ["SARS", "DISEASE", 346, 350], ["NPA", "CHEMICAL", 101, 104], ["nasal swabs", "PATHOLOGICAL_FORMATION", 11, 22], ["NPA specimens", "CELL", 52, 65], ["Throat and nasal swabs", "TEST", 0, 22], ["the NPA specimens", "TEST", 48, 65], ["the high viral load in NPA", "PROBLEM", 78, 104], ["Severe acute respiratory syndrome", "PROBLEM", 220, 253], ["The evaluations", "TEST", 260, 275], ["commercial PCR kits", "TEST", 279, 298], ["SARS diagnostic", "TEST", 346, 361], ["nasal", "ANATOMY", 11, 16], ["swabs", "OBSERVATION", 17, 22], ["less significant", "OBSERVATION_MODIFIER", 26, 42], ["viral load", "OBSERVATION", 87, 97], ["acute", "OBSERVATION_MODIFIER", 227, 232], ["respiratory syndrome", "OBSERVATION", 233, 253]]], ["The sensitivity of RT-PCR is higher compared to two antigen-ELISAs [114] as RNA of SARS-CoV can be detected earlier in fecal specimens in around 80% of patients and in 25% of urine samples.", [["fecal specimens", "ANATOMY", 119, 134], ["urine samples", "ANATOMY", 175, 188], ["SARS-CoV", "ORGANISM", 83, 91], ["fecal specimens", "ORGANISM_SUBSTANCE", 119, 134], ["patients", "ORGANISM", 152, 160], ["urine samples", "ORGANISM_SUBSTANCE", 175, 188], ["patients", "SPECIES", 152, 160], ["SARS-CoV", "SPECIES", 83, 91], ["RT-PCR", "TEST", 19, 25], ["two antigen", "TEST", 48, 59], ["ELISAs", "TEST", 60, 66], ["SARS", "PROBLEM", 83, 87], ["CoV", "PROBLEM", 88, 91], ["fecal specimens", "TEST", 119, 134], ["urine samples", "TEST", 175, 188]]], ["Based on all these findings, RT-PCR is the method of choice for early diagnosis of SARS CoV infection [115, 116] .Severe acute respiratory syndrome (SARS)The co-presence of viral RNA and antibodies in plasma was observed over three weeks in two cases [117] .", [["plasma", "ANATOMY", 201, 207], ["SARS CoV infection", "DISEASE", 83, 101], ["acute respiratory syndrome", "DISEASE", 121, 147], ["SARS", "DISEASE", 149, 153], ["SARS CoV", "ORGANISM", 83, 91], ["plasma", "ORGANISM_SUBSTANCE", 201, 207], ["viral RNA", "RNA", 173, 182], ["antibodies", "PROTEIN", 187, 197], ["SARS CoV", "SPECIES", 83, 91], ["RT-PCR", "TEST", 29, 35], ["SARS CoV infection", "PROBLEM", 83, 101], ["Severe acute respiratory syndrome", "PROBLEM", 114, 147], ["SARS", "PROBLEM", 149, 153], ["viral RNA", "PROBLEM", 173, 182], ["antibodies in plasma", "PROBLEM", 187, 207], ["acute", "OBSERVATION_MODIFIER", 121, 126], ["respiratory syndrome", "OBSERVATION", 127, 147], ["viral RNA", "OBSERVATION", 173, 182]]], ["In addition, the SARS-CoV was isolated from stool or urine specimens for longer than 4 weeks [118] .", [["stool", "ANATOMY", 44, 49], ["urine specimens", "ANATOMY", 53, 68], ["SARS", "DISEASE", 17, 21], ["SARS-CoV", "ORGANISM", 17, 25], ["stool", "ORGANISM_SUBSTANCE", 44, 49], ["urine specimens", "ORGANISM_SUBSTANCE", 53, 68], ["SARS-CoV", "SPECIES", 17, 25], ["the SARS-CoV", "PROBLEM", 13, 25], ["stool or urine specimens", "TEST", 44, 68]]], ["Since the detection of SARS virus is possible in various clinical samples (NPA, throat-swab, fecal, cerebrospinal fluid, blood and urine) by viral culture or RT-PCR clear and significant recommendations for diagnostic of SARS based on the previous experiments worked out by the WHO and the Multi-Centre Collaborative Network require an appropriate update.", [["samples", "ANATOMY", 66, 73], ["throat-swab", "ANATOMY", 80, 91], ["fecal", "ANATOMY", 93, 98], ["cerebrospinal fluid", "ANATOMY", 100, 119], ["blood", "ANATOMY", 121, 126], ["urine", "ANATOMY", 131, 136], ["SARS", "DISEASE", 23, 27], ["SARS", "DISEASE", 221, 225], ["SARS virus", "ORGANISM", 23, 33], ["samples", "CANCER", 66, 73], ["NPA", "CANCER", 75, 78], ["throat", "ORGANISM_SUBDIVISION", 80, 86], ["fecal", "ORGANISM_SUBSTANCE", 93, 98], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 100, 119], ["blood", "ORGANISM_SUBSTANCE", 121, 126], ["urine", "ORGANISM_SUBSTANCE", 131, 136], ["SARS virus", "SPECIES", 23, 33], ["SARS virus", "PROBLEM", 23, 33], ["NPA, throat-swab", "TEST", 75, 91], ["fecal, cerebrospinal fluid, blood and urine", "TEST", 93, 136], ["viral culture", "TEST", 141, 154], ["RT-PCR", "TEST", 158, 164], ["SARS", "PROBLEM", 221, 225], ["SARS virus", "OBSERVATION", 23, 33], ["fecal", "ANATOMY", 93, 98]]], ["Even though SARS did not appear any more after the outbreak except for the two laboratory infections thereafter .Severe acute respiratory syndrome (SARS)Bats are the most likely animal vector for CoVs [121] .", [["SARS", "DISEASE", 12, 16], ["infections", "DISEASE", 90, 100], ["acute respiratory syndrome", "DISEASE", 120, 146], ["SARS", "DISEASE", 148, 152], ["SARS", "PROBLEM", 12, 16], ["the two laboratory infections", "PROBLEM", 71, 100], ["Severe acute respiratory syndrome", "PROBLEM", 113, 146], ["SARS)Bats", "PROBLEM", 148, 157], ["infections", "OBSERVATION", 90, 100], ["acute", "OBSERVATION_MODIFIER", 120, 125], ["respiratory syndrome", "OBSERVATION", 126, 146]]], ["Also experiments in mice and rhesus macaque analyzing the viral pathogenesis for the development of effective strategies for diagnosis, prevention, therapy and vaccine design was further evaluated [122, 123] .", [["mice", "ORGANISM", 20, 24], ["rhesus macaque", "ORGANISM", 29, 43], ["mice", "SPECIES", 20, 24], ["rhesus macaque", "SPECIES", 29, 43], ["mice", "SPECIES", 20, 24], ["rhesus macaque", "SPECIES", 29, 43], ["the viral pathogenesis", "PROBLEM", 54, 76], ["therapy", "TREATMENT", 148, 155], ["vaccine", "TREATMENT", 160, 167]]], ["Since salivary gland epithelial cells were affected as a first target after infection the immunization with virus like particles might be eliciting a protective immune response against SARS-CoV generating a mucosal immunity.", [["salivary gland epithelial cells", "ANATOMY", 6, 37], ["mucosal", "ANATOMY", 207, 214], ["infection", "DISEASE", 76, 85], ["SARS", "DISEASE", 185, 189], ["salivary gland epithelial cells", "CELL", 6, 37], ["SARS-CoV", "ORGANISM", 185, 193], ["mucosal", "ORGAN", 207, 214], ["salivary gland epithelial cells", "CELL_TYPE", 6, 37], ["SARS-CoV", "SPECIES", 185, 193], ["salivary gland epithelial cells", "PROBLEM", 6, 37], ["infection the immunization", "TREATMENT", 76, 102], ["virus like particles", "PROBLEM", 108, 128], ["SARS", "PROBLEM", 185, 189], ["salivary gland", "ANATOMY", 6, 20], ["epithelial cells", "OBSERVATION", 21, 37], ["infection", "OBSERVATION", 76, 85]]], ["This new vaccine approach provides important information for future vaccine design.Middle East respiratory syndrome coronavirus (MERS-CoV)A boost of nearly 50 publications on alternative sampling within three years demonstrates the importance and documents the public health concern with this respiratory disease caused by a new Corona virus (CoV) (Additional file 1: Table S8 ).", [["respiratory", "ANATOMY", 293, 304], ["Middle East respiratory syndrome coronavirus", "DISEASE", 83, 127], ["respiratory disease", "DISEASE", 293, 312], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 83, 127], ["MERS-CoV", "ORGANISM", 129, 137], ["Corona virus", "ORGANISM", 329, 341], ["Corona virus", "SPECIES", 329, 341], ["Middle East respiratory syndrome coronavirus", "SPECIES", 83, 127], ["MERS-CoV", "SPECIES", 129, 137], ["Corona virus", "SPECIES", 329, 341], ["CoV", "SPECIES", 343, 346], ["This new vaccine approach", "TREATMENT", 0, 25], ["future vaccine design", "TREATMENT", 61, 82], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 83, 127], ["alternative sampling", "TREATMENT", 175, 195], ["this respiratory disease", "PROBLEM", 288, 312], ["a new Corona virus", "PROBLEM", 323, 341], ["respiratory syndrome", "OBSERVATION", 95, 115]]], ["The publications can be roughly categorized as follows 11 case reports, 7 descriptions of pathogenesis, 11 on recommendation and investigation of diagnostics, 7 on recommendation and analysis of risks for health care workers, 2 recommendations for patient management and 5 on control and prevention including treatment and vaccine development.", [["patient", "ORGANISM", 248, 255], ["patient", "SPECIES", 248, 255], ["diagnostics", "TEST", 146, 157], ["patient management", "TREATMENT", 248, 266], ["prevention", "TREATMENT", 288, 298], ["treatment", "TREATMENT", 309, 318], ["vaccine development", "TREATMENT", 323, 342]]], ["Only a few selected publications were considered for this review.", [["few", "OBSERVATION_MODIFIER", 7, 10]]], ["Bronchoalveolar and lower respiratory tract fluids were highly positive for MERS-CoV in the two identified cases [124] , while urine samples were only positive on day 13.", [["Bronchoalveolar", "ANATOMY", 0, 15], ["lower respiratory tract fluids", "ANATOMY", 20, 50], ["urine samples", "ANATOMY", 127, 140], ["Bronchoalveolar", "MULTI-TISSUE_STRUCTURE", 0, 15], ["lower", "ORGANISM_SUBDIVISION", 20, 25], ["respiratory tract", "ORGANISM_SUBDIVISION", 26, 43], ["fluids", "ORGANISM_SUBSTANCE", 44, 50], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 76, 84], ["urine samples", "ORGANISM_SUBSTANCE", 127, 140], ["MERS-CoV", "PROTEIN", 76, 84], ["MERS-CoV", "SPECIES", 76, 84], ["Bronchoalveolar and lower respiratory tract fluids", "TEST", 0, 50], ["MERS", "PROBLEM", 76, 80], ["urine samples", "TEST", 127, 140], ["lower", "ANATOMY_MODIFIER", 20, 25], ["respiratory tract", "ANATOMY", 26, 43]]], ["Stool samples and oro-nasal swabs contained very low MERS-CoV copy number on days 12 and 16, respectively, and no virus was detected in blood.", [["Stool samples", "ANATOMY", 0, 13], ["oro-nasal swabs", "ANATOMY", 18, 33], ["blood", "ANATOMY", 136, 141], ["Stool samples", "ORGANISM_SUBSTANCE", 0, 13], ["oro-nasal swabs", "ORGANISM_SUBSTANCE", 18, 33], ["blood", "ORGANISM_SUBSTANCE", 136, 141], ["MERS", "PROTEIN", 53, 57], ["MERS-CoV", "SPECIES", 53, 61], ["Stool samples", "TEST", 0, 13], ["oro-nasal swabs", "TEST", 18, 33], ["very low MERS", "PROBLEM", 44, 57], ["virus", "PROBLEM", 114, 119], ["no", "UNCERTAINTY", 111, 113], ["virus", "OBSERVATION", 114, 119]]], ["Therefore, the virus replication in the kidney with potential shedding in urine was further investigated [125] .", [["kidney", "ANATOMY", 40, 46], ["urine", "ANATOMY", 74, 79], ["kidney", "ORGAN", 40, 46], ["urine", "ORGANISM_SUBSTANCE", 74, 79], ["the virus replication", "TREATMENT", 11, 32], ["potential shedding in urine", "PROBLEM", 52, 79], ["virus", "OBSERVATION", 15, 20], ["kidney", "ANATOMY", 40, 46]]], ["To clarify the different transmission routes a prediction model for oral-fecal and/or oral-saliva transmission routes for MERS-CoV was developed and evaluated [126] .", [["oral", "ANATOMY", 68, 72], ["fecal", "ANATOMY", 73, 78], ["oral", "ANATOMY", 86, 90], ["oral", "ORGANISM_SUBDIVISION", 68, 72], ["fecal", "ORGANISM_SUBSTANCE", 73, 78], ["oral", "ORGANISM_SUBDIVISION", 86, 90], ["saliva", "ORGANISM_SUBSTANCE", 91, 97], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 122, 130], ["MERS-CoV", "SPECIES", 122, 130], ["oral-fecal", "TREATMENT", 68, 78], ["oral-saliva transmission routes", "TREATMENT", 86, 117], ["MERS", "PROBLEM", 122, 126], ["CoV", "PROBLEM", 127, 130], ["fecal", "ANATOMY", 73, 78]]], ["Very soon camels as contributing animal host for MERS-CoV infection got into focus of investigation and it became obvious that also dromedary camels in Eastern Africa and the Arabian Peninsula have a very high seroprevalence of MERS-CoV antibodies [127] .", [["MERS-CoV infection", "DISEASE", 49, 67], ["MERS-CoV", "ORGANISM", 49, 57], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 228, 236], ["MERS-CoV antibodies", "PROTEIN", 228, 247], ["MERS-CoV", "SPECIES", 49, 57], ["MERS-CoV", "SPECIES", 228, 236], ["MERS", "PROBLEM", 49, 53], ["CoV infection", "PROBLEM", 54, 67], ["CoV antibodies", "TEST", 233, 247], ["infection", "OBSERVATION", 58, 67]]], ["For further surveillance studies in camels, hedgehogs, and bats very often non-invasive samples like urine, saliva, fecal nasal swaps, fecal swaps or camel milk were used to analyze for MERS-CoV RNA or specific antibodies [128] .", [["samples", "ANATOMY", 88, 95], ["urine", "ANATOMY", 101, 106], ["nasal", "ANATOMY", 122, 127], ["fecal", "ANATOMY", 135, 140], ["milk", "ANATOMY", 156, 160], ["camels", "ORGANISM", 36, 42], ["urine", "ORGANISM_SUBSTANCE", 101, 106], ["saliva", "ORGANISM_SUBSTANCE", 108, 114], ["nasal", "ORGANISM_SUBDIVISION", 122, 127], ["fecal", "ORGANISM_SUBSTANCE", 135, 140], ["camel", "ORGANISM", 150, 155], ["milk", "ORGANISM_SUBSTANCE", 156, 160], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 186, 194], ["MERS-CoV RNA", "RNA", 186, 198], ["camel", "SPECIES", 150, 155], ["camels", "SPECIES", 36, 42], ["camel", "SPECIES", 150, 155], ["MERS-CoV", "SPECIES", 186, 194], ["further surveillance studies", "TEST", 4, 32], ["urine", "TEST", 101, 106], ["saliva", "TEST", 108, 114], ["fecal nasal swaps", "TREATMENT", 116, 133], ["fecal swaps", "TREATMENT", 135, 146], ["camel milk", "TREATMENT", 150, 160], ["MERS", "PROBLEM", 186, 190], ["CoV RNA", "TEST", 191, 198], ["specific antibodies", "TEST", 202, 221], ["fecal nasal", "ANATOMY", 116, 127], ["fecal", "ANATOMY", 135, 140]]], ["In summer 2015, 183 confirmed cases of MERS and 33 fatalities were reported in the Republic of Korea caused by a nosocomial outbreak [129] .Middle East respiratory syndrome coronavirus (MERS-CoV)The timing and intensity of respiratory viral shedding in MERS-CoV infected patients is still of major interest as airborne transmission from human to human by droplets seems to be the dominant infection route [130] [131] [132] .", [["respiratory", "ANATOMY", 223, 234], ["MERS", "DISEASE", 39, 43], ["fatalities", "DISEASE", 51, 61], ["Middle East respiratory syndrome coronavirus", "DISEASE", 140, 184], ["MERS-CoV infected", "DISEASE", 253, 270], ["infection", "DISEASE", 389, 398], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 140, 184], ["MERS-CoV", "ORGANISM", 186, 194], ["MERS-CoV", "ORGANISM", 253, 261], ["patients", "ORGANISM", 271, 279], ["human", "ORGANISM", 337, 342], ["human", "ORGANISM", 346, 351], ["MERS-CoV", "SPECIES", 253, 261], ["patients", "SPECIES", 271, 279], ["human", "SPECIES", 337, 342], ["human", "SPECIES", 346, 351], ["Middle East respiratory syndrome coronavirus", "SPECIES", 140, 184], ["MERS-CoV", "SPECIES", 186, 194], ["MERS-CoV", "SPECIES", 253, 261], ["human", "SPECIES", 337, 342], ["human", "SPECIES", 346, 351], ["a nosocomial outbreak", "PROBLEM", 111, 132], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 140, 184], ["respiratory viral shedding in MERS", "PROBLEM", 223, 257], ["respiratory syndrome", "OBSERVATION", 152, 172], ["respiratory", "ANATOMY", 223, 234], ["viral", "OBSERVATION", 235, 240], ["dominant", "OBSERVATION_MODIFIER", 380, 388], ["infection", "OBSERVATION", 389, 398]]], ["It might be that the introduction of the isothermal amplification (LAMP or RPA) for detecting of emerging diseases provides a useful tool for quick and reliable diagnostic of acute cases and might lead to an immediate public health response including the appropriate safety precautions for the medical personal [133, 134] .Middle East respiratory syndrome coronavirus (MERS-CoV)Based on the experience with other respiratory infections and based on the lessons learned from the previous SARS outbreak the analysis of respiratory samples are parts of the routine samples taken for diagnostic of suspected MERS patients.ConclusionsThe analysis of using other non-invasive samples for virus diagnostics clearly shows that the procedures for the optimal sampling strategy of the different viral infections are not seriously investigated table S9.", [["respiratory", "ANATOMY", 413, 424], ["respiratory samples", "ANATOMY", 517, 536], ["samples", "ANATOMY", 562, 569], ["samples", "ANATOMY", 670, 677], ["Middle East respiratory syndrome coronavirus", "DISEASE", 323, 367], ["respiratory infections", "DISEASE", 413, 435], ["SARS", "DISEASE", 487, 491], ["MERS", "DISEASE", 604, 608], ["viral infections", "DISEASE", 785, 801], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 323, 367], ["MERS-CoV", "ORGANISM", 369, 377], ["patients", "ORGANISM", 609, 617], ["RPA", "PROTEIN", 75, 78], ["patients", "SPECIES", 609, 617], ["Middle East respiratory syndrome coronavirus", "SPECIES", 323, 367], ["MERS-CoV", "SPECIES", 369, 377], ["the isothermal amplification", "TREATMENT", 37, 65], ["emerging diseases", "PROBLEM", 97, 114], ["acute cases", "PROBLEM", 175, 186], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 323, 367], ["other respiratory infections", "PROBLEM", 407, 435], ["respiratory samples", "TEST", 517, 536], ["the routine samples", "TEST", 550, 569], ["The analysis", "TEST", 629, 641], ["other non-invasive samples", "TEST", 651, 677], ["virus diagnostics", "TEST", 682, 699], ["the procedures", "TREATMENT", 719, 733], ["the optimal sampling strategy", "TREATMENT", 738, 767], ["the different viral infections", "PROBLEM", 771, 801], ["respiratory syndrome", "OBSERVATION", 335, 355], ["respiratory", "ANATOMY", 413, 424], ["infections", "OBSERVATION", 425, 435], ["viral infections", "OBSERVATION", 785, 801]]], ["In the following overview it became obvious that for the newly emerging viruses like CHIK, MersCoV and Zika more and broader attempts for sampling strategies were performed and investigated than for well known viruses like YF and dengue.ConclusionsThe application of saliva as a sample of choice for the diagnosis of CHIK fever infections in small children or patients whose blood samples are difficult to obtain is of great significant.", [["blood samples", "ANATOMY", 375, 388], ["YF", "DISEASE", 223, 225], ["dengue", "DISEASE", 230, 236], ["fever", "DISEASE", 322, 327], ["infections", "DISEASE", 328, 338], ["CHIK", "GENE_OR_GENE_PRODUCT", 85, 89], ["YF", "ORGANISM", 223, 225], ["saliva", "ORGANISM_SUBSTANCE", 267, 273], ["CHIK", "ORGANISM", 317, 321], ["children", "ORGANISM", 348, 356], ["patients", "ORGANISM", 360, 368], ["blood samples", "MULTI-TISSUE_STRUCTURE", 375, 388], ["children", "SPECIES", 348, 356], ["patients", "SPECIES", 360, 368], ["YF", "SPECIES", 223, 225], ["dengue", "SPECIES", 230, 236], ["the newly emerging viruses", "PROBLEM", 53, 79], ["CHIK", "PROBLEM", 85, 89], ["Zika", "PROBLEM", 103, 107], ["sampling strategies", "TEST", 138, 157], ["well known viruses", "PROBLEM", 199, 217], ["dengue", "PROBLEM", 230, 236], ["saliva", "TREATMENT", 267, 273], ["CHIK fever infections", "PROBLEM", 317, 338], ["blood samples", "TEST", 375, 388], ["viruses", "OBSERVATION", 210, 217], ["small", "OBSERVATION_MODIFIER", 342, 347]]], ["However, all recommendations/fact sheets for CHIK from national and international organizations (CDC, PAHO, WHO, ECDC) do not mention saliva or urine samples as suitable material for diagnosis because of the missing of meaningful studies that evaluate saliva and urine as diagnostic samples compared with blood.", [["urine samples", "ANATOMY", 144, 157], ["saliva", "ANATOMY", 252, 258], ["urine", "ANATOMY", 263, 268], ["samples", "ANATOMY", 283, 290], ["blood", "ANATOMY", 305, 310], ["saliva", "ORGANISM_SUBSTANCE", 134, 140], ["urine samples", "ORGANISM_SUBSTANCE", 144, 157], ["saliva", "ORGANISM_SUBSTANCE", 252, 258], ["urine", "ORGANISM_SUBSTANCE", 263, 268], ["blood", "ORGANISM_SUBSTANCE", 305, 310], ["CHIK", "PROBLEM", 45, 49], ["urine samples", "TEST", 144, 157], ["meaningful studies", "TEST", 219, 237], ["saliva and urine", "TEST", 252, 268], ["diagnostic samples", "TEST", 272, 290], ["blood", "TEST", 305, 310]]], ["Hopefully, there will be studies performed answering these questions with a representative number of CHIK patients in the future.ConclusionsThe use of saliva and urine for the diagnosis of acute dengue infections is of great importance and requires more attention.", [["urine", "ANATOMY", 162, 167], ["dengue infections", "DISEASE", 195, 212], ["patients", "ORGANISM", 106, 114], ["saliva", "ORGANISM_SUBSTANCE", 151, 157], ["urine", "ORGANISM_SUBSTANCE", 162, 167], ["patients", "SPECIES", 106, 114], ["dengue", "SPECIES", 195, 201], ["saliva and urine", "TEST", 151, 167], ["acute dengue infections", "PROBLEM", 189, 212], ["acute", "OBSERVATION_MODIFIER", 189, 194], ["dengue", "OBSERVATION", 195, 201]]], ["Present studies show the usefulness for these samples for diagnostics and also the monitoring of the severity of infection.", [["samples", "ANATOMY", 46, 53], ["infection", "DISEASE", 113, 122], ["Present studies", "TEST", 0, 15], ["these samples", "TEST", 40, 53], ["diagnostics", "TEST", 58, 69], ["the monitoring", "TEST", 79, 93], ["infection", "PROBLEM", 113, 122], ["infection", "OBSERVATION", 113, 122]]], ["In particular for surveillance studies and/or investigation of small children the noninvasive approach using saliva or urine for the laboratory diagnosis of dengue cases should be considered when blood samples are difficult to obtain.", [["urine", "ANATOMY", 119, 124], ["blood samples", "ANATOMY", 196, 209], ["dengue", "DISEASE", 157, 163], ["children", "ORGANISM", 69, 77], ["saliva", "ORGANISM_SUBSTANCE", 109, 115], ["urine", "ORGANISM_SUBSTANCE", 119, 124], ["blood samples", "ORGANISM_SUBSTANCE", 196, 209], ["children", "SPECIES", 69, 77], ["dengue", "SPECIES", 157, 163], ["surveillance studies", "TEST", 18, 38], ["saliva or urine", "TEST", 109, 124], ["dengue cases", "PROBLEM", 157, 169], ["blood samples", "TEST", 196, 209], ["small", "OBSERVATION_MODIFIER", 63, 68]]], ["Although the application of alternative samples for the diagnostic became more popular in the recent years, further studies and improvements are necessary to establish these samples equally to common plasma or serum samples.", [["samples", "ANATOMY", 40, 47], ["samples", "ANATOMY", 174, 181], ["plasma", "ANATOMY", 200, 206], ["serum samples", "ANATOMY", 210, 223], ["plasma", "ORGANISM_SUBSTANCE", 200, 206], ["serum samples", "ORGANISM_SUBSTANCE", 210, 223], ["further studies", "TEST", 108, 123], ["these samples", "TEST", 168, 181], ["serum samples", "TEST", 210, 223]]], ["Commercial assays as well as appropriate sampling equipment have to be verified for diagnostic applicability in representative cohorts and during the course of the disease.", [["Commercial assays", "TEST", 0, 17], ["appropriate sampling equipment", "TREATMENT", 29, 59], ["the disease", "PROBLEM", 160, 171], ["disease", "OBSERVATION", 164, 171]]], ["It seems that the increased awareness of alternative samples stimulates such studies for dengue diagnosis as demonstrated in the recent publications mentioned above.ConclusionsIn particular for diagnostic of VHF cases, the investigation of the usefulness of non-invasive taken samples should have high priority since blood sampling from such patients is highly risky and often dangerous for patients with hemorrhagic symptoms while continuous bleeding occurs.", [["samples", "ANATOMY", 53, 60], ["samples", "ANATOMY", 277, 284], ["blood", "ANATOMY", 317, 322], ["dengue", "DISEASE", 89, 95], ["hemorrhagic symptoms", "DISEASE", 405, 425], ["bleeding", "DISEASE", 443, 451], ["blood", "ORGANISM_SUBSTANCE", 317, 322], ["patients", "ORGANISM", 342, 350], ["patients", "ORGANISM", 391, 399], ["patients", "SPECIES", 342, 350], ["patients", "SPECIES", 391, 399], ["dengue", "SPECIES", 89, 95], ["such studies", "TEST", 72, 84], ["dengue diagnosis", "TEST", 89, 105], ["non-invasive taken samples", "TEST", 258, 284], ["blood sampling", "TEST", 317, 331], ["hemorrhagic symptoms", "PROBLEM", 405, 425], ["continuous bleeding", "PROBLEM", 432, 451], ["increased", "OBSERVATION_MODIFIER", 18, 27]]], ["The virus load in sever cases of VHF is very high in body fluid and the NAT is the method of choice since the production of specific IgM and/or IgG antibodies takes a few days.", [["body fluid", "ANATOMY", 53, 63], ["body fluid", "ORGANISM_SUBSTANCE", 53, 63], ["IgM", "GENE_OR_GENE_PRODUCT", 133, 136], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 144, 158], ["IgM", "PROTEIN", 133, 136], ["IgG antibodies", "PROTEIN", 144, 158], ["The virus load", "TEST", 0, 14], ["VHF", "PROBLEM", 33, 36], ["very high in body fluid", "PROBLEM", 40, 63], ["specific IgM", "TEST", 124, 136], ["IgG antibodies", "PROBLEM", 144, 158], ["virus load", "OBSERVATION", 4, 14], ["sever", "OBSERVATION_MODIFIER", 18, 23], ["cases", "OBSERVATION", 24, 29], ["VHF", "OBSERVATION", 33, 36], ["very", "OBSERVATION_MODIFIER", 40, 44], ["high", "OBSERVATION_MODIFIER", 45, 49], ["body", "OBSERVATION_MODIFIER", 53, 57], ["fluid", "OBSERVATION", 58, 63]]], ["In very severe cases, the patient even can pass away before developing a detectable antibody reaction, while a general viremia affecting several organs and is detectable in most body fluids.", [["organs", "ANATOMY", 145, 151], ["body fluids", "ANATOMY", 178, 189], ["viremia", "DISEASE", 119, 126], ["patient", "ORGANISM", 26, 33], ["organs", "ORGAN", 145, 151], ["body", "ORGANISM_SUBDIVISION", 178, 182], ["fluids", "ORGANISM_SUBSTANCE", 183, 189], ["patient", "SPECIES", 26, 33], ["a detectable antibody reaction", "PROBLEM", 71, 101], ["a general viremia", "PROBLEM", 109, 126], ["very", "OBSERVATION_MODIFIER", 3, 7], ["severe", "OBSERVATION_MODIFIER", 8, 14], ["cases", "OBSERVATION", 15, 20], ["antibody reaction", "OBSERVATION", 84, 101], ["viremia", "OBSERVATION", 119, 126], ["most body", "OBSERVATION_MODIFIER", 173, 182]]], ["In less severe cases, the exact moment becomes an important issue since viremia only remains for just a few days (3-4 days) and often patient samples were taken too late for successful NAT thus requiring laborious serology testing with in-house assays and risk of false positive reactivity.", [["samples", "ANATOMY", 142, 149], ["viremia", "DISEASE", 72, 79], ["patient", "ORGANISM", 134, 141], ["patient", "SPECIES", 134, 141], ["viremia", "PROBLEM", 72, 79], ["laborious serology testing", "TEST", 204, 230], ["false positive reactivity", "PROBLEM", 264, 289], ["less", "OBSERVATION_MODIFIER", 3, 7], ["severe", "OBSERVATION_MODIFIER", 8, 14], ["cases", "OBSERVATION", 15, 20], ["viremia", "OBSERVATION", 72, 79], ["false", "OBSERVATION", 264, 269], ["positive reactivity", "OBSERVATION", 270, 289]]], ["Onset of disease is also not a well-defined point of time because the perception of a disease might be different in developing compared to developed countries.", [["disease", "PROBLEM", 9, 16], ["a disease", "PROBLEM", 84, 93], ["disease", "OBSERVATION", 9, 16], ["disease", "OBSERVATION", 86, 93], ["different", "OBSERVATION_MODIFIER", 103, 112]]], ["This makes the comparison of clinical symptoms and diagnostic findings during the course of the disease even more difficult.ConclusionsAlthough the analysis of different body fluids during the recent Ebola virus outbreak expands our knowledge of virus transmissibility via eye fluid and semen tremendously, systematic studies on which and for how long the different body fluids will contain viral RNA and/or infectious viruses are still missing.", [["body fluids", "ANATOMY", 170, 181], ["eye fluid", "ANATOMY", 273, 282], ["body fluids", "ANATOMY", 366, 377], ["Ebola virus", "DISEASE", 200, 211], ["body", "ORGANISM_SUBDIVISION", 170, 174], ["Ebola virus", "ORGANISM", 200, 211], ["eye fluid", "MULTI-TISSUE_STRUCTURE", 273, 282], ["semen", "ORGANISM_SUBSTANCE", 287, 292], ["body", "ORGANISM_SUBDIVISION", 366, 370], ["Ebola virus", "SPECIES", 200, 211], ["Ebola virus", "SPECIES", 200, 211], ["clinical symptoms", "PROBLEM", 29, 46], ["diagnostic findings", "TEST", 51, 70], ["the disease", "PROBLEM", 92, 103], ["the analysis", "TEST", 144, 156], ["different body fluids", "TREATMENT", 160, 181], ["the recent Ebola virus", "PROBLEM", 189, 211], ["virus transmissibility", "PROBLEM", 246, 268], ["eye fluid", "TEST", 273, 282], ["systematic studies", "TEST", 307, 325], ["the different body fluids", "TREATMENT", 352, 377], ["viral RNA", "PROBLEM", 391, 400], ["infectious viruses", "PROBLEM", 408, 426], ["viral RNA", "OBSERVATION", 391, 400], ["infectious", "OBSERVATION_MODIFIER", 408, 418]]], ["Recommendations on how non-invasive sampling should be performed, what kind of samples are necessary and how they should be stabilized and transported under African environmental conditions are still missing and require thoroughly investigations.ConclusionsFor WNV infections the use of urine is a suitable alternative diagnostic sample compared to serum and should be listed in fact sheets from national and international organizations.", [["samples", "ANATOMY", 79, 86], ["urine", "ANATOMY", 287, 292], ["serum", "ANATOMY", 349, 354], ["WNV infections", "DISEASE", 261, 275], ["samples", "CANCER", 79, 86], ["WNV", "ORGANISM", 261, 264], ["urine", "ORGANISM_SUBSTANCE", 287, 292], ["serum", "ORGANISM_SUBSTANCE", 349, 354], ["WNV", "SPECIES", 261, 264], ["non-invasive sampling", "TEST", 23, 44], ["thoroughly investigations", "TEST", 220, 245], ["WNV infections", "PROBLEM", 261, 275], ["serum", "TEST", 349, 354]]], ["Further studies are needed investigating if urine samples are a useful source for surveillance studies on WNV distribution and for analyzing the severity of the disease in patients with neuro-invasive and/or kidney manifestation.", [["urine samples", "ANATOMY", 44, 57], ["kidney", "ANATOMY", 208, 214], ["urine samples", "ORGANISM_SUBSTANCE", 44, 57], ["WNV", "ORGANISM", 106, 109], ["patients", "ORGANISM", 172, 180], ["kidney", "ORGAN", 208, 214], ["patients", "SPECIES", 172, 180], ["WNV", "SPECIES", 106, 109], ["Further studies", "TEST", 0, 15], ["urine samples", "TEST", 44, 57], ["surveillance studies", "TEST", 82, 102], ["WNV distribution", "TEST", 106, 122], ["the disease", "PROBLEM", 157, 168], ["neuro-invasive and/or kidney manifestation", "PROBLEM", 186, 228], ["disease", "OBSERVATION", 161, 168], ["kidney", "ANATOMY", 208, 214]]], ["The emergence of Zika virus tremendously stimulated the investigation of using non-invasive samples as saliva and urine for diagnostic of Zika virus infections.", [["samples", "ANATOMY", 92, 99], ["saliva", "ANATOMY", 103, 109], ["urine", "ANATOMY", 114, 119], ["Zika virus infections", "DISEASE", 138, 159], ["Zika virus", "ORGANISM", 17, 27], ["saliva", "ORGANISM_SUBSTANCE", 103, 109], ["urine", "ORGANISM_SUBSTANCE", 114, 119], ["Zika virus", "ORGANISM", 138, 148], ["Zika virus", "SPECIES", 17, 27], ["Zika virus", "SPECIES", 138, 148], ["Zika virus", "PROBLEM", 17, 27], ["non-invasive samples", "TEST", 79, 99], ["saliva and urine", "TEST", 103, 119], ["Zika virus infections", "PROBLEM", 138, 159]]], ["From the start of the Zika outbreak in French Polynesia saliva was considered as alternative material for the diagnostics.", [["saliva", "ORGANISM_SUBSTANCE", 56, 62], ["the diagnostics", "TEST", 106, 121]]], ["The investigation of urine and saliva shows a higher virus load compared to blood making these samples a suitable alternative to blood.", [["urine", "ANATOMY", 21, 26], ["blood", "ANATOMY", 76, 81], ["samples", "ANATOMY", 95, 102], ["blood", "ANATOMY", 129, 134], ["urine", "ORGANISM_SUBSTANCE", 21, 26], ["saliva", "ORGANISM_SUBSTANCE", 31, 37], ["blood", "ORGANISM_SUBSTANCE", 76, 81], ["blood", "ORGANISM_SUBSTANCE", 129, 134], ["The investigation of urine and saliva", "TEST", 0, 37], ["a higher virus load", "PROBLEM", 44, 63]]], ["However, this information has to be forwarded to the physicians as it is already part of the PAHO and WHO recommendations.ConclusionsFor YF diagnostic one can hope that the integration of saliva and urine as alternative samples into the recommendation worked out by the WHO for the recent outbreak will help to implement this method into the medical procedure and create some meaningful results for future outbreak scenarios.ConclusionsEven although SARS seems to have disappeared from the globe, the experience and findings on which and when the different diagnostic samples should be used for a quick and reliable diagnostic should be carefully evaluated, since respiratory infections are on the rise as we have seen a few years later by the influenza and MERS-CoV outbreaks.", [["urine", "ANATOMY", 199, 204], ["samples", "ANATOMY", 568, 575], ["respiratory", "ANATOMY", 664, 675], ["SARS", "DISEASE", 450, 454], ["respiratory infections", "DISEASE", 664, 686], ["influenza", "DISEASE", 744, 753], ["saliva", "ORGANISM_SUBSTANCE", 188, 194], ["urine", "ORGANISM_SUBSTANCE", 199, 204], ["MERS-CoV", "ORGANISM", 758, 766], ["MERS-CoV", "SPECIES", 758, 766], ["saliva and urine", "TEST", 188, 204], ["the medical procedure", "TREATMENT", 338, 359], ["SARS", "PROBLEM", 450, 454], ["respiratory infections", "PROBLEM", 664, 686], ["the influenza", "PROBLEM", 740, 753], ["globe", "ANATOMY", 490, 495], ["infections", "OBSERVATION", 676, 686]]], ["The great variety on which, how and when respiratory samples have to be taken is reflected by the list of nomenclature found in the publications: for upper respiratory specimens (nasal swab, exudate nose, oronasal swab, pharyngeal swab, tracheal swab, exudate mouth, saliva and sputum) and lower respiratory specimens (bronchoalveolar fluid, bronchoalveolar lavage).", [["respiratory samples", "ANATOMY", 41, 60], ["upper respiratory specimens", "ANATOMY", 150, 177], ["nasal swab", "ANATOMY", 179, 189], ["exudate nose", "ANATOMY", 191, 203], ["oronasal swab", "ANATOMY", 205, 218], ["pharyngeal swab", "ANATOMY", 220, 235], ["tracheal swab", "ANATOMY", 237, 250], ["exudate mouth", "ANATOMY", 252, 265], ["saliva", "ANATOMY", 267, 273], ["sputum", "ANATOMY", 278, 284], ["lower respiratory specimens", "ANATOMY", 290, 317], ["bronchoalveolar fluid", "ANATOMY", 319, 340], ["bronchoalveolar lavage", "ANATOMY", 342, 364], ["nasal swab", "MULTI-TISSUE_STRUCTURE", 179, 189], ["exudate nose", "MULTI-TISSUE_STRUCTURE", 191, 203], ["oronasal swab", "MULTI-TISSUE_STRUCTURE", 205, 218], ["pharyngeal swab", "MULTI-TISSUE_STRUCTURE", 220, 235], ["tracheal swab", "MULTI-TISSUE_STRUCTURE", 237, 250], ["exudate mouth", "MULTI-TISSUE_STRUCTURE", 252, 265], ["saliva", "ORGANISM_SUBSTANCE", 267, 273], ["bronchoalveolar fluid", "MULTI-TISSUE_STRUCTURE", 319, 340], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 342, 364], ["respiratory samples", "TEST", 41, 60], ["upper respiratory specimens", "TEST", 150, 177], ["nasal swab", "TEST", 179, 189], ["exudate nose", "TEST", 191, 203], ["oronasal swab", "TEST", 205, 218], ["pharyngeal swab", "TEST", 220, 235], ["tracheal swab, exudate mouth, saliva and sputum", "TEST", 237, 284], ["lower respiratory specimens", "TEST", 290, 317], ["bronchoalveolar fluid", "TEST", 319, 340], ["bronchoalveolar lavage", "TEST", 342, 364], ["great", "OBSERVATION_MODIFIER", 4, 9], ["variety", "OBSERVATION_MODIFIER", 10, 17], ["nasal", "ANATOMY", 179, 184], ["pharyngeal", "ANATOMY", 220, 230], ["tracheal", "ANATOMY", 237, 245], ["lower respiratory", "ANATOMY", 290, 307], ["bronchoalveolar fluid", "OBSERVATION", 319, 340], ["bronchoalveolar lavage", "OBSERVATION", 342, 364]]], ["Recommendations for standardized procedures for sampling and handling of the respiratory samples will help to allow a better comparison of the findings and provide a better preparedness for the next respiratory disease outbreak.ConclusionsBecause of a higher virus load, samples from the lower respiratory tract are more suitable for diagnostic.", [["respiratory samples", "ANATOMY", 77, 96], ["respiratory", "ANATOMY", 199, 210], ["samples", "ANATOMY", 271, 278], ["lower respiratory tract", "ANATOMY", 288, 311], ["respiratory disease", "DISEASE", 199, 218], ["lower", "ORGANISM_SUBDIVISION", 288, 293], ["respiratory tract", "ORGANISM_SUBDIVISION", 294, 311], ["standardized procedures", "TREATMENT", 20, 43], ["sampling", "TEST", 48, 56], ["the respiratory samples", "TEST", 73, 96], ["the next respiratory disease outbreak", "PROBLEM", 190, 227], ["a higher virus load", "PROBLEM", 250, 269], ["samples from the lower respiratory tract", "TEST", 271, 311], ["virus load", "OBSERVATION", 259, 269], ["lower", "ANATOMY_MODIFIER", 288, 293], ["respiratory tract", "ANATOMY", 294, 311]]], ["However, the sampling of bronchoalveolar-lavage fluid is also invasive and requires an experienced physician and holds a certain risk of nosocomial infections by aerosols.", [["bronchoalveolar-lavage fluid", "ANATOMY", 25, 53], ["infections", "DISEASE", 148, 158], ["the sampling of bronchoalveolar-lavage fluid", "TEST", 9, 53], ["nosocomial infections", "PROBLEM", 137, 158], ["bronchoalveolar", "ANATOMY", 25, 40], ["lavage fluid", "OBSERVATION", 41, 53], ["nosocomial", "OBSERVATION_MODIFIER", 137, 147], ["infections", "OBSERVATION", 148, 158]]], ["Other non-invasive samples like urine, nasal, pharyngeal, tracheal and rectal swabs were included in the diagnostic analysis for analyzing the pathogenesis and the kinetic of virus release by the different body fluids.", [["samples", "ANATOMY", 19, 26], ["urine", "ANATOMY", 32, 37], ["nasal", "ANATOMY", 39, 44], ["pharyngeal", "ANATOMY", 46, 56], ["tracheal", "ANATOMY", 58, 66], ["rectal swabs", "ANATOMY", 71, 83], ["body fluids", "ANATOMY", 206, 217], ["urine", "ORGANISM_SUBSTANCE", 32, 37], ["nasal", "ORGANISM_SUBDIVISION", 39, 44], ["pharyngeal", "ORGANISM_SUBDIVISION", 46, 56], ["tracheal", "MULTI-TISSUE_STRUCTURE", 58, 66], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 71, 83], ["body", "ORGANISM_SUBDIVISION", 206, 210], ["Other non-invasive samples", "TEST", 0, 26], ["urine, nasal, pharyngeal, tracheal and rectal swabs", "TEST", 32, 83], ["the diagnostic analysis", "TEST", 101, 124], ["the pathogenesis", "PROBLEM", 139, 155], ["virus release", "TREATMENT", 175, 188], ["urine", "OBSERVATION", 32, 37], ["nasal", "ANATOMY", 39, 44], ["pharyngeal", "ANATOMY", 46, 56], ["tracheal", "ANATOMY", 58, 66], ["rectal", "ANATOMY", 71, 77]]], ["Like for SARS standardized procedures for sampling and handling of the respiratory samples will help to allow a better comparison of the findings and provide a better preparedness for future respiratory disease outbreak.ConclusionsThe present review clearly shows that there is still the need to perform more diligent studies analyzing non-invasive patient samples in comparison with blood and serum samples, which used for routine diagnostic of emerging viral diseases.", [["respiratory samples", "ANATOMY", 71, 90], ["samples", "ANATOMY", 357, 364], ["blood", "ANATOMY", 384, 389], ["serum samples", "ANATOMY", 394, 407], ["SARS", "DISEASE", 9, 13], ["respiratory disease", "DISEASE", 191, 210], ["viral diseases", "DISEASE", 455, 469], ["patient", "ORGANISM", 349, 356], ["blood", "ORGANISM_SUBSTANCE", 384, 389], ["serum samples", "ORGANISM_SUBSTANCE", 394, 407], ["patient", "SPECIES", 349, 356], ["SARS standardized procedures", "TREATMENT", 9, 37], ["sampling", "TREATMENT", 42, 50], ["future respiratory disease outbreak", "PROBLEM", 184, 219], ["diligent studies", "TEST", 309, 325], ["blood and serum samples", "TEST", 384, 407], ["emerging viral diseases", "PROBLEM", 446, 469], ["viral diseases", "OBSERVATION", 455, 469]]], ["While for some diseases like the respiratory infections, the sampling of nasal swaps and saliva is part of routine sampling, for other viral infections, blood or serum seems the predominant and only type of sample used for laboratory diagnosis.", [["respiratory", "ANATOMY", 33, 44], ["nasal", "ANATOMY", 73, 78], ["blood", "ANATOMY", 153, 158], ["serum", "ANATOMY", 162, 167], ["sample", "ANATOMY", 207, 213], ["respiratory infections", "DISEASE", 33, 55], ["viral infections", "DISEASE", 135, 151], ["nasal swaps", "MULTI-TISSUE_STRUCTURE", 73, 84], ["saliva", "ORGANISM_SUBSTANCE", 89, 95], ["blood", "ORGANISM_SUBSTANCE", 153, 158], ["serum", "ORGANISM_SUBSTANCE", 162, 167], ["some diseases", "PROBLEM", 10, 23], ["the respiratory infections", "PROBLEM", 29, 55], ["nasal swaps", "TREATMENT", 73, 84], ["routine sampling", "TEST", 107, 123], ["other viral infections", "PROBLEM", 129, 151], ["blood or serum", "TEST", 153, 167], ["laboratory diagnosis", "TEST", 223, 243], ["respiratory", "ANATOMY", 33, 44], ["infections", "OBSERVATION", 45, 55], ["nasal", "ANATOMY", 73, 78], ["infections", "OBSERVATION", 141, 151]]], ["This is in particular disappointing because non-invasive sampling offers a real alternative avoiding additional risk for the patient and the medical personal.", [["patient", "ORGANISM", 125, 132], ["patient", "SPECIES", 125, 132], ["non-invasive sampling", "TEST", 44, 65]]], ["Patients suspected to be infected by VHF usually have a very high virus load.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["VHF", "PROBLEM", 37, 40], ["a very high virus load", "PROBLEM", 54, 76], ["suspected to be", "UNCERTAINTY", 9, 24], ["infected", "OBSERVATION", 25, 33]]], ["Therefore, the analysis of saliva or urine should be routinely performed in parallel to investigation of blood samples.", [["saliva", "ANATOMY", 27, 33], ["urine", "ANATOMY", 37, 42], ["blood samples", "ANATOMY", 105, 118], ["saliva", "ORGANISM_SUBSTANCE", 27, 33], ["urine", "ORGANISM_SUBSTANCE", 37, 42], ["blood samples", "ORGANISM_SUBSTANCE", 105, 118], ["the analysis of saliva or urine", "TEST", 11, 42], ["blood samples", "TEST", 105, 118]]], ["Based on a solid database it will be possible to determine the most appropriate sample for a viral diagnosis before it gets implemented in the routine diagnostic procedure.", [["a solid database", "TEST", 9, 25], ["the routine diagnostic procedure", "TREATMENT", 139, 171]]], ["Diagnostic laboratories and physicians have to gain knowledge when and how alternative samples have to be considered for analyzing an acute or convalescent viral infection.", [["samples", "ANATOMY", 87, 94], ["viral infection", "DISEASE", 156, 171], ["samples", "CANCER", 87, 94], ["Diagnostic laboratories", "TEST", 0, 23], ["an acute or convalescent viral infection", "PROBLEM", 131, 171], ["acute", "OBSERVATION_MODIFIER", 134, 139], ["convalescent", "OBSERVATION_MODIFIER", 143, 155], ["viral", "OBSERVATION_MODIFIER", 156, 161], ["infection", "OBSERVATION", 162, 171]]], ["Even though, we have with NAT a very sensitive diagnostic tool, the best point in time during the course of the disease together with the optimal sampling, sample storage and sample preparation are essential to get optimal results for a laboratory diagnosis.", [["sample", "ANATOMY", 175, 181], ["the disease", "PROBLEM", 108, 119], ["sample storage", "TEST", 156, 170], ["sample preparation", "TEST", 175, 193], ["a laboratory diagnosis", "TEST", 235, 257]]], ["In patients presenting with a moderate or mild disease, the viremia is mostly very short lasting just 1-3 days.", [["viremia", "DISEASE", 60, 67], ["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["a moderate or mild disease", "PROBLEM", 28, 54], ["the viremia", "PROBLEM", 56, 67], ["moderate", "OBSERVATION_MODIFIER", 30, 38], ["mild", "OBSERVATION_MODIFIER", 42, 46], ["disease", "OBSERVATION", 47, 54], ["viremia", "OBSERVATION", 60, 67], ["mostly", "OBSERVATION_MODIFIER", 71, 77], ["very", "OBSERVATION_MODIFIER", 78, 82], ["short", "OBSERVATION_MODIFIER", 83, 88]]], ["For these patients the positive NAT is sometimes difficult to achieve and a negative finding is of no predictive value since the virus titer might be just below the detection limit or sample storage and sample preparation is not optimal in case of non-invasive sampling such as saliva and urine.", [["sample", "ANATOMY", 203, 209], ["saliva", "ANATOMY", 278, 284], ["urine", "ANATOMY", 289, 294], ["patients", "ORGANISM", 10, 18], ["saliva", "ORGANISM_SUBSTANCE", 278, 284], ["urine", "ORGANISM_SUBSTANCE", 289, 294], ["patients", "SPECIES", 10, 18], ["the virus titer", "PROBLEM", 125, 140], ["sample storage", "TEST", 184, 198], ["sample preparation", "TEST", 203, 221], ["non-invasive sampling", "TEST", 248, 269], ["saliva and urine", "TEST", 278, 294]]], ["Although the virus disappeared from the blood, the virus genome will be still detectable in the urine as consequence of the clearance process as we have found in Yellow Fever vaccinees or other for Zika [97, 104] .", [["blood", "ANATOMY", 40, 45], ["urine", "ANATOMY", 96, 101], ["Fever", "DISEASE", 169, 174], ["blood", "ORGANISM_SUBSTANCE", 40, 45], ["urine", "ORGANISM_SUBSTANCE", 96, 101], ["virus genome", "DNA", 51, 63], ["the virus", "PROBLEM", 9, 18], ["the blood", "TEST", 36, 45], ["the virus genome", "PROBLEM", 47, 63], ["the urine", "TEST", 92, 101], ["the clearance process", "PROBLEM", 120, 141], ["Yellow Fever vaccinees", "PROBLEM", 162, 184], ["Zika", "PROBLEM", 198, 202], ["virus", "OBSERVATION", 13, 18], ["blood", "ANATOMY", 40, 45], ["virus genome", "OBSERVATION", 51, 63]]], ["In contrast, we find a high viral load in patients developing a severe disease sometimes with a general infection affecting several organs.", [["organs", "ANATOMY", 132, 138], ["infection", "DISEASE", 104, 113], ["patients", "ORGANISM", 42, 50], ["organs", "ORGAN", 132, 138], ["patients", "SPECIES", 42, 50], ["a high viral load", "PROBLEM", 21, 38], ["a severe disease", "PROBLEM", 62, 78], ["a general infection", "PROBLEM", 94, 113], ["high", "OBSERVATION_MODIFIER", 23, 27], ["viral load", "OBSERVATION", 28, 38], ["severe", "OBSERVATION_MODIFIER", 64, 70], ["disease", "OBSERVATION", 71, 78], ["infection", "OBSERVATION", 104, 113]]], ["In particular in those patients, the detection of the pathogenic virus by NAT is not difficult analyzing different types of samples.", [["samples", "ANATOMY", 124, 131], ["patients", "ORGANISM", 23, 31], ["samples", "CANCER", 124, 131], ["patients", "SPECIES", 23, 31], ["the pathogenic virus", "PROBLEM", 50, 70], ["pathogenic virus", "OBSERVATION", 54, 70]]], ["Very often the viral load also reflects the severity of the disease and can be used as prognostic marker for progression of the disease in the patient.", [["patient", "ORGANISM", 143, 150], ["patient", "SPECIES", 143, 150], ["Very often the viral load", "PROBLEM", 0, 25], ["the disease", "PROBLEM", 56, 67], ["prognostic marker", "TEST", 87, 104], ["the disease", "PROBLEM", 124, 135], ["viral load", "OBSERVATION", 15, 25], ["disease", "OBSERVATION", 60, 67], ["disease", "OBSERVATION", 128, 135]]], ["Exactly for these patients the non-invasive sampling is less stressful as frequent bleeding performed with the current procedure.", [["bleeding", "DISEASE", 83, 91], ["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["the non-invasive sampling", "TEST", 27, 52], ["frequent bleeding", "PROBLEM", 74, 91], ["the current procedure", "TREATMENT", 107, 128]]], ["This becomes even more important, if point of care diagnostic allows a more frequent monitoring of infection parameters of the diseased patient in the future.", [["infection", "DISEASE", 99, 108], ["patient", "ORGANISM", 136, 143], ["patient", "SPECIES", 136, 143], ["infection parameters", "PROBLEM", 99, 119], ["diseased", "OBSERVATION", 127, 135]]], ["For the recently emerging CHIK and Zika in South America, the analysis of throat swaps, saliva and urine samples were already analyzed for their usability in diagnostics.", [["throat", "ANATOMY", 74, 80], ["saliva", "ANATOMY", 88, 94], ["urine samples", "ANATOMY", 99, 112], ["throat", "ORGANISM_SUBDIVISION", 74, 80], ["saliva", "ORGANISM_SUBSTANCE", 88, 94], ["urine samples", "ORGANISM_SUBSTANCE", 99, 112], ["the analysis", "TEST", 58, 70], ["throat swaps", "TEST", 74, 86], ["saliva and urine samples", "TEST", 88, 112], ["CHIK", "OBSERVATION", 26, 30], ["throat", "ANATOMY", 74, 80]]], ["However, the findings are based on case studies or small studies and require a more systematic approach.", [["case studies", "TEST", 35, 47], ["small studies", "TEST", 51, 64], ["a more systematic approach", "TREATMENT", 77, 103]]], ["Preferably there should be performed a systematic analysis of different invasive samples (blood, bronchoalveolar lavage) and non-invasive samples (saliva, urine, etc.) for their diagnostic value using different diagnostic methods for patients with acute and convalescent disease when new infections emerge.", [["samples", "ANATOMY", 81, 88], ["blood", "ANATOMY", 90, 95], ["bronchoalveolar lavage", "ANATOMY", 97, 119], ["samples", "ANATOMY", 138, 145], ["saliva", "ANATOMY", 147, 153], ["urine", "ANATOMY", 155, 160], ["infections", "DISEASE", 288, 298], ["blood", "ORGANISM_SUBSTANCE", 90, 95], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 97, 119], ["saliva", "ORGANISM_SUBSTANCE", 147, 153], ["urine", "ORGANISM_SUBSTANCE", 155, 160], ["patients", "ORGANISM", 234, 242], ["patients", "SPECIES", 234, 242], ["a systematic analysis", "TEST", 37, 58], ["bronchoalveolar lavage", "TEST", 97, 119], ["non-invasive samples (saliva, urine", "TEST", 125, 160], ["their diagnostic value", "TEST", 172, 194], ["acute and convalescent disease", "PROBLEM", 248, 278], ["new infections emerge", "PROBLEM", 284, 305], ["infections", "OBSERVATION", 288, 298]]], ["This also implies that the procedure taking samples has to be somehow standardized.", [["the procedure", "TREATMENT", 23, 36]]], ["This became very obvious by the large number of terms for upper and lower respiratory samples most likely reflecting the great variety how the samples were taken.", [["respiratory samples", "ANATOMY", 74, 93], ["samples", "ANATOMY", 143, 150], ["upper", "ORGANISM_SUBDIVISION", 58, 63], ["samples", "CANCER", 143, 150], ["upper and lower respiratory samples", "PROBLEM", 58, 93], ["large", "OBSERVATION_MODIFIER", 32, 37], ["upper", "ANATOMY_MODIFIER", 58, 63], ["lower", "ANATOMY_MODIFIER", 68, 73], ["respiratory", "ANATOMY", 74, 85]]], ["This makes the comparability of diagnostic findings presented in different studies very difficult.", [["diagnostic findings", "TEST", 32, 51], ["different studies", "TEST", 65, 82]]], ["To address this problem a clear recommendation for the sampling procedure would help to overcome this imponderability.", [["the sampling procedure", "TREATMENT", 51, 73]]], ["Furthermore, the methods for storage of the samples regarding temperature and stabilization needs to be worked out to allow an optimal transport and preparation of the diagnostic sample.", [["the samples", "TEST", 40, 51], ["stabilization", "TREATMENT", 78, 91], ["the diagnostic sample", "TEST", 164, 185]]], ["For example there are special sampling tubes with stabilizer available for both saliva (DNAgard Saliva by biomatrica, USA) and urine (VACUETTE Urine CCM tubes by Greiner Bio-One, Germany and Urine Monovette by Sarstedt, Germany), which will help preserves the integrity of sample at room temperature.", [["urine", "ANATOMY", 127, 132], ["saliva", "ORGANISM_SUBSTANCE", 80, 86], ["urine", "ORGANISM_SUBSTANCE", 127, 132], ["special sampling tubes", "TREATMENT", 22, 44], ["stabilizer", "TREATMENT", 50, 60], ["urine", "TEST", 127, 132], ["VACUETTE Urine CCM tubes", "TREATMENT", 134, 158]]], ["Sample preparation from urine and saliva could be also challenging especially for molecular diagnostics, therefore it is very important to optimize protocols using clinical samples rather than spiked mock-samples.", [["urine", "ANATOMY", 24, 29], ["samples", "ANATOMY", 173, 180], ["samples", "ANATOMY", 205, 212], ["urine", "ORGANISM_SUBSTANCE", 24, 29], ["saliva", "ORGANISM_SUBSTANCE", 34, 40], ["Sample preparation from urine", "TEST", 0, 29], ["saliva", "TREATMENT", 34, 40], ["molecular diagnostics", "TEST", 82, 103], ["clinical samples", "TEST", 164, 180]]], ["Our personal experience showed that the optimized sample preparation method on real clinical samples was not as efficient as on spiked mock samples.ConclusionsThe increasing number of publications considering alternative sampling for diagnostic of the recent outbreaks MERS-CoV, CHIK, Ebola and Zika are promising.", [["sample", "ANATOMY", 50, 56], ["samples", "ANATOMY", 93, 100], ["samples", "ANATOMY", 140, 147], ["Ebola", "DISEASE", 285, 290], ["Zika", "DISEASE", 295, 299], ["MERS-CoV", "ORGANISM", 269, 277], ["Ebola", "ORGANISM", 285, 290], ["MERS-CoV", "SPECIES", 269, 277], ["spiked mock samples", "TEST", 128, 147], ["alternative sampling", "TREATMENT", 209, 229], ["CHIK", "PROBLEM", 279, 283], ["Ebola", "PROBLEM", 285, 290], ["Zika", "PROBLEM", 295, 299], ["increasing", "OBSERVATION_MODIFIER", 163, 173], ["number", "OBSERVATION_MODIFIER", 174, 180]]], ["However, systematic studies are rare and for some infectious disease outbreaks like the recent yellow fever in Angola, non-invasive samples for diagnostic are still uncommon and require further investigation.", [["samples", "ANATOMY", 132, 139], ["yellow fever", "DISEASE", 95, 107], ["samples", "CANCER", 132, 139], ["systematic studies", "TEST", 9, 27], ["some infectious disease outbreaks", "PROBLEM", 45, 78], ["the recent yellow fever", "PROBLEM", 84, 107], ["non-invasive samples", "TEST", 119, 139], ["further investigation", "TEST", 186, 207]]], ["Just for diseases like yellow fever, non-invasive samples like urine or saliva might be a very practical alternative, since the first index patients are detected often very late, while blood will be negative by NAT in patients with mild disease and from patients with a severe disease it is difficult taking blood because of a hemorrhage clinical picture.", [["samples", "ANATOMY", 50, 57], ["urine", "ANATOMY", 63, 68], ["blood", "ANATOMY", 185, 190], ["blood", "ANATOMY", 308, 313], ["yellow fever", "DISEASE", 23, 35], ["hemorrhage", "DISEASE", 327, 337], ["urine", "ORGANISM_SUBSTANCE", 63, 68], ["saliva", "ORGANISM_SUBSTANCE", 72, 78], ["patients", "ORGANISM", 140, 148], ["blood", "ORGANISM_SUBSTANCE", 185, 190], ["patients", "ORGANISM", 218, 226], ["patients", "ORGANISM", 254, 262], ["blood", "ORGANISM_SUBSTANCE", 308, 313], ["patients", "SPECIES", 140, 148], ["patients", "SPECIES", 218, 226], ["patients", "SPECIES", 254, 262], ["diseases", "PROBLEM", 9, 17], ["yellow fever", "PROBLEM", 23, 35], ["non-invasive samples like urine or saliva", "PROBLEM", 37, 78], ["blood", "TEST", 185, 190], ["mild disease", "PROBLEM", 232, 244], ["a severe disease", "PROBLEM", 268, 284], ["a hemorrhage clinical picture", "PROBLEM", 325, 354], ["mild", "OBSERVATION_MODIFIER", 232, 236], ["disease", "OBSERVATION", 237, 244], ["severe", "OBSERVATION_MODIFIER", 270, 276], ["disease", "OBSERVATION", 277, 284], ["hemorrhage", "OBSERVATION", 327, 337]]], ["Non-invasive samples might be also a great alternative for investigations of children or other patients were collection of blood samples is difficult [18, 30, 88] .", [["samples", "ANATOMY", 13, 20], ["blood samples", "ANATOMY", 123, 136], ["children", "ORGANISM", 77, 85], ["patients", "ORGANISM", 95, 103], ["blood samples", "ORGANISM_SUBSTANCE", 123, 136], ["children", "SPECIES", 77, 85], ["patients", "SPECIES", 95, 103], ["Non-invasive samples", "TEST", 0, 20], ["blood samples", "TEST", 123, 136]]], ["Also for large surveillance studies, non-invasive samples like saliva and/or urine could be performed without medical personal for collecting blood.", [["samples", "ANATOMY", 50, 57], ["saliva", "ANATOMY", 63, 69], ["urine", "ANATOMY", 77, 82], ["blood", "ANATOMY", 142, 147], ["saliva", "ORGANISM_SUBSTANCE", 63, 69], ["urine", "ORGANISM_SUBSTANCE", 77, 82], ["blood", "ORGANISM_SUBSTANCE", 142, 147], ["large surveillance studies", "TEST", 9, 35], ["non-invasive samples", "TEST", 37, 57], ["saliva and/or urine", "TEST", 63, 82], ["collecting blood", "TEST", 131, 147]]], ["However, the usability of these samples for serology or NAT has to be evaluated in comparison to conventional use of sera.", [["samples", "ANATOMY", 32, 39], ["sera", "ANATOMY", 117, 121], ["samples", "CANCER", 32, 39], ["sera", "ORGANISM_SUBSTANCE", 117, 121], ["these samples", "TEST", 26, 39], ["serology", "TEST", 44, 52]]], ["Therefore, it is necessary to introduce non-invasive sampling strategies in recommendations as done for the \"Yellow Fever Laboratory Diagnostic Algorithm\" worked out for the epidemic and non-epidemic countries in Africa during the YF outbreak in Angola by WHO expert team [135] .", [["Fever", "DISEASE", 116, 121], ["YF", "DISEASE", 231, 233], ["non-invasive sampling strategies", "TREATMENT", 40, 72], ["the \"Yellow Fever", "PROBLEM", 104, 121]]], ["Since these investigations could be only performed during an outbreak situation the preparation of a scheme for evaluation of sampling for respiratory as well as for other infectious diseases including the further processing for laboratory diagnostic is highly recommended.", [["respiratory", "ANATOMY", 139, 150], ["infectious diseases", "DISEASE", 172, 191], ["these investigations", "TEST", 6, 26], ["evaluation", "TEST", 112, 122], ["sampling", "TEST", 126, 134], ["other infectious diseases", "PROBLEM", 166, 191], ["laboratory diagnostic", "TEST", 229, 250]]], ["This more structured approach will help to improve the diagnostic of emerging infectious diseases significantly as new diagnostic methods and platforms are developed continuously and require effective evaluation under real conditions.ConclusionsFor confirmation of a clinical diagnosis a correct laboratory diagnosis is essential for all further steps of patient's treatment and handling.", [["infectious diseases", "DISEASE", 78, 97], ["patient", "ORGANISM", 355, 362], ["patient", "SPECIES", 355, 362], ["emerging infectious diseases", "PROBLEM", 69, 97], ["new diagnostic methods", "TEST", 115, 137], ["effective evaluation", "TEST", 191, 211], ["patient's treatment", "TREATMENT", 355, 374], ["infectious", "OBSERVATION", 78, 88]]], ["In particular for new and/or emerging diseases, the conditions for the best sampling regarding time and source (blood, serum, saliva, urine, etc.) are often not known.", [["blood", "ANATOMY", 112, 117], ["serum", "ANATOMY", 119, 124], ["saliva", "ANATOMY", 126, 132], ["urine", "ANATOMY", 134, 139], ["blood", "ORGANISM_SUBSTANCE", 112, 117], ["serum", "ORGANISM_SUBSTANCE", 119, 124], ["saliva", "ORGANISM_SUBSTANCE", 126, 132], ["urine", "ORGANISM_SUBSTANCE", 134, 139], ["emerging diseases", "PROBLEM", 29, 46], ["blood, serum, saliva, urine", "TEST", 112, 139], ["new", "OBSERVATION_MODIFIER", 18, 21]]], ["Since every disease has its own course of symptoms and affected organs, the optimal sampling schema might change and require different strategies regarding sample preparation and processing.", [["organs", "ANATOMY", 64, 70], ["sample", "ANATOMY", 156, 162], ["organs", "ORGAN", 64, 70], ["symptoms", "PROBLEM", 42, 50], ["affected organs", "PROBLEM", 55, 70], ["the optimal sampling schema", "PROBLEM", 72, 99], ["different strategies", "TREATMENT", 125, 145], ["sample preparation", "TREATMENT", 156, 174], ["organs", "ANATOMY", 64, 70]]], ["While in the early phase when disease symptoms appear often the viral pathogen could be detected by nucleic acid testing in blood or other body fluids in the later phase only antibodies are detectable in serum.ConclusionsIn the present article, we analyzed over 700 scientific publications on diagnostic approaches for dengue, West Nile, SARS, chikungunya, MERS-CoV, Ebola, Zika and Yellow Fever regarding their relevance for using alternative samples like saliva and urine for their versatility for virus diagnostic.", [["blood", "ANATOMY", 124, 129], ["body fluids", "ANATOMY", 139, 150], ["serum", "ANATOMY", 204, 209], ["samples", "ANATOMY", 444, 451], ["saliva", "ANATOMY", 457, 463], ["urine", "ANATOMY", 468, 473], ["nucleic acid", "CHEMICAL", 100, 112], ["dengue", "DISEASE", 319, 325], ["SARS", "DISEASE", 338, 342], ["chikungunya", "DISEASE", 344, 355], ["Ebola", "DISEASE", 367, 372], ["Fever", "DISEASE", 390, 395], ["blood", "ORGANISM_SUBSTANCE", 124, 129], ["body", "ORGANISM_SUBDIVISION", 139, 143], ["serum", "ORGANISM_SUBSTANCE", 204, 209], ["MERS-CoV", "ORGANISM", 357, 365], ["Ebola", "ORGANISM", 367, 372], ["saliva", "ORGANISM_SUBSTANCE", 457, 463], ["urine", "ORGANISM_SUBSTANCE", 468, 473], ["antibodies", "PROTEIN", 175, 185], ["Ebola", "SPECIES", 367, 372], ["MERS-CoV", "SPECIES", 357, 365], ["disease symptoms", "PROBLEM", 30, 46], ["the viral pathogen", "PROBLEM", 60, 78], ["nucleic acid testing", "TEST", 100, 120], ["other body fluids", "TEST", 133, 150], ["diagnostic approaches", "TEST", 293, 314], ["dengue", "PROBLEM", 319, 325], ["SARS", "PROBLEM", 338, 342], ["chikungunya", "PROBLEM", 344, 355], ["Ebola", "PROBLEM", 367, 372], ["Zika", "PROBLEM", 374, 378], ["Yellow Fever", "PROBLEM", 383, 395], ["alternative samples", "TREATMENT", 432, 451], ["saliva and urine", "TEST", 457, 473], ["virus diagnostic", "PROBLEM", 500, 516]]], ["The use of non-invasive samples offers a suitable alternative for improving the diagnostic performance and significantly reduces the risk for medical personal and patients for routine diagnostic and during an outbreak situation.", [["samples", "ANATOMY", 24, 31], ["patients", "ORGANISM", 163, 171], ["patients", "SPECIES", 163, 171], ["non-invasive samples", "TEST", 11, 31], ["routine diagnostic", "TEST", 176, 194]]], ["The advantage of using non-invasive samples for the diagnostic has to be seriously analyzed and investigated before implementing in the routine diagnostics.Additional fileAdditional file 1: Figure S1 .", [["samples", "ANATOMY", 36, 43], ["non-invasive samples", "TEST", 23, 43], ["the routine diagnostics", "TEST", 132, 155]]], ["Abbreviation: CHIV = Chikungunya Virus, VHF = Viral Hemorrhagic Fever, WN = West Nile, YF = Yellow fever.", [["Chikungunya Virus", "DISEASE", 21, 38], ["Viral Hemorrhagic Fever", "DISEASE", 46, 69], ["WN = West Nile", "DISEASE", 71, 85], ["YF", "DISEASE", 87, 89], ["Yellow fever", "DISEASE", 92, 104], ["Chikungunya Virus", "ORGANISM", 21, 38], ["Chikungunya Virus, VHF = Viral Hemorrhagic Fever, WN = West Nile, YF = Yellow fever", "SPECIES", 21, 104], ["CHIV", "PROBLEM", 14, 18], ["Chikungunya Virus", "PROBLEM", 21, 38], ["VHF", "PROBLEM", 40, 43], ["Viral Hemorrhagic Fever", "PROBLEM", 46, 69], ["Yellow fever", "PROBLEM", 92, 104], ["Viral", "OBSERVATION_MODIFIER", 46, 51], ["Hemorrhagic", "OBSERVATION_MODIFIER", 52, 63], ["Fever", "OBSERVATION", 64, 69], ["Yellow", "OBSERVATION_MODIFIER", 92, 98], ["fever", "OBSERVATION", 99, 104]]], ["Availability of data and materials All publications evaluated for the analysis are provided in the supplement part of the manuscript.Additional fileAuthors' contributions MN, PP, AA, SY made substantial contributions to conception and design, or acquisition of data, and analysis and interpretation of data.", [["AA", "CHEMICAL", 179, 181], ["the analysis", "TEST", 66, 78], ["PP", "TEST", 175, 177], ["acquisition of data", "TEST", 246, 265], ["analysis", "TEST", 271, 279], ["interpretation of data", "TEST", 284, 306]]], ["MN, PP, AA, RS are involved in drafting the manuscript or revising it critically for important intellectual content.", [["AA", "CHEMICAL", 8, 10]]], ["All authors (MN, PP, AA, RS, SY) have participated sufficiently in the work and given final approval of the version to be published.", [["the version", "TREATMENT", 104, 115]]]], "0129fd3130ef50c5b2a994944c7bb4e8df7fce8a": [["Introduction. -Du fait du probl\u00e8me de sant\u00e9 publique que constitue la polym\u00e9dication chez la personne \u00e2g\u00e9e (PA) l'union r\u00e9gionale des m\u00e9decins lib\u00e9raux et l'union r\u00e9gionale des caisses d'assurance maladie du Languedoc-Roussillon ont mis en place un programme de sensibilisation des m\u00e9decins.", [["l'union r\u00e9gionale des", "TREATMENT", 112, 133]]]], "PMC7475719": [["COVID-19 patients and pulmonary surfactantSARS-CoV-2 enters and replicates in the alveolar type II cells impacting the production and turnover of pulmonary surfactants.", [["pulmonary", "ANATOMY", 22, 31], ["alveolar type II cells", "ANATOMY", 82, 104], ["pulmonary", "ANATOMY", 146, 155], ["patients", "ORGANISM", 9, 17], ["pulmonary", "ORGAN", 22, 31], ["CoV-2", "GENE_OR_GENE_PRODUCT", 47, 52], ["alveolar type II cells", "CELL", 82, 104], ["pulmonary", "ORGAN", 146, 155], ["alveolar type II cells", "CELL_TYPE", 82, 104], ["patients", "SPECIES", 9, 17], ["COVID", "TEST", 0, 5], ["pulmonary surfactantSARS", "TEST", 22, 46], ["CoV", "TEST", 47, 50], ["pulmonary surfactants", "TREATMENT", 146, 167], ["pulmonary", "ANATOMY", 22, 31], ["alveolar", "ANATOMY", 82, 90], ["pulmonary", "ANATOMY", 146, 155], ["surfactants", "OBSERVATION", 156, 167]]], ["This results in alveolar collapse and inflammation leading to increased capillary permeability, edema, and microvascular thrombosis; where the associated ARDS clinical picture closely resembles NRDS.", [["alveolar", "ANATOMY", 16, 24], ["capillary", "ANATOMY", 72, 81], ["edema", "ANATOMY", 96, 101], ["microvascular", "ANATOMY", 107, 120], ["inflammation", "DISEASE", 38, 50], ["edema", "DISEASE", 96, 101], ["microvascular thrombosis", "DISEASE", 107, 131], ["ARDS", "DISEASE", 154, 158], ["alveolar", "MULTI-TISSUE_STRUCTURE", 16, 24], ["capillary", "TISSUE", 72, 81], ["edema", "PATHOLOGICAL_FORMATION", 96, 101], ["microvascular", "TISSUE", 107, 120], ["alveolar collapse", "PROBLEM", 16, 33], ["inflammation", "PROBLEM", 38, 50], ["increased capillary permeability", "PROBLEM", 62, 94], ["edema", "PROBLEM", 96, 101], ["microvascular thrombosis", "PROBLEM", 107, 131], ["the associated ARDS clinical picture", "PROBLEM", 139, 175], ["NRDS", "PROBLEM", 194, 198], ["alveolar", "ANATOMY", 16, 24], ["collapse", "OBSERVATION", 25, 33], ["inflammation", "OBSERVATION", 38, 50], ["increased", "OBSERVATION_MODIFIER", 62, 71], ["capillary permeability", "OBSERVATION", 72, 94], ["edema", "OBSERVATION", 96, 101], ["microvascular", "ANATOMY", 107, 120], ["thrombosis", "OBSERVATION", 121, 131], ["ARDS", "OBSERVATION", 154, 158]]], ["Of importance, as ARDS progresses, vascular permeability increases and surfactant deactivates making the lung increasingly unstable [2].", [["vascular", "ANATOMY", 35, 43], ["lung", "ANATOMY", 105, 109], ["ARDS", "DISEASE", 18, 22], ["vascular", "MULTI-TISSUE_STRUCTURE", 35, 43], ["lung", "ORGAN", 105, 109], ["ARDS", "PROBLEM", 18, 22], ["vascular permeability", "TEST", 35, 56], ["surfactant deactivates", "TREATMENT", 71, 93], ["vascular", "ANATOMY", 35, 43], ["lung", "ANATOMY", 105, 109]]], ["Thus, clinical studies have provided promising data on the effect of surfactant treatment in patients with ARDS [3].", [["ARDS", "DISEASE", 107, 111], ["surfactant", "SIMPLE_CHEMICAL", 69, 79], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["clinical studies", "TEST", 6, 22], ["surfactant treatment", "TREATMENT", 69, 89], ["ARDS", "PROBLEM", 107, 111], ["ARDS", "OBSERVATION", 107, 111]]], ["These pathophysiological findings have prompted several groups to investigate if surfactant administration could improve the COVID-19 patient outcome.", [["surfactant", "SIMPLE_CHEMICAL", 81, 91], ["patient", "ORGANISM", 134, 141], ["patient", "SPECIES", 134, 141], ["surfactant administration", "TREATMENT", 81, 106], ["the COVID", "TEST", 121, 130]]], ["Interventional trials are currently underway in the UK, USA, and Canada (ClinicalTrials.gov IDs: NCT04375735, NCT04362059, NCT04384731).COVID-19 patients and pulmonary surfactantTreatment of NRDS with rescue surfactant and continuous positive airway pressure (CPAP), when compared to mechanical ventilation, results in reduced development of pulmonary fibrosis; a complication also reported in intubated COVID-19 patients.", [["pulmonary", "ANATOMY", 158, 167], ["airway", "ANATOMY", 243, 249], ["pulmonary", "ANATOMY", 342, 351], ["NRDS", "DISEASE", 191, 195], ["pulmonary fibrosis", "DISEASE", 342, 360], ["patients", "ORGANISM", 145, 153], ["pulmonary", "ORGAN", 158, 167], ["NRDS", "SIMPLE_CHEMICAL", 191, 195], ["airway", "MULTI-TISSUE_STRUCTURE", 243, 249], ["pulmonary", "ORGAN", 342, 351], ["patients", "ORGANISM", 413, 421], ["patients", "SPECIES", 145, 153], ["patients", "SPECIES", 413, 421], ["Interventional trials", "TREATMENT", 0, 21], ["COVID", "TEST", 136, 141], ["pulmonary surfactant", "TREATMENT", 158, 178], ["NRDS", "PROBLEM", 191, 195], ["rescue surfactant", "TREATMENT", 201, 218], ["continuous positive airway pressure", "TREATMENT", 223, 258], ["CPAP", "TREATMENT", 260, 264], ["mechanical ventilation", "TREATMENT", 284, 306], ["pulmonary fibrosis", "PROBLEM", 342, 360], ["a complication", "PROBLEM", 362, 376], ["pulmonary", "ANATOMY", 158, 167], ["surfactant", "OBSERVATION", 168, 178], ["airway pressure", "OBSERVATION", 243, 258], ["pulmonary", "ANATOMY", 342, 351], ["fibrosis", "OBSERVATION", 352, 360]]], ["Antenatal corticosteroid treatment may also accelerate fetal lung maturation in the risk of preterm birth.", [["fetal lung", "ANATOMY", 55, 65], ["preterm birth", "DISEASE", 92, 105], ["fetal lung", "MULTI-TISSUE_STRUCTURE", 55, 65], ["Antenatal corticosteroid treatment", "TREATMENT", 0, 34], ["fetal lung maturation", "PROBLEM", 55, 76], ["preterm birth", "PROBLEM", 92, 105], ["lung", "ANATOMY", 61, 65], ["maturation", "OBSERVATION", 66, 76]]], ["A multicentre trial evaluates whether surfactant plus budesonide improves survival in NRDS [4].", [["budesonide", "CHEMICAL", 54, 64], ["budesonide", "CHEMICAL", 54, 64], ["surfactant", "SIMPLE_CHEMICAL", 38, 48], ["budesonide", "SIMPLE_CHEMICAL", 54, 64], ["A multicentre trial", "TREATMENT", 0, 19], ["surfactant", "TREATMENT", 38, 48], ["budesonide", "TREATMENT", 54, 64]]], ["In COVID-19 patients, dexamethasone seems to improve the outcome.COVID-19 patients and pulmonary surfactantWe suggest assessment of surfactant levels should be added to the evaluation of COVID-19 patients.", [["pulmonary", "ANATOMY", 87, 96], ["dexamethasone", "CHEMICAL", 22, 35], ["dexamethasone", "CHEMICAL", 22, 35], ["patients", "ORGANISM", 12, 20], ["dexamethasone", "SIMPLE_CHEMICAL", 22, 35], ["patients", "ORGANISM", 74, 82], ["pulmonary", "ORGAN", 87, 96], ["surfactant", "SIMPLE_CHEMICAL", 132, 142], ["patients", "ORGANISM", 196, 204], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 74, 82], ["patients", "SPECIES", 196, 204], ["dexamethasone", "TREATMENT", 22, 35], ["COVID", "TEST", 65, 70], ["pulmonary surfactantWe", "TREATMENT", 87, 109], ["assessment of surfactant levels", "TEST", 118, 149], ["the evaluation", "TEST", 169, 183], ["COVID", "TEST", 187, 192], ["pulmonary", "ANATOMY", 87, 96]]], ["A point-of-care test for fast measuring surfactant at birth in premature babies has been developed [5].", [["surfactant", "CHEMICAL", 40, 50], ["care test", "TEST", 11, 20], ["fast measuring surfactant", "TREATMENT", 25, 50], ["premature babies", "PROBLEM", 63, 79]]], ["This method may be suitable for determining the surfactant in tracheal fluid obtained from critically ill adults.", [["tracheal fluid", "ANATOMY", 62, 76], ["critically ill", "DISEASE", 91, 105], ["surfactant", "SIMPLE_CHEMICAL", 48, 58], ["tracheal fluid", "MULTI-TISSUE_STRUCTURE", 62, 76], ["the surfactant in tracheal fluid", "TREATMENT", 44, 76], ["tracheal", "ANATOMY", 62, 70], ["fluid", "OBSERVATION", 71, 76]]], ["Knowledge of surfactant levels contributes to understanding pathophysiology in COVID-19 patients.", [["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["surfactant levels", "TEST", 13, 30]]], ["Surfactant treatment may be considered included with other interventions for the treatment of COVID-19 induced respiratory failure.", [["respiratory", "ANATOMY", 111, 122], ["COVID-19", "CHEMICAL", 94, 102], ["respiratory failure", "DISEASE", 111, 130], ["COVID-19", "CHEMICAL", 94, 102], ["Surfactant", "SIMPLE_CHEMICAL", 0, 10], ["Surfactant treatment", "TREATMENT", 0, 20], ["other interventions", "TREATMENT", 53, 72], ["the treatment", "TREATMENT", 77, 90], ["COVID", "TEST", 94, 99], ["respiratory failure", "PROBLEM", 111, 130], ["respiratory failure", "OBSERVATION", 111, 130]]]], "582f92ff7d1c2d627834fa40c2a8c57bd3c6427a": [["IntroductionAlthough the common cold is the most prevalent illness in humans, information on the pathogenesis of symptoms and relationship of the infection to atopic diseases such as asthma has been difficult to obtain.", [["illness", "DISEASE", 59, 66], ["infection", "DISEASE", 146, 155], ["atopic diseases", "DISEASE", 159, 174], ["asthma", "DISEASE", 183, 189], ["humans", "ORGANISM", 70, 76], ["humans", "SPECIES", 70, 76], ["humans", "SPECIES", 70, 76], ["symptoms", "PROBLEM", 113, 121], ["the infection", "PROBLEM", 142, 155], ["atopic diseases", "PROBLEM", 159, 174], ["asthma", "PROBLEM", 183, 189], ["most prevalent", "OBSERVATION_MODIFIER", 44, 58], ["infection", "OBSERVATION", 146, 155]]], ["A recent study has implicated human rhinoviruses (HRV) as the major factor in association with up to 60% of exacerbations of asthma in children, a view based on studies employing a sensitive polymerase chain reaction for diagnosis [1] .IntroductionCorrespondence: Dr P. G. Bardin, University Medicine (Centre Block), Southampton General Hospital, Tremona Road, Southampton SO9 4XY, UK.", [["asthma", "DISEASE", 125, 131], ["human", "ORGANISM", 30, 35], ["rhinoviruses", "ORGANISM", 36, 48], ["children", "ORGANISM", 135, 143], ["human", "SPECIES", 30, 35], ["children", "SPECIES", 135, 143], ["human rhinoviruses", "SPECIES", 30, 48], ["HRV", "SPECIES", 50, 53], ["A recent study", "TEST", 0, 14], ["human rhinoviruses", "PROBLEM", 30, 48], ["exacerbations", "PROBLEM", 108, 121], ["asthma", "PROBLEM", 125, 131], ["studies", "TEST", 161, 168], ["a sensitive polymerase chain reaction", "PROBLEM", 179, 216], ["rhinoviruses", "OBSERVATION", 36, 48], ["asthma", "OBSERVATION", 125, 131]]], ["Some investigators have suggested that worsening of atopic disease may be mediated by way of increased sensitivity of the atopic individual, manifesting as augmented airway responsiveness and the induction of late asthmatic reactions by HRV [2] ; atopic subjects may thus intrinsically be more prone to develop severe cold symptoms including chest symptoms.IntroductionEarly investigations into the epidemiology, spread, serological responses and infectivity of HRV were conducted in studies employing human experimental disease in volunteers [3, 4] .", [["airway", "ANATOMY", 166, 172], ["chest", "ANATOMY", 342, 347], ["atopic disease", "DISEASE", 52, 66], ["atopic", "DISEASE", 122, 128], ["chest symptoms", "DISEASE", 342, 356], ["airway", "MULTI-TISSUE_STRUCTURE", 166, 172], ["chest", "ORGANISM_SUBDIVISION", 342, 347], ["human", "ORGANISM", 502, 507], ["human", "SPECIES", 502, 507], ["human", "SPECIES", 502, 507], ["atopic disease", "PROBLEM", 52, 66], ["increased sensitivity", "PROBLEM", 93, 114], ["the atopic individual", "PROBLEM", 118, 139], ["augmented airway responsiveness", "PROBLEM", 156, 187], ["late asthmatic reactions", "PROBLEM", 209, 233], ["atopic subjects", "PROBLEM", 247, 262], ["severe cold symptoms", "PROBLEM", 311, 331], ["chest symptoms", "PROBLEM", 342, 356], ["serological responses", "TEST", 421, 442], ["HRV", "PROBLEM", 462, 465], ["atopic", "OBSERVATION", 52, 58], ["airway", "ANATOMY", 166, 172], ["chest", "ANATOMY", 342, 347]]], ["More recently this model has been expanded to investigate the interrelationship between HRV and allergic diseases [5, 6] and important aspects interacting with atopic status such as symptom scores, viral shedding and serological responses have been evaluated.", [["allergic diseases", "DISEASE", 96, 113], ["allergic diseases", "PROBLEM", 96, 113], ["symptom scores", "PROBLEM", 182, 196], ["viral shedding", "PROBLEM", 198, 212], ["serological responses", "TEST", 217, 238], ["allergic diseases", "OBSERVATION", 96, 113]]], ["No definite link was established and controversy remains as to whether atopic individuals are more susceptible to the consequences of rhinoviral infections.IntroductionWe have postulated that clinical expression of rhinoviral colds is modulated by the allergic status of an individual.", [["rhinoviral infections", "DISEASE", 134, 155], ["colds", "DISEASE", 226, 231], ["allergic", "DISEASE", 252, 260], ["rhinoviral", "ORGANISM", 134, 144], ["rhinoviral colds", "ORGANISM", 215, 231], ["atopic individuals", "PROBLEM", 71, 89], ["rhinoviral infections", "PROBLEM", 134, 155], ["rhinoviral colds", "PROBLEM", 215, 231], ["the allergic status", "PROBLEM", 248, 267], ["definite", "UNCERTAINTY", 3, 11], ["infections", "OBSERVATION", 145, 155]]], ["This report details the development of a programme for the induction of HRV serotype 16 (HRV 16) colds in adult volunteers and evaluates the clinical severity of infection, serological responses and associated factors that may determine the expression of disease in both normal and atopic volunteers.PatientsThe study was conducted in 11 normal non-smoking volunteers and 11 non-smoking atopic subjects (six asthmatics), who had no measurable antibody to HRV 16 in their serum (< 1:2 dilution) at initial screening.", [["serum", "ANATOMY", 471, 476], ["colds", "DISEASE", 97, 102], ["infection", "DISEASE", 162, 171], ["atopic", "DISEASE", 387, 393], ["HRV serotype 16", "ORGANISM", 72, 87], ["volunteers", "ORGANISM", 112, 122], ["volunteers", "ORGANISM", 289, 299], ["Patients", "ORGANISM", 300, 308], ["volunteers", "ORGANISM", 357, 367], ["asthmatics", "ORGANISM", 408, 418], ["serum", "ORGANISM_SUBSTANCE", 471, 476], ["Patients", "SPECIES", 300, 308], ["HRV serotype", "TEST", 72, 84], ["colds in adult volunteers", "PROBLEM", 97, 122], ["infection", "PROBLEM", 162, 171], ["serological responses", "PROBLEM", 173, 194], ["disease", "PROBLEM", 255, 262], ["The study", "TEST", 308, 317], ["measurable antibody", "PROBLEM", 432, 451], ["HRV", "TEST", 455, 458], ["their serum", "TEST", 465, 476], ["initial screening", "TEST", 497, 514], ["infection", "OBSERVATION", 162, 171], ["normal", "OBSERVATION", 271, 277]]], ["Asthmatic patients were controlled by the use of as required /i2-agonists only and had baseline FEVi > 80% predicted.", [["Asthmatic", "DISEASE", 0, 9], ["patients", "ORGANISM", 10, 18], ["i2", "PROTEIN", 62, 64], ["patients", "SPECIES", 10, 18], ["Asthmatic patients", "PROBLEM", 0, 18], ["baseline FEVi", "TEST", 87, 100]]], ["Asthma was defined as a PEF variability of > 15% and histamine hyperresponsiveness (PC20<4 mg/ml).", [["Asthma", "DISEASE", 0, 6], ["histamine", "CHEMICAL", 53, 62], ["histamine", "CHEMICAL", 53, 62], ["histamine", "SIMPLE_CHEMICAL", 53, 62], ["Asthma", "PROBLEM", 0, 6], ["a PEF variability", "TEST", 22, 39], ["histamine hyperresponsiveness", "PROBLEM", 53, 82], ["PC20", "TEST", 84, 88]]], ["All subjects gave informed consent before enrolling in the study.", [["the study", "TEST", 55, 64]]], ["The study had been approved by the Southampton Hospitals and University Ethical Subcommittee,Study designSubjects were studied in three phases.", [["The study", "TEST", 0, 9], ["Study designSubjects", "TEST", 93, 113]]], ["Phase 1: baseline observations were conducted on the 2 days prior to viral inoculation and included skin-prick testing to common allergens, total serum IgE, serum for repeat of neutralizing antibody and nasal washing for viral culture.", [["skin", "ANATOMY", 100, 104], ["serum", "ANATOMY", 146, 151], ["serum", "ANATOMY", 157, 162], ["nasal", "ANATOMY", 203, 208], ["skin", "ORGAN", 100, 104], ["serum", "ORGANISM_SUBSTANCE", 146, 151], ["IgE", "GENE_OR_GENE_PRODUCT", 152, 155], ["serum", "ORGANISM_SUBSTANCE", 157, 162], ["total serum IgE", "PROTEIN", 140, 155], ["neutralizing antibody", "PROTEIN", 177, 198], ["viral inoculation", "PROBLEM", 69, 86], ["skin-prick testing", "TEST", 100, 118], ["total serum IgE", "TEST", 140, 155], ["serum", "TEST", 157, 162], ["neutralizing antibody", "TEST", 177, 198], ["nasal washing", "TREATMENT", 203, 216], ["viral culture", "TEST", 221, 234], ["skin", "ANATOMY", 100, 104]]], ["This took place in the Infectious Diseases Unit (IDU) at Southampton General Hospital, where subjects were isolated for 7 days during the experimental HRV 16 infection.", [["infection", "DISEASE", 158, 167], ["subjects", "ORGANISM", 93, 101], ["the experimental HRV 16 infection", "PROBLEM", 134, 167], ["Infectious", "OBSERVATION", 23, 33], ["infection", "OBSERVATION", 158, 167]]], ["Phase 2: following HRV 16 inoculation, subjects had daily nasal washes, assessment of symptoms and repeat serology.", [["nasal", "ANATOMY", 58, 63], ["nasal", "ORGANISM_SUBDIVISION", 58, 63], ["HRV", "TEST", 19, 22], ["daily nasal washes", "TREATMENT", 52, 70], ["symptoms", "PROBLEM", 86, 94], ["repeat serology", "TEST", 99, 114]]], ["Phase 3: all the above investigations were repeated at weeks 8-10,Measurement of neutralizing antibodiesThis was undertaken on serum (obtained 1-2 months prior to inoculation) from all volunteers before admission to the study (screening) as well as on the day prior to inoculation with HRV 16, day 3 of experimental disease (day 5 of admission) and finally 8-10 weeks later.", [["serum", "ANATOMY", 127, 132], ["serum", "ORGANISM_SUBSTANCE", 127, 132], ["volunteers", "ORGANISM", 185, 195], ["neutralizing antibodies", "PROTEIN", 81, 104], ["all the above investigations", "TEST", 9, 37], ["neutralizing antibodies", "TEST", 81, 104], ["serum", "TEST", 127, 132], ["the study", "TEST", 216, 225], ["screening", "TEST", 227, 236], ["HRV", "TEST", 286, 289], ["experimental disease", "PROBLEM", 303, 323]]], ["The test could not be repeated in three volunteers who had moved elsewhere in the UK or overseas, A micro-neutralization test in 96 well tissue culture plates was used.", [["volunteers", "ORGANISM", 40, 50], ["The test", "TEST", 0, 8], ["A micro-neutralization test", "TEST", 98, 125], ["tissue culture plates", "TEST", 137, 158]]], ["Briefly, serial doubling dilutions of sera (0-05 ml) were made in diluent (HeLa maintenance, 2% fetal calf serum).", [["sera", "ANATOMY", 38, 42], ["HeLa", "ANATOMY", 75, 79], ["fetal calf serum", "ANATOMY", 96, 112], ["sera", "ORGANISM_SUBSTANCE", 38, 42], ["HeLa", "CELL", 75, 79], ["fetal calf", "MULTI-TISSUE_STRUCTURE", 96, 106], ["serum", "ORGANISM_SUBSTANCE", 107, 112], ["calf", "SPECIES", 102, 106], ["serial doubling dilutions of sera", "TREATMENT", 9, 42], ["diluent (HeLa maintenance", "TREATMENT", 66, 91], ["2% fetal calf serum)", "TREATMENT", 93, 113], ["calf", "ANATOMY", 102, 106]]], ["This was added to an equal volume of virus at concentrations of 40-50 tissue culture infective doses-50%/ml (TCID50/ml) in a volume of 0 05 ml and incubated at room temperature for 15 h.", [["tissue", "ANATOMY", 70, 76], ["an equal volume of virus", "TREATMENT", 18, 42]]], ["To the serial dilutions were added freshly stripped HeLa cells at 3 x 10^ cells/ml and the plates incubated at 33\u00b0C, Appropriate serum, cell and viral controls were included, Cytopathic effects (CPE) were read microscopically after 2-4 days' incubation and confirmed by fixing and staining plates.", [["HeLa cells", "ANATOMY", 52, 62], ["cells", "ANATOMY", 74, 79], ["serum", "ANATOMY", 129, 134], ["cell", "ANATOMY", 136, 140], ["HeLa cells", "CELL", 52, 62], ["serum", "ORGANISM_SUBSTANCE", 129, 134], ["cell", "CELL", 136, 140], ["HeLa cells", "CELL_LINE", 52, 62], ["the serial dilutions", "TREATMENT", 3, 23], ["freshly stripped HeLa cells", "TREATMENT", 35, 62], ["the plates", "TEST", 87, 97], ["viral controls", "PROBLEM", 145, 159], ["Cytopathic effects (CPE", "PROBLEM", 175, 198], ["staining plates", "TEST", 281, 296]]], ["All assays were performed in duplicate.Measurement of neutralizing antibodiesAssessment of atopic status: (a) Skin-prick tests: the tests were performed using a standard set of allergens {Dermatophagoidespteronyssinus, mixed grass pollen, cat dander, dog hair, feathers, Candida alhicans and Aspergillus fumigatus) with histamine used as a positive control (Bencard, Brentford, Middlesex, UK), Atopic individuals were defined as those with at least two positive tests (> 2 mm weal response than diluent control) to the allergens used, (b) IgE measurements: serum IgE values were determined by a double-antibody solid-phase ELISA (Enzygnost IgE, Calbiochem, Behring Corp,, La Jolla, CA, USA), Symptom assessment: all subjects completed a validated questionnaire daily for 2 weeks prior to, during and for 8-10 weeks after HRV 16 infection.", [["hair", "ANATOMY", 255, 259], ["feathers", "ANATOMY", 261, 269], ["serum", "ANATOMY", 557, 562], ["Candida alhicans", "DISEASE", 271, 287], ["histamine", "CHEMICAL", 320, 329], ["infection", "DISEASE", 828, 837], ["histamine", "CHEMICAL", 320, 329], ["Dermatophagoidespteronyssinus", "ORGANISM", 188, 217], ["cat", "ORGANISM", 239, 242], ["dander", "ORGANISM_SUBDIVISION", 243, 249], ["dog", "ORGANISM", 251, 254], ["hair", "ORGANISM_SUBDIVISION", 255, 259], ["feathers", "ORGANISM_SUBDIVISION", 261, 269], ["Candida alhicans", "ORGANISM", 271, 287], ["Aspergillus fumigatus", "ORGANISM", 292, 313], ["histamine", "SIMPLE_CHEMICAL", 320, 329], ["serum", "ORGANISM_SUBSTANCE", 557, 562], ["IgE", "GENE_OR_GENE_PRODUCT", 563, 566], ["neutralizing antibodies", "PROTEIN", 54, 77], ["IgE", "PROTEIN", 539, 542], ["IgE", "PROTEIN", 563, 566], ["IgE", "PROTEIN", 640, 643], ["cat dander", "SPECIES", 239, 249], ["dog", "SPECIES", 251, 254], ["Candida alhicans", "SPECIES", 271, 287], ["Aspergillus fumigatus", "SPECIES", 292, 313], ["cat dander", "SPECIES", 239, 249], ["Candida alhicans", "SPECIES", 271, 287], ["Aspergillus fumigatus", "SPECIES", 292, 313], ["All assays", "TEST", 0, 10], ["Measurement of neutralizing antibodies", "TEST", 39, 77], ["Skin-prick tests", "TEST", 110, 126], ["the tests", "TEST", 128, 137], ["a standard set of allergens", "TREATMENT", 159, 186], ["Dermatophagoidespteronyssinus", "TREATMENT", 188, 217], ["mixed grass pollen", "TREATMENT", 219, 237], ["cat dander", "TREATMENT", 239, 249], ["Candida alhicans", "TREATMENT", 271, 287], ["Aspergillus fumigatus", "PROBLEM", 292, 313], ["histamine", "TREATMENT", 320, 329], ["Atopic individuals", "PROBLEM", 394, 412], ["positive tests", "TEST", 453, 467], ["diluent control", "TREATMENT", 495, 510], ["IgE measurements", "TEST", 539, 555], ["serum IgE values", "TEST", 557, 573], ["a double-antibody solid", "TEST", 593, 616], ["ELISA", "TEST", 623, 628], ["Calbiochem", "TEST", 645, 655], ["Symptom assessment", "TEST", 692, 710], ["HRV 16 infection", "PROBLEM", 821, 837], ["neutralizing antibodies", "OBSERVATION", 54, 77], ["Skin", "ANATOMY", 110, 114], ["infection", "OBSERVATION", 828, 837]]], ["Symptoms were graded 0-3 according to severity and the criteria for a cold were based on that proposed by Jackson et al. [7] , Clinical illness was considered present if a volunteer had a minimum cumulative symptom score of 14 over a 4-day period, and had a subjective impression that he had a cold, or if rhinorrhea was present on at least 3 of the 4 days of observation.", [["illness", "DISEASE", 136, 143], ["rhinorrhea", "DISEASE", 306, 316], ["Symptoms", "PROBLEM", 0, 8], ["a cold", "PROBLEM", 68, 74], ["a cold", "PROBLEM", 292, 298], ["rhinorrhea", "PROBLEM", 306, 316]]], ["Any baseline rhinitic symptoms for 4 days prior to inoculation were subtracted from new cold symptoms.", [["Any baseline rhinitic symptoms", "PROBLEM", 0, 30], ["inoculation", "PROBLEM", 51, 62], ["new cold symptoms", "PROBLEM", 84, 101]]], ["Rhinitis was assessed as either absent, mild or severe on the basis of a history of nasal blockage, sneezing, and rhinorrhea over the preceding year.", [["nasal", "ANATOMY", 84, 89], ["Rhinitis", "DISEASE", 0, 8], ["nasal blockage", "DISEASE", 84, 98], ["sneezing", "DISEASE", 100, 108], ["rhinorrhea", "DISEASE", 114, 124], ["nasal", "ORGANISM_SUBDIVISION", 84, 89], ["Rhinitis", "PROBLEM", 0, 8], ["nasal blockage", "PROBLEM", 84, 98], ["sneezing", "PROBLEM", 100, 108], ["rhinorrhea", "PROBLEM", 114, 124], ["mild", "OBSERVATION_MODIFIER", 40, 44], ["severe", "OBSERVATION_MODIFIER", 48, 54], ["nasal", "ANATOMY", 84, 89], ["blockage", "OBSERVATION", 90, 98], ["sneezing", "OBSERVATION", 100, 108], ["rhinorrhea", "OBSERVATION", 114, 124]]], ["Because a recent report has suggested that cold symptoms are influenced by alcohol intake [8] , all subjects were contacted and their intake at the time quantified as the average number of drinks per day [8] , Nasal lavage: nasal washing was undertaken by instilling 5 ml of pre-warmed Hanks' balanced salt solution (HBSS) with 0-5% gelatin into each nostril, holding for 5 s and then expelling into a sterile petri dish.", [["Nasal lavage", "ANATOMY", 210, 222], ["nasal", "ANATOMY", 224, 229], ["nostril", "ANATOMY", 351, 358], ["alcohol", "CHEMICAL", 75, 82], ["gelatin", "CHEMICAL", 333, 340], ["alcohol", "CHEMICAL", 75, 82], ["alcohol", "SIMPLE_CHEMICAL", 75, 82], ["nostril", "ORGAN", 351, 358], ["cold symptoms", "PROBLEM", 43, 56], ["Nasal lavage", "TREATMENT", 210, 222], ["nasal washing", "TREATMENT", 224, 237], ["Hanks' balanced salt solution", "TREATMENT", 286, 315], ["0-5% gelatin", "TREATMENT", 328, 340], ["a sterile petri dish", "TREATMENT", 400, 420], ["Nasal", "ANATOMY", 210, 215], ["lavage", "OBSERVATION", 216, 222], ["nasal", "ANATOMY", 224, 229], ["petri dish", "OBSERVATION", 410, 420]]], ["Samples were aliquotted and frozen at -70\u00b0C until analysed.Measurement of neutralizing antibodiesAlbumin measurement: measurements on coded samples were done by rocket immunoelectrophoresis [9] , Sensitivity of the assay was 1 /\u00abg/ml and the coefficient of variation of repeated measurements was <5%, Nasal inoculation with virus: nasal inoculation was performed by instilling 0 25 ml of HRV 16 suspension (kindly supplied by Drs E, Dick & W, Busse, Madison, Wisconsin, USA) into each nostril by pipette (1-5 x 10^T CID50/ml) on two consecutive days in addition to spraying approximately the same amount into each nostril with an atomiser (No, 286; De Vilbiss Co,, Heston, UK) using a hand-bulb (no, 5 bulb, De Vilbiss Co,) so that the spray coated the nasal activity [2] ,Measurement of neutralizing antibodiesConfirmation of viral infection: nasal washes were inoculated onto Ohio HeLa cell cultures and HRV shedding and infection diagnosed by means of the typical CPE on light microscopy.", [["Samples", "ANATOMY", 0, 7], ["samples", "ANATOMY", 140, 147], ["nasal", "ANATOMY", 331, 336], ["nostril", "ANATOMY", 485, 492], ["nostril", "ANATOMY", 614, 621], ["hand-bulb", "ANATOMY", 685, 694], ["nasal", "ANATOMY", 753, 758], ["nasal", "ANATOMY", 844, 849], ["HeLa cell cultures", "ANATOMY", 883, 901], ["viral infection", "DISEASE", 827, 842], ["infection", "DISEASE", 923, 932], ["Albumin", "GENE_OR_GENE_PRODUCT", 97, 104], ["nasal", "ORGAN", 331, 336], ["nostril", "ORGAN", 485, 492], ["bulb", "ORGANISM_SUBDIVISION", 702, 706], ["HeLa cell cultures", "CELL", 883, 901], ["neutralizing antibodies", "PROTEIN", 74, 97], ["Albumin", "PROTEIN", 97, 104], ["neutralizing antibodies", "PROTEIN", 788, 811], ["Ohio HeLa cell cultures", "CELL_LINE", 878, 901], ["Samples", "TEST", 0, 7], ["Measurement of neutralizing antibodiesAlbumin measurement", "TEST", 59, 116], ["coded samples", "TEST", 134, 147], ["rocket immunoelectrophoresis", "TEST", 161, 189], ["Sensitivity", "TEST", 196, 207], ["the assay", "TEST", 211, 220], ["repeated measurements", "TEST", 270, 291], ["Nasal inoculation with virus", "PROBLEM", 301, 329], ["nasal inoculation", "TREATMENT", 331, 348], ["the spray", "TREATMENT", 732, 741], ["neutralizing antibodies", "TREATMENT", 788, 811], ["viral infection", "PROBLEM", 827, 842], ["nasal washes", "TREATMENT", 844, 856], ["Ohio HeLa cell cultures", "TEST", 878, 901], ["HRV shedding", "PROBLEM", 906, 918], ["infection", "PROBLEM", 923, 932], ["the typical CPE", "PROBLEM", 955, 970], ["light microscopy", "TEST", 974, 990], ["Nasal", "ANATOMY", 301, 306], ["nasal", "ANATOMY", 331, 336], ["bulb", "ANATOMY", 690, 694], ["nasal", "ANATOMY", 753, 758], ["viral infection", "OBSERVATION", 827, 842], ["nasal", "ANATOMY", 844, 849], ["infection", "OBSERVATION", 923, 932]]], ["Cultures were examined daily and regarded as negative if they showed no CPE after two passes in cell culture.", [["cell", "ANATOMY", 96, 100], ["cell", "CELL", 96, 100], ["Cultures", "TEST", 0, 8], ["CPE", "PROBLEM", 72, 75], ["cell culture", "TEST", 96, 108]]], ["The presence of virus in nasal washes was determined by culture on HeLa cells, and confirmed by neutralisation by HRV 16 specific antiserum (ATCC, Cat, no, V1O5-5O1-558, Natl, Inst, Allergy, Infect, Dis,, Bethesda, Maryland, USA), Positive infection was established by at least one identified viral isolate and/or a fourfold rise in titre of neutralizing antibody.", [["nasal", "ANATOMY", 25, 30], ["HeLa cells", "ANATOMY", 67, 77], ["V1O5-5O1-558", "CHEMICAL", 156, 168], ["infection", "DISEASE", 240, 249], ["nasal", "ORGAN", 25, 30], ["HeLa cells", "CELL", 67, 77], ["antiserum", "ORGANISM_SUBSTANCE", 130, 139], ["ATCC", "CELL", 141, 145], ["HeLa cells", "CELL_LINE", 67, 77], ["neutralizing antibody", "PROTEIN", 342, 363], ["ATCC", "SPECIES", 141, 145], ["virus in nasal washes", "PROBLEM", 16, 37], ["culture", "TEST", 56, 63], ["HeLa cells", "TEST", 67, 77], ["HRV", "TEST", 114, 117], ["ATCC", "TEST", 141, 145], ["Cat", "TEST", 147, 150], ["V1O5", "TEST", 156, 160], ["Positive infection", "PROBLEM", 231, 249], ["viral isolate", "PROBLEM", 293, 306], ["a fourfold rise", "PROBLEM", 314, 329], ["neutralizing antibody", "PROBLEM", 342, 363], ["virus", "OBSERVATION", 16, 21], ["nasal", "ANATOMY", 25, 30], ["washes", "OBSERVATION", 31, 37], ["infection", "OBSERVATION", 240, 249], ["viral isolate", "OBSERVATION", 293, 306], ["neutralizing antibody", "OBSERVATION", 342, 363]]], ["Because quantification of viral shedding is difficult, a scoring system for viral culture was devised.", [["viral shedding", "PROBLEM", 26, 40], ["a scoring system", "TEST", 55, 71], ["viral culture", "TEST", 76, 89], ["viral", "OBSERVATION", 26, 31]]], ["For each of 3 days of lavage collection, the CPE observed in HeLa cultures were scored (0-4) by the same observer and then summated over the 3-day period of lavage collection, with a maximum cumulative score of 12 (3x4), Statistical analysis: symptom scores, albumin levels and IgE levels in sub-groups were compared by Mann-Whitney t/-test.", [["HeLa cultures", "ANATOMY", 61, 74], ["HeLa cultures", "CELL", 61, 74], ["albumin", "GENE_OR_GENE_PRODUCT", 259, 266], ["IgE", "GENE_OR_GENE_PRODUCT", 278, 281], ["HeLa cultures", "CELL_LINE", 61, 74], ["albumin", "PROTEIN", 259, 266], ["IgE", "PROTEIN", 278, 281], ["lavage collection", "TREATMENT", 22, 39], ["the CPE", "TEST", 41, 48], ["HeLa cultures", "TEST", 61, 74], ["lavage collection", "PROBLEM", 157, 174], ["a maximum cumulative score", "TEST", 181, 207], ["Statistical analysis", "TEST", 221, 241], ["symptom scores", "TEST", 243, 257], ["albumin levels", "TEST", 259, 273], ["IgE levels", "TEST", 278, 288], ["lavage", "OBSERVATION", 22, 28], ["lavage", "OBSERVATION", 157, 163]]], ["Overall differences between the four groups were assessed by Kruskal-Wallis one-way ANOVA, For evaluation of associations between symptom scores and age, albumin or IgE values, we employed the Pearson correlation test.", [["albumin", "GENE_OR_GENE_PRODUCT", 154, 161], ["IgE", "GENE_OR_GENE_PRODUCT", 165, 168], ["IgE", "PROTEIN", 165, 168], ["evaluation", "TEST", 95, 105], ["symptom scores", "TEST", 130, 144], ["albumin or IgE values", "TEST", 154, 175]]], ["All other associations were examined using the Spearman rank correlation test, 05 was considered significant.Patients and response to infectionA total of 64 volunteers were initially screened for the presence of serum neutralizing antibody; 33 (51%) had antibody present and nine were deemed unsuitable for personal reasons.", [["serum", "ANATOMY", 212, 217], ["Patients", "ORGANISM", 109, 117], ["volunteers", "ORGANISM", 157, 167], ["serum", "ORGANISM_SUBSTANCE", 212, 217], ["serum neutralizing antibody", "PROTEIN", 212, 239], ["Patients", "SPECIES", 109, 117], ["the Spearman rank correlation test", "TEST", 43, 77], ["infectionA", "TEST", 134, 144], ["serum neutralizing antibody", "TEST", 212, 239], ["antibody", "TEST", 254, 262]]], ["The baseline characteristics of the 22 volunteers who participated in studies are shown in Table 1 , The group consisted of 11 normal subjects (seven female) and 11 atopic individuals (two female), six of whom had asthma.", [["asthma", "DISEASE", 214, 220], ["volunteers", "ORGANISM", 39, 49], ["asthma", "PROBLEM", 214, 220], ["asthma", "OBSERVATION", 214, 220]]], ["No differences in age and sex distribution were noted; the atopic group had significantly higher IgE levels (/' = 0 002), A definite clinical cold developed in 17/22 subjects as assessed by symptom scores.", [["atopic", "DISEASE", 59, 65], ["IgE", "GENE_OR_GENE_PRODUCT", 97, 100], ["IgE", "PROTEIN", 97, 100], ["the atopic group", "TEST", 55, 71], ["significantly higher IgE levels", "PROBLEM", 76, 107], ["A definite clinical cold", "PROBLEM", 122, 146], ["differences", "OBSERVATION_MODIFIER", 3, 14]]], ["Negative by scoring were subjects 1, 2, 4, 8 and 11, all of whom were normal individuals.", [["normal", "OBSERVATION", 70, 76]]], ["However, they all had either positive viral shedding and cultures or significant rises in neutralizing antibody to HRV 16, All atopic volunteers had clinical colds based on symptom scores calculated after baseline rhinitic symptoms had been subtracted.", [["colds", "DISEASE", 158, 163], ["volunteers", "ORGANISM", 134, 144], ["neutralizing antibody", "PROTEIN", 90, 111], ["positive viral shedding", "PROBLEM", 29, 52], ["cultures", "TEST", 57, 65], ["significant rises", "PROBLEM", 69, 86], ["neutralizing antibody", "TEST", 90, 111], ["HRV", "TEST", 115, 118], ["All atopic volunteers", "PROBLEM", 123, 144], ["clinical colds", "PROBLEM", 149, 163], ["symptom scores", "TEST", 173, 187], ["baseline rhinitic symptoms", "PROBLEM", 205, 231], ["positive", "OBSERVATION_MODIFIER", 29, 37], ["viral", "OBSERVATION", 38, 43], ["significant", "OBSERVATION_MODIFIER", 69, 80], ["rises", "OBSERVATION_MODIFIER", 81, 86]]], ["Two subjects in each group had baseline rhinitic scores that were taken into account (Table 1) , Median symptom score was 15 in normal subjects (range 5-36) and 24 (range 14-36) in atopic volunteers.", [["volunteers", "ORGANISM", 188, 198], ["baseline rhinitic scores", "PROBLEM", 31, 55], ["Median symptom score", "TEST", 97, 117]]], ["Comparison of scores was not significantly different (/' = 017), partly as a result of a few very high scores in the normal volunteers.Patients and response to infectionNo associations were found between age and symptom scores, CPE scores or changes in serology.", [["volunteers", "ORGANISM", 124, 134], ["Patients", "ORGANISM", 135, 143], ["Patients", "SPECIES", 135, 143], ["Comparison of scores", "TEST", 0, 20], ["a few very high scores", "PROBLEM", 87, 109], ["infectionNo associations", "PROBLEM", 160, 184], ["symptom scores", "PROBLEM", 212, 226], ["CPE scores", "PROBLEM", 228, 238], ["changes in serology", "PROBLEM", 242, 261], ["significantly different", "OBSERVATION_MODIFIER", 29, 52], ["few", "OBSERVATION_MODIFIER", 89, 92], ["very", "OBSERVATION_MODIFIER", 93, 97], ["high", "OBSERVATION", 98, 102], ["normal volunteers", "OBSERVATION", 117, 134]]], ["Also, no differences were noted in alcohol intake between normal and atopic volunteers and no influence on symptom scores was present.Viral cultureViral shedding and culture was positive in all subjects although low CPE scores were recorded in one subject (patient 15), Median CPE score was 12 in normal subjects and eight in atopies, a discrepancy likely related to the difference in preinoculation antibody present in the groups.", [["atopies", "ANATOMY", 326, 333], ["alcohol", "CHEMICAL", 35, 42], ["atopies", "DISEASE", 326, 333], ["alcohol", "CHEMICAL", 35, 42], ["alcohol", "SIMPLE_CHEMICAL", 35, 42], ["volunteers", "ORGANISM", 76, 86], ["Viral", "ORGANISM", 134, 139], ["patient", "ORGANISM", 257, 264], ["atopies", "CANCER", 326, 333], ["preinoculation antibody", "PROTEIN", 385, 408], ["patient", "SPECIES", 257, 264], ["influence on symptom scores", "PROBLEM", 94, 121], ["Viral cultureViral shedding", "TEST", 134, 161], ["culture", "TEST", 166, 173], ["low CPE scores", "PROBLEM", 212, 226], ["Median CPE score", "TEST", 270, 286], ["a discrepancy", "PROBLEM", 335, 348], ["the difference in preinoculation antibody", "PROBLEM", 367, 408], ["no", "UNCERTAINTY", 6, 8], ["low CPE", "OBSERVATION_MODIFIER", 212, 219], ["preinoculation antibody", "OBSERVATION", 385, 408]]], ["No differences were noted between the groups in measurements such as first day of positive CPE and median number of days of viral shedding (data not shown),Serological respon.sesSerology was performed 1-2 months before actual inoculation to screen subjects for admission (neutralizing antibody titre <1:2) into the study.", [["positive CPE", "PROBLEM", 82, 94], ["viral shedding", "PROBLEM", 124, 138], ["Serological respon.sesSerology", "TEST", 156, 186], ["neutralizing antibody titre", "TEST", 272, 299], ["the study", "TEST", 311, 320]]], ["Repeat baseline serology on the day before inoculation yielded unexpected results.", [["Repeat baseline serology", "TEST", 0, 24]]], ["In the normal group four volunteers had developed an increase in antibody to 1:8 dilution or less and in the atopic volunteers this had occurred in six individuals.", [["volunteers", "ORGANISM", 25, 35], ["volunteers", "ORGANISM", 116, 126], ["an increase in antibody", "PROBLEM", 50, 73], ["normal", "OBSERVATION", 7, 13], ["increase", "OBSERVATION_MODIFIER", 53, 61]]], ["No rises greater than 1:8 were recorded.", [["rises", "OBSERVATION_MODIFIER", 3, 8], ["greater", "OBSERVATION_MODIFIER", 9, 16]]], ["The presence of neutralizing antibody in concentrations equivalent to 1:8 dilution was correlated with the absence of any change in serology at 8-10 weeks after the cold in all cases (patients 4, 13, 15 and 18 in Table 1 ), as well as delayed viral shedding.", [["patients", "ORGANISM", 184, 192], ["neutralizing antibody", "PROTEIN", 16, 37], ["patients", "SPECIES", 184, 192], ["neutralizing antibody in concentrations", "PROBLEM", 16, 55], ["serology", "TEST", 132, 140], ["the cold in all cases", "PROBLEM", 161, 182], ["delayed viral shedding", "PROBLEM", 235, 257], ["neutralizing antibody", "OBSERVATION", 16, 37], ["viral shedding", "OBSERVATION", 243, 257]]], ["Median CPE scores in them on the first day of sampling their cold was 0 5 as opposed to a median score of 4 for the other 18 subjects.", [["Median CPE scores", "PROBLEM", 0, 17]]], ["The latter four subjects also tended to have low viral culture CPE scores (Table 1) ; median CPE score was calculated as 4 vs a score of 12 for the rest of the group.Serological respon.sesTaking pre-inoculation antibody into account, a Normal volunteers with detectable antibody present (^1:2 dilution) tended to have mild symptoms in keeping with lower culture scores and attenuated development of neutralizing antibody.", [["volunteers", "ORGANISM", 243, 253], ["Serological respon.sesTaking pre-inoculation antibody", "PROTEIN", 166, 219], ["neutralizing antibody", "PROTEIN", 399, 420], ["low viral culture CPE scores", "PROBLEM", 45, 73], ["median CPE score", "TEST", 86, 102], ["Serological respon.sesTaking pre-inoculation antibody", "TEST", 166, 219], ["detectable antibody", "PROBLEM", 259, 278], ["mild symptoms", "PROBLEM", 318, 331], ["lower culture scores", "PROBLEM", 348, 368], ["neutralizing antibody", "PROBLEM", 399, 420], ["mild", "OBSERVATION_MODIFIER", 318, 322], ["symptoms", "OBSERVATION", 323, 331], ["neutralizing antibody", "OBSERVATION", 399, 420]]], ["This finding was in contrast to atopic individuals who had high cold symptom scores after correction in spite ofthe presence of preinoculation antibody, low culture scores and mild or absent serum antibody responses.", [["serum", "ANATOMY", 191, 196], ["serum", "ORGANISM_SUBSTANCE", 191, 196], ["preinoculation antibody", "PROTEIN", 128, 151], ["serum antibody", "PROTEIN", 191, 205], ["high cold symptom scores", "PROBLEM", 59, 83], ["preinoculation antibody", "PROBLEM", 128, 151], ["low culture scores", "PROBLEM", 153, 171], ["mild or absent serum antibody responses", "PROBLEM", 176, 215], ["mild", "OBSERVATION_MODIFIER", 176, 180]]], ["The trend was for normals to have mild to severe symptoms whereas atopies tended to all have severe symptoms irrespective of preinoculation neutralizing antibody status (Table 2) , Although the subgroups were small, the differences in symptom scores between normal and atopic preinoculation antibody positive individuals were highly significant (/' = 0-014), It was noteworthy that normal volunteers with absence of antibody developed some of the most severe colds (cases 5,6, 10- Table 1) , Levels of IgE were not correlated with symptom scores, viral CPE scores or serological responses.Measurement of albumin in nasal washesNasal washes were obtained on day 2 (before inoculation) and on day 5 (third day of cold).", [["nasal", "ANATOMY", 615, 620], ["Nasal", "ANATOMY", 627, 632], ["atopies", "DISEASE", 66, 73], ["colds", "DISEASE", 459, 464], ["volunteers", "ORGANISM", 389, 399], ["IgE", "GENE_OR_GENE_PRODUCT", 502, 505], ["albumin", "GENE_OR_GENE_PRODUCT", 604, 611], ["nasal", "ORGANISM_SUBDIVISION", 615, 620], ["IgE", "PROTEIN", 502, 505], ["albumin", "PROTEIN", 604, 611], ["mild to severe symptoms", "PROBLEM", 34, 57], ["atopies", "PROBLEM", 66, 73], ["severe symptoms", "PROBLEM", 93, 108], ["preinoculation neutralizing antibody status", "PROBLEM", 125, 168], ["symptom scores", "TEST", 235, 249], ["atopic preinoculation antibody", "TEST", 269, 299], ["antibody", "PROBLEM", 416, 424], ["the most severe colds", "PROBLEM", 443, 464], ["cases", "TEST", 466, 471], ["Levels of IgE", "TEST", 492, 505], ["symptom scores", "TEST", 531, 545], ["viral CPE scores", "TEST", 547, 563], ["serological responses", "TEST", 567, 588], ["Measurement of albumin", "TEST", 589, 611], ["nasal washesNasal washes", "TREATMENT", 615, 639], ["mild", "OBSERVATION_MODIFIER", 34, 38], ["severe", "OBSERVATION_MODIFIER", 42, 48], ["severe", "OBSERVATION_MODIFIER", 93, 99], ["small", "OBSERVATION_MODIFIER", 209, 214], ["normal", "OBSERVATION", 382, 388], ["albumin", "OBSERVATION_MODIFIER", 604, 611], ["nasal", "ANATOMY", 615, 620]]], ["Results of albumin measurements on the respective days are shown in Table 2 , Normal subjects with neutralizing antibody present (^1:2) had a median decrease in nasal wash albumin of 8-5 ;ug/ml.", [["nasal", "ANATOMY", 161, 166], ["albumin", "GENE_OR_GENE_PRODUCT", 11, 18], ["nasal", "ORGANISM_SUBDIVISION", 161, 166], ["albumin", "GENE_OR_GENE_PRODUCT", 172, 179], ["albumin", "PROTEIN", 11, 18], ["albumin measurements", "TEST", 11, 31], ["neutralizing antibody", "TEST", 99, 120], ["a median decrease", "PROBLEM", 140, 157], ["nasal wash albumin", "TEST", 161, 179], ["neutralizing antibody", "OBSERVATION", 99, 120], ["decrease", "OBSERVATION_MODIFIER", 149, 157], ["nasal", "ANATOMY", 161, 166]]], ["When pre-inoculation antibody was absent, normal subjects developed an increased nasal albumin (median increase 74-5 /ig/ml) during the cold.Measurement of albumin in nasal washesContrasting results were obtained in the atopic group.", [["nasal", "ANATOMY", 81, 86], ["nasal", "ANATOMY", 167, 172], ["atopic", "DISEASE", 220, 226], ["nasal", "ORGANISM_SUBDIVISION", 81, 86], ["albumin", "GENE_OR_GENE_PRODUCT", 87, 94], ["albumin", "GENE_OR_GENE_PRODUCT", 156, 163], ["nasal", "ORGAN", 167, 172], ["pre-inoculation antibody", "PROTEIN", 5, 29], ["albumin", "PROTEIN", 156, 163], ["pre-inoculation antibody", "TEST", 5, 29], ["an increased nasal albumin", "PROBLEM", 68, 94], ["Measurement of albumin in nasal washes", "TEST", 141, 179], ["increased", "OBSERVATION_MODIFIER", 71, 80], ["nasal", "ANATOMY", 81, 86], ["albumin", "OBSERVATION_MODIFIER", 156, 163], ["nasal", "ANATOMY", 167, 172]]], ["In spite of neutralizing antibody being present, atopic individuals developed significant increases in nasal albumin levels (median increase 22-5 yug/ml-P = 0 01 vs normals).", [["nasal", "ANATOMY", 103, 108], ["nasal", "ORGANISM_SUBDIVISION", 103, 108], ["albumin", "GENE_OR_GENE_PRODUCT", 109, 116], ["neutralizing antibody", "PROTEIN", 12, 33], ["neutralizing antibody", "TREATMENT", 12, 33], ["atopic individuals", "PROBLEM", 49, 67], ["significant increases", "PROBLEM", 78, 99], ["nasal albumin levels", "TEST", 103, 123], ["neutralizing antibody", "OBSERVATION", 12, 33], ["significant", "OBSERVATION_MODIFIER", 78, 89], ["increases", "OBSERVATION_MODIFIER", 90, 99], ["nasal", "ANATOMY", 103, 108], ["albumin levels", "OBSERVATION", 109, 123]]], ["This difference was not present in the antibody negative group (atopic vs normals: P = 0-9), or in the normal vs atopic group as a whole (P = 0-54), There was a graded increase in nasal albumin changes associated with a cold, being lowest in normal antibody positive individuals and highest in atopic antibody negative subjects, again confirming increased sensitivity conferred by the atopic trait (/' = 0-04), No significant correlations were found between IgE and nasal albumin (normals: r= -0-2, /' = 0-57; atopies: r = O-l, P = 0-8), In pre-inoculation antibody positive subjects symptom scores were correlated with nasal albumin (r = 0-78, /\" = 0-007) but not in antibody negative individuals (r = 0-36, P = 0-33),DiscussionWe have produced experimental HRV infection in normal and atopic volunteers.", [["nasal", "ANATOMY", 180, 185], ["nasal", "ANATOMY", 466, 471], ["nasal", "ANATOMY", 620, 625], ["atopic", "DISEASE", 64, 70], ["atopic", "DISEASE", 113, 119], ["atopic trait", "DISEASE", 385, 397], ["HRV infection", "DISEASE", 759, 772], ["nasal", "ORGANISM_SUBDIVISION", 180, 185], ["albumin", "GENE_OR_GENE_PRODUCT", 186, 193], ["IgE", "GENE_OR_GENE_PRODUCT", 458, 461], ["nasal", "ORGANISM_SUBDIVISION", 466, 471], ["albumin", "GENE_OR_GENE_PRODUCT", 472, 479], ["nasal", "ORGANISM_SUBDIVISION", 620, 625], ["albumin", "GENE_OR_GENE_PRODUCT", 626, 633], ["volunteers", "ORGANISM", 794, 804], ["IgE", "PROTEIN", 458, 461], ["the antibody", "TEST", 35, 47], ["P", "TEST", 83, 84], ["a graded increase in nasal albumin changes", "PROBLEM", 159, 201], ["a cold", "PROBLEM", 218, 224], ["atopic antibody", "TEST", 294, 309], ["increased sensitivity", "PROBLEM", 346, 367], ["the atopic trait", "TEST", 381, 397], ["IgE", "TEST", 458, 461], ["nasal albumin", "TEST", 466, 479], ["atopies", "TEST", 510, 517], ["O-l", "TEST", 523, 526], ["P", "TEST", 528, 529], ["pre-inoculation antibody", "TEST", 541, 565], ["symptom scores", "TEST", 584, 598], ["nasal albumin", "TEST", 620, 633], ["P", "TEST", 709, 710], ["experimental HRV infection", "PROBLEM", 746, 772], ["normal", "OBSERVATION", 103, 109], ["graded", "OBSERVATION_MODIFIER", 161, 167], ["increase", "OBSERVATION_MODIFIER", 168, 176], ["nasal", "ANATOMY", 180, 185], ["albumin changes", "OBSERVATION", 186, 201], ["antibody positive individuals", "OBSERVATION", 249, 278], ["infection", "OBSERVATION", 763, 772], ["normal", "OBSERVATION", 776, 782]]], ["Good clinical colds were induced as assessed by symptom scores and infection was confirmed by viral shedding with culture and serology.DiscussionAtopic individuals, in contrast to normal volunteers, tended to have more severe cold symptoms as well as greater increases in nasal albumin levels and this was not prevented by pre-inoculation neutralizing antibody.", [["nasal", "ANATOMY", 272, 277], ["colds", "DISEASE", 14, 19], ["infection", "DISEASE", 67, 76], ["volunteers", "ORGANISM", 187, 197], ["nasal", "ORGANISM_SUBDIVISION", 272, 277], ["albumin", "GENE_OR_GENE_PRODUCT", 278, 285], ["pre-inoculation neutralizing antibody", "PROTEIN", 323, 360], ["Good clinical colds", "PROBLEM", 0, 19], ["infection", "PROBLEM", 67, 76], ["culture", "TEST", 114, 121], ["serology", "TEST", 126, 134], ["DiscussionAtopic individuals", "PROBLEM", 135, 163], ["more severe cold symptoms", "PROBLEM", 214, 239], ["greater increases in nasal albumin levels", "PROBLEM", 251, 292], ["infection", "OBSERVATION", 67, 76], ["greater", "OBSERVATION_MODIFIER", 251, 258], ["increases", "OBSERVATION_MODIFIER", 259, 268], ["nasal", "ANATOMY", 272, 277], ["albumin levels", "OBSERVATION", 278, 292]]], ["High IgE levels did not correlate with more severe clinical disease.DiscussionHistorically, induction of experimental infectious disease in volunteers was initiated to permit exploration of various infectious, epidemiological and pathogenetic aspects under controlled conditions.", [["infectious disease", "DISEASE", 118, 136], ["IgE", "GENE_OR_GENE_PRODUCT", 5, 8], ["volunteers", "ORGANISM", 140, 150], ["IgE", "PROTEIN", 5, 8], ["High IgE levels", "TEST", 0, 15], ["more severe clinical disease", "PROBLEM", 39, 67], ["experimental infectious disease", "PROBLEM", 105, 136], ["exploration", "TEST", 175, 186], ["various infectious", "PROBLEM", 190, 208], ["disease", "OBSERVATION", 60, 67], ["infectious", "OBSERVATION", 118, 128], ["various", "OBSERVATION_MODIFIER", 190, 197], ["infectious", "OBSERVATION", 198, 208]]], ["Such human models have been particularly useful in the investigation of viral diseases and have helped to clarify transmission and disease patterns of many respiratory viruses, including rhinoviruses [3, 4, 10] , Recently, attention has focused on the interaction of diseases such as asthma and bronchiec-tasis with respiratory viruses, and studies have examined their role in either direct causation [11] or exacerbations of pre-existing disease [1] .", [["viral diseases", "DISEASE", 72, 86], ["respiratory viruses", "DISEASE", 156, 175], ["rhinoviruses", "DISEASE", 187, 199], ["asthma", "DISEASE", 284, 290], ["bronchiec-tasis", "DISEASE", 295, 310], ["respiratory viruses", "DISEASE", 316, 335], ["human", "ORGANISM", 5, 10], ["human", "SPECIES", 5, 10], ["human", "SPECIES", 5, 10], ["viral diseases", "PROBLEM", 72, 86], ["disease patterns", "PROBLEM", 131, 147], ["many respiratory viruses", "PROBLEM", 151, 175], ["rhinoviruses", "PROBLEM", 187, 199], ["diseases", "PROBLEM", 267, 275], ["asthma", "PROBLEM", 284, 290], ["bronchiec", "TREATMENT", 295, 304], ["respiratory viruses", "PROBLEM", 316, 335], ["pre-existing disease", "PROBLEM", 426, 446], ["many", "OBSERVATION_MODIFIER", 151, 155], ["respiratory viruses", "OBSERVATION", 156, 175], ["diseases", "OBSERVATION", 267, 275], ["respiratory viruses", "OBSERVATION", 316, 335]]], ["Experimental HRV disease has in the past involved groups of normal volunteers in studies of viral transmission and antibody responses, and a few studies have reported data obtained in patient subgroups at particular risk for respiratory complications, such as atopies and asthmatics [5, 12] .", [["respiratory", "ANATOMY", 225, 236], ["HRV disease", "DISEASE", 13, 24], ["respiratory complications", "DISEASE", 225, 250], ["atopies", "DISEASE", 260, 267], ["volunteers", "ORGANISM", 67, 77], ["patient", "ORGANISM", 184, 191], ["patient", "SPECIES", 184, 191], ["Experimental HRV disease", "PROBLEM", 0, 24], ["antibody responses", "TEST", 115, 133], ["a few studies", "TEST", 139, 152], ["respiratory complications", "PROBLEM", 225, 250], ["asthmatics", "PROBLEM", 272, 282], ["disease", "OBSERVATION", 17, 24], ["normal", "OBSERVATION", 60, 66], ["respiratory complications", "OBSERVATION", 225, 250]]], ["Doyle et al. [6] found no evidence to support increased susceptibility of atopic individuals to HRV 39 in spite of a battery of sophisticated and sensitive investigations.DiscussionIn the past, experimental HRV colds have often been induced by instillation of virus-containing drops by pipette into the nose [13] .", [["nose", "ANATOMY", 303, 307], ["atopic", "DISEASE", 74, 80], ["HRV colds", "DISEASE", 207, 216], ["increased susceptibility of atopic individuals", "PROBLEM", 46, 92], ["HRV", "TEST", 96, 99], ["experimental HRV colds", "PROBLEM", 194, 216], ["virus", "TREATMENT", 260, 265], ["no evidence to", "UNCERTAINTY", 23, 37], ["nose", "ANATOMY", 303, 307]]], ["Aerosolized viruses may induce colds more reliably [14] , and recent studies have suggested that the use of an atomiser releasing a fine spray may mimic naturally occurring HRV transmission better [15] .", [["colds", "DISEASE", 31, 36], ["atomiser", "SIMPLE_CHEMICAL", 111, 119], ["Aerosolized viruses", "PROBLEM", 0, 19], ["colds", "PROBLEM", 31, 36], ["recent studies", "TEST", 62, 76], ["an atomiser releasing a fine spray", "TREATMENT", 108, 142], ["viruses", "OBSERVATION", 12, 19]]], ["We have employed both methods and, coupled to relatively high inoculation titres of virus, this method yielded high infection rates as assessed by viral shedding and seroconversion.", [["infection", "DISEASE", 116, 125], ["high inoculation titres of virus", "PROBLEM", 57, 89], ["high infection rates", "PROBLEM", 111, 131], ["viral shedding", "PROBLEM", 147, 161], ["seroconversion", "PROBLEM", 166, 180], ["high", "OBSERVATION_MODIFIER", 111, 115], ["infection", "OBSERVATION", 116, 125]]], ["A high percentage of subjects developed clinical colds as measured by symptom scores and atopic volunteers tended to have moderate to severe colds irrespective of preinoculation neutralizing antibody.", [["colds", "DISEASE", 49, 54], ["colds", "DISEASE", 141, 146], ["volunteers", "ORGANISM", 96, 106], ["preinoculation neutralizing antibody", "PROTEIN", 163, 199], ["clinical colds", "PROBLEM", 40, 54], ["symptom scores", "PROBLEM", 70, 84], ["atopic volunteers", "PROBLEM", 89, 106], ["moderate to severe colds", "PROBLEM", 122, 146], ["preinoculation neutralizing antibody", "PROBLEM", 163, 199], ["high", "OBSERVATION_MODIFIER", 2, 6], ["percentage", "OBSERVATION_MODIFIER", 7, 17], ["moderate", "OBSERVATION_MODIFIER", 122, 130], ["severe", "OBSERVATION_MODIFIER", 134, 140], ["colds", "OBSERVATION", 141, 146], ["neutralizing antibody", "OBSERVATION", 178, 199]]], ["This contrasted with normal subjects who had only mild symptoms when preinoculation antibody in excess of 1:2 dilution was demonstrated.", [["preinoculation antibody", "PROTEIN", 69, 92], ["mild symptoms", "PROBLEM", 50, 63], ["preinoculation antibody", "TEST", 69, 92], ["1:2 dilution", "TREATMENT", 106, 118], ["mild", "OBSERVATION_MODIFIER", 50, 54]]], ["This relatively subjective observation was supported by changes in nasal wash albumin levels found during the cold.", [["nasal", "ANATOMY", 67, 72], ["nasal", "ORGANISM_SUBDIVISION", 67, 72], ["albumin", "GENE_OR_GENE_PRODUCT", 78, 85], ["albumin", "PROTEIN", 78, 85], ["nasal wash albumin levels", "TEST", 67, 92], ["nasal", "ANATOMY", 67, 72]]], ["Naclerio et al. [16] have found a good correlation between intensity of cold symptoms and albumin levels in the nose and we employed the same measurement to obtain an objective parameter of severity in our group of volunteers.", [["nose", "ANATOMY", 112, 116], ["albumin", "GENE_OR_GENE_PRODUCT", 90, 97], ["nose", "ORGAN", 112, 116], ["volunteers", "ORGANISM", 215, 225], ["albumin", "PROTEIN", 90, 97], ["cold symptoms", "PROBLEM", 72, 85], ["albumin levels", "TEST", 90, 104], ["nose", "ANATOMY", 112, 116]]], ["Albumin influx represents a passive transudation of plasma likely reflecting degrees of nasal mucosal inflammation associated with clinical cold symptoms.", [["plasma", "ANATOMY", 52, 58], ["nasal mucosal", "ANATOMY", 88, 101], ["inflammation", "DISEASE", 102, 114], ["Albumin", "GENE_OR_GENE_PRODUCT", 0, 7], ["plasma", "ORGANISM_SUBSTANCE", 52, 58], ["nasal mucosal", "PATHOLOGICAL_FORMATION", 88, 101], ["Albumin influx", "TEST", 0, 14], ["a passive transudation of plasma", "PROBLEM", 26, 58], ["nasal mucosal inflammation", "PROBLEM", 88, 114], ["clinical cold symptoms", "PROBLEM", 131, 153], ["passive transudation", "OBSERVATION", 28, 48], ["likely", "UNCERTAINTY", 59, 65], ["reflecting degrees", "OBSERVATION_MODIFIER", 66, 84], ["nasal mucosal", "ANATOMY", 88, 101], ["inflammation", "OBSERVATION", 102, 114]]], ["Changes in albumin levels during the cold were significantly higher in atopic subjects who had neutralizing antibodies present compared with normal individuals ( Table 2 ).", [["albumin", "GENE_OR_GENE_PRODUCT", 11, 18], ["albumin", "PROTEIN", 11, 18], ["neutralizing antibodies", "PROTEIN", 95, 118], ["Changes in albumin levels", "PROBLEM", 0, 25], ["neutralizing antibodies", "TEST", 95, 118], ["albumin levels", "OBSERVATION_MODIFIER", 11, 25]]], ["The largest changes in albumin levels were noted in atopic antibody negative volunteers, but when total groups were compared irrespective of pre-inoculation antibody, no differences were noted for either symptom scores or albumin levels.DiscussionOur results suggest that the presence or absence of neutralizing antibody is the primary determinant of the host's clinical response to a HRV cold.", [["atopic antibody negative", "DISEASE", 52, 76], ["albumin", "GENE_OR_GENE_PRODUCT", 23, 30], ["volunteers", "ORGANISM", 77, 87], ["albumin", "GENE_OR_GENE_PRODUCT", 222, 229], ["albumin", "PROTEIN", 23, 30], ["pre-inoculation antibody", "PROTEIN", 141, 165], ["albumin", "PROTEIN", 222, 229], ["neutralizing antibody", "PROTEIN", 299, 320], ["The largest changes in albumin levels", "PROBLEM", 0, 37], ["atopic antibody negative volunteers", "PROBLEM", 52, 87], ["pre-inoculation antibody", "PROBLEM", 141, 165], ["symptom scores", "TEST", 204, 218], ["albumin levels", "TEST", 222, 236], ["neutralizing antibody", "PROBLEM", 299, 320], ["a HRV cold", "PROBLEM", 383, 393], ["largest", "OBSERVATION_MODIFIER", 4, 11], ["albumin levels", "OBSERVATION", 23, 37], ["neutralizing antibody", "OBSERVATION", 299, 320]]], ["This overrides the effects of atopy and conceals its infiuence in any comparisons because of the relative severity of disease in normal antibody negative individuals.", [["atopy", "DISEASE", 30, 35], ["atopy", "PROBLEM", 30, 35], ["disease", "PROBLEM", 118, 125], ["disease", "OBSERVATION", 118, 125], ["normal antibody", "OBSERVATION", 129, 144]]], ["However, when these antibody negative normal and atopic groups are excluded from analysis, the increased sensitivity of atopie subjeets becomes obvious.", [["these antibody", "TEST", 14, 28], ["atopic groups", "PROBLEM", 49, 62], ["analysis", "TEST", 81, 89], ["the increased sensitivity of atopie subjeets", "PROBLEM", 91, 135]]], ["We cannot exclude that we have identified pre-existing rhinitic symptoms; however, baseline symptoms, if present, were subtracted to adjust the final scores.", [["pre-existing rhinitic symptoms", "PROBLEM", 42, 72], ["baseline symptoms", "PROBLEM", 83, 100], ["cannot exclude", "UNCERTAINTY", 3, 17]]], ["Furthermore, only two atopic subjects in this sub-group had a history of atopic rhinitis and symptom scores were corroborated by changes in nasal albumin levels.DiscussionOur data do not correspond to the findings of Doyle et al. [6] .", [["nasal", "ANATOMY", 140, 145], ["atopic", "DISEASE", 22, 28], ["atopic rhinitis", "DISEASE", 73, 88], ["nasal", "ORGANISM_SUBDIVISION", 140, 145], ["albumin", "GENE_OR_GENE_PRODUCT", 146, 153], ["two atopic subjects", "PROBLEM", 18, 37], ["atopic rhinitis", "PROBLEM", 73, 88], ["symptom scores", "PROBLEM", 93, 107], ["nasal albumin levels", "TEST", 140, 160], ["DiscussionOur data", "TEST", 161, 179], ["two", "OBSERVATION_MODIFIER", 18, 21], ["atopic", "OBSERVATION", 22, 28], ["atopic rhinitis", "OBSERVATION", 73, 88], ["nasal", "ANATOMY", 140, 145], ["albumin levels", "OBSERVATION", 146, 160]]], ["All subjects in their study were antibody negative at screening and for reasons outlined above, differences between atopic and normal individuals would not have been apparent unless stratification was possible for positive and negative preinoculation antibody levels.", [["atopic", "DISEASE", 116, 122], ["their study", "TEST", 16, 27], ["antibody", "TEST", 33, 41], ["atopic", "PROBLEM", 116, 122], ["positive and negative preinoculation antibody levels", "PROBLEM", 214, 266]]], ["Although other studies [17] have also tried to compare severity and found no differences, their study design and methods were not comparable to our study.", [["other studies", "TEST", 9, 22], ["their study", "TEST", 90, 101], ["our study", "TEST", 144, 153]]], ["In support of our results a study of experimental coronavirus 229E infection suggested that atopy may be related to the severity of cold symptoms.", [["coronavirus 229E infection", "DISEASE", 50, 76], ["atopy", "DISEASE", 92, 97], ["coronavirus 229E", "ORGANISM", 50, 66], ["coronavirus", "SPECIES", 50, 61], ["coronavirus 229E", "SPECIES", 50, 66], ["a study", "TEST", 26, 33], ["experimental coronavirus 229E infection", "PROBLEM", 37, 76], ["atopy", "PROBLEM", 92, 97], ["cold symptoms", "PROBLEM", 132, 145]]], ["Associations were also found between clinical cold scores and nasal and serum IgE concentrations [18] .DiscussionThe discrepancy between absent initial H RV 16 neutralizing antibody levels and low titres on the day prior to inoculation was unexpected.", [["nasal", "ANATOMY", 62, 67], ["serum", "ANATOMY", 72, 77], ["nasal", "ORGANISM_SUBDIVISION", 62, 67], ["serum", "ORGANISM_SUBSTANCE", 72, 77], ["IgE", "ORGANISM_SUBSTANCE", 78, 81], ["IgE", "PROTEIN", 78, 81], ["clinical cold scores", "TEST", 37, 57], ["nasal and serum IgE concentrations", "TREATMENT", 62, 96], ["neutralizing antibody levels", "TEST", 160, 188], ["low titres", "PROBLEM", 193, 203], ["inoculation", "PROBLEM", 224, 235], ["nasal", "ANATOMY", 62, 67]]], ["Our repeat measurements of neutralizing antibody titres on the same sample are within one doubling dilution and assays were always performed in duplicate.", [["sample", "ANATOMY", 68, 74], ["Our repeat measurements", "TEST", 0, 23], ["neutralizing antibody titres", "TEST", 27, 55], ["assays", "TEST", 112, 118]]], ["Because of consistent results in duplicate experiments and minor variability in repeat assays, technical factors are unlikely to explain changes.", [["minor variability", "PROBLEM", 59, 76], ["repeat assays", "TEST", 80, 93], ["minor", "OBSERVATION_MODIFIER", 59, 64], ["variability", "OBSERVATION_MODIFIER", 65, 76]]], ["A possible reason may be the development of crossreactive neutralizing antibody as a response to HRV colds caused by other serotypes.", [["colds", "DISEASE", 101, 106], ["crossreactive neutralizing antibody", "PROTEIN", 44, 79], ["crossreactive neutralizing antibody", "PROBLEM", 44, 79], ["HRV colds", "PROBLEM", 97, 106], ["other serotypes", "PROBLEM", 117, 132], ["possible reason may be", "UNCERTAINTY", 2, 24], ["crossreactive", "OBSERVATION_MODIFIER", 44, 57], ["neutralizing antibody", "OBSERVATION", 58, 79]]], ["This phenomenon has been reported and an antibody crossreactive relationship has been demonstrated between HRV lA and 30 heterotypic serotypes [19] .", [["lA", "GENE_OR_GENE_PRODUCT", 111, 113], ["an antibody crossreactive relationship", "PROBLEM", 38, 76], ["HRV lA", "TEST", 107, 113]]], ["Although we bave no definite evidence, we surmise that the majority of these volunteers had developed HRV-associated colds in the interim period before inoculation and developed neutralizing antibody crossreactive to HRV 16.", [["colds", "DISEASE", 117, 122], ["volunteers", "ORGANISM", 77, 87], ["neutralizing antibody", "PROTEIN", 178, 199], ["HRV", "PROBLEM", 102, 105], ["associated colds", "PROBLEM", 106, 122], ["inoculation", "PROBLEM", 152, 163], ["neutralizing antibody", "TEST", 178, 199], ["HRV", "TEST", 217, 220], ["no definite evidence", "UNCERTAINTY", 17, 37], ["neutralizing antibody", "OBSERVATION", 178, 199]]], ["Previous inoculation studies have reported a similar lack of serological response after a cold in the presence of neutralizing antibody levels equal to or exceeding 1:8 dilution [20] as demonstrated in this study.", [["neutralizing antibody", "PROTEIN", 114, 135], ["Previous inoculation studies", "TEST", 0, 28], ["serological response", "PROBLEM", 61, 81], ["neutralizing antibody levels", "TEST", 114, 142], ["this study", "TEST", 202, 212]]], ["This low level antibody did not prevent the development of infection in both normal and atopic volunteers, probably the result of the relatively high doses of virus used for inoculation.", [["infection", "DISEASE", 59, 68], ["volunteers", "ORGANISM", 95, 105], ["This low level antibody", "PROBLEM", 0, 23], ["infection", "PROBLEM", 59, 68], ["virus", "TREATMENT", 159, 164], ["inoculation", "PROBLEM", 174, 185], ["infection", "OBSERVATION", 59, 68], ["normal", "OBSERVATION", 77, 83]]], ["No associations were found between age and sex and the various parameters of infection; a finding similar to earlier reports [4] .DiscussionThe role of high IgE serum levels as a marker of increased susceptibility to rhinoviral disease has not been evaluated.", [["serum", "ANATOMY", 161, 166], ["rhinoviral", "ANATOMY", 217, 227], ["infection", "DISEASE", 77, 86], ["rhinoviral disease", "DISEASE", 217, 235], ["IgE", "GENE_OR_GENE_PRODUCT", 157, 160], ["serum", "ORGANISM_SUBSTANCE", 161, 166], ["IgE", "PROTEIN", 157, 160], ["infection", "PROBLEM", 77, 86], ["high IgE serum levels", "TEST", 152, 173], ["increased susceptibility to rhinoviral disease", "PROBLEM", 189, 235], ["infection", "OBSERVATION", 77, 86], ["increased", "OBSERVATION_MODIFIER", 189, 198], ["rhinoviral disease", "OBSERVATION", 217, 235]]], ["Although our data in a limited number of subjects suggests greater susceptibility of atopic individuals (as defined by skin testing), severity of symptoms and nasal albumin levels were not correlated with IgE levels.", [["skin", "ANATOMY", 119, 123], ["nasal", "ANATOMY", 159, 164], ["atopic", "DISEASE", 85, 91], ["skin", "ORGAN", 119, 123], ["nasal", "ORGANISM_SUBDIVISION", 159, 164], ["albumin", "GENE_OR_GENE_PRODUCT", 165, 172], ["IgE", "GENE_OR_GENE_PRODUCT", 205, 208], ["IgE", "PROTEIN", 205, 208], ["our data", "TEST", 9, 17], ["greater susceptibility of atopic individuals", "PROBLEM", 59, 103], ["skin testing", "TEST", 119, 131], ["severity of symptoms", "PROBLEM", 134, 154], ["nasal albumin levels", "TEST", 159, 179], ["IgE levels", "TEST", 205, 215], ["greater", "OBSERVATION_MODIFIER", 59, 66], ["susceptibility", "OBSERVATION_MODIFIER", 67, 81], ["skin", "ANATOMY", 119, 123], ["nasal", "ANATOMY", 159, 164]]], ["Tissue events may not parallel serum markers and serum IgE may thus not reflect levels of IgE or other atopy-associated mediators in nasal and other tissues.", [["Tissue", "ANATOMY", 0, 6], ["serum", "ANATOMY", 31, 36], ["serum", "ANATOMY", 49, 54], ["nasal", "ANATOMY", 133, 138], ["tissues", "ANATOMY", 149, 156], ["Tissue", "TISSUE", 0, 6], ["serum", "ORGANISM_SUBSTANCE", 31, 36], ["serum", "ORGANISM_SUBSTANCE", 49, 54], ["IgE", "GENE_OR_GENE_PRODUCT", 55, 58], ["IgE", "GENE_OR_GENE_PRODUCT", 90, 93], ["nasal", "MULTI-TISSUE_STRUCTURE", 133, 138], ["tissues", "TISSUE", 149, 156], ["serum markers", "PROTEIN", 31, 44], ["serum IgE", "PROTEIN", 49, 58], ["IgE", "PROTEIN", 90, 93], ["Tissue events", "PROBLEM", 0, 13], ["parallel serum markers", "TEST", 22, 44], ["serum IgE", "TEST", 49, 58], ["levels of IgE", "PROBLEM", 80, 93], ["other atopy", "PROBLEM", 97, 108], ["associated mediators in nasal and other tissues", "PROBLEM", 109, 156], ["nasal", "ANATOMY", 133, 138], ["other tissues", "ANATOMY", 143, 156]]], ["Alternatively, although the symptom score that we employed is sensitive to detect colds, it may be relatively insensitive in the presence of severe symptoms and not suitable to discriminate between moderately severe and very severe colds.", [["colds", "DISEASE", 82, 87], ["colds", "DISEASE", 232, 237], ["the symptom score", "PROBLEM", 24, 41], ["colds", "PROBLEM", 82, 87], ["severe symptoms", "PROBLEM", 141, 156], ["moderately severe and very severe colds", "PROBLEM", 198, 237], ["severe", "OBSERVATION_MODIFIER", 141, 147], ["moderately", "OBSERVATION_MODIFIER", 198, 208], ["severe", "OBSERVATION_MODIFIER", 209, 215], ["very", "OBSERVATION_MODIFIER", 220, 224], ["severe", "OBSERVATION_MODIFIER", 225, 231], ["colds", "OBSERVATION", 232, 237]]], ["Lack of such distinction will naturally hamper correlations sought with IgE levels, Atopic individuals may therefore exhibit an increased sensitivity to the consequences of a common cold, prompting the suggestion that allergic tissues were 'preprimed' by the existing allergic disease [21], Although the mediators involved in cold symptoms are not defined, it can be speculated that the quantities of various cytokines (for example IL-8, GM-CSF) as well as inflammatory mediators (leukotrienes, kinins) may be amplified in atopic tissues, causing more severe symptoms when released, Kinins are potent vasoactive peptides identified in nasal secretions during colds; they cause vasodilation and increased vascular permeability, and are probably generated in the nose during a cold [16] , Additionally, because intercellular adhesion molecule-1 (ICAM-1) is the cellular receptor for the major group of HRVs and may be upregulated in allergic inflammation, atopic individuals may be predisposed to higher rates of HRV infection and even further increases in ICAM-1 accompanied by the nasal recruitment of mediator cells able to amplify existing inflammation [22] , In summary, our studies employing an experimental HRV disease programme in normal and atopic volunteers yielded significant upper airway cold symptoms of greater severity in the atopic group.", [["tissues", "ANATOMY", 227, 234], ["tissues", "ANATOMY", 530, 537], ["nasal secretions", "ANATOMY", 635, 651], ["vascular", "ANATOMY", 704, 712], ["nose", "ANATOMY", 761, 765], ["cellular", "ANATOMY", 859, 867], ["nasal", "ANATOMY", 1081, 1086], ["cells", "ANATOMY", 1111, 1116], ["upper airway", "ANATOMY", 1286, 1298], ["allergic", "DISEASE", 218, 226], ["allergic disease", "DISEASE", 268, 284], ["atopic tissues", "DISEASE", 523, 537], ["colds", "DISEASE", 659, 664], ["allergic inflammation", "DISEASE", 931, 952], ["HRV infection", "DISEASE", 1011, 1024], ["inflammation", "DISEASE", 1142, 1154], ["HRV disease", "DISEASE", 1212, 1223], ["atopic", "DISEASE", 1340, 1346], ["IgE", "GENE_OR_GENE_PRODUCT", 72, 75], ["allergic tissues", "TISSUE", 218, 234], ["IL-8", "GENE_OR_GENE_PRODUCT", 432, 436], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 438, 444], ["leukotrienes", "SIMPLE_CHEMICAL", 481, 493], ["kinins", "GENE_OR_GENE_PRODUCT", 495, 501], ["atopic tissues", "TISSUE", 523, 537], ["Kinins", "GENE_OR_GENE_PRODUCT", 583, 589], ["nasal secretions", "ORGANISM_SUBSTANCE", 635, 651], ["vascular", "MULTI-TISSUE_STRUCTURE", 704, 712], ["nose", "ORGAN", 761, 765], ["intercellular adhesion molecule-1", "GENE_OR_GENE_PRODUCT", 809, 842], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 844, 850], ["cellular", "CELL", 859, 867], ["HRVs", "GENE_OR_GENE_PRODUCT", 900, 904], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 1055, 1061], ["nasal", "ORGANISM_SUBDIVISION", 1081, 1086], ["cells", "CELL", 1111, 1116], ["volunteers", "ORGANISM", 1255, 1265], ["upper airway", "ORGANISM_SUBDIVISION", 1286, 1298], ["IgE", "PROTEIN", 72, 75], ["cytokines", "PROTEIN", 409, 418], ["IL-8", "PROTEIN", 432, 436], ["GM", "PROTEIN", 438, 440], ["CSF", "PROTEIN", 441, 444], ["inflammatory mediators", "PROTEIN", 457, 479], ["ICAM", "PROTEIN", 844, 848], ["ICAM-1", "PROTEIN", 1055, 1061], ["mediator cells", "CELL_TYPE", 1102, 1116], ["IgE levels", "TEST", 72, 82], ["Atopic individuals", "PROBLEM", 84, 102], ["an increased sensitivity", "PROBLEM", 125, 149], ["a common cold", "PROBLEM", 173, 186], ["allergic tissues", "PROBLEM", 218, 234], ["the existing allergic disease", "PROBLEM", 255, 284], ["cold symptoms", "PROBLEM", 326, 339], ["various cytokines", "TEST", 401, 418], ["IL", "TEST", 432, 434], ["inflammatory mediators (leukotrienes, kinins", "TREATMENT", 457, 501], ["more severe symptoms", "PROBLEM", 547, 567], ["potent vasoactive peptides", "PROBLEM", 594, 620], ["nasal secretions", "PROBLEM", 635, 651], ["colds", "PROBLEM", 659, 664], ["vasodilation", "PROBLEM", 677, 689], ["increased vascular permeability", "PROBLEM", 694, 725], ["intercellular adhesion molecule", "TEST", 809, 840], ["ICAM", "TEST", 844, 848], ["HRVs", "TREATMENT", 900, 904], ["allergic inflammation", "PROBLEM", 931, 952], ["atopic individuals", "PROBLEM", 954, 972], ["HRV infection", "PROBLEM", 1011, 1024], ["ICAM", "TEST", 1055, 1059], ["the nasal recruitment of mediator cells", "TREATMENT", 1077, 1116], ["our studies", "TEST", 1174, 1185], ["an experimental HRV disease programme", "PROBLEM", 1196, 1233], ["significant upper airway cold symptoms", "PROBLEM", 1274, 1312], ["greater severity in the atopic group", "PROBLEM", 1316, 1352], ["nasal", "ANATOMY", 635, 640], ["secretions", "OBSERVATION", 641, 651], ["increased", "OBSERVATION_MODIFIER", 694, 703], ["vascular permeability", "OBSERVATION", 704, 725], ["nose", "ANATOMY", 761, 765], ["may be", "UNCERTAINTY", 909, 915], ["allergic inflammation", "OBSERVATION", 931, 952], ["infection", "OBSERVATION", 1015, 1024], ["nasal", "ANATOMY", 1081, 1086], ["significant", "OBSERVATION_MODIFIER", 1274, 1285], ["upper", "ANATOMY_MODIFIER", 1286, 1291], ["airway", "ANATOMY", 1292, 1298], ["greater", "OBSERVATION_MODIFIER", 1316, 1323], ["severity", "OBSERVATION_MODIFIER", 1324, 1332]]], ["Further utilization of this or similar protocols will allow the clarification of some ofthe operative pathophysiological mechanisms and their relationship to atopy and asthma.", [["atopy", "DISEASE", 158, 163], ["asthma", "DISEASE", 168, 174], ["atopy", "PROBLEM", 158, 163], ["asthma", "PROBLEM", 168, 174], ["asthma", "OBSERVATION", 168, 174]]]], "20f1d4a18b2f757fe76adc91cfb61d07d444fabb": [["Apoptosis is initiated in a receptor-mediated manner through the extrinsic pathway, or through altered mitochondrial permeability via the intrinsic pathway.", [["mitochondrial", "ANATOMY", 103, 116], ["mitochondrial", "CELLULAR_COMPONENT", 103, 116], ["Apoptosis", "PROBLEM", 0, 9], ["the extrinsic pathway", "TEST", 61, 82], ["altered mitochondrial permeability", "PROBLEM", 95, 129], ["mitochondrial permeability", "OBSERVATION", 103, 129]]], ["Activation of either results in the assembly of macromolecular complexes that lead to initiator caspase activation, and, in turn, to the activation of effector caspases such as caspase-3.", [["caspase", "GENE_OR_GENE_PRODUCT", 96, 103], ["caspases", "GENE_OR_GENE_PRODUCT", 160, 168], ["caspase-3", "GENE_OR_GENE_PRODUCT", 177, 186], ["macromolecular complexes", "PROTEIN", 48, 72], ["caspase", "PROTEIN", 96, 103], ["effector caspases", "PROTEIN", 151, 168], ["caspase-3", "PROTEIN", 177, 186], ["macromolecular complexes", "PROBLEM", 48, 72], ["initiator caspase activation", "TREATMENT", 86, 114], ["effector caspases", "TREATMENT", 151, 168], ["caspase", "TREATMENT", 177, 184]]], ["This process can be inhibited by intracellular inhibitor of apoptosis proteins, and the action of these, in turn, can be blocked by proteins such as Smac/DIABLO.", [["intracellular", "ANATOMY", 33, 46], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 33, 46], ["Smac", "GENE_OR_GENE_PRODUCT", 149, 153], ["DIABLO", "GENE_OR_GENE_PRODUCT", 154, 160], ["apoptosis proteins", "PROTEIN", 60, 78], ["Smac", "PROTEIN", 149, 153], ["DIABLO", "PROTEIN", 154, 160], ["apoptosis proteins", "PROBLEM", 60, 78], ["Smac/DIABLO", "TREATMENT", 149, 160]]]], "PMC4830774": [["BackgroundAs one of the most common type of liver cancer, hepatocellular carcinoma (HCC) is the third cause of malignant deaths from cancer-associated worldwide [1\u20133].", [["liver cancer", "ANATOMY", 44, 56], ["hepatocellular carcinoma", "ANATOMY", 58, 82], ["HCC", "ANATOMY", 84, 87], ["cancer", "ANATOMY", 133, 139], ["liver cancer", "DISEASE", 44, 56], ["hepatocellular carcinoma", "DISEASE", 58, 82], ["HCC", "DISEASE", 84, 87], ["deaths", "DISEASE", 121, 127], ["cancer", "DISEASE", 133, 139], ["liver cancer", "CANCER", 44, 56], ["hepatocellular carcinoma", "CANCER", 58, 82], ["HCC", "CANCER", 84, 87], ["malignant deaths", "CANCER", 111, 127], ["cancer", "CANCER", 133, 139], ["liver cancer", "PROBLEM", 44, 56], ["hepatocellular carcinoma", "PROBLEM", 58, 82], ["HCC", "PROBLEM", 84, 87], ["malignant deaths", "PROBLEM", 111, 127], ["cancer", "PROBLEM", 133, 139], ["most common", "OBSERVATION_MODIFIER", 24, 35], ["liver", "ANATOMY", 44, 49], ["cancer", "OBSERVATION", 50, 56], ["hepatocellular carcinoma", "OBSERVATION", 58, 82], ["malignant", "OBSERVATION_MODIFIER", 111, 120], ["cancer", "OBSERVATION", 133, 139]]], ["Unfortunately, the diagnosis of HCC is difficult in its earliest stages without screening tests available [4].", [["HCC", "ANATOMY", 32, 35], ["HCC", "DISEASE", 32, 35], ["HCC", "CANCER", 32, 35], ["HCC", "PROBLEM", 32, 35], ["screening tests", "TEST", 80, 95], ["HCC", "OBSERVATION", 32, 35]]], ["Meanwhile, owing to its poor sensitivity to chemotherapeutic agents, high metastatic potential, and resistance to traditional drugs, it is dismal to the overall prognosis of patients with HCC.", [["HCC", "ANATOMY", 188, 191], ["HCC", "DISEASE", 188, 191], ["patients", "ORGANISM", 174, 182], ["HCC", "CANCER", 188, 191], ["patients", "SPECIES", 174, 182], ["chemotherapeutic agents", "TREATMENT", 44, 67], ["high metastatic potential", "PROBLEM", 69, 94], ["traditional drugs", "TREATMENT", 114, 131], ["HCC", "PROBLEM", 188, 191], ["metastatic", "OBSERVATION_MODIFIER", 74, 84], ["HCC", "OBSERVATION", 188, 191]]], ["Thus, it is imperative to develop efficient chemotherapy that has become the great challenge in clinical treatment [5, 6].", [["efficient chemotherapy", "TREATMENT", 34, 56], ["clinical treatment", "TREATMENT", 96, 114]]], ["In addition, most of current anticancer agents usually have short half-life in the blood circulation and poor aqueous solubility, which hampers therapeutic efficacy of chemotherapy [7, 8].", [["anticancer", "ANATOMY", 29, 39], ["blood", "ANATOMY", 83, 88], ["aqueous", "ANATOMY", 110, 117], ["anticancer", "CANCER", 29, 39], ["blood", "ORGANISM_SUBSTANCE", 83, 88], ["aqueous", "ORGANISM_SUBSTANCE", 110, 117], ["current anticancer agents", "TREATMENT", 21, 46], ["poor aqueous solubility", "PROBLEM", 105, 128], ["chemotherapy", "TREATMENT", 168, 180], ["blood", "ANATOMY", 83, 88], ["poor", "OBSERVATION_MODIFIER", 105, 109], ["aqueous solubility", "OBSERVATION", 110, 128]]], ["Recently, nanomaterials have been widely used in biomedical field due to its unique physicochemical properties, including their size distribution, stability of dispersion, morphology, crystalline structure, and thermal properties, that might have the potential to overcome these problems [9].", [["dispersion, morphology, crystalline structure", "PROBLEM", 160, 205], ["these problems", "PROBLEM", 273, 287], ["physicochemical properties", "OBSERVATION", 84, 110], ["size", "OBSERVATION_MODIFIER", 128, 132], ["distribution", "OBSERVATION_MODIFIER", 133, 145], ["stability", "OBSERVATION_MODIFIER", 147, 156], ["dispersion", "OBSERVATION_MODIFIER", 160, 170], ["morphology", "OBSERVATION_MODIFIER", 172, 182], ["crystalline structure", "OBSERVATION", 184, 205], ["thermal properties", "OBSERVATION_MODIFIER", 211, 229]]], ["The increased of application of nanomaterials resulted in raising hopes for employing nanoparticles as alternative anticancer agents [10, 11].BackgroundSilver nanoparticles (AgNPs) are less toxic than other form of silver that has obtained an easy access to cells and tissues [12, 13].", [["anticancer", "ANATOMY", 115, 125], ["cells", "ANATOMY", 258, 263], ["tissues", "ANATOMY", 268, 275], ["BackgroundSilver nanoparticles", "CHEMICAL", 142, 172], ["AgNPs", "CHEMICAL", 174, 179], ["silver", "CHEMICAL", 215, 221], ["silver", "CHEMICAL", 215, 221], ["anticancer", "CANCER", 115, 125], ["BackgroundSilver nanoparticles", "SIMPLE_CHEMICAL", 142, 172], ["AgNPs", "SIMPLE_CHEMICAL", 174, 179], ["silver", "SIMPLE_CHEMICAL", 215, 221], ["cells", "CELL", 258, 263], ["tissues", "TISSUE", 268, 275], ["application of nanomaterials", "TREATMENT", 17, 45], ["employing nanoparticles", "TREATMENT", 76, 99], ["alternative anticancer agents", "TREATMENT", 103, 132], ["BackgroundSilver nanoparticles (AgNPs", "PROBLEM", 142, 179], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["less toxic", "OBSERVATION_MODIFIER", 185, 195]]], ["AgNPs attract considerable public attention in consumer and medical products compared to other metal materials for their excellent surface enhanced Raman scattering and unique antimicrobial activities [14\u201317].", [["surface", "ANATOMY", 131, 138], ["AgNPs", "CHEMICAL", 0, 5], ["AgNPs", "SIMPLE_CHEMICAL", 0, 5], ["medical products", "TREATMENT", 60, 76], ["other metal materials", "TREATMENT", 89, 110]]], ["Silver nanoparticles have been used widely as antibacterial agents in food storage and environmental [18\u201321].", [["Silver nanoparticles", "CHEMICAL", 0, 20], ["Silver", "CHEMICAL", 0, 6], ["Silver nanoparticles", "SIMPLE_CHEMICAL", 0, 20], ["Silver nanoparticles", "TREATMENT", 0, 20], ["antibacterial agents", "TREATMENT", 46, 66]]], ["Furthermore, AgNPs exhibit low toxicity in humans and have diverse in vitro and in vivo application [22\u201324].", [["AgNPs", "CHEMICAL", 13, 18], ["toxicity", "DISEASE", 31, 39], ["AgNPs", "SIMPLE_CHEMICAL", 13, 18], ["humans", "ORGANISM", 43, 49], ["humans", "SPECIES", 43, 49], ["humans", "SPECIES", 43, 49], ["low toxicity in humans", "PROBLEM", 27, 49], ["low toxicity", "OBSERVATION", 27, 39], ["diverse", "OBSERVATION_MODIFIER", 59, 66]]], ["Moreover, AgNPs have also been shown to combine with corona virus and restrain to bind host cells [25].", [["cells", "ANATOMY", 92, 97], ["AgNPs", "CHEMICAL", 10, 15], ["AgNPs", "SIMPLE_CHEMICAL", 10, 15], ["corona virus", "ORGANISM", 53, 65], ["cells", "CELL", 92, 97], ["host cells", "CELL_TYPE", 87, 97], ["corona virus", "SPECIES", 53, 65], ["corona virus", "PROBLEM", 53, 65]]], ["Thus, exposure to silver nanoparticles as a promising anticancer silver species is becoming increasing intimate and widespread.BackgroundReactive oxygen species (ROS) encompasses highly reactive molecules, including superoxide anion radical, oxygen free radicals, hydroxyl radical, hydrogen peroxide, and singlet oxygen [26].", [["anticancer", "ANATOMY", 54, 64], ["silver nanoparticles", "CHEMICAL", 18, 38], ["silver", "CHEMICAL", 65, 71], ["oxygen", "CHEMICAL", 146, 152], ["ROS", "CHEMICAL", 162, 165], ["superoxide", "CHEMICAL", 216, 226], ["oxygen", "CHEMICAL", 242, 248], ["hydroxyl", "CHEMICAL", 264, 272], ["hydrogen peroxide", "CHEMICAL", 282, 299], ["oxygen", "CHEMICAL", 313, 319], ["silver", "CHEMICAL", 18, 24], ["silver", "CHEMICAL", 65, 71], ["oxygen", "CHEMICAL", 146, 152], ["superoxide", "CHEMICAL", 216, 226], ["oxygen", "CHEMICAL", 242, 248], ["hydroxyl", "CHEMICAL", 264, 272], ["hydrogen peroxide", "CHEMICAL", 282, 299], ["oxygen", "CHEMICAL", 313, 319], ["silver nanoparticles", "SIMPLE_CHEMICAL", 18, 38], ["anticancer", "CANCER", 54, 64], ["BackgroundReactive oxygen species", "SIMPLE_CHEMICAL", 127, 160], ["ROS", "SIMPLE_CHEMICAL", 162, 165], ["superoxide anion radical", "SIMPLE_CHEMICAL", 216, 240], ["oxygen free radicals", "SIMPLE_CHEMICAL", 242, 262], ["hydroxyl radical", "SIMPLE_CHEMICAL", 264, 280], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 282, 299], ["singlet oxygen", "SIMPLE_CHEMICAL", 305, 319], ["silver nanoparticles", "TREATMENT", 18, 38], ["a promising anticancer silver species", "PROBLEM", 42, 79], ["BackgroundReactive oxygen species", "PROBLEM", 127, 160], ["highly reactive molecules", "PROBLEM", 179, 204], ["superoxide anion radical", "TREATMENT", 216, 240], ["oxygen free radicals", "TREATMENT", 242, 262], ["hydroxyl radical", "TREATMENT", 264, 280], ["hydrogen peroxide", "TREATMENT", 282, 299], ["singlet oxygen", "TREATMENT", 305, 319], ["anticancer silver species", "OBSERVATION", 54, 79], ["increasing", "OBSERVATION_MODIFIER", 92, 102], ["widespread", "OBSERVATION_MODIFIER", 116, 126], ["oxygen species", "OBSERVATION", 146, 160], ["reactive molecules", "OBSERVATION", 186, 204]]], ["As a marked imbalance, oxidative stress is the most often described between cellular defense mechanisms and consumption of ROS [27].", [["cellular", "ANATOMY", 76, 84], ["ROS", "CHEMICAL", 123, 126], ["cellular", "CELL", 76, 84], ["ROS", "SIMPLE_CHEMICAL", 123, 126], ["a marked imbalance", "PROBLEM", 3, 21], ["oxidative stress", "PROBLEM", 23, 39], ["marked", "OBSERVATION_MODIFIER", 5, 11], ["imbalance", "OBSERVATION", 12, 21], ["oxidative stress", "OBSERVATION", 23, 39]]], ["The ROS play an important role in many physiological processes.", [["ROS", "CHEMICAL", 4, 7], ["ROS", "SIMPLE_CHEMICAL", 4, 7]]], ["The redox imbalance is associated with many pathologies, such as skin disease, diabetes, cancer, Leigh syndrome, and other diseases [28].", [["skin", "ANATOMY", 65, 69], ["cancer", "ANATOMY", 89, 95], ["skin disease", "DISEASE", 65, 77], ["diabetes", "DISEASE", 79, 87], ["cancer", "DISEASE", 89, 95], ["Leigh syndrome", "DISEASE", 97, 111], ["skin", "ORGAN", 65, 69], ["cancer", "CANCER", 89, 95], ["The redox imbalance", "PROBLEM", 0, 19], ["many pathologies", "PROBLEM", 39, 55], ["skin disease", "PROBLEM", 65, 77], ["diabetes", "PROBLEM", 79, 87], ["cancer", "PROBLEM", 89, 95], ["Leigh syndrome", "PROBLEM", 97, 111], ["other diseases", "PROBLEM", 117, 131], ["redox imbalance", "OBSERVATION", 4, 19], ["associated with", "UNCERTAINTY", 23, 38], ["many", "OBSERVATION_MODIFIER", 39, 43], ["pathologies", "OBSERVATION", 44, 55], ["skin", "ANATOMY", 65, 69], ["disease", "OBSERVATION", 70, 77], ["diabetes", "OBSERVATION", 79, 87], ["cancer", "OBSERVATION", 89, 95], ["Leigh syndrome", "OBSERVATION", 97, 111]]], ["Although many research groups describe the toxicity of AgNP induction of oxidative stress, little is known about the anticancer mechanisms of AgNPs [29].", [["anticancer", "ANATOMY", 117, 127], ["toxicity", "DISEASE", 43, 51], ["AgNP", "CHEMICAL", 55, 59], ["AgNPs", "CHEMICAL", 142, 147], ["AgNP", "CHEMICAL", 55, 59], ["AgNP", "SIMPLE_CHEMICAL", 55, 59], ["anticancer", "CANCER", 117, 127], ["AgNPs", "SIMPLE_CHEMICAL", 142, 147], ["AgNP induction", "TREATMENT", 55, 69], ["oxidative stress", "PROBLEM", 73, 89]]], ["It is of great interest to ascertain this mechanism of AgNPs.", [["AgNPs", "CHEMICAL", 55, 60], ["AgNPs", "SIMPLE_CHEMICAL", 55, 60], ["AgNPs", "OBSERVATION", 55, 60]]], ["This study was to determine how AgNP-associated changes in redox balance will induce HePG-2 cells apoptosis.Materials ::: MethodsHePG-2 cells were purchased from American Type Culture Collection (ATCC, Manassas, Virginia).", [["HePG-2 cells", "ANATOMY", 85, 97], ["MethodsHePG-2 cells", "ANATOMY", 122, 141], ["AgNP", "CHEMICAL", 32, 36], ["AgNP", "CHEMICAL", 32, 36], ["AgNP", "SIMPLE_CHEMICAL", 32, 36], ["HePG-2 cells", "CELL", 85, 97], ["MethodsHePG-2 cells", "CELL", 122, 141], ["HePG-2 cells", "CELL_LINE", 85, 97], ["MethodsHePG-2 cells", "CELL_LINE", 122, 141], ["ATCC", "SPECIES", 196, 200], ["This study", "TEST", 0, 10], ["changes in redox balance", "PROBLEM", 48, 72], ["HePG", "TEST", 85, 89], ["2 cells apoptosis", "PROBLEM", 90, 107], ["MethodsHePG-2 cells", "TREATMENT", 122, 141]]], ["Fetal bovine serum (FBS) and Dulbecco\u2019s modified Eagle\u2019s medium (DMEM) were purchased from Gibco.", [["Fetal bovine serum", "ANATOMY", 0, 18], ["FBS", "ANATOMY", 20, 23], ["Fetal", "ORGANISM_SUBSTANCE", 0, 5], ["bovine", "ORGANISM", 6, 12], ["serum", "ORGANISM_SUBSTANCE", 13, 18], ["FBS", "ORGANISM_SUBSTANCE", 20, 23], ["bovine", "SPECIES", 6, 12], ["bovine", "SPECIES", 6, 12], ["Fetal bovine serum", "TEST", 0, 18], ["FBS", "TEST", 20, 23], ["Dulbecco", "TEST", 29, 37]]], ["AKT, p53, PARP, and cleaved caspase-3 antibody were obtained from Cell Signaling Technology.", [["Cell", "ANATOMY", 66, 70], ["AKT", "GENE_OR_GENE_PRODUCT", 0, 3], ["p53", "GENE_OR_GENE_PRODUCT", 5, 8], ["PARP", "GENE_OR_GENE_PRODUCT", 10, 14], ["caspase-3", "GENE_OR_GENE_PRODUCT", 28, 37], ["Cell", "CELL", 66, 70], ["AKT", "PROTEIN", 0, 3], ["p53", "PROTEIN", 5, 8], ["PARP", "PROTEIN", 10, 14], ["cleaved caspase-3 antibody", "PROTEIN", 20, 46], ["AKT", "TEST", 0, 3], ["p53", "TEST", 5, 8], ["PARP", "TEST", 10, 14], ["cleaved caspase-3 antibody", "TEST", 20, 46]]], ["Silver nitrate (AgNO3) and vitamin C (VC) were obtained from Sigma.", [["Silver nitrate", "CHEMICAL", 0, 14], ["AgNO3", "CHEMICAL", 16, 21], ["vitamin C", "CHEMICAL", 27, 36], ["Silver nitrate", "CHEMICAL", 0, 14], ["AgNO3", "CHEMICAL", 16, 21], ["vitamin C", "CHEMICAL", 27, 36], ["VC", "CHEMICAL", 38, 40], ["Silver nitrate", "SIMPLE_CHEMICAL", 0, 14], ["AgNO3", "SIMPLE_CHEMICAL", 16, 21], ["vitamin C", "SIMPLE_CHEMICAL", 27, 36], ["VC", "SIMPLE_CHEMICAL", 38, 40], ["Silver nitrate (AgNO3)", "TREATMENT", 0, 22], ["vitamin C (VC)", "TREATMENT", 27, 41]]], ["Thiazolyl blue tetrazolium bromide (MTT), 4\u20326-diamidino-2-phenyindole (DAPI), 2\u2032,7\u2032-dichlorofluorescein diacetate (DCF-DA), bicinchoninic acid (BCA), 6-coumarin, and propidium iodide (PI) were obtained from Sigma.", [["Thiazolyl blue tetrazolium bromide", "CHEMICAL", 0, 34], ["MTT", "CHEMICAL", 36, 39], ["4\u20326-diamidino-2-phenyindole", "CHEMICAL", 42, 69], ["DAPI", "CHEMICAL", 71, 75], ["2\u2032,7\u2032-dichlorofluorescein diacetate", "CHEMICAL", 78, 113], ["DCF-DA", "CHEMICAL", 115, 121], ["bicinchoninic acid", "CHEMICAL", 124, 142], ["BCA", "CHEMICAL", 144, 147], ["6-coumarin", "CHEMICAL", 150, 160], ["propidium iodide", "CHEMICAL", 166, 182], ["Thiazolyl blue tetrazolium bromide", "CHEMICAL", 0, 34], ["MTT", "CHEMICAL", 36, 39], ["4\u20326-diamidino-2-phenyindole", "CHEMICAL", 42, 69], ["DAPI", "CHEMICAL", 71, 75], ["2\u2032,7\u2032-dichlorofluorescein diacetate", "CHEMICAL", 78, 113], ["DCF-DA", "CHEMICAL", 115, 121], ["bicinchoninic acid", "CHEMICAL", 124, 142], ["BCA", "CHEMICAL", 144, 147], ["6-coumarin", "CHEMICAL", 150, 160], ["propidium iodide", "CHEMICAL", 166, 182], ["Thiazolyl blue tetrazolium bromide", "SIMPLE_CHEMICAL", 0, 34], ["MTT", "SIMPLE_CHEMICAL", 36, 39], ["4\u20326-diamidino-2-phenyindole", "SIMPLE_CHEMICAL", 42, 69], ["DAPI", "SIMPLE_CHEMICAL", 71, 75], ["2\u2032,7\u2032-dichlorofluorescein diacetate", "SIMPLE_CHEMICAL", 78, 113], ["DCF-DA", "SIMPLE_CHEMICAL", 115, 121], ["bicinchoninic acid", "SIMPLE_CHEMICAL", 124, 142], ["BCA", "SIMPLE_CHEMICAL", 144, 147], ["6-coumarin", "SIMPLE_CHEMICAL", 150, 160], ["propidium iodide", "SIMPLE_CHEMICAL", 166, 182], ["PI", "SIMPLE_CHEMICAL", 184, 186], ["Thiazolyl blue tetrazolium bromide", "TREATMENT", 0, 34], ["diamidino", "TREATMENT", 46, 55], ["dichlorofluorescein diacetate", "TREATMENT", 84, 113], ["bicinchoninic acid (BCA", "TREATMENT", 124, 147], ["coumarin", "TREATMENT", 152, 160], ["propidium iodide", "TREATMENT", 166, 182]]], ["LysoTracker Deep Red was obtained from Invitrogen.", [["LysoTracker", "SIMPLE_CHEMICAL", 0, 11]]], ["The water was supplied by Milli-Q water purification from Millipore in all experiments.Synthesis of AgNPs ::: MethodsA stock solution of AgNO3 (400 \u03bcg/ml) was prepared by dissolving 16 mg AgNO3 powder in 40 ml Milli-Q water.", [["AgNPs", "CHEMICAL", 100, 105], ["AgNO3", "CHEMICAL", 137, 142], ["AgNO3", "CHEMICAL", 188, 193], ["AgNO3", "CHEMICAL", 137, 142], ["AgNO3", "CHEMICAL", 188, 193], ["water", "SIMPLE_CHEMICAL", 4, 9], ["AgNPs ::", "SIMPLE_CHEMICAL", 100, 108], ["MethodsA", "SIMPLE_CHEMICAL", 110, 118], ["AgNO3", "SIMPLE_CHEMICAL", 137, 142], ["AgNO3", "SIMPLE_CHEMICAL", 188, 193], ["The water", "TREATMENT", 0, 9], ["Milli-Q water purification", "TREATMENT", 26, 52], ["MethodsA stock solution of AgNO3", "TREATMENT", 110, 142]]], ["Vitamin C (400 \u03bcg/ml) was also prepared by dissolving 16 mg vitamin C in 40 ml Milli-Q water.", [["Vitamin C", "CHEMICAL", 0, 9], ["vitamin C", "CHEMICAL", 60, 69], ["Vitamin C", "CHEMICAL", 0, 9], ["vitamin C", "CHEMICAL", 60, 69], ["Vitamin C", "SIMPLE_CHEMICAL", 0, 9], ["vitamin C", "SIMPLE_CHEMICAL", 60, 69], ["Milli-Q water", "SIMPLE_CHEMICAL", 79, 92], ["Vitamin C", "TREATMENT", 0, 9], ["vitamin C", "TREATMENT", 60, 69]]], ["AgNPs were prepared as follows: briefly, 0.1 ml of 400 \u03bcg/ml vitamin C was drop by drop added into 4 ml of 400 \u03bcg/ml AgNO3 under magnetic stirring for 2 h.", [["AgNPs", "CHEMICAL", 0, 5], ["vitamin C", "CHEMICAL", 61, 70], ["AgNO3", "CHEMICAL", 117, 122], ["vitamin C", "CHEMICAL", 61, 70], ["AgNO3", "CHEMICAL", 117, 122], ["AgNPs", "SIMPLE_CHEMICAL", 0, 5], ["vitamin C", "SIMPLE_CHEMICAL", 61, 70], ["AgNO3", "SIMPLE_CHEMICAL", 117, 122], ["vitamin C", "TREATMENT", 61, 70], ["magnetic stirring", "TREATMENT", 129, 146]]], ["The excess VC and AgNO3 were eliminated by dialysis against Milli-Q water for 24 h.", [["AgNO3", "CHEMICAL", 18, 23], ["AgNO3", "CHEMICAL", 18, 23], ["VC", "SIMPLE_CHEMICAL", 11, 13], ["AgNO3", "SIMPLE_CHEMICAL", 18, 23], ["AgNO3", "TREATMENT", 18, 23], ["dialysis", "TREATMENT", 43, 51], ["VC", "OBSERVATION_MODIFIER", 11, 13]]], ["The solution containing nanoparticles was sonicated (KQ-100VDB) by using a water bath for 2 min and pass through filters of 0.2-\u03bcm pore size before each experiment.", [["pore", "ANATOMY", 131, 135], ["KQ-100VDB", "CHEMICAL", 53, 62], ["The solution containing nanoparticles", "TREATMENT", 0, 37], ["a water bath", "TREATMENT", 73, 85], ["size", "OBSERVATION_MODIFIER", 136, 140]]], ["The AgNP concentration was detected by ICP-AES (inductively coupled plasma-atomic emission spectrometry).Characterization of AgNPs ::: MethodsThe morphology of silver nanoparticles was characterized by transmission electron microscope (TEM, Hitachi, H-7650).", [["AgNP", "CHEMICAL", 4, 8], ["AgNPs", "CHEMICAL", 125, 130], ["silver nanoparticles", "CHEMICAL", 160, 180], ["H-7650", "CHEMICAL", 250, 256], ["silver", "CHEMICAL", 160, 166], ["AgNP", "SIMPLE_CHEMICAL", 4, 8], ["AgNPs", "SIMPLE_CHEMICAL", 125, 130], ["silver nanoparticles", "SIMPLE_CHEMICAL", 160, 180], ["AgNP", "PROTEIN", 4, 8], ["The AgNP concentration", "TEST", 0, 22], ["ICP", "TEST", 39, 42], ["plasma-atomic emission spectrometry", "TEST", 68, 103], ["AgNP concentration", "OBSERVATION", 4, 22], ["AgNPs", "OBSERVATION", 125, 130], ["silver nanoparticles", "OBSERVATION", 160, 180]]], ["The size distribution and zeta potential of AgNPs were detected through Zetasizer Nano ZS (Malvern Instruments Limited) particle analyzer.", [["AgNPs", "CHEMICAL", 44, 49], ["AgNPs", "SIMPLE_CHEMICAL", 44, 49], ["AgNPs", "PROBLEM", 44, 49], ["Zetasizer Nano ZS (Malvern Instruments", "TREATMENT", 72, 110], ["size", "OBSERVATION_MODIFIER", 4, 8], ["distribution", "OBSERVATION_MODIFIER", 9, 21], ["zeta", "OBSERVATION_MODIFIER", 26, 30], ["AgNPs", "OBSERVATION_MODIFIER", 44, 49]]], ["EDX analysis was carried out on an EX-250 system (Horiba) and employed to examine the elemental composition of AgNPs.Cell Viability Assay ::: MethodsHePG-2 cells were incubated in DMEM supplemented with antibiotic and 10 % FBS, penicillin, and streptomycin in a humidified incubator with 5 % CO2 atmosphere at 37 \u00b0C. The cytotoxicity of AgNPs was detected by MTT assay as previously published [30].", [["Cell", "ANATOMY", 117, 121], ["MethodsHePG-2 cells", "ANATOMY", 142, 161], ["AgNPs", "CHEMICAL", 111, 116], ["FBS", "CHEMICAL", 223, 226], ["penicillin", "CHEMICAL", 228, 238], ["streptomycin", "CHEMICAL", 244, 256], ["CO2", "CHEMICAL", 292, 295], ["AgNPs", "CHEMICAL", 337, 342], ["penicillin", "CHEMICAL", 228, 238], ["streptomycin", "CHEMICAL", 244, 256], ["CO2", "CHEMICAL", 292, 295], ["MTT", "CHEMICAL", 359, 362], ["AgNPs", "SIMPLE_CHEMICAL", 111, 116], ["Cell", "CELL", 117, 121], ["MethodsHePG-2 cells", "CELL", 142, 161], ["FBS", "ORGANISM_SUBSTANCE", 223, 226], ["penicillin", "SIMPLE_CHEMICAL", 228, 238], ["streptomycin", "SIMPLE_CHEMICAL", 244, 256], ["CO2", "SIMPLE_CHEMICAL", 292, 295], ["AgNPs", "SIMPLE_CHEMICAL", 337, 342], ["MethodsHePG-2 cells", "CELL_LINE", 142, 161], ["EDX analysis", "TEST", 0, 12], ["Cell Viability Assay", "TEST", 117, 137], ["MethodsHePG-2 cells", "TREATMENT", 142, 161], ["antibiotic", "TREATMENT", 203, 213], ["10 % FBS", "TREATMENT", 218, 226], ["penicillin", "TREATMENT", 228, 238], ["streptomycin", "TREATMENT", 244, 256], ["a humidified incubator", "TREATMENT", 260, 282], ["5 % CO2 atmosphere", "TREATMENT", 288, 306], ["The cytotoxicity of AgNPs", "TEST", 317, 342], ["MTT assay", "TEST", 359, 368], ["AgNPs", "OBSERVATION", 111, 116], ["AgNPs", "OBSERVATION_MODIFIER", 337, 342]]], ["Briefly, cell viability was determined by measuring the ability of cells to transform MTT to a purple formazan dye.", [["cell", "ANATOMY", 9, 13], ["cells", "ANATOMY", 67, 72], ["formazan", "CHEMICAL", 102, 110], ["MTT", "CHEMICAL", 86, 89], ["formazan", "CHEMICAL", 102, 110], ["cell", "CELL", 9, 13], ["cells", "CELL", 67, 72], ["MTT", "SIMPLE_CHEMICAL", 86, 89], ["formazan dye", "SIMPLE_CHEMICAL", 102, 114], ["a purple formazan dye", "TREATMENT", 93, 114], ["cell viability", "OBSERVATION", 9, 23], ["formazan dye", "OBSERVATION", 102, 114]]], ["HePG-2 cells were seeded in 96-well culture plates at a density of 4 \u00d7 104 cells per well at 37 \u00b0C for 24 h.", [["HePG-2 cells", "ANATOMY", 0, 12], ["cells", "ANATOMY", 75, 80], ["HePG-2 cells", "CELL", 0, 12], ["cells", "CELL", 75, 80], ["HePG-2 cells", "CELL_LINE", 0, 12], ["HePG", "TEST", 0, 4], ["culture plates", "TEST", 36, 50]]], ["Then, the cells were treated with AgNPs at different concentrations for 72 h.", [["cells", "ANATOMY", 10, 15], ["AgNPs", "CHEMICAL", 34, 39], ["cells", "CELL", 10, 15], ["AgNPs", "SIMPLE_CHEMICAL", 34, 39], ["AgNPs", "TREATMENT", 34, 39]]], ["After treatment, 20 \u03bcl/well of MTT solution (5 mg/ml in PBS) was added and incubated for another 5 h.", [["MTT", "CHEMICAL", 31, 34], ["MTT", "CHEMICAL", 31, 34], ["MTT", "SIMPLE_CHEMICAL", 31, 34], ["treatment", "TREATMENT", 6, 15], ["MTT solution", "TREATMENT", 31, 43]]], ["The medium was removed and replaced with 150 \u03bcl/well DMSO to dissolve the formazan crystals.", [["DMSO", "CHEMICAL", 53, 57], ["formazan", "CHEMICAL", 74, 82], ["DMSO", "CHEMICAL", 53, 57], ["formazan", "CHEMICAL", 74, 82], ["DMSO", "SIMPLE_CHEMICAL", 53, 57], ["formazan crystals", "SIMPLE_CHEMICAL", 74, 91], ["DMSO", "TREATMENT", 53, 57], ["the formazan crystals", "TREATMENT", 70, 91], ["medium", "OBSERVATION_MODIFIER", 4, 10], ["formazan crystals", "OBSERVATION", 74, 91]]], ["The color intensity of the formazan solution, which reflects the cell viability, was measured at 570 nm using a microplate spectrophotometer (Versammax).", [["cell", "ANATOMY", 65, 69], ["formazan", "CHEMICAL", 27, 35], ["formazan", "CHEMICAL", 27, 35], ["formazan", "SIMPLE_CHEMICAL", 27, 35], ["cell", "CELL", 65, 69], ["the formazan solution", "TREATMENT", 23, 44], ["the cell viability", "TEST", 61, 79], ["a microplate spectrophotometer (Versammax", "TREATMENT", 110, 151], ["color", "OBSERVATION_MODIFIER", 4, 9], ["intensity", "OBSERVATION_MODIFIER", 10, 19], ["cell viability", "OBSERVATION", 65, 79]]], ["The number of test repetitions was three times.Intracellular Trafficking of AgNPs ::: MethodsTo determine the in vitro cellular uptake of AgNPs, the nanoparticles containing a fluorescent dye 6-coumarin were added to the reaction system.", [["Intracellular", "ANATOMY", 47, 60], ["cellular", "ANATOMY", 119, 127], ["AgNPs", "CHEMICAL", 76, 81], ["AgNPs", "CHEMICAL", 138, 143], ["6-coumarin", "CHEMICAL", 192, 202], ["6-coumarin", "CHEMICAL", 192, 202], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 47, 60], ["AgNPs", "SIMPLE_CHEMICAL", 76, 81], ["cellular", "CELL", 119, 127], ["AgNPs", "SIMPLE_CHEMICAL", 138, 143], ["nanoparticles", "SIMPLE_CHEMICAL", 149, 162], ["fluorescent dye 6-coumarin", "SIMPLE_CHEMICAL", 176, 202], ["test repetitions", "TEST", 14, 30], ["the nanoparticles", "TREATMENT", 145, 162], ["a fluorescent dye", "TREATMENT", 174, 191], ["coumarin", "TREATMENT", 194, 202], ["AgNPs", "OBSERVATION_MODIFIER", 76, 81], ["uptake of AgNPs", "OBSERVATION", 128, 143]]], ["The incorporated dye as a probe for AgNPs offers a sensitive method to determine their intracellular localization.", [["intracellular", "ANATOMY", 87, 100], ["AgNPs", "CHEMICAL", 36, 41], ["AgNPs", "SIMPLE_CHEMICAL", 36, 41], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 87, 100], ["a probe for AgNPs", "TREATMENT", 24, 41]]], ["The localization of 6-coumarin-labeled 5 \u03bcg/ml AgNPs in HePG-2 cells was monitored by DAPI and Lyso Tracker as before [31].", [["HePG-2 cells", "ANATOMY", 56, 68], ["6-coumarin", "CHEMICAL", 20, 30], ["AgNPs", "CHEMICAL", 47, 52], ["6-coumarin", "CHEMICAL", 20, 30], ["DAPI", "CHEMICAL", 86, 90], ["6-coumarin", "SIMPLE_CHEMICAL", 20, 30], ["AgNPs", "SIMPLE_CHEMICAL", 47, 52], ["HePG-2 cells", "CELL", 56, 68], ["DAPI", "SIMPLE_CHEMICAL", 86, 90], ["HePG-2 cells", "CELL_LINE", 56, 68], ["coumarin-labeled", "TREATMENT", 22, 38], ["HePG-2 cells", "TREATMENT", 56, 68]]], ["The treated cells cultured in 2-cm cell culture dishes to 70 % confluence were incubated with Lyso Tracker Red (stained for 2 h), and DAPI H33258 was added (stained for 30 min).", [["cells", "ANATOMY", 12, 17], ["cell", "ANATOMY", 35, 39], ["DAPI H33258", "CHEMICAL", 134, 145], ["Lyso Tracker Red", "CHEMICAL", 94, 110], ["DAPI H33258", "CHEMICAL", 134, 145], ["cells", "CELL", 12, 17], ["DAPI H33258", "SIMPLE_CHEMICAL", 134, 145], ["treated cells", "CELL_LINE", 4, 17], ["The treated cells", "TREATMENT", 0, 17], ["cell culture", "TEST", 35, 47], ["DAPI", "TEST", 134, 138], ["2-cm cell", "OBSERVATION_MODIFIER", 30, 39]]], ["The cells were rinsed with PBS three times and then incubated with 6-coumarin-loaded AgNPs from 0 to 120 min which were detected by fluorescence microscope.Flow Cytometric Analysis ::: MethodsFlow cytometric was used to characterize the effect of AgNPs on cell cycle distribution as previously reported [32, 33].", [["cells", "ANATOMY", 4, 9], ["cell", "ANATOMY", 256, 260], ["6-coumarin", "CHEMICAL", 67, 77], ["AgNPs", "CHEMICAL", 85, 90], ["AgNPs", "CHEMICAL", 247, 252], ["6-coumarin", "CHEMICAL", 67, 77], ["cells", "CELL", 4, 9], ["6-coumarin", "SIMPLE_CHEMICAL", 67, 77], ["AgNPs", "SIMPLE_CHEMICAL", 85, 90], ["AgNPs", "SIMPLE_CHEMICAL", 247, 252], ["cell", "CELL", 256, 260], ["PBS", "TREATMENT", 27, 30], ["6-coumarin-loaded AgNPs", "TREATMENT", 67, 90], ["Methods", "TREATMENT", 185, 192], ["Flow cytometric", "TEST", 192, 207], ["AgNPs", "OBSERVATION", 247, 252], ["cell cycle", "OBSERVATION", 256, 266]]], ["Briefly, the cells incubated with AgNPs for 24 h were collected and centrifuged at 1500 rpm for 5 min.", [["cells", "ANATOMY", 13, 18], ["AgNPs", "CHEMICAL", 34, 39], ["cells", "CELL", 13, 18], ["AgNPs", "SIMPLE_CHEMICAL", 34, 39], ["AgNPs", "TREATMENT", 34, 39]]], ["The harvested cells were fixed with pre-cooled 70 % ethanol at \u221220 \u00b0C for 24 h.", [["cells", "ANATOMY", 14, 19], ["ethanol", "CHEMICAL", 52, 59], ["ethanol", "CHEMICAL", 52, 59], ["cells", "CELL", 14, 19], ["ethanol", "SIMPLE_CHEMICAL", 52, 59], ["The harvested cells", "TREATMENT", 0, 19], ["harvested cells", "OBSERVATION", 4, 19]]], ["Cells were followed by PI staining for half an hour in the dark.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["PI", "SIMPLE_CHEMICAL", 23, 25], ["Cells", "TEST", 0, 5], ["PI staining", "TEST", 23, 34]]], ["Apoptotic cells with hypodiploid DNA content were measured by using Multicycle software.Determination of ROS Generation ::: MethodsThe intracellular ROS generation by AgNP-treated HePG-2 cells were detected by staining cells with DCF fluorescence as previously reported [34, 35].", [["cells", "ANATOMY", 10, 15], ["intracellular", "ANATOMY", 135, 148], ["HePG-2 cells", "ANATOMY", 180, 192], ["cells", "ANATOMY", 219, 224], ["ROS", "CHEMICAL", 149, 152], ["AgNP", "CHEMICAL", 167, 171], ["DCF", "CHEMICAL", 230, 233], ["AgNP", "CHEMICAL", 167, 171], ["DCF", "CHEMICAL", 230, 233], ["cells", "CELL", 10, 15], ["DNA", "CELLULAR_COMPONENT", 33, 36], ["ROS", "SIMPLE_CHEMICAL", 105, 108], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 135, 148], ["ROS", "SIMPLE_CHEMICAL", 149, 152], ["AgNP", "SIMPLE_CHEMICAL", 167, 171], ["HePG-2 cells", "CELL", 180, 192], ["cells", "CELL", 219, 224], ["DCF", "SIMPLE_CHEMICAL", 230, 233], ["Apoptotic cells", "CELL_TYPE", 0, 15], ["AgNP-treated HePG-2 cells", "CELL_LINE", 167, 192], ["Apoptotic cells", "PROBLEM", 0, 15], ["hypodiploid DNA content", "PROBLEM", 21, 44], ["Methods", "TREATMENT", 124, 131], ["The intracellular ROS generation", "TEST", 131, 163], ["AgNP", "TEST", 167, 171], ["DCF fluorescence", "TEST", 230, 246], ["hypodiploid DNA content", "OBSERVATION", 21, 44]]], ["Briefly, cells were collected and suspended in PBS with DCFH-DA at a final concentration of 10 mM at 37 \u00b0C for 30 min.", [["cells", "ANATOMY", 9, 14], ["DCFH-DA", "CHEMICAL", 56, 63], ["cells", "CELL", 9, 14], ["DCFH-DA", "SIMPLE_CHEMICAL", 56, 63], ["DCFH", "TEST", 56, 60]]], ["Then, the stained cells were collected and resuspended in PBS.", [["cells", "ANATOMY", 18, 23], ["cells", "CELL", 18, 23], ["stained cells", "CELL_TYPE", 10, 23], ["the stained cells", "TEST", 6, 23]]], ["The ROS level was examined by detecting the fluorescence intensity using fluorescence microscope and microplate reader with excitation an emission wavelengths set at 500 and 529 nm, respectively.", [["ROS", "SIMPLE_CHEMICAL", 4, 7], ["The ROS level", "TEST", 0, 13], ["fluorescence microscope", "TEST", 73, 96]]], ["Experiments were performed in triplicate.Western Blotting Analysis ::: MethodsThe effects of AgNPs on the expression levels of various intracellular proteins in HePG-2 cells were detected by Western blotting as previously reported [36, 37].", [["intracellular", "ANATOMY", 135, 148], ["HePG-2 cells", "ANATOMY", 161, 173], ["AgNPs", "CHEMICAL", 93, 98], ["AgNPs", "SIMPLE_CHEMICAL", 93, 98], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 135, 148], ["HePG-2 cells", "CELL", 161, 173], ["intracellular proteins", "PROTEIN", 135, 157], ["HePG-2 cells", "CELL_LINE", 161, 173], ["Methods", "TREATMENT", 71, 78], ["AgNPs", "TREATMENT", 93, 98], ["the expression levels", "TEST", 102, 123], ["various intracellular proteins", "TEST", 127, 157], ["AgNPs", "OBSERVATION_MODIFIER", 93, 98], ["intracellular proteins", "OBSERVATION", 135, 157]]], ["HePG-2 cell treatments with AgNPs were incubated with lysis buffer to obtain total cellular proteins.", [["HePG-2 cell", "ANATOMY", 0, 11], ["cellular", "ANATOMY", 83, 91], ["AgNPs", "CHEMICAL", 28, 33], ["HePG-2 cell", "CELL", 0, 11], ["AgNPs", "SIMPLE_CHEMICAL", 28, 33], ["cellular", "CELL", 83, 91], ["cellular proteins", "PROTEIN", 83, 100], ["HePG", "TEST", 0, 4], ["2 cell treatments", "TREATMENT", 5, 22], ["AgNPs", "TREATMENT", 28, 33], ["lysis buffer", "TREATMENT", 54, 66], ["total cellular proteins", "PROBLEM", 77, 100]]], ["The protein concentration was examined by BCA assay.", [["The protein concentration", "TEST", 0, 25]]], ["Protein (10 \u03bcg) was subjected to each well.", [["Protein", "TEST", 0, 7]]], ["The membranes were incubated with primary and secondary antibodies at 1:1000 dilution in 5 % non-fat milk.", [["membranes", "ANATOMY", 4, 13], ["fat milk", "ANATOMY", 97, 105], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["fat milk", "ORGANISM_SUBSTANCE", 97, 105], ["primary and secondary antibodies", "TREATMENT", 34, 66]]], ["Protein bands were visualized with using enhanced chemiluminescence detection reagent (ECL).Statistical Analysis ::: MethodsExperiments were performed and repeated at least three times.", [["Protein bands", "TEST", 0, 13], ["enhanced chemiluminescence detection", "TEST", 41, 77], ["MethodsExperiments", "TEST", 117, 135]]], ["Difference with P < 0.05(*) or P < 0.01(**) was considered statistically significant.", [["P", "TEST", 16, 17], ["significant", "OBSERVATION_MODIFIER", 73, 84]]], ["These analyses were carried out using SPSS 13.0 for windows.Preparation and Characterization of AgNPs ::: Results and DiscussionIn this study, a simple method was used to synthesize AgNPs; various methods were used to characterize the product.", [["AgNPs", "CHEMICAL", 96, 101], ["AgNPs", "CHEMICAL", 182, 187], ["AgNPs", "SIMPLE_CHEMICAL", 96, 101], ["AgNPs", "SIMPLE_CHEMICAL", 182, 187], ["These analyses", "TEST", 0, 14], ["SPSS", "TEST", 38, 42], ["this study", "TEST", 131, 141], ["a simple method", "TREATMENT", 143, 158], ["various methods", "TREATMENT", 189, 204]]], ["As shown in Fig. 1a, TEM images of AgNPs, which demonstrated that the AgNPs presented a uniformity and monodisperse spherical particles, the SAED pattern, and clear lattice fringes (0.2 nm) observed in HRTEM collectively suggested that the nanoparticle possessed a pure crystal structure.", [["AgNPs", "CHEMICAL", 35, 40], ["AgNPs", "CHEMICAL", 70, 75], ["AgNPs", "SIMPLE_CHEMICAL", 35, 40], ["AgNPs", "SIMPLE_CHEMICAL", 70, 75], ["TEM images of AgNPs", "TEST", 21, 40], ["the AgNPs", "PROBLEM", 66, 75], ["a uniformity and monodisperse spherical particles", "PROBLEM", 86, 135], ["the SAED pattern", "TEST", 137, 153], ["AgNPs", "OBSERVATION", 70, 75], ["monodisperse", "OBSERVATION_MODIFIER", 103, 115], ["spherical particles", "OBSERVATION", 116, 135], ["clear", "OBSERVATION_MODIFIER", 159, 164], ["lattice fringes", "OBSERVATION", 165, 180], ["pure crystal", "OBSERVATION", 265, 277]]], ["In Fig. 1b, EDX indicated the presence of Ag atoms (57 %) with Cu atom signal (43 %).", [["Ag", "CHEMICAL", 42, 44], ["Cu", "CHEMICAL", 63, 65], ["Ag", "CHEMICAL", 42, 44], ["Cu", "CHEMICAL", 63, 65], ["Ag atoms", "SIMPLE_CHEMICAL", 42, 50], ["Cu atom", "SIMPLE_CHEMICAL", 63, 70], ["Ag atoms", "PROTEIN", 42, 50], ["EDX", "TEST", 12, 15], ["Ag atoms", "TEST", 42, 50], ["Cu atom signal", "TEST", 63, 77]]], ["The presence of Cu comes from copper grids.", [["Cu", "CHEMICAL", 16, 18], ["copper", "CHEMICAL", 30, 36], ["Cu", "CHEMICAL", 16, 18], ["copper", "CHEMICAL", 30, 36], ["Cu", "SIMPLE_CHEMICAL", 16, 18], ["copper grids", "SIMPLE_CHEMICAL", 30, 42], ["copper grids", "PROBLEM", 30, 42]]], ["The atom of Ag indicates that silver nanoparticles were successfully prepared.", [["Ag", "CHEMICAL", 12, 14], ["silver nanoparticles", "CHEMICAL", 30, 50], ["Ag", "CHEMICAL", 12, 14], ["silver", "CHEMICAL", 30, 36], ["silver nanoparticles", "SIMPLE_CHEMICAL", 30, 50], ["Ag", "PROTEIN", 12, 14], ["silver nanoparticles", "TREATMENT", 30, 50]]], ["To examine the effects of stability and surface properties of AgNPs, we detected the size distribution and zeta potential of AgNPs.", [["surface", "ANATOMY", 40, 47], ["AgNPs", "CHEMICAL", 62, 67], ["AgNPs", "CHEMICAL", 125, 130], ["AgNPs", "SIMPLE_CHEMICAL", 62, 67], ["AgNPs", "SIMPLE_CHEMICAL", 125, 130], ["AgNPs", "PROBLEM", 125, 130], ["stability", "OBSERVATION_MODIFIER", 26, 35], ["AgNPs", "OBSERVATION", 62, 67], ["size", "OBSERVATION_MODIFIER", 85, 89], ["zeta", "OBSERVATION_MODIFIER", 107, 111], ["AgNPs", "OBSERVATION_MODIFIER", 125, 130]]], ["As shown in Fig. 1c, the average particle size of AgNPs was 2 nm.", [["AgNPs", "CHEMICAL", 50, 55], ["AgNPs", "SIMPLE_CHEMICAL", 50, 55], ["average", "OBSERVATION_MODIFIER", 25, 32], ["particle", "OBSERVATION_MODIFIER", 33, 41], ["size", "OBSERVATION_MODIFIER", 42, 46], ["AgNPs", "OBSERVATION_MODIFIER", 50, 55]]], ["Furthermore, in Fig. 1d, the zeta potential of AgNPs was \u221215 mV.Localization and Uptake Pathways of AgNPs ::: Results and DiscussionEndocytosis is one of the primary pathways for cellular uptake of nanoparticles [38].", [["cellular", "ANATOMY", 179, 187], ["AgNPs", "CHEMICAL", 47, 52], ["AgNPs", "CHEMICAL", 100, 105], ["AgNPs", "SIMPLE_CHEMICAL", 47, 52], ["AgNPs", "SIMPLE_CHEMICAL", 100, 105], ["cellular", "CELL", 179, 187], ["AgNPs", "TEST", 47, 52], ["cellular uptake of nanoparticles", "TEST", 179, 211], ["AgNPs", "OBSERVATION_MODIFIER", 47, 52]]], ["To examine the intracellular translocation of the nanoparticles, the localization of AgNPs in HePG-2 cells was tracked by simultaneous staining of cell nucleus.Localization and Uptake Pathways of AgNPs ::: Results and DiscussionAs shown in Fig. 2, the co-localization of AgNPs and lysosomes was found accumulated in HePG-2 cell membrane and gradually enhanced after then.", [["intracellular", "ANATOMY", 15, 28], ["HePG-2 cells", "ANATOMY", 94, 106], ["cell nucleus", "ANATOMY", 147, 159], ["lysosomes", "ANATOMY", 281, 290], ["HePG-2 cell membrane", "ANATOMY", 316, 336], ["AgNPs", "CHEMICAL", 85, 90], ["AgNPs", "CHEMICAL", 196, 201], ["AgNPs", "CHEMICAL", 271, 276], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 15, 28], ["AgNPs", "SIMPLE_CHEMICAL", 85, 90], ["HePG-2 cells", "CELL", 94, 106], ["cell nucleus", "CELLULAR_COMPONENT", 147, 159], ["AgNPs", "SIMPLE_CHEMICAL", 196, 201], ["AgNPs", "SIMPLE_CHEMICAL", 271, 276], ["lysosomes", "CELLULAR_COMPONENT", 281, 290], ["HePG-2 cell", "CELL", 316, 327], ["membrane", "CELLULAR_COMPONENT", 328, 336], ["HePG-2 cells", "CELL_LINE", 94, 106], ["HePG", "PROTEIN", 316, 320], ["simultaneous staining of cell nucleus", "PROBLEM", 122, 159], ["HePG", "TEST", 316, 320], ["AgNPs", "OBSERVATION_MODIFIER", 85, 90], ["simultaneous staining", "OBSERVATION", 122, 143], ["cell nucleus", "OBSERVATION", 147, 159], ["AgNPs", "OBSERVATION_MODIFIER", 271, 276], ["2 cell", "ANATOMY_MODIFIER", 321, 327], ["membrane", "ANATOMY_MODIFIER", 328, 336], ["gradually", "OBSERVATION_MODIFIER", 341, 350], ["enhanced", "OBSERVATION_MODIFIER", 351, 359]]], ["AgNPs escaped from lysosome after 60 min, transported into the cytosol, and distributed in cells after 120 min.", [["lysosome", "ANATOMY", 19, 27], ["cytosol", "ANATOMY", 63, 70], ["cells", "ANATOMY", 91, 96], ["AgNPs", "CHEMICAL", 0, 5], ["AgNPs", "SIMPLE_CHEMICAL", 0, 5], ["lysosome", "CELLULAR_COMPONENT", 19, 27], ["cytosol", "CELLULAR_COMPONENT", 63, 70], ["cells", "CELL", 91, 96], ["lysosome", "OBSERVATION_MODIFIER", 19, 27], ["cytosol", "ANATOMY", 63, 70]]], ["This result demonstrates that lysosome is the target organelle of AgNPs.In Vitro Anticancer Activity of AgNPs ::: Results and DiscussionThe cytotoxic effect of AgNPs on HePG-2 cells was evaluated by MTT assay.", [["lysosome", "ANATOMY", 30, 38], ["HePG-2 cells", "ANATOMY", 169, 181], ["AgNPs", "CHEMICAL", 66, 71], ["AgNPs", "CHEMICAL", 104, 109], ["AgNPs", "CHEMICAL", 160, 165], ["MTT", "CHEMICAL", 199, 202], ["lysosome", "CELLULAR_COMPONENT", 30, 38], ["organelle", "CELLULAR_COMPONENT", 53, 62], ["AgNPs", "SIMPLE_CHEMICAL", 66, 71], ["AgNPs", "SIMPLE_CHEMICAL", 104, 109], ["AgNPs", "SIMPLE_CHEMICAL", 160, 165], ["HePG-2 cells", "CELL", 169, 181], ["HePG-2 cells", "CELL_LINE", 169, 181], ["AgNPs on HePG-2 cells", "TREATMENT", 160, 181], ["MTT assay", "TEST", 199, 208], ["lysosome", "OBSERVATION", 30, 38], ["AgNPs", "OBSERVATION_MODIFIER", 66, 71], ["Anticancer Activity", "OBSERVATION", 81, 100]]], ["As shown in Fig. 3a, the AgNPs significantly inhibited the growth of HePG-2 cells in a dose-dependent manner.In Vitro Anticancer Activity of AgNPs ::: Results and DiscussionHePG-2 cells treated with 5 \u03bcg/ml AgNPs for 72 h reduced cell viability to 95 %.", [["HePG-2 cells", "ANATOMY", 69, 81], ["DiscussionHePG-2 cells", "ANATOMY", 163, 185], ["cell", "ANATOMY", 230, 234], ["AgNPs", "CHEMICAL", 25, 30], ["AgNPs", "CHEMICAL", 141, 146], ["AgNPs", "CHEMICAL", 207, 212], ["AgNPs", "SIMPLE_CHEMICAL", 25, 30], ["HePG-2 cells", "CELL", 69, 81], ["AgNPs", "SIMPLE_CHEMICAL", 141, 146], ["DiscussionHePG-2 cells", "CELL", 163, 185], ["AgNPs", "SIMPLE_CHEMICAL", 207, 212], ["cell", "CELL", 230, 234], ["HePG-2 cells", "CELL_LINE", 69, 81], ["the AgNPs", "TEST", 21, 30], ["HePG", "TEST", 69, 73], ["AgNPs", "TREATMENT", 207, 212], ["reduced cell viability", "PROBLEM", 222, 244], ["growth", "OBSERVATION_MODIFIER", 59, 65], ["Anticancer Activity", "OBSERVATION", 118, 137]]], ["At the concentrations of 10 and 20 \u03bcg/ml, AgNPs decreased the cell viability to 83 and 49 %, respectively.", [["cell", "ANATOMY", 62, 66], ["AgNPs", "CHEMICAL", 42, 47], ["AgNPs", "SIMPLE_CHEMICAL", 42, 47], ["cell", "CELL", 62, 66], ["AgNPs", "TREATMENT", 42, 47], ["the cell viability", "TEST", 58, 76], ["cell viability", "OBSERVATION", 62, 76]]], ["The anticancer activity effects of AgNPs were also further confirmed as shown in Fig. 3b.", [["anticancer", "ANATOMY", 4, 14], ["AgNPs", "CHEMICAL", 35, 40], ["anticancer", "CANCER", 4, 14], ["AgNPs", "SIMPLE_CHEMICAL", 35, 40], ["AgNPs", "TREATMENT", 35, 40], ["anticancer activity", "OBSERVATION", 4, 23]]], ["Cell treated with AgNPs showed cytoplasm shrinkage and loss of cell-to-cell contact.", [["Cell", "ANATOMY", 0, 4], ["cytoplasm", "ANATOMY", 31, 40], ["cell", "ANATOMY", 63, 67], ["cell", "ANATOMY", 71, 75], ["AgNPs", "CHEMICAL", 18, 23], ["Cell", "CELL", 0, 4], ["AgNPs", "SIMPLE_CHEMICAL", 18, 23], ["cytoplasm", "ORGANISM_SUBSTANCE", 31, 40], ["cell", "CELL", 63, 67], ["cell", "CELL", 71, 75], ["AgNPs", "TREATMENT", 18, 23], ["cytoplasm shrinkage", "PROBLEM", 31, 50], ["loss of cell", "PROBLEM", 55, 67], ["cytoplasm shrinkage", "OBSERVATION", 31, 50], ["loss of cell", "OBSERVATION", 55, 67]]], ["Taken together, these results indicated that AgNPs inhibited cancer cell growth in a dose-dependent manner.Induction of Cell Apoptosis by AgNPs ::: Results and DiscussionApoptosis plays an essential role in a wide variety of different biological systems, including normal cell cycle, the immune system, embryonic development, morphologic change, and chemical-induced cell death [39].", [["cancer cell", "ANATOMY", 61, 72], ["Cell", "ANATOMY", 120, 124], ["cell", "ANATOMY", 272, 276], ["immune system", "ANATOMY", 288, 301], ["embryonic", "ANATOMY", 303, 312], ["cell", "ANATOMY", 367, 371], ["AgNPs", "CHEMICAL", 45, 50], ["cancer", "DISEASE", 61, 67], ["AgNPs", "CHEMICAL", 138, 143], ["death", "DISEASE", 372, 377], ["AgNPs", "SIMPLE_CHEMICAL", 45, 50], ["cancer cell", "CELL", 61, 72], ["Cell", "CELL", 120, 124], ["AgNPs", "SIMPLE_CHEMICAL", 138, 143], ["cell", "CELL", 272, 276], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 303, 312], ["cell", "CELL", 367, 371], ["AgNPs inhibited cancer cell growth", "PROBLEM", 45, 79], ["morphologic change", "PROBLEM", 326, 344], ["chemical-induced cell death", "PROBLEM", 350, 377], ["cancer cell", "OBSERVATION", 61, 72], ["growth", "OBSERVATION_MODIFIER", 73, 79], ["Cell Apoptosis", "OBSERVATION", 120, 134], ["normal cell cycle", "OBSERVATION", 265, 282], ["cell death", "OBSERVATION", 367, 377]]], ["Therefore, flow cytometry was used to investigate whether apoptosis was involved in cell death by AgNPs.", [["cell", "ANATOMY", 84, 88], ["death", "DISEASE", 89, 94], ["AgNPs", "CHEMICAL", 98, 103], ["cell", "CELL", 84, 88], ["AgNPs", "SIMPLE_CHEMICAL", 98, 103], ["flow cytometry", "TEST", 11, 25], ["apoptosis", "PROBLEM", 58, 67], ["cell death", "PROBLEM", 84, 94]]], ["The apoptotic cells which have DNA fragmentation show a typical sub-G1 peak in DNA histogram.", [["cells", "ANATOMY", 14, 19], ["cells", "CELL", 14, 19], ["DNA", "CELLULAR_COMPONENT", 31, 34], ["DNA", "CELLULAR_COMPONENT", 79, 82], ["apoptotic cells", "CELL_TYPE", 4, 19], ["The apoptotic cells", "PROBLEM", 0, 19], ["DNA fragmentation", "PROBLEM", 31, 48], ["DNA histogram", "TEST", 79, 92], ["apoptotic cells", "OBSERVATION", 4, 19], ["typical", "OBSERVATION_MODIFIER", 56, 63], ["sub", "OBSERVATION_MODIFIER", 64, 67], ["G1 peak", "OBSERVATION", 68, 75]]], ["As shown in Fig. 4a, b, 5 \u03bcg/ml of AgNPs increased the percentage of apoptotic cells to 8.62 %.", [["cells", "ANATOMY", 79, 84], ["AgNPs", "CHEMICAL", 35, 40], ["AgNPs", "SIMPLE_CHEMICAL", 35, 40], ["cells", "CELL", 79, 84], ["apoptotic cells", "CELL_TYPE", 69, 84], ["AgNPs", "TREATMENT", 35, 40], ["apoptotic cells", "OBSERVATION", 69, 84]]], ["However, the sub-G1 apoptotic cell population was significantly increased in a dose-dependent manner.", [["cell", "ANATOMY", 30, 34], ["cell", "CELL", 30, 34], ["sub-G1 apoptotic cell population", "CELL_LINE", 13, 45], ["the sub-G1 apoptotic cell population", "PROBLEM", 9, 45], ["sub", "OBSERVATION_MODIFIER", 13, 16], ["apoptotic cell population", "OBSERVATION", 20, 45], ["significantly", "OBSERVATION_MODIFIER", 50, 63], ["increased", "OBSERVATION_MODIFIER", 64, 73]]], ["At concentrations of 10 and 20 \u03bcg/ml, AgNPs increased the apoptotic cells to 19.83 and 25.11 %, respectively.", [["cells", "ANATOMY", 68, 73], ["AgNPs", "CHEMICAL", 38, 43], ["AgNPs", "SIMPLE_CHEMICAL", 38, 43], ["cells", "CELL", 68, 73], ["apoptotic cells", "CELL_TYPE", 58, 73], ["AgNPs", "TREATMENT", 38, 43], ["the apoptotic cells", "TEST", 54, 73], ["apoptotic cells", "OBSERVATION", 58, 73]]], ["The results indicated that AgNPs depressed HePG-2 cells proliferation.Induction of ROS Generation by AgNPs ::: Results and DiscussionROS has been regarded as a critical activator of cell apoptosis, especially that induced by anticancer drugs [40].", [["HePG-2 cells", "ANATOMY", 43, 55], ["cell", "ANATOMY", 182, 186], ["anticancer", "ANATOMY", 225, 235], ["AgNPs", "CHEMICAL", 27, 32], ["depressed", "DISEASE", 33, 42], ["ROS", "CHEMICAL", 83, 86], ["AgNPs", "CHEMICAL", 101, 106], ["AgNPs", "SIMPLE_CHEMICAL", 27, 32], ["HePG-2 cells", "CELL", 43, 55], ["ROS", "SIMPLE_CHEMICAL", 83, 86], ["AgNPs", "SIMPLE_CHEMICAL", 101, 106], ["cell", "CELL", 182, 186], ["anticancer", "CANCER", 225, 235], ["HePG-2 cells", "CELL_LINE", 43, 55], ["DiscussionROS", "PROTEIN", 123, 136], ["AgNPs depressed HePG", "PROBLEM", 27, 47], ["2 cells proliferation", "PROBLEM", 48, 69], ["cell apoptosis", "PROBLEM", 182, 196], ["AgNPs", "OBSERVATION_MODIFIER", 27, 32], ["depressed", "OBSERVATION_MODIFIER", 33, 42], ["2 cells proliferation", "OBSERVATION", 48, 69], ["cell apoptosis", "OBSERVATION", 182, 196]]], ["Therefore, in this study, the ROS generation was determined by DCF fluorescence assay to reveal its role the action mechanisms of AgNPs.", [["ROS", "CHEMICAL", 30, 33], ["DCF", "CHEMICAL", 63, 66], ["AgNPs", "CHEMICAL", 130, 135], ["DCF", "CHEMICAL", 63, 66], ["ROS", "SIMPLE_CHEMICAL", 30, 33], ["DCF", "SIMPLE_CHEMICAL", 63, 66], ["AgNPs", "SIMPLE_CHEMICAL", 130, 135], ["this study", "TEST", 14, 24], ["DCF fluorescence assay", "TEST", 63, 85]]], ["As shown in Fig. 5a, b, AgNPs gradually increased the intracellular ROS generation in HePG-2 cells; the stronger fluorescent intensity of DCF was found in HePG-2 cells at the concentration 20 \u03bcg/ml.", [["intracellular", "ANATOMY", 54, 67], ["HePG-2 cells", "ANATOMY", 86, 98], ["HePG-2 cells", "ANATOMY", 155, 167], ["AgNPs", "CHEMICAL", 24, 29], ["ROS", "CHEMICAL", 68, 71], ["DCF", "CHEMICAL", 138, 141], ["DCF", "CHEMICAL", 138, 141], ["AgNPs", "SIMPLE_CHEMICAL", 24, 29], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 54, 67], ["ROS", "SIMPLE_CHEMICAL", 68, 71], ["HePG-2 cells", "CELL", 86, 98], ["DCF", "SIMPLE_CHEMICAL", 138, 141], ["HePG-2 cells", "CELL", 155, 167], ["HePG-2 cells", "CELL_LINE", 86, 98], ["HePG-2 cells", "CELL_LINE", 155, 167], ["the intracellular ROS", "PROBLEM", 50, 71], ["HePG", "TEST", 86, 90], ["DCF", "TEST", 138, 141], ["HePG", "TEST", 155, 159]]], ["As shown in Fig. 5c, AgNPs increased the intracellular ROS generation to 153, 229, and 290 % at concentration of 5, 10, and 20 \u03bcg/ml, respectively.", [["intracellular", "ANATOMY", 41, 54], ["AgNPs", "CHEMICAL", 21, 26], ["ROS", "CHEMICAL", 55, 58], ["AgNPs", "SIMPLE_CHEMICAL", 21, 26], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 41, 54], ["ROS", "SIMPLE_CHEMICAL", 55, 58], ["the intracellular ROS", "TEST", 37, 58], ["AgNPs", "OBSERVATION_MODIFIER", 21, 26], ["increased", "OBSERVATION_MODIFIER", 27, 36]]], ["The dates indicate that the involvement of ROS may play an important role in the anticancer action.Activation of ROS-Mediated Signaling Pathways by AgNPs ::: Results and DiscussionIntracellular ROS overproduction could trigger DNA damage and cell apoptosis by activating of AKT, MAPKs, and p53 signaling pathways.", [["anticancer", "ANATOMY", 81, 91], ["Intracellular", "ANATOMY", 180, 193], ["cell", "ANATOMY", 242, 246], ["ROS", "CHEMICAL", 43, 46], ["ROS", "CHEMICAL", 113, 116], ["AgNPs", "CHEMICAL", 148, 153], ["ROS", "CHEMICAL", 194, 197], ["ROS", "SIMPLE_CHEMICAL", 43, 46], ["anticancer", "CANCER", 81, 91], ["ROS", "SIMPLE_CHEMICAL", 113, 116], ["AgNPs", "SIMPLE_CHEMICAL", 148, 153], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 180, 193], ["ROS", "SIMPLE_CHEMICAL", 194, 197], ["DNA", "CELLULAR_COMPONENT", 227, 230], ["cell", "CELL", 242, 246], ["AKT", "GENE_OR_GENE_PRODUCT", 274, 277], ["MAPKs", "GENE_OR_GENE_PRODUCT", 279, 284], ["p53", "GENE_OR_GENE_PRODUCT", 290, 293], ["AKT", "PROTEIN", 274, 277], ["MAPKs", "PROTEIN", 279, 284], ["p53", "PROTEIN", 290, 293], ["Intracellular ROS overproduction", "PROBLEM", 180, 212], ["DNA damage", "PROBLEM", 227, 237], ["cell apoptosis", "PROBLEM", 242, 256], ["MAPKs", "TEST", 279, 284], ["cell apoptosis", "OBSERVATION", 242, 256]]], ["The effects on the ROS-mediated downstream pathways were examined by using Western blotting.", [["ROS", "CHEMICAL", 19, 22], ["ROS", "SIMPLE_CHEMICAL", 19, 22], ["the ROS", "TEST", 15, 22]]], ["As shown in Fig. 6a, treatments of cells with AgNPs significantly increased the expression levels of p53.", [["cells", "ANATOMY", 35, 40], ["AgNPs", "CHEMICAL", 46, 51], ["cells", "CELL", 35, 40], ["AgNPs", "SIMPLE_CHEMICAL", 46, 51], ["p53", "GENE_OR_GENE_PRODUCT", 101, 104], ["p53", "PROTEIN", 101, 104], ["treatments of cells", "TREATMENT", 21, 40], ["AgNPs", "TREATMENT", 46, 51], ["the expression levels", "TEST", 76, 97], ["Fig", "OBSERVATION", 12, 15]]], ["Meanwhile, as a biochemical marker of DNA damage, H2X was significantly activated by AgNPs.", [["AgNPs", "CHEMICAL", 85, 90], ["DNA", "CELLULAR_COMPONENT", 38, 41], ["H2X", "GENE_OR_GENE_PRODUCT", 50, 53], ["AgNPs", "SIMPLE_CHEMICAL", 85, 90], ["H2X", "PROTEIN", 50, 53], ["DNA damage", "PROBLEM", 38, 48], ["H2X", "PROBLEM", 50, 53], ["AgNPs", "OBSERVATION_MODIFIER", 85, 90]]], ["Moreover, as shown in Fig. 6b, AgNP treatment triggered differential effects on JNK, ERK, and p38.", [["AgNP", "CHEMICAL", 31, 35], ["AgNP", "CHEMICAL", 31, 35], ["AgNP", "SIMPLE_CHEMICAL", 31, 35], ["JNK", "GENE_OR_GENE_PRODUCT", 80, 83], ["ERK", "GENE_OR_GENE_PRODUCT", 85, 88], ["p38", "GENE_OR_GENE_PRODUCT", 94, 97], ["JNK", "PROTEIN", 80, 83], ["ERK", "PROTEIN", 85, 88], ["p38", "PROTEIN", 94, 97], ["JNK", "TEST", 80, 83], ["ERK", "TEST", 85, 88], ["p38", "TEST", 94, 97]]], ["AgNPs significantly inhibited total ERK and increased the JNK and p38.", [["AgNPs", "CHEMICAL", 0, 5], ["AgNPs", "SIMPLE_CHEMICAL", 0, 5], ["ERK", "GENE_OR_GENE_PRODUCT", 36, 39], ["JNK", "GENE_OR_GENE_PRODUCT", 58, 61], ["p38", "GENE_OR_GENE_PRODUCT", 66, 69], ["ERK", "PROTEIN", 36, 39], ["JNK", "PROTEIN", 58, 61], ["p38", "PROTEIN", 66, 69], ["AgNPs", "TEST", 0, 5], ["total ERK", "TEST", 30, 39], ["p38", "TEST", 66, 69], ["significantly", "OBSERVATION_MODIFIER", 6, 19], ["inhibited", "OBSERVATION_MODIFIER", 20, 29], ["total", "OBSERVATION_MODIFIER", 30, 35], ["ERK", "OBSERVATION_MODIFIER", 36, 39], ["increased", "OBSERVATION_MODIFIER", 44, 53], ["JNK", "ANATOMY", 58, 61]]], ["Meanwhile, treatment of the cells with AgNPs effectively suppressed the expression levels of total AKT in HePG-2 cells as shown in Fig. 6d.", [["cells", "ANATOMY", 28, 33], ["HePG-2 cells", "ANATOMY", 106, 118], ["AgNPs", "CHEMICAL", 39, 44], ["cells", "CELL", 28, 33], ["AgNPs", "SIMPLE_CHEMICAL", 39, 44], ["AKT", "GENE_OR_GENE_PRODUCT", 99, 102], ["HePG-2 cells", "CELL", 106, 118], ["AKT", "PROTEIN", 99, 102], ["HePG-2 cells", "CELL_LINE", 106, 118], ["the cells", "PROBLEM", 24, 33], ["AgNPs", "TREATMENT", 39, 44], ["total AKT", "TEST", 93, 102], ["HePG", "TEST", 106, 110]]], ["The caspase family exhibits important functions in the regulation process of cell apoptosis.", [["cell", "ANATOMY", 77, 81], ["caspase", "GENE_OR_GENE_PRODUCT", 4, 11], ["cell", "CELL", 77, 81], ["caspase family", "PROTEIN", 4, 18], ["cell apoptosis", "PROBLEM", 77, 91], ["cell apoptosis", "OBSERVATION", 77, 91]]], ["Caspase-3 acts as a central regulator in the signaling network [41].", [["Caspase-3", "GENE_OR_GENE_PRODUCT", 0, 9], ["Caspase-3", "PROTEIN", 0, 9], ["Caspase", "TREATMENT", 0, 7], ["a central regulator", "TREATMENT", 18, 37]]], ["Therefore, the cleavage of caspase-3 and PARP was examined to evaluate their involvement and contribution to cell apoptosis.", [["cell", "ANATOMY", 109, 113], ["caspase-3", "GENE_OR_GENE_PRODUCT", 27, 36], ["PARP", "GENE_OR_GENE_PRODUCT", 41, 45], ["cell", "CELL", 109, 113], ["caspase-3", "PROTEIN", 27, 36], ["PARP", "PROTEIN", 41, 45], ["the cleavage of caspase", "TREATMENT", 11, 34], ["PARP", "TREATMENT", 41, 45], ["cell apoptosis", "PROBLEM", 109, 123], ["cell apoptosis", "OBSERVATION", 109, 123]]], ["As shown in Fig. 6c, AgNPs significantly enhanced the activation of caspase-3 and the cleavage of downstream effect PARP.", [["AgNPs", "CHEMICAL", 21, 26], ["AgNPs", "SIMPLE_CHEMICAL", 21, 26], ["caspase-3", "GENE_OR_GENE_PRODUCT", 68, 77], ["PARP", "GENE_OR_GENE_PRODUCT", 116, 120], ["caspase-3", "PROTEIN", 68, 77], ["PARP", "PROTEIN", 116, 120], ["caspase", "TEST", 68, 75], ["PARP", "PROBLEM", 116, 120]]], ["Taken together, these results support that AgNPs induce HePG-2 cells apoptosis by regulation of ROS-mediated AKT, MAPKs, and p53 signaling pathways.ConclusionsIn summary, a simple chemical method under redox system for preparation of silver nanoparticles has been described in this study.", [["HePG-2 cells", "ANATOMY", 56, 68], ["AgNPs", "CHEMICAL", 43, 48], ["silver nanoparticles", "CHEMICAL", 234, 254], ["silver", "CHEMICAL", 234, 240], ["AgNPs", "SIMPLE_CHEMICAL", 43, 48], ["HePG-2 cells", "CELL", 56, 68], ["ROS", "SIMPLE_CHEMICAL", 96, 99], ["AKT", "GENE_OR_GENE_PRODUCT", 109, 112], ["MAPKs", "GENE_OR_GENE_PRODUCT", 114, 119], ["p53", "GENE_OR_GENE_PRODUCT", 125, 128], ["silver nanoparticles", "SIMPLE_CHEMICAL", 234, 254], ["AKT", "PROTEIN", 109, 112], ["MAPKs", "PROTEIN", 114, 119], ["p53", "PROTEIN", 125, 128], ["AgNPs", "TEST", 43, 48], ["HePG", "TEST", 56, 60], ["2 cells apoptosis", "PROBLEM", 61, 78], ["ROS", "TEST", 96, 99], ["MAPKs", "TEST", 114, 119], ["p53 signaling pathways", "PROBLEM", 125, 147], ["a simple chemical method under redox system", "TREATMENT", 171, 214], ["preparation of silver nanoparticles", "TREATMENT", 219, 254], ["this study", "TEST", 277, 287], ["silver nanoparticles", "OBSERVATION", 234, 254]]], ["AgNPs exhibit greater abilities to inhibit HePG-2 cells proliferation and enhanced cellular uptake at the average size of 2 nm.", [["HePG-2 cells", "ANATOMY", 43, 55], ["cellular", "ANATOMY", 83, 91], ["AgNPs", "CHEMICAL", 0, 5], ["AgNPs", "SIMPLE_CHEMICAL", 0, 5], ["HePG-2 cells", "CELL", 43, 55], ["cellular", "CELL", 83, 91], ["HePG-2 cells", "CELL_LINE", 43, 55], ["HePG", "TEST", 43, 47], ["2 cells proliferation", "PROBLEM", 48, 69], ["enhanced cellular uptake", "PROBLEM", 74, 98], ["greater", "OBSERVATION_MODIFIER", 14, 21], ["cellular uptake", "OBSERVATION", 83, 98], ["average", "OBSERVATION_MODIFIER", 106, 113], ["size", "OBSERVATION_MODIFIER", 114, 118], ["2 nm", "OBSERVATION_MODIFIER", 122, 126]]], ["AgNPs with dose-dependent manner significantly increased the apoptotic cell population (sub-G1).", [["cell", "ANATOMY", 71, 75], ["AgNPs", "CHEMICAL", 0, 5], ["AgNPs", "SIMPLE_CHEMICAL", 0, 5], ["cell", "CELL", 71, 75], ["apoptotic cell population", "CELL_TYPE", 61, 86], ["dependent manner", "PROBLEM", 16, 32], ["the apoptotic cell population", "PROBLEM", 57, 86], ["dependent manner", "OBSERVATION_MODIFIER", 16, 32], ["significantly", "OBSERVATION_MODIFIER", 33, 46], ["increased", "OBSERVATION_MODIFIER", 47, 56], ["apoptotic cell population", "OBSERVATION", 61, 86]]], ["The studies on the underlying molecular mechanisms revealed that the major mode of cell death induced by AgNPs was cell apoptosis.", [["cell", "ANATOMY", 83, 87], ["cell", "ANATOMY", 115, 119], ["death", "DISEASE", 88, 93], ["AgNPs", "CHEMICAL", 105, 110], ["cell", "CELL", 83, 87], ["AgNPs", "SIMPLE_CHEMICAL", 105, 110], ["cell", "CELL", 115, 119], ["The studies", "TEST", 0, 11], ["cell death", "PROBLEM", 83, 93], ["cell apoptosis", "PROBLEM", 115, 129], ["cell death", "OBSERVATION", 83, 93], ["AgNPs", "OBSERVATION_MODIFIER", 105, 110], ["cell apoptosis", "OBSERVATION", 115, 129]]], ["The mechanisms indicated that AgNPs promote caspase-3-mediated apoptosis by the involvement of ROS generation.", [["AgNPs", "CHEMICAL", 30, 35], ["ROS", "CHEMICAL", 95, 98], ["AgNPs", "SIMPLE_CHEMICAL", 30, 35], ["caspase-3", "GENE_OR_GENE_PRODUCT", 44, 53], ["ROS", "SIMPLE_CHEMICAL", 95, 98], ["caspase-3", "PROTEIN", 44, 53], ["AgNPs", "TREATMENT", 30, 35], ["caspase", "TEST", 44, 51], ["mediated apoptosis", "PROBLEM", 54, 72], ["ROS generation", "OBSERVATION", 95, 109]]], ["Further investigations on apoptotic signaling pathway triggered by the AgNPs in HePG-2 cells are p53, AKT, and MAPKs pathways.", [["HePG-2 cells", "ANATOMY", 80, 92], ["AgNPs", "CHEMICAL", 71, 76], ["AgNPs", "SIMPLE_CHEMICAL", 71, 76], ["HePG-2 cells", "CELL", 80, 92], ["p53", "GENE_OR_GENE_PRODUCT", 97, 100], ["AKT", "GENE_OR_GENE_PRODUCT", 102, 105], ["MAPKs", "GENE_OR_GENE_PRODUCT", 111, 116], ["HePG-2 cells", "CELL_LINE", 80, 92], ["p53", "PROTEIN", 97, 100], ["AKT", "PROTEIN", 102, 105], ["MAPKs", "PROTEIN", 111, 116], ["Further investigations", "TEST", 0, 22], ["apoptotic signaling pathway", "TEST", 26, 53], ["the AgNPs in HePG", "TEST", 67, 84], ["p53", "TEST", 97, 100], ["AKT", "TEST", 102, 105], ["MAPKs pathways", "TEST", 111, 125]]], ["Taken together, our findings suggest that AgNP is a prospect silver species with anticancer properties.", [["anticancer", "ANATOMY", 81, 91], ["AgNP", "CHEMICAL", 42, 46], ["silver", "CHEMICAL", 61, 67], ["AgNP", "SIMPLE_CHEMICAL", 42, 46], ["silver species", "SIMPLE_CHEMICAL", 61, 75], ["anticancer", "CANCER", 81, 91], ["anticancer properties", "TREATMENT", 81, 102], ["AgNP", "OBSERVATION", 42, 46], ["anticancer properties", "OBSERVATION", 81, 102]]]], "PMC7286275": [["IntroductionIn early December 2019, the first cases of a pneumonia-like disease emerged in Wuhan, Hubei Province, China1.", [["pneumonia", "DISEASE", 57, 66], ["a pneumonia-like disease", "PROBLEM", 55, 79], ["pneumonia", "OBSERVATION", 57, 66]]], ["All cases were linked to a seafood market in the same city2 and were confirmed to be associated with a novel RNA betacoronavirus, which was later named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)3,4.", [["acute respiratory syndrome coronavirus", "DISEASE", 159, 197], ["severe acute respiratory syndrome coronavirus", "SPECIES", 152, 197], ["SARS-CoV-2", "SPECIES", 201, 211], ["a novel RNA betacoronavirus", "PROBLEM", 101, 128], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 152, 197], ["SARS-CoV", "TEST", 201, 209], ["severe", "OBSERVATION_MODIFIER", 152, 158], ["acute", "OBSERVATION_MODIFIER", 159, 164], ["respiratory syndrome", "OBSERVATION", 165, 185]]], ["On 11 February 2020, the novel disease was named coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO) which declared a pandemic on 11 March 20205.", [["coronavirus disease", "DISEASE", 49, 68], ["the novel disease", "PROBLEM", 21, 38], ["coronavirus disease", "PROBLEM", 49, 68], ["COVID", "TEST", 75, 80], ["coronavirus disease", "OBSERVATION", 49, 68]]], ["COVID-19\u2019s high reproduction number has led to worldwide expansion of the disease6 and has gripped the world in a health and economic crisis7,8.Structure and genome sequence of SARS-CoV-2 ::: Etiology \u2013 Pathophysiology of SARS-CoV-2 infectionSARS-CoV-2 is a round or elliptic betacoronavirus and has a diameter of approximately 60\u2013140 nm9.", [["COVID-19", "CHEMICAL", 0, 8], ["SARS", "DISEASE", 177, 181], ["SARS", "DISEASE", 222, 226], ["SARS-CoV-2 infectionSARS-CoV-2", "ORGANISM", 222, 252], ["betacoronavirus", "CANCER", 276, 291], ["SARS-CoV", "SPECIES", 177, 185], ["SARS-CoV-2 infectionSARS-CoV-2", "SPECIES", 222, 252], ["COVID", "TEST", 0, 5], ["the disease6", "PROBLEM", 70, 82], ["SARS", "PROBLEM", 222, 226], ["CoV", "TEST", 227, 230], ["2 infectionSARS", "PROBLEM", 231, 246], ["CoV", "PROBLEM", 247, 250], ["a round or elliptic betacoronavirus", "PROBLEM", 256, 291], ["SARS", "OBSERVATION", 222, 226], ["round", "OBSERVATION_MODIFIER", 258, 263], ["elliptic betacoronavirus", "OBSERVATION", 267, 291], ["diameter", "OBSERVATION_MODIFIER", 302, 310]]], ["It belongs to the large family of coronaviruses, which are responsible for 5-10% of all respiratory tract infections10.", [["respiratory tract", "ANATOMY", 88, 105], ["respiratory tract infections", "DISEASE", 88, 116], ["coronaviruses", "ORGANISM", 34, 47], ["tract", "ORGANISM_SUBDIVISION", 100, 105], ["coronaviruses", "PROBLEM", 34, 47], ["all respiratory tract infections", "PROBLEM", 84, 116], ["large", "OBSERVATION_MODIFIER", 18, 23], ["coronaviruses", "OBSERVATION", 34, 47], ["respiratory tract", "ANATOMY", 88, 105], ["infections", "OBSERVATION", 106, 116]]], ["Coronaviruses have also been the cause of two previous infectious disease outbreaks; severe acute respiratory syndrome (SARS)11 and Middle East respiratory syndrome (MERS)12.", [["infectious disease", "DISEASE", 55, 73], ["acute respiratory syndrome", "DISEASE", 92, 118], ["SARS", "DISEASE", 120, 124], ["Middle East respiratory syndrome", "DISEASE", 132, 164], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["Middle East respiratory syndrome (MERS)12", "SPECIES", 132, 173], ["Coronaviruses", "PROBLEM", 0, 13], ["two previous infectious disease outbreaks", "PROBLEM", 42, 83], ["severe acute respiratory syndrome (SARS)", "PROBLEM", 85, 125], ["Middle East respiratory syndrome", "PROBLEM", 132, 164], ["infectious", "OBSERVATION_MODIFIER", 55, 65], ["severe", "OBSERVATION_MODIFIER", 85, 91], ["acute", "OBSERVATION_MODIFIER", 92, 97], ["respiratory syndrome", "OBSERVATION", 98, 118], ["Middle", "ANATOMY_MODIFIER", 132, 138], ["respiratory syndrome", "OBSERVATION", 144, 164]]], ["Comparative homology analysis has revealed the close relation of SARS-CoV-2 with bat coronavirus (RaTG13) demonstrating an overall sequence homology of 96.2%13, whereas the association with SARS-CoV (approximately 79% sequence identity) and MERS-CoV (approximately 50% sequence identity) was less significant4.Viral cell entry ::: Etiology \u2013 Pathophysiology of SARS-CoV-2 infectionAngiotensin converting enzyme 2 (ACE2), a type 1 membrane protein expressed in intestine, kidneys, heart and type II alveolar cells in the lungs14, has been recognized as a cell receptor for SARS-CoV15,16 and can also serve as a cell receptor for the novel SARS-CoV-213,17.", [["cell", "ANATOMY", 316, 320], ["membrane", "ANATOMY", 430, 438], ["intestine", "ANATOMY", 460, 469], ["kidneys", "ANATOMY", 471, 478], ["heart", "ANATOMY", 480, 485], ["type II alveolar cells", "ANATOMY", 490, 512], ["lungs", "ANATOMY", 520, 525], ["cell", "ANATOMY", 554, 558], ["cell", "ANATOMY", 610, 614], ["SARS", "DISEASE", 190, 194], ["SARS", "DISEASE", 361, 365], ["Angiotensin", "CHEMICAL", 381, 392], ["SARS-CoV-2", "ORGANISM", 65, 75], ["bat coronavirus", "ORGANISM", 81, 96], ["RaTG13", "GENE_OR_GENE_PRODUCT", 98, 104], ["SARS-CoV", "ORGANISM", 190, 198], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 241, 249], ["Viral cell", "CELL", 310, 320], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 361, 371], ["Angiotensin converting enzyme 2", "GENE_OR_GENE_PRODUCT", 381, 412], ["ACE2", "GENE_OR_GENE_PRODUCT", 414, 418], ["type 1", "GENE_OR_GENE_PRODUCT", 423, 429], ["membrane", "CELLULAR_COMPONENT", 430, 438], ["intestine", "ORGAN", 460, 469], ["kidneys", "ORGAN", 471, 478], ["heart", "ORGAN", 480, 485], ["type II alveolar cells", "CELL", 490, 512], ["lungs", "ORGAN", 520, 525], ["cell", "CELL", 554, 558], ["SARS-CoV15,16", "GENE_OR_GENE_PRODUCT", 572, 585], ["cell", "CELL", 610, 614], ["SARS-CoV-213,17", "ORGANISM", 638, 653], ["MERS-CoV", "DNA", 241, 249], ["Angiotensin converting enzyme 2", "PROTEIN", 381, 412], ["ACE2", "PROTEIN", 414, 418], ["type 1 membrane protein", "PROTEIN", 423, 446], ["type II alveolar cells", "CELL_TYPE", 490, 512], ["bat coronavirus", "SPECIES", 81, 96], ["SARS-CoV", "SPECIES", 65, 73], ["bat coronavirus", "SPECIES", 81, 96], ["SARS-CoV", "SPECIES", 190, 198], ["MERS-CoV", "SPECIES", 241, 249], ["SARS-CoV-2", "SPECIES", 361, 371], ["SARS-CoV-213,17", "SPECIES", 638, 653], ["Comparative homology analysis", "TEST", 0, 29], ["SARS", "PROBLEM", 65, 69], ["CoV", "TEST", 70, 73], ["bat coronavirus", "PROBLEM", 81, 96], ["an overall sequence homology", "TEST", 120, 148], ["SARS", "TEST", 190, 194], ["CoV", "TEST", 195, 198], ["MERS", "TEST", 241, 245], ["SARS", "PROBLEM", 361, 365], ["CoV", "TEST", 366, 369], ["2 infection", "PROBLEM", 370, 381], ["Angiotensin converting enzyme", "TEST", 381, 410], ["ACE2", "TEST", 414, 418], ["a type 1 membrane protein", "TEST", 421, 446], ["type II alveolar cells in the lungs", "PROBLEM", 490, 525], ["SARS", "PROBLEM", 572, 576], ["a cell receptor", "TREATMENT", 608, 623], ["the novel SARS", "TEST", 628, 642], ["CoV", "TEST", 643, 646], ["cell entry", "OBSERVATION", 316, 326], ["SARS", "OBSERVATION", 361, 365], ["intestine", "ANATOMY", 460, 469], ["kidneys", "ANATOMY", 471, 478], ["heart", "ANATOMY", 480, 485], ["alveolar cells", "OBSERVATION", 498, 512], ["lungs", "ANATOMY", 520, 525]]], ["The spike glycoprotein (S protein) on the virion surface of SARS-CoV is responsible for receptor recognition and membrane fusion18.", [["virion surface", "ANATOMY", 42, 56], ["membrane", "ANATOMY", 113, 121], ["SARS", "DISEASE", 60, 64], ["spike glycoprotein", "GENE_OR_GENE_PRODUCT", 4, 22], ["S protein", "GENE_OR_GENE_PRODUCT", 24, 33], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 60, 68], ["membrane", "CELLULAR_COMPONENT", 113, 121], ["spike glycoprotein", "PROTEIN", 4, 22], ["S protein", "PROTEIN", 24, 33], ["membrane fusion18", "PROTEIN", 113, 130], ["SARS-CoV", "SPECIES", 60, 68], ["The spike glycoprotein (S protein", "TREATMENT", 0, 33], ["SARS", "PROBLEM", 60, 64], ["receptor recognition", "PROBLEM", 88, 108], ["membrane fusion18", "TREATMENT", 113, 130]]], ["Similarly, an S protein on the surface of the novel SARS-CoV-2 binds to the peptidase domain of ACE2 at least ten times more tightly than of (SARS)\u2013CoV19 and subsequently causes membrane fusion, releasing its RNA into the host cell19,20.", [["surface", "ANATOMY", 31, 38], ["membrane", "ANATOMY", 178, 186], ["cell", "ANATOMY", 227, 231], ["SARS", "DISEASE", 52, 56], ["surface", "CELLULAR_COMPONENT", 31, 38], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 52, 62], ["ACE2", "GENE_OR_GENE_PRODUCT", 96, 100], ["CoV19", "GENE_OR_GENE_PRODUCT", 148, 153], ["membrane", "CELLULAR_COMPONENT", 178, 186], ["cell", "CELL", 227, 231], ["S protein", "PROTEIN", 14, 23], ["peptidase domain", "PROTEIN", 76, 92], ["ACE2", "PROTEIN", 96, 100], ["CoV19", "PROTEIN", 148, 153], ["SARS-CoV", "SPECIES", 52, 60], ["ACE2", "TEST", 96, 100], ["membrane fusion", "TREATMENT", 178, 193], ["membrane fusion", "OBSERVATION", 178, 193], ["host cell", "OBSERVATION", 222, 231]]], ["Transmembrane Serine Protease 2 (TMPRSS2) is essential for viral entry being involved in S protein priming and cleavage of the site21.", [["Transmembrane Serine Protease 2", "GENE_OR_GENE_PRODUCT", 0, 31], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 33, 40], ["S protein", "GENE_OR_GENE_PRODUCT", 89, 98], ["site21", "GENE_OR_GENE_PRODUCT", 127, 133], ["Transmembrane Serine Protease 2", "PROTEIN", 0, 31], ["TMPRSS2", "PROTEIN", 33, 40], ["S protein", "PROTEIN", 89, 98], ["site21", "PROTEIN", 127, 133], ["Transmembrane Serine Protease 2 (TMPRSS2)", "TREATMENT", 0, 41], ["viral entry", "PROBLEM", 59, 70], ["S protein priming", "TREATMENT", 89, 106]]], ["Ou et al. reported that phosphoinositide 5-kinase (PIKfyve), two-pore segment channel 2 (TPC2), and cathepsin L are also critical for viral entry22.", [["phosphoinositide 5-kinase", "GENE_OR_GENE_PRODUCT", 24, 49], ["PIKfyve", "GENE_OR_GENE_PRODUCT", 51, 58], ["two-pore segment channel 2", "GENE_OR_GENE_PRODUCT", 61, 87], ["TPC2", "GENE_OR_GENE_PRODUCT", 89, 93], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 100, 111], ["phosphoinositide 5-kinase", "PROTEIN", 24, 49], ["PIKfyve", "PROTEIN", 51, 58], ["-pore segment channel 2", "PROTEIN", 64, 87], ["TPC2", "PROTEIN", 89, 93], ["cathepsin L", "PROTEIN", 100, 111], ["viral entry22", "PROTEIN", 134, 147], ["phosphoinositide", "TEST", 24, 40], ["PIKfyve", "TEST", 51, 58], ["two-pore segment channel 2 (TPC2)", "TREATMENT", 61, 94], ["cathepsin", "TREATMENT", 100, 109], ["viral entry22", "TREATMENT", 134, 147], ["segment channel", "ANATOMY_MODIFIER", 70, 85]]], ["Once endocytosis is completed, SARS-CoV-2 RNA is translated into viral polyproteins, which are assembled with genome RNA into virions and transported via exocytosis out of the host cell23.", [["virions", "ANATOMY", 126, 133], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 31, 41], ["genome", "CELLULAR_COMPONENT", 110, 116], ["cell23", "GENE_OR_GENE_PRODUCT", 181, 187], ["SARS-CoV-2 RNA", "RNA", 31, 45], ["viral polyproteins", "RNA", 65, 83], ["genome RNA", "RNA", 110, 120], ["cell23", "DNA", 181, 187], ["SARS", "PROBLEM", 31, 35], ["viral polyproteins", "PROBLEM", 65, 83], ["genome RNA into virions", "PROBLEM", 110, 133], ["viral polyproteins", "OBSERVATION", 65, 83]]], ["The SARS-CoV-2 binding to the ACE2 receptors and the subsequent membrane fusion and viral invasion result in the downregulation and the loss of the catalytic effect of ACE2 receptors at the external site of the cell membrane24.Epidemiology of COVID-19On 24 January 2020, the first three cases of COVID-19 were reported in Europe, all located in France25.", [["membrane", "ANATOMY", 64, 72], ["cell", "ANATOMY", 211, 215], ["SARS", "DISEASE", 4, 8], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 4, 14], ["ACE2", "GENE_OR_GENE_PRODUCT", 30, 34], ["membrane", "CELLULAR_COMPONENT", 64, 72], ["ACE2", "GENE_OR_GENE_PRODUCT", 168, 172], ["cell", "CELL", 211, 215], ["ACE2 receptors", "PROTEIN", 30, 44], ["ACE2 receptors", "PROTEIN", 168, 182], ["The SARS", "TEST", 0, 8], ["the ACE2 receptors", "TREATMENT", 26, 44], ["the subsequent membrane fusion", "TREATMENT", 49, 79], ["viral invasion", "PROBLEM", 84, 98], ["the downregulation", "PROBLEM", 109, 127], ["ACE2 receptors", "TREATMENT", 168, 182], ["COVID", "TEST", 243, 248], ["COVID", "TEST", 296, 301], ["membrane fusion", "OBSERVATION", 64, 79], ["viral invasion", "OBSERVATION", 84, 98], ["loss", "OBSERVATION_MODIFIER", 136, 140], ["external", "ANATOMY_MODIFIER", 190, 198], ["cell membrane24", "OBSERVATION", 211, 226]]], ["At that point, Asia had already recorded 1312 COVID-19 cases and 41 deaths26.", [["deaths", "DISEASE", 68, 74], ["COVID", "TEST", 46, 51]]], ["In Greece, the first confirmed patient with COVID-19 was reported on 26 February 202027.", [["patient", "ORGANISM", 31, 38], ["patient", "SPECIES", 31, 38], ["COVID", "TEST", 44, 49]]], ["As of 18 May 2020, the World Health Organization has confirmed 4,819,372 cases, 316,961 deaths and 1,864,269 recovered patients worldwide28.", [["deaths", "DISEASE", 88, 94], ["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 119, 127]]], ["The overall fatality rate is currently at 6,6%, however there are wide variations depending on age, comorbidities and country29.", [["wide variations", "PROBLEM", 66, 81], ["comorbidities", "PROBLEM", 100, 113], ["overall", "OBSERVATION_MODIFIER", 4, 11], ["fatality", "OBSERVATION_MODIFIER", 12, 20], ["wide", "OBSERVATION_MODIFIER", 66, 70], ["variations", "OBSERVATION_MODIFIER", 71, 81]]], ["In comparison, SARS\u2010CoV had 8,098 confirmed cases and 774 deaths from November 2002 to July 2003 (mortality 9.6%)30 and MERS\u2010CoV had 2,494 confirmed cases and 858 deaths from September 2012 to September 2019 (mortality 34.4%)31.Epidemiology of COVID-19The high sequence homology of SARS-CoV-2 with bat coronavirus13 and the vast number of coronaviruses carried by distinct bat species32,33 have suggested that SARS-CoV-2 has originated from bats13.", [["SARS", "DISEASE", 15, 19], ["deaths", "DISEASE", 58, 64], ["deaths", "DISEASE", 163, 169], ["COVID-19", "CHEMICAL", 244, 252], ["SARS", "DISEASE", 282, 286], ["SARS", "DISEASE", 410, 414], ["COVID-19", "CHEMICAL", 244, 252], ["SARS\u2010CoV", "ORGANISM", 15, 23], ["SARS-CoV-2", "ORGANISM", 282, 292], ["bat coronavirus13", "ORGANISM", 298, 315], ["coronaviruses", "ORGANISM", 339, 352], ["bat species32,33", "ORGANISM", 373, 389], ["SARS-CoV-2", "ORGANISM", 410, 420], ["bat coronavirus13", "SPECIES", 298, 315], ["SARS\u2010CoV", "SPECIES", 15, 23], ["MERS\u2010CoV", "SPECIES", 120, 128], ["bat coronavirus13", "SPECIES", 298, 315], ["mortality", "TEST", 98, 107], ["MERS\u2010CoV", "TEST", 120, 128], ["COVID", "TEST", 244, 249], ["SARS", "TEST", 282, 286], ["CoV", "TEST", 287, 290], ["bat coronavirus13", "TREATMENT", 298, 315], ["coronaviruses", "PROBLEM", 339, 352], ["SARS", "PROBLEM", 410, 414], ["coronaviruses", "OBSERVATION", 339, 352]]], ["The transmission of SARS\u2010CoV-2 occurs mainly from person to person via respiratory droplets34, 35, 36 and has an incubation period ranging from 2 to 14 days37 or in extreme cases up to 32 days38.", [["SARS", "DISEASE", 20, 24], ["CoV-2", "GENE_OR_GENE_PRODUCT", 25, 30], ["person", "SPECIES", 50, 56], ["person", "SPECIES", 60, 66]]], ["Li et al. analyzed the first 425 cases in Wuhan by 22 January 2020 and estimated the mean incubation period of COVID-19 at 5.2 days with the 95th percentile of the distribution at 12.5 days36.", [["Li", "CHEMICAL", 0, 2], ["COVID", "TEST", 111, 116]]], ["Airborne transmission39 and transmission through the oral-faecal route40 have also been recorded.", [["oral", "ANATOMY", 53, 57], ["oral", "ORGANISM_SUBDIVISION", 53, 57], ["faecal", "ORGANISM_SUBSTANCE", 58, 64], ["route40", "ORGANISM_SUBSTANCE", 65, 72]]], ["Of note, Zou et al. reported that the viral load of SARS\u2010CoV-2 in asymptomatic patients was comparable to that in symptomatic patients41, suggesting potential transmission by asymptomatic patients in concordance with other studies also reporting transmission from asymptomatic SARS\u2010CoV-2 carriers42,43.", [["SARS", "DISEASE", 52, 56], ["SARS", "DISEASE", 277, 281], ["CoV-2", "GENE_OR_GENE_PRODUCT", 57, 62], ["patients", "ORGANISM", 79, 87], ["patients", "ORGANISM", 126, 134], ["patients", "ORGANISM", 188, 196], ["patients", "SPECIES", 79, 87], ["patients", "SPECIES", 126, 134], ["patients", "SPECIES", 188, 196], ["the viral load", "TEST", 34, 48], ["SARS\u2010CoV", "TEST", 52, 60], ["other studies", "TEST", 217, 230], ["asymptomatic SARS", "PROBLEM", 264, 281], ["CoV", "TEST", 282, 285], ["carriers", "TEST", 288, 296], ["viral load", "OBSERVATION", 38, 48]]], ["Despite the ability of SARS-CoV-2 to infect different pet species44, the risk of human contamination from pets has not been elucidated so far45.Epidemiology of COVID-19On 23 January 2020, the World Health Organization estimated the basic reproductive number (R0) of COVID-19 at 1.4-2.546.", [["SARS-CoV-2", "ORGANISM", 23, 33], ["human", "ORGANISM", 81, 86], ["far45", "GENE_OR_GENE_PRODUCT", 138, 143], ["far45", "PROTEIN", 138, 143], ["human", "SPECIES", 81, 86], ["SARS-CoV", "SPECIES", 23, 31], ["human", "SPECIES", 81, 86], ["SARS", "PROBLEM", 23, 27], ["human contamination from pets", "PROBLEM", 81, 110], ["COVID", "TEST", 266, 271]]], ["Liu et al suggested that SARS\u2010CoV-2 has a higher R0 in comparison to SARS\u2010CoV, estimating the mean R0 of SARS\u2010CoV-2 at 3.28 by analyzing data from 12 studies47.", [["SARS", "DISEASE", 25, 29], ["SARS", "DISEASE", 69, 73], ["CoV-2", "GENE_OR_GENE_PRODUCT", 30, 35], ["CoV", "ORGANISM", 74, 77], ["CoV", "SPECIES", 74, 77], ["CoV", "TEST", 74, 77], ["SARS", "TEST", 105, 109], ["CoV", "TEST", 110, 113], ["analyzing data", "TEST", 127, 141]]], ["However, since there has not been adequate evidence regarding how asymptomatic carriers contribute to the transmission rate of this novel infectious disease and how each treatment or preventive strategy affects it, the accurate estimation of R0 is difficult.Epidemiology of COVID-19Gender differences have been reported in the epidemiology of COVID-19, as women have lower infection and mortality rates than men29,48.", [["infectious disease", "DISEASE", 138, 156], ["infection", "DISEASE", 373, 382], ["women", "ORGANISM", 356, 361], ["women", "SPECIES", 356, 361], ["how asymptomatic carriers", "PROBLEM", 62, 87], ["this novel infectious disease", "PROBLEM", 127, 156], ["preventive strategy", "TREATMENT", 183, 202], ["COVID", "TEST", 343, 348], ["lower infection", "PROBLEM", 367, 382], ["mortality rates", "TEST", 387, 402], ["lower", "OBSERVATION_MODIFIER", 367, 372], ["infection", "OBSERVATION", 373, 382]]], ["A recent study in patients with heart failure found that circulating levels of ACE2 were higher in men than in women, suggesting increased ACE2 tissue expression which could contribute to susceptibility to SARS\u2010CoV-2 infection and disease progress49.", [["heart", "ANATOMY", 32, 37], ["tissue", "ANATOMY", 144, 150], ["heart failure", "DISEASE", 32, 45], ["SARS", "DISEASE", 206, 210], ["infection", "DISEASE", 217, 226], ["patients", "ORGANISM", 18, 26], ["heart", "ORGAN", 32, 37], ["ACE2", "GENE_OR_GENE_PRODUCT", 79, 83], ["men", "ORGANISM", 99, 102], ["women", "ORGANISM", 111, 116], ["ACE2", "GENE_OR_GENE_PRODUCT", 139, 143], ["tissue", "TISSUE", 144, 150], ["CoV-2", "ORGANISM", 211, 216], ["ACE2", "PROTEIN", 79, 83], ["ACE2", "PROTEIN", 139, 143], ["patients", "SPECIES", 18, 26], ["men", "SPECIES", 99, 102], ["women", "SPECIES", 111, 116], ["A recent study", "TEST", 0, 14], ["heart failure", "PROBLEM", 32, 45], ["ACE2", "TEST", 79, 83], ["increased ACE2 tissue expression", "PROBLEM", 129, 161], ["SARS", "PROBLEM", 206, 210], ["CoV-2 infection", "PROBLEM", 211, 226], ["heart", "ANATOMY", 32, 37], ["failure", "OBSERVATION", 38, 45], ["higher", "OBSERVATION_MODIFIER", 89, 95], ["increased", "OBSERVATION_MODIFIER", 129, 138], ["ACE2 tissue expression", "OBSERVATION", 139, 161], ["infection", "OBSERVATION", 217, 226]]], ["However, further studies are needed to elucidate the gap between sex difference and COVID-19 susceptibility and prognosis.Direct ACE2-mediated myocardial cell invasion ::: Myocardial injury ::: Cardiovascular complications in patients with COVID-19As already described, high ACE2 expression is detected in cardiac tissue63 and may therefore facilitate cellular entry of the virus resulting in endothelial dysfunction and myocardial damage (Table 6).", [["myocardial cell", "ANATOMY", 143, 158], ["Myocardial", "ANATOMY", 172, 182], ["Cardiovascular", "ANATOMY", 194, 208], ["cardiac tissue63", "ANATOMY", 306, 322], ["cellular", "ANATOMY", 352, 360], ["endothelial", "ANATOMY", 393, 404], ["myocardial", "ANATOMY", 421, 431], ["Myocardial injury", "DISEASE", 172, 189], ["Cardiovascular complications", "DISEASE", 194, 222], ["COVID-19As", "CHEMICAL", 240, 250], ["endothelial dysfunction", "DISEASE", 393, 416], ["myocardial damage", "DISEASE", 421, 438], ["ACE2", "GENE_OR_GENE_PRODUCT", 129, 133], ["myocardial cell", "CELL", 143, 158], ["Myocardial", "MULTI-TISSUE_STRUCTURE", 172, 182], ["patients", "ORGANISM", 226, 234], ["COVID-19As", "GENE_OR_GENE_PRODUCT", 240, 250], ["ACE2", "GENE_OR_GENE_PRODUCT", 275, 279], ["cardiac tissue63", "CANCER", 306, 322], ["cellular", "CELL", 352, 360], ["endothelial", "TISSUE", 393, 404], ["myocardial", "MULTI-TISSUE_STRUCTURE", 421, 431], ["ACE2", "PROTEIN", 129, 133], ["ACE2", "PROTEIN", 275, 279], ["patients", "SPECIES", 226, 234], ["further studies", "TEST", 9, 24], ["COVID", "TEST", 84, 89], ["Direct ACE2", "TEST", 122, 133], ["Myocardial injury", "PROBLEM", 172, 189], ["Cardiovascular complications", "PROBLEM", 194, 222], ["COVID", "TEST", 240, 245], ["high ACE2 expression", "PROBLEM", 270, 290], ["the virus", "PROBLEM", 370, 379], ["endothelial dysfunction", "PROBLEM", 393, 416], ["myocardial damage", "PROBLEM", 421, 438], ["myocardial", "ANATOMY", 143, 153], ["cell invasion", "OBSERVATION", 154, 167], ["injury", "OBSERVATION", 183, 189], ["complications", "OBSERVATION", 209, 222], ["cardiac", "ANATOMY", 306, 313], ["endothelial dysfunction", "OBSERVATION", 393, 416], ["myocardial", "ANATOMY", 421, 431], ["damage", "OBSERVATION", 432, 438]]], ["In particular, ACE2 is widely expressed in cardiomyocytes, cardiac pericytes and coronary endothelial cells64.", [["cardiomyocytes", "ANATOMY", 43, 57], ["cardiac pericytes", "ANATOMY", 59, 76], ["coronary endothelial cells", "ANATOMY", 81, 107], ["ACE2", "GENE_OR_GENE_PRODUCT", 15, 19], ["cardiomyocytes", "CELL", 43, 57], ["cardiac pericytes", "CELL", 59, 76], ["coronary endothelial cells", "CELL", 81, 107], ["ACE2", "PROTEIN", 15, 19], ["cardiomyocytes", "CELL_TYPE", 43, 57], ["cardiac pericytes", "CELL_TYPE", 59, 76], ["coronary endothelial cells", "CELL_TYPE", 81, 107], ["coronary endothelial cells", "TEST", 81, 107], ["cardiomyocytes", "ANATOMY", 43, 57], ["cardiac", "ANATOMY", 59, 66], ["pericytes", "ANATOMY_MODIFIER", 67, 76], ["coronary endothelial", "ANATOMY", 81, 101]]], ["Therefore, SARS-CoV-2 could directly enter cardiomyocytes and provoke myocardial injury.", [["cardiomyocytes", "ANATOMY", 43, 57], ["myocardial", "ANATOMY", 70, 80], ["myocardial injury", "DISEASE", 70, 87], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 11, 21], ["cardiomyocytes", "CELL", 43, 57], ["myocardial", "MULTI-TISSUE_STRUCTURE", 70, 80], ["cardiomyocytes", "CELL_TYPE", 43, 57], ["SARS-CoV", "SPECIES", 11, 19], ["SARS", "PROBLEM", 11, 15], ["myocardial injury", "PROBLEM", 70, 87], ["cardiomyocytes", "ANATOMY", 43, 57], ["myocardial", "ANATOMY", 70, 80], ["injury", "OBSERVATION", 81, 87]]], ["Further, pericytes, which are perivascular mural cells with high ACE2 expression, have been suggested as target host cells by SARS-CoV-264.", [["pericytes", "ANATOMY", 9, 18], ["perivascular mural cells", "ANATOMY", 30, 54], ["cells", "ANATOMY", 117, 122], ["SARS-CoV-264", "CHEMICAL", 126, 138], ["pericytes", "CELL", 9, 18], ["perivascular mural cells", "CELL", 30, 54], ["ACE2", "GENE_OR_GENE_PRODUCT", 65, 69], ["host cells", "CELL", 112, 122], ["SARS-CoV-264", "ORGANISM", 126, 138], ["pericytes", "CELL_TYPE", 9, 18], ["perivascular mural cells", "CELL_TYPE", 30, 54], ["ACE2", "PROTEIN", 65, 69], ["host cells", "CELL_TYPE", 112, 122], ["SARS-CoV-264", "SPECIES", 126, 138], ["perivascular mural cells", "PROBLEM", 30, 54], ["high ACE2 expression", "PROBLEM", 60, 80], ["SARS", "TEST", 126, 130], ["CoV", "TEST", 131, 134], ["pericytes", "OBSERVATION", 9, 18], ["perivascular", "ANATOMY_MODIFIER", 30, 42], ["mural cells", "OBSERVATION", 43, 54], ["high", "OBSERVATION_MODIFIER", 60, 64], ["ACE2 expression", "OBSERVATION", 65, 80]]], ["Considering the essential role of cardiac pericytes in maintaining endothelial cell function in capillary vessels, their infection could lead to coronary microvascular dysfunction and cardiac injury64.", [["cardiac pericytes", "ANATOMY", 34, 51], ["endothelial cell", "ANATOMY", 67, 83], ["capillary vessels", "ANATOMY", 96, 113], ["coronary", "ANATOMY", 145, 153], ["microvascular", "ANATOMY", 154, 167], ["cardiac", "ANATOMY", 184, 191], ["infection", "DISEASE", 121, 130], ["coronary microvascular dysfunction", "DISEASE", 145, 179], ["cardiac pericytes", "CELL", 34, 51], ["endothelial cell", "CELL", 67, 83], ["capillary vessels", "MULTI-TISSUE_STRUCTURE", 96, 113], ["coronary microvascular", "MULTI-TISSUE_STRUCTURE", 145, 167], ["cardiac", "ORGAN", 184, 191], ["cardiac pericytes", "CELL_TYPE", 34, 51], ["cardiac pericytes", "PROBLEM", 34, 51], ["their infection", "PROBLEM", 115, 130], ["coronary microvascular dysfunction", "PROBLEM", 145, 179], ["cardiac injury64", "PROBLEM", 184, 200], ["cardiac", "ANATOMY", 34, 41], ["pericytes", "OBSERVATION", 42, 51], ["endothelial cell function", "OBSERVATION", 67, 92], ["capillary", "ANATOMY_MODIFIER", 96, 105], ["vessels", "ANATOMY", 106, 113], ["infection", "OBSERVATION", 121, 130], ["coronary microvascular", "ANATOMY", 145, 167], ["dysfunction", "OBSERVATION", 168, 179], ["cardiac", "ANATOMY", 184, 191], ["injury64", "OBSERVATION", 192, 200]]], ["SARS-CoV-2 has also been shown to infect human blood vessel organoids in vitro65.", [["blood vessel organoids", "ANATOMY", 47, 69], ["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["human", "ORGANISM", 41, 46], ["blood vessel organoids", "CELL", 47, 69], ["vitro65", "GENE_OR_GENE_PRODUCT", 73, 80], ["human blood vessel organoids", "CELL_TYPE", 41, 69], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 41, 46], ["vessel", "ANATOMY", 53, 59]]], ["Recent pathology reports provided evidence of direct endothelial cell infection and diffuse endothelial inflammation, which could suggest the induction of \u201cendotheliitis\u201d and endothelial dysfunction, potentially contributing to destabilization of coronary plaques, atherothrombosis and vascular disease66.Systemic Hyperinflammation ::: Myocardial injury ::: Cardiovascular complications in patients with COVID-19Viral infections are recognized as one of the most frequent causes of infectious myocarditis which trigger the activation of the host antiviral immune response, including natural killer cells, macrophages and virus-specific T lymphocytes67.", [["endothelial cell", "ANATOMY", 53, 69], ["endothelial", "ANATOMY", 92, 103], ["endothelial", "ANATOMY", 175, 186], ["coronary plaques", "ANATOMY", 247, 263], ["vascular", "ANATOMY", 286, 294], ["Myocardial", "ANATOMY", 336, 346], ["Cardiovascular", "ANATOMY", 358, 372], ["natural killer cells", "ANATOMY", 583, 603], ["macrophages", "ANATOMY", 605, 616], ["T lymphocytes67", "ANATOMY", 636, 651], ["infection", "DISEASE", 70, 79], ["inflammation", "DISEASE", 104, 116], ["endotheliitis", "DISEASE", 156, 169], ["endothelial dysfunction", "DISEASE", 175, 198], ["coronary plaques", "DISEASE", 247, 263], ["atherothrombosis", "DISEASE", 265, 281], ["Hyperinflammation", "DISEASE", 314, 331], ["Myocardial injury", "DISEASE", 336, 353], ["Cardiovascular complications", "DISEASE", 358, 386], ["infections", "DISEASE", 418, 428], ["myocarditis", "DISEASE", 493, 504], ["endothelial cell", "CELL", 53, 69], ["endothelial", "TISSUE", 92, 103], ["endothelial", "CELL", 175, 186], ["coronary", "MULTI-TISSUE_STRUCTURE", 247, 255], ["vascular", "MULTI-TISSUE_STRUCTURE", 286, 294], ["Myocardial", "MULTI-TISSUE_STRUCTURE", 336, 346], ["patients", "ORGANISM", 390, 398], ["COVID-19Viral", "ORGANISM", 404, 417], ["natural killer cells", "CELL", 583, 603], ["macrophages", "CELL", 605, 616], ["T lymphocytes67", "CELL", 636, 651], ["natural killer cells", "CELL_TYPE", 583, 603], ["macrophages", "CELL_TYPE", 605, 616], ["T lymphocytes67", "CELL_TYPE", 636, 651], ["patients", "SPECIES", 390, 398], ["Recent pathology", "TEST", 0, 16], ["direct endothelial cell infection", "PROBLEM", 46, 79], ["diffuse endothelial inflammation", "PROBLEM", 84, 116], ["\u201cendotheliitis", "PROBLEM", 155, 169], ["endothelial dysfunction", "PROBLEM", 175, 198], ["coronary plaques", "PROBLEM", 247, 263], ["atherothrombosis", "PROBLEM", 265, 281], ["vascular disease66", "PROBLEM", 286, 304], ["Myocardial injury", "PROBLEM", 336, 353], ["Cardiovascular complications", "PROBLEM", 358, 386], ["COVID", "TEST", 404, 409], ["19Viral infections", "PROBLEM", 410, 428], ["infectious myocarditis", "PROBLEM", 482, 504], ["natural killer cells", "PROBLEM", 583, 603], ["macrophages", "PROBLEM", 605, 616], ["virus", "PROBLEM", 621, 626], ["evidence of", "UNCERTAINTY", 34, 45], ["endothelial cell infection", "OBSERVATION", 53, 79], ["diffuse", "OBSERVATION_MODIFIER", 84, 91], ["endothelial inflammation", "OBSERVATION", 92, 116], ["endothelial dysfunction", "OBSERVATION", 175, 198], ["coronary", "ANATOMY", 247, 255], ["plaques", "OBSERVATION", 256, 263], ["atherothrombosis", "OBSERVATION", 265, 281], ["vascular", "ANATOMY", 286, 294], ["disease66", "OBSERVATION", 295, 304], ["Hyperinflammation", "OBSERVATION", 314, 331], ["injury", "OBSERVATION", 347, 353], ["complications", "OBSERVATION", 373, 386], ["infections", "OBSERVATION", 418, 428], ["infectious", "OBSERVATION_MODIFIER", 482, 492], ["myocarditis", "OBSERVATION", 493, 504], ["natural killer cells", "OBSERVATION", 583, 603]]], ["Similarly, an aberrant T-cell and monocyte response has been observed in COVID-19 patients leading to a systemic hyper-inflammatory response characterized by increased proinflammatory cytokine and chemokine production (tumor necrosis factor, IL-2, IL-6, IL-7 and CCL2 among others)34,48,50,68,69 (Table 5), (Figure 2).", [["T-cell", "ANATOMY", 23, 29], ["monocyte", "ANATOMY", 34, 42], ["tumor", "DISEASE", 219, 224], ["necrosis", "DISEASE", 225, 233], ["T-cell", "CELL", 23, 29], ["monocyte", "CELL", 34, 42], ["patients", "ORGANISM", 82, 90], ["tumor necrosis factor", "GENE_OR_GENE_PRODUCT", 219, 240], ["IL-2", "GENE_OR_GENE_PRODUCT", 242, 246], ["IL-6", "GENE_OR_GENE_PRODUCT", 248, 252], ["IL-7", "GENE_OR_GENE_PRODUCT", 254, 258], ["CCL2", "GENE_OR_GENE_PRODUCT", 263, 267], ["proinflammatory cytokine", "PROTEIN", 168, 192], ["chemokine", "PROTEIN", 197, 206], ["tumor necrosis factor, IL-2, IL-6", "PROTEIN", 219, 252], ["IL", "PROTEIN", 254, 256], ["CCL2", "PROTEIN", 263, 267], ["patients", "SPECIES", 82, 90], ["an aberrant T-cell", "PROBLEM", 11, 29], ["COVID", "TEST", 73, 78], ["a systemic hyper-inflammatory response", "PROBLEM", 102, 140], ["increased proinflammatory cytokine", "PROBLEM", 158, 192], ["chemokine production", "PROBLEM", 197, 217], ["tumor necrosis factor", "PROBLEM", 219, 240], ["IL", "TEST", 242, 244], ["IL", "TEST", 248, 250], ["IL", "TEST", 254, 256], ["aberrant", "OBSERVATION_MODIFIER", 14, 22], ["-cell", "OBSERVATION_MODIFIER", 24, 29], ["monocyte response", "OBSERVATION", 34, 51], ["systemic", "OBSERVATION_MODIFIER", 104, 112], ["hyper", "OBSERVATION", 113, 118], ["inflammatory response", "OBSERVATION", 119, 140], ["increased", "OBSERVATION_MODIFIER", 158, 167], ["proinflammatory cytokine", "OBSERVATION", 168, 192], ["chemokine production", "OBSERVATION", 197, 217], ["tumor", "OBSERVATION_MODIFIER", 219, 224], ["necrosis", "OBSERVATION_MODIFIER", 225, 233]]], ["This could lead to consequent myocardial damage as suggested by autopsy reports describing inflammatory mononuclear cell infiltration in cardiac tissues of patients with fulminant myocarditis and high SARS\u2010CoV-2 viral load59,70.", [["myocardial", "ANATOMY", 30, 40], ["inflammatory mononuclear cell", "ANATOMY", 91, 120], ["cardiac tissues", "ANATOMY", 137, 152], ["myocardial damage", "DISEASE", 30, 47], ["myocarditis", "DISEASE", 180, 191], ["SARS", "DISEASE", 201, 205], ["myocardial", "MULTI-TISSUE_STRUCTURE", 30, 40], ["inflammatory mononuclear cell", "CELL", 91, 120], ["cardiac tissues", "TISSUE", 137, 152], ["patients", "ORGANISM", 156, 164], ["CoV-2", "GENE_OR_GENE_PRODUCT", 206, 211], ["patients", "SPECIES", 156, 164], ["consequent myocardial damage", "PROBLEM", 19, 47], ["inflammatory mononuclear cell infiltration", "PROBLEM", 91, 133], ["fulminant myocarditis", "PROBLEM", 170, 191], ["high SARS", "PROBLEM", 196, 205], ["CoV", "TEST", 206, 209], ["viral load", "TEST", 212, 222], ["myocardial", "ANATOMY", 30, 40], ["damage", "OBSERVATION", 41, 47], ["inflammatory", "OBSERVATION_MODIFIER", 91, 103], ["mononuclear cell infiltration", "OBSERVATION", 104, 133], ["cardiac tissues", "ANATOMY", 137, 152], ["fulminant", "OBSERVATION_MODIFIER", 170, 179], ["myocarditis", "OBSERVATION", 180, 191], ["high SARS", "OBSERVATION", 196, 205]]], ["Systemic inflammation could further stimulate tissue-resident macrophages and leukocyte adhesion molecule expression on the endothelial cells of preexisting atherosclerotic lesions, enhancing their propensity to be disrupted and cause an acute coronary syndrome71.", [["tissue", "ANATOMY", 46, 52], ["macrophages", "ANATOMY", 62, 73], ["leukocyte", "ANATOMY", 78, 87], ["endothelial cells", "ANATOMY", 124, 141], ["atherosclerotic lesions", "ANATOMY", 157, 180], ["coronary", "ANATOMY", 244, 252], ["inflammation", "DISEASE", 9, 21], ["atherosclerotic lesions", "DISEASE", 157, 180], ["tissue", "TISSUE", 46, 52], ["macrophages", "CELL", 62, 73], ["leukocyte", "CELL", 78, 87], ["endothelial cells", "CELL", 124, 141], ["atherosclerotic lesions", "PATHOLOGICAL_FORMATION", 157, 180], ["resident macrophages", "CELL_TYPE", 53, 73], ["leukocyte adhesion molecule", "PROTEIN", 78, 105], ["endothelial cells", "CELL_TYPE", 124, 141], ["Systemic inflammation", "PROBLEM", 0, 21], ["leukocyte adhesion molecule expression", "PROBLEM", 78, 116], ["the endothelial cells", "TEST", 120, 141], ["preexisting atherosclerotic lesions", "PROBLEM", 145, 180], ["an acute coronary syndrome71", "PROBLEM", 235, 263], ["inflammation", "OBSERVATION", 9, 21], ["macrophages", "OBSERVATION", 62, 73], ["leukocyte adhesion", "OBSERVATION", 78, 96], ["endothelial", "ANATOMY", 124, 135], ["atherosclerotic", "OBSERVATION_MODIFIER", 157, 172], ["lesions", "OBSERVATION", 173, 180], ["acute", "OBSERVATION_MODIFIER", 238, 243], ["coronary", "ANATOMY", 244, 252], ["syndrome71", "OBSERVATION", 253, 263]]], ["Elevated circulating cytokines can also activate the microvascular endothelium, provoking dysfunction of the coronary microvasculature, and consequent myocardial ischemia and injury72.", [["microvascular endothelium", "ANATOMY", 53, 78], ["coronary microvasculature", "ANATOMY", 109, 134], ["myocardial", "ANATOMY", 151, 161], ["myocardial ischemia", "DISEASE", 151, 170], ["microvascular endothelium", "TISSUE", 53, 78], ["coronary microvasculature", "TISSUE", 109, 134], ["myocardial", "MULTI-TISSUE_STRUCTURE", 151, 161], ["cytokines", "PROTEIN", 21, 30], ["Elevated circulating cytokines", "PROBLEM", 0, 30], ["the microvascular endothelium", "PROBLEM", 49, 78], ["dysfunction of the coronary microvasculature", "PROBLEM", 90, 134], ["consequent myocardial ischemia", "PROBLEM", 140, 170], ["injury72", "PROBLEM", 175, 183], ["circulating cytokines", "OBSERVATION", 9, 30], ["microvascular endothelium", "ANATOMY", 53, 78], ["coronary microvasculature", "ANATOMY", 109, 134], ["myocardial", "ANATOMY", 151, 161], ["ischemia", "OBSERVATION", 162, 170]]], ["In line with this concept, blockade of IL-6, which is central in leukocyte transmigration into peripheral tissues, has shown promising results in severe cases of COVID-1973,74.", [["leukocyte", "ANATOMY", 65, 74], ["peripheral tissues", "ANATOMY", 95, 113], ["COVID-1973,74", "CHEMICAL", 162, 175], ["COVID-1973,74", "CHEMICAL", 162, 175], ["IL-6", "GENE_OR_GENE_PRODUCT", 39, 43], ["leukocyte", "CELL", 65, 74], ["peripheral tissues", "TISSUE", 95, 113], ["IL-6", "PROTEIN", 39, 43], ["blockade of IL", "TREATMENT", 27, 41], ["COVID", "TEST", 162, 167], ["central", "OBSERVATION_MODIFIER", 54, 61], ["leukocyte transmigration", "OBSERVATION", 65, 89], ["peripheral tissues", "ANATOMY", 95, 113], ["severe", "OBSERVATION_MODIFIER", 146, 152]]], ["Despite the low severity and low mortality of COVID-19 in children75, there have been reports of severe Kawasaki-like disease (which is a type of vasculitis) cases across Europe76.", [["Kawasaki-like disease", "DISEASE", 104, 125], ["vasculitis", "DISEASE", 146, 156], ["COVID-19", "GENE_OR_GENE_PRODUCT", 46, 54], ["the low severity", "PROBLEM", 8, 24], ["COVID", "TEST", 46, 51], ["severe Kawasaki-like disease", "PROBLEM", 97, 125], ["vasculitis", "PROBLEM", 146, 156], ["low severity", "OBSERVATION_MODIFIER", 12, 24], ["severe", "OBSERVATION_MODIFIER", 97, 103], ["Kawasaki", "OBSERVATION", 104, 112], ["vasculitis", "OBSERVATION", 146, 156]]], ["Macrophage activation syndrome-like manifestations, classically associated with rheumatic diseases including Kawasaki disease77, have also been reported in COVID-19 patients supporting the hypothesis that the increase of Kawasaki-like presentations could be a result of COVID-19-induced systemic hyperinflammation and consequent vasculitis78.Imbalance between myocardial oxygen supply and demand ::: Myocardial injury ::: Cardiovascular complications in patients with COVID-19Myocardial injury can be the result of a mismatch between myocardial oxygen supply and demand, being classified as type 2 myocardial infarction61.", [["Macrophage", "ANATOMY", 0, 10], ["myocardial", "ANATOMY", 360, 370], ["Myocardial", "ANATOMY", 400, 410], ["Cardiovascular", "ANATOMY", 422, 436], ["myocardial", "ANATOMY", 534, 544], ["myocardial", "ANATOMY", 598, 608], ["rheumatic diseases", "DISEASE", 80, 98], ["Kawasaki disease77", "DISEASE", 109, 127], ["Kawasaki-like presentations", "DISEASE", 221, 248], ["COVID-19", "CHEMICAL", 270, 278], ["hyperinflammation", "DISEASE", 296, 313], ["vasculitis", "DISEASE", 329, 339], ["oxygen", "CHEMICAL", 371, 377], ["Myocardial injury", "DISEASE", 400, 417], ["Cardiovascular complications", "DISEASE", 422, 450], ["19Myocardial injury", "DISEASE", 474, 493], ["oxygen", "CHEMICAL", 545, 551], ["myocardial infarction61", "DISEASE", 598, 621], ["COVID-19", "CHEMICAL", 270, 278], ["oxygen", "CHEMICAL", 371, 377], ["oxygen", "CHEMICAL", 545, 551], ["Macrophage", "CELL", 0, 10], ["patients", "ORGANISM", 165, 173], ["COVID-19", "GENE_OR_GENE_PRODUCT", 270, 278], ["myocardial", "MULTI-TISSUE_STRUCTURE", 360, 370], ["oxygen", "SIMPLE_CHEMICAL", 371, 377], ["Myocardial", "MULTI-TISSUE_STRUCTURE", 400, 410], ["patients", "ORGANISM", 454, 462], ["myocardial", "MULTI-TISSUE_STRUCTURE", 534, 544], ["oxygen", "SIMPLE_CHEMICAL", 545, 551], ["myocardial", "MULTI-TISSUE_STRUCTURE", 598, 608], ["patients", "SPECIES", 165, 173], ["patients", "SPECIES", 454, 462], ["Macrophage activation syndrome", "PROBLEM", 0, 30], ["like manifestations", "PROBLEM", 31, 50], ["rheumatic diseases", "PROBLEM", 80, 98], ["Kawasaki disease77", "PROBLEM", 109, 127], ["COVID", "TEST", 270, 275], ["systemic hyperinflammation", "PROBLEM", 287, 313], ["consequent vasculitis", "PROBLEM", 318, 339], ["myocardial oxygen supply", "TREATMENT", 360, 384], ["Myocardial injury", "PROBLEM", 400, 417], ["Cardiovascular complications", "PROBLEM", 422, 450], ["COVID", "TEST", 468, 473], ["19Myocardial injury", "PROBLEM", 474, 493], ["myocardial oxygen supply", "TREATMENT", 534, 558], ["type 2 myocardial infarction61", "PROBLEM", 591, 621], ["activation syndrome", "OBSERVATION", 11, 30], ["rheumatic", "OBSERVATION_MODIFIER", 80, 89], ["systemic", "ANATOMY", 287, 295], ["hyperinflammation", "OBSERVATION", 296, 313], ["vasculitis", "OBSERVATION", 329, 339], ["myocardial", "ANATOMY", 360, 370], ["oxygen supply", "OBSERVATION", 371, 384], ["injury", "OBSERVATION", 411, 417], ["complications", "OBSERVATION", 437, 450], ["injury", "OBSERVATION", 487, 493], ["mismatch", "OBSERVATION", 517, 525], ["myocardial", "ANATOMY", 534, 544], ["oxygen supply", "OBSERVATION", 545, 558], ["myocardial", "ANATOMY", 598, 608], ["infarction61", "OBSERVATION", 609, 621]]], ["Severe respiratory complications and potential subsequent hypoxia are common findings in patients with COVID-19 48,53,79\u201381.", [["respiratory", "ANATOMY", 7, 18], ["respiratory complications", "DISEASE", 7, 32], ["hypoxia", "DISEASE", 58, 65], ["COVID-19 48,53,79\u201381", "CHEMICAL", 103, 123], ["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["Severe respiratory complications", "PROBLEM", 0, 32], ["potential subsequent hypoxia", "PROBLEM", 37, 65], ["COVID", "TEST", 103, 108], ["respiratory", "ANATOMY", 7, 18], ["complications", "OBSERVATION", 19, 32], ["hypoxia", "OBSERVATION", 58, 65]]], ["In a meta-analysis of 19 studies, including a total of 2,874 patients, the most predominant chest x-ray finding was bilateral pneumonia (72.9%, 95% CI 58.6\u201387.1%), with ground-glass opacity being reported in 68.5% (95% CI 51.8\u201385.2%) of patients82.", [["pneumonia", "DISEASE", 126, 135], ["patients", "ORGANISM", 61, 69], ["chest", "ORGAN", 92, 97], ["patients", "ORGANISM", 237, 245], ["patients", "SPECIES", 61, 69], ["patients", "SPECIES", 237, 245], ["chest x-ray", "TEST", 92, 103], ["bilateral pneumonia", "PROBLEM", 116, 135], ["CI", "TEST", 148, 150], ["ground-glass opacity", "PROBLEM", 169, 189], ["CI", "TEST", 219, 221], ["chest", "ANATOMY", 92, 97], ["bilateral", "ANATOMY_MODIFIER", 116, 125], ["pneumonia", "OBSERVATION", 126, 135], ["glass opacity", "OBSERVATION", 176, 189]]], ["In addition, ground-glass opacity was the most frequent chest CT finding (97.6%) in a Chinese cohort of 83 patients with COVID-19-related pneumonia and was associated with severe outcomes in all (100%) patients83.", [["chest", "ANATOMY", 56, 61], ["COVID-19", "CHEMICAL", 121, 129], ["pneumonia", "DISEASE", 138, 147], ["patients", "ORGANISM", 107, 115], ["patients", "ORGANISM", 202, 210], ["patients", "SPECIES", 107, 115], ["patients", "SPECIES", 202, 210], ["ground-glass opacity", "PROBLEM", 13, 33], ["frequent chest CT", "TEST", 47, 64], ["COVID", "TEST", 121, 126], ["pneumonia", "PROBLEM", 138, 147], ["severe outcomes", "PROBLEM", 172, 187], ["ground", "OBSERVATION_MODIFIER", 13, 19], ["glass opacity", "OBSERVATION", 20, 33], ["chest", "ANATOMY", 56, 61], ["pneumonia", "OBSERVATION", 138, 147], ["severe", "OBSERVATION_MODIFIER", 172, 178]]], ["Hypoxia may also contribute to the development of tissue inflammation which in turn may lead to cardiac damage84.", [["tissue", "ANATOMY", 50, 56], ["cardiac", "ANATOMY", 96, 103], ["Hypoxia", "DISEASE", 0, 7], ["inflammation", "DISEASE", 57, 69], ["tissue", "TISSUE", 50, 56], ["cardiac", "ORGAN", 96, 103], ["Hypoxia", "PROBLEM", 0, 7], ["tissue inflammation", "PROBLEM", 50, 69], ["cardiac damage84", "TEST", 96, 112], ["may also contribute to", "UNCERTAINTY", 8, 30], ["tissue", "ANATOMY", 50, 56], ["inflammation", "OBSERVATION", 57, 69]]], ["Further, hypotension, a frequent clinical sign in sepsis and in cytokine storm syndrome, can also reduce myocardial oxygen supply72.", [["myocardial", "ANATOMY", 105, 115], ["hypotension", "DISEASE", 9, 20], ["sepsis", "DISEASE", 50, 56], ["oxygen", "CHEMICAL", 116, 122], ["oxygen", "CHEMICAL", 116, 122], ["myocardial", "MULTI-TISSUE_STRUCTURE", 105, 115], ["oxygen", "SIMPLE_CHEMICAL", 116, 122], ["cytokine", "PROTEIN", 64, 72], ["hypotension", "PROBLEM", 9, 20], ["sepsis", "PROBLEM", 50, 56], ["cytokine storm syndrome", "PROBLEM", 64, 87], ["myocardial oxygen supply72", "TREATMENT", 105, 131], ["hypotension", "OBSERVATION", 9, 20], ["sepsis", "OBSERVATION", 50, 56], ["cytokine storm syndrome", "OBSERVATION", 64, 87], ["oxygen supply72", "OBSERVATION", 116, 131]]], ["On the other hand, systemic infection and fever increase the metabolic needs of peripheral tissues and end-organs resulting in a rise of the metabolic demands of the myocardial cells85.", [["peripheral tissues", "ANATOMY", 80, 98], ["end-organs", "ANATOMY", 103, 113], ["myocardial cells", "ANATOMY", 166, 182], ["infection", "DISEASE", 28, 37], ["fever", "DISEASE", 42, 47], ["peripheral tissues", "TISSUE", 80, 98], ["organs", "ORGAN", 107, 113], ["myocardial cells", "CELL", 166, 182], ["myocardial cells", "CELL_TYPE", 166, 182], ["systemic infection", "PROBLEM", 19, 37], ["fever", "PROBLEM", 42, 47], ["the myocardial cells", "TEST", 162, 182], ["systemic", "OBSERVATION_MODIFIER", 19, 27], ["infection", "OBSERVATION", 28, 37], ["fever", "OBSERVATION", 42, 47], ["peripheral tissues", "ANATOMY", 80, 98], ["metabolic demands", "OBSERVATION", 141, 158], ["myocardial cells", "ANATOMY", 166, 182]]], ["The decrease in diastolic perfusion time during tachycardia can induce inadequate subendocardial perfusion in patients with coronary artery disease, resulting in cardiac injury86.", [["subendocardial", "ANATOMY", 82, 96], ["coronary artery", "ANATOMY", 124, 139], ["cardiac", "ANATOMY", 162, 169], ["tachycardia", "DISEASE", 48, 59], ["coronary artery disease", "DISEASE", 124, 147], ["subendocardial", "MULTI-TISSUE_STRUCTURE", 82, 96], ["patients", "ORGANISM", 110, 118], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 124, 139], ["cardiac", "ORGAN", 162, 169], ["patients", "SPECIES", 110, 118], ["The decrease in diastolic perfusion time", "PROBLEM", 0, 40], ["tachycardia", "PROBLEM", 48, 59], ["inadequate subendocardial perfusion", "PROBLEM", 71, 106], ["coronary artery disease", "PROBLEM", 124, 147], ["cardiac injury86", "PROBLEM", 162, 178], ["decrease", "OBSERVATION_MODIFIER", 4, 12], ["diastolic perfusion", "OBSERVATION", 16, 35], ["subendocardial perfusion", "OBSERVATION", 82, 106], ["coronary artery", "ANATOMY", 124, 139], ["disease", "OBSERVATION", 140, 147], ["cardiac", "ANATOMY", 162, 169], ["injury86", "OBSERVATION", 170, 178]]], ["Therefore, the viral infection caused by SARS-CoV-2 may provoke myocardial oxygen supply and demand imbalance, which is translated into myocardial ischemia and injury.Loss of ACE2-mediated cardioprotection ::: Myocardial injury ::: Cardiovascular complications in patients with COVID-19ACE2 plays an important role in the renin\u2013angiotensin system by catalyzing the conversion of the vasoconstrictor angiotensin II to the vasodilator angiotensin 1-7, which exerts anti-arrhythmogenic and anti-remodeling protective effects in the cardiovascular system87,88.", [["myocardial", "ANATOMY", 64, 74], ["myocardial", "ANATOMY", 136, 146], ["Myocardial", "ANATOMY", 210, 220], ["Cardiovascular", "ANATOMY", 232, 246], ["cardiovascular", "ANATOMY", 529, 543], ["viral infection", "DISEASE", 15, 30], ["SARS", "DISEASE", 41, 45], ["oxygen", "CHEMICAL", 75, 81], ["myocardial ischemia", "DISEASE", 136, 155], ["Myocardial injury", "DISEASE", 210, 227], ["Cardiovascular complications", "DISEASE", 232, 260], ["COVID-19ACE2", "CHEMICAL", 278, 290], ["angiotensin II", "CHEMICAL", 399, 413], ["angiotensin 1-7", "CHEMICAL", 433, 448], ["oxygen", "CHEMICAL", 75, 81], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 41, 51], ["myocardial", "MULTI-TISSUE_STRUCTURE", 64, 74], ["oxygen", "SIMPLE_CHEMICAL", 75, 81], ["myocardial", "MULTI-TISSUE_STRUCTURE", 136, 146], ["ACE2", "GENE_OR_GENE_PRODUCT", 175, 179], ["Myocardial", "MULTI-TISSUE_STRUCTURE", 210, 220], ["patients", "ORGANISM", 264, 272], ["COVID-19ACE2", "GENE_OR_GENE_PRODUCT", 278, 290], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 399, 413], ["angiotensin 1-7", "GENE_OR_GENE_PRODUCT", 433, 448], ["ACE2", "PROTEIN", 175, 179], ["patients", "SPECIES", 264, 272], ["SARS-CoV", "SPECIES", 41, 49], ["the viral infection", "PROBLEM", 11, 30], ["SARS", "PROBLEM", 41, 45], ["myocardial oxygen supply", "TREATMENT", 64, 88], ["demand imbalance", "PROBLEM", 93, 109], ["myocardial ischemia", "PROBLEM", 136, 155], ["injury", "PROBLEM", 160, 166], ["Myocardial injury", "PROBLEM", 210, 227], ["Cardiovascular complications", "PROBLEM", 232, 260], ["COVID", "TEST", 278, 283], ["the vasoconstrictor angiotensin II", "TREATMENT", 379, 413], ["the vasodilator angiotensin", "TREATMENT", 417, 444], ["the cardiovascular system", "TEST", 525, 550], ["viral", "OBSERVATION_MODIFIER", 15, 20], ["infection", "OBSERVATION", 21, 30], ["oxygen supply", "OBSERVATION", 75, 88], ["myocardial", "ANATOMY", 136, 146], ["ischemia", "OBSERVATION", 147, 155], ["injury", "OBSERVATION", 160, 166], ["injury", "OBSERVATION", 221, 227], ["complications", "OBSERVATION", 247, 260], ["vasoconstrictor angiotensin", "OBSERVATION", 383, 410], ["cardiovascular system", "ANATOMY", 529, 550]]], ["Angiotensin 1-7 has also antiproliferative effects on vascular smooth muscle cells89 and cardiac fibroblasts90.", [["vascular smooth muscle cells89", "ANATOMY", 54, 84], ["cardiac fibroblast", "ANATOMY", 89, 107], ["Angiotensin 1-7", "CHEMICAL", 0, 15], ["Angiotensin 1-7", "GENE_OR_GENE_PRODUCT", 0, 15], ["vascular smooth muscle cells89", "CELL", 54, 84], ["cardiac fibroblast", "CELL", 89, 107], ["vascular smooth muscle cells89", "CELL_TYPE", 54, 84], ["cardiac fibroblast", "CELL_TYPE", 89, 107], ["Angiotensin", "TEST", 0, 11], ["vascular smooth muscle cells89", "TEST", 54, 84], ["cardiac fibroblasts", "PROBLEM", 89, 108], ["vascular", "ANATOMY", 54, 62], ["smooth muscle", "ANATOMY", 63, 76], ["cardiac", "ANATOMY", 89, 96], ["fibroblasts", "OBSERVATION", 97, 108]]], ["Additionally, ACE2 has counter-regulatory function to ACE1, which hydrolyzes angiotensin I to the octapeptide angiotensin II and inactivates the vasodilator bradykinin91.", [["angiotensin I", "CHEMICAL", 77, 90], ["angiotensin II", "CHEMICAL", 110, 124], ["bradykinin91", "CHEMICAL", 157, 169], ["bradykinin91", "CHEMICAL", 157, 169], ["ACE2", "GENE_OR_GENE_PRODUCT", 14, 18], ["ACE1", "GENE_OR_GENE_PRODUCT", 54, 58], ["angiotensin I", "GENE_OR_GENE_PRODUCT", 77, 90], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 110, 124], ["bradykinin91", "GENE_OR_GENE_PRODUCT", 157, 169], ["ACE2", "PROTEIN", 14, 18], ["ACE1", "PROTEIN", 54, 58], ["angiotensin I", "PROTEIN", 77, 90], ["ACE2", "TEST", 14, 18], ["ACE1", "TEST", 54, 58], ["the octapeptide angiotensin II", "TREATMENT", 94, 124], ["the vasodilator bradykinin91", "TREATMENT", 141, 169]]], ["The activation of angiotensin II elicits heterogeneous signaling cascades in the vasculature, which can result in expression of proinflammatory mediators and endothelial dysfunction92.", [["vasculature", "ANATOMY", 81, 92], ["endothelial", "ANATOMY", 158, 169], ["angiotensin II", "CHEMICAL", 18, 32], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 18, 32], ["vasculature", "MULTI-TISSUE_STRUCTURE", 81, 92], ["endothelial", "CELL", 158, 169], ["angiotensin II", "PROTEIN", 18, 32], ["proinflammatory mediators", "PROTEIN", 128, 153], ["heterogeneous signaling cascades in the vasculature", "PROBLEM", 41, 92], ["proinflammatory mediators", "PROBLEM", 128, 153], ["endothelial dysfunction92", "PROBLEM", 158, 183], ["angiotensin II", "OBSERVATION_MODIFIER", 18, 32], ["heterogeneous", "OBSERVATION_MODIFIER", 41, 54], ["signaling cascades", "OBSERVATION", 55, 73], ["vasculature", "ANATOMY", 81, 92], ["proinflammatory mediators", "OBSERVATION", 128, 153], ["endothelial dysfunction92", "OBSERVATION", 158, 183]]], ["The binding of SARS-CoV-2 to ACE2 is expected to lead to internalization of ACE2 and loss of the external ACE2 catalytic effect24,93.", [["SARS", "DISEASE", 15, 19], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 15, 25], ["ACE2", "GENE_OR_GENE_PRODUCT", 29, 33], ["ACE2", "GENE_OR_GENE_PRODUCT", 76, 80], ["ACE2", "GENE_OR_GENE_PRODUCT", 106, 110], ["ACE2", "PROTEIN", 29, 33], ["ACE2", "PROTEIN", 76, 80], ["ACE2", "PROTEIN", 106, 110], ["SARS", "PROBLEM", 15, 19], ["ACE2", "TEST", 76, 80], ["the external ACE2 catalytic effect", "TREATMENT", 93, 127]]], ["Therefore, the possible downregulation of ACE2 and the subsequent increase of the pro-atherosclerotic angiotensin II together with the decrease of the cardioprotective angiotensin 1-7 in patients with COVID-19 may ultimately compromise heart function94,95.", [["heart", "ANATOMY", 236, 241], ["angiotensin II", "CHEMICAL", 102, 116], ["angiotensin 1-7", "CHEMICAL", 168, 183], ["COVID-19", "CHEMICAL", 201, 209], ["COVID-19", "CHEMICAL", 201, 209], ["ACE2", "GENE_OR_GENE_PRODUCT", 42, 46], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 102, 116], ["angiotensin 1-7", "GENE_OR_GENE_PRODUCT", 168, 183], ["patients", "ORGANISM", 187, 195], ["heart", "ORGAN", 236, 241], ["ACE2", "PROTEIN", 42, 46], ["pro-atherosclerotic angiotensin II", "PROTEIN", 82, 116], ["patients", "SPECIES", 187, 195], ["downregulation of ACE2", "PROBLEM", 24, 46], ["the pro-atherosclerotic angiotensin II", "TREATMENT", 78, 116], ["the cardioprotective angiotensin", "TREATMENT", 147, 179], ["COVID", "TEST", 201, 206], ["heart function", "TEST", 236, 250], ["possible", "UNCERTAINTY", 15, 23], ["downregulation", "OBSERVATION_MODIFIER", 24, 38], ["increase", "OBSERVATION_MODIFIER", 66, 74], ["pro-atherosclerotic angiotensin", "OBSERVATION", 82, 113], ["decrease", "OBSERVATION_MODIFIER", 135, 143]]], ["Remarkably, severe COVID-19 has been associated with hypokalemia and higher blood pressure, supporting suggestions of decreased ACE2 function and augmented levels of angiotensin II after SARS-CoV-2 infection96.Heart failure ::: Cardiovascular complications in patients with COVID-19Current data regarding the incidence of heart failure among patients with COVID-19 are limited (Table 1).", [["blood", "ANATOMY", 76, 81], ["Heart", "ANATOMY", 210, 215], ["Cardiovascular", "ANATOMY", 228, 242], ["heart", "ANATOMY", 322, 327], ["COVID-19", "CHEMICAL", 19, 27], ["hypokalemia", "DISEASE", 53, 64], ["angiotensin II", "CHEMICAL", 166, 180], ["Heart failure", "DISEASE", 210, 223], ["Cardiovascular complications", "DISEASE", 228, 256], ["heart failure", "DISEASE", 322, 335], ["COVID-19", "CHEMICAL", 19, 27], ["COVID-19", "GENE_OR_GENE_PRODUCT", 19, 27], ["blood", "ORGANISM_SUBSTANCE", 76, 81], ["ACE2", "GENE_OR_GENE_PRODUCT", 128, 132], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 166, 180], ["SARS-CoV-2 infection96", "ORGANISM", 187, 209], ["Heart", "ORGAN", 210, 215], ["patients", "ORGANISM", 260, 268], ["heart", "ORGAN", 322, 327], ["patients", "ORGANISM", 342, 350], ["ACE2", "PROTEIN", 128, 132], ["angiotensin II", "PROTEIN", 166, 180], ["patients", "SPECIES", 260, 268], ["patients", "SPECIES", 342, 350], ["severe COVID", "PROBLEM", 12, 24], ["hypokalemia", "PROBLEM", 53, 64], ["higher blood pressure", "PROBLEM", 69, 90], ["decreased ACE2 function", "PROBLEM", 118, 141], ["angiotensin II", "PROBLEM", 166, 180], ["SARS", "PROBLEM", 187, 191], ["CoV-2 infection96", "PROBLEM", 192, 209], ["Heart failure", "PROBLEM", 210, 223], ["Cardiovascular complications", "PROBLEM", 228, 256], ["COVID", "TEST", 274, 279], ["heart failure", "PROBLEM", 322, 335], ["COVID", "TEST", 356, 361], ["severe", "OBSERVATION_MODIFIER", 12, 18], ["hypokalemia", "OBSERVATION", 53, 64], ["decreased", "OBSERVATION_MODIFIER", 118, 127], ["ACE2 function", "OBSERVATION", 128, 141], ["failure", "OBSERVATION", 216, 223], ["complications", "OBSERVATION", 243, 256], ["heart", "ANATOMY", 322, 327], ["failure", "OBSERVATION", 328, 335]]], ["Viral infections are the most common cause of myocarditis97.", [["Viral infections", "DISEASE", 0, 16], ["Viral", "ORGANISM", 0, 5], ["myocarditis97", "CANCER", 46, 59], ["Viral infections", "PROBLEM", 0, 16], ["myocarditis97", "PROBLEM", 46, 59], ["infections", "OBSERVATION", 6, 16], ["most common", "OBSERVATION_MODIFIER", 25, 36], ["myocarditis97", "OBSERVATION", 46, 59]]], ["Despite the high recovery rates, nearly one out of three biopsy-proven myocarditis patients will later develop dilated cardiomyopathy98.", [["myocarditis", "DISEASE", 71, 82], ["dilated cardiomyopathy", "DISEASE", 111, 133], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["three biopsy", "TEST", 51, 63], ["myocarditis", "PROBLEM", 71, 82], ["dilated cardiomyopathy", "PROBLEM", 111, 133], ["myocarditis", "OBSERVATION", 71, 82], ["dilated", "OBSERVATION_MODIFIER", 111, 118], ["cardiomyopathy", "OBSERVATION", 119, 133]]], ["Recurrent viral myocarditis and persistent viral replication have also been associated with deterioration of myocardial function99,100.", [["myocardial", "ANATOMY", 109, 119], ["myocarditis", "DISEASE", 16, 27], ["myocardial", "MULTI-TISSUE_STRUCTURE", 109, 119], ["Recurrent viral myocarditis", "PROBLEM", 0, 27], ["persistent viral replication", "PROBLEM", 32, 60], ["myocardial function", "TEST", 109, 128], ["viral", "OBSERVATION_MODIFIER", 10, 15], ["myocarditis", "OBSERVATION", 16, 27], ["persistent", "OBSERVATION_MODIFIER", 32, 42], ["viral replication", "OBSERVATION", 43, 60], ["myocardial function", "OBSERVATION", 109, 128]]], ["Similarly, fulminant myocarditis, which may be a clinical manifestation of COVID-1957,58, can result in left ventricular systolic dysfunction and even cardiogenic shock101,102.Heart failure ::: Cardiovascular complications in patients with COVID-19Viruses can also contribute to the etiology of heart failure through immune-mediated and inflammatory myocardial damage103.", [["left ventricular", "ANATOMY", 104, 120], ["Heart", "ANATOMY", 176, 181], ["Cardiovascular", "ANATOMY", 194, 208], ["heart", "ANATOMY", 295, 300], ["myocardial", "ANATOMY", 350, 360], ["myocarditis", "DISEASE", 21, 32], ["COVID-1957,58", "CHEMICAL", 75, 88], ["left ventricular systolic dysfunction", "DISEASE", 104, 141], ["cardiogenic shock", "DISEASE", 151, 168], ["Heart failure", "DISEASE", 176, 189], ["Cardiovascular complications", "DISEASE", 194, 222], ["COVID-19Viruses", "CHEMICAL", 240, 255], ["heart failure", "DISEASE", 295, 308], ["myocardial damage", "DISEASE", 350, 367], ["COVID-1957,58", "CHEMICAL", 75, 88], ["COVID-19Viruses", "CHEMICAL", 240, 255], ["ventricular", "MULTI-TISSUE_STRUCTURE", 109, 120], ["Heart", "ORGAN", 176, 181], ["patients", "ORGANISM", 226, 234], ["COVID-19Viruses", "SIMPLE_CHEMICAL", 240, 255], ["heart", "ORGAN", 295, 300], ["myocardial", "MULTI-TISSUE_STRUCTURE", 350, 360], ["patients", "SPECIES", 226, 234], ["fulminant myocarditis", "PROBLEM", 11, 32], ["COVID", "TEST", 75, 80], ["left ventricular systolic dysfunction", "PROBLEM", 104, 141], ["cardiogenic shock", "PROBLEM", 151, 168], ["Heart failure", "PROBLEM", 176, 189], ["Cardiovascular complications", "PROBLEM", 194, 222], ["COVID-19Viruses", "TREATMENT", 240, 255], ["heart failure", "PROBLEM", 295, 308], ["inflammatory myocardial damage", "PROBLEM", 337, 367], ["fulminant", "OBSERVATION_MODIFIER", 11, 20], ["myocarditis", "OBSERVATION", 21, 32], ["may be", "UNCERTAINTY", 40, 46], ["left ventricular", "ANATOMY", 104, 120], ["systolic dysfunction", "OBSERVATION", 121, 141], ["cardiogenic shock", "OBSERVATION", 151, 168], ["failure", "OBSERVATION", 182, 189], ["complications", "OBSERVATION", 209, 222], ["heart", "ANATOMY", 295, 300], ["failure", "OBSERVATION", 301, 308], ["inflammatory", "OBSERVATION_MODIFIER", 337, 349]]], ["Acute systemic inflammation and septic shock can result in an increase of left ventricular end-diastolic volume together with depression of myocardial function104,105.", [["left ventricular", "ANATOMY", 74, 90], ["myocardial", "ANATOMY", 140, 150], ["inflammation", "DISEASE", 15, 27], ["septic shock", "DISEASE", 32, 44], ["depression", "DISEASE", 126, 136], ["left ventricular", "MULTI-TISSUE_STRUCTURE", 74, 90], ["myocardial", "MULTI-TISSUE_STRUCTURE", 140, 150], ["Acute systemic inflammation", "PROBLEM", 0, 27], ["septic shock", "PROBLEM", 32, 44], ["depression of myocardial function", "PROBLEM", 126, 159], ["systemic", "OBSERVATION_MODIFIER", 6, 14], ["inflammation", "OBSERVATION", 15, 27], ["septic shock", "OBSERVATION", 32, 44], ["increase", "OBSERVATION_MODIFIER", 62, 70], ["left ventricular", "ANATOMY", 74, 90], ["diastolic volume", "OBSERVATION", 95, 111], ["myocardial function", "OBSERVATION", 140, 159]]], ["Moreover, an excessive T lymphocyte response in enterovirus-induced myocarditis has been reported to provoke left ventricular dilatation and/or dysfunction106.", [["T lymphocyte", "ANATOMY", 23, 35], ["left ventricular", "ANATOMY", 109, 125], ["myocarditis", "DISEASE", 68, 79], ["left ventricular dilatation", "DISEASE", 109, 136], ["T lymphocyte", "CELL", 23, 35], ["enterovirus", "ORGANISM", 48, 59], ["left ventricular", "MULTI-TISSUE_STRUCTURE", 109, 125], ["an excessive T lymphocyte response", "PROBLEM", 10, 44], ["enterovirus", "PROBLEM", 48, 59], ["myocarditis", "PROBLEM", 68, 79], ["left ventricular dilatation", "PROBLEM", 109, 136], ["dysfunction", "PROBLEM", 144, 155], ["excessive", "OBSERVATION_MODIFIER", 13, 22], ["lymphocyte response", "OBSERVATION", 25, 44], ["enterovirus", "OBSERVATION", 48, 59], ["myocarditis", "OBSERVATION", 68, 79], ["left ventricular", "ANATOMY", 109, 125], ["dilatation", "OBSERVATION", 126, 136]]], ["Finally, high levels of circulating cytokines, such as TNF-\u03b1, IL-1\u03b2 and IL\u20106 have been shown to cause deterioration of myocardial cell contraction and relaxation in vitro107,108 and could suggest a potential relation between COVID-19-induced hyperinflammatory syndrome and myocardial dysfunction.Heart failure ::: Cardiovascular complications in patients with COVID-19Chen et al. reported heart failure as a complication in 24.4% (n=43) of a Chinese COVID-19 population (n=176), using age-related amino-terminal pro-brain natriuretic peptide cut-offs, which yielded 90% sensitivity and 84% specificity for acute heart failure56; there was remarkable difference in the prevalence of heart failure between COVID-19 survivors and non-survivors (3.2% vs. 49.4%)56.", [["myocardial cell", "ANATOMY", 119, 134], ["myocardial", "ANATOMY", 273, 283], ["Heart", "ANATOMY", 296, 301], ["Cardiovascular", "ANATOMY", 314, 328], ["heart", "ANATOMY", 389, 394], ["heart", "ANATOMY", 612, 617], ["heart", "ANATOMY", 682, 687], ["COVID-19", "CHEMICAL", 225, 233], ["hyperinflammatory syndrome", "DISEASE", 242, 268], ["myocardial dysfunction", "DISEASE", 273, 295], ["Heart failure", "DISEASE", 296, 309], ["Cardiovascular complications", "DISEASE", 314, 342], ["heart failure", "DISEASE", 389, 402], ["acute heart failure56", "DISEASE", 606, 627], ["heart failure", "DISEASE", 682, 695], ["COVID-19", "CHEMICAL", 225, 233], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 55, 60], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 62, 67], ["IL\u20106", "GENE_OR_GENE_PRODUCT", 72, 76], ["myocardial cell", "CELL", 119, 134], ["COVID-19", "GENE_OR_GENE_PRODUCT", 225, 233], ["myocardial", "MULTI-TISSUE_STRUCTURE", 273, 283], ["Heart", "ORGAN", 296, 301], ["patients", "ORGANISM", 346, 354], ["heart", "ORGAN", 389, 394], ["heart", "ORGAN", 612, 617], ["heart", "ORGAN", 682, 687], ["circulating cytokines", "PROTEIN", 24, 45], ["TNF", "PROTEIN", 55, 58], ["IL-1\u03b2", "PROTEIN", 62, 67], ["IL\u20106", "PROTEIN", 72, 76], ["patients", "SPECIES", 346, 354], ["high levels of circulating cytokines", "PROBLEM", 9, 45], ["TNF", "TEST", 55, 58], ["IL", "TEST", 62, 64], ["myocardial cell contraction", "PROBLEM", 119, 146], ["relaxation in vitro", "TEST", 151, 170], ["COVID", "TEST", 225, 230], ["hyperinflammatory syndrome", "PROBLEM", 242, 268], ["myocardial dysfunction", "PROBLEM", 273, 295], ["Heart failure", "PROBLEM", 296, 309], ["Cardiovascular complications", "PROBLEM", 314, 342], ["COVID", "TEST", 360, 365], ["heart failure", "PROBLEM", 389, 402], ["a complication", "PROBLEM", 406, 420], ["a Chinese COVID", "TEST", 440, 455], ["related amino-terminal pro-brain natriuretic peptide", "PROBLEM", 489, 541], ["acute heart failure56", "PROBLEM", 606, 627], ["heart failure", "PROBLEM", 682, 695], ["COVID", "TEST", 704, 709], ["non-survivors", "TEST", 727, 740], ["myocardial cell contraction", "OBSERVATION", 119, 146], ["hyperinflammatory syndrome", "OBSERVATION", 242, 268], ["myocardial", "ANATOMY", 273, 283], ["dysfunction", "OBSERVATION", 284, 295], ["failure", "OBSERVATION", 302, 309], ["complications", "OBSERVATION", 329, 342], ["heart", "ANATOMY", 389, 394], ["failure", "OBSERVATION", 395, 402], ["heart", "ANATOMY", 612, 617], ["failure56", "OBSERVATION", 618, 627], ["heart", "ANATOMY", 682, 687], ["failure", "OBSERVATION", 688, 695]]], ["Another study including 191 patients reported heart failure as a cardiovascular complication in 23.0% (n=44) of the population, 63.6% (n=28) of which had a fatal outcome48 (Table 3).", [["heart", "ANATOMY", 46, 51], ["cardiovascular", "ANATOMY", 65, 79], ["heart failure", "DISEASE", 46, 59], ["cardiovascular complication", "DISEASE", 65, 92], ["patients", "ORGANISM", 28, 36], ["heart", "ORGAN", 46, 51], ["patients", "SPECIES", 28, 36], ["Another study", "TEST", 0, 13], ["heart failure", "PROBLEM", 46, 59], ["a cardiovascular complication", "PROBLEM", 63, 92], ["the population", "TEST", 112, 126], ["heart", "ANATOMY", 46, 51], ["failure", "OBSERVATION", 52, 59]]], ["Lastly, in a meta-analysis of 43 studies involving 3,600 patients, the prevalence of heart failure as a complication was 17.1% (95%, CI: 1.5\u201342.2%) among critically-ill patients compared to 1.9% (95% CI: 0.0-26.0%) among non-critically ill patients109.Arrhythmias ::: Cardiovascular complications in patients with COVID-19Sustained ventricular arrhythmias are significant clinical features of acute myocarditis102, which is increasingly being reported as a clinical complication of COVID-1957\u201360.", [["heart", "ANATOMY", 85, 90], ["Cardiovascular", "ANATOMY", 268, 282], ["ventricular", "ANATOMY", 332, 343], ["heart failure", "DISEASE", 85, 98], ["critically-ill", "DISEASE", 154, 168], ["non-critically ill", "DISEASE", 221, 239], ["Arrhythmias", "DISEASE", 252, 263], ["Cardiovascular complications", "DISEASE", 268, 296], ["ventricular arrhythmias", "DISEASE", 332, 355], ["myocarditis", "DISEASE", 399, 410], ["COVID-1957\u201360", "CHEMICAL", 482, 495], ["COVID-1957\u201360", "CHEMICAL", 482, 495], ["patients", "ORGANISM", 57, 65], ["heart", "ORGAN", 85, 90], ["patients", "ORGANISM", 169, 177], ["patient", "ORGANISM", 240, 247], ["patients", "ORGANISM", 300, 308], ["ventricular", "MULTI-TISSUE_STRUCTURE", 332, 343], ["COVID-1957\u201360", "SIMPLE_CHEMICAL", 482, 495], ["patients", "SPECIES", 57, 65], ["patients", "SPECIES", 169, 177], ["patient", "SPECIES", 240, 247], ["patients", "SPECIES", 300, 308], ["heart failure", "PROBLEM", 85, 98], ["a complication", "PROBLEM", 102, 116], ["CI", "TEST", 133, 135], ["CI", "TEST", 200, 202], ["Arrhythmias", "PROBLEM", 252, 263], ["Cardiovascular complications", "PROBLEM", 268, 296], ["COVID", "TEST", 314, 319], ["19Sustained ventricular arrhythmias", "PROBLEM", 320, 355], ["acute myocarditis", "PROBLEM", 393, 410], ["COVID", "TEST", 482, 487], ["heart", "ANATOMY", 85, 90], ["failure", "OBSERVATION", 91, 98], ["complications", "OBSERVATION", 283, 296], ["ventricular", "ANATOMY", 332, 343], ["arrhythmias", "OBSERVATION", 344, 355], ["acute", "OBSERVATION_MODIFIER", 393, 398], ["myocarditis", "OBSERVATION", 399, 410]]], ["Guo et al. reported sustained ventricular tachycardia or ventricular fibrillation in 5.9% (n=11) of 187 patients in a designated hospital to treat patients with COVID-19 in China55.", [["ventricular", "ANATOMY", 30, 41], ["ventricular", "ANATOMY", 57, 68], ["ventricular tachycardia", "DISEASE", 30, 53], ["ventricular fibrillation", "DISEASE", 57, 81], ["ventricular", "ORGAN", 30, 41], ["ventricular", "ORGAN", 57, 68], ["patients", "ORGANISM", 104, 112], ["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 104, 112], ["patients", "SPECIES", 147, 155], ["sustained ventricular tachycardia", "PROBLEM", 20, 53], ["ventricular fibrillation", "PROBLEM", 57, 81], ["COVID", "TEST", 161, 166], ["et al", "OBSERVATION", 4, 9], ["ventricular", "ANATOMY", 30, 41], ["tachycardia", "OBSERVATION", 42, 53], ["ventricular", "ANATOMY", 57, 68], ["fibrillation", "OBSERVATION", 69, 81]]], ["Arrhythmias could also be precipitated by electrolyte imbalances which have been observed in populations with COVID-1956.", [["Arrhythmias", "DISEASE", 0, 11], ["Arrhythmias", "PROBLEM", 0, 11], ["electrolyte imbalances", "PROBLEM", 42, 64], ["COVID", "TEST", 110, 115], ["electrolyte imbalances", "OBSERVATION", 42, 64]]], ["The interaction of SARS-CoV-2 with the renin-angiotensin-aldosterone system has caused increasing concern about sodium and potassium disorders which may increase vulnerability to various tachyarrhythmias96,110.", [["SARS", "DISEASE", 19, 23], ["angiotensin", "CHEMICAL", 45, 56], ["aldosterone", "CHEMICAL", 57, 68], ["sodium", "CHEMICAL", 112, 118], ["potassium", "CHEMICAL", 123, 132], ["tachyarrhythmias", "DISEASE", 187, 203], ["aldosterone", "CHEMICAL", 57, 68], ["sodium", "CHEMICAL", 112, 118], ["potassium", "CHEMICAL", 123, 132], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 19, 29], ["renin-angiotensin-aldosterone", "GENE_OR_GENE_PRODUCT", 39, 68], ["sodium", "SIMPLE_CHEMICAL", 112, 118], ["potassium", "SIMPLE_CHEMICAL", 123, 132], ["renin", "PROTEIN", 39, 44], ["SARS-CoV", "SPECIES", 19, 27], ["SARS", "TEST", 19, 23], ["CoV", "TEST", 24, 27], ["the renin", "TREATMENT", 35, 44], ["angiotensin-aldosterone system", "TREATMENT", 45, 75], ["sodium and potassium disorders", "PROBLEM", 112, 142], ["various tachyarrhythmias", "PROBLEM", 179, 203], ["tachyarrhythmias", "OBSERVATION", 187, 203]]], ["In addition, hypoxia, a common clinical manifestation of severe COVID-1948,53,79\u201381, has been associated with alterations of cardiomyocyte gap-junctions which could contribute to the development of atrial arrhythmias, especially atrial fibrillation111.", [["cardiomyocyte gap-junctions", "ANATOMY", 125, 152], ["atrial", "ANATOMY", 198, 204], ["atrial", "ANATOMY", 229, 235], ["hypoxia", "DISEASE", 13, 20], ["COVID-1948,53,79\u201381", "CHEMICAL", 64, 83], ["atrial arrhythmias", "DISEASE", 198, 216], ["atrial fibrillation", "DISEASE", 229, 248], ["COVID-1948,53,79\u201381", "CHEMICAL", 64, 83], ["cardiomyocyte", "CELL", 125, 138], ["junctions", "CELLULAR_COMPONENT", 143, 152], ["atrial", "MULTI-TISSUE_STRUCTURE", 198, 204], ["hypoxia", "PROBLEM", 13, 20], ["severe COVID", "PROBLEM", 57, 69], ["atrial arrhythmias", "PROBLEM", 198, 216], ["atrial fibrillation", "PROBLEM", 229, 248], ["hypoxia", "OBSERVATION", 13, 20], ["severe", "OBSERVATION_MODIFIER", 57, 63], ["cardiomyocyte gap", "OBSERVATION", 125, 142], ["atrial", "ANATOMY", 198, 204], ["arrhythmias", "OBSERVATION", 205, 216], ["atrial fibrillation", "OBSERVATION", 229, 248]]], ["A recent retrospective case series study characterizing the first 393 consecutive patients with COVID-19 in two hospitals in New York City found that patients who received mechanical ventilation were more likely to have atrial arrhythmias (18.5% vs. 1.9%)112.Arrhythmias ::: Cardiovascular complications in patients with COVID-19Arrhythmias can also be induced by novel medical therapies for COVID-19; despite the unclear data about the effectiveness of chloroquine phosphate and hydroxychloroquine sulfate for the treatment of COVID-19113, the Food and Drug Administration of the United States of America issued an emergency authorization for their use under determined circumstances in patients with COVID-19114.", [["atrial", "ANATOMY", 220, 226], ["Cardiovascular", "ANATOMY", 275, 289], ["atrial arrhythmias", "DISEASE", 220, 238], ["Arrhythmias", "DISEASE", 259, 270], ["Cardiovascular complications", "DISEASE", 275, 303], ["COVID-19Arrhythmias", "CHEMICAL", 321, 340], ["chloroquine phosphate", "CHEMICAL", 454, 475], ["hydroxychloroquine sulfate", "CHEMICAL", 480, 506], ["COVID-19113", "CHEMICAL", 528, 539], ["COVID-19114", "CHEMICAL", 702, 713], ["chloroquine phosphate", "CHEMICAL", 454, 475], ["hydroxychloroquine sulfate", "CHEMICAL", 480, 506], ["COVID-19113", "CHEMICAL", 528, 539], ["COVID-19114", "CHEMICAL", 702, 713], ["patients", "ORGANISM", 82, 90], ["patients", "ORGANISM", 150, 158], ["atrial", "MULTI-TISSUE_STRUCTURE", 220, 226], ["patients", "ORGANISM", 307, 315], ["chloroquine phosphate", "SIMPLE_CHEMICAL", 454, 475], ["hydroxychloroquine sulfate", "SIMPLE_CHEMICAL", 480, 506], ["patients", "ORGANISM", 688, 696], ["patients", "SPECIES", 82, 90], ["patients", "SPECIES", 150, 158], ["patients", "SPECIES", 307, 315], ["patients", "SPECIES", 688, 696], ["A recent retrospective case series study", "TEST", 0, 40], ["COVID", "TEST", 96, 101], ["mechanical ventilation", "TREATMENT", 172, 194], ["atrial arrhythmias", "PROBLEM", 220, 238], ["Arrhythmias", "PROBLEM", 259, 270], ["Cardiovascular complications", "PROBLEM", 275, 303], ["COVID", "TREATMENT", 321, 326], ["novel medical therapies", "TREATMENT", 364, 387], ["COVID", "TEST", 392, 397], ["chloroquine phosphate", "TREATMENT", 454, 475], ["hydroxychloroquine sulfate", "TREATMENT", 480, 506], ["COVID", "TREATMENT", 528, 533], ["COVID", "TEST", 702, 707], ["atrial", "ANATOMY", 220, 226], ["arrhythmias", "OBSERVATION", 227, 238], ["complications", "OBSERVATION", 290, 303]]], ["Both agents may increase the risk for Torsades de Pointes or other ventricular arrhythmias via QTc prolongation115 and could also lead to advanced types of atrioventricular block116.The role of cardiovascular comorbidities and preexisting CVD in the development of CVD complications ::: Cardiovascular complications in patients with COVID-19Preexisting cardiovascular disease and cardiovascular comorbidities, including arterial hypertension and type 2 diabetes mellitus, are predictors of myocardial injury in hospitalized patients with COVID-19117 (Table 1, Table 2, Table 3, Table 4).", [["ventricular", "ANATOMY", 67, 78], ["atrioventricular", "ANATOMY", 156, 172], ["cardiovascular", "ANATOMY", 194, 208], ["Cardiovascular", "ANATOMY", 287, 301], ["cardiovascular", "ANATOMY", 353, 367], ["cardiovascular", "ANATOMY", 380, 394], ["arterial", "ANATOMY", 420, 428], ["myocardial", "ANATOMY", 490, 500], ["Torsades de Pointes", "DISEASE", 38, 57], ["ventricular arrhythmias", "DISEASE", 67, 90], ["atrioventricular block", "DISEASE", 156, 178], ["cardiovascular comorbidities", "DISEASE", 194, 222], ["CVD", "DISEASE", 239, 242], ["CVD", "DISEASE", 265, 268], ["Cardiovascular complications", "DISEASE", 287, 315], ["cardiovascular disease", "DISEASE", 353, 375], ["cardiovascular comorbidities", "DISEASE", 380, 408], ["arterial hypertension", "DISEASE", 420, 441], ["type 2 diabetes mellitus", "DISEASE", 446, 470], ["myocardial injury", "DISEASE", 490, 507], ["COVID-19117", "CHEMICAL", 538, 549], ["COVID-19117", "CHEMICAL", 538, 549], ["ventricular", "ORGAN", 67, 78], ["cardiovascular", "ANATOMICAL_SYSTEM", 194, 208], ["patients", "ORGANISM", 319, 327], ["cardiovascular", "ANATOMICAL_SYSTEM", 380, 394], ["arterial", "MULTI-TISSUE_STRUCTURE", 420, 428], ["myocardial", "MULTI-TISSUE_STRUCTURE", 490, 500], ["patients", "ORGANISM", 524, 532], ["patients", "SPECIES", 319, 327], ["patients", "SPECIES", 524, 532], ["Torsades de Pointes", "PROBLEM", 38, 57], ["other ventricular arrhythmias", "PROBLEM", 61, 90], ["QTc prolongation", "PROBLEM", 95, 111], ["atrioventricular block", "PROBLEM", 156, 178], ["cardiovascular comorbidities", "PROBLEM", 194, 222], ["preexisting CVD", "PROBLEM", 227, 242], ["CVD complications", "PROBLEM", 265, 282], ["Cardiovascular complications", "PROBLEM", 287, 315], ["COVID", "TEST", 333, 338], ["19Preexisting cardiovascular disease", "PROBLEM", 339, 375], ["cardiovascular comorbidities", "PROBLEM", 380, 408], ["arterial hypertension", "PROBLEM", 420, 441], ["type 2 diabetes mellitus", "PROBLEM", 446, 470], ["myocardial injury", "PROBLEM", 490, 507], ["COVID", "TEST", 538, 543], ["complications", "OBSERVATION", 302, 315], ["cardiovascular", "ANATOMY", 353, 367], ["disease", "OBSERVATION", 368, 375], ["cardiovascular", "ANATOMY", 380, 394], ["comorbidities", "OBSERVATION", 395, 408], ["arterial", "ANATOMY", 420, 428], ["hypertension", "OBSERVATION", 429, 441], ["diabetes mellitus", "OBSERVATION", 453, 470], ["myocardial", "ANATOMY", 490, 500], ["injury", "OBSERVATION", 501, 507]]], ["An association between preexisting cardiac disease and higher frequency of cardiovascular complications has been previously shown among patients with pneumonia118,119.", [["cardiac", "ANATOMY", 35, 42], ["cardiovascular", "ANATOMY", 75, 89], ["cardiac disease", "DISEASE", 35, 50], ["cardiovascular complications", "DISEASE", 75, 103], ["pneumonia", "DISEASE", 150, 159], ["cardiac", "ORGAN", 35, 42], ["cardiovascular", "ANATOMICAL_SYSTEM", 75, 89], ["patients", "ORGANISM", 136, 144], ["patients", "SPECIES", 136, 144], ["preexisting cardiac disease", "PROBLEM", 23, 50], ["cardiovascular complications", "PROBLEM", 75, 103], ["pneumonia", "PROBLEM", 150, 159], ["cardiac", "ANATOMY", 35, 42], ["disease", "OBSERVATION", 43, 50], ["higher", "OBSERVATION_MODIFIER", 55, 61], ["cardiovascular", "ANATOMY", 75, 89], ["complications", "OBSERVATION", 90, 103], ["pneumonia", "OBSERVATION", 150, 159]]], ["Recent results indicate multi-organ tropism of SARS-CoV-2, including heart, vascular system and the circulation, which is speculated to influence the course of the disease as well as aggravate preexisting conditions120.", [["multi-organ", "ANATOMY", 24, 35], ["heart", "ANATOMY", 69, 74], ["vascular system", "ANATOMY", 76, 91], ["SARS", "DISEASE", 47, 51], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 47, 57], ["heart", "ORGAN", 69, 74], ["vascular system", "MULTI-TISSUE_STRUCTURE", 76, 91], ["SARS-CoV", "SPECIES", 47, 55], ["SARS", "PROBLEM", 47, 51], ["CoV", "TEST", 52, 55], ["the disease", "PROBLEM", 160, 171], ["aggravate preexisting conditions", "PROBLEM", 183, 215], ["multi-organ tropism", "OBSERVATION", 24, 43], ["heart", "ANATOMY", 69, 74], ["vascular system", "ANATOMY", 76, 91], ["circulation", "ANATOMY", 100, 111], ["disease", "OBSERVATION", 164, 171]]], ["The increased myocardial expression of ACE2 in patients with cardiovascular disease and COVID-19121,122 has been suggested as a possible mechanism of myocardial cell invasion and injury leading to worse outcomes64 (Figure 1).The role of cardiovascular comorbidities and preexisting CVD in the development of CVD complications ::: Cardiovascular complications in patients with COVID-19In a cohort of 416 COVID-19 patients, individuals with cardiac injury were more commonly affected by arterial hypertension (59.8% vs 23.4%), diabetes (24.4% vs 12.0%), coronary heart disease (29.3% vs 6.0%) and chronic heart failure (14.6% vs 1.5%) compared to patients without cardiac injury54.", [["myocardial", "ANATOMY", 14, 24], ["cardiovascular", "ANATOMY", 61, 75], ["myocardial cell", "ANATOMY", 150, 165], ["cardiovascular", "ANATOMY", 237, 251], ["Cardiovascular", "ANATOMY", 330, 344], ["cardiac", "ANATOMY", 439, 446], ["arterial", "ANATOMY", 485, 493], ["coronary", "ANATOMY", 552, 560], ["heart", "ANATOMY", 561, 566], ["heart", "ANATOMY", 603, 608], ["cardiac", "ANATOMY", 662, 669], ["cardiovascular disease", "DISEASE", 61, 83], ["COVID-19121,122", "CHEMICAL", 88, 103], ["myocardial cell invasion", "DISEASE", 150, 174], ["cardiovascular comorbidities", "DISEASE", 237, 265], ["CVD", "DISEASE", 282, 285], ["CVD", "DISEASE", 308, 311], ["Cardiovascular complications", "DISEASE", 330, 358], ["cardiac injury", "DISEASE", 439, 453], ["arterial hypertension", "DISEASE", 485, 506], ["diabetes", "DISEASE", 525, 533], ["coronary heart disease", "DISEASE", 552, 574], ["chronic heart failure", "DISEASE", 595, 616], ["cardiac injury54", "DISEASE", 662, 678], ["COVID-19121,122", "CHEMICAL", 88, 103], ["myocardial", "MULTI-TISSUE_STRUCTURE", 14, 24], ["ACE2", "GENE_OR_GENE_PRODUCT", 39, 43], ["patients", "ORGANISM", 47, 55], ["cardiovascular", "ANATOMICAL_SYSTEM", 61, 75], ["COVID-19121,122", "GENE_OR_GENE_PRODUCT", 88, 103], ["myocardial cell", "CELL", 150, 165], ["cardiovascular", "ANATOMICAL_SYSTEM", 237, 251], ["patients", "ORGANISM", 362, 370], ["patients", "ORGANISM", 412, 420], ["cardiac", "ORGAN", 439, 446], ["arterial", "MULTI-TISSUE_STRUCTURE", 485, 493], ["heart", "ORGAN", 561, 566], ["heart", "ORGAN", 603, 608], ["patients", "ORGANISM", 645, 653], ["cardiac", "ORGAN", 662, 669], ["ACE2", "PROTEIN", 39, 43], ["patients", "SPECIES", 47, 55], ["patients", "SPECIES", 362, 370], ["patients", "SPECIES", 412, 420], ["patients", "SPECIES", 645, 653], ["The increased myocardial expression of ACE2", "PROBLEM", 0, 43], ["cardiovascular disease", "PROBLEM", 61, 83], ["COVID", "TEST", 88, 93], ["myocardial cell invasion", "PROBLEM", 150, 174], ["injury", "PROBLEM", 179, 185], ["cardiovascular comorbidities", "PROBLEM", 237, 265], ["preexisting CVD", "PROBLEM", 270, 285], ["CVD complications", "PROBLEM", 308, 325], ["Cardiovascular complications", "PROBLEM", 330, 358], ["COVID", "TEST", 376, 381], ["COVID", "TEST", 403, 408], ["cardiac injury", "PROBLEM", 439, 453], ["arterial hypertension", "PROBLEM", 485, 506], ["diabetes", "TEST", 525, 533], ["coronary heart disease", "PROBLEM", 552, 574], ["chronic heart failure", "PROBLEM", 595, 616], ["cardiac injury54", "PROBLEM", 662, 678], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["myocardial expression", "OBSERVATION", 14, 35], ["possible mechanism of", "UNCERTAINTY", 128, 149], ["myocardial cell invasion", "OBSERVATION", 150, 174], ["complications", "OBSERVATION", 345, 358], ["cardiac", "ANATOMY", 439, 446], ["injury", "OBSERVATION", 447, 453], ["arterial", "ANATOMY", 485, 493], ["hypertension", "OBSERVATION", 494, 506], ["coronary", "ANATOMY", 552, 560], ["heart", "ANATOMY", 561, 566], ["disease", "OBSERVATION", 567, 574], ["chronic", "OBSERVATION_MODIFIER", 595, 602], ["heart", "ANATOMY", 603, 608], ["failure", "OBSERVATION", 609, 616], ["without", "UNCERTAINTY", 654, 661], ["cardiac", "ANATOMY", 662, 669], ["injury54", "OBSERVATION", 670, 678]]], ["Similarly, 52 COVID-19 patients with elevated troponin T levels had significantly higher rates of comorbidities including arterial hypertension (63.5% vs 20.7%), coronary heart disease (32.7% vs 3.0%), cardiomyopathy (15.4% vs 0%) and diabetes (30.8% vs 8.9%) in comparison to 135 patients with normal troponin T levels55.", [["arterial", "ANATOMY", 122, 130], ["coronary", "ANATOMY", 162, 170], ["heart", "ANATOMY", 171, 176], ["arterial hypertension", "DISEASE", 122, 143], ["coronary heart disease", "DISEASE", 162, 184], ["cardiomyopathy", "DISEASE", 202, 216], ["diabetes", "DISEASE", 235, 243], ["patients", "ORGANISM", 23, 31], ["troponin T", "GENE_OR_GENE_PRODUCT", 46, 56], ["arterial", "MULTI-TISSUE_STRUCTURE", 122, 130], ["heart", "ORGAN", 171, 176], ["patients", "ORGANISM", 281, 289], ["troponin T", "GENE_OR_GENE_PRODUCT", 302, 312], ["patients", "SPECIES", 23, 31], ["patients", "SPECIES", 281, 289], ["COVID", "TEST", 14, 19], ["elevated troponin T levels", "PROBLEM", 37, 63], ["significantly higher rates of comorbidities", "PROBLEM", 68, 111], ["arterial hypertension", "PROBLEM", 122, 143], ["coronary heart disease", "PROBLEM", 162, 184], ["cardiomyopathy", "PROBLEM", 202, 216], ["diabetes", "PROBLEM", 235, 243], ["normal troponin T levels", "TEST", 295, 319], ["arterial", "ANATOMY", 122, 130], ["hypertension", "OBSERVATION", 131, 143], ["coronary heart", "ANATOMY", 162, 176], ["disease", "OBSERVATION", 177, 184], ["cardiomyopathy", "OBSERVATION", 202, 216]]], ["On the other hand, rates of smoking did not differ significantly between those with normal or elevated troponin T levels (8.1% vs 13.5%)55.", [["troponin T", "GENE_OR_GENE_PRODUCT", 103, 113], ["elevated troponin T levels", "PROBLEM", 94, 120]]], ["The data about the contribution of smoking to the severity of COVID-19 are conflicting.", [["smoking", "CHEMICAL", 35, 42], ["COVID-19", "CHEMICAL", 62, 70]]], ["Although a preliminary meta-analysis of 1,399 Chinese patients with COVID-19 suggested that current smoking is not associated with increased risk of developing severe disease123, another systematic review of five studies including a total of 1,549 patients concluded that smoking is most likely associated with worse outcomes124, probably due to its detrimental effects in lungs and cardiovascular system.", [["lungs", "ANATOMY", 373, 378], ["cardiovascular system", "ANATOMY", 383, 404], ["smoking", "CHEMICAL", 100, 107], ["smoking", "CHEMICAL", 272, 279], ["patients", "ORGANISM", 54, 62], ["patients", "ORGANISM", 248, 256], ["lungs", "ORGAN", 373, 378], ["cardiovascular", "ANATOMICAL_SYSTEM", 383, 397], ["system", "ANATOMICAL_SYSTEM", 398, 404], ["patients", "SPECIES", 54, 62], ["patients", "SPECIES", 248, 256], ["a preliminary meta-analysis", "TEST", 9, 36], ["COVID", "TEST", 68, 73], ["developing severe disease", "PROBLEM", 149, 174], ["five studies", "TEST", 208, 220], ["its detrimental effects in lungs and cardiovascular system", "PROBLEM", 346, 404], ["severe", "OBSERVATION_MODIFIER", 160, 166], ["disease", "OBSERVATION", 167, 174], ["most likely", "UNCERTAINTY", 283, 294], ["probably due to", "UNCERTAINTY", 330, 345], ["lungs", "ANATOMY", 373, 378], ["cardiovascular system", "ANATOMY", 383, 404]]], ["On the other hand, decreased levels of ACE2 have been observed in smokers125,126, while current smoking was reported in less than 17% of patients with severe disease in all 5 original studies included herein (Table 2).The role of cardiovascular comorbidities and preexisting CVD in the development of CVD complications ::: Cardiovascular complications in patients with COVID-19Insufficient glycaemic control in patients with diabetes has been strongly associated with overall risk of serious infections127.", [["cardiovascular", "ANATOMY", 230, 244], ["Cardiovascular", "ANATOMY", 323, 337], ["smoking", "CHEMICAL", 96, 103], ["cardiovascular comorbidities", "DISEASE", 230, 258], ["CVD", "DISEASE", 275, 278], ["CVD", "DISEASE", 301, 304], ["Cardiovascular complications", "DISEASE", 323, 351], ["diabetes", "DISEASE", 425, 433], ["infections", "DISEASE", 492, 502], ["ACE2", "GENE_OR_GENE_PRODUCT", 39, 43], ["patients", "ORGANISM", 137, 145], ["cardiovascular", "ANATOMICAL_SYSTEM", 230, 244], ["patients", "ORGANISM", 355, 363], ["patients", "ORGANISM", 411, 419], ["ACE2", "PROTEIN", 39, 43], ["patients", "SPECIES", 137, 145], ["patients", "SPECIES", 355, 363], ["patients", "SPECIES", 411, 419], ["decreased levels of ACE2", "PROBLEM", 19, 43], ["severe disease", "PROBLEM", 151, 165], ["cardiovascular comorbidities", "PROBLEM", 230, 258], ["preexisting CVD", "PROBLEM", 263, 278], ["CVD complications", "PROBLEM", 301, 318], ["Cardiovascular complications", "PROBLEM", 323, 351], ["COVID-19Insufficient glycaemic control", "TREATMENT", 369, 407], ["diabetes", "PROBLEM", 425, 433], ["serious infections", "PROBLEM", 484, 502], ["decreased", "OBSERVATION", 19, 28], ["severe", "OBSERVATION_MODIFIER", 151, 157], ["disease", "OBSERVATION", 158, 165], ["complications", "OBSERVATION", 338, 351], ["serious", "OBSERVATION_MODIFIER", 484, 491], ["infections", "OBSERVATION", 492, 502]]], ["A recent study revealed the central role of deregulated glucose metabolism in influenza virus-induced cytokine storm through O-GlcNAcylation of IRF-5128.", [["glucose", "CHEMICAL", 56, 63], ["IRF-5128", "CHEMICAL", 144, 152], ["glucose", "CHEMICAL", 56, 63], ["O", "CHEMICAL", 125, 126], ["glucose", "SIMPLE_CHEMICAL", 56, 63], ["influenza virus", "ORGANISM", 78, 93], ["O-GlcNAcylation", "SIMPLE_CHEMICAL", 125, 140], ["IRF-5128", "GENE_OR_GENE_PRODUCT", 144, 152], ["cytokine", "PROTEIN", 102, 110], ["IRF", "PROTEIN", 144, 147], ["influenza virus", "SPECIES", 78, 93], ["A recent study", "TEST", 0, 14], ["deregulated glucose metabolism", "PROBLEM", 44, 74], ["influenza virus", "PROBLEM", 78, 93], ["IRF", "PROBLEM", 144, 147], ["central", "ANATOMY_MODIFIER", 28, 35], ["glucose metabolism", "OBSERVATION", 56, 74], ["influenza virus", "OBSERVATION", 78, 93]]], ["Considering that a cytokine storm syndrome has been reported as a potential cause of COVID-19 complications129, a similar mechanism may be present in diabetic patients with SARS-CoV-2 infection.", [["diabetic", "DISEASE", 150, 158], ["SARS-CoV-2 infection", "DISEASE", 173, 193], ["patients", "ORGANISM", 159, 167], ["SARS-CoV-2", "ORGANISM", 173, 183], ["cytokine", "PROTEIN", 19, 27], ["patients", "SPECIES", 159, 167], ["a cytokine storm syndrome", "PROBLEM", 17, 42], ["COVID-19 complications", "PROBLEM", 85, 107], ["SARS", "PROBLEM", 173, 177], ["CoV-2 infection", "PROBLEM", 178, 193], ["may be", "UNCERTAINTY", 132, 138], ["diabetic", "OBSERVATION", 150, 158], ["infection", "OBSERVATION", 184, 193]]], ["Lastly, Liraglutide, a glucagon-like peptide 1 receptor, has been found to increase ACE2 expression in rat models130 and could therefore facilitate viral infection in accordance with the aforementioned hypothesis of the potential ACE2 role in COVID-19 cardiovascular complications.Current treatment strategies for CVD patientsThere are limited data to guide the clinical treatment strategies for COVID-19 and its cardiovascular complications.", [["cardiovascular", "ANATOMY", 252, 266], ["cardiovascular", "ANATOMY", 413, 427], ["Liraglutide", "CHEMICAL", 8, 19], ["viral infection", "DISEASE", 148, 163], ["cardiovascular complications", "DISEASE", 252, 280], ["CVD", "DISEASE", 314, 317], ["cardiovascular complications", "DISEASE", 413, 441], ["Liraglutide", "CHEMICAL", 8, 19], ["Liraglutide", "SIMPLE_CHEMICAL", 8, 19], ["glucagon-like peptide 1 receptor", "GENE_OR_GENE_PRODUCT", 23, 55], ["ACE2", "GENE_OR_GENE_PRODUCT", 84, 88], ["rat", "ORGANISM", 103, 106], ["ACE2", "GENE_OR_GENE_PRODUCT", 230, 234], ["patients", "ORGANISM", 318, 326], ["cardiovascular", "ANATOMICAL_SYSTEM", 413, 427], ["glucagon-like peptide 1 receptor", "PROTEIN", 23, 55], ["ACE2", "PROTEIN", 84, 88], ["ACE2", "PROTEIN", 230, 234], ["rat", "SPECIES", 103, 106], ["patients", "SPECIES", 318, 326], ["Liraglutide", "TREATMENT", 8, 19], ["a glucagon", "TREATMENT", 21, 31], ["ACE2 expression in rat models", "PROBLEM", 84, 113], ["viral infection", "PROBLEM", 148, 163], ["19 cardiovascular complications", "PROBLEM", 249, 280], ["Current treatment strategies", "TREATMENT", 281, 309], ["the clinical treatment strategies", "TREATMENT", 358, 391], ["COVID", "TEST", 396, 401], ["its cardiovascular complications", "PROBLEM", 409, 441], ["increase", "OBSERVATION_MODIFIER", 75, 83], ["ACE2 expression", "OBSERVATION", 84, 99], ["viral", "OBSERVATION_MODIFIER", 148, 153], ["infection", "OBSERVATION", 154, 163], ["cardiovascular", "ANATOMY", 252, 266], ["complications", "OBSERVATION", 267, 280], ["cardiovascular", "ANATOMY", 413, 427], ["complications", "OBSERVATION", 428, 441]]], ["Numerous clinical trials are currently testing experimental therapies or re-purposing of current drugs for the treatment of COVID-19131.Current treatment strategies for CVD patientsThe participation of ACE2 in the pathogenesis of COVID-19, acting as a cell receptor for SARS\u2010CoV-213 has caused increasing concern about the role of antihypertensive therapy with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) in patients with COVID-19132.", [["cell", "ANATOMY", 252, 256], ["COVID-19131", "CHEMICAL", 124, 135], ["CVD", "DISEASE", 169, 172], ["COVID-19", "CHEMICAL", 230, 238], ["SARS", "DISEASE", 270, 274], ["CoV-213", "CHEMICAL", 275, 282], ["angiotensin", "CHEMICAL", 361, 372], ["angiotensin II", "CHEMICAL", 414, 428], ["COVID-19132", "CHEMICAL", 471, 482], ["COVID-19131", "CHEMICAL", 124, 135], ["COVID-19", "CHEMICAL", 230, 238], ["COVID-19132", "CHEMICAL", 471, 482], ["COVID-19131", "SIMPLE_CHEMICAL", 124, 135], ["patients", "ORGANISM", 173, 181], ["ACE2", "GENE_OR_GENE_PRODUCT", 202, 206], ["COVID-19", "GENE_OR_GENE_PRODUCT", 230, 238], ["cell", "CELL", 252, 256], ["angiotensin-converting enzyme inhibitors", "SIMPLE_CHEMICAL", 361, 401], ["ACEIs", "SIMPLE_CHEMICAL", 403, 408], ["angiotensin II receptor blockers", "SIMPLE_CHEMICAL", 414, 446], ["ARBs", "SIMPLE_CHEMICAL", 448, 452], ["patients", "ORGANISM", 457, 465], ["COVID-19132", "SIMPLE_CHEMICAL", 471, 482], ["ACE2", "PROTEIN", 202, 206], ["patients", "SPECIES", 173, 181], ["patients", "SPECIES", 457, 465], ["testing experimental therapies", "TREATMENT", 39, 69], ["current drugs", "TREATMENT", 89, 102], ["COVID", "TEST", 124, 129], ["Current treatment strategies", "TREATMENT", 136, 164], ["COVID", "TEST", 230, 235], ["antihypertensive therapy", "TREATMENT", 331, 355], ["angiotensin", "TREATMENT", 361, 372], ["converting enzyme inhibitors", "TREATMENT", 373, 401], ["ACEIs", "TREATMENT", 403, 408], ["angiotensin II receptor blockers", "TREATMENT", 414, 446], ["ARBs", "TREATMENT", 448, 452], ["COVID", "TEST", 471, 476]]], ["An observational analysis in a cohort of 12,594 patients who were tested for COVID-19 in New York City indicated that previous treatment with medications acting on the renin angiotensin aldosterone system (RAAS) was not associated with a higher risk of either testing positive for COVID-19 or developing severe COVID-19133.", [["angiotensin", "CHEMICAL", 174, 185], ["aldosterone", "CHEMICAL", 186, 197], ["COVID-19133", "CHEMICAL", 311, 322], ["aldosterone", "CHEMICAL", 186, 197], ["COVID-19133", "CHEMICAL", 311, 322], ["patients", "ORGANISM", 48, 56], ["renin angiotensin aldosterone", "GENE_OR_GENE_PRODUCT", 168, 197], ["COVID-19133", "SIMPLE_CHEMICAL", 311, 322], ["renin", "PROTEIN", 168, 173], ["patients", "SPECIES", 48, 56], ["An observational analysis", "TEST", 0, 25], ["COVID", "TEST", 77, 82], ["previous treatment", "TREATMENT", 118, 136], ["medications", "TREATMENT", 142, 153], ["the renin angiotensin aldosterone system", "TREATMENT", 164, 204], ["COVID", "TEST", 281, 286], ["developing severe COVID", "PROBLEM", 293, 316], ["severe", "OBSERVATION_MODIFIER", 304, 310]]], ["Of interest, another retrospective, multi-center study including 1,128 hospitalized hypertensive patients diagnosed with COVID-19 showed that inpatient use of ACEIs or ARBs was associated with lower risk of all-cause mortality compared to ACEI/ARB non-users (adjusted HR, 0.42; 95% CI, 0.19-0.92)134.", [["hypertensive", "DISEASE", 84, 96], ["ACEIs", "CHEMICAL", 159, 164], ["ARBs", "CHEMICAL", 168, 172], ["ACEI", "CHEMICAL", 239, 243], ["ARB", "CHEMICAL", 244, 247], ["patients", "ORGANISM", 97, 105], ["ACEIs", "SIMPLE_CHEMICAL", 159, 164], ["ARBs", "SIMPLE_CHEMICAL", 168, 172], ["patients", "SPECIES", 97, 105], ["multi-center study", "TEST", 36, 54], ["COVID", "TEST", 121, 126], ["ACEIs", "TREATMENT", 159, 164], ["ARBs", "TREATMENT", 168, 172], ["ACEI", "TREATMENT", 239, 243], ["ARB", "TREATMENT", 244, 247], ["HR", "TEST", 268, 270], ["CI", "TEST", 282, 284]]], ["Despite initial concerns that the use of RAAS-inhibitors in COVID-19 patients could increase ACE2 expression and therefore facilitate viral entry135,136, no evident association between RAAS use and more severe COVID-19 course has been observed in large clinical cohorts to date49,133,134,137,138.", [["RAAS", "GENE_OR_GENE_PRODUCT", 41, 45], ["COVID-19", "ORGANISM", 60, 68], ["patients", "ORGANISM", 69, 77], ["ACE2", "GENE_OR_GENE_PRODUCT", 93, 97], ["ACE2", "PROTEIN", 93, 97], ["RAAS", "PROTEIN", 185, 189], ["patients", "SPECIES", 69, 77], ["RAAS-inhibitors", "TREATMENT", 41, 56], ["COVID", "TEST", 60, 65], ["increase ACE2 expression", "PROBLEM", 84, 108], ["viral entry", "TEST", 134, 145], ["more severe COVID", "PROBLEM", 198, 215], ["large", "OBSERVATION_MODIFIER", 247, 252]]], ["Thus, the European Society of Cardiology and Heart Failure Society of America/American College of Cardiology/American Heart Association guidelines suggest no change in treatment with RAAS-antagonists139,140.Current treatment strategies for CVD patientsChloroquine, an antimalarial agent with known anti-viral effects141, has been proven to have beneficial effects against SARS-CoV infection142, opening the possibility of its implementation in the prophylaxis and treatment of COVID-19.", [["Heart Failure", "DISEASE", 45, 58], ["CVD", "DISEASE", 240, 243], ["Chloroquine", "CHEMICAL", 252, 263], ["SARS-CoV infection", "DISEASE", 372, 390], ["Chloroquine", "CHEMICAL", 252, 263], ["RAAS-antagonists", "GENE_OR_GENE_PRODUCT", 183, 199], ["patients", "ORGANISM", 244, 252], ["Chloroquine", "SIMPLE_CHEMICAL", 252, 263], ["SARS-CoV", "ORGANISM", 372, 380], ["patients", "SPECIES", 244, 252], ["SARS-CoV", "SPECIES", 372, 380], ["RAAS", "TEST", 183, 187], ["antagonists", "TREATMENT", 188, 199], ["Current treatment strategies", "TREATMENT", 207, 235], ["Chloroquine", "TREATMENT", 252, 263], ["an antimalarial agent", "TREATMENT", 265, 286], ["SARS", "PROBLEM", 372, 376], ["CoV infection", "PROBLEM", 377, 390], ["the prophylaxis", "TREATMENT", 444, 459], ["COVID", "TEST", 477, 482], ["Heart", "ANATOMY", 45, 50], ["Failure", "OBSERVATION", 51, 58], ["Heart", "ANATOMY", 118, 123], ["no", "UNCERTAINTY", 155, 157]]], ["The available published data have been conflicting so far113,143, 144, 145, highlighting the necessity of awaiting the results of randomized controlled clinical trials.Current treatment strategies for CVD patientsAnother agent being tested in several clinical trials is Remdesivir131.", [["CVD", "DISEASE", 201, 204], ["Remdesivir131", "CHEMICAL", 270, 283], ["Remdesivir131", "CHEMICAL", 270, 283], ["patients", "ORGANISM", 205, 213], ["patients", "SPECIES", 205, 213], ["randomized controlled clinical trials", "TREATMENT", 130, 167], ["Current treatment strategies", "TREATMENT", 168, 196], ["Another agent", "TREATMENT", 213, 226], ["Remdesivir", "TEST", 270, 280]]], ["It acts as a chain terminator during RNA replication and was initially developed for the treatment of Ebola virus disease146.", [["Ebola virus disease", "DISEASE", 102, 121], ["Ebola virus", "ORGANISM", 102, 113], ["Ebola virus", "SPECIES", 102, 113], ["Ebola virus", "SPECIES", 102, 113], ["a chain terminator", "TREATMENT", 11, 29], ["RNA replication", "TREATMENT", 37, 52], ["Ebola virus disease", "PROBLEM", 102, 121], ["Ebola virus", "OBSERVATION", 102, 113]]], ["Activity of Remdesivir against SARS-CoV-2 has been indicated in vitro147, while clinical data have shown improvement in patients with severe forms of COVID-19148.Current treatment strategies for CVD patientsIn addition, severe forms of COVID-19 have been associated with nonspecific widespread immune reactions and cytokine storm syndromes129.", [["Remdesivir", "CHEMICAL", 12, 22], ["SARS", "DISEASE", 31, 35], ["COVID-19148", "CHEMICAL", 150, 161], ["CVD", "DISEASE", 195, 198], ["COVID-19", "CHEMICAL", 236, 244], ["COVID-19148", "CHEMICAL", 150, 161], ["COVID-19", "CHEMICAL", 236, 244], ["Remdesivir", "SIMPLE_CHEMICAL", 12, 22], ["SARS-CoV-2", "ORGANISM", 31, 41], ["vitro147", "SIMPLE_CHEMICAL", 64, 72], ["patients", "ORGANISM", 120, 128], ["COVID-19148", "SIMPLE_CHEMICAL", 150, 161], ["patients", "ORGANISM", 199, 207], ["COVID-19", "GENE_OR_GENE_PRODUCT", 236, 244], ["cytokine", "PROTEIN", 315, 323], ["patients", "SPECIES", 120, 128], ["patients", "SPECIES", 199, 207], ["SARS-CoV", "SPECIES", 31, 39], ["CoV", "TEST", 36, 39], ["severe forms of COVID", "PROBLEM", 134, 155], ["Current treatment strategies", "TREATMENT", 162, 190], ["COVID", "TEST", 236, 241], ["nonspecific widespread immune reactions", "PROBLEM", 271, 310], ["cytokine storm syndromes", "PROBLEM", 315, 339], ["severe", "OBSERVATION_MODIFIER", 220, 226], ["associated with", "UNCERTAINTY", 255, 270], ["nonspecific", "OBSERVATION_MODIFIER", 271, 282], ["widespread", "OBSERVATION_MODIFIER", 283, 293], ["immune reactions", "OBSERVATION", 294, 310]]], ["In line with this, increased levels of inflammatory biomarkers have been associated with high risk of critical COVID-19 and death34,48,50.", [["increased levels of inflammatory biomarkers", "PROBLEM", 19, 62], ["critical COVID", "TEST", 102, 116], ["inflammatory", "OBSERVATION", 39, 51]]], ["Consequently, monoclonal IL-6 receptor inhibitors, such as tocilizumab and siltuximab, IL-1 receptor antagonists (Anakinra), fully human anti-interferon-gamma antibodies (Emapalumab), azithromycin and corticosteroids are currently being investigated in clinical trials131, as they have proven their efficacy against exaggerated immune activation149, 150, 151, 152, 153.", [["tocilizumab", "CHEMICAL", 59, 70], ["siltuximab", "CHEMICAL", 75, 85], ["Anakinra", "CHEMICAL", 114, 122], ["Emapalumab", "CHEMICAL", 171, 181], ["azithromycin", "CHEMICAL", 184, 196], ["siltuximab", "CHEMICAL", 75, 85], ["azithromycin", "CHEMICAL", 184, 196], ["corticosteroids", "CHEMICAL", 201, 216], ["IL-6 receptor", "GENE_OR_GENE_PRODUCT", 25, 38], ["tocilizumab", "SIMPLE_CHEMICAL", 59, 70], ["siltuximab", "SIMPLE_CHEMICAL", 75, 85], ["IL-1 receptor antagonists", "GENE_OR_GENE_PRODUCT", 87, 112], ["Anakinra", "SIMPLE_CHEMICAL", 114, 122], ["human", "ORGANISM", 131, 136], ["anti-interferon-gamma antibodies", "GENE_OR_GENE_PRODUCT", 137, 169], ["Emapalumab", "SIMPLE_CHEMICAL", 171, 181], ["azithromycin", "SIMPLE_CHEMICAL", 184, 196], ["corticosteroids", "SIMPLE_CHEMICAL", 201, 216], ["human anti-interferon-gamma antibodies", "PROTEIN", 131, 169], ["human", "SPECIES", 131, 136], ["human", "SPECIES", 131, 136], ["monoclonal IL-6 receptor inhibitors", "TREATMENT", 14, 49], ["tocilizumab", "TREATMENT", 59, 70], ["siltuximab", "TREATMENT", 75, 85], ["IL", "TREATMENT", 87, 89], ["receptor antagonists", "TREATMENT", 92, 112], ["Anakinra", "TREATMENT", 114, 122], ["fully human anti-interferon-gamma antibodies", "TREATMENT", 125, 169], ["Emapalumab)", "TREATMENT", 171, 182], ["azithromycin", "TREATMENT", 184, 196], ["corticosteroids", "TREATMENT", 201, 216], ["exaggerated immune activation", "PROBLEM", 316, 345]]], ["Finally, in view of colchicine\u2019s favorable anti-inflammatory profile154, including its use in the treatment of pericarditis and post-pericardiotomy syndrome155, a prospective, randomized, controlled study in Greece (among others) will investigate the effects of colchicine in the prognosis of COVID-19156.Future perspectivesEpidemiologists have forecasted that 40\u201370% of the world's population will be infected by SARS-CoV-2 in the coming year and will present with a wide range of clinical manifestations157.", [["colchicine", "CHEMICAL", 20, 30], ["pericarditis", "DISEASE", 111, 123], ["post-pericardiotomy syndrome", "DISEASE", 128, 156], ["colchicine", "CHEMICAL", 262, 272], ["COVID-19156", "CHEMICAL", 293, 304], ["SARS", "DISEASE", 414, 418], ["colchicine", "CHEMICAL", 20, 30], ["colchicine", "CHEMICAL", 262, 272], ["COVID-19156", "CHEMICAL", 293, 304], ["colchicine", "SIMPLE_CHEMICAL", 20, 30], ["profile154", "SIMPLE_CHEMICAL", 61, 71], ["colchicine", "SIMPLE_CHEMICAL", 262, 272], ["COVID-19156", "CELL", 293, 304], ["SARS-CoV-2", "ORGANISM", 414, 424], ["SARS-CoV", "SPECIES", 414, 422], ["colchicine", "TREATMENT", 20, 30], ["pericarditis", "PROBLEM", 111, 123], ["post-pericardiotomy syndrome", "PROBLEM", 128, 156], ["controlled study", "TEST", 188, 204], ["colchicine", "TREATMENT", 262, 272], ["COVID", "TEST", 293, 298], ["pericarditis", "OBSERVATION", 111, 123]]], ["Apart from the direct effects of SARS-CoV-2 infection, patients who avoid infection may be affected by self-isolation and social distancing158.", [["infection", "DISEASE", 44, 53], ["infection", "DISEASE", 74, 83], ["SARS-CoV-2", "ORGANISM", 33, 43], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["SARS-CoV", "SPECIES", 33, 41], ["SARS", "PROBLEM", 33, 37], ["CoV-2 infection", "PROBLEM", 38, 53], ["infection", "PROBLEM", 74, 83], ["infection", "OBSERVATION", 44, 53]]], ["Hospital attendance and hospital admissions for diseases other than COVID-19 have been significantly decreased since the beginning of the pandemic159.", [["COVID-19", "CHEMICAL", 68, 76], ["diseases", "PROBLEM", 48, 56], ["COVID", "TEST", 68, 73], ["decreased", "OBSERVATION_MODIFIER", 101, 110]]], ["There have been reports of significant decrease in the number of patients with acute coronary syndromes as well as large delays in presentation160.", [["coronary", "ANATOMY", 85, 93], ["acute coronary syndromes", "DISEASE", 79, 103], ["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["significant decrease", "PROBLEM", 27, 47], ["acute coronary syndromes", "PROBLEM", 79, 103], ["large delays", "PROBLEM", 115, 127], ["significant", "OBSERVATION_MODIFIER", 27, 38], ["decrease", "OBSERVATION_MODIFIER", 39, 47], ["acute", "OBSERVATION_MODIFIER", 79, 84], ["coronary", "ANATOMY", 85, 93], ["syndromes", "OBSERVATION", 94, 103], ["large", "OBSERVATION_MODIFIER", 115, 120], ["delays", "OBSERVATION_MODIFIER", 121, 127]]], ["The reduced healthcare staffing levels along with the increasing ICU demands are causing services to become overwhelmed161, while elective procedures and outpatient clinics are being postponed or cancelled162.", [["The reduced healthcare staffing levels", "PROBLEM", 0, 38], ["elective procedures", "TREATMENT", 130, 149], ["reduced", "OBSERVATION_MODIFIER", 4, 11]]], ["The impact of these factors on the care of cardiovascular warrants further investigation.Future perspectivesCardiologists offering front-line services during the COVID-19 crisis have a pivotal role in the composition of appropriate therapeutic schemes.", [["cardiovascular", "ANATOMY", 43, 57], ["cardiovascular", "ANATOMICAL_SYSTEM", 43, 57], ["further investigation", "TEST", 67, 88], ["front-line services", "TREATMENT", 131, 150]]], ["Possible delay in the management of urgent cardiac conditions could lead to a remarkable rise of morbidity and mortality.", [["cardiac", "ANATOMY", 43, 50], ["urgent cardiac conditions", "PROBLEM", 36, 61], ["morbidity", "PROBLEM", 97, 106], ["morbidity", "OBSERVATION", 97, 106]]], ["It is crucial for patients with new or worsening symptoms to be encouraged to seek medical assistance.", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["new or worsening symptoms", "PROBLEM", 32, 57]]], ["The management of acute coronary syndromes, especially ST-elevation myocardial infarctions, requires calculated measures163, particularly in the era of a pandemic.", [["coronary", "ANATOMY", 24, 32], ["myocardial", "ANATOMY", 68, 78], ["acute coronary syndromes", "DISEASE", 18, 42], ["ST-elevation myocardial infarctions", "DISEASE", 55, 90], ["coronary", "MULTI-TISSUE_STRUCTURE", 24, 32], ["myocardial", "MULTI-TISSUE_STRUCTURE", 68, 78], ["acute coronary syndromes", "PROBLEM", 18, 42], ["especially ST-elevation myocardial infarctions", "PROBLEM", 44, 90], ["acute", "OBSERVATION_MODIFIER", 18, 23], ["coronary", "ANATOMY", 24, 32], ["syndromes", "OBSERVATION", 33, 42], ["myocardial", "ANATOMY", 68, 78], ["infarctions", "OBSERVATION", 79, 90], ["pandemic", "OBSERVATION", 154, 162]]], ["We believe further research is needed towards the establishment of comprehensive guidelines, which will provide sufficient preparation and knowledge for such extraordinary conditions.ConclusionsCOVID-19 poses an outstanding clinical hazard to the general population and the healthcare community.", [["such extraordinary conditions", "PROBLEM", 153, 182], ["ConclusionsCOVID", "TEST", 183, 199]]], ["Although most patients develop no or mild symptoms, approximately 20% experience severe or critical COVID-19164.ConclusionsFor the infected patients, underlying cardiovascular comorbidities and especially pre-existing cardiovascular disease are linked to worse outcomes34,48,50,51,79,80,164, 165, 166, 167, while the development of cardiovascular complications, including myocardial injury, heart failure and arrhythmias, are associated with higher mortality rates34,48,50, 51, 52, 53, 54, 55, 56,79,109,112.", [["cardiovascular", "ANATOMY", 161, 175], ["cardiovascular", "ANATOMY", 218, 232], ["cardiovascular", "ANATOMY", 332, 346], ["myocardial", "ANATOMY", 372, 382], ["heart", "ANATOMY", 391, 396], ["COVID-19164", "CHEMICAL", 100, 111], ["cardiovascular comorbidities", "DISEASE", 161, 189], ["cardiovascular disease", "DISEASE", 218, 240], ["cardiovascular complications", "DISEASE", 332, 360], ["myocardial injury", "DISEASE", 372, 389], ["heart failure", "DISEASE", 391, 404], ["arrhythmias", "DISEASE", 409, 420], ["COVID-19164", "CHEMICAL", 100, 111], ["patients", "ORGANISM", 14, 22], ["patients", "ORGANISM", 140, 148], ["cardiovascular", "ANATOMICAL_SYSTEM", 161, 175], ["cardiovascular", "ANATOMICAL_SYSTEM", 218, 232], ["cardiovascular", "ANATOMICAL_SYSTEM", 332, 346], ["myocardial", "MULTI-TISSUE_STRUCTURE", 372, 382], ["heart", "ORGAN", 391, 396], ["patients", "SPECIES", 14, 22], ["patients", "SPECIES", 140, 148], ["mild symptoms", "PROBLEM", 37, 50], ["the infected patients", "PROBLEM", 127, 148], ["underlying cardiovascular comorbidities", "PROBLEM", 150, 189], ["pre-existing cardiovascular disease", "PROBLEM", 205, 240], ["cardiovascular complications", "PROBLEM", 332, 360], ["myocardial injury", "PROBLEM", 372, 389], ["heart failure", "PROBLEM", 391, 404], ["arrhythmias", "PROBLEM", 409, 420], ["mild", "OBSERVATION_MODIFIER", 37, 41], ["symptoms", "OBSERVATION", 42, 50], ["infected", "OBSERVATION_MODIFIER", 131, 139], ["cardiovascular", "ANATOMY", 161, 175], ["comorbidities", "OBSERVATION", 176, 189], ["cardiovascular disease", "OBSERVATION", 218, 240], ["cardiovascular", "ANATOMY", 332, 346], ["complications", "OBSERVATION", 347, 360], ["myocardial", "ANATOMY", 372, 382], ["injury", "OBSERVATION", 383, 389], ["heart", "ANATOMY", 391, 396], ["failure", "OBSERVATION", 397, 404], ["arrhythmias", "OBSERVATION", 409, 420]]], ["Continuous efforts are underway to uncover the pathogenetic mechanisms of COVID-19\u2019s cardiovascular complications and develop the appropriate and targeted treatment strategies, with repurposing of available drugs and identification of novel therapeutic targets.", [["cardiovascular", "ANATOMY", 85, 99], ["cardiovascular complications", "DISEASE", 85, 113], ["COVID-19", "CHEMICAL", 74, 82], ["cardiovascular", "ANATOMICAL_SYSTEM", 85, 99], ["COVID", "TEST", 74, 79], ["cardiovascular complications", "PROBLEM", 85, 113], ["targeted treatment strategies", "TREATMENT", 146, 175], ["available drugs", "TREATMENT", 197, 212], ["novel therapeutic targets", "TREATMENT", 235, 260]]], ["However, the acuteness and rapid spread of the COVID-19 pandemic has complicated the elucidation of effective preventive and therapeutic schemes.ConclusionsOn the whole, our knowledge of the pathogenesis, diagnosis, clinical course and treatment of COVID-19 is expeditiously evolving.", [["COVID-19", "CHEMICAL", 249, 257], ["the acuteness", "PROBLEM", 9, 22], ["the COVID", "TEST", 43, 52], ["therapeutic schemes", "TREATMENT", 125, 144], ["COVID", "TEST", 249, 254], ["rapid", "OBSERVATION_MODIFIER", 27, 32], ["spread", "OBSERVATION_MODIFIER", 33, 39], ["effective", "OBSERVATION_MODIFIER", 100, 109]]], ["Nevertheless, in the wake of these unprecedented times, the scientific world has rallied united to progress the understanding of COVID-19 and develop optimal treatment solutions.Declarations of interestnone.Sources of FundingDr.", [["interestnone", "CHEMICAL", 194, 206], ["interestnone", "CHEMICAL", 194, 206], ["interestnone", "SIMPLE_CHEMICAL", 194, 206], ["COVID", "TEST", 129, 134], ["optimal treatment solutions", "TREATMENT", 150, 177], ["interestnone", "TREATMENT", 194, 206], ["Funding", "OBSERVATION", 218, 225]]], ["K. Stellos is supported by grants from the European Research Council (ERC) under the European Union\u2019s Horizon 2020 research and innovation programme (grant agreement No 759248) and the DFG (SFB834 project number 75732319).Disclosuresnone.Uncited reference", [["K", "CHEMICAL", 0, 1], ["K", "GENE_OR_GENE_PRODUCT", 0, 1], ["K", "TEST", 0, 1]]]], "c1ed15f94995fe8345f9cea4f1601816ef778759": [["IntroductionPandemics are a recurring natural phenomenon that throughout human history have caused not only widespread sickness and death but also economic disruption on a massive scale.", [["sickness", "DISEASE", 119, 127], ["death", "DISEASE", 132, 137], ["human", "ORGANISM", 73, 78], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 73, 78], ["a recurring natural phenomenon", "PROBLEM", 26, 56], ["widespread sickness", "PROBLEM", 108, 127], ["death", "PROBLEM", 132, 137], ["economic disruption", "PROBLEM", 147, 166], ["a massive scale", "TREATMENT", 170, 185], ["widespread", "OBSERVATION_MODIFIER", 108, 118], ["sickness", "OBSERVATION", 119, 127], ["economic", "OBSERVATION_MODIFIER", 147, 155], ["disruption", "OBSERVATION", 156, 166]]], ["The COVID-19 pandemic is no exception, with the International Monetary Fund estimating global economic losses at $9 trillion (IMF 2020b).", [["The COVID", "TEST", 0, 9], ["no exception", "UNCERTAINTY", 25, 37]]], ["But unlike other economically destructive natural phenomena such as hurricanes, earthquakes and wildfires, the losses from which are substantively financed by private insurers (at least in advanced economies), very little private insurance exists to manage the financial consequences of pandemic risk.", [["earthquakes", "DISEASE", 80, 91], ["pandemic", "DISEASE", 287, 295], ["other economically destructive natural phenomena", "PROBLEM", 11, 59], ["pandemic risk", "PROBLEM", 287, 300], ["economically", "OBSERVATION_MODIFIER", 17, 29], ["destructive", "OBSERVATION_MODIFIER", 30, 41]]], ["Opinions stated in this paper are the authors' personal views.Introductionpaper examines the failure of private insurance markets and alternative risk-sharing mechanisms to adequately address economic losses arising from pandemics.", [["private insurance markets", "TREATMENT", 104, 129], ["economic losses", "PROBLEM", 192, 207], ["pandemics", "PROBLEM", 221, 230]]], ["The paper also identifies potential reasons for the lack of insurance, as well as potential solutions.IntroductionThe analysis and discussion are divided into three parts.", [["The analysis", "TEST", 114, 126]]], ["While there are examples of private insurance coverage for pandemic losses, the market for private pandemic insurance is exceedingly thin in the sense that coverage options, especially those for business interruption, are extremely limited or nonexistent for most individual entities.", [["private insurance coverage", "TREATMENT", 28, 54], ["pandemic losses", "PROBLEM", 59, 74], ["coverage options", "TREATMENT", 156, 172]]], ["Payments by private insurers to businesses suffering economic losses associated with the COVID-19 pandemic are expected to account for only a small fraction of total economic losses.", [["economic losses", "PROBLEM", 53, 68], ["the COVID", "TEST", 85, 94], ["total economic losses", "PROBLEM", 160, 181], ["small", "OBSERVATION_MODIFIER", 142, 147], ["fraction", "OBSERVATION_MODIFIER", 148, 156], ["total", "OBSERVATION_MODIFIER", 160, 165], ["economic losses", "OBSERVATION", 166, 181]]], ["3, we provide a conceptual framework that helps explain why the private market for pandemic insurance coverage is naturally thin.", [["pandemic insurance coverage", "TREATMENT", 83, 110]]], ["We conclude that a risk-sharing arrangement that operates over time could be beneficial, in part to avoid the negative macroeconomic externalities associated with a prolonged shutdown of many firms without pandemic business interruption coverage.", [["the negative macroeconomic externalities", "PROBLEM", 106, 146], ["pandemic business interruption coverage", "TREATMENT", 206, 245]]], ["Such an arrangement needs to involve a government with the ability to borrow and tax.", [["tax", "PROTEIN", 81, 84]]], ["4, along with an analysis of how the alternatives differ on important dimensions.", [["an analysis", "TEST", 14, 25]]], ["The paper concludes with a short summary.Review of pandemic risk in property/casualty insurance and reinsurance marketsInsuring against economic losses from pandemics poses a set of challenges to property/casualty insurers that collectively have severely limited the insurability of the risk in the private sector on a large scale.", [["pandemics", "DISEASE", 157, 166], ["economic losses", "PROBLEM", 136, 151], ["pandemics", "PROBLEM", 157, 166], ["a large scale", "TREATMENT", 317, 330]]], ["The result is that few products designed to specifically address the risk of pandemics have ever been brought to market by property-casualty insurers and reinsurers.", [["pandemics", "DISEASE", 77, 86], ["pandemics", "PROBLEM", 77, 86]]], ["Consequently, there exists a large gap between the economic consequences associated with pandemics and the ability of insurers and reinsurers to provide protection products to address those consequences.", [["a large gap", "PROBLEM", 27, 38], ["pandemics", "PROBLEM", 89, 98], ["insurers", "TREATMENT", 118, 126], ["reinsurers", "TREATMENT", 131, 141], ["protection products", "TREATMENT", 153, 172], ["large", "OBSERVATION_MODIFIER", 29, 34], ["gap", "OBSERVATION_MODIFIER", 35, 38]]], ["This paper will explore many of the practical, institutional and theoretical obstacles insurers confront in the underwriting and pricing of pandemic risk.", [["pandemic", "DISEASE", 140, 148]]], ["The main obstacle is the extreme aggregation/accumulation risk associated with pandemics, which severely diminishes the ability to diversify and spread risk.", [["the extreme aggregation/accumulation risk", "PROBLEM", 21, 62], ["pandemics", "PROBLEM", 79, 88], ["main", "OBSERVATION_MODIFIER", 4, 8], ["obstacle", "OBSERVATION", 9, 17], ["extreme", "OBSERVATION_MODIFIER", 25, 32], ["aggregation", "OBSERVATION", 33, 44], ["accumulation risk", "OBSERVATION", 45, 62], ["pandemics", "OBSERVATION", 79, 88]]], ["In addition, there is a balance sheet risk stemming from the negative correlation between the expected magnitude of insured losses and the market value of financial assets held in the insurer's investment portfolio.", [["insured losses", "PROBLEM", 116, 130]]], ["Consider, for example, that pandemic-related business continuity (i.e., business interruption) losses alone across all businesses in the United States are estimated at $1 trillion per month, yet at yearend 2019 the total capital resources (policyholder surplus) of the U.S. property-casualty insurance industry stood at approximately $800 billion (Hartwig and Gordon 2020) .Review of pandemic risk in property/casualty insurance and reinsurance marketsTo illustrate the importance of each of the obstacles mentioned above, it is useful to consider how pandemic risk differs from other types of catastrophe risks, such as hurricanes, earthquakes, and wildfires, which are routinely underwritten by insurers and reinsurers.", [["pandemic", "DISEASE", 28, 36], ["pandemic", "DISEASE", 552, 560], ["catastrophe", "DISEASE", 594, 605], ["earthquakes", "DISEASE", 633, 644], ["catastrophe risks", "PROBLEM", 594, 611], ["catastrophe", "OBSERVATION", 594, 605]]], ["Each of these natural disasters impacts a limited number of policyholders for a limited period of time.", [["natural", "OBSERVATION_MODIFIER", 14, 21], ["disasters", "OBSERVATION", 22, 31]]], ["1 The property and business continuity (i.e., business interruption) losses associated with hurricanes, for example, are largely a coastal phenomenon with damaging winds typically dissipating over the span of hours.", [["a coastal phenomenon", "PROBLEM", 129, 149], ["coastal phenomenon", "OBSERVATION", 131, 149]]], ["In contrast, business continuity losses arising from pandemics, by definition, have the potential to impact virtually all policyholders, irrespective of location and nearly simultaneously, with losses continuing over the span of months or even years.", [["pandemics", "DISEASE", 53, 62], ["pandemics", "PROBLEM", 53, 62]]], ["The resulting accumulation of losses of the many (rather than the few) prevents the pooling and redistribution of those losses, as essentially all policyholders are impacted, requiring the insurer to hold prohibitively large amounts of capital.", [["the pooling", "PROBLEM", 80, 91], ["those losses", "PROBLEM", 114, 126], ["the insurer", "TREATMENT", 185, 196], ["accumulation of", "OBSERVATION", 14, 29], ["losses", "OBSERVATION_MODIFIER", 30, 36], ["many", "OBSERVATION_MODIFIER", 44, 48], ["pooling", "OBSERVATION", 84, 91], ["redistribution", "OBSERVATION_MODIFIER", 96, 110], ["those losses", "OBSERVATION", 114, 126], ["impacted", "OBSERVATION_MODIFIER", 165, 173]]], ["Pandemic risk therefore cannot be readily spread, shared or diversified across policyholders.", [["Pandemic risk", "PROBLEM", 0, 13], ["cannot be", "UNCERTAINTY", 24, 33]]], ["Further, as the COVID-19 experience during the first quarter of 2020 demonstrated, pandemic-related losses are correlated with both financial market losses and other insurance losses.", [["pandemic", "DISEASE", 83, 91], ["the COVID", "TEST", 12, 21], ["pandemic-related losses", "PROBLEM", 83, 106]]], ["During the first quarter of 2020, the policyholder surplus of the U.S. property-casualty insurance industry fell by 9.3% to $744.9 billion, due in large part to a sharp decline in asset prices as well as the establishment of COVID-19 loss reserves across numerous lines of insurance (Best 2020 ).Supply and demand for pandemic insurance pre-COVID-19Given the characteristics of pandemic losses and their financial impact on world economies, insurers and reinsurers have generally asserted that with some exceptions, large-scale pandemic risk is not insurable in the private sector (see Sect.", [["a sharp decline", "PROBLEM", 161, 176], ["COVID", "TEST", 225, 230], ["pandemic losses", "PROBLEM", 378, 393], ["sharp", "OBSERVATION_MODIFIER", 163, 168], ["decline", "OBSERVATION", 169, 176], ["large", "OBSERVATION_MODIFIER", 516, 521]]], ["For this reason, insurers have no alternative but to exclude coverage for virtually all future pandemic exposures from insurance policies and reinsurance treaties.", [["reinsurance treaties", "TREATMENT", 142, 162]]], ["This does not mean that property-casualty insurers have no exposure to pandemic-related losses.", [["pandemic", "DISEASE", 71, 79], ["pandemic-related losses", "PROBLEM", 71, 94]]], ["Indeed, Lloyd's of London in May 2020 estimated that global insured losses arising from COVID-19 to the non-life insurance industry could total $107 billion.", [["COVID-19", "CHEMICAL", 88, 96], ["global insured losses", "PROBLEM", 53, 74], ["COVID", "TEST", 88, 93]]], ["Looking toward the future: research indicates that pandemic risks are intensifying as globalization and urbanization proceed apace, potentially costing as much as $23.5 trillion over the next 30 years (Hilsenrath 2020) .Supply and demand for pandemic insurance pre-COVID-19The apparent paradox-that the paucity of pandemic insurance available in the market does not preclude potentially large losses-results from several factors.", [["pre-COVID-19", "CHEMICAL", 261, 273], ["large losses", "PROBLEM", 387, 399], ["paradox", "OBSERVATION", 286, 293], ["large", "OBSERVATION_MODIFIER", 387, 392], ["losses", "OBSERVATION", 393, 399]]], ["That latter exposure represents a large and difficult-to-quantify liability for insurers, the ultimate cost for which will likely not be known for years.", [["large", "OBSERVATION_MODIFIER", 34, 39]]], ["The enormous range in estimates stems largely from uncertainty related to litigation, regulation and legislation and from uncertainty about the severity of the pandemic.Supply and demand for pandemic insurance pre-COVID-19In the subsections that follow, we examine the insurance market for \"pure\" pandemic risk.", [["pandemic", "DISEASE", 297, 305], ["the pandemic", "PROBLEM", 156, 168], ["enormous", "OBSERVATION_MODIFIER", 4, 12], ["range", "OBSERVATION_MODIFIER", 13, 18], ["pandemic", "OBSERVATION", 160, 168]]], ["We then focus our discussion on COVID-19 and potential losses arising from specific lines of insurance with contingent exposure to pandemics or where exposure is incidental though still material in magnitude.", [["COVID", "TEST", 32, 37], ["potential losses", "PROBLEM", 45, 61], ["pandemics", "PROBLEM", 131, 140]]], ["We conclude with an examination of shifts in market dynamics precipitated by the COVID-19 pandemic in terms of changes in underwriting practices, pricing and the ability of the industry attract capital.Insurance markets for pandemic riskAs discussed above, property-casualty insurers have long maintained that insuring against large-scale pandemic risk is economically infeasible.", [["pandemic", "DISEASE", 339, 347], ["an examination", "TEST", 17, 31]]], ["Note that this stands in direct contrast to life insurers, where pandemic risk is inherent in all mortalitybased policies sold with no material adverse impact on the price or availability of coverage.", [["pandemic", "DISEASE", 65, 73]]], ["2 This observation once again begs the question as to why pandemic risk is deemed largely uninsurable in the context of property-casualty insurance.Pure pandemic riskThe history of property-casualty insurance products specifically designed to manage pandemic risk is a short one.", [["pandemic", "DISEASE", 58, 66], ["pandemic", "DISEASE", 250, 258], ["Pure pandemic risk", "PROBLEM", 148, 166], ["pandemic", "OBSERVATION", 153, 161]]], ["We now examine two of the most recent approaches to providing \"pure\" pandemic coverage in a market that historically has offered littleto-no coverage to the majority of potential buyers.", [["\"pure\" pandemic coverage", "TREATMENT", 62, 86], ["littleto", "TREATMENT", 129, 137], ["coverage", "TREATMENT", 141, 149]]], ["Also, Solvency II includes capital charges for life catastrophe risks, e.g., caused by pandemics.", [["Solvency II", "CHEMICAL", 6, 17], ["Solvency II", "PROTEIN", 6, 17], ["life catastrophe risks", "PROBLEM", 47, 69], ["pandemics", "PROBLEM", 87, 96]]], ["3 \"Pure\" pandemic coverage refers to insurance that covers pandemic-related losses and nothing else.", [["Pure\" pandemic coverage", "TREATMENT", 3, 26]]], ["Later we consider other types of insurance where pandemic risk is just one of many types of risk that could cause claims. of the key challenges insurers and capital markets encounter in the market for pandemic insurance, driven by actual experience immediately prior to and during the COVID-19 pandemic.", [["pandemic", "DISEASE", 49, 57], ["the COVID", "TEST", 281, 290], ["pandemic", "PROBLEM", 294, 302]]], ["3 of this paper.Traditional insurance approach: PathogenRXPathogenRX is arguably the best-known recent example of a property-casualty insurance product designed to address pure pandemic risk.", [["PathogenRXPathogenRX", "CHEMICAL", 48, 68], ["pandemic", "DISEASE", 177, 185], ["pure pandemic risk", "PROBLEM", 172, 190]]], ["Marketed by the global commercial insurance broker Marsh LLC, PathogenRX was jointly developed by Munich Re, one of the world's largest reinsurers, and Metabiotica, a start-up focused on helping governments and industry estimate, mitigate and manage epidemic risk.", [["Marsh LLC", "OBSERVATION", 51, 60]]], ["PathogenRX was introduced in 2018, approximately 18 months before the first confirmed cases of COVID-19 were reported in Wuhan, China, in late 2019.", [["PathogenRX", "TEST", 0, 10], ["COVID", "TEST", 95, 100]]], ["Despite the propitious timing of PathogenRX's launch and its backing by some of the largest and best-known insurance names in the world, only one policy was ever sold in the pre-COVID era (Ratliff 2020) .Traditional insurance approach: PathogenRXThe failure of PathogenRX in the market occurred despite very flexible terms and conditions and a general recognition by corporations and governments that pandemics posed a material risk to their operations even before COVID-19, based in part on their experience with the 2003 Severe Acute Respiratory Syndrome (SARS) pandemic.", [["PathogenRX", "CHEMICAL", 261, 271], ["Acute Respiratory Syndrome", "DISEASE", 530, 556], ["SARS", "DISEASE", 558, 562], ["PathogenRX's launch", "TREATMENT", 33, 52], ["PathogenRXThe failure of PathogenRX", "PROBLEM", 236, 271], ["Severe Acute Respiratory Syndrome", "PROBLEM", 523, 556], ["pandemic", "PROBLEM", 564, 572], ["largest", "OBSERVATION_MODIFIER", 84, 91], ["Severe", "OBSERVATION_MODIFIER", 523, 529], ["Acute", "OBSERVATION_MODIFIER", 530, 535], ["Respiratory Syndrome", "OBSERVATION", 536, 556]]], ["According to Marsh's marketing materials, PathogenRX also offers buyers:Traditional insurance approach: PathogenRX\u2022 The ability to model and estimate infectious disease risks, \u2022 Customizable insurance coverage for losses stemming from infectious diseases, including for loss of gross profit, loss of revenue, and extra expense, and \u2022 Parametric (i.e., pre-defined) coverage triggers, such as a mortality count or public health emergency declaration.Traditional insurance approach: PathogenRXMarsh's target clients included companies in industries particularly vulnerable to outbreaks, epidemics and pandemics, including hospitality and travel, sports and entertainment, higher education, retail, manufacturing and mining .Traditional insurance approach: PathogenRXIt should be noted that PathogenRX as of this writing (August 2020) continues to be offered by Marsh and the product's marketing materials have been revised to mention COVID-19.", [["infectious diseases", "DISEASE", 235, 254], ["loss of gross profit", "DISEASE", 270, 290], ["pandemics", "DISEASE", 599, 608], ["Customizable insurance coverage", "TREATMENT", 178, 209], ["losses stemming", "PROBLEM", 214, 229], ["infectious diseases", "PROBLEM", 235, 254], ["loss of gross profit", "PROBLEM", 270, 290], ["loss of revenue", "PROBLEM", 292, 307], ["a mortality count", "TEST", 392, 409], ["PathogenRXIt", "TREATMENT", 754, 766], ["COVID", "TEST", 932, 937]]], ["It is unclear whether the pandemic has led to actual sales.", [["unclear whether", "UNCERTAINTY", 6, 21]]], ["However, property-casualty insurers typically experience a surge in sales after major catastrophic events (e.g., sales of flood and earthquake insurance have been documented to increase after major events), perhaps as market participants gain a better understanding of the risk, the risk becomes more salient, or risk aversion increases.", [["earthquake", "DISEASE", 132, 142], ["participants", "SPECIES", 225, 237], ["major catastrophic events", "PROBLEM", 80, 105]]], ["4 At the same time, it is likely that underwriting and pricing have been adjusted to reflect actual COVID-19 experience, resulting in more restrictive terms and conditions and higher premiums.Capital market approach: the World Bank's Pandemic Emergency Financing FacilityAnother notable but structurally very different approach to using insurance to manage pandemic risk involved the World Bank's Pandemic Emergency Financing Facility (PEF).", [["pandemic", "DISEASE", 357, 365], ["is likely", "UNCERTAINTY", 23, 32], ["more restrictive", "OBSERVATION_MODIFIER", 134, 150], ["higher premiums", "OBSERVATION", 176, 191]]], ["Interestingly, the PEF has been widely derided and deemed a failure even though the facility performed exactly as intended, paying out $195.8 million to 64 of the world's lowest income countries affected by the COVID-19 pandemic.", [["PEF", "PROTEIN", 19, 22], ["a failure", "PROBLEM", 58, 67], ["the COVID", "TEST", 207, 216], ["pandemic", "PROBLEM", 220, 228], ["failure", "OBSERVATION", 60, 67]]], ["Criticism of the PEF has focused on its perceived slowness to pay and its cost.", [["Criticism of the PEF", "PROBLEM", 0, 20]]], ["The severity of criticism led the World Bank in July 2020 to formally abandon plans for a \"PEF 2.0,\" despite a concurrent intensification of the pandemic throughout much of the developing world (Hodgson 2020) .", [["a \"PEF", "TREATMENT", 88, 94], ["the pandemic", "PROBLEM", 141, 153], ["criticism", "OBSERVATION", 16, 25], ["pandemic", "OBSERVATION", 145, 153]]], ["The perceived failure of the PEF despite its functional success derives from the parametric triggers used to determine if and when payouts would be made.", [["The perceived failure", "PROBLEM", 0, 21], ["the PEF", "PROBLEM", 25, 32], ["failure", "OBSERVATION", 14, 21]]], ["The facility was designed to provide payouts to cover \"surge costs\" incurred by poor countries in the event of pandemics arising from six categories of virus, coronavirus being one of them.", [["pandemics", "DISEASE", 111, 120], ["coronavirus", "DISEASE", 159, 170], ["coronavirus", "ORGANISM", 159, 170], ["pandemics", "PROBLEM", 111, 120], ["virus", "PROBLEM", 152, 157], ["coronavirus", "PROBLEM", 159, 170]]], ["These triggers were related to the number of infections and deaths, rates of spread, degree of geographic spread and duration of the pandemic.", [["infections", "DISEASE", 45, 55], ["deaths", "DISEASE", 60, 66], ["infections", "PROBLEM", 45, 55], ["deaths", "PROBLEM", 60, 66], ["geographic spread", "PROBLEM", 95, 112], ["the pandemic", "PROBLEM", 129, 141], ["infections", "OBSERVATION", 45, 55], ["geographic", "OBSERVATION_MODIFIER", 95, 105], ["spread", "OBSERVATION_MODIFIER", 106, 112]]], ["In the view of many, the lag deprived poor nations of the funds desperately needed to battle the spread of the virus precisely when those funds were needed most.", [["the virus", "PROBLEM", 107, 116]]], ["The PEF has also been criticized as overly generous to investors who collectively received interest payments totaling nearly $100 million through February 2020, the result of annual coupons on the bonds that ranged as high as 11.5%.Capital market approach: the World Bank's Pandemic Emergency Financing FacilityIt is worth noting that the \"failure\" of World Bank's Pandemic Emergency Financing Facility is a somewhat subjective characterization (Lane and Beckwith 2020) .", [["the bonds", "TEST", 193, 202], ["the \"failure", "PROBLEM", 335, 347]]], ["The reality is that bonds bearing the 11.5% coupon-associated with the B tranche of the issuance-carried a material 9.44% (i.e., nearly 1-in-10) chance of sustaining at least some loss each year over the facility's three-year term.", [["loss", "OBSERVATION", 180, 184]]], ["The relatively high probability of loss reflects the broad spectrum of infectious diseases covered-coronavirus (e.g., SARS, MERS, COVID-19), Ebola, Rift Valley Fever and Lassa Fever, among others.", [["infectious diseases covered-coronavirus", "DISEASE", 71, 110], ["SARS", "DISEASE", 118, 122], ["Ebola", "DISEASE", 141, 146], ["Rift Valley Fever", "DISEASE", 148, 165], ["Lassa Fever", "DISEASE", 170, 181], ["Ebola", "ORGANISM", 141, 146], ["Rift Valley Fever", "ORGANISM", 148, 165], ["infectious diseases", "PROBLEM", 71, 90], ["coronavirus", "PROBLEM", 99, 110], ["SARS", "PROBLEM", 118, 122], ["MERS", "TEST", 124, 128], ["COVID", "TEST", 130, 135], ["Ebola", "PROBLEM", 141, 146], ["Rift Valley Fever", "PROBLEM", 148, 165], ["Lassa Fever", "PROBLEM", 170, 181], ["high", "OBSERVATION_MODIFIER", 15, 19], ["loss", "OBSERVATION", 35, 39], ["broad", "OBSERVATION_MODIFIER", 53, 58], ["infectious", "OBSERVATION", 71, 81]]], ["Moreover, as the bonds began to trade on the secondary market shortly after issuance, market quotes remained close to par, suggesting fair pricing relative to the opportunity cost of capital at that time (mid-2017).Capital market approach: the World Bank's Pandemic Emergency Financing FacilityOne additional criticism of the PEF centers on the assertion that insurance, including ILS, are relatively expensive methods for delivering disaster relief and that funds for recovery from large-scale disasters (including pandemics) can be more cheaply accessed via after-the-fact borrowing.", [["pandemics", "DISEASE", 516, 525], ["disaster relief", "TREATMENT", 434, 449], ["large-scale disasters", "TREATMENT", 483, 504]]], ["3 below, the fact that very few pure pandemic risk products have ever been brought to market by insurers likely reflects the impracticality of insuring against pandemics in general, at least in the private sector, given the enormous capital requirements to underwrite the risk.", [["pandemic", "DISEASE", 37, 45], ["pandemics", "DISEASE", 160, 169], ["very", "OBSERVATION_MODIFIER", 23, 27], ["few", "OBSERVATION_MODIFIER", 28, 31], ["enormous", "OBSERVATION_MODIFIER", 224, 232], ["capital requirements", "OBSERVATION", 233, 253]]], ["The problems faced by Marsh's PathogenRX and the World Bank's PEF suggest that even very sophisticated efforts to provide pandemic risk solutions can fail in the marketplace for a multitude of reasons.Contingent coverage for pandemic riskIn contrast to the market for pure pandemic risk in which coverage options are a rarity, pandemic risk is sometimes explicitly covered in the form of contingency coverages.", [["The problems", "PROBLEM", 0, 12], ["Marsh's PathogenRX", "TREATMENT", 22, 40], ["pandemic risk solutions", "TREATMENT", 122, 145], ["pandemic riskIn contrast", "TREATMENT", 225, 249], ["pure pandemic risk", "PROBLEM", 268, 286], ["pandemic risk", "PROBLEM", 327, 340], ["contingency coverages", "TREATMENT", 388, 409]]], ["The best known and largest market for contingency coverage is event cancellation insurance.", [["largest", "OBSERVATION_MODIFIER", 19, 26]]], ["Such policies are highly customized but are typically underwritten with communicable disease exclusions which preclude coverage for epidemics and pandemics.", [["communicable disease exclusions", "PROBLEM", 72, 103], ["epidemics", "PROBLEM", 132, 141], ["pandemics", "PROBLEM", 146, 155]]], ["However, communicable disease coverage can sometimes be purchased as an extension to the policy for an additional premium.", [["communicable disease coverage", "PROBLEM", 9, 38]]], ["While relatively few buyers purchase the extension, there are some high-profile exceptions.", [["few", "OBSERVATION_MODIFIER", 17, 20], ["high-profile", "OBSERVATION_MODIFIER", 67, 79]]], ["Cancellation of the 2020 tournament due to COVID-19 resulted in a reported payout of $141 million by the event's insurers (Forbes 2020).", [["COVID-19", "CHEMICAL", 43, 51], ["COVID", "TEST", 43, 48]]], ["5 The International Olympic Committee (IOC), organizer of the 2020 Tokyo Olympics-which were postponed until 2021-likewise purchased coverage that included cancellation due to pandemics.", [["pandemics", "PROBLEM", 176, 185]]], ["The IOC received a negotiated sum to cover some of the losses associated with the postponement.Other coverages with potentially material pandemic risk exposureBeyond event cancellation insurance, a wide range of other coverages exist that can give rise to direct and indirect pandemic-related losses.", [["the losses", "PROBLEM", 51, 61], ["other coverages", "TREATMENT", 212, 227], ["indirect pandemic-related losses", "PROBLEM", 267, 299]]], ["A detailed discussion of all potentially exposed lines of insurance is beyond the scope of this paper, but a few key lines are worth mentioning both to illustrate the breadth of existing industry exposure and gauge the magnitude of the coverage gap.", [["a few key lines", "TREATMENT", 107, 122]]], ["Among the lines with the most incidental exposure to pandemic loss are workers' compensation, commercial general liability, trade credit and directors and officer's insurance.", [["pandemic loss", "DISEASE", 53, 66]]], ["The nature of each line's exposure to pandemic and potential COVID-19 losses is discussed below:Other coverages with potentially material pandemic risk exposure\u2022 Workers' compensation insurance provides wage replacement, medical and death benefits for all injuries and illnesses that occur in the course of employment, including those arising from occupational exposure to communicable diseases.", [["pandemic", "DISEASE", 38, 46], ["death", "DISEASE", 233, 238], ["injuries", "DISEASE", 256, 264], ["communicable diseases", "DISEASE", 373, 394], ["each line's exposure", "PROBLEM", 14, 34], ["pandemic", "PROBLEM", 38, 46], ["potential COVID-19 losses", "PROBLEM", 51, 76], ["wage replacement", "TREATMENT", 203, 219], ["all injuries", "PROBLEM", 252, 264], ["illnesses", "PROBLEM", 269, 278], ["communicable diseases", "PROBLEM", 373, 394]]], ["As discussed previously, workers' compensation insurers are expected to incur billions in COVID-19 claims.", [["COVID", "TEST", 90, 95]]], ["Their ability to claim workers' compensation benefits depends on a demonstration that COVID-19 was contracted out of the course of their employment.", [["COVID", "TEST", 86, 91]]], ["As mentioned previously, estimated COVID-19 losses in the workers' compensation line are highly uncertain, ranging from $0.2 billion to $92 billion (Willis Towers Watson 2020). \u2022 Commercial general liability insurance protects businesses from a variety of claims that can arise during business operations.", [["estimated COVID", "TEST", 25, 40], ["the workers' compensation line", "TREATMENT", 54, 84]]], ["The insurers that write these policies are therefore concerned that U.S. businesses could be the subject of extensive litigation alleging negligence in allowing the coronavirus to spread (e.g., to customers, students, etc.).", [["coronavirus", "ORGANISM", 165, 176], ["the coronavirus", "PROBLEM", 161, 176]]], ["To address this concern, insurers and businesses support federal efforts to implement a temporary liability shield that would protect businesses, healthcare facilities and educational institutions against most COVID-related litigation (Werner et al. 2020 ). \u2022 Trade credit insurance is purchased by businesses wishing to insure their accounts receivable against the possibility of default or insolvency of the counterparty in the transaction.", [["COVID", "CHEMICAL", 210, 215], ["a temporary liability shield", "TREATMENT", 86, 114]]], ["Trade credit insurance therefore reduces credit risk.", [["credit risk", "OBSERVATION", 41, 52]]], ["It is instrumental in facilitating international trade where complex supply chains amplify the risk.", [["complex supply chains", "TREATMENT", 61, 82], ["instrumental", "OBSERVATION_MODIFIER", 6, 18]]], ["The deep, global economic recession that ensued as countries attempted to contain the spread of the coronavirus precipitated a massive increase in credit risk.", [["coronavirus", "DISEASE", 100, 111], ["coronavirus", "ORGANISM", 100, 111], ["The deep, global economic recession", "PROBLEM", 0, 35], ["the coronavirus", "PROBLEM", 96, 111], ["a massive increase in credit risk", "PROBLEM", 125, 158], ["deep", "ANATOMY_MODIFIER", 4, 8], ["global", "OBSERVATION_MODIFIER", 10, 16], ["economic recession", "OBSERVATION", 17, 35], ["coronavirus", "OBSERVATION", 100, 111], ["massive", "OBSERVATION_MODIFIER", 127, 134], ["increase", "OBSERVATION_MODIFIER", 135, 143], ["credit risk", "OBSERVATION", 147, 158]]], ["The deteriorating finances of businesses around the world exposed insurers in the U.S. and London markets (where the majority of this coverage is written) to losses estimated to be as high as $6 billion (Willis Towers Watson 2020).", [["deteriorating", "OBSERVATION_MODIFIER", 4, 17]]], ["The COVID-19 pandemic is expected to lead to extensive litigation against corporations, their boards and managers arising from allegations that the company's response to the pandemic was inadequate and/or that statements the company made regarding its exposure to loss and finances were misleading and caused financial injury to stakeholders (e.g., shareholders).", [["financial injury", "PROBLEM", 309, 325]]], ["The sharp increase in business bankruptcies during the pandemic had by mid-2020 already contributed to an increase in D&O claims.", [["bankruptcies", "DISEASE", 31, 43], ["an increase in D&O claims", "PROBLEM", 103, 128], ["sharp", "OBSERVATION_MODIFIER", 4, 9], ["increase", "OBSERVATION_MODIFIER", 10, 18], ["business bankruptcies", "OBSERVATION", 22, 43], ["increase", "OBSERVATION_MODIFIER", 106, 114]]], ["Willis Towers Watson estimates that losses in the D&O line could reach $4 billion.Pandemic coverage post-COVIDThe immediate impact of COVID-19 on property-casualty insurance markets has been to intensify a pre-existing \"hard market\" for most major lines of commercial insurance.", [["COVID-19", "CHEMICAL", 134, 142], ["the D&O line", "TREATMENT", 46, 58], ["Pandemic coverage", "TREATMENT", 82, 99], ["COVID", "TREATMENT", 134, 139]]], ["Hard markets are typically characterized by a tightening of underwriting criteria and a sustained upward trend in pricing-reflecting both a reassessment of risk and reduction in available capacity.", [["a tightening of underwriting criteria", "PROBLEM", 44, 81], ["a sustained upward trend in pricing", "PROBLEM", 86, 121], ["tightening", "OBSERVATION_MODIFIER", 46, 56], ["sustained", "OBSERVATION_MODIFIER", 88, 97], ["upward", "OBSERVATION_MODIFIER", 98, 104], ["trend", "OBSERVATION_MODIFIER", 105, 110]]], ["Market surveys for the first quarter of 2020 revealed the largest and broadest rate increases since 2003, a period when markets were still absorbing the shock of the September 11, 2001 terrorist attacks (Council of Insurance Agents and Brokers 2020).", [["shock", "DISEASE", 153, 158], ["Market surveys", "TEST", 0, 14], ["Insurance Agents", "TREATMENT", 215, 231], ["largest", "OBSERVATION_MODIFIER", 58, 65], ["broadest", "OBSERVATION_MODIFIER", 70, 78], ["rate", "OBSERVATION_MODIFIER", 79, 83], ["increases", "OBSERVATION_MODIFIER", 84, 93]]], ["Amid the pandemic, numerous insurers and reinsurers in the U.S., Europe and in the Bermuda market have collectively raised billions of dollars in the form of both equity and debt offerings.", [["numerous", "OBSERVATION_MODIFIER", 19, 27], ["insurers", "OBSERVATION", 28, 36]]], ["These companies and investors have cited the favorable rate environment and numerous market dislocations to which capital can be opportunistically deployed at attractive rates of return.", [["dislocations", "DISEASE", 92, 104], ["numerous market dislocations", "PROBLEM", 76, 104], ["numerous", "OBSERVATION_MODIFIER", 76, 84], ["market dislocations", "OBSERVATION", 85, 104]]], ["These capital raises are consistent with a pattern observed for decades within the industry whereby hard market periods, which generally occur following major market shocks (e.g., September 11 attacks, Hurricane Katrina), serve to attract additional capital even amid heightened uncertainty.Pandemic coverage post-COVIDAt least some of this capital will likely be allocated to new product offerings that involve pandemic risk, often through excess and surplus lines markets which offer insurers more flexibility in terms of price and policy language.", [["Pandemic coverage", "TREATMENT", 291, 308], ["surplus lines markets", "TREATMENT", 452, 473], ["capital", "OBSERVATION", 6, 13], ["consistent with", "UNCERTAINTY", 25, 40]]], ["Lloyd's, for example, has established an innovation accelerator-Lloyd's Lab-which is working with a variety of start-up firms to expedite COVID-19 related products and innovations and to improve understanding of how to model and create products that better protect customers against future pandemics and other systemic risks (Lloyd's 2020).Section summaryInsurers, reinsurers and capital markets have historically struggled to bring commercially viable pandemic insurance products to market.", [["pandemics", "DISEASE", 290, 299], ["expedite COVID", "TREATMENT", 129, 143]]], ["Potential losses can easily exceed the industry's capital, surplus and premium resources.", [["Potential losses", "PROBLEM", 0, 16]]], ["Pandemic losses are also correlated with financial market losses.", [["Pandemic losses", "PROBLEM", 0, 15]]], ["Collectively, these factors pose a systemic risk to the industry and potentially the overall economy.", [["overall", "OBSERVATION_MODIFIER", 85, 92], ["economy", "OBSERVATION", 93, 100]]], ["These environmental obstacles compound the inherent challenges in modeling pandemic risk.", [["pandemic", "DISEASE", 75, 83]]], ["Under such conditions, frequency and severity of losses cannot be precisely modeled, creating an obstacle to accurate pricing.", [["severity of losses", "PROBLEM", 37, 55]]], ["Consequently, it is unlikely that private insurance markets will be able to offer affordable, widely available commercial insurance products that insure against some of the costliest economic consequences of pandemics, especially those arising from business continuity risks.", [["pandemics", "DISEASE", 208, 217], ["commercial insurance products", "TREATMENT", 111, 140], ["pandemics", "PROBLEM", 208, 217], ["unlikely", "UNCERTAINTY", 20, 28]]], ["4 we discuss the potential role of a government in overcoming those challenges.A framework for analyzing pandemic insuranceThe previous section documented that prior to COVID-19 the private insurance market for economic losses from pandemics related to a pause of economic activity was thin in the sense that relatively few entities had coverage and the amount of coverage that was purchased was low relative to the potential size of losses.", [["pandemics", "DISEASE", 232, 241], ["COVID", "TEST", 169, 174], ["economic losses", "PROBLEM", 211, 226], ["pandemics", "PROBLEM", 232, 241], ["a pause of economic activity", "PROBLEM", 253, 281], ["coverage", "TREATMENT", 337, 345], ["coverage", "TREATMENT", 364, 372], ["relatively", "OBSERVATION_MODIFIER", 309, 319], ["few", "OBSERVATION_MODIFIER", 320, 323], ["size", "OBSERVATION_MODIFIER", 426, 430]]], ["7 In this section, we examine a number of non-mutually exclusive, potential explanations for a thin pandemic insurance market.A framework for analyzing pandemic insuranceSome potential explanations can be viewed as originating on the demand side and arise from an underestimation of either the likelihood and/or the severity of pandemic losses.", [["pandemic losses", "PROBLEM", 328, 343], ["underestimation", "OBSERVATION", 264, 279], ["pandemic", "OBSERVATION", 328, 336]]], ["The underestimation of pandemic risk could occur for many reasons, including decision makers underestimating the probability of a pandemic, or underestimating the speed and/or extent to which a virus spreads, or underestimating the probability and/or duration of a government imposed shutdown of economic activity, or being overly optimistic about the ability of scientists to develop treatments and vaccines.", [["pandemic", "DISEASE", 23, 31], ["pandemic risk", "PROBLEM", 23, 36], ["a pandemic", "PROBLEM", 128, 138], ["a virus spreads", "PROBLEM", 192, 207], ["treatments", "TREATMENT", 385, 395], ["vaccines", "TREATMENT", 400, 408]]], ["Regardless of why, underestimation of the risk could lead to low demand and therefore a thin market.", [["low demand", "PROBLEM", 61, 71], ["a thin market", "TREATMENT", 86, 99]]], ["Demand can be further reduced by people's perception that if a truly disastrous pandemic event occurs, governments likely will intervene and provide disaster assistance.A framework for analyzing pandemic insuranceIt is unlikely that widespread underestimation of pandemic risk will occur in the near future given the recent experience with COVID-19.", [["pandemic", "DISEASE", 263, 271], ["COVID-19", "CHEMICAL", 340, 348], ["people", "ORGANISM", 33, 39], ["people", "SPECIES", 33, 39], ["a truly disastrous pandemic event", "PROBLEM", 61, 94], ["pandemic risk", "PROBLEM", 263, 276], ["COVID", "TEST", 340, 345], ["unlikely that", "UNCERTAINTY", 219, 232], ["widespread", "OBSERVATION_MODIFIER", 233, 243], ["pandemic", "OBSERVATION", 263, 271]]], ["8 On the other hand, the response of governments in developed countries to COVID-19 in providing aid (see Richter and Wilson 2020 and Sect.", [["COVID-19", "CHEMICAL", 75, 83]]], ["4 ) has likely increased the perception that governments will react similarly in future pandemics, which will decrease the incentive of entities to mitigate risk and to purchase insurance for losses caused by pandemics.A framework for analyzing pandemic insuranceWhile we acknowledge that a lack of demand likely contributes to a thin market, we focus in this section on why it is costly to supply insurance for economic losses caused by a pandemic.", [["pandemics", "PROBLEM", 209, 218], ["economic losses", "PROBLEM", 412, 427], ["a pandemic", "PROBLEM", 438, 448], ["likely", "UNCERTAINTY", 8, 14], ["increased", "OBSERVATION_MODIFIER", 15, 24]]], ["To focus attention on the supply side of insurance, we assume that those exposed to pandemic risk have a good understanding of the risk and would be willing to pay a \"reasonable\" loading over and above the expected loss for insurance if it was available.", [["pandemic", "DISEASE", 84, 92]]], ["Risk aversion on the part of individuals can explain their willingness to pay more than the expected loss, and financial market imperfections (see e.g., Froot and Stein 1997) can explain businesses' willingness to pay more than the expected loss.", [["Risk aversion", "PROBLEM", 0, 13]]], ["Of course, as the loading (price) on the insurance increases, the quantity of insurance demanded is expected to decline, i.e., the market is expected to become thinner.A framework for analyzing pandemic insuranceWe discuss both a private market supplying the insurance and a government supplying the insurance for the purpose of identifying situations in which one would have advantages/disadvantages relative to the other.", [["advantages/disadvantages", "TREATMENT", 376, 400]]], ["It is therefore conceptual, not descriptive nor empirical.Conceptual framework/settingWe consider the risk associated with insuring N entities for the economic losses associated with business closures due to an infectious disease.", [["infectious disease", "DISEASE", 211, 229], ["insuring N entities", "PROBLEM", 123, 142], ["the economic losses", "PROBLEM", 147, 166], ["business closures", "TREATMENT", 183, 200], ["an infectious disease", "PROBLEM", 208, 229], ["infectious", "OBSERVATION", 211, 221]]], ["Without specifying the size or economic conditions of an entity, assume that entity i has a probability of p i of economic losses L i from a breakout of an infectious disease in a given year.", [["infectious disease", "DISEASE", 156, 174], ["economic losses L i", "PROBLEM", 114, 133], ["an infectious disease", "PROBLEM", 153, 174], ["size", "OBSERVATION_MODIFIER", 23, 27], ["economic", "OBSERVATION_MODIFIER", 31, 39], ["infectious", "OBSERVATION", 156, 166]]], ["Presumably L i is related to the amount of economic activity in i.", [["L i", "GENE_OR_GENE_PRODUCT", 11, 14], ["L i", "OBSERVATION_MODIFIER", 11, 14], ["amount", "OBSERVATION_MODIFIER", 33, 39], ["economic activity", "OBSERVATION", 43, 60]]], ["For now, we will not specify a probability distribution for p or L, as below we consider various hypothetical examples.Conceptual framework/settingWe consider the possibility that the probability of a loss and/or the severity of a loss could be correlated across entities, with the idea that epidemics (disease is contained to a few entities) would be characterized by a low correlation, and that pandemics (disease spreads across many entities) would be characterized by a relatively high correlation.", [["a loss", "PROBLEM", 199, 205], ["a loss", "PROBLEM", 229, 235], ["epidemics (disease", "PROBLEM", 292, 310], ["pandemics (disease spreads", "PROBLEM", 397, 423], ["loss", "OBSERVATION", 201, 205], ["loss", "OBSERVATION", 231, 235]]], ["We specify the correlation structure in examples 3 and 4.Conceptual framework/settingNote that the underlying risk structure (the probability distributions for the probability of a loss, p, the severity of losses, L, and the correlation structure is assumed to be constant over time periods.", [["a loss", "PROBLEM", 179, 185], ["the severity of losses, L, and the correlation structure", "PROBLEM", 190, 246], ["loss", "OBSERVATION", 181, 185], ["L", "ANATOMY_MODIFIER", 214, 215]]], ["This type of stationarity is almost certainly violated in practice as, all else equal, the likelihood that multiple entities would experience losses (the correlations) increases with economic integration (globalization) and decreases with advances in medicine.", [["economic integration", "TREATMENT", 183, 203], ["advances in medicine", "TREATMENT", 239, 259], ["multiple", "OBSERVATION_MODIFIER", 107, 115], ["entities", "OBSERVATION", 116, 124], ["decreases", "OBSERVATION_MODIFIER", 224, 233]]], ["Similarly, the probability that an entity i experiences a loss can change over time and the magnitude of economic losses can change over time, e.g., with economic activity and medical breakthroughs.", [["a loss", "PROBLEM", 56, 62], ["economic losses", "PROBLEM", 105, 120], ["medical breakthroughs", "PROBLEM", 176, 197], ["entity", "OBSERVATION", 35, 41], ["loss", "OBSERVATION", 58, 62]]], ["These aspects of the problem are ignored.The capital required for pooling risk cross-sectionallyInitially, we focus on the amount of capital needed to provide a credible mechanism to pay claims that occur in a given time period.", [["pooling risk", "PROBLEM", 66, 78], ["capital", "OBSERVATION", 45, 52]]], ["We ignore all administrative costs (e.g., costs incurred to enroll entities and pay claims) associated with implementing a pooling mechanism.", [["a pooling mechanism", "TREATMENT", 121, 140]]], ["To achieve this high probability, the pooling mechanism must have access to sufficient financial resources to pay most losses that could occur, which we somewhat arbitrarily set as the 99th percentile value of total potential losses.", [["this high probability", "PROBLEM", 11, 32], ["the pooling mechanism", "PROBLEM", 34, 55], ["total potential losses", "PROBLEM", 210, 232]]], ["9 We consider the pooling mechanism as occurring at the aggregate level that includes all N entities.", [["the pooling mechanism", "PROBLEM", 14, 35]]], ["Regardless of whether a private market or a government solution is used, we assume that the pandemic risk is managed as a standalone pool of risk, independent from the rest of the risks that exist.", [["pandemic", "DISEASE", 92, 100], ["a government solution", "TREATMENT", 42, 63], ["the pandemic risk", "PROBLEM", 88, 105]]], ["Under these assumptions, each insurer/reinsurer, would pay a proportion of all pandemic losses, although the proportion could vary across insurers/reinsurers based on their risk tolerance, which we do not specify.", [["all pandemic losses", "PROBLEM", 75, 94], ["reinsurers", "TREATMENT", 147, 157], ["pandemic", "OBSERVATION", 79, 87]]], ["Also, with this assumption, the total amount of financial resources needed to provide a credible (99% probability) pooling mechanism of all pandemic losses would be the same for a private market as for a standalone government program.The capital required for pooling risk cross-sectionallyBelow we calculate the amount of financial resources needed in several hypothetical examples to illustrate some of the factors that determine the cost of providing a credible insurance mechanism.", [["financial resources", "TREATMENT", 48, 67], ["a credible", "TEST", 86, 96], ["pooling mechanism", "PROBLEM", 115, 132], ["all pandemic losses", "PROBLEM", 136, 155], ["a standalone government program", "TREATMENT", 202, 233], ["pooling risk cross-sectionally", "PROBLEM", 259, 289], ["financial resources", "TREATMENT", 322, 341], ["capital", "OBSERVATION", 238, 245]]], ["In each of the examples, we define the aggregate liability for pandemic risk as the expected value of pandemic losses, the assets needed to credibly insure the risk as the 99th percentile value of the distribution of total pandemic losses, and the required capital as the difference between the assets and the liability.", [["pandemic", "DISEASE", 63, 71], ["pandemic", "DISEASE", 223, 231], ["pandemic risk", "PROBLEM", 63, 76], ["pandemic losses", "PROBLEM", 102, 117], ["total pandemic losses", "PROBLEM", 217, 238], ["total", "OBSERVATION_MODIFIER", 217, 222], ["pandemic losses", "OBSERVATION", 223, 238]]], ["Figure 1 illustrates these definitions for an arbitrary probability density function for pandemic losses.", [["an arbitrary probability density function", "PROBLEM", 43, 84], ["pandemic losses", "PROBLEM", 89, 104]]], ["For simplicity, we initially assume that the assets are invested in risk-free, zero-return securities.The capital required for pooling risk cross-sectionallyWe assume that a private market has a cost of holding capital.", [["pooling risk", "PROBLEM", 127, 139], ["capital", "OBSERVATION", 106, 113]]], ["The difference is that there is likely to be more information frictions (agency costs and information asymmetry costs) with an investment in the insurer because the insurer's managers are not only managing the asset portfolio but also the liability side of the balance sheet (Kielholz 2000) .", [["likely to be", "UNCERTAINTY", 32, 44]]], ["In addition, there are potential tax costs associated with the insurer investment (see e.g., Niehaus 2020).", [["tax costs", "OBSERVATION", 33, 42]]], ["The purpose of this paper is to focus on the amount of capital needed, not the capital costs per dollar of capital.The capital required for pooling risk cross-sectionallyThe nature of the costs associated with a government holding the necessary level of capital is likely to differ from a private market.", [["pooling risk cross-sectionally", "PROBLEM", 140, 170], ["capital", "OBSERVATION", 119, 126], ["costs", "OBSERVATION", 188, 193]]], ["For example, there would not be tax costs associated with the government holding the capital.", [["capital", "ANATOMY", 85, 92]]], ["However, there would likely be other costs.", [["would likely be", "UNCERTAINTY", 15, 30], ["costs", "OBSERVATION", 37, 42]]], ["For example, politicians might be tempted to use the funds for other purposes or invest the funds to achieve other political goals besides providing a pooling mechanism for infectious disease costs.", [["infectious disease", "DISEASE", 173, 191], ["infectious disease costs", "PROBLEM", 173, 197]]], ["There may also be efficiency losses in having a government entity manage the pooling arrangement as opposed to private insurers.", [["efficiency losses", "PROBLEM", 18, 35], ["the pooling arrangement", "TREATMENT", 73, 96], ["may also be", "UNCERTAINTY", 6, 17], ["efficiency", "OBSERVATION_MODIFIER", 18, 28], ["losses", "OBSERVATION", 29, 35]]], ["4.The capital required for pooling risk cross-sectionallyWe now present a series of hypothetical examples.", [["pooling risk", "PROBLEM", 27, 39], ["capital", "OBSERVATION", 6, 13]]], ["The purpose of these relatively elementary examples is to illustrate how the required amount of capital varies with important characteristics of pandemic risk, specifically, with uncertain loss severity, cross-sectional correlation in the frequency of losses, and cross-sectional correlation in the severity of losses.", [["pandemic", "DISEASE", 145, 153], ["pandemic risk", "PROBLEM", 145, 158], ["uncertain loss severity", "PROBLEM", 179, 202]]], ["The focus is not on the absolute amount of capital needed in a given example, but on the relative amount of capital across the examples.", [["capital", "OBSERVATION", 43, 50], ["capital", "OBSERVATION", 108, 115]]], ["The examples might be useful for students and those new to the underlying principles of insurance.Example 1: ideal conditionsAssume that there are 1000 entities, the probability of an event (p) is 0.02 for each entity, and the severity of an event (L) is the same for each entity and equals $100.", [["ideal conditions", "PROBLEM", 109, 125]]], ["In this simple case, the distribution for total losses for all 1000 entities has a binomial distribution with an expected value $2000 and a 99th percentile value equal to $3100.", [["total losses", "PROBLEM", 42, 54], ["a 99th percentile value", "TEST", 138, 161], ["binomial distribution", "OBSERVATION", 83, 104]]], ["On a per entity basis, the expected cost is $2, and the amount of capital required is $1.1.", [["amount", "OBSERVATION_MODIFIER", 56, 62], ["capital", "OBSERVATION", 66, 73]]], ["Stated differently, the required capital per entity is 55% of the expected loss.Example 1: ideal conditionsThis example illustrates the great benefits of pooling risk.", [["ideal conditions", "PROBLEM", 91, 107], ["pooling risk", "PROBLEM", 154, 166], ["pooling risk", "OBSERVATION", 154, 166]]], ["The contribution is just 55% more than each entity's expected loss.", [["55%", "OBSERVATION_MODIFIER", 25, 28], ["expected loss", "OBSERVATION", 53, 66]]], ["11 This example assumes ideal conditions for pooling risk and therefore provides a benchmark for the subsequent examples.", [["pooling risk", "PROBLEM", 45, 57]]], ["The probability of a loss and the size of the loss if it occurs are known and are the same for all entities, the outcomes across entities are independent of each other, the outcomes do not depend on the decisions of any of the participants, and there are a relatively large number of entities.", [["participants", "SPECIES", 227, 239], ["a loss", "PROBLEM", 19, 25], ["the loss", "PROBLEM", 42, 50], ["loss", "OBSERVATION", 21, 25], ["size", "OBSERVATION_MODIFIER", 34, 38], ["loss", "OBSERVATION", 46, 50], ["relatively", "OBSERVATION_MODIFIER", 257, 267], ["large", "OBSERVATION_MODIFIER", 268, 273], ["number", "OBSERVATION_MODIFIER", 274, 280], ["entities", "OBSERVATION", 284, 292]]], ["The remaining examples relax some of these assumptions by incorporating characteristics of pandemic risk.", [["pandemic", "DISEASE", 91, 99], ["pandemic risk", "PROBLEM", 91, 104]]], ["As we will see, the pandemic characteristics generally make pooling risk more costly.", [["pooling risk", "PROBLEM", 60, 72]]], ["12Example 2: uncertainty in severity of lossesThe magnitude of the losses that an entity incurs from a pandemic is highly uncertain, because economic shutdowns can vary in terms of scope (how many businesses stop operating), degree (is there a complete shutdown or reduced activity),Probability Density LossesTotal Losses Expected Value 9 9 th %\u019fle Liability A ssets Fig. 1 Illustration of assets and capital needed for a credible pooling mechanism for a given probability density function for total losses 11 Finding the exact amount of capital to raise is more complicated than this paragraph suggests as the premium depends on the amount of capital and the amount of capital depends on the premium.", [["Losses", "DISEASE", 315, 321], ["reduced activity)", "PROBLEM", 265, 282], ["Value", "TEST", 331, 336], ["a credible pooling mechanism", "PROBLEM", 420, 448], ["total losses", "PROBLEM", 494, 506], ["magnitude", "OBSERVATION_MODIFIER", 50, 59], ["more complicated", "OBSERVATION_MODIFIER", 558, 574], ["capital", "OBSERVATION", 644, 651], ["amount", "OBSERVATION_MODIFIER", 660, 666], ["capital", "OBSERVATION", 670, 677]]], ["Of course, finding the optimal amount of capital in practice is much more complicated.", [["optimal", "OBSERVATION_MODIFIER", 23, 30], ["amount", "OBSERVATION_MODIFIER", 31, 37], ["capital", "OBSERVATION", 41, 48], ["more complicated", "OBSERVATION_MODIFIER", 69, 85]]], ["12 If entities differ in their underlying probability distributions, specifically with respect to the \"fatness\" of the tail of the distribution, then pooling exposures may not be beneficial.", [["tail", "ANATOMY_MODIFIER", 119, 123], ["may not be", "UNCERTAINTY", 168, 178]]], ["We therefore introduce uncertainty in the magnitude of the loss if a loss occurs (hereafter referred to as severity), but we continue to keep the probability of a loss equal to 0.02.", [["a loss", "PROBLEM", 67, 73]]], ["We assume that each entity has the same probability distribution for severity.", [["severity", "PROBLEM", 69, 77]]], ["13 With this assumption, the expected severity is the same as in the previous example, $100, but there is considerable uncertainty in the magnitude of the losses that each entity with a loss experiences.", [["a loss experiences", "PROBLEM", 184, 202], ["considerable", "OBSERVATION_MODIFIER", 106, 118], ["uncertainty", "OBSERVATION", 119, 130]]], ["Figure 2 illustrates the density function of the assumed lognormal distribution.Probability Density LossesWith these assumptions, the expected loss per entity is still $2, but the 99th percentile value is $5.4 per entity, implying that in a mutual arrangement, each entity would need to contribute 170% [($5.4 \u2212 $2)/$2] more than their expected loss, or a little over three times the amount that was needed in Example 1 when losses were fixed at $100.", [["their expected loss", "PROBLEM", 330, 349], ["density", "OBSERVATION", 25, 32], ["lognormal", "OBSERVATION_MODIFIER", 57, 66], ["distribution", "OBSERVATION_MODIFIER", 67, 79], ["Density", "OBSERVATION", 92, 99], ["loss", "OBSERVATION_MODIFIER", 143, 147], ["loss", "OBSERVATION", 345, 349]]], ["The more uncertainty there is in losses, all else equal, the greater the cost of providing a credible pooling arrangement.Example 2b: incorporating limitsInsurers can reduce the uncertainty in their loss payments by incorporating limits on their coverage.", [["a credible pooling arrangement", "TREATMENT", 91, 121], ["their coverage", "TREATMENT", 240, 254], ["more uncertainty", "OBSERVATION_MODIFIER", 4, 20], ["losses", "OBSERVATION_MODIFIER", 33, 39], ["greater", "OBSERVATION_MODIFIER", 61, 68]]], ["Suppose, for example, that the pooling mechanism provides coverage only for losses up to $500 per entity in the pooling arrangement described in Example 2.", [["the pooling mechanism", "PROBLEM", 27, 48]]], ["Given the assumed lognormal distribution for losses, only about 3% of the participants would have losses exceeding this amount.", [["participants", "ORGANISM", 74, 86], ["participants", "SPECIES", 74, 86], ["lognormal", "OBSERVATION_MODIFIER", 18, 27], ["distribution", "OBSERVATION_MODIFIER", 28, 40]]], ["Consequently, the required contribution per entity would drop from 170% to about 100% of the expected claim payment.Example 2b: incorporating limitsThe lower the coverage limit, the less capital required to provide a credible insurance mechanism for the coverage provided, all else equal.", [["lower", "OBSERVATION_MODIFIER", 152, 157]]], ["However, the lower the limit, the less coverage that is being provided, i.e., less risk sharing is taking place.", [["lower", "OBSERVATION_MODIFIER", 13, 18]]], ["Nevertheless, coverage limits can be an effective tool to promote a private market for relatively low pandemic losses.", [["relatively low pandemic losses", "PROBLEM", 87, 117]]], ["The desirability of coupling a private market with relatively low limits with a government offering (or possibly requiring) excess coverage above the private market limits, either directly 13 We are assuming that severity has a lognormal distribution with a mean of $100 and a standard deviation of $200, not that the log of severity is normally distributed with a mean of $100 and a standard deviation of $200.", [["excess coverage", "TREATMENT", 124, 139], ["low limits", "OBSERVATION_MODIFIER", 62, 72]]], ["In that case, the actual mean and standard deviation of the lognormally distributed random variable are exp(m + s 2 /2) and exp(m + s 2 /2))(exp(s 2 \u2212 1) 1/2 . to consumers or through a reinsurance arrangement with private insurers will be discussed in Sect.", [["exp(m + s", "TEST", 124, 133], ["variable", "OBSERVATION_MODIFIER", 91, 99], ["exp", "OBSERVATION", 104, 107]]], ["14Example 3: correlation in loss severityIn the previous examples, all the entities were assumed to have the same probability distribution for the frequency and severity of losses and the outcomes for one entity were independent of the other entities.", [["loss severity", "PROBLEM", 28, 41], ["severity of losses", "PROBLEM", 161, 179], ["loss severity", "OBSERVATION_MODIFIER", 28, 41]]], ["In this setting, if the average severity is larger (or lower) than expected, then that higher (lower) than expected severity applies to all of the entities that have a loss, which intuitively induces a positive correlation in the individual entities' losses conditional on a loss occurring.", [["a loss", "PROBLEM", 166, 172], ["a loss", "PROBLEM", 273, 279], ["larger", "OBSERVATION_MODIFIER", 44, 50], ["higher", "OBSERVATION_MODIFIER", 87, 93], ["loss", "OBSERVATION", 168, 172]]], ["We continue to assume that the probability of a loss for all entities is 0.02 and independent of each other.Example 3: correlation in loss severityThe result is that the amount of capital required to have a credible pooling arrangement increases dramatically.", [["a loss", "PROBLEM", 46, 52], ["loss severity", "PROBLEM", 134, 147], ["a credible pooling arrangement", "TREATMENT", 205, 235], ["loss severity", "OBSERVATION_MODIFIER", 134, 147], ["amount", "OBSERVATION_MODIFIER", 170, 176], ["capital", "OBSERVATION", 180, 187], ["pooling", "OBSERVATION", 216, 223], ["increases", "OBSERVATION_MODIFIER", 236, 245], ["dramatically", "OBSERVATION_MODIFIER", 246, 258]]], ["For a mutual pooling arrangement, each entity would have to contribute capital equal to $15 in addition to the expected loss of $2.", [["a mutual pooling arrangement", "TREATMENT", 4, 32]]], ["14 We also investigate allowing the probability that an entity has a loss, p, to be uncertain such that the expected probability for each entity still equals 0.02.", [["a loss", "PROBLEM", 67, 73], ["entity", "OBSERVATION", 56, 62]]], ["Specifically, for each individual entity, we assume that the probability of a loss is independently drawn from a Beta distribution with parameters equal to 1 and 49.", [["a loss", "PROBLEM", 76, 82], ["loss", "OBSERVATION", 78, 82]]], ["We keep the severity of the loss if it occurs as a lognormal distribution with a mean of $100 and standard deviation of $200 (as in Example 2).", [["the loss", "PROBLEM", 24, 32], ["loss", "OBSERVATION", 28, 32]]], ["Even though we have added uncertainty in the probability that an entity has a loss, the amount of capital needed is very similar to Example 2.Example 4: additional correlation through the frequency of a lossIn the next example, we assume that the loss frequency that applies to all entities is uncertain.", [["a loss", "PROBLEM", 76, 82], ["a loss", "PROBLEM", 201, 207], ["the loss frequency", "PROBLEM", 243, 261], ["entity", "OBSERVATION", 65, 71], ["loss", "OBSERVATION", 78, 82], ["amount", "OBSERVATION_MODIFIER", 88, 94], ["capital", "OBSERVATION", 98, 105], ["loss", "OBSERVATION", 203, 207]]], ["That is, a probability of a loss is selected randomly and that probability applies to all the entities.", [["a loss", "PROBLEM", 26, 32], ["loss", "OBSERVATION", 28, 32]]], ["This is a way of incorporating correlation in the occurrence of a loss across entities (see Hisakado et al. 2006) .", [["a loss across entities", "PROBLEM", 64, 86]]], ["Intuitively, when one entity has a higher (lower) than expected probability of a loss, then all the entities have a higher (lower) than expected probability of a loss.", [["a loss", "PROBLEM", 79, 85], ["a loss", "PROBLEM", 160, 166], ["higher", "OBSERVATION_MODIFIER", 35, 41], ["loss", "OBSERVATION", 81, 85], ["higher", "OBSERVATION_MODIFIER", 116, 122], ["loss", "OBSERVATION", 162, 166]]], ["Specifically, we assume that the probability of a loss that applies to all entities is drawn from a Beta distribution with parameters 1 and 49, which is illustrated in Fig. 3 .", [["a loss", "PROBLEM", 48, 54], ["loss", "OBSERVATION", 50, 54]]], ["This distribution implies that, on average, the probability of an entity having a loss is 0.02, as has been the case in all of the examples.", [["entity", "OBSERVATION", 66, 72], ["loss", "OBSERVATION_MODIFIER", 82, 86]]], ["In a mutual arrangement, each entity would need to contribute 950% more than their expected loss to have a credible pooling arrangement.", [["a credible pooling arrangement", "TREATMENT", 105, 135]]], ["Thus, correlation in the occurrence of losses also has a significant effect on the amount of required capital.Example 5: pandemic versus natural catastrophe riskWe now provide an example to compare insurance for pandemic risk to insurance for a natural catastrophe risk.", [["pandemic", "PROBLEM", 121, 129], ["natural catastrophe", "PROBLEM", 137, 156], ["a natural catastrophe risk", "PROBLEM", 243, 269], ["significant", "OBSERVATION_MODIFIER", 57, 68], ["effect", "OBSERVATION_MODIFIER", 69, 75]]], ["The idea underlying the example is that natural catastrophe risk is usually limited in that it impacts only entities within a given geographical region.", [["natural catastrophe risk", "PROBLEM", 40, 64], ["catastrophe", "OBSERVATION", 48, 59]]], ["Therefore, catastrophe risk is likely to have correlation in losses for entities in a given geographical area, but not for all entities.", [["catastrophe risk", "PROBLEM", 11, 27]]], ["In comparison to the setting described above for pandemic risk, natural catastrophe risk would likely cause correlation within groups of entities, not across all entities.", [["pandemic", "DISEASE", 49, 57], ["pandemic risk", "PROBLEM", 49, 62], ["natural catastrophe risk", "PROBLEM", 64, 88]]], ["We therefore estimate the capital that would be needed to provide a credible pooling arrangement if instead of applying the probabilistic assumptions of Example 4 to all 1000 entities, they were applied to separate groups of 20 entities each.", [["a credible pooling arrangement", "TREATMENT", 66, 96]]], ["The amount of capital required per entity in this case is about $4.4, or 220% of the expected loss.", [["amount", "OBSERVATION_MODIFIER", 4, 10], ["capital", "OBSERVATION_MODIFIER", 14, 21]]], ["This is high, but not close to the 950% that we found for the pandemic risk in Example 4.Summary of the examplesThese hypothetical examples, which are summarized in Table 1 , illustrate that the amount of capital required to provide a credible cross-sectional pooling arrangement increases substantially if there is correlation in the frequency and severity of losses, both of which characterize pandemic losses.", [["pandemic", "DISEASE", 62, 70], ["a credible cross-sectional pooling arrangement", "PROBLEM", 233, 279], ["severity of losses", "PROBLEM", 349, 367], ["pandemic losses", "PROBLEM", 396, 411], ["high", "OBSERVATION_MODIFIER", 8, 12]]], ["Example 1 provides a baseline case of when pooling works well-i.e., a large number of exposure units, loss distributions are known, losses are not correlated across exposures, and the interested parties cannot influence the loss distribution.", [["loss distributions", "PROBLEM", 102, 120], ["large", "OBSERVATION_MODIFIER", 70, 75], ["loss", "OBSERVATION", 224, 228]]], ["In this case, the capital required is 55% of the expected loss costs.", [["the expected loss costs", "PROBLEM", 45, 68], ["loss", "OBSERVATION", 58, 62]]], ["Correlation in the average severity of losses across entities (Example 3) increases the required capital substantially to about 750% of the expected loss costs.", [["the expected loss costs", "PROBLEM", 136, 159], ["capital", "OBSERVATION_MODIFIER", 97, 104], ["loss", "OBSERVATION", 149, 153]]], ["If there is also correlation in the probability of the probability of a loss (Example 4), then the required capital is about 950% of the expected loss costs.", [["a loss (Example 4", "PROBLEM", 70, 87], ["the expected loss costs", "PROBLEM", 133, 156], ["loss", "OBSERVATION", 72, 76], ["loss", "OBSERVATION", 146, 150]]], ["Of course, these numbers are contingent on the specific assumptions made about the probability distributions, but they illustrate the important general point that even when pooling arrangements can be organized and managed at zero costs (which is what we assumed), the capital required to provide a credible pooling arrangement for pandemic risk would be substantial.", [["pandemic", "DISEASE", 332, 340], ["a credible pooling arrangement", "TREATMENT", 297, 327], ["pandemic risk", "PROBLEM", 332, 345], ["substantial", "OBSERVATION_MODIFIER", 355, 366]]], ["15Pooling over timeThe previous section indicates that a credible cross-sectional pooling arrangement for the economic losses associated with pandemics can require a large amount of capital.", [["pandemics", "DISEASE", 142, 151], ["a credible cross-sectional pooling arrangement", "PROBLEM", 55, 101], ["the economic losses", "PROBLEM", 106, 125], ["pandemics", "PROBLEM", 142, 151], ["large", "OBSERVATION_MODIFIER", 166, 171], ["amount", "OBSERVATION_MODIFIER", 172, 178], ["capital", "OBSERVATION", 182, 189]]], ["To do this, we estimate the probability distribution of aggregate losses from Example 4 and assume that a separate independent draw from this estimated distribution determines the aggregate loss in each of the 50 years.", [["aggregate losses", "PROBLEM", 56, 72], ["aggregate losses", "OBSERVATION", 56, 72], ["aggregate loss", "OBSERVATION", 180, 194]]], ["We then simulate the mean and 99th percentile value of the average loss over the 50 years, which are used to find the amount of capital needed as the difference between the 99th percentile value and the mean value.", [["the average loss", "PROBLEM", 55, 71], ["the mean value", "TEST", 199, 213], ["average", "OBSERVATION_MODIFIER", 59, 66], ["loss", "OBSERVATION_MODIFIER", 67, 71]]], ["The details are in the \"Appendix\".", [["Appendix", "ANATOMY", 24, 32]]], ["Note that the sequential nature of time is ignored in this analysis.", [["this analysis", "TEST", 54, 67]]], ["Alternatively, one can think of the pooling arrangement as receiving funds each year and paying out losses each year as they occur, where any excess funds are carried over to the following year and any deficit is borrowed from the participants at a zero interest rate.Pooling over timeThe exact results depend on the distributional assumptions for aggregate losses each year, but the message is clear: the amount of overall capital required would be substantially lower than in Example 4.", [["participants", "SPECIES", 231, 243], ["any deficit", "PROBLEM", 198, 209], ["aggregate losses", "PROBLEM", 348, 364], ["capital", "OBSERVATION", 424, 431]]], ["Under one distributional assumption (Inverse Gauss distribution), the capital required per entity per year is 125% of the expected loss, which is substantially lower than what would be required in a cross-sectional pooling arrangement, which was 950% of the expected loss.", [["loss", "OBSERVATION", 131, 135], ["substantially", "OBSERVATION_MODIFIER", 146, 159], ["lower", "OBSERVATION_MODIFIER", 160, 165]]], ["Under an alternative distribution assumption (Lognormal distribution), each entity would need to contribute capital equal to 325% of the expected loss each year with pooling over time.Pooling over timeA problem with pooling risk over time is finding a way to actually implement the arrangement so that sufficient funds are available each year that a large loss could occur.", [["Pooling over timeA problem", "PROBLEM", 184, 210], ["pooling risk", "PROBLEM", 216, 228], ["a large loss", "PROBLEM", 348, 360], ["large", "OBSERVATION_MODIFIER", 350, 355], ["loss", "OBSERVATION", 356, 360]]], ["This amount exceeds the expected annual payout of $2000, but a large loss could occur in one of the early years before a sufficient buffer has been accumulated.", [["a large loss", "PROBLEM", 61, 73], ["large", "OBSERVATION_MODIFIER", 63, 68], ["loss", "OBSERVATION", 69, 73]]], ["Indeed, in the example, there is over a 10% probability that a loss larger than $4500 could occur in any given year, including the first year.Pooling over timeA potential response is that the pool can borrow funds to make up any shortfall that might occur.", [["a loss", "PROBLEM", 61, 67], ["loss", "OBSERVATION_MODIFIER", 63, 67], ["larger", "OBSERVATION_MODIFIER", 68, 74]]], ["In a dynamic economy with exit and entry, the arrangement would need to identify the terms under which entities could leave and newly created entities could join the arrangement over time.Pooling over timeThere are additional reasons that a viable pooling arrangement over time would be difficult, if not impossible, to arrange and implement in a private market setting.", [["a viable pooling arrangement", "PROBLEM", 239, 267]]], ["For example, if there are changes over time in the underlying probability distributions describing the frequency and/or the severity of losses that are different across entities, then those entities that experience lower frequency and/or severity might defect from the large pool, and possibly form smaller pools with other entities that have similar changes.", [["the severity of losses", "PROBLEM", 120, 142], ["lower frequency and/or severity might defect", "PROBLEM", 215, 259], ["smaller pools with other entities", "PROBLEM", 299, 332], ["different", "OBSERVATION_MODIFIER", 152, 161], ["lower frequency", "OBSERVATION_MODIFIER", 215, 230], ["defect", "OBSERVATION", 253, 259], ["large", "OBSERVATION_MODIFIER", 269, 274], ["pool", "OBSERVATION_MODIFIER", 275, 279], ["possibly form", "UNCERTAINTY", 285, 298], ["smaller", "OBSERVATION_MODIFIER", 299, 306], ["pools", "OBSERVATION_MODIFIER", 307, 312]]], ["16 Therefore, differential changes across entities in economic growth or in the quality of public health services might make a pooling arrangement unstable over time.", [["economic growth", "PROBLEM", 54, 69], ["economic", "OBSERVATION_MODIFIER", 54, 62], ["growth", "OBSERVATION_MODIFIER", 63, 69]]], ["In addition, given that frequency and severity of losses can change because of an entity's actions and policies regarding public health and economic growth, there is also a moral hazard problem associated with pooling over time.Pooling over timeGiven the problems associated with arranging a private market pool over time, it is reasonable to ask whether a government could arrange such a pooling arrangement.", [["frequency and severity of losses", "PROBLEM", 24, 56], ["economic growth", "PROBLEM", 140, 155], ["a moral hazard problem", "PROBLEM", 171, 193], ["a pooling arrangement", "TREATMENT", 387, 408]]], ["In addition, a government has fiat power to force participation, which could help reduce adverse selection.", [["adverse selection", "PROBLEM", 89, 106]]], ["On the other hand, pooling over time requires a long-term commitment, and governments will be tempted to react to short-term political developments.", [["a long-term commitment", "TREATMENT", 46, 68]]], ["4, we further discuss the potential advantages and disadvantages with implementing a government solution to pooling risk over time.Other considerations affecting the cost and benefits of a pooling arrangementThe previous sections focused on the amount of capital associated with providing a credible pooling mechanism for the economic losses from pandemics.", [["sections", "ANATOMY", 221, 229], ["a government solution", "TREATMENT", 83, 104], ["a pooling arrangement", "TREATMENT", 187, 208], ["The previous sections", "TEST", 208, 229], ["a credible pooling mechanism", "PROBLEM", 289, 317], ["the economic losses", "PROBLEM", 322, 341], ["pandemics", "PROBLEM", 347, 356]]], ["There are other characteristics of pandemics that could make a private market \"thin\" in the sense that coverage is available for only a relatively small proportion of potential or expected losses.", [["pandemics", "PROBLEM", 35, 44], ["expected losses", "PROBLEM", 180, 195], ["pandemics", "OBSERVATION", 35, 44]]], ["We now discuss some of these factors.Correlation of asset values to lossesAs discussed above, pooling arrangements need to hold assets in excess of their expected loss payments.", [["asset values", "TEST", 52, 64]]], ["These assets typically are invested in financial securities, which ideally generate positive returns from interest, dividends, and capital gains.Correlation of asset values to lossesIn general, the returns on the financial securities held by insurers are uncertain, which when combined with the uncertainty associated with loss payments (discussed above) can affect the credibility of the pooling arrangement to pay all losses.", [["asset values", "TEST", 160, 172]]], ["The overall effect of uncertain asset returns depends on three factors.", [["overall", "OBSERVATION_MODIFIER", 4, 11], ["effect", "OBSERVATION_MODIFIER", 12, 18]]], ["First, higher expected returns on the assets, all else equal, increases the credibility of the pooling arrangement.", [["higher", "OBSERVATION_MODIFIER", 7, 13]]], ["Second, greater the uncertainty associated with investment returns (sometimes measured by standard deviation of returns), all else equal, reduces credibility.", [["greater", "OBSERVATION_MODIFIER", 8, 15]]], ["Third, the problem with the pandemic losses is that they arise from an economic slowdown or shutdown, which also tends to lower asset returns.", [["the pandemic losses", "PROBLEM", 24, 43], ["economic", "OBSERVATION_MODIFIER", 71, 79], ["slowdown", "OBSERVATION", 80, 88]]], ["Thus, when pandemic losses are high, asset returns tend to be low.", [["pandemic losses", "PROBLEM", 11, 26], ["high", "OBSERVATION_MODIFIER", 31, 35]]], ["The greater is the negative correlation between asset returns and loss payments, all else equal, the lower is the credibility of a pooling mechanism.", [["loss payments", "PROBLEM", 66, 79], ["a pooling mechanism", "PROBLEM", 129, 148], ["greater", "OBSERVATION_MODIFIER", 4, 11], ["negative", "OBSERVATION", 19, 27]]], ["To maintain the same credibility, the pooling mechanism will need to hold additional capital, which makes the pooling arrangement even more costly to operate.Expected frequency and severity differs across entitiesIn the examples above, we assumed that prior to the revelation of any random variables, all of the entities, as well as the insurer, were homogeneous in their expectation of the probability of an entity having a loss (0.02) and in their expectation of the magnitude of the loss if a loss occurred ($100).", [["the pooling mechanism", "PROBLEM", 34, 55], ["Expected frequency and severity differs across entities", "PROBLEM", 158, 213], ["any random variables", "PROBLEM", 279, 299], ["the loss", "PROBLEM", 482, 490], ["a loss", "PROBLEM", 494, 500], ["homogeneous", "OBSERVATION_MODIFIER", 351, 362], ["entity", "OBSERVATION", 409, 415], ["loss", "OBSERVATION_MODIFIER", 425, 429]]], ["In practice, both the severity of losses and the probability of a loss are likely to vary across entities in observable ways.", [["a loss", "PROBLEM", 64, 70], ["losses", "OBSERVATION", 34, 40], ["loss", "OBSERVATION", 66, 70]]], ["Loss severity will be higher, for example, for entities with greater economic activity (revenue), those engaged in activities that are not viewed as being essential, those with a more cautious clientele, those located in more densely populated areas, etc. Similarly, the probability of a loss will be higher for entities located in areas with a more mobile population and that are more densely populated.Expected frequency and severity differs across entitiesIn theory, this heterogeneity, provided it is symmetrically known, does not present insurmountable problems for a pooling arrangement.", [["Loss severity", "PROBLEM", 0, 13], ["a loss", "PROBLEM", 286, 292], ["a more mobile population", "PROBLEM", 343, 367], ["Expected frequency and severity differs across entities", "PROBLEM", 404, 459], ["insurmountable problems", "PROBLEM", 543, 566], ["a pooling arrangement", "TREATMENT", 571, 592], ["densely", "OBSERVATION_MODIFIER", 226, 233], ["populated", "OBSERVATION", 234, 243], ["loss", "OBSERVATION", 288, 292], ["higher", "OBSERVATION_MODIFIER", 301, 307], ["more", "OBSERVATION_MODIFIER", 345, 349], ["mobile", "OBSERVATION_MODIFIER", 350, 356], ["population", "OBSERVATION", 357, 367], ["more", "OBSERVATION_MODIFIER", 381, 385], ["densely", "OBSERVATION_MODIFIER", 386, 393], ["populated", "OBSERVATION", 394, 403]]], ["To avoid an adverse selection problem (the high expected loss entities participate but the low expected loss entities do not), the contributions to a mutual pooling arrangement or the premiums paid to a private insurer would need to vary based on the expected losses of each entity.", [["an adverse selection problem", "PROBLEM", 9, 37], ["the high expected loss entities", "PROBLEM", 39, 70], ["the low expected loss entities", "PROBLEM", 87, 117], ["a mutual pooling arrangement", "TREATMENT", 148, 176]]], ["This approach, however, would likely give rise to political costs as those entities with low expected losses would want to reduce their subsidization of those entities with high expected costs.Expected frequency and severity differs across entitiesA more difficult problem arises if those who are operating the pooling arrangement cannot distinguish entities with high expected losses from those with low expected losses, but that the entities know their own expected losses.", [["low expected losses", "PROBLEM", 89, 108], ["low expected losses", "PROBLEM", 401, 420]]], ["In this case, the adverse selection problems cannot be solved by varying contributions/premiums because the information needed to determine the appropriate premiums is private.", [["the adverse selection problems", "PROBLEM", 14, 44]]], ["On the other hand, understanding the scope, degree, and duration of a pandemic often requires specialized scientific knowledge, and thus the \"experts\" (scientists) are the ones who will likely have superior information, not the exposed entities.Expected frequency and severity differs across entitiesVariation across entities in their expected losses also raises the issue of whether a pooling arrangement should provide equal compensation to all participants even though they may differ in their actual losses.", [["participants", "SPECIES", 447, 459], ["a pooling arrangement", "PROBLEM", 384, 405]]], ["The downside with providing compensation based on the size of the loss is that it requires measuring the loss, which is costly.", [["the loss", "PROBLEM", 62, 70], ["the loss", "PROBLEM", 101, 109], ["size", "OBSERVATION_MODIFIER", 54, 58], ["loss", "OBSERVATION", 66, 70], ["loss", "OBSERVATION_MODIFIER", 105, 109]]], ["In addition to reducing administrative costs, a flat benefit can also reduce moral hazard, a topic to which we now turn.Moral hazardPotential moral hazard problems arise whenever the actions of participants in a pooling arrangement can influence either the probability of a loss or the severity of a loss.", [["participants", "SPECIES", 194, 206], ["moral hazard", "PROBLEM", 77, 89], ["Moral hazard", "PROBLEM", 120, 132], ["Potential moral hazard problems", "PROBLEM", 132, 163], ["a loss", "PROBLEM", 272, 278], ["a loss", "PROBLEM", 298, 304], ["loss", "OBSERVATION", 300, 304]]], ["Another way to mitigate moral hazard is to limit the extent to which risk is shared by including deductibles, coinsurance, limits, exclusions, etc. Regarding the latter approach, making participants pay part of the losses that occur (i.e., placing some of the risk on participants) forces the participants to internalize the impact of their behavior on the expected losses.", [["participants", "SPECIES", 186, 198], ["participants", "SPECIES", 268, 280], ["participants", "SPECIES", 293, 305]]], ["A third method of mitigating moral hazard is to have nonindemnity insurance contracts in which the payment by the insurer is determined by either a set of event parameters (e.g., the number of countries affected or number of deaths) and/or a loss index (e.g., the losses suffered in a geographical region), which are correlated with an individual entity's losses but not directly influenced by the entity.", [["deaths", "DISEASE", 225, 231], ["a loss index", "PROBLEM", 240, 252], ["an individual entity's losses", "PROBLEM", 333, 362], ["entity", "OBSERVATION", 398, 404]]], ["These parametric and index triggers are sometimes used in insurance-linked securities, such as catastrophe bonds.", [["These parametric and index triggers", "PROBLEM", 0, 35], ["catastrophe bonds", "PROBLEM", 95, 112], ["index", "OBSERVATION_MODIFIER", 21, 26], ["catastrophe bonds", "OBSERVATION", 95, 112]]], ["2 used a parametric trigger.Moral hazardMoral hazard is likely to be an issue with pandemic risk for several reasons.", [["a parametric trigger", "TREATMENT", 7, 27], ["Moral hazard", "PROBLEM", 28, 40], ["Moral hazard", "PROBLEM", 40, 52], ["likely to be", "UNCERTAINTY", 56, 68]]], ["The economic costs associated with an interruption of normal business activity depend on managers' actions to control costs and generate revenue during the interruption period.", [["normal", "OBSERVATION", 54, 60]]], ["Also, decisions regarding the timing, extent, and duration of business interruptions are often made by a regional or national governing body, and political officials will naturally tend to initiate, broaden, and extend a forced interruption if the cost is born mostly by future generations or taxpayers who are not the politician's constituents.Samaritan's dilemmaIf participation in either a private or public pooling mechanism is voluntary, then some entities may not participate, because they have the expectation that if a major loss occurs, public assistance will provide ex post coverage at no cost.", [["body", "ANATOMY", 136, 140], ["body", "ORGANISM_SUBDIVISION", 136, 140], ["Samaritan's dilemmaIf participation", "TREATMENT", 345, 380], ["a major loss", "PROBLEM", 525, 537], ["public assistance", "TREATMENT", 546, 563], ["ex post coverage", "TREATMENT", 577, 593]]], ["A solution is mandatory participation.Positive externalities associated with a pooling mechanismMost of the discussion to this point has focused on the private costs and benefits associated with pooling risk, i.e., the benefits and costs to the entities in the pooling arrangement.", [["A solution", "TREATMENT", 0, 10], ["Positive externalities", "PROBLEM", 38, 60], ["a pooling mechanism", "PROBLEM", 77, 96], ["pooling risk", "PROBLEM", 195, 207], ["externalities", "OBSERVATION", 47, 60]]], ["However, an important consideration is the potential benefits that others in society receive as a result of having a pooling arrangement that compensates entities for their loss.", [["a pooling arrangement", "TREATMENT", 115, 136], ["their loss", "PROBLEM", 167, 177]]], ["One potential external benefit is that it reduces the likelihood that business relationships among contracting parties or between the business and its employees will be damaged or disrupted.", [["external benefit", "OBSERVATION", 14, 30]]], ["Also, by helping to maintain economic activity, even at a lower than normal level, compensation to entities that experience a loss can reduce the magnitude and duration of a recessionary economic period.", [["a loss", "PROBLEM", 124, 130]]], ["A disadvantage of purely private insurance mechanism is that these positive externalities would not be taken into consideration in the pricing and distribution of the insurance.", [["these positive externalities", "PROBLEM", 61, 89]]], ["Potential solutions include government subsidies for private insurance or even government provision of the insurance at reduced rates.Positive externalities associated with a pooling mechanismAlso, the lack of insurance for the economic losses associated with a business interruption implies that additional risk is placed on lending institutions.", [["Potential solutions", "TREATMENT", 0, 19], ["Positive externalities", "PROBLEM", 134, 156], ["a pooling mechanismAlso", "PROBLEM", 173, 196], ["the economic losses", "PROBLEM", 224, 243], ["a business interruption", "TREATMENT", 260, 283], ["externalities", "OBSERVATION", 143, 156]]], ["In short, there is potential failure of, or significant damage to, the entire financial system (systemic risk) due to uninsured pandemic losses.", [["potential failure", "PROBLEM", 19, 36], ["significant damage", "PROBLEM", 44, 62], ["uninsured pandemic losses", "PROBLEM", 118, 143], ["short", "OBSERVATION_MODIFIER", 3, 8], ["potential", "UNCERTAINTY", 19, 28], ["failure", "OBSERVATION", 29, 36], ["significant", "OBSERVATION_MODIFIER", 44, 55], ["damage", "OBSERVATION", 56, 62], ["pandemic", "OBSERVATION", 128, 136]]], ["To the extent that a functional risk-transfer mechanism for the economic losses from a pandemic can reduce the likelihood of a bad recession, there is a positive externality associated with having such a risk-transfer mechanism.Section summaryThe most important problem facing the private supply of pandemic insurance is the large amount of capital required to make the insurance credible.", [["the economic losses", "PROBLEM", 60, 79], ["a pandemic", "PROBLEM", 85, 95], ["a bad recession", "PROBLEM", 125, 140], ["a positive externality", "PROBLEM", 151, 173], ["bad recession", "OBSERVATION", 127, 140], ["large", "OBSERVATION_MODIFIER", 325, 330], ["amount", "OBSERVATION_MODIFIER", 331, 337]]], ["Other problems (correlation between pandemic losses and insurer assets, moral hazard, adverse selection, low take-up rates due to underestimation of risk) are also important considerations.", [["Other problems", "PROBLEM", 0, 14], ["moral hazard", "PROBLEM", 72, 84], ["adverse selection", "TREATMENT", 86, 103]]], ["While a private market could provide some coverage by limiting the amount of coverage and the number of entities covered, widespread, high-limit coverage is not likely to be forthcoming from the private market.", [["some coverage", "TREATMENT", 37, 50], ["the amount of coverage", "TREATMENT", 63, 85], ["not likely to be", "UNCERTAINTY", 157, 173]]], ["There are, however, positive externalities associated with avoiding long periods of depressed economic activity, which broad coverage could help prevent.", [["depressed", "DISEASE", 84, 93], ["positive externalities", "PROBLEM", 20, 42], ["depressed economic activity", "PROBLEM", 84, 111], ["broad coverage", "TREATMENT", 119, 133], ["positive", "OBSERVATION_MODIFIER", 20, 28], ["externalities", "OBSERVATION", 29, 42], ["depressed", "OBSERVATION_MODIFIER", 84, 93], ["economic activity", "OBSERVATION", 94, 111]]], ["Comprehensive government programs designed to directly address large-scale business continuity losses from pandemics are necessary to address this risk prospectively and could, over time, potentially encourage the innovation of limited specialized pandemic coverages by private insurers and reinsurers.", [["limited specialized pandemic coverages", "TREATMENT", 228, 266]]], ["It is useful to think about broad coverage provided by a government as a pooling arrangement over time, which utilizes the government's ability to transfer resources over long time periods by borrowing and taxing.", [["broad coverage", "TREATMENT", 28, 42]]], ["The tradeoffs associated with different ways of organizing a government mechanism are analyzed in the next section.Government's roleSince society has a vested interest in mitigating and compensating pandemic losses and a private market alone cannot provide sufficient insurance coverage, we consider how a government can promote greater sharing of future pandemic risks.", [["pandemic", "DISEASE", 355, 363], ["compensating pandemic losses", "PROBLEM", 186, 214], ["government mechanism", "OBSERVATION", 61, 81]]], ["During COVID-19, governments around the world not only imposed social-distancing measures to control the spread of the virus, but also actively provided significant financial resources to businesses and individuals, with the intention to protect employment and avoid bankruptcies.", [["bankruptcies", "DISEASE", 267, 279], ["COVID", "TEST", 7, 12], ["distancing measures", "TREATMENT", 70, 89], ["the virus", "PROBLEM", 115, 124]]], ["In this section, we outline four general approaches available to governments which aim to facilitate and support the sharing of pandemic risk.", [["pandemic", "DISEASE", 128, 136]]], ["We evaluate these four approaches based on the degree to which they are likely to achieve specific public policy goals.Approach 1: provide post-event aidOne approach is for the government to let the private market deal with pandemic risk without government involvement.", [["pandemic", "DISEASE", 224, 232]]], ["As explained above, the private market will fail to provide substantial coverage and many entities will suffer large uncompensated losses if a pandemic occurs.", [["substantial coverage", "TREATMENT", 60, 80], ["large uncompensated losses", "PROBLEM", 111, 137], ["a pandemic occurs", "PROBLEM", 141, 158], ["uncompensated", "OBSERVATION", 117, 130]]], ["This approach, which is depicted in Fig. 4 , involves no pre-event financing nor pre-event commitment for how the aid will be allocated if an event occurs.", [["This approach", "TREATMENT", 0, 13], ["Fig", "OBSERVATION_MODIFIER", 36, 39]]], ["The government reacts to a pandemic event as it is occurring and allocates resources to the entities affected by the pandemic.", [["a pandemic event", "PROBLEM", 25, 41]]], ["The necessary funds are borrowed, placing the cost burden on current and future taxpayers.Approach 1: provide post-event aidThe COVID-19 pandemic was handled by most governments using the post-event aid approach.", [["the cost burden", "PROBLEM", 42, 57], ["The COVID", "TREATMENT", 124, 133], ["the post-event aid approach", "TREATMENT", 184, 211]]], ["The Coronavirus Aid, Relief, and Economic Security (CARES) Act in the U.S. is an example of post-event aid; it deployed over $2 trillion in economic relief to workers, families and small businesses.", [["Relief", "OBSERVATION_MODIFIER", 21, 27], ["small", "OBSERVATION_MODIFIER", 181, 186], ["businesses", "OBSERVATION", 187, 197]]], ["The UK's government subsidized up to 80% of the salaries of eligible workers when the COVID-19 outbreak occurred in the country.", [["the COVID", "TEST", 82, 91]]], ["Germany initiated an Economic Stabilization Fund with $650 billion to support loan payments and take equity stakes in struggling companies.", [["loan payments", "TREATMENT", 78, 91]]], ["It subsequently provided $54 billion to small businesses and the self-employed to cover operating costs.", [["small", "OBSERVATION_MODIFIER", 40, 45], ["businesses", "OBSERVATION", 46, 56]]], ["It is worth noting that in addition to explicit government relief funds, post-event aid can also be provided in implicit forms, such as legislation that limits a company' liability from pandemic-related lawsuits or reduces a firm's payroll taxes.Approach 2: provide reinsurancePrior to a pandemic event, a government could provide reinsurance to insurers that sell primary pandemic coverage to businesses.", [["pandemic", "DISEASE", 186, 194], ["pandemic", "DISEASE", 373, 381], ["explicit government relief funds", "TREATMENT", 39, 71], ["a firm's payroll taxes", "TREATMENT", 223, 245], ["a pandemic event", "PROBLEM", 286, 302], ["firm", "OBSERVATION_MODIFIER", 225, 229]]], ["The reinsurance coverage would be for losses above a designated threshold and would have a designated limit and might contain a co-share provision.", [["The reinsurance coverage", "TREATMENT", 0, 24]]], ["The government reinsurer would reimburse insurers based on the terms of the reinsurance contract.", [["the reinsurance contract", "TREATMENT", 72, 96]]], ["Although the government reinsurer could have accumulated some resources during periods without an event, a major pandemic would likely require government borrowing with tax payments to support the debt.", [["tax", "PROTEIN", 169, 172], ["tax payments", "TREATMENT", 169, 181]]], ["This approach is depicted in Fig. 5 .Approach 2: provide reinsuranceSeveral countries use government reinsurance schemes to cover terrorism risk.", [["reinsuranceSeveral countries", "TREATMENT", 57, 85], ["government reinsurance schemes", "TREATMENT", 90, 120], ["Fig", "OBSERVATION_MODIFIER", 29, 32]]], ["19Approach 3: provide insuranceThe government could provide voluntary insurance coverage directly to entities that are exposed to pandemic risk.", [["pandemic", "DISEASE", 130, 138], ["voluntary insurance coverage", "TREATMENT", 60, 88]]], ["With this scheme, the government insurer collects premiums and is authorized to borrow funds in case a pandemic occurs prior to accumulation of sufficient premiums.", [["a pandemic", "PROBLEM", 101, 111]]], ["Since pandemics are relatively rare events, it would likely not be efficient for the government to develop a new organizational structure to pay claims; instead, it could pay claims through existing government entities, such as the Federal Emergency Management Agency (FEMA) in the U.S., or third parties such as banks, insurers, or claims processing companies in the private market.Approach 3: provide insuranceThe National Flood Insurance Program (NFIP) in the U.S.is an example of a government program that directly indemnifies against future losses.", [["pandemics", "PROBLEM", 6, 15], ["a government program", "TREATMENT", 484, 504]]], ["20 Outside the U.S., governments of many countries also face insurance coverage issues related to catastrophe risk and often provide insurance directly to the policyholders.", [["catastrophe", "DISEASE", 98, 109], ["catastrophe risk", "PROBLEM", 98, 114]]], ["21 For example, Taiwan has material earthquake risk and therefore established Taiwan Residential Earthquake Insurance Fund (TREIF) to provide residential earthquake insurance.", [["earthquake", "DISEASE", 36, 46], ["earthquake", "DISEASE", 154, 164]]], ["In New Zealand, the Earthquake Commission (EQC) also supplies residential earthquake insurance directly to homeowners.Approach 4: provide social insuranceUnder a social insurance scheme, many or all entities are required to participate, and all participating entities are entitled to receive event-contingent benefits.", [["New", "OBSERVATION_MODIFIER", 3, 6], ["Zealand", "OBSERVATION_MODIFIER", 7, 14]]], ["By the end of 2019, Pool Re accumulated a fund of \u00a36.7B to pay potential claims (Ralph 2020) and it purchased \u00a32.4B of private reinsurance coverage to enhance its claim-paying capacity in 2020 (Evans 2020b) .", [["private reinsurance coverage", "TREATMENT", 119, 147]]], ["21 Individual states in the U.S. also provide residual market mechanisms for catastrophe risk.", [["catastrophe", "DISEASE", 77, 88], ["catastrophe risk", "PROBLEM", 77, 93], ["catastrophe risk", "OBSERVATION", 77, 93]]], ["For example, states on the gulf coast and in the southeast have residual markets for coastal property.Approach 4: provide social insuranceparticipants are required to make pre-event payments, often in the form of a tax.", [["tax", "PROTEIN", 215, 218], ["residual markets", "OBSERVATION", 64, 80], ["coastal property", "OBSERVATION", 85, 101]]], ["An administrative system is needed to process and pay the contingent benefits.", [["An administrative system", "TREATMENT", 0, 24]]], ["For most schemes, both the pre-event payments and the benefits paid from a social insurance system increase with potential losses, and are capped at a relatively modest level of potential losses.", [["a social insurance system", "TREATMENT", 73, 98]]], ["The idea is to provide modest coverage for a broad spectrum of population.", [["modest coverage", "TREATMENT", 23, 38], ["population", "OBSERVATION", 63, 73]]], ["Payroll taxes are used to pay the retirement and disability benefits of workers.Approach 4: provide social insuranceGermany has a social insurance program called Kurzarbeit, which pays workers who have been furloughed a percentage of their lost wages.", [["Payroll taxes", "TREATMENT", 0, 13]]], ["For example, if an employee without children is moved from full-time employment to half-time employment, then the program will pay 60% of one-half of the employee's salary (IMF 2020a; Chazan and Milne 2020).", [["children", "ORGANISM", 36, 44], ["children", "SPECIES", 36, 44]]], ["Italy's Cassa Integrazione Ordinaria, which is a program similar to Germany's Kurzarbeit, has been expanded as result of the COVID-19 pandemic.", [["Germany's Kurzarbeit", "TREATMENT", 68, 88], ["the COVID", "TEST", 121, 130], ["pandemic", "PROBLEM", 134, 142]]], ["Under this system, employers who have suspended or reduced work activity due to the pandemic can apply for emergency support that would entitle most employees to 80% of their salary.", [["emergency support", "TREATMENT", 107, 124]]], ["In this sense, the SURE Program is akin to a social reinsurance scheme in that it is the social insurance mechanism in the member state that is the recipient of assistance.Evaluation of the four approachesSections 2 and 3 identified the need for government intervention, and Sect.", [["Evaluation", "TEST", 172, 182], ["government intervention", "TREATMENT", 246, 269]]], ["Specifically, we consider the following four goals: (1) operational efficiency, (2) matching compensation with losses, (3) incentives for risk mitigation, and (4) macroeconomic impacts.Goal 1: operational efficiencyOperational efficiency can be defined as how much money is used to cover operating expenses as opposed to indemnify losses.", [["risk mitigation", "PROBLEM", 138, 153], ["macroeconomic impacts", "PROBLEM", 163, 184], ["operational efficiency", "OBSERVATION_MODIFIER", 193, 215]]], ["In the insurance market, this is an important consideration.", [["important consideration", "UNCERTAINTY", 36, 59]]], ["For example, the U.S. P&C insurance industry has an expense ratio of 27%, according to National Association of Insurance Commissioners (2019), meaning 27% of the P&C industry premium collected is spent on agency fees, broker commissions, employee salaries, and other operational costs.", [["an expense ratio", "TEST", 49, 65]]], ["Operational efficiency is influenced by both system design and business execution.", [["efficiency", "OBSERVATION", 12, 22]]], ["A common view is that private business is more effective than government regarding (b) but that well-designed government involvement can reduce middlemen.Goal 1: operational efficiencyAmong the four government schemes, an advantage of a social insurance scheme is that it cuts out the \"middlemen\" because it can use existing government entities, such as the tax authority, to collect payments from participants.", [["participants", "SPECIES", 398, 410], ["operational efficiency", "OBSERVATION_MODIFIER", 162, 184]]], ["Alternatively, benefits could follow a schedule based on payroll or revenue, which would improve operating efficiency, but worsen the matching of compensation to losses (see below).", [["payroll", "TREATMENT", 57, 64]]], ["Yet another option would involve a parametric trigger (e.g., official pandemic declaration) with benefits being paid to all eligible entities without any regard to actual Fig. 7 Provide social insurance loss.", [["insurance loss", "DISEASE", 193, 207], ["a parametric trigger", "PROBLEM", 33, 53]]], ["While this approach avoids entirely the need for auditors to determine loss, thereby accelerating the payment of losses and materially lowering administration costs, it is the worst option in terms of matching compensation to losses.Goal 1: operational efficiencyPost-event aid may appear to be relatively efficient as well, especially considering that the administrative costs are only incurred when a pandemic occurs, which (hopefully) is relatively rare.", [["auditors", "TREATMENT", 49, 57], ["loss", "PROBLEM", 71, 75], ["materially lowering administration costs", "TREATMENT", 124, 164], ["a pandemic", "PROBLEM", 401, 411], ["operational efficiency", "OBSERVATION_MODIFIER", 241, 263]]], ["On the other hand, the ad hoc nature and the lack of planning associated with post-event aid is likely to lead to inefficiencies in the distribution of relief funds and poor matching of compensation with losses.", [["relief funds", "TREATMENT", 152, 164]]], ["To reach as many entities as possible, as quickly as possible, and without prior planning, the government will likely incur high costs; also, the potential for graft is high.Goal 1: operational efficiencyIf the government serves as the reinsurer or insurer, costs will be incurred in developing the administrative structure for distribution, financial management, claim services, etc., as well as the ongoing operating costs of providing these administrative functions, once they are established.", [["graft", "ANATOMY", 160, 165], ["graft", "TISSUE", 160, 165], ["graft", "TREATMENT", 160, 165], ["financial management", "TREATMENT", 342, 362], ["graft", "OBSERVATION", 160, 165], ["high", "OBSERVATION", 169, 173], ["operational efficiency", "OBSERVATION_MODIFIER", 182, 204]]], ["These costs are likely to be greater if the government directly provides insurance rather than reinsurance (since the latter involves interaction just with private insurers, while the former requires dealing with the primary insured entities and potentially their intermediaries (i.e., agents and brokers).", [["likely to be", "UNCERTAINTY", 16, 28], ["greater", "OBSERVATION_MODIFIER", 29, 36]]], ["Moreover, the lack of competitive forces could reasonably be expected to make a government insurer less efficient than a private insurer.Goal 1: operational efficiencyIn Table 2 , we summarize this discussion by ranking the operational efficiency of providing post-event aid as medium, reinsurance as medium, insurance as low, and social insurance as high.Goal 2: matching compensation with lossesAn effective insurance mechanism would accurately measure losses and provide compensation based on those losses.", [["An effective insurance mechanism", "TREATMENT", 397, 429]]], ["This is important from the perspective of the welfare of the individual insureds and from the societal perspective of using an insurance mechanism to reduce the impact of a pandemic on the macroeconomy.", [["a pandemic on the macroeconomy", "PROBLEM", 171, 201]]], ["We discuss the macroeconomic issues below; here we focus on the individual insureds.Goal 2: matching compensation with lossesIdeally, a pandemic insurance mechanism would replace a substantial share of an entity's losses, but to mitigate moral hazard (see below), it would not fully compensate for all losses.", [["a pandemic insurance mechanism", "TREATMENT", 134, 164], ["an entity's losses", "PROBLEM", 202, 220], ["all losses", "PROBLEM", 298, 308]]], ["Finding the optimal amount of coverage depends on many factors, but all else equal it is better to have a higher correlation between compensation and losses.", [["optimal", "OBSERVATION_MODIFIER", 12, 19], ["amount", "OBSERVATION_MODIFIER", 20, 26]]], ["As a consequence, it is likely to sacrifice the goal of matching compensation with losses in order to get aid distributed quickly.", [["likely to", "UNCERTAINTY", 24, 33]]], ["In response to COVID-19, the U.S. government's Economic Impact Payments were sent to individuals through the tax system.", [["tax", "PROTEIN", 109, 112], ["COVID", "TEST", 15, 20], ["Economic Impact Payments", "TREATMENT", 47, 71]]], ["24 Likewise, the Federal Pandemic Compensation Program, which provided unemployed workers with an additional $600 above their state unemployment insurance benefit, resulted in a median wage replacement rate of 134%, with 68% of workers receiving more in unemployment benefits than they earned from their jobs (Ganong et al. 2020) .", [["a median wage replacement rate", "TREATMENT", 176, 206]]], ["Also, the U.S. Paycheck Protection Program (PPP) for COVID-19 business relief was distributed through the banking system, so business owners needed to apply for PPP at the banks.", [["COVID-19 business relief", "TREATMENT", 53, 77], ["business owners", "TREATMENT", 125, 140], ["PPP", "PROBLEM", 161, 164]]], ["Different banks have different policies, systems and practices, which created discrepancies in fund distributions.Goal 2: matching compensation with lossesA social insurance mechanism that provides a relatively uniform amount of compensation compared to the losses suffered by entities is likely to have a relatively low correlation between compensation and losses.", [["fund distributions", "OBSERVATION", 95, 113]]], ["Moreover, attempts to improve a social insurance scheme along this margin are likely to undermine some or all of the operational efficiency advantages of social insurance discussed above.Goal 2: matching compensation with lossesProvided entities understand the risk, a private insurance market with voluntary primary coverage (and government provided reinsurance) is likely to be significantly better at achieving this second goal, since it allows entities with greater coverage needs to voluntarily choose to purchase more insurance coverage from private insurers.", [["a social insurance scheme", "TREATMENT", 30, 55]]], ["25 There are multiple channels through which the government can distribute compensation payments, including the tax authority (IRS), the disaster management system (FEMA), and entities with lending authorities (SBA and Federal Reserve).", [["multiple", "OBSERVATION_MODIFIER", 13, 21], ["channels", "OBSERVATION", 22, 30]]], ["The tax authority likely has the broadest reach, and therefore would likely be an appropriate entity to disburse funds in a pandemic.", [["a pandemic", "PROBLEM", 122, 132]]], ["Evidence of low take-up rates exists in several existing insurance programs.", [["low take-up rates", "PROBLEM", 12, 29], ["low", "OBSERVATION_MODIFIER", 12, 15]]], ["For example, the current terrorism take-up rate for the coverage provided by the Terrorism Risk and Insurance Act (TRIA) embedded in property policies is about 60% (Marsh 2019) .", [["the coverage", "TREATMENT", 52, 64]]], ["The takeup rate of residential earthquake insurance in California is only about 10% (Marshall 2018).Goal 2: matching compensation with lossesAs summarized in Table 2 , our ranking of how the various schemes match compensation with losses is as follows: when the government provides post-event aidlow, reinsurance-high, insurance-medium, and social insurance-low.Goal 3: incentives for risk mitigationReducing risk by compensating entities for their pandemic losses (which is a good thing) can also adversely affect their incentives to reduce the probability of a loss occurring and/or reduce the magnitude of the loss once it occurs (which is a bad thing).", [["earthquake", "DISEASE", 31, 41], ["pandemic", "DISEASE", 449, 457], ["their pandemic losses", "PROBLEM", 443, 464], ["a loss", "PROBLEM", 561, 567], ["the loss", "PROBLEM", 609, 617]]], ["Therefore, the impact of a risk-sharing scheme on incentives for risk mitigation is an important consideration when evaluating alternative ways that a government can be involved in providing pandemic risk insurance.", [["risk mitigation", "TREATMENT", 65, 80]]], ["(Note that mitigation incentives should include incentives for innovation to help businesses continue to operate, while keeping employees and customers safe.)Goal 3: incentives for risk mitigationPrivate insurance typically provides incentives for risk mitigation through the underwriting process and by having insureds bear some risk through various policy provisions, such as deductibles, coinsurance, limits, and exclusions.", [["mitigation incentives", "TREATMENT", 11, 32]]], ["For example, when residents living in Florida make their houses more resistant to hurricane damage, they usually can receive a reduced premium.", [["hurricane damage", "PROBLEM", 82, 98], ["a reduced premium", "TREATMENT", 125, 142]]], ["Thus, an important argument for including the private insurance sector in the pandemic risk solution is to incentivize risk mitigation.", [["the pandemic risk solution", "TREATMENT", 74, 100]]], ["However, a monopoly government insurer would not face competitive pressures to develop and use innovative approaches to provide incentives for insured entities to mitigate risk.", [["innovative approaches", "TREATMENT", 95, 116]]], ["Furthermore, a government insurance program would likely be subject to political pressure to suppress rates for insureds with the greatest pandemic risk, 27 thus blunting the effectiveness of underwriting as method of providing incentives for risk mitigation.", [["a government insurance program", "TREATMENT", 13, 43], ["political pressure", "TREATMENT", 71, 89], ["risk mitigation", "TREATMENT", 243, 258]]], ["First, mitigation efforts are costly and therefore it is not optimal to eliminate moral hazard.", [["moral hazard", "PROBLEM", 82, 94]]], ["Second, some types of moral hazard will not be impacted by commercial insurance contracts.", [["moral hazard", "PROBLEM", 22, 34]]], ["For example, a population's vulnerability to a pandemic depends on a number of co-morbidities of the individuals in the population, which depend largely on individual behavior, not business practices.", [["a population's vulnerability", "PROBLEM", 13, 41]]], ["27 For examples of rate suppression in the National Flood Insurance Program, see Kousky and Shabman (2014) .Goal 3: incentives for risk mitigationSocial insurance programs tend to treat participants similarly in terms of pricing and benefits.", [["participants", "SPECIES", 186, 198], ["risk mitigationSocial insurance programs", "TREATMENT", 131, 171]]], ["This occurs in part because social insurance programs typically place greater emphasis on covering as many people as possible and on maintaining relatively equal treatment of the insureds.", [["people", "ORGANISM", 107, 113], ["people", "SPECIES", 107, 113], ["social insurance programs", "TREATMENT", 28, 53]]], ["Consequently, underwriting is likely to be limited compared to the private insurance sector, and the tax or premium formula used by a social insurance program is not likely to reflect risk mitigation measures or have as much differentiation of across observable risk classes.", [["tax", "PROTEIN", 101, 104], ["risk mitigation measures", "TREATMENT", 184, 208], ["not likely", "UNCERTAINTY", 162, 172]]], ["28 The mitigation incentives provided by a post-event aid scheme depends on the public's perception of the likelihood that aid will be provided and the comprehensiveness of that aid.", [["The mitigation incentives", "TREATMENT", 3, 28]]], ["If entities view that the government will compensate most losses, then the entities will have little incentive to mitigate pandemic risk.", [["pandemic", "DISEASE", 123, 131]]], ["On the other hand, if entities do not perceive that aid will be forthcoming but they understand the magnitude of the risk that they face, then they will have strong incentives to mitigate.Goal 3: incentives for risk mitigationTo summarize, among the four government schemes discussed, private insurance companies underwriting pandemic risk upfront and the government serving as the insurance industry's backstop reinsurer is likely the most effective approach from the risk mitigation perspective; it therefore receives a ranking of high in our Summary Table 2 .", [["pandemic", "DISEASE", 326, 334]]], ["The government serving as an insurer receives a grade of medium, and both the post-event aid and social insurance programs receive a low grade.Impact on the overall economyA pandemic insurance mechanism is important for the overall health of the economy.", [["social insurance programs", "TREATMENT", 97, 122], ["a low grade", "PROBLEM", 131, 142], ["low grade", "OBSERVATION_MODIFIER", 133, 142]]], ["This point is illustrated by the impact of terrorism insurance coverage post 9/11.", [["terrorism insurance coverage", "TREATMENT", 43, 71]]], ["Examples include business loans not being approved and construction projects halted because there was no proof of insurance coverage.", [["insurance coverage", "TREATMENT", 114, 132]]], ["29 The same situation could emerge for pandemic insurance post COVID-19.", [["COVID", "TEST", 63, 68]]], ["Insurance, whether provided directly by the government or through the private sector (and then reinsured), helps to avoid this type of market failure.", [["market failure", "PROBLEM", 135, 149], ["failure", "OBSERVATION", 142, 149]]], ["More generally, a pandemic insurance mechanism can keep businesses operating, reduce unemployment, and help maintain consumer spending, all of which help prevent an extended recessionary period.Impact on the overall economyDo the four mechanisms differ in their impact on the overall economy?", [["economy", "OBSERVATION_MODIFIER", 216, 223]]], ["It must first work its way through the political process, which creates at least temporary macroeconomic damage as well as uncertainty about the extent to which business will be able to recover from a shutdown.", [["temporary macroeconomic damage", "PROBLEM", 81, 111], ["temporary", "OBSERVATION_MODIFIER", 81, 90], ["macroeconomic damage", "OBSERVATION", 91, 111]]], ["It can be scaled based on the damage observed and adjusted over time.", [["the damage", "PROBLEM", 26, 36]]], ["As we have mentioned several times already, the possibility of augmenting benefits, however, makes the Samaritan's dilemma worse.Impact on the overall economyMandatory social insurance is likely to provide greater macroeconomic benefits to society because of its broad reach and because a large proportion of benefits paid will go to those with a high marginal propensity to consume (e.g., low-to-middle income families, small businesses).", [["the Samaritan's dilemma", "PROBLEM", 99, 122]]], ["30 Therefore, as summarized in Table 2 , we give post-event aid, reinsurance, and insurance a grade of medium, and social insurance a grade of high.Section summaryOur evaluation of the four pandemic risk-financing schemes is summarized in Table 2 using the four goals discussed above.", [["Our evaluation", "TEST", 163, 177], ["financing schemes", "TREATMENT", 204, 221]]], ["There is not a clear conclusion that can be drawn based on these analyses, as each approach has its own advantages and disadvantages.", [["these analyses", "TEST", 59, 73]]], ["The one goal on which it ranks relatively high is operational efficiency, in large part because it does not incur costs until another pandemic event occurs.", [["operational efficiency", "OBSERVATION", 50, 72]]], ["30 Another consideration is adverse selection, which is likely to be important in the context of pandemic risk because of the high level of heterogeneity and information asymmetry.", [["adverse selection", "PROBLEM", 28, 45], ["pandemic risk", "PROBLEM", 97, 110], ["adverse selection", "OBSERVATION", 28, 45], ["likely to be", "UNCERTAINTY", 56, 68]]], ["Eventually, the risk pool will consist of mostly high-risk insureds, effectively leading to underfunding and insufficient coverage.", [["the risk pool", "PROBLEM", 12, 25]]], ["A solution for adverse selection is to make the insurance mandatory.", [["A solution", "TREATMENT", 0, 10]]], ["Of the four government insurance schemes discussed in this paper, only social insurance is mandatory.ConclusionPandemics represent a recurrent scourge on humanity that throughout recorded history are responsible for not only incalculable human suffering but also extreme and lasting economic damage.", [["human", "ORGANISM", 238, 243], ["human", "SPECIES", 238, 243], ["human", "SPECIES", 238, 243], ["economic damage", "PROBLEM", 283, 298], ["recurrent", "OBSERVATION_MODIFIER", 133, 142]]], ["The COVID-19 pandemic, which swept through the world in 2020 and is still developing in many countries, was no exception.", [["The COVID", "TEST", 0, 9]]], ["Unquestionably, economic interdependencies in our modern, globalized society accelerated the spread of the virus and intensified its economic consequences, throwing the global economy into its sharpest contraction since the Great Depression.ConclusionCertainly, many executives, risk managers, and insurance professionals knew that the occurrence of a pandemic and its associated economic losses was a possibility, if not a certainty at some point in the future.", [["Depression", "DISEASE", 230, 240], ["pandemic", "DISEASE", 352, 360], ["economic interdependencies", "PROBLEM", 16, 42], ["the virus", "PROBLEM", 103, 112], ["the Great Depression", "PROBLEM", 220, 240], ["a pandemic", "PROBLEM", 350, 360], ["its associated economic losses", "PROBLEM", 365, 395], ["economic", "OBSERVATION_MODIFIER", 16, 24], ["interdependencies", "OBSERVATION", 25, 42], ["sharpest contraction", "OBSERVATION", 193, 213], ["Great", "OBSERVATION_MODIFIER", 224, 229], ["Depression", "OBSERVATION", 230, 240]]], ["2 of this paper, the private insurance market provided limited insurance coverage for economic losses caused by a pandemic.", [["economic losses", "PROBLEM", 86, 101], ["a pandemic", "PROBLEM", 112, 122]]], ["Indeed, very few insurance products protecting against \"pure\" pandemic risk have ever been brought to market.", [["pandemic", "DISEASE", 62, 70], ["very", "OBSERVATION_MODIFIER", 8, 12], ["few", "OBSERVATION_MODIFIER", 13, 16]]], ["While insurers are exposed to pandemic loss through some products with contingent or incidental exposures, our analysis suggests that the overwhelming majority of pandemic risk is uninsured.ConclusionWhat explains the limited coverage provided by the private market?", [["pandemic loss", "DISEASE", 30, 43], ["pandemic", "DISEASE", 163, 171], ["pandemic loss", "PROBLEM", 30, 43], ["our analysis", "TEST", 107, 119], ["pandemic loss", "OBSERVATION", 30, 43]]], ["While acknowledging there might be reasons on the demand side, such as underestimation of the frequency and severity of pandemics, we argue in Sect.", [["pandemics", "PROBLEM", 120, 129]]], ["3 that a pandemic insurance market fails largely because the amount of capital needed to supply credible insurance coverage is prohibitively high.", [["a pandemic insurance market", "TREATMENT", 7, 34], ["credible insurance coverage", "TREATMENT", 96, 123]]], ["More specifically, we use hypothetical examples to explain how correlation in the frequency and severity of losses, both key characteristics of pandemics, leads to an extraordinarily high capital requirement.", [["severity of losses", "PROBLEM", 96, 114], ["pandemics", "PROBLEM", 144, 153], ["an extraordinarily high capital requirement", "PROBLEM", 164, 207], ["extraordinarily", "OBSERVATION_MODIFIER", 167, 182], ["high", "OBSERVATION_MODIFIER", 183, 187], ["capital requirement", "OBSERVATION", 188, 207]]], ["The examples also illustrate that the required capital drops considerably if the risk is pooled over time, as opposed to across entities in a given time period.ConclusionWe conclude that government involvement is needed to solve the private insurance market failure, due to government's unique ability to tax, borrow and pool risk across time.", [["tax", "PROTEIN", 305, 308], ["capital drops", "TREATMENT", 47, 60]]], ["Moreover, we argue that an effective pandemic risk-sharing mechanism would generate positive externalities for the macroeconomy by reducing the disruption in economic activity and preventing a prolonged economic recession.ConclusionThe paper then suggests that a government can support the sharing of pandemic risk by providing either (1) post-event aid, (2) reinsurance, (3) primary insurance, or (4) social insurance.", [["pandemic", "DISEASE", 301, 309], ["an effective pandemic risk", "PROBLEM", 24, 50], ["the macroeconomy", "TREATMENT", 111, 127], ["the disruption in economic activity", "PROBLEM", 140, 175], ["a prolonged economic recession", "PROBLEM", 191, 221], ["economic activity", "OBSERVATION", 158, 175], ["prolonged", "OBSERVATION_MODIFIER", 193, 202], ["economic", "OBSERVATION_MODIFIER", 203, 211], ["recession", "OBSERVATION", 212, 221]]], ["We evaluate the strengths and weaknesses of these schemes based on four policy goals: operational efficiency, matching compensation with losses, incentives for risk mitigation, and macroeconomic impacts.", [["these schemes", "TREATMENT", 44, 57], ["risk mitigation", "TREATMENT", 160, 175], ["macroeconomic impacts", "PROBLEM", 181, 202]]]]}